niacinamide and sorafenib

niacinamide has been researched along with sorafenib in 4071 studies

Research

Studies (4,071)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's671 (16.48)29.6817
2010's3328 (81.75)24.3611
2020's72 (1.77)2.80

Authors

AuthorsStudies
Hirte, HW; Hotte, SJ1
Chien, DS; Wilhelm, S1
Bauer, RJ; Hedley, D; Hilger, RA; Kredke, S; Moeller, JG; Scheulen, ME; Seeber, S; Stellberg, W; Strumberg, D1
Beling, C; Hilger, RA; Kredtke, S; Moeller, JG; Richly, H; Scheulen, ME; Seeber, S; Strumberg, D; Voliotis, D1
Beeram, M; Patnaik, A1
Lee, JT; McCubrey, JA1
Bauer, S; Díaz-Carballo, D; Hilger, RA; Kredtke, S; Scheulen, ME; Seeber, S; Strumberg, D1
Heim, M; Hilger, RA; Scheulen, ME; Seeber, S; Sharifi, M; Strumberg, D1
Baas, F; Brendel, E; Buss, P; Mersmann, S; Mross, K; Reil, M; Schwartz, B; Steinbild, S; Voliotis, D1
Grubert, M; Hilger, RA; Kredtke, S; Kupsch, P; Passage, K; Richly, H; Scheulen, ME; Seeber, S; Strumberg, D; Voliotis, D1
Bollag, G; Freeman, S; Lyons, JF; Post, LE1
Götz, R; Kramer, BW; Rapp, UR1
Chiloeches, A; Friedlos, F; Hayward, R; Hedley, D; Karasarides, M; Marais, R; Marshall, CJ; Martin, J; Niculescu-Duvaz, D; Ogilvie, L; Scanlon, I; Springer, CJ1
Afify, S; Högger, P; Rapp, UR1
Ahmad, T; Eisen, T1
Adnane, L; Auclair, D; Bollag, G; Cao, Y; Carter, C; Chen, C; Eveleigh, D; Gawlak, S; Gedrich, R; Liu, L; Lynch, M; McHugh, M; McNabola, A; Post, LE; Riedl, B; Rong, H; Rowley, B; Shujath, J; Tang, L; Taylor, I; Trail, PA; Vincent, P; Voznesensky, A; Wilhelm, SM; Wilkie, D; Zhang, X1
Fagin, JA1
Hilger, RA; Kredtke, S; Scheulen, ME; Seeber, S; Strumberg, D1
Brendel, E; Christensen, O; Grubert, M; Haase, CG; Hilger, RA; Kupsch, P; Passage, K; Richly, H; Schwartz, B; Strumberg, D; Voigtmann, R1
Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D1
Heim, M; Jaehde, U; Scharifi, M; Seeber, S; Strumberg, D; Voliotis, D; Zisowsky, J1
Seeber, S; Strumberg, D1
Desai, AA; Stadler, WM1
Robertson, GP; Sharma, A; Smith, CD; Trivedi, NR; Tuveson, DA; Zimmerman, MA1
Hedley, D; Siu, LL; Sridhar, SS1
Awada, A; Bartholomeus, S; Brendel, E; de Valeriola, D; Gil, T; Haase, CG; Hendlisz, A; Mano, M; Piccart, M; Schwartz, B; Strumberg, D1
Herbst, RS; Onn, A; Sandler, A1
Marx, J1
Gravell, A; Wright, JJ; Zerivitz, K2
Branca, MA1
Lyons, J; Thompson, N1
Armand, JP; Boige, V; Escudier, B; Le Cesne, A; Le Chevalier, T; Lhomme, C; Malka, D; Pautier, P; Robert, C; Soria, JC; Spatz, A; Wechsler, J1
Cihon, F; Hirte, HW; Hotte, SJ; Lathia, C; Moore, M; Oza, A; Petrenciuc, O; Schwartz, B; Siu, L1
Adjei, AA; Bruzek, LM; Carter, CA; Gores, GJ; Kaufmann, SH; Meng, XW; Yu, C1
Motzer, RJ; Rini, BI; Sosman, JA1
Clark, JW; Eder, JP; Lathia, C; Lenz, HJ; Ryan, D1
Armand, JP; Escudier, B; Faivre, S; Raymond, E; Robert, C1
Cooney, MM; Remick, SC; Vogelzang, NJ2
Bauer, C; Davis, EM; Dent, P; Grant, S; Rahmani, M1
Cihon, F; Gallentine, M; Lathia, C; Lettieri, J; Radtke, M; Sundaresan, P1
Schiller, JH; Wakelee, HA1
Beeram, M; Patnaik, A; Rowinsky, EK2
Baek, WS; Pytel, P; Rubeiz, H; Undevia, SD1
Brendel, E; Christensen, O; Henning, BF; Hilger, RA; Hofstra, E; Kupsch, P; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R; Wiesemann, K1
Soff, G; Zakarija, A1
Awada, A; Giannaris, T; Lathia, C; Moore, MJ; Petrenciuc, O; Piccart, M; Schwartz, B; Siu, LL; Takimoto, CH1
Bürckstümmer, T; Hildt, E; Kriegs, M; Lupberger, J; Pauli, EK; Schmittel, S1
Gollob, JA1
Awada, A; Brueckner, A; Christensen, O; Clark, JW; Hirte, H; Hofstra, E; Piccart, P; Schwartz, B; Seeber, S; Strumberg, D; Voliotis, D1
Flaherty, KT; Gallagher, M; Mosenkis, A; O'Dwyer, PJ; Stevenson, JP; Townsend, RR; Veronese, ML1
Atkins, MB; Mier, JW; Panka, DJ; Wang, W1
Chaganti, RS; Motzer, RJ; Patel, PH1
Strumberg, D3
Kanetake, H; Koga, S1
Chow, S; Hedley, D; Tong, FK1
Brendel, E; Christensen, O; Flashar, C; Grubert, M; Henning, BF; Hilger, RA; Kupsch, P; Ludwig, M; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R1
Rini, BI7
Anaganti, S; Carlomagno, F; Guida, T; Salvatore, G; Santoro, M; Troncone, G; Wilhelm, SM1
Frantz, S1
Carlomagno, F; De Falco, V; Melillo, RM; Nappi, TC; Pepe, S; Salerno, P; Salvatore, G; Santoro, M; Troncone, G; Wilhelm, SM1
Von Hoff, DD1
Ardizzoni, A; Franciosi, V; Tiseo, M1
Abbruzzese, JL; Desai, AA; Eisen, T; Flaherty, KT; Gore, M; Kaye, SB; O'Dwyer, PJ; Patnaik, A; Ratain, MJ; Rosner, GL; Rowinsky, E; Schwartz, B; Simantov, R; Stadler, WM; Xia, C; Xiong, HQ1
Boogaerts, M; Cools, J; Folens, C; Lierman, E; Marynen, P; Mentens, N; Scheers, W; Stover, EH; Van Miegroet, H; Vandenberghe, P1
Colombi, M; Kiser, KF; Moroni, C1
Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X1
Bukowski, RM; Reddy, GK1
Adnane, L; Taylor, I; Trail, PA; Wilhelm, SM1
Budillon, A; Caraglia, M; Marra, M; Tagliaferri, P; Tassone, P; Venuta, S1
Escudier, B; Gore, ME1
Bukowski, RM3
Baker, SD; Hafner, FT; He, P; Hidalgo, M; Messersmith, WA; Radtke, M; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M1
Desai, A; Lacouture, ME; Laumann, AE; Petronic-Rosic, V; Ratain, MJ; Soltani, K; Stadler, WM1
Hampton, T2
Eto, M; Naito, S1
Bukowski, RM; Rini, BI; Shaheen, PE1
McCormick, F; Oda, K; Okada, J; Rauen, K; Rodriguez-Viciana, P; Tetsu, O1
Ahmad, T; Eisen, T; Flaherty, KT; Gibbens, I; Gore, M; Hackett, S; James, M; Kaye, S; Marais, R; Nathanson, KL; O'Dwyer, PJ; Poulin-Costello, M; Ratain, MJ; Schuchter, LM; Schwartz, B; Simantov, R; Xia, C1
Carter, C; Gollob, JA; Kelley, SL; Wilhelm, S1
Rapp, UR; Schreck, R1
Mancuso, A; Sternberg, CN1
Abou-Alfa, GK; Amadori, D; De Greve, J; Douillard, JY; Figer, A; Lathia, C; Moscovici, M; Ricci, S; Saltz, LB; Santoro, A; Schwartz, B; Schwartz, L; Taylor, I1
Biedrzycki, BA1
King, CR1
Jane, EP; Pollack, IF; Premkumar, DR1
Chami, L; Escudier, B; Lamuraglia, M; Lassau, N; Leclère, J; Roche, A; Schwartz, B1
Figg, WD; Jain, L; Venitz, J1
Stadler, W1
Curtiss, FR1
Adjei, AA; Carter, CA; Friday, BB; Kaufmann, SH; Kay, NE; Lai, JP; Roberts, LR; Sarkaria, J; Yang, L; Yu, C1
Hahn, O; Stadler, W1
Adusumilli, J; Baxter, DL; El-Khoueiry, A; Govindarajan, R; Harik, SI1
Berry, WR; Galsky, MD; Hutson, TE; Sonpavde, G1
Carter, C; Dumas, J; Kelley, S; Lowinger, T; Lynch, M; Schwartz, B; Simantov, R; Smith, RA; Wilhelm, S1
Haseke, N; Heinemann, G; Schöppler, G; Stadler, T; Staehler, M; Stief, CG1
Burton, A1
Carter, C; Feldman, MD; Lassoued, W; Lee, WM; Makonnen, S; Murphy, DA1
Gascón, P; Mellado, B1
Baas, F; Brendel, E; Christensen, O; Gmehling, D; Mross, K; Radtke, M; Steinbild, S; Unger, C; Voliotis, D1
Blanke, C1
Arslan, MA; Basaga, H; Kutuk, O1
Chung, NM; Gutierrez, M; Turner, ML1
Wetherbee, SL1
Bukowski, RM; Motzer, RJ1
Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D1
Fesik, SW; Huang, X; Li, L; Lin, X; Morgan-Lappe, S; Shen, Y; Vernetti, LA; Zakula, DM1
Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X1
Culine, S; Pouessel, D3
Chadalavada, RS; Chaganti, RS; Motzer, RJ; Patel, PH1
Booth, B; Chidambaram, N; Farrell, AT; Garvey, P; Jee, JM; Justice, R; Kane, RC; Liang, C; Morse, D; Pazdur, R; Saber, H; Sridhara, R; Tang, S; Williams, G1
Azad, NS; Cowen, EW; Dahut, W; Gutierrez, M; Kong, HH; Turner, ML1
Abriola, L; Auclair, D; Burd, A; Carter, C; Chang, Y; Dumas, J; Gedrich, R; Lynch, M; Miller, D; Pickett, W; Rocks, S; Shi, H; Trail, PA; Vasavada, H; Wilhelm, SM; Wilkie, D; Yatsula, V; Zhang, X1
Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Freeman, S; Gore, M; Hutson, TE; Negrier, S; Oudard, S; Rolland, F; Schwartz, B; Shan, M; Siebels, M; Simantov, R; Solska, E; Stadler, WM; Szczylik, C1
Brugarolas, J1
Cools, J; Lahortiga, I; Lierman, E; Marynen, P; Mentens, N; Van Miegroet, H1
Kuzel, T; Lacouture, ME; Lai, SE1
Dreicer, R1
Creel, P; George, D; Speca, J; Yenser, S1
Herbst, RS1
Grossman, ME; MacGregor, JL; Sherman, WH; Silvers, DN1
Flaherty, KT3
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D2
Hussar, DA1
Clemetson, KJ1
Miller, K1
Colantuoni, G; Comunale, D; De Vita, A; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A1
Schneider, BP; Sledge, GW1
McKeage, K; Wagstaff, AJ1
Figlin, RA1
Arnold, R; Bartsch, DK; Fendrich, V; Hörsch, D; Karhoff, D; Sauer, S; Schrader, J1
Angevin, E; Armand, JP; Brendel, E; Chami, L; Escudier, B; Lamuraglia, M; Landreau, V; Lassau, N; Robert, C; Schwartz, B; Soria, JC; Zafarana, E1
Michaelson, MD1
Miroglu, C; Silay, MS1
Hauschild, A1
Busch, S; Garbe, C; Herlyn, M; Kulms, D; Lasithiotakis, K; Maczey, E; Meier, F; Schittek, B1
Alexandrescu, DT; Dasanu, CA; Dutcher, J1
Acs, G; Brafford, P; Chen, L; Edwards, R; Herlyn, M; Kazianis, S; Kumar, SM; Xu, X; Yu, H1
Dudek, AZ; Mulamalla, K; Truskinovsky, AM1
Hanna, N1
Amar, S; Tan, WW; Wu, KJ1
Autran Gomez, AM; Di Silverio, F; Gentile, V; Gentilucci, A; Parente, U; Salciccia, S; Sciarra, A1
Kruck, S; Kuczyk, M; Merseburger, AS1
Linehan, WM; Novakovic, KR; Pinto, PA; Vira, MA1
Ardizzoni, A; Tiseo, M1
Force, T; Krause, DS; Van Etten, RA1
Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A1
De Mulder, PH; Mulder, SF; van Spronsen, DJ1
Brocheriou, I; Deray, G; Izzedine, H; Rixe, O1
Awada, A; Clark, JW; Eder, JP; Hendlisz, A; Hirte, HW; Lenz, HJ; Moore, MJ; Richly, H; Schwartz, B; Strumberg, D1
Senan, S; Smit, EF1
Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C1
Kamba, T; McDonald, DM1
Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P1
Anaganti, S; Carlomagno, F; Gedrich, R; Guida, T; Provitera, L; Santoro, M; Sullivan, E; Wilhelm, SM1
Crabtree, TR; Davis, EM; Dent, P; Grant, S; Habibi, JR; Nguyen, TK; Rahmani, M1
Bukowski, R; Cella, D; Escudier, B; Gondek, K1
Ernstoff, MS; George, DJ; Kasibhatla, M; Meyer, J; Steinberg, P1
Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A1
Escudier, B3
Di Lorenzo, G1
Calzada, G; El-Naggar, AK; Jasser, SA; Kim, S; Myers, JN; Wang, ZY; Yazici, YD; Younes, MN1
Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L1
Bracarda, S; Caserta, C; Crinò, L; Hamzay, A; Rossi, M; Sordini, L1
Hobday, TJ; McWilliams, RR; Morris, JC; Robinson, SI; Sathananthan, A1
Dent, P; Grant, S; Nguyen, TK; Rahmani, M1
Flaherty, KT; Stein, MN1
Atkins, MB1
Chiao, PJ; Dicker, DT; El-Deiry, WS; Flaherty, KT; Jin, Z; Kim, SH; Ling, J; Liu, YY; Ogi, K; Plastaras, JP; Ricci, MS; Smith, CD; Wang, W1
Rini, BI; Unnithan, J1
Batt, D; Li, N; Warmuth, M1
Dai, Y; Dasmahapatra, G; Dent, P; Grant, S; Yerram, N1
Cabebe, E; Wakelee, H1
Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI1
Atkins, MB; Goldberg, SN; Hakimé, A; Hines-Peralta, A; Peddi, H; Regan, M; Signoretti, S; Sukhatme, VP1
Albers, P; Bergmann, L; Geschwend, JE; Jäger, E; Jakse, G; Marschner, N; Miller, K1
Goldspiel, BR; Grandinetti, CA1
Bodrogi, I1
Barford, D; Gambacorti-Passerini, C; Hofstra, RM; Isacke, CM; Links, TP; Magee, AI; Mologni, L; Plaza-Menacho, I; Sala, E1
Gollob, JA; Grigson, G; Gu, L; Marino, CB; Miller, EK; Peterson, BL; Rathmell, WK; Richmond, TM; Watkins, C; Wright, JJ1
Beer, TM; Crawford, ED; Drabkin, HA; Goldman, BH; Lara, PN; Lemmon, D; Mack, PC; Pan, CX; Ryan, CW; Tangen, CM1
Kibble, A; Shumoogam, J1
Buer, J; Hegele, A; Hofmann, R; Jeron, A; Olbert, P; Schrader, AJ1
Adjei, AA; Dai, H; Dai, NT; Flatten, K; Karp, JE; Kaufmann, SH; Kumar, SK; Lee, SH; Loegering, D; Meng, XW; Schneider, P; Smith, BD; Yu, C1
Chen, EX; Dancey, J; Duan, L; Duran, I; Hirte, H; Hotté, SJ; Lathia, C; MacLean, M; Pond, GR; Siu, LL; Turner, S; Walsh, S; Wright, JJ1
Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC1
Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E1
Raspollini, MR1
Blum, HE; Mohr, L; Spangenberg, HC; Thimme, R1
George, D; Medioni, J; Motzer, R; Oudard, S1
Armand, JP; Mir, O; Ropert, S1
Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L1
Robert, C1
Distelrath, A; Hoeffkes, HG; Hofmann, E; Ranze, O1
Duyster, J; Grundler, R; Kancha, RK; Peschel, C1
Fiedler, W; Grünwald, V; Heinzer, H1
Hutson, TE2
Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM1
Tan, W1
Li, M; Srinivas, S1
Kampik, A; Kernt, M; Neubauer, AS; Staehler, M; Stief, C1
Cerniglia, G; Dicker, DT; Diehl, JA; Dorsey, JF; El-Deiry, WS; Flaherty, KT; Gupta, A; Kim, SH; Liu, YY; McDonough, J; Plastaras, JP; Rajendran, RR; Rustgi, AK; Smith, CD1
Almenara, JA; Coe, S; Grant, S; Rosato, RR1
Almhanna, K; Kalmadi, S; Kim, R; Pelley, R1
Alba, E; Medina, MA; Quesada, AR1
Bjelogrlic, SK; Radulovic, S1
Akaza, H; Murai, M; Naito, S; Nakajima, K; Tsukamoto, T1
Furuse, J; Ishii, H; Nakachi, K; Nakajima, K; Shimizu, S; Suzuki, E1
Manchen, B; Wood, LS1
Bukowski, R; Dreicer, R; Elson, P; Garcia, J; Ioachimescu, AG; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L1
Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC1
Thomas, X1
Albanell, J; Bellmunt, J; Climent, MA; González-Larriba, JL; López-Vivanco, G; Urruticoechea, L1
Easson, AM; Eng, FC; Knox, JJ; Szentgyorgyi, E1
Faivre, S; Le Tourneau, C; Raymond, E1
Atkins, MB; Cho, DC; Mier, JW; Panka, DJ1
Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z1
Bukowski, RM; Dreicer, R; Elson, P; Garcia, JA; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L1
Awada, A; Takimoto, CH1
Culine, S; Patard, JJ; Pouessel, D; Verhoest, G1
Burkholder, I; Dittrich, C; Edler, L; Frost, A; Gillessen, S; Hanauske, AR; Hochhaus, A; Morant, R; Mross, K; Scheulen, M; Steinbild, S; Strumberg, D1
Zhu, AX5
Bhojani, N; Hutterer, G; Jeldres, C; Karakiewicz, PI; Oudard, S; Patard, JJ; Patenaude, F; Perrotte, P; Suardi, N1
Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W1
Chang, JW; Chang, YC; Chuang, CK; Hsieh, JJ; Kuo, TT; Lin, WC; Lin, YC; Pang, ST; Yang, CH1
Imarisio, I; Paglino, C; Porta, C2
O'Neil, BH; Venook, AP1
Bukowski, RM; Choueiri, TK; Elson, P; Escudier, B; Negrier, S; Oudard, S; Plantade, A; Ravaud, A; Rini, BI; Zhou, M1
Aragon-Ching, JB; Arlen, PM; Cao, L; Chen, CC; Dahut, WL; Figg, WD; Gulley, JL; Jain, L; Jones, E; Posadas, E; Scripture, C; Steinberg, SM; Venitz, J; Wright, JJ; Yu, Y1
Bonomi, L; Imarisio, I; Paglino, C; Porta, C1
Hiles, JJ; Kolesar, JM1
Keating, GM; Simpson, D1
Andreeff, M; Bornmann, WG; Cortes, J; Evans, RL; Konopleva, M; McCubrey, J; McQueen, T; Ruvolo, VR; Zhang, W1
Claflin, JE; Crean, S; Lahn, M; Linz, H; Noel, JK; Ranganathan, G1
Chu, D; Fillos, T; Lacouture, ME; Wu, S1
Flaherty, KT; Gallagher, ML; Heitjan, DF; O'Dwyer, PJ; Rosen, MA; Schnall, MD; Schwartz, B1
Chen, JJ; Kudelka, A; Lu, J; Wu, S; Zhu, X1
Bui, B; Italiano, A1
Di Fiore, F; Michel, P1
Tuma, RS2
Andreeff, M; Cortes, J; Estrov, Z; Harris, D; Konopleva, M; Ling, X; McQueen, T; Quintás-Cardama, A; Shi, YX; Small, D; Zhang, W1
Collett, LC; Diago, T; Link, TP; Molina, JR; Pulido, JS; Ryan, EH1
Lang, L1
Cohen, AF; Dubois, EA; Osanto, S; van Bronswijk, H1
Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Yoshida, J1
Demetri, GD; George, S; Humphreys, BD; Maki, RG; Morgan, JA; Patel, TV; Quigley, M1
Ehninger, G; Illmer, T1
Giordano, S; Petrelli, A1
Annunziata, CM; Azad, NS; Chow, C; Kohn, EC; Kotz, HL; Minasian, L; Premkumar, A; Steinberg, SM1
Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA1
Bruix, J; Llovet, JM4
Dahut, W; Figg, WD; Gardner, ER; Jain, L; Venitz, J1
Brauer, KM; Brossart, P; Hilf, N; Hipp, MM; Radsak, MP; Singh-Jasuja, H; Walter, S; Weinschenk, T; Werth, D1
Angelotti, U; Antonaci, S; Fransvea, E; Giannelli, G1
Allison, RR; Cavalieri, R; Finley, J; Gay, HA; Quan, WD1
Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW1
Stewart, DJ1
Chow, S; Goolsby, C; Hedley, DW; Shankey, TV1
Hersey, P; Hong, A; Moncrieff, M; Shannon, K; Thompson, J1
Gu, YH; Qu, BQ; Song, R; Xu, Q; Zhao, W1
Barbare, JC; Boige, V; Rosmorduc, O1
Autier, J; Mateus, C; Robert, C; Spatz, A; Wechsler, J1
Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V1
Burgin, S; Heidary, N; Naik, H1
Bellersen, L1
Fenning, R; Gudena, V; Kizziah, M; Montero, AJ; Post, G; Verma, N1
Burris, H; Rocha-Lima, C1
de Mulder, PH; Gietema, JA; Groenewegen, G; Haanen, JB; Jansen, RL; Kruit, WH; Mulders, PF; Osanto, S; Richel, DJ; Sleijfer, S; van den Eertwegh, AJ; Voest, EE1
El-Deiry, WS; Kim, SH; Ricci, MS1
Berthold, DR; Chin, S; Knox, JJ; Moore, MJ; Riechelmann, RP; Tannock, IF; Wang, L1
Godley, P; Rathmell, WK; Rini, BI1
Athar, U; Gentile, TC1
Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B1
Ambrosini, G; Cheema, HS; Sambol, EB; Schwartz, GK; Seelman, S; Singer, S; Teed, A1
Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E1
Chintala, L; El Naggar, AK; Gagel, R; Hong, D; Kurzrock, R; Wright, J; Ye, L1
Agarwala, S; Beeram, M; Cranmer, L; Frenette, G; Gonzalez, R; Hersh, E; Hodi, FS; Jakub, JW; Kirkwood, J; Lewis, K; Linette, GP; McDermott, DF; Patel, K; Puzanov, I; Richards, J; Sosman, JA; Tarantolo, S; White, JM; Xia, C1
Peters, NA; Richel, DJ; Stalpers, LJ; Verhoeff, JJ1
Lee, CB; Socinski, MA1
Araki, K; Ebi, H; Kawada, K; Kim, YI; Kitagawa, K; Minami, H; Mukai, H; Nakajima, H; Nakajima, K; Tahara, M1
Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A1
Buhl, R; Fischer, B1
Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG1
Cui, YZ; Luo, RC; Wu, J; Zhang, H1
Sherman, SI2
Gettinger, S1
Bissonnette, M; Cerda, S; Chumsangsri, A; Delgado, JS; Dougherty, U; Fichera, A; Lichtenstein, L; Mustafi, R; Yee, J1
Kester, M; Robertson, GP; Smith, CD; Tran, MA1
Blumenschein, G1
Adjei, AA1
Heinemann, V; Stemmler, HJ1
Brose, MS; Flaherty, KT; Gupta-Abramson, V; Loevner, LA; Mandel, SJ; Nellore, A; O'Dwyer, PJ; Puttaswamy, K; Ransone, K; Redlinger, M; Troxel, AB1
Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM1
Chung, CY; Wu, SS; Yen, HH1
Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ1
Chanco Turner, ML; Chevreau, C; Fojo, T; Hornyak, TJ; Kong, HH; Sibaud, V1
Del Conte, G; Guibal, A; Rüegg, C; Sessa, C1
Lountzis, NI; Maroon, MS1
Atkins, MB; Goldberg, SN; Kruskal, JB; Rahmanuddin, S; Raptopoulos, VD; Sabir, A; Schor-Bardach, R; Signoretti, S; Wilcox, CJ1
Clark, M1
Bruns, I; Czibere, A; Dienst, A; Fenk, R; Haas, R; Kobbe, G; Reinecke, P; Safaian, NN1
Brouwers, AH; Hospers, GA; Mulder, NH; Siemerink, EJ1
Andrea, A; Di Silverio, F; Panebianco, V; Parente, U; Passariello, R; Sciarra, A; Von Heland, M1
Hakenberg, OW1
Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F1
Kuczyk, MA; Merseburger, AS1
Figlin, R; Moldawer, NP1
Bierer, S; Bolenz, C; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C1
Egberts, F; Hauschild, A; Kahler, KC; Livingstone, E1
Bart, S; Billemont, B; Bitker, MO; Izzedine, H; Rixe, O; Sultan, V; Thibault, F1
Bouffard, D; Joncas, V; Krasny, M; Provost, N; Sammour, R1
Gakis, G; Kramer, MW; Kruck, S; Kuczyk, MA; Merseburger, AS; Stenzl, A1
Bauer, S; Bode, B; Knuth, A; Liewen, H; Renner, C; Samaras, P; Stenner, F; Tchinda, J; Weber, A; Zweifel, M1
Pár, A; Pár, G1
Bukowski, RM; Choueiri, TK; Cotta, C; Dreicer, R; Elson, P; Garcia, J; Khasawneh, MK; Mekhail, T; Rini, BI; Unnithan, J; Wood, L1
Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M1
Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J1
Ardavanis, A; Doufexis, D; Kountourakis, P; Rigatos, G1
Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S1
Roberts, LR1
Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y1
Chen, EX; Ng, R1
Cannistra, SA1
Annunziata, CM; Azad, NS; Cao, L; Chen, HX; Chow, C; Figg, WD; Jain, L; Kohn, EC; Kotz, HL; Kwitkowski, VE; McNally, D; Minasian, L; Posadas, EM; Premkumar, A; Sarosy, G; Steinberg, SM; Wright, JJ1
Rini, BI; Vakkalanka, BK1
Albertini, MR; Brose, MS; Elder, D; Flaherty, KT; Hingorani, SR; Jacobetz, MA; Lathia, C; Liu, G; O'Dwyer, PJ; Petrenciuc, O; Redlinger, M; Schiller, J; Schuchter, LM; Tuveson, DA; Van Belle, PA; Weber, BL; Xia, C1
Ahn, SH; Clayman, GL; Henderson, YC; Kang, Y1
Chang, CJ; Chen, YJ; Ding, Q; Hsu, JM; Hung, MC; Huo, L; Kuo, HP; Lai, CC; Lee, DF; Li, LY; Liao, Y; Lin, CY; Tsai, CH; Tsai, FJ; Wei, Y; Xia, W; Yang, JY; Yang, Y; Yen, CJ1
Agulnik, M; Wang, LX1
Rübben, H1
Amin, C; Calvo, BF; Godley, PA; Pruthi, RS; Rathmell, WK; Wallen, E1
Culine, S; Patard, JJ; Pouessel, D2
Checcaglini, F; Colloca, G; Venturino, A1
Chun, FK; Eichelberg, C; Heinzer, H; Heuer, R; Hinrichs, K; Huland, H; Zacharias, M1
Awada, A; D'Hondt, V; Dal Lago, L1
Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J1
O'Dowd, A1
Bierer, S; Hertle, L; Nitschmann, S1
Bensalah, K; Cornu, JN; Oudard, S; Patard, JJ; Rouprêt, M1
Amaravadi, R; Fecher, LA; Schuchter, LM1
Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R1
Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L1
Bar-Eli, M; Melnikova, VO1
Bierer, S; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C1
Rey, PM; Villavicencio, H1
Billemont, B; Boudou-Rouquette, P; Goldwasser, F; Loriot, Y; Ropert, S1
Palmer, D1
Moch, H1
Curiel, DT; Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Lee, R; Martin, AP; Mitchell, C; Park, MA; Rahmani, M; Roberts, JD; Yacoub, A; Zhang, G1
Alexandrescu, DT; Anderson, RT; Atkins, MB; Dutcher, JP; Garbe, C; Guitart, J; Hauschild, A; Kong, HH; Lacouture, ME; Puzanov, I; Robert, C; Wood, L; Wu, S1
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I1
Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Hylemon, PB; Liu, X; Martin, AP; Mitchell, C; Norris, J; Park, MA; Rahmani, M; Ryan, K; Spiegel, S; Zhang, G1
Elder, DE; Flaherty, KT; Herlyn, M; Letrero, R; Nathanson, KL; Nguyen, TK; Smalley, KS; Van Belle, P; Villanueva, J; Wang, Y; Xiao, M1
Lohse, AW; Schramm, C; Schuch, G1
Fujioka, T; Obara, W1
Kakehi, Y1
Aguilar-Ponce, JL; Buzaid, AC; de la Garza, J; Fernandes, Gdos S; Kann, AG; Maluf, FC1
Bukowski, RM; Vakkalanka, BK1
Chaparro, M; González Moreno, L; Medina, J; Moreno-Otero, R; Trapero-Marugán, M1
Chen, FS; Cui, YZ; Luo, RC; Wu, J; Zhang, H1
Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N1
Hahn, OM; Karczmar, G; Karrison, T; Kistner, E; Manchen, E; Medved, M; Mitchell, M; Ratain, MJ; Stadler, WM; Yang, C1
Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K1
Chowdhury, S; Gore, ME; Larkin, JM1
Ferrière, JM; Grenier, N; Kilkoski, F; Ravaud, A; Sire, M; Wallerand, H1
Gish, R; Marrero, JB; Tong, MJ1
Figlin, RA; Hutson, TE; Kuhn, JG; Motzer, RJ1
Lenihan, DJ1
Bojic, A; Bojic, M; Hejna, M; Ruhsam, M; Schmidinger, H; Schmidinger, M; Schukro, C; Vogl, UM; Zielinski, CC1
Bissonnette, M; Chumsangsri, A; Cohen, EE; Delgado, J; Keswani, RN; Mustafi, R1
Anderson, S; Bukowski, R; Cihon, F; Eisen, T; Escudier, B; Gravis, G; Heinzer, H; Middleton, R; Oudard, S; Shah, S; Szczylik, C1
Brautigan, DL; McSkimming, CC; Molhoek, KR; Olson, WC; Slingluff, CL1
Döme, B; Magyar, M1
Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH1
Chen, Q; Huang, WX; Li, XF; Ye, YB1
Adnane, L; Llovet, JM; Lynch, M; Newell, P; Villanueva, A; Wilhelm, SM1
Daher, IN; Yeh, ET1
Bekaii-Saab, T; Bloomston, MA; Patel, T; So, BJ1
Bennani-Lahlou, M; Escudier, B; Massard, C; Mateus, C; Robert, C; Soria, JC; Spatz, A1
Hwu, P; Kim, K; Lazar, AJ; Quintás-Cardama, A; Ross, M; Woodman, SE1
Bamias, A1
Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J1
Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N1
Evans, TR; Roxburgh, P1
Cicek, D; Dagli, FA; Haligur, BD; Kandi, B; Karaoglu, A1
Kroog, GS; Motzer, RJ1
Arena, S; Bardelli, A; De Dosso, S; Di Nicolantonio, F; Frattini, M; Martini, M; Mazzucchelli, L; Molinari, F; Saletti, P; Sartore-Bianchi, A; Siena, S1
Buettner, R; Chen, MY; Hedvat, M; Jove, R; Kirschbaum, M; Kowolik, CM; Liang, W; Mepani, N; Mirosevich, J; Nam, S; Tye, G; Van Meter, TE; Yang, F1
Bauer, C; Przybilla, B; Ruëff, F1
Hakenberg, OW; Klebingat, KJ; Protzel, C; Ruppin, S1
Greten, TF; Korangy, F; Malek, NP; Manns, MP1
Azizi, M; Bobrie, G; Bouché, O; Deray, G; des Guetz, G; Halimi, JM; Lecomte, T; Levy, B; Mourad, JJ; Nochy, D; Oudard, S; Rieu, P; Sahali, D1
Escudier, B; Mateus, C; Robert, C; Spatz, A; Wechsler, J1
Byeon, SH; Chung, EJ; Koh, HJ; Lee, JH; Lim, HJ; Yoo, S1
Kelley, RK; Venook, AP1
Chan, P; Epstein, R; Poon, RT; Yau, T2
Carroll, S; Dale, P; Knox, J; Maroun, J; McDonald, H; Muszbek, N; Shah, S1
Büchler, MW; Glimm, H; Heining, C; Hoffmann, K; Jaeger, D; Radeleff, B; Richter, G; Schemmer, P; Schenkel, I; Schirrmacher, P; Schmidt, J; von Kalle, C; Zahlten-Hinguranage, A1
Iwata, C; Kano, MR; Kataoka, K; Komuta, Y; Miyazono, K; Morishita, Y; Oka, M; Ouchi, Y; Shirai, YT1
Aburatani, H; Hamakubo, T; Ishiguro, T; Kinoshita, Y; Kodama, T; Miyazaki, Y; Nakano, K; Ohizumi, I; Sugimoto, M; Sugo, I; Tsuchiya, M; Tsunoda, H; Yamada-Okabe, H1
Fitch, TR; Flynn, PJ; Hillman, DW; Lingle, WL; Moreno-Aspitia, A; Morton, RF; Perez, EA; Rowland, KM; Wiesenfeld, M1
Bergh, J1
Dham, A; Dudek, AZ; Lindgren, BR; Szczylik, C; Zolnierek, J1
Paggi, S; Spinzi, G1
Poust, J1
Andreef, M; Cortes, J; Kantarjian, H; Mori, S; Ravandi, F; Zhang, W1
Aydin, H; Bukowski, RM; Elson, P; Garcia, JA; George, S; Golshayan, AR; Heng, DY; Mekhail, TM; Rini, BI; Wood, LS; Zhou, M1
Copur, MS1
Palmer, DH1
Chen, CK; Chen, YJ; Hsieh, CH; Jeng, KS; Lin, CC; Lin, CP; Liu, CY; Shueng, PW; Tai, HC; Wang, CH1
Borrás-Blasco, J; Casterá, ME; Galán Brotons, A; Rosique-Robles, JD; Vicent Verge, JM1
Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM1
Foreman, B; Hicks, MD; LaRocca, RV; Mull, L1
Burock, K; Chen, Z; Cheng, AL; Feng, J; Guan, Z; Kang, YK; Kim, JS; Liang, H; Liu, J; Luo, R; Pan, H; Qin, S; Sun, Y; Tak, WY; Tsao, CJ; Voliotis, D; Wang, J; Xu, J; Yang, TS; Ye, S; Zou, J1
Bellot, P; Llanos, L; Pérez-Mateo, M; Such, J; Zapater, P1
Adamietz, IA; Brendel, E; Christensen, O; Grubert, M; Hilger, RA; Kupsch, P; Ludwig, M; Richly, H; Schultheis, B; Strumberg, D1
Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T1
Billingham, L; Johnson, P1
Kung, EF; Maddox, JS; Petronic-Rosic, V; Sethi, A1
Beijnen, JH; Lagas, JS; Schellens, JH; Schinkel, AH; Sparidans, RW; Vlaming, ML1
Masumori, N; Ohmoto, Y; Tochizawa, S; Tsukamoto, T; Yabuuchi, Y; Yanai, Y1
Bosch, J; Fernandez, M; Garcia-Pras, E; Mejias, M; Miquel, R; Tiani, C1
Chow, PK; Chung, A; Huynh, H; Lam, IW; Lee, JW; Lew, GB; Ngo, VC; Ong, HS; Soo, KC1
Booth, B; Chattopadhyay, S; Farrell, AT; Justice, R; Kane, RC; Madabushi, R; Pazdur, R; Sridhara, R1
Abou-Alfa, GK3
Graziadei, I; Königsberg, R; Kornek, G; Maieron, A; Peck-Radosavljevic, M; Pinter, M; Plank, C; Sieghart, W; Vogel, W; Weissmann, A1
Clark, JW; Zhu, AX1
Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Draper, D; Figg, WD; Gulley, JL; Jain, L; Jones, E; Steinberg, SM; Venitz, J; Wright, JJ1
Greten, TF; Malek, N; Manns, MP1
Befeler, AS; Gogia, S1
Berger, W; Lamm, W; Micksche, M; Pichelmeyer, O; Pirker, C; Schmidinger, M; Vogl, UM; Zielinski, CC1
Bukowski, RM; Cella, D; Demkow, T; Escudier, B; Hutson, TE; Laferriere, N; Negrier, S; Rolland, F; Scheuring, UJ; Shah, S; Staehler, M; Szczylik, C1
Mills, EJ; O'Regan, C; Perri, D; Rachlis, B; Thabane, L1
Bergmann, L; Jäger, E; Jakse, G; Keilholz, U; Miller, K; Wirth, M1
Alken, P; Bolenz, C; Häcker, A; Herrmann, E; Honeck, P; Michel, MS; Schöppler, G; Trojan, L1
Schneeberger, A; Tatzreiter, G; Udvardi, A; Volc-Platzer, B; Wolber, C1
Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C1
Becker, JC; Hofmeister, V; Houben, R; Noelke, C; Schrama, D; Voigt, H1
Antonucci, M; Cabibbo, G; Craxì, A; Latteri, F1
Hill, KL; Lipson, AC; Sheehan, JM1
Eberhardt, W; Grubert, M; Hense, J; Hilger, RA; Kredtke, S; Richly, H; Scheulen, ME; Schuler, M; Thyssen, D1
Boucher, E; Bruix, J; Forner, A; Reig, M1
Ansari, J; Bhatt, RI; Chaudhri, S; Fatima, A; James, ND; Wallace, M1
Apostolidis, L; Horstmann, S; Jäger, D; Kahlert, C; Lordick, F; Siegmund, A; Thom, R1
Arbiser, JL1
Moretti, L; Salemi, S; Scapozza, L; Schmid, I; Simon, D; Simon, HU; Yousefi, S1
Basso, U; Bertuzzi, A; Brunello, A; Santoro, A1
Beullens, E; Cools, J; Lierman, E; Marynen, P; Michaux, L; Pierre, P; Vandenberghe, P1
Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM1
Choo, SP; Chow, P; Chung, A; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Soo, KC; Thng, CH1
Keating, GM; Santoro, A1
Aragon-Ching, JB; Azad, NS; Dahut, WL; Figg, WD; Gutierrez, M; Jain, L; Kohn, EC; Kong, HH; Steinberg, SM; Turner, ML1
Ayuso, C; Bru, C; Bruix, J; Buti, M; de la Mata, M; Forner, A; Isabel Real, M; Llovet, JM; Martí-Bonmatí, L; Robles, R; Sangro, B; Sastre, J; Tabernero, J; Varela, M1
Abou-Alfa, G; Dees, EC; Desai, A; Edelman, MJ; Fakih, MG; Frank, RC; Hohl, RJ; Hollis, DR; Hwang, J; Kennedy, EB; Lewis, LD; Millard, F; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA1
Arbogast, D; Collamore, M; Grever, M; Hall, NC; King, M; Kloos, RT; Knopp, MV; Liang, J; Ringel, MD; Rittenberry, J; Saji, M; Shah, MH; Stevens, R; Vasko, VV; Wakely, PE; Wei, L; Wright, JJ1
Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A1
Bellmunt, J; Calvo, E; Castellano, D; Climent, MA; Esteban, E; García del Muro, X; González-Larriba, JL; Maroto, P; Trigo, JM1
Choueiri, TK; Chowdhury, S1
Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S1
Lee, WM; Tsai, JH1
Alfaro, C; Dubrot, J; Erro, L; Gonzalez, A; Grande-Pulido, E; Gurpide, A; Hervas-Stubbs, S; Lopez-Picazo, JM; Melero, I; Palazon, A; Perez-Gracia, JL; Solano, S; Suarez, N1
Benichou, AS; Billemont, B; Blanchet, B; Chhun, S; Cramard, J; Dauphin, A; Goldwasser, F; Harcouet, L; Ropert, S; Tod, M1
Amadori, D; Arienti, C; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W1
Mizutani, Y1
Dreyer, C; Faivre, S; Raymond, E1
Di Micoli, A; Frigerio, M; Santi, V; Trevisani, F1
Bhat-Nakshatri, P; Maluccio, MA; Nakshatri, H; Saxena, R; Sheng, H; Skill, NJ; Wu, JM; Yu, M1
El-Serag, HB; Hussain, K1
Eskens, FA; Verheul, HM; Verhoef, C; Witjes, CD1
Bakken, GA; Yu, N1
Aberg, E; Duyster, J; Engh, RA; Peschel, C; Sänger, J; von Bubnoff, N1
Rosmorduc, O1
Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K1
Jarkowski, A; Wong, MK1
Bruix, J; Shah, VH1
Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F2
Oseini, AM; Roberts, LR1
Elfiky, AA; Rosenberg, JE1
Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T1
Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B1
Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Stark, C; Trebicka, J1
Carrie, C; Diaz, O; Martin, E; Mazeron, R1
Cao, MR; Li, AM; Lü, CW; Luo, RC; Su, N; Wei, L; Yan, X; Zheng, DY1
Aburatani, H; Hirakawa, K; Iwata, C; Johansson, E; Kano, MR; Kiyono, K; Komuro, A; Matsumoto, Y; Miyazono, K; Miyoshi, H; Morishita, Y; Shirai, YT; Suzuki, HI; Watanabe, A; Yashiro, M1
Armand, JP; Domont, J; Lassau, N; Le Cesne, A; Massard, C; Soria, JC1
Clayman, GL; Herzog, CE; Sherman, SI; Waguespack, SG; Williams, MD1
Goldfarb, M; Hodin, R; Nucera, C; Parangi, S1
Horn, L; Sandler, AB1
Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N1
Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL1
Bregman, H; Marmorstein, R; Meggers, E; Pagano, N; Qin, J; Streu, C; Xie, P1
Maitland, ML; Snider, KL1
Chen, MH1
Ball, SA; Plowman, PN; Reznek, R; Richards, TM1
Jonkers, IJAM; van Buren, M1
Cheung, YK1
Chiang, D; Llovet, JM; Mínguez, B; Tovar, V; Villanueva, A1
Burchert, A; Chaturvedi, A; Eilers, M; Enghofer, E; Metzelder, S; Neubauer, A; Teichler, S; Wang, Y; Wanzel, M; Wollmer, E1
Ye, SL2
Barreiros, AP; Galle, PR; Krupp, M; Maass, T; Strand, S; Teufel, A; Thieringer, F; Wang, C; Wörns, MA1
Ravaud, A; Sire, M1
Secasan, CC1
De Roover, A; Delwaide, J; Detry, O; Honoré, P; Lamproye, A; Meunier, P; Polus, M; Van Daele, D1
Billemont, B; Kelly, RJ; Rixe, O1
Jansen, PL; Kuiken, SD; Richel, DJ; van Delden, OM1
Ferraris, E; Imarisio, I; Paglino, C; Porta, C1
Drummond, M; Evans, B; Karakiewicz, P; LeLorier, J; MacLeod, S; Martin, D; Tugwell, P1
Balleyguier, C; Celier, C; Escudier, B; Gautier, J; Medioni, J; Negrier, S; Oudard, S; Ravaud, A; Sablin, MP1
Molina, AM; Motzer, RJ1
Antonescu, CR; Blachère, NE; Brockstein, B; Cooney, MM; D'Adamo, DR; Edgar, MA; Elias, AD; Hensley, ML; Keohan, ML; Kraft, AS; Livingston, MB; Maki, RG; Mita, MM; Qin, LX; Saulle, M; Schuetze, SM; Schwartz, GK; Schwartz, LH; Takimoto, CH; Undevia, SD1
Anderson, S; Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Gore, M; Hofilena, G; Hutson, TE; Lathia, C; Negrier, S; Oudard, S; Pena, C; Rolland, F; Shan, M; Stadler, WM; Staehler, M; Szczylik, C1
Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ1
Cui, YZ; Huang, N; Li, AM; Lü, CW; Luo, RC; Wei, L; Yang, L; Zheng, DY; Zheng, H1
Bisagni, G; Boni, C; Cavazza, A; Gardini, G; Rossi, G; Sartori, G1
Dhomen, N; Marais, R1
Alsop, DC; Atkins, MB; Goldberg, SN; Lenkinski, RE; Marquis, RP; Pedrosa, I; Regan, M; Schor-Bardach, R; Signoretti, S; Solazzo, SA; Wang, X1
Dent, P; Graf, M; Grant, S; Houghton, PJ; Mitchell, C; Park, MA; Rahmani, M; Voelkel-Johnson, C; Walker, T; Yacoub, A1
Dent, P; Grant, S; Häussinger, D; Martin, AP; Mitchell, C; Park, MA; Rahmani, M; Reinehr, R; Thorburn, A; Walker, T1
Shibuya, M1
English, BC; Figg, WD; Price, DK1
Feito Rodríguez, M; Feltes, RA; González-Beato, MJ1
Rimassa, L; Santoro, A2
Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B1
Brower, V2
Berchem, G; Dewilde, S; Mahassen, P1
Bilaç, C; Ermertcan, AT; Kayhan, TC; Müezzinoğlu, T; Oztürkcan, S; Temeltaş, G; Temiz, P1
Boijsen, M; Lundstam, S; Lyrdal, D; Stierner, U; Suurküla, M1
Alasker, A; Guevremont, C; Karakiewicz, PI1
Abel, EJ; Wood, CG1
Cortés-Funes, H1
DiPaola, R; Dreicer, R; Eleff, M; Li, H; Roth, BJ; Stein, M; Wilding, G1
Burkemper, NM; Chappell, JA; Semchyshyn, N1
Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ1
Akaza, H; Miyanaga, N1
Crowley, J; Leblanc, M; Rankin, C1
Brüning, A; Burger, P; Burges, A; Friese, K; Gingelmaier, A; Vogel, M1
Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC1
Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C1
Dai, Z; Fan, J; Yu, L; Zhou, J1
Braun, M; Buness, A; Conrad, J; Falk, CS; Krapfenbauer, U; Kuner, R; Lund, P; Mang-Fatehi, S; Poustka, A; Ruschhaupt, M; Schäfer, R; Sers, C; Stelniec, I; Sueltmann, H1
Frieling, T; Heise, J; Wassilew, SW1
Getlik, M; Grütter, C; Pawar, V; Rabiller, M; Rauh, D; Simard, JR; Wulfert, S1
Barbaro, B; Gasbarrini, A; Lauritano, EC; Novi, M; Piscaglia, AC; Pompili, M; Zocco, MA1
Mendizabal, M; Reddy, KR1
Chen, HX; Cleck, JN1
Abe, H; Fukabori, Y; Furuya, N; Kamai, T; Tokui, N; Yoshida, K1
Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J1
Aractingi, S; Arnault, JP; Escudier, B; Grange, JD; Malka, D; Mateus, C; Poirier-Colame, V; Robert, C; Sibaud, V; Soria, JC; Spatz, A; Tomasic, G; Wechsler, J1
Kong, HH; Turner, ML1
Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M1
Aragon-Ching, JB; Dahut, WL2
Dai, B; Dong, B; Huang, Y; Lu, JJ; Shen, Y; Yao, X; Ye, D; Zhang, H; Zhang, S; Zhu, Y1
Awasthi, S; Rao Lelsani, PC; Sahu, M; Sehrawat, A; Singhal, P; Singhal, SS; Vatsyayan, R; Yadav, S1
Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L1
Guo, W; Ji, T; Li, DS; Li, X; Peng, CL; Qu, HY; Ren, T; Tang, S; Tang, XD; Yan, TQ; Yang, Y1
Dudley, AC; Klagsbrun, M1
Qin, LX; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY1
Fukuoka, M; Hatashita, E; Nakagawa, K; Okamoto, I; Takezawa, K; Yamada, Y; Yonesaka, K1
Walker, JG1
Balis, FM; Kim, A; Widemann, BC1
Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Ficorella, C; Giannarini, G; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Pignata, S; Rescigno, P; Rizzo, M; Tudini, M1
Blumenschein, GR; Cihon, F; Cupit, L; Fossella, F; Gatzemeier, U; O'Leary, J; Reck, M; Stewart, DJ1
Dutcher, JP; Hudes, G; Kim, S; Rini, BI; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC; Wilding, G; Wood, L1
Carlo-Stella, C; Giacomini, A; Gianni, AM; Lavazza, C; Righi, M; Sia, D1
Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP1
Haley, H; Hamza, S; Skelton, HG; Smith, KJ1
Flaherty, KT; Smalley, KS1
Li, M; Li, N; Wu, T; Zhang, Y1
Egerbacher, M; Gerner, W; Heiduschka, G; Skalicky, M; Thalhammer, JG; Tonar, Z; Walter, I; Wolfesberger, B1
Alsinet, C; Bruix, J; Cabellos, L; Chiang, DY; Deniz, K; Fiel, MI; Friedman, SL; Hoshida, Y; Lim, KH; Llovet, JM; Mazzaferro, V; Melgar-Lesmes, P; Minguez, B; Newell, P; Peix, J; Roayaie, S; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tovar, V; Villanueva, A; Yea, S1
Samlowski, W; Vogelzang, NJ; Weissman, A1
Hammock, BD; Hwang, SH; Liu, JY; Morisseau, C; Park, SH; Weiss, RH1
Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R1
Gopal, LD; Heller, T; Kohn, EC; von Rosenvinge, EC; Yao, MD1
Heilbrun, L; Parsa, V; Sethi, A; Smith, D; Vaishampayan, U1
Benghiat, H; Collins, S; James, N; Karina, M; Oldroyd, A; Parry, H; Pascoe, J; Porfiri, E; Ray, D; Zachariah, A1
Shen, H; Wang, D; Wang, Y; Zhang, Z; Zhou, X1
Cella, D2
Cascinu, S1
Jaworsky, C; Kish, LS; Kwon, EJ1
Daniele, B; Di Maio, M; Perrone, F1
Baumert, TF; Blum, HE; Hildt, E; Himmelsbach, K; Ludwig, L; Sauter, D1
Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J1
Dudek, AZ; Franklin, MJ; Spector, E; Truskinovsky, AM1
Pappo, A; Paulino, AC1
Lee, SH; Paietta, E; Racevskis, J; Wiernik, PH1
Subbiah, V; Wolff, JE1
Chong, LW; Chow, P; Chung, A; Huynh, H; Koong, HN; Lam, WL; Lee, J; Lee, SS; Lew, GB; Ngo, VC; Ong, HS; Ong, WJ; Soo, KC; Thng, CH; Yang, S1
Balabanov, S; Benten, D; Braig, M; Brummendorf, TH; Gontarewicz, A; Keller, G; Lohse, AW; Moll, J; Quaas, A; Schrader, J; Wege, H1
Angermayr, B; Gangl, A; Mitterhauser, M; Peck-Radosavljevic, M; Reiberger, T; Rohr-Udilova, N; Schwabl, P1
Bai, S; Datta, J; Ghoshal, K; Hsu, SH; Kumar, P; Kutay, H; Nasser, MW; Nuovo, G; Wang, B; Yadav, A1
Gelderblom, H; Guchelaar, HJ; van Erp, NP1
Ivy, SP; Kaufman, BM; Wick, JY1
Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR1
Cheng, AL; Fan, HH; Hsu, C; Liang, JD; Liou, JY; Lu, YS; Ou, DL; Shen, YC; Wang, DS; Yu, SL1
Bergamini, L; Bianchi, G; Gianni, L; Laferriere, N; Lathia, C; Loibl, S; Peña, C; Raab, G; Salvagni, S; Siena, S; Zamagni, C1
Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB1
Anderson, S; Bellmunt, J; Bukowski, R; Cihon, F; Escudier, B; Jäger, E; Lewis, J; McDermott, D; Moore, M; Negrier, S; Porta, C1
Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S1
Huang, WS; Yang, CH1
Choueiri, TK; Je, Y; Schutz, FA1
Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S1
Bitzer, M; Claussen, CD; Horger, M; Lauer, U; Martirosian, P; Schraml, C; Schwenzer, NF1
Chiou, JF; Jen, YM; Liu, TZ; Shiau, CY; Tai, CJ; Wang, YH1
Corssmit, EP; Gelderblom, H; Heemstra, KA; Hoftijzer, H; Huijberts, M; Kapiteijn, E; Morreau, H; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Weijers, K1
Black, HR; Elliott, WJ; Karrison, T; Kasza, KE; Maitland, ML; Moshier, K; Ratain, MJ; Sit, L; Stadler, WM; Undevia, SD1
Baker, SD; Chen, Z; Franke, R; Hu, S; Orwick, S; Rudek, MA; Sparreboom, A; Zhao, M1
Botella-Estrada, R; Echeverría, B; Guillén, C; Llombart, B1
Banik, NL; Karmakar, S; Ray, SK; Roy Choudhury, S1
Fujino, H; Kawashima, T; Kiuchi, Y; Matsumoto, I; Matsuzawa, Y; Murayama, T; Nakamura, H; Toyomura, K1
Song, IH1
Atkins, MB; Humphreys, BD1
Garnock-Jones, KP; Keating, GM1
Bruera, G; Giordano, AV; Lapecorella, M; Lucchesi, A; Mariani, G; Napolitano, M; Ricevuto, E; Tudini, M1
Printz, C1
Gil, R; Grueso, J; Hernandez-Losa, J; López-Fauqued, M; Moliné, T; Pujol, A; Recio, JA1
Blechacz, BR; Bronk, SF; Gores, GJ; Sirica, AE; Smoot, RL; Werneburg, NW1
Atkins, MB; Bukowski, RM; Cheng, T; Chi, KN; Choueiri, TK; Eigl, BJ; Golshayan, AR; Heng, DY; Knox, JJ; Kollmannsberger, C; McDermott, DF; North, S; Oh, WK; Regan, MM; Rini, BI; Ruether, JD; Sahi, C; Venner, P; Warren, MA; Xie, W1
Kuczyk, MA; Merseburger, AS; Simon, A; Waalkes, S1
An, J; Chang, YJ; Chiou, JF; Huang, MT; Liu, TZ; Tai, CJ; Wang, YH; Wei, PL; Wu, CH1
Crouthamel, MC; Gontarek, RR; King, AG; Kumar, R; Levin, RA; Rominger, DH; Tummino, PJ1
Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J1
Hasegawa, Y; Matsubara, A; Mita, K; Ohdan, H1
Wilkes, GM1
Andreu, J; Carles, J; Serrano, C; Suárez, C1
Boere, IA; Hamberg, P; Sleijfer, S1
Coupe, P; Fournier, P; Gautier, S; Gerard, R; Marks, AB1
Aparicio, A; Ashe, RG; Corn, P; Johnson, MM; Jonasch, E; Ng, C; Pagliaro, LC; Tamboli, P; Tannir, NM; Warneke, CL; Wright, JJ1
Angeli, P; Burra, P; Cillo, U; Farinati, F; Lonardi, S; Pastorelli, D; Vitale, A; Volk, ML1
Figueiredo, J; Gonçalves, J; Meireles, AM; Preto, A; Rebocho, AP; Rocha, AS; Seca, H; Seruca, R; Soares, P; Sobrinho-Simões, M; Vasconcelos, HM1
Dumortier, J; Guillet, M; Lombard-Bohas, C; Scoazec, JY; Vial, T; Walter, T1
Goldschmeding, R; Overkleeft, EN; van Reekum, F; Verheul, HM; Voest, EE1
Breau, RH; Leibovich, BC1
Bruix, J; Reig, M1
Chevreau, C; Delord, JP; Sibaud, V1
Akita, H1
Furukawa, M; Hakariya, T; Ide, S; Ishimoto, H; Kohno, S; Nagashima, S; Nakamura, Y; Sawai, T; Soda, H; Takemoto, S; Tomari, S1
Cho, JH; Choi, JH; El-Gamal, MI; Hah, JM; Hong, JH; Jung, MH; Kim, H; Kim, HJ; Lee, SH; Oh, CH; Sim, TB; Yoo, KH1
Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L1
Choo, SP; Chow, P; Chung, A; Goh, BC; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Smith, PD; Soo, KC; Thng, CH; Toh, HC1
Johnston, KW; Walid, MS1
Cheng, CL; Dahm, P; Ou, YC; Wang, SS1
Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC1
Hasinoff, BB; Patel, D1
DeNicola, GM; Karreth, FA; Tuveson, DA; Winter, SP1
Montalvo, RO; Moretti, LV1
Lipworth, AD; Robert, C; Zhu, AX1
Tai, CJ1
Cabrera, R; Nelson, DR1
Cowey, CL; Fielding, JR; Rathmell, WK1
Mayor, S1
Adjei, AA; Haug, JL; Kimlinger, TK; Kumar, S; Rajkumar, SV; Ramakrishnan, V; Timm, M; Wellik, LE; Witzig, TE1
Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S1
Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Staehler, M; Varga, Z1
Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A1
Ajani, JA; Cheng, H; Gusani, NJ; Jiang, Y; Kimchi, ET; Staveley-O'Carroll, KF1
Arima, Y; Fukushima, H; Nakamura, S; Noda, K; Ogawa, H; Oshima, S; Shono, M; Taniguchi, I1
Ahmed, A; Balfe, P; Bicknell, R; Farquhar, MJ; Harris, HJ; Hu, K; Maurel, P; McKeating, JA; Mee, CJ; Ramma, W1
Digue, L; Ravaud, A; Smith, D; Trufflandier, N1
Thompson, JA1
Wood, LS1
Brade, AM; Chung, C; Dawson, LA; Joshua, AM1
Gore, M; Larkin, J1
Saif, MW2
Polliack, A; Tadmor, T; Tallman, MS1
Aglietta, M; Alberghini, M; Bottos, A; Bruno, S; Bussolino, F; Camussi, G; Cavalloni, G; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Migliardi, G; Motta, M; Picci, P; Pignochino, Y; Tapparo, M; Torchio, B1
Dupre-Goetghebeur, D; Jantzem, H; Merrer, J; Spindler, P1
Baessler, T; Kampa, KM; Krusch, M; Mayer, F; Salih, HR; Salih, J; Schlicke, M1
Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A1
Archer, SL; Barst, RJ; Bond, L; Coslet, S; Gomberg-Maitland, M; Lacouture, ME; Maitland, ML; Perrino, TJ; Ratain, MJ; Sugeng, L1
Broxterman, HJ; de Haas, RR; Lind, JS; Smit, EF; van Hinsbergh, VW; Verheul, HM; Vroling, L1
Aksoy, S; Altundag, K; Arslan, C; Dede, DS; Dogan, E1
Dudek, AZ; Kamada, P1
Amadori, D; Arienti, C; Brigliadori, G; Fabbri, F; Leonetti, C; Passardi, A; Scarsella, M; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W; Zupi, G1
Cheng, P; Ding, X; Gao, H; Liu, H; Su, X; Wang, D; Wei, D; Zhang, T1
Cupit, L; Flaherty, KT; Judson, IR; Kaye, SB; O'Dwyer, PJ; Pacey, S; Ratain, MJ; Rowinsky, EK; Xia, C1
Finn, RS; Saab, S; Yeganeh, M1
Wang, ZY1
Liu, ZZ; Piao, Y; Xie, XD1
Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, ZJ1
Autorino, R; Di Lorenzo, G1
Green, C; Hoyle, M; Liu, Z; Moxham, T; Stein, K; Thompson Coon, J; Welch, K1
Bitzer, M; Claussen, CD; Hartmann, JT; Horger, M; Maksimovic, O; Pintoffl, J; Schraml, C1
Lieber, ML; Shah, SN; Smith, AD1
Chernick, MS; Figg, WD; Gardner, ER; Jain, L; Kong, HH1
Cozzio, A; Donghi, D; Dummer, R1
Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C1
Bruix, J; Navasa, M1
Le Moulec, S; Loriot, Y; Soria, JC1
Aracil, C; Bruix, J; Bustamante, J; de la Mata, M; Del Val, A; Matilla, A; Pascasio, JM; Pascual, S; Reig, M; Rodríguez, M; Turnes, J; Varela, M1
Chao, G; Dicker, DT; El-Deiry, WS; Ferrara, T; Katz, SI; Smith, CD; Wang, W; Zhou, L1
Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B1
Braillon, A1
Bellmunt, J; Dutcher, JP; Escudier, B; Tannir, N1
De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F1
Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B1
Annunziata, CM; Azad, N; Houston, N; Kohn, EC; Kotz, H; Lee, JM; Minasian, L; Sarosy, GA; Squires, J1
Alfano, RW; Bugge, TH; Duesbery, NS; Frankel, AE; Lairmore, TC; Leppla, SH; Liu, S; Mitchell, IC; Nwariaku, F; Ortiz, JM1
Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG1
Forner, A; Llovet, JM; Minguez, B; Reig, M; Villanueva, A1
Büchner, T; Krug, U; Lübbert, M1
Finn, RS4
Dolcet, X; Domingo, M; Eritja, N; Gonzalez-Tallada, FJ; Llobet, D; Matias-Guiu, X; Pallares, J; Santacana, M; Sorolla, A; Yeramian, A1
Hasskarl, J2
Shoemaker, RH1
Altorki, NK; Alvarez, H; Beer, DG; Boonstra, JJ; Chaves, P; Darnton, SJ; Dinjens, WN; Eshleman, JR; Klimstra, DS; Lin, L; Pereira, AD; Ribeiro, C; Roque, L; Schrump, DS; Shimada, Y; Tang, LH; Tilanus, HW; van Dekken, H; van Marion, R1
Adham, M; Boschetti, G; Cassier, P; Dumortier, J; Hervieu, V; Lombard-Bohas, C; Scoazec, JY; Walter, T1
Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B1
Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; George, JR; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C1
Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB; Venner, P1
Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB1
Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L1
Peter, S; Rohde, D; Tong, TQ1
Hayashi, N; Hosui, A; Ishida, H; Kohga, K; Miyagi, T; Takehara, T; Tatsumi, T1
Beijnen, JH; Lagas, JS; Schinkel, AH; Sparidans, RW; van Waterschoot, RA; Wagenaar, E1
Brose, MS; Cohen, MA; Keefe, SM1
Braconi, C; Croce, CM; Gasparini, P; Huang, N; Nuovo, G; Patel, T; Suzuki, T; Taccioli, C; Valeri, N1
Smilde, T; Toonen, F1
Brüning, A; Friese, K; Gingelmaier, A; Rahmeh, M1
Abe, K; Amagai, Y; Hojo, K; Ide, N; Iguchi, M; Kato, A; Matsumoto, M; Shichijo, M; Tanaka, H; Wada, T1
Brandwein, J; Buckstein, R; Crump, M; Eisenhauer, E; Hedley, D; Kamel-Reid, S; Kassis, J; Leber, B; Matthews, J; McIntosh, L; Minden, M; Robinson, S; Seymour, L; Turner, R; Wells, R1
Akriviadis, E; Dedes, I; Drevelegas, A; Papalavrentios, L; Sinakos, E1
Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL1
Dent, P; Fisher, RI; Friedberg, J; Grant, S; Jordan, N; Nguyen, TK1
Yen, Y; Zhou, W1
Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P1
Kurzrock, R; Lenihan, D; Tsimberidou, AM; Vaklavas, C1
Oya, M1
Aitini, E; Cengarle, R; Costa, P; Fibbia, GC; Morandini, B; Perboni, G; Scalzini, A; Tagliani, A1
Chen, Z; Gu, K; Jiang, GL; Li, WT; Liu, J; Liu, LM; Ren, ZG; Xu, ZY; Zhao, JD; Zhou, ZH1
Chung, JY; Hah, JM; Kim, H; Lee, J; Oh, CH; Sim, T; Yoo, KH; Yu, H1
Kurashige, Y; Otani, A; Yoshimura, N1
Minor, DR2
Billemont, B; Boccon-Gibod, L; Bompas, E; Camparo, P; Couturier, J; Dutcher, J; Escudier, B; Guillot, A; Malouf, GG; Molinié, V; Oudard, S; Rixe, O; Rustine, A; Schleiermacher, G; Theodore, C1
Amin, C; Cowey, CL; Crane, J; Fielding, JR; Godley, PA; Grigson, G; Jalkut, M; Kim, WY; Moore, DT; Nance, KV; Nielsen, ME; Pruthi, RS; Rathmell, WK; Wallen, EM; Watkins, C; Whang, YE1
Albanell, J; Bellmunt, J; Calvo, E; Carles, J; Lázaro, M; López, R; Pérez-Gracia, JL; Rubió, J; Trigo, JM; Virizuela, JA1
Gschwend, JE1
Eibl, KH; Haritoglou, C; Kampik, A; Kernt, M; Lackerbauer, CA; Liegl, RG; Neubauer, AS; Rueping, J; Ulbig, MW1
Bose, D; Ellis, LM; Flaherty, KT; Hofstetter, W; Meric-Bernstam, F; Reardon, DA1
Bruix, J; de Lope, CR; Forner, A; Reig, ME1
Fournier, C; Tisman, G1
Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Klar, U; Merk, J; Rolff, J; Sommer, A1
Bierer, S; Herrmann, E; Wülfing, C1
Chevreau, C; Dielenseger, P; Ederhy, S; Goldwasser, F; Grange, JD; Mortier, L; Neidhardt-Berard, ME; Robert, C; Rosmorduc, O; Scotté, F; Seitz, JF1
Blattler, C; Eisen, A; Hotte, SJ; McWhirter, E; Moore, MJ; Mukherjee, SD; Sridhar, SS; Tannock, IF; Wang, L; Winquist, E; Wright, JJ1
Bandarchi-Chamkhaleh, B; Chen, EX; Do, T; Duran, I; Le Tourneau, C; MacLean, M; Mak, TW; Metser, U; Nayyar, R; Pham, NA; Quintela-Fandino, M; Siu, LL; Tsao, M; Tusche, MW; Wang, L; Wright, JJ1
Huang, S; Sinicrope, FA1
Bertsch, A; Henneges, C; Jung, S; Kohlbacher, O; Nahnsen, S; Nordheim, A; Pfeifer, N; Zerck, A1
Burgess, S; Echeverria, V1
Coch, C; Eckhardt, M; Hartmann, G; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Wolfgarten, M1
Garcia, JG; Moreno-Vinasco, L1
Abrão Miziara, JE; Albert, I; Arén, O; Balint, B; Barrios, CH; Cihon, F; Csollak, M; Cupit, L; De Marinis, F; Dimatteo, S; Grossi, F; Hanna, N; Keller, A; Krzakowski, M; Novello, S; Pereira, JR; Reck, M; Scagliotti, G; Thomas, M; von Pawel, J1
Andreeff, M; Bekele, BN; Borthakur, G; Brandt, M; Byrd, A; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, HM; Konopleva, MY; Levis, M; Luthra, R; O'Brien, S; Pierce, SR; Pratz, K; Ravandi, F; Thomas, D1
Chon, SY; Diamantis, ML1
Amato, AM; Atkins, MB; Cho, DC; Choueiri, TK; Clement, J; McDermott, D; Oh, WK; Regan, MM; Rosenberg, JE; Signoretti, S1
Kerbel, RS; Lee, CR; Man, S; Tang, TC; Xu, P1
Bouattour, M; Castelnau, C; Degos, F; Farges, O; Ozenne, V; Paradis, V; Pernot, S; Valla, D; Vullierme, MP1
Fujimoto, T; Itatani, H; Kamoto, A; Kanemitu, T; Kobayashi, Y; Mori, N; Satoh, M; Sekii, K; Yoshioka, T1
Carr, BI; Wang, M; Wei, G1
Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY1
Byrnes, A; Pancoast, JR; Rixe, O; Verma, S; Wang, SX1
Bali, MA; Devière, J; Maréchal, R; Van Laethem, JL; Verset, G1
Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Ueno, H1
Hutson, T1
Bukhtiyarova, M; Karpusas, M; Lee, Y; Namboodiri, HV; Ramcharan, J; Springman, EB1
Inui, K; Kamba, T; Mizuno, T; Nakamura, E; Ogawa, O; Shinsako, K; Terada, T; Watanabe, J1
Barbastefano, J; Campbell, SC; Dreicer, R; Elson, P; Garcia, JA; Lane, BR; Rini, BI; Wood, LS1
Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC1
Doki, Y; Hayashi, N; Hikita, H; Hosui, A; Ishida, H; Kodama, T; Miyagi, T; Mori, M; Nagano, H; Noda, T; Shimizu, S; Takehara, T; Tatsumi, T1
Bhoori, S; Germini, A; Lampis, A; Mazzaferro, V; Pellegrinelli, A; Sposito, C; Toffanin, S1
Hurlstone, A; Wellbrock, C1
Bellmunt, J; Choueiri, TK; Je, Y; Rosenberg, JE; Schutz, FA1
Grossgoupil, M; Ravaud, A1
Arbogast, D; Collamore, M; Hall, NC; Kloos, RT; Knopp, MV; Lam, ET; Liang, J; Moley, JF; Prior, TW; Ringel, MD; Saji, M; Sammet, S; Shah, MH; Snyder, PJ; Vasko, VV; Villalona-Calero, MA; Wakely, PE; Wei, L; Wright, JJ1
Kudo, M8
Brown, C; Buettner, R; Hedvat, M; Jensen, M; Jove, R; Schroeder, A; Scuto, A; Starr, R; Yang, F1
Dobrovic, A; Hamilton, AL; Handolias, D; Kerr, L; McArthur, GA; Moodie, K; Salemi, R; Tan, A1
Galle, PR; Wörns, MA2
Grothey, A; Hubbard, J1
Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Ulivi, P; Zoli, W1
Greten, TF; Manns, MP; Plentz, RR1
Choueiri, TK1
Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD1
Bekers, O; Dingemans, AM; Giovannetti, E; Groen, HJ; Heideman, DA; Honeywell, RJ; Lind, JS; Peters, GJ; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ1
Kriener, S; Mönch, C; Trojan, J; Welker, MW; Zangos, S; Zeuzem, S1
Bellmunt, J; Eisen, T; Fishman, M; Quinn, D2
Cuesta Alcalá, JA; De Pablo Cárdenas, A; Millán Serrano, JA; Sánchez Zalabardo, D1
Hara, T; Hatano, K; Inoue, H; Kinoshita, T; Kinouchi, T; Kobayashi, M; Nonomura, N; Takada, T1
Engel, K; Gnoth, MJ; Radtke, M; Sandmann, S1
Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC1
Fesler, MJ; Petruska, PJ; Richart, JM1
Albouy, B; Escudier, B; Gross Goupil, M; Massard, C1
Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E1
Escudier, B; Gross-Goupil, M1
Boyle, H; Fléchon, A; Négrier, S1
Dingemans, AM; Hochstenbach, MM; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ1
Balsom, SM; Bekaii-Saab, TS; Bloomston, M; Li, X; Patel, T; Rose, J; Trolli, E1
Eto, M; Inokuchi, J; Kuroiwa, K; Masubuchi, D; Naito, S; Seki, N; Shiota, M; Tada, Y; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A1
Carr, BI; Wang, M; Wang, Z1
Kondo, M; Nieder, C; Norum, J1
Saadati, H; Saif, MW1
Hirose, R; Vagefi, PA2
Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ1
Gao, J; Jiang, H; Ma, J; Wang, Y; Zhang, D; Zhang, J1
Vaishampayan, U1
Rini, BI; Shah, SN1
Ansari, RH; Benson, AB; Catalano, P; O'Dwyer, PJ; Powell, M; Sun, W1
Karakiewicz, PI; Lughezzani, G; Perrotte, P; Sun, M1
Guha-Thakurta, N; Korshunov, A; Pfister, S; Remke, M; Rokes, CA; Witt, O; Wolff, JE1
Moreno-Aspitia, A1
Altieri, DC; Gilbert, CA; Raskett, CM; Ross, AH; Siegelin, MD1
Chen, N; Chen, XQ; Huang, R; Huang, Y; Zeng, H1
Beljanski, V; Knaak, C; Smith, CD; Zhuang, Y1
Crea, F; Landolfi, R; Leo, A; Miele, L; Pompili, M; Porto, I1
Alter, M; Degen, A; Gutzmer, R; Kapp, A; Satzger, I; Schenck, F; Völker, B1
Deville, JL; Duffaud, F; Huynh, T; Salas, S1
Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M1
Abdulrahman, RM; Corssmit, EP; Gelderblom, H; Hoftijzer, H; Hovens, GC; Kapiteijn, E; Pereira, AM; Reiners, C; Romijn, JA; Smit, JW; Verburg, E; Verloop, H; Visser, TJ1
Albers, P; Bergmann, L; Gschwend, J; Jäger, E; Keilholz, U; Miller, K1
Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD2
Brown, RE; Chai, H; Luo, AZ; Weerasinghe, P1
Amadori, D; Arienti, C; Carloni, S; Chiadini, E; Fabbri, F; Leonetti, C; Milandri, C; Orlandi, A; Passeri, D; Scarsella, M; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W; Zupi, G1
Fehér, J; Lengyel, G1
Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH1
Demers, A; Green, MR; Li, L; Moser, RP; Ross, AH; Sheng, Z; Smith, TW; Zhu, LJ1
Lee, YC; Park, YH; Roh, SY1
Guaglianone, PP; Huang, CH; LeBlanc, M; Moon, J; Urba, SG; Williamson, SK; Wolf, GT1
Baumbusch, T; Hastka, J; Metzgeroth, G; Reiter, A; Ströbel, P1
Bayliss, S; Connock, M; Greenheld, W; Moore, D; Round, J; Tubeuf, S1
Farnebo, M; Grandér, D; Kharaziha, P; Lennartsson, L; Mahmoudi, S; Nilsson, S; Panaretakis, T; Thyrell, L; Ullén, A1
Akisik, MF; Bu, G; Chiorean, EG; Hutchins, GD; Lin, C; Sandrasegaran, K1
Ichijo, T; Joshita, S; Kamijo, A; Kobayashi, S; Komatsu, M; Matsumoto, A; Morita, S; Sano, K; Sekiguchi, T; Tanaka, E; Umemura, T; Yoshizawa, K1
Duyster, J; Menzel, H; Peschel, C; Rummelt, C; Sigl, M; von Bubnoff, N1
Appleman, LJ; Cihon, F; Mazzu, A; Mita, AC; Shapiro, GI; Sundaresan, PR; Tolcher, AW1
Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O1
Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN1
Fagin, JA; Pfister, DG; Tuttle, RM1
Amoh, Y; Eto, H; Iwamura, M; Katsuoka, K; Mii, S; Tanabe, K1
Baumann, B; Büchler, MW; Gladkich, J; Herr, I; Kallifatidis, G; Liu, L; Mattern, J; Rausch, V; Salnikov, AV; Schemmer, P; Wirth, T; Zöller, M1
Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M1
Sato, Y1
Ikeda, K1
Brandes, AA; Franceschi, E; Girardi, F1
Balvay, D; Banu, E; Chatellier, G; Cuenod, CA; Fournier, LS; Frija, G; Medioni, J; Oudard, S; Thiam, R; Trinquart, L1
Bigatti, GL; Castagneto, B; Cosimi, MF; Giorcelli, L; Montefiore, F; Pisacco, P; Stevani, I1
Fujisawa, M; Inoue, TA; Kondo, Y; Kurahashi, T; Miyake, H; Takenaka, A; Yamanaka, K1
Iordanov, MS; Magun, BE; Magun, EA; Sauter, KA1
Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ1
Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V1
Bechstein, WO; Engels, K; Gog, C; Herrmann, E; Lubomierski, N; Trojan, J; Vogl, TJ; Welker, MW; Zeuzem, S1
Cheng, AL; Hsu, C; Shen, YC1
Auberdiac, P; Chargari, C; Magné, N; Merrouche, Y; Moncharmont, C; Spano, JP1
Kong, LQ; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, W; Zhu, XD; Zhuang, PY1
Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA1
Fukui, I; Hatake, K; Kodaira, M; Saotome, T; Takahashi, S; Takeuchi, K; Yonese, J; Yuasa, T1
Brown, RS; Magun, A; Olsen, SK; Siegel, AB1
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM1
Fetterly, G; Iyer, R; Lugade, A; Thanavala, Y1
Abou-Alfa, GK; Geschwind, JF; Krishnan, S; Salem, R; Schwarz, RE; Venook, AP1
Burak, KW; Thomas, MB; Zhu, AX1
Beck, J; Bellmunt, J; Escudier, B1
Barbare, JC; Belghiti, J; Castaing, D; Chirica, M; Farges, O; Paradis, V; Soubrane, O; Vullierme, MP1
Eto, M; Itsumi, M; Naito, S; Shiota, M; Tada, Y; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A1
Davies, L; Hedley, D; Kirk, R; Lopes, F; Manne, HA; Marais, R; Ménard, D; Niculescu-Duvaz, D; Niculescu-Duvaz, I; Nourry, A; Ogilvie, LM; Preece, N; Springer, CJ; Suijkerbuijk, BM; Whittaker, S; Zambon, A1
Fischer, L; Herden, U; Nashan, B; Schäfer, H; Sterneck, M; von Baehr, V1
Antón-Torres, A; Bellmunt, J; Carles, J; Guillem, V; López-Martín, JA; Maroto-Rey, P; Trigo, JM; Urruticoechea, L1
Chen, E; Coatney, RW; Davis, CB; Frazier, KS; French, KJ; Gales, TL; Hu, CX; McSurdy-Freed, J; Renninger, JP; Storck, LM; Zhao, S1
Kudo, M; Ueshima, K2
Han, KH; Lee, JM1
Dietrich, J; Hulme, C; Hurley, LH1
de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C1
Kallert, S; Mackensen, A; Meidenbauer, N; Rech, D; Rech, J; Roesler, W; Winkler, J1
Baum, CE; Dahut, WL; Danesi, R; English, BC; Figg, WD; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Liewehr, D; Price, DK; Sissung, TM; Venitz, J; Venzon, D; Yarchoan, R1
Allegood, J; Dent, P; Fisher, PB; Grant, S; Häussinger, D; Larner, A; Mitchell, C; Ogretmen, B; Park, MA; Reinehr, R; Spiegel, S; Voelkel-Johnson, C; Yacoub, A; Zhang, G1
Barbaro, D1
Eames, T; Staehler, M; Wollenberg, A1
Aucejo, F; Kim, R; Menon, N1
Chang, JW; Chang, NJ; Chuang, CK; Hou, MM; Hsieh, JJ; Hsu, T; Huang, HY; Wang, HM1
Herrmann, TR; Kramer, M; Kuczyk, MA; Merseburger, AS; Schrader, AJ; Waalkes, S1
Bureik, M; Drăgan, CA; Maurer, HH; Neunzig, I; Peters, FT; Schwaninger, AE; Widjaja, M1
Edwards, JP; Emens, LA1
Udagawa, T; Wood, M1
Ambrosini, V; D'Errico-Grigioni, A; Fanti, S; Fini, M; Franchi, R; Giavaresi, G; Malvi, D; Nanni, C; Quarta, C; Torricelli, P; Zinzani, PL1
Kudo, M; Lencioni, R; Marrero, J; Venook, A; Ye, SL1
Najarian, DJ; Packianathan, V; Zeitouni, NC1
Barbare, JC; Chatelain, D; Descamps, V; Duverlie, G; Ezzoukhry, Z; François, C; Galmiche, A; Godin, C; Joly, JP; Louandre, C; Mazière, JC; Nguyen-Khac, E; Regimbeau, JM; Sabbagh, C; Trouillet, N1
Fischer, JW; Grandoch, M; Rose, A; Rosenkranz, A; Rübben, H; vom Dorp, F; Weber, AA1
Fukasawa, S; Ichikawa, T; Imamura, Y; Komaru, A; Maruoka, M; Naya, Y; Nihei, N; Sazuka, T; Suyama, T; Ueda, T1
Bukowski, RM; Escudier, B; Lathia, C; Peña, C; Shan, M1
Fricke, HJ; Hochhaus, A; Klink, A; Muegge, LO; Scholl, S; Spies-Weisshart, B1
Agaimy, A; Hartmann, A; Ocker, M; Strobel, D; Wich, C; Wissniowski, TT1
Anderson, S; Bellmunt, J; Bukowski, R; Eisen, T; Escudier, B; Hutson, TE; Nadel, A; Porta, C; Staehler, M; Szczylik, C1
Dann, F; Kelly, K; Laquer, V; Saedi, N1
Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Watkins, A1
Spinzi, G; Terreni, N1
Armstrong, C; Hull, D1
Dent, P; Grant, S; Häussinger, D; Ogretmen, B; Park, MA; Reinehr, R; Voelkel-Johnson, C; Yacoub, A1
Arrivé, L; Fartoux, L; Lewin, M; Menu, Y; Rosmorduc, O; Vignaud, A1
Dawson, LA; Horgan, AM; Knox, JJ; Swaminath, A1
Lekili, M; Muezzinoglu, T; Nese, N; Temeltas, G1
Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J1
An, J; Bilenky, M; Birol, I; Butterfield, YS; Cezard, T; Chuah, E; Corbett, R; Fejes, AP; Griffith, M; Griffith, OL; Hirst, M; Holt, RA; Huntsman, DG; Jones, SJ; Laskin, J; Li, YY; Marra, MA; Martin, M; Mayo, M; Melnyk, N; Moore, RA; Morin, RD; Pugh, TJ; Severson, T; Shah, SP; Sutcliffe, M; Tam, A; Terry, J; Thiessen, N; Thomson, T; Varhol, R; Yee, J; Zeng, T; Zhao, Y1
Bader, M; Haseke, N; Karl, A; Roosen, A; Siebels, M; Stadler, T; Staehler, M; Stief, CG1
Hashimoto, Y; Iizuka, J; Kobayashi, H; Kondo, T; Nakano, M; Nishikawa, T; Tanabe, K1
Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F1
Duerden, M1
Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M1
Chan, P; Pang, R; Poon, RT; Yau, T1
Downing, L; Galoforo, S; Marples, B; Martinez, AA; McGonagle, M; Robertson, JM; Suen, AW; Wilson, GD1
Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N1
Dralle, H; Machens, A1
Crea, F; Danesi, R; Del Tacca, M; Mey, V; Nannizzi, S; Pasqualetti, G; Ricciardi, S1
Aucejo, F; Kim, R1
Degen, A; Gutzmer, R; Hauschild, A; Kapp, A; Satzger, I; Voelker, B1
Cools, J1
Tomita, Y1
Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P1
Eschenhagen, T; Hansen, A1
Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C1
Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C1
Merle, P; Mornex, F1
Dank, M1
Antoniu, SA1
Burchert, A; Metzelder, SK; Neubauer, A; Wollmer, E1
Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Iwase, K; Kanto, T; Kodama, T; Li, W; Miyagi, T; Shigekawa, M; Shimizu, S; Takehara, T; Tatsumi, T1
Berardi, R; Cascinu, S; Del Prete, M; Di Pietro Paolo, M; Faloppi, L; Maccaroni, E; Scartozzi, M1
Agamah, E; Hall, MJ; Kindler, HL; Locker, G; Nattam, S; Stadler, WM; Vokes, EE; Wallace, JA; Wroblewski, K1
Cinatl, J; Dauth, S; Doerr, HW; Löschmann, N; Michaelis, M; Nevels, M; Paulus, C; Stange, E1
Bukowski, RM; Cowey, CL; Dreicer, R; Elson, P; Garcia, JA; Gilligan, T; Hutson, TE; Nemec, C; Rini, BI1
Büchler, T1
Chamalidou, E; Chelis, L; Deftereos, S; Kakolyris, S; Maltezos, E; Ntinos, N; Souftas, V; Xenidis, N1
Guo, K; He, Y; Huang, Y; Li, Y; Wang, Y1
Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D1
Calvet, JP; Reif, GA; Wallace, DP; Yamaguchi, T1
Sas, KM1
Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P1
Guo, W; Lu, X; Ren, T; Tang, X; Zhao, H1
Rowe, IA1
Kan, HP; Tan, YF; Wang, Y; Zhou, J1
Chen, H; Chen, HJ; Huang, Y; Li, X; Wei, Q; Wu, YJ; Xie, X; Yang, YR; Zeng, H; Zhou, Q; Zhu, YC1
Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC1
Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK1
Beck-Peccoz, P; Fugazzola, L; Iavarone, M; Perrino, M; Viganò, M1
Frank-Raue, K; Ganten, M; Kreissl, MC; Raue, F1
Barbier, EL; Bouchet, A; Coquery, N; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Robert, P; Serduc, R; Troprès, I1
Chang, HM; Choi, YH; Kang, BW; Kang, YK; Kim, C; Kim, TW; Lee, JL; Ryu, MH1
Adema, GJ; de Vries, IJ; Desar, IM; Hulsbergen-vandeKaa, CA; Jacobs, JH; Mulders, PF; Oyen, WJ; van der Graaf, WT; van Herpen, CM1
Banerji, U; Berns, B; de Boer, C; Edmonds, K; Ferguson, TR; Gore, ME; James, MG; Larkin, JM; Pickering, LM; Thomas, K1
Baba, S; Kinoshita, M; Kurita, Y; Kyono, Y; Mugiya, S; Ozono, S; Takayama, T1
Bojic, M; Clodi, M; Haitel, A; Heinzl, H; Kramer, G; Lamm, W; Schmidinger, M; Vogl, UM; Zielinski, CC1
Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ1
Bustamante, J; Castells, L; de La Mata, M; Delgado, M; Forner, A; Matilla, A; Moreno, JM; Reig, M; Varela, M1
Josephs, DH; Ross, PJ1
Avril, MF; Barete, S; Billemont, B; Blanchet, B; Carlotti, A; Francès, C; Franck, N; Goldwasser, F; Moguelet, P; Ropert, S1
Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S1
Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W1
Baker, SD; Li, L; Navid, F; Pratz, K; Rudek, MA; Smith, BD; Zhao, M1
Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ1
Gu, Y; Meng, F; Qu, B; Shen, Y; Shu, Y; Sun, Y; Wu, X; Xu, Q; Zhang, T; Zhao, W; Zhu, X1
Bury, MJ; Floyd, JD; Gandara, DR; Gitlitz, BJ; Glisson, BS; Ho, C; Moon, J; Reimers, HJ; Schulz, TK; Sundaram, PK1
Iiduka, H; Ishida-Yamamoto, A; Komatsu, S; Minami-Hori, M1
Sahai, S; Swick, BL1
De Onzoño, LI; García-Arpa, M; Martinez-Martínez, ML; Rodríguez-Vázquez, M1
Aglietta, M; Aieta, M; Buonerba, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Felici, A; Imbimbo, C; Longo, N; Milella, M; Mirone, V; Ortega, C; Palmieri, G; Rescigno, P; Ruggeri, EM1
Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Li, PK; Lin, YC; Liu, TH; Shiau, CW; Tai, WT1
Fischer, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Kohistani, Z; Körner, C; Krämer, B; Nischalke, HD; Sauerbruch, T; Stark, C; Trebicka, J1
Bawa, O; Benatsou, B; Koscielny, S; Lassau, N; Leguerney, I; Massard, C; Opolon, P; Peronneau, P; Roche, A; Rodrigues, M; Rouffiac, V; Thalmensi, J1
Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D1
De Falco, V; Jo, YS; Kim, DW; Kim, JM; Kim, SJ; Kim, YK; Kweon, GR; Lee, JU; Lee, MH; Lee, SE; Park, JH; Ryu, MJ; Shong, M1
Heinz, WJ; Helle-Beyersdorf, A; Kahle, K; Keller, D; Klinker, H; Langmann, P; Lenker, U; Schirmer, D1
Frederick, RT; Frenette, CT; Gish, RG1
Duffy, A; Greten, T1
Audrain, O; Boucher, E; Leroux, C; Pracht, M; Raoul, JL; Vauléon, E; Zoheir, Y1
Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Safaian, NN; Saure, C; Schroeder, T; Zohren, F1
Malek, NP; Manns, MP; Vogel, A1
Hagymási, K; Tulassay, Z1
Beck, D; Berger, A; Flaherty, K; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Mauthe, M; Meier, F; Niessner, H; Proikas-Cezanne, T; Schadendorf, D; Schaller, M; Schittek, B; Sinnberg, T; Toulany, M; Venturelli, S1
Childs, R; Lundqvist, A; Su, S; Yokoyama, H1
Homma, Y; Kaneko, T; Matsushima, H; Morimoto, H; Tsuzaka, Y1
Cruikshanks, N; Curiel, DT; Dent, P; Dmitriev, IP; Eulitt, PJ; Fisher, PB; Hossein, H; Park, MA; Yacoub, A; Yang, C1
Amoroso, F; Boldt, S; Dahlhaus, M; Etro, D; Freund, M; Fuellen, G; Glass, A; Junghanss, C; Lange, S; Neri, LM; Ruck, S; Sawitzky, M; Schult, C; Wolkenhauer, O1
Agarwal, S; Elmquist, WF; Ohlfest, JR; Sane, R1
Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W1
Arai, K; Kaneko, S; Yamashita, T1
Fujisawa, M; Miyake, H1
Bernardini, R; Duntas, LH1
Figlin, RA; Pal, SK1
Hoshida, Y; Newell, P; Villanueva, A1
Boerman, OC; Desar, IM; Leenders, WP; Mulders, PF; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van der Graaf, WT; van Herpen, CM1
Alge, CS; Hirneiss, C; Kampik, A; Kernt, M; Liegl, RG; Neubauer, AS; Ulbig, MW; Wolf, A1
Abalı, H; Beşen, AA; Dişel, U; Karadeniz, C; Köse, F; Nursal, GN; Oztuzcu, S; Ozyılkan, O; Sezer, A; Sümbül, AT1
Aberg, E; Duyster, J; Engh, RA; Gorantla, SP; Oliveira, TM; Peschel, C; Thöne, S; von Bubnoff, N1
Rosen, N; Solit, D1
Chung, GG; Cohen, P; Creswell, K; Eng-Wong, J; Herbolsheimer, P; Isaacs, C; Liu, MC; Novielli, A; Ottaviano, Y; Slack, R; Smith, KL; Warren, R; Wilkinson, M1
Li, H; Shi, GH; Wang, CF; Yang, LF; Yang, ZY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y1
Hu, BS; Huang, GM; Huang, JW; Li, Y; Lu, LG; Shao, PJ; Wei, ZG; Zhang, L1
Eto, M; Kiyoshima, K; Naito, S; Oki, T; Takeuchi, A; Tatsugami, K; Yamada, H; Yoshikai, Y1
Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z1
Carr, BI; Carroll, S; Gondek, K; Muszbek, N1
Baba, T; Hamanishi, J; Kang, HS; Konishi, I; Mandai, M; Matsui, S; Matsumura, N; Mori, S; Murphy, SK; Okamoto, T; Oura, T; Yamaguchi, K; Yamamura, S1
Burger, DM; Desar, IM; Timmer-Bonte, JN; van der Graaf, WT; van Herpen, CM1
Bednaríková, D; Kocák, I1
Chen, KF; Cheng, AL; Fan, HH; Feng, WC; Hsu, C; Lin, LI; Ou, DL; Shen, YC; Wang, CT; Yeh, PY; Yu, SL1
Schaab, C1
Andersen, JL; Andersson, M; Kamby, C; Nielsen, DL1
Izumi, N; Kuzuya, T; Tsuchiya, K1
Aucejo, F; Byrne, M; Chang, YD; El-Gazzaz, G; Elson, P; Kim, R; Tan, A1
Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA1
Balis, FM; Cole, DE; Cruz, R; Fox, E; Kim, A; McCully, C; Widemann, BC1
Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; Lampard, JG; McDermott, DF; North, S; Rini, BI; Xie, W1
Emmenegger, U; Francia, G; Hashimoto, K; Kerbel, RS; Man, S; Tang, TC; Xu, P1
Bellmunt, J; Eisen, T; Mulders, P; Porta, C; Szczylik, C1
Bharati, IS; Fecteau, JF; Handel, TM; Kipps, TJ; Messmer, D; O'Hayre, M2
Abou-Alfa, GK; Capanu, M; Davidenko, I; Gansukh, B; Johnson, P; Knox, JJ; Lacava, J; Leung, T; Saltz, LB1
Halff, G; Speeg, KV; Wang, Y; Washburn, WK1
Sulkes, A1
Ausoni, G; Bayer, AJ; Bellesi, S; Chiusolo, P; Giammarco, S; Laurenti, L; Leone, G; Mario, B; Metafuni, E; Sica, S; Sorà, F; Zini, G1
Birrer, MJ; Bristow, RE; Calvert, V; Cohn, D; DeGeest, K; Farley, J; Lankes, HA; Matei, D; Mutch, D; Petricoin, EF; Sill, MW; Yamada, SD1
Jung, O; Kang, M; Kim, H; Kim, HJ; Kwak, TK; Lee, JW; Lee, MS; Lee, SA; Park, KH; Ryu, HW1
FENG, FL; JIANG, XQ; LAU, WY; LIU, C; LUO, XJ; QIU, YH; Qiu, ZQ; RAN, RZ; TAN, WF; WANG, JH; WU, MC; YAN, PN; YI, B; YU, Y; ZHANG, BH1
Hofmann, WP; Trojan, J; Waidmann, O; Zeuzem, S1
Chen, XP; Dagher, L; Lencioni, R; Venook, AP1
Büchler, MW; Franz, C; Hoffmann, K; Mohr, E; Schemmer, P; Serba, S; Xiao, Z1
Rini, B1
Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH1
Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L1
Biglietto, M; Buonerba, C; Cartenì, G; Chiurazzi, B; Di Lorenzo, G; Riccardi, F; Scognamiglio, F1
Busuttil, RW; Finn, RS; McTigue, M; Saab, S1
Fesler, MJ1
Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A1
Asemissen, A; Braun, F; Busse, A; Fusi, A; Keilholz, U; Miller, K; Nonnenmacher, A; Ochsenreither, S; Schmittel, A; Stather, D; Thiel, E1
Aglietta, M; Capellero, S; Cavalloni, G; Gammaitoni, L; Giordano, S; Migliardi, G; Milani, A; Moggio, A; Montemurro, F; Pecchioni, C; Peraldo-Neia, C; Petrelli, A; Sapino, A; Valabrega, G; Zaccarello, G1
Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B1
Di Stefano, G; Fiume, L; Manerba, M; Vettraino, M2
Bozorgzadeh, A; Grossman, S; Piperdi, B; Rawson, AP; Saidi, RF; Shah, SA1
Nelson, KC; Puri, PK; Raymond, AK; Selim, MA; Tyler, DS1
Chung, YH; Jin, YJ; Kang, YK; Kim, KM; Ko, GY; Lee, HC; Lee, JL; Lee, YS; Lim, YS; Shim, JH; Suh, DJ; Sung, KB; Yoo, DJ; Yoon, HK1
Jungmeechoke, K; Kanjanapayak, B; Ruangkanchanasetr, P1
Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R1
Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J; Koch, A1
Oudard, S1
Lolkema, MP; van Hillegersberg, R; Verheul, HM; Voest, EE; Walraven, M; Witteveen, PO1
Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R1
Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A1
Carroll, AR; Coleman, RL; Sood, AK1
Aburto, MR; Magariños, M; Muñoz-Agudo, C; Rapp, UR; Sánchez-Calderón, H; Varela-Nieto, I1
Colombo, M; Sangiovanni, A3
Bouattour, M; Faivre, S; Raymond, E1
Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Feng, WC; Hsu, CH; Tai, WT1
Bhujanga Rao, AK; Pulla Reddy, M; Ravikumar, K; Sridhar, B1
Buckley, M; Christos, PJ; Goldberg, L; Hamilton, A; Liebes, L; Min, C; Osman, I; Ott, PA; Pavlick, AC; Polsky, D; Safarzadeh-Amiri, S; Wright, JJ; Yee, H; Yoon, J1
Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N1
Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G1
Asemissen, AM; Braun, F; Busse, A; Fusi, A; Keilholz, U; Miller, K; Nonnenmacher, A; Ochsenreither, S; Schmittel, A; Stather, D; Thiel, E1
Chang, CJ; Chao, CH; Chen, CT; Hortobagyi, GN; Hsu, JM; Hung, MC; Woodward, WA; Xia, W; Xie, X; Yang, JY1
Aramendi, T; Balbin, E; Diaz-Sanchez, A; Rodriguez-Salas, N1
Adjei, AA; Dy, GK; Hillman, SL; Mandrekar, S; Molina, JR; Nair, S; Rowland, KM; Schild, SE; Steen, PD; Wender, DB1
Aomatsu, K; Arao, T; Fujita, Y; Furuta, K; Kaneda, H; Kimura, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D1
Becker, JC; Berking, C; Degen, A; Egberts, F; Frey, L; Garbe, C; Gutzmer, R; Hassel, JC; Hauschild, A; Kaehler, KC; Livingstone, E; Mauch, C; Mohr, P; Rass, K; Schadendorf, D; Schenck, F; Trefzer, U; Ugurel, S; Weichenthal, M; Wilhelm, T1
Huang, FK; Shi, Z1
Cao, L; Choyke, P; Force, J; Giaccone, G; Gutierrez, M; Keen, C; Kelly, RJ; Kummar, S; Lopez-Chavez, A; Raffeld, M; Rajan, A; Steinberg, SM; Turkbey, B; Wright, JJ; Xi, L; Yu, Y1
Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M1
Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y1
Guan, YS; He, Q1
Lord, R; Ross, PJ; Suddle, A1
Girard, N; Mornex, F1
Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W; Wrba, F1
Altomare, E; Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Capria, A; Gianluigi, G; Romano, A; Sacco, R1
Donaldson, MR; Smith, JL; Stetson, CL1
Baek, YH; Cho, JH; Han, JS; Han, SY; Kim, BG; Kim, SO; Lee, SW; Nam, KJ1
Fujii, H; Fukino, K; Hamamoto, Y; Hashine, K; Niwakawa, M; Sumiyoshi, Y; Tanigawa, T; Yamaguchi, R1
Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, S; Park, JY; Yoon, SH1
Eibl, KH; Haritoglou, C; Hirneiss, C; Kampik, A; Kernt, M; Lackerbauer, CA; Neubauer, AS; Thiele, S; Ulbig, MW; Wolf, A1
Dunn, RL; Filson, CP; Miller, DC; Redman, BG1
Beljanski, V; Lewis, CS; Smith, CD1
Borg, C; Curtit, E; Di Martino, V; Heyd, B; Nguyen, T; Pivot, X; Thiery-Vuillemin, A1
Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X1
Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A1
Akiyama, Y; Fujita, K; Murayama, N; Sasaki, Y; Sugiyama, M; Yamazaki, H1
Brion, N; Paule, B1
Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ1
Dufour, JF; Hora, C; Romanque, P1
Eskens, FA; Mathijssen, RH; Peeters, RP; van der Lugt, A; van Doorn, L; Visser, TJ1
Choi, BI; Kim, KW; Lee, JM1
Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P1
Bornschein, J; Csepregi, A; Malfertheiner, P; Ricke, J; Rühl, R; Schütte, K; Zimmermann, L1
Lowe, SW; Pardee, TS; Zuber, J1
Bidyasar, S; Busaidy, NL; Cabanillas, ME; El Naggar, AK; Hernandez, M; Hong, DS; Kurzrock, R; Naing, A; Sherman, SI; Tsimberidou, AM; Waguespack, SG; Wheler, J; Wright, J; Ye, L1
Decker, T; Huber, S; Kuhnt, T; Lutzny, G; Oelsner, M; Oostendorp, RA; Peschel, C; Ringshausen, I; Schmidt, B; Wagner, M; zum Büschenfelde, CM1
Atkins, MB; Choueiri, TK; Guo, M; Heng, DY; Jagannathan, J; Krajewski, KM; McDermott, DF; Pedrosa, I; Ramaiya, N; Schutz, FA; Van den Abbeele, AD; Yap, J1
Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E1
Fukui, I; Hatake, K; Inamura, K; Ishikwa, Y; Kodaira, M; Nakano, K; Takahashi, S; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T1
Cripe, TP; Dombi, E; Jousma, E; Kim, A; Kim, MO; Lindquist, D; Ratner, N; Schnell, BM; Scott Dunn, R; Widemann, BC; Wu, J1
Bellini, E; Berruti, A; Brizzi, MP; Dogliotti, L; Pia, A; Tampellini, M; Terzolo, M; Torta, M1
Cabrera, R; Cao, M; Gabrilovich, D; Liu, C; Nelson, DR; Xu, Y; Youn, JI; Zhang, X1
Bajetta, E; Beck, J; Bokemeyer, C; Bracarda, S; Burock, K; Escudier, B; Keilholz, U; Mersmann, S; Negrier, S; Procopio, G; Richel, DJ; Staehler, M; Strauss, UP; Szczylik, C1
Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D1
Baba, N; Hyodo, I; Ishige, K; Matsuda, S; Nakanuma, Y; Onodera, M; Onuki, K; Shoda, J; Sugiyama, H; Takeuchi, K; Ueda, T; Yamamoto, M; Yamato, M1
Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G1
Adnot-Desanlis, L; Bernard, P; Reguiaï, Z1
Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW1
Prasad, SR; Sahani, DV; Shanbhogue, AK; Takahashi, N; Vikram, R1
Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O1
Adachi, M; Akaza, H; Fukino, K; Furuse, J; Iijima, M; Minami, H; Murai, M; Naito, S; Tsukamoto, T1
Lanzuela, M; Lao, J; Pazo Cid, RA1
Katsahian, S; O'Quigley, J; Zohar, S1
Borentain, P; Durieux, O; Garcia, S; Gérolami, R; Gregoire, E; Hardwigsen, J; Le Treut, YP1
Fliegel, L; Karki, P; Li, X; Schrama, D1
Ravaud, A1
Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L1
Abe, H; Fukuda, T; Furuya, N; Kamai, T; Kambara, T; Mizuno, T; Nakamura, F; Nakanishi, K; Shirataki, H; Yanai, Y; Yoshida, K1
Carr, BI; Hyslop, T; Wang, M; Wang, Z; Wei, G1
Demlová, R; Komínek, J; Ondrácková, B1
Alpini, G; Cleary, JP; DeMorrow, S; Francis, H; Glaser, SS; Han, Y; Hubble, L; Kumar, P; Liu, CG; Liu, X; Meng, F; Passarini, JD; Priester, S; Sharma, J; Staloch, D; Stokes, A; Venter, J1
Hah, JM; Kim, H; Kim, M; Kim, MH; Sim, T; Yoo, KH; Yu, H1
Allen, GI; Chung, BI; Gill, HS; Harshman, LC; Srinivas, S; Yu, RJ1
Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Huang, JW; Shiau, CW; Tai, WT1
Friedrich, MJ1
Chen, YL; Ding, X; Li, HP; Liu, CH; Liu, P; Lv, J; Min, LH; Sun, MY; Xu, Q; Ye, XL1
Barbara, C; Barni, S; Cabiddu, M; Colombo, S; Corti, D; Elia, S; Ghilardi, M; Petrelli, F; Stringhi, E1
Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K1
Aster, J; Christie, AL; DePinho, RA; Gao, D; Gutierrez, A; Gygi, SP; Inuzuka, H; Kung, AL; Lau, AW; Look, T; Maser, RS; Nakayama, KI; Onoyama, I; Settleman, J; Shaik, S; Tseng, A; Wan, L; Wei, W; Xiao, Y; Zhai, B1
Adams, DR; Lynch, MC; Straub, R1
Choi, JI; Kim, MJ; Lee, JS; Park, JW1
Ikeda, R; Iseki, K; Maeda, H; Nakano, K; Shibayama, Y; Sugawara, M; Taguchi, M; Takeda, Y; Yamada, K1
Bruix, J; Sherman, M1
Jin-hui, T; Ke-hu, Y; Li, M; Ling-lin, Z1
Abe, K; Alzoubi, A; Fagan, KA; Gairhe, S; Gerthoffer, WT; Ito, M; Koubsky, K; McMurtry, IF; Oka, M; Ota, H; Toba, M1
Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D1
Takami, HE1
Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L1
Oberstein, PE; Saif, MW1
Brocks, DR; Fong, L; Harzstark, AL; Lin, AM; Rosenberg, JE; Ryan, CJ; Small, EJ; Sun, J; Weinberg, VK1
Dahut, WL; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Mould, DR; Venitz, J; Woo, S; Yarchoan, R1
Behnsawy, HM; Fujisawa, M; Fukuhara, T; Inoue, TA; Kusuda, Y; Miyake, H1
Cheng, CW; Chong, TW; Huynh, H; Lau, WK; Sim, MY; Siml, HG; Yuen, JS1
Cohen, PR; Stewart, DJ; Williams, VL1
Kim, DY1
Asakawa, C; Fujinaga, M; Fukumura, T; Hatori, A; Kato, K; Kawamura, K; Kumata, K; Ogawa, M; Yamasaki, T; Yui, J; Zhang, MR1
Arranz, JÁ; Climent, MÁ; González-Larriba, JL; León, L; Maroto, JP1
El-Khoueiry, AB; Gandara, D; Lenz, HJ; Ramanathan, RK; Shibata, S; Wright, JJ; Yang, DY; Zhang, W1
Liu, Y; Shi, Y; Sun, Y; Wang, L; Wang, Y; Yu, S; Zhang, X1
Bell, JC; Breitbach, CJ; Falls, T; Heo, J; Hickman, T; Hwang, TH; Kim, CW; Kim, MK; Kirn, DH; Lee, YK; Moon, A; Oh, SY; Parato, K; Patt, R; Rhee, BG; Rintoul, J; Woo, HY1
Li, QH; Liu, BC; Liu, KQ; Mi, YC; Wang, JX; Wei, H; Wei, SN; Zhou, CL1
Gong, P; Li, G; Li, W; Pu, Y; Zhai, X; Zhong, Z1
Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C1
Chang, HM; Kang, YK; Kim, JE; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Suh, DJ2
Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K1
Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K1
Bajetta, E; Bracarda, S; Miceli, R; Porta, C; Procopio, G; Ricci, S; Ridolfi, L; Sacco, C; Verzoni, E; Zilembo, N2
Amri, A; Arguello, M; Borden, K; Cormack, G; Kraljacic, BC1
Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M1
Blumenstengel, K; Grimm, MO; Groschek, M; Herrmann, E; Hutzschenreuter, U; Marschner, N; Ohlmann, CH; Overkamp, F; Pühse, G; Steiner, T1
Maráz, A1
Du, DZ; Herynk, MH; Heymach, JV; Jonasch, E; Khajavi, M; Logothetis, CJ; McKee, KS; Tannir, NM; Tran, HT; Wang, X; Xu, L; Yan, S; Zurita, AJ1
Abbass, K; Baumann, MA; Dewani, S; Kaplon, MK; Markert, R1
Bushmakin, AG; Bycott, P; Cappelleri, JC; Kim, S; Rini, B; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC1
Duh, MS; Feinberg, BA; Fortner, B; Gilmore, J; Jolly, P; Neary, MP; Scott, J; Wang, ST1
Tanji, N; Yokoyama, M1
Dai, B; Shen, YJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP1
Akaza, H; Fukino, K; Murai, M; Naito, S; Tsukamoto, T1
Clerc, J; Coriat, R; Goldwasser, F; Mir, O; Ropert, S1
Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R1
Allen, P; Jonasch, E; Mahajan, A; Tannir, N; Verma, J1
Afthinos, M; Djonov, V; Dufour, JF; Hlushchuk, R; McSheehy, PM; Piguet, AC; Radojevic, V; Saar, B; St-Pierre, MV; Terracciano, L1
Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S1
Chen, YJ; Liang, CP; Shen, JL; Yang, CS1
Ma, L; Wang, Y; Wu, Z; Zhang, L; Zhou, Q1
Busch, J; Flörcken, A; Grünwald, V; Johannsen, M; Keilholz, U; Kempkensteffen, C; Miller, K; Weikert, S; Weinkauf, L; Westermann, J; Zimmermann, K1
Boeykens, E; Rutsaert, R; Stappaerts, I; Van Loo, S1
Dörken, B; Engert, A; Janz, M; Köchert, K; Lamprecht, B; Mathas, S; Ullrich, K; Wurster, KD1
Choi, JI; Kim, CM; Kim, HB; Kim, HK; Kim, HY; Kim, TH; Nam, BH; Park, JW1
Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ; Xiong, MJ2
Abbruzzese, A; Addeo, R; Caraglia, M; Giuberti, G; Marra, M; Montella, L; Murolo, M; Naviglio, S; Prete, SD; Sperlongano, P; Stiuso, P; Vincenzi, B1
Fernández-Contreras, ME; Hinojar-Gutiérrez, A; Mendoza, J; Mera-Menéndez, F; Moreno, R; Nieto-Llanos, S1
Aglietta, M; Asaftei, SD; Casali, PG; D'Ambrosio, L; Dileo, P; Fagioli, F; Ferrari, S; Grignani, G; Mercuri, M; Palmerini, E; Picci, P; Pignochino, Y1
Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S1
Hua, SC; Li, Y; Liu, J; Liu, L; Ma, CY; Yang, M; Yuan, Q; Zhang, X; Zhou, C1
Chen, KF; Chen, PJ; Chen, WL; Cheng, AL; Hsu, CY; Huang, JW; Shiau, CW; Tai, WT1
Abrahamova, J; Brabec, P; Buchler, T; Dusek, L; Klapka, R; Melichar, B; Vyzula, R1
El-Deiry, WS; Ferrara, TA; Katz, SI; Mayes, PA; Smith, CD; Wang, W; Zhou, L1
Eto, M; Inokuchi, J; Kiyoshima, K; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES1
Aucejo, F; Byrne, MT; Kim, R; Tan, A1
Burak, KW1
Gores, GJ; Razumilava, N1
Chao, CC; Kuo, TC; Lu, HP1
Arai, Y; Imazu, T; Inoue, H; Kajikawa, J; Kawashima, A; Kinoshita, T; Nin, M; Nishimura, K; Nonomura, N; Takada, S; Takayama, H; Tanigawa, G; Tsujimura, A; Yasunaga, Y1
Couto, JP; Martins, TC; Prazeres, H; Rodrigues, F; Soares, P; Sobrinho-Simões, M; Torres, J; Trovisco, V; Vinagre, J1
Kumar, B; Kumar, P; Teknos, TN; Yadav, A1
Boldrini, R; Cortesi, E; De Pasquale, MD; Donfrancesco, A; Ilari, I; Jenkner, A; Pessolano, R1
Chong, LW; Huynh, H; Jong, CT; Lam, IW; Lee, SS; Li, PY; Luu, DA; Ong, RW; Yang, S1
Burris, HA; Greco, FA; Hainsworth, JD; Kommor, M; Molthrop, DC; Peacock, N; Spigel, DR; Vazquez, ER; Yardley, DA1
Block, MS; Kohli, M1
Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Collins, MP; Goldberg, SN; Libermann, T; Mier, JW; Panka, D; Putheti, P; Schor-Bardach, R; Signoretti, S; Wang, X; Zhang, L1
Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Varga, Z1
Ahmed, M; Barbachano, Y; Harrington, KJ; Hickey, J; Marais, R; Newbold, KL; Nutting, CM; Riddell, A; Viros, A1
Hashemolhosseini, S; Hellerbrand, C; Klinger, N; Neureiter, D; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Wege, H1
Blechacz, B; Ehman, R; Glaser, K; Huebert, R; Lomberk, G; Masyuk, T; Patel, L; Ritman, E; Routray, C; Shah, V; Shergill, U; Thabut, D; Urrutia, R; Vercnocke, A1
Chen, M; Orsini, LS; Qiao, YL; Therneau, T1
Flaig, MJ; Prinz, JC; Rübsam, K; Ruzicka, T1
Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J1
Chen, CL; Naib, T; Steingart, RM1
El-Gamal, MI; Jung, MH; Lee, WS; Oh, CH; Sim, T; Yoo, KH1
Bruners, P; Frei, P; Geier, A; Herweg, C; Mahnken, AH; Martin, IV; Mertens, JC; Müllhaupt, B; Schmitt, J1
Bertolotto, C; Bourcier, C; Grépin, R; Griseri, P; Mazure, N; Pagès, G1
Abou-Alfa, GK; Carter, WD; Chan, SL; Chiorean, EG; Gutheil, JC; Holcombe, RF; Lin, CC; Melink, TJ; Mulcahy, MF; Patel, K; Tsao, CJ; Wilson, WR1
Geoerger, B; Leblond, P1
Abou-Alfa, GK; Gish, RG; Tong, MJ1
Buonerba, C; Casciano, R; De Placido, S; Di Lorenzo, G; Liu, Z; Malangone, E; Sherman, S; Wang, X; Willet, J1
Wu, Y; Zhao, Y1
Bajetta, E; Bearz, A; Calcagno, A; Cartenì, G; Chiappino, I; Guadalupi, V; Imarisio, I; Landi, L; Paglino, C; Porta, C; Procopio, G; Re, GL; Ricotta, R; Rizzo, M; Ruggeri, EM; Sabbatini, R; Verzoni, E; Zustovich, F1
Espinosa, E; González, R; Merino, M; Pinto, A1
An, S; Choe, TB; Hong, SI; Jin, HO; Kim, YS; Lee, KH; Lee, SJ; Park, IC; Seo, SK; Woo, SH1
Caja, L; Campbell, JS; Fabregat, I; Fausto, N; Fernández-Rodriguez, CM; Fernando, J; Lledó, JL; Sancho, P1
Cramer, T; Daskalow, K; Decker, G; Gonzalez-Carmona, MA; Hirt, S; Raskopf, E; Sauerbruch, T; Schmitz, V; Standop, J; Vogt, A1
Cabrera, R; Caridi, J; Clark, V; Firpi, RJ; George, TJ; Morelli, G; Nelson, DR; Pannu, DS; Soldevila-Pico, C; Suman, A1
Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S1
Dombi, E; Force, J; Giaccone, G; Rajan, A; Steinberg, SM1
Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ1
Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY1
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Eulitt, P; Fisher, PB; Grant, S; Hamed, HA; Hubbard, N; Moran, RG; Nephew, KP; Park, MA; Tang, Y; Tye, G; Yacoub, A1
Allen, E; Hanahan, D; Walters, IB1
Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA1
Chen, W; Collins, R; Tirado, CA; Wakim, JJ1
Cunningham, D; Okines, AF; Reynolds, AR1
Belghiti, J; Botti, M; Boussaha, T; Dubreuil, O; Housset, M; Landi, B; Rougier, P; Taieb, J; Trouilloud, I; Williet, N1
Abbadessa, G; Carrillo-Infante, C; Cucchi, E; Pressiani, T; Rimassa, L; Santoro, A1
Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F1
Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A1
Airoldi, A; Mancuso, A; Pinzello, G; Vigano, R1
He, JT; Zhang, D1
Chida, N; Furuse, J; Hayashi, N; Hori, T; Imanaka, K; Kaneko, S; Kudo, M; Kumada, H; Matsui, O; Meinhardt, G; Nakachi, K; Ohya, T; Okita, K; Okusaka, T; Suh, DJ; Tak, WY; Takayama, T; Tanaka, K; Tsubouchi, H; Wada, M; Yamaguchi, I; Yoon, JH1
Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E1
Dai, Z; Fan, J; Hu, J; Huang, XW; Qiu, SJ; Tan, CJ; Wang, Z; Zhou, J1
Barbier, EL; Christen, T; Duchamp, O; Farion, R; Fondraz, N; Genne, P; Lemasson, B; Provent, P; Remy, C; Segebarth, C; Tizon, X1
Caponigro, F; Ciarmiello, A; Milano, A; Perri, F1
Chapuy, B; Dohm, A; Hand, E; Panse, M; Schroers, R; Schuelper, N; Truemper, L; Wulf, GG1
Dai, Z; Ding, ZB; Fan, J; Gu, CY; Hui, B; Ke, AW; Peng, YF; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Zhou, J1
Abbas, H; Bancelin, N; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Ropert, S; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M1
Cohen, JD; Gallegos, AC; Lau, SS; Mastrandrea, NJ; Monks, TJ; Tham, KY1
Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS1
Spicák, J; Suchánková, G1
Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE1
Cui, Z; He, B; Qu, W; Wang, JC; Wang, YB; Zhang, H; Zhang, JY; Zhang, Q1
Boulinguez, S1
Chan, AL; Leung, HW1
Bloor, A; Cross, NC; Erben, P; Gesk, S; Haferlach, C; Haferlach, T; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Ritter, M; Score, J; Telford, N; Walz, C1
Chang, YI; Chao, YS; Chen, CP; Chen, CT; Chen, CW; Cheng, AH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Huang, YL; Jiaang, WT; Lin, WH; Lu, CT; Tseng, YJ; Yeh, TK; Yen, KR; Yen, SC1
de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC1
Boucher, E; Edeline, J; Le Roux, C; Perrin, C; Pracht, M; Raoul, JL; Rolland, Y; Vauléon, E1
Curtit, E; Le Tourneau, C; Mansi, L; Medioni, J; Viel, E1
Desbois-Mouthon, C; Rosmorduc, O1
Ahn, HK; Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, SH; Park, YS; Sun, JM1
Bergmann, L; Gschwend, J; Keilholz, U; Miller, K1
Aller, S; Gosiengfiao, Y; Morgan, E; Popescu, A; Rao, S1
Bodnar, L; Górnas, M; Szczylik, C1
Fujii, M; Fujisawa, M; Kitajima, K; Maeda, T; Miyake, H; Ohno, Y; Sugimura, K; Takahashi, S; Yoshikawa, T1
Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W1
Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Navaraj, A; Smith, CD; Wang, W1
Adjei, AA; Blumenschein, GR; Gatzemeier, U; Heigener, D; Hillman, S; Mandrekar, S1
Shen, YF; Zhang, SJ; Zhou, XJ1
Baumann, M; Cerny, T; Koeberle, D; Sommacal, A1
Carr, BI; Cavallini, A; D'Alessandro, R; Refolo, MG; Wang, M; Wang, Z1
Huang, C; Nan, K; Suo, A; Yao, Y; Zhang, L; Zhang, M; Zhang, W1
Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M1
Hong, SH; Jeon, EK; Jeong, HK; Ko, YH; Lee, SL; Roh, SY; Shin, OR; Won, HS1
Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE1
Keresztes, RS; Wu, S1
Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, JD; Lee, JH; Park, JY; Seo, HJ1
Ben-Josef, E; Blanke, CD; El-Khoueiry, AB; Eng, C; Gold, PJ; Govindarajan, R; Hamilton, RD; Lenz, HJ; Rankin, CJ1
Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP1
Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C1
Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M1
Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S1
Busch, J; Grünwald, V; Hinz, S; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Weinkauf, L; Wolff, I1
Aubourg, A; Bacq, Y; Lucas, E; Perarnau, JM1
Paz, C; Querfeld, C; Shea, CR1
Albiges, L; Escudier, B; Rini, B; Salem, M1
Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C1
Andreeff, M; Bashir, Q; Bayraktar, UD; Champlin, RE; Chen, J; Chiattone, A; Cortes, J; de Lima, M; Giralt, S; Kantarjian, H; Kebriaei, P; Konopleva, M; McCue, D; Qazilbash, M; Ravandi, F; Sharma, M1
Caldwell, GA; Caldwell, KA; Dawson, TM; Dawson, VL; Hamamichi, S; Lee, BD; Liu, Z; Ray, A; Smith, WW; Yang, D1
Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA1
Connock, M; Hyde, C; Moore, D1
Al-Osaimi, AM; Argo, CK; Caldwell, SH; Northup, PG; Schmitt, TM; Shah, NL; Truesdale, AE1
Beardsley, EK; Chi, KN; Ellard, SL; Hotte, SJ; Kollmannsberger, C; Mukherjee, SD; North, S; Winquist, E1
Broneshter, R; Iancu, TC; Manov, I; Pollak, Y1
Demartines, N; Dormond, O; Dormond-Meuwly, A; Dufour, M; Roulin, D; Waselle, L1
Budak, K; Pestalozzi, B; Weisshaupt, Ch1
Ballarin, R; Berretta, M; D'Amico, G; De Ruvo, N; Di Benedetto, F; Gerunda, GE; Iemmolo, RM; Tarantino, G1
Busch, J; Grünwald, V; Hinz, S; Johannsen, M; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Wolff, I1
Bollag, G1
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y1
Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F1
Cross, NC; Erben, P; Hochhaus, A; Hofmann, WK; Klippstein, T; Martin, H; Metzgeroth, G; Mousset, S; Reiter, A; Teichmann, M; Walz, C1
Cunningham, D; Yim, KL1
Hu, ML; Huang, CS; Lyu, SC1
Atkins, M; Bukowski, R; Choueiri, TK; Dutcher, J; Eisen, T; Elson, P; Escudier, B; Heng, DY; Manola, J; Mazumdar, M; McCormack, JB; Motzer, R; Négrier, S; Royston, P1
Kim, HY; Park, JW1
Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Sakurai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N1
Geliebter, J; Moscatello, AL; Nowicki, TS; Schantz, S; Shin, E; Tiwari, RK1
Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC1
Brose, MS; Chung, J; Kalmus, J; Kappeler, C; Nutting, CM; Reike, G; Schlumberger, M; Sherman, SI; Shong, YK; Smit, JW1
Aguillo Gutiérrez, E; Altemir Trallero, J; Cabrejas Gómez, Mdel C; Lázaro Sierra, J; Ocón Bretón, J1
Fan, JM; Jia, ZR; Liu, YO; Wang, XQ; Zhang, Q; Zhao, B1
Chan, JL; Chen, S; Goydos, JS; Lee, HJ; Namkoong, J; Rosenberg, S; Shin, SS; Wall, BA; Wangari-Talbot, J1
Crespo, O; Daneman, R; Ho, PP; Kang, SC; Lindstrom, TM; Robinson, WH; Sobel, RA; Steinman, L1
Calvani, N; Cinefra, M; Cinieri, S; Gnoni, A; Leo, S; Lombardi, L; Lorusso, V; Maiello, E; Morelli, F; Orlando, L1
Fujita, N; Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Kanto, T; Kodama, T; Miyagi, T; Shimizu, S; Takehara, T; Tatsumi, T; Tsunematsu, H; Yoshimori, T1
Becker, C; Berger, F; Hittinger, M; Reiser, M; Schramm, N; Staehler, M; Ubleis, C1
Anders, RA; Bai, H; Chenna, V; Fan, J; Hu, C; Khan, M; Maitra, A; Sun, HX; Sun, YF; Xu, Y; Yang, XR; Zhu, QF1
Hammock, BD; Hwang, SH; Inoue, H; Wecksler, AT; Weiss, RH1
Ballini, JP; Griffioen, AW; Lovisa, B; Nowak-Sliwinska, P; van Beijnum, JR; van den Bergh, H; Weiss, A; Wong, TJ1
Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K1
Buder, R; Graziadei, I; Grünberger, B; Hucke, F; Königsberg, R; Kornek, G; Maieron, A; Matejka, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Schöniger-Hekele, M; Sieghart, W; Stauber, R; Vogel, W; Weissmann, A1
Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Inoue, T; Nakano, K; Narita, S; Saito, M; Takahashi, S; Tsuchiya, N; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T1
Chan, P; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T1
Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C1
Caronia, LM; Phay, JE; Shah, MH1
Hasegawa, Y; Itou, N; Nitta, H; Takahara, T; Takahashi, M; Wakabayashi, G1
Adamus, G; Anitori, R; Golchet, P; Jampol, LM; Mets, RB; Shaw, J; Wilson, D1
Bhagat, N; Cosgrove, D; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK1
Joly, F1
Fukumoto, M; Ichida, T; Matsuda, Y1
Albert, MH; Corbacioglu, S; Fröhlich, B; Graf, N; Häberle, B; Kammer, B; Kontny, U; Leuschner, I; Scheel-Walter, HG; Scheurlen, W; Schmid, I; von Schweinitz, D; Werner, S; Wiesel, T1
Bellesi, S; Chiusolo, P; Giammarco, S; Laurenti, L; Leone, G; Metafuni, E; Sica, S; Sorà, F; Za, T1
Liu, Q; Mier, JW; Panka, DJ1
Borbujo, JM; Córdoba, S; Espinosa, P; Martínez-Morán, C; Meseguer-Yebra, C; Nájera, L; Romero-Maté, A; Ruiz-Casado, AI1
Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M1
Anderson, KC; Podar, K1
Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Eschbach, R; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; von Einem, JC; Wintersperger, BJ1
Ciampi Dopazo, JJ; de Artaza Varasa, T; de la Cruz Perez, G; Gómez Moreno, AZ; Gómez Rodríguez, R; González de Frutos, C; Lanciego Pérez, C; Romero Gutiérrez, M1
Kong, D; Ma, W; Song, T; Wu, Q; Zhang, W1
Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A1
Li, XH; Liu, Y; Yang, DH; Zhong, KB; Zhou, J1
Grünberger, B1
Cho, HG; Choi, HS; El-Gamal, MI; Hong, JH; Oh, CH; Yoo, KH1
Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X1
Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C1
Boleslawski, E; Cattan, S; Dharancy, S; Ernst, O; Hebbar, M; Hollebecque, A; Louvet, A; Mathurin, P; Mourad, A; Pruvot, FR; Romano, O; Sergent, G; Truant, S1
Giménez-Bachs, JM; Nam Cha, S; Salinas-Sánchez, AS; Sánchez-Prieto, R; Serrano-Oviedo, L1
Bihari, C; Gupta, NL; Jain, D; Rastogi, A; Sarin, SK1
Hara, T; Kajikawa, J; Kawashima, A; Meguro, N; Miyoshi, S; Nishimura, K; Nonomura, N; Oka, T; Takayama, H; Tanigawa, G; Yamaguchi, S; Yosioka, T1
Doudican, NA; Orlow, SJ; Quay, E; Zhang, S1
Asghar, U; Meyer, T1
Altomare, E; Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bozzi, E; Bresci, G; Di Biase, M; Ginanni, B; Romano, A; Sacco, R; Tumino, E1
Rexer, H3
Jirillo, A; Mazurek, M; Palozzo, AC; Trojniak, MP1
Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA1
Chen, TJ; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC1
Mori, M; Sprague, J1
Hara, F; Hirano, N; Iida, K; Ishii, K; Kikuchi, Y; Shiozawa, K; Sumino, Y; Wakui, N; Watanabe, M1
Cheng, H; Dicker, AP; Force, T; Kari, G; Koch, WJ; Rodeck, U1
Fiedler, W; Wellbrock, J1
Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V1
Abbas, H; Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Goldwasser, F; Harcouet, L; Hornecker, M; Mir, O; Ropert, S; Sassi, H; Taieb, F; Tod, M1
Awasthi, S; Nagaprashantha, LD; Singhal, J; Singhal, SS; Vatsyayan, R1
Fukushima, H; Gao, D; Inuzuka, H; Lau, AW; Liu, P; Wan, L; Wang, Z; Wei, W1
Han, KH; Kim, DY2
Hagihara, H; Ikeda, F; Kobayashi, S; Kuwaki, K; Miyahara, K; Miyake, Y; Nakamura, S; Nouso, K; Onishi, H; Shiraha, H; Takaki, A; Tomoda, T; Toshimori, J; Yamamoto, K1
Beckett, L; Eddings, C; Gandara, D; Lara, PN; Lau, DH; Pan, CX; Semrad, TJ1
Gomez, P; Lacouture, ME1
Berger, DM; Collins, K; Frommer, E; Hu, Y; Powell, D; Salaski, EJ; Wang, X; Wojciechowicz, D1
Fan, J; Gao, Q; Gu, FM; Huang, XY; Jiang, JH; Li, QL; Pan, JF; Zhou, J1
Cheng, S; Moslehi, J; Uraizee, I1
Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W1
El-Gamal, MI; Lee, YS; Oh, CH; Park, JH1
Busch, J; Fenner, M; Ganser, A; Grünwald, V; Seidel, C; Weikert, S1
Bartolozzi, C; Iannopollo, M; Lencioni, M; Oliveri, F; Orlandini, C; Petrini, I; Ricasoli, M; Ricci, S1
de Waal, R; Hulsbergen-van de Kaa, C; Kats-Ugurlu, G; Leenders, W; Maass, C; Mulders, P; Oosterwijk, E; van Herpen, C1
Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B1
Lachenmayer, A; Mínguez, B1
Cabibbo, G; De Giorgio, M; Genco, C; Pressiani, T; Rolle, E; Sacco, R; Spada, F1
Procopio, G1
How, GF; Linn, YC; Loh, Y; Mohan, BP1
Hughes, M; Pickert, A; Wells, M1
Cooper, T; Watt, TC1
Berdel, WE; Brandts, C; Ehninger, G; Haibach, M; Hentrich, M; Junghanß, C; Krämer, A; Kramer, M; Krause, SW; Müller-Tidow, C; Pflüger, KH; Ritter, B; Röllig, C; Schleyer, E; Serve, H; Shaid, S1
Bex, A; Haanen, J1
Castellano, D; Cella, D; Chen, C; Escudier, B; Gorbunova, VA; Gore, ME; Hutson, TE; Kaprin, A; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Negrier, S; Ou, YC; Rini, BI; Rosbrook, B; Rusakov, IG; Szczylik, C; Tarazi, J; Tomczak, P; Uemura, H1
Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Mackenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wang, Y; Wood, L1
Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M1
Ardlie, K; Chalk, CJ; Dziunycz, P; Garraway, LA; Hofbauer, GF; Jones, R; Kamsukom, N; Kee, D; MacConaill, LE; McArthur, GA; Oberholzer, PA; Palescandolo, E; Piris, A; Robert, C; Roden, C; Schadendorf, D; Sucker, A1
Reed, MW; Young, RJ1
Baba, S; Bessho, H; Fujita, T; Ishikawa, W; Iwamura, M; Maeyama, R; Sugita, A; Tabata, K; Tokuyama, Y; Yoshida, K1
Pratz, KW; Rudek, MA; Smith, BD; Villarroel, MC; Wright, JJ; Xu, L1
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A1
Di Fiore, F; Ménager, C; Michel, P; Pfister, C; Rigal, O1
Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H; Sakai, I1
André, J; Arnault, JP; Boussemart, L; Druillennec, S; Dumaz, N; Eggermont, AM; Escudier, B; Eychène, A; Hollville, E; Kamsu-Kom, N; Lacroix, L; Larcher, M; Malka, D; Mateus, C; Robert, C; Sarasin, A; Soria, JC; Spatz, A; Tomasic, G; Vagner, S; Wechsler, J1
Liu, H; Shen, Y; Yang, Y; Yao, X1
Chen, R; Curley, SA; Liu, H; McConkey, DJ; Ward, JF; Zhang, T1
Amiand, MB; Bard, JM; Bobin-Dubigeon, C; Bouché, O; Heurgue-Berlot, A; Le Guellec, C1
Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C1
Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M1
Asahina, Y; Hoshioka, T; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Nakanishi, H; Suzuki, Y; Takahashi, Y; Tamaki, S; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y1
Fang, Z; Wang, ZX; Wei, P; Yang, Z1
Calvo Aller, E; Castellano, D; Díaz Cerezo, S; González Larriba, JL; Kreif, N; López-Brea, M; Maroto, P; Martí, B1
Farley-Loftus, R; Lewin, J; Pomeranz, MK1
Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, RW; Poon, R; Tang, YF; Wong, H; Yao, TJ; Yau, T1
Lencioni, R1
Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J1
Chen, HC; Chen, YL; Hsu, HC; Jeng, YM; Yuan, RH1
Chlenski, A; Cohn, SL; Guerrero, LJ; Kakodkar, NC; Maitland, ML; Peddinti, RR; Salwen, HR; Tian, Y; Yang, Q1
Kim, H; Lim, HY1
Dörken, B; Flörcken, A; Hopfenmüller, W; Pezzutto, A; Singh, A; Takvorian, A; Van Lessen, A; Westermann, J1
Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE1
Amato, RJ; Flaherty, AL; Stepankiw, M1
Chen, X; Guan, W; Hu, Z; Li, Y; Liu, F; Peng, E; Ye, Z; Zhuang, Q1
Ciardiello, F; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T1
Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Fuchs, J; Kirchner, B; Warmann, SW1
Fukumoto, M; Matsuda, Y1
Gotoh, M; Kashiwagi, Y; Nakano, Y; Takeda, H; Yoshino, Y1
Chen, KF; Chen, PJ; Cheng, AL; Ko, CH; Lin, MW; Liu, CY; Shiau, CW; Tai, WT1
Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Villamor, N; Xargay-Torrent, S1
Hatano, E; Iida, T; Ishii, T; Isoda, H; Kitamura, K; Machimito, T; Shibata, T; Taura, K; Uemoto, S; Yamanaka, K; Yasuchika, K1
Dai, X; He, F; Lian, J; Ni, Z; Smith, AR; Su, C; Xu, L1
Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Brown, V; Goldberg, SN; Mier, JW; Signoretti, S; Wang, X; Zhang, L1
Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M1
Adjei, AA; Halling, T; Haug, JL; Kimlinger, TK; Kumar, S; Rajkumar, SV; Ramakrishnan, V; Timm, M; Wellik, LE; Witzig, TE1
Heuer, V; Kummer, G; Neumann, H; Roy, R; Schultheis, B; Strumberg, D1
Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T2
Egawa, C; Kato, T; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Okishiro, M; Suzuki, R; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S1
Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H1
Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V1
Alonso, S; Calabrò, F; Caristo, R; Catalano, A; Cerbone, L; Di Paola, ED; Leone, A; Mancuso, A; Messina, C; Sternberg, CN; Vigna, L; Zivi, A1
Sia, D; Villanueva, A1
Lee, IJ; Seong, J1
Bae, SH; Guan, S; Lim, HY; Park, HC; Seong, J; Tak, WY; Tanaka, M; Zeng, ZC1
Choi, JY1
Henmi, S; Inuzuka, T; Kimura, T; Kita, R; Kudo, M; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Sekikawa, A; Takeda, H1
Gadaleta, CD; Gadaleta-Caldarola, G; Goffredo, V; Mangia, A; Patruno, R; Ranieri, G; Rizzo, A; Sciorsci, RL1
Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W1
Bassett, RL; Bedikian, AY; Culotta, KS; Dancey, JE; Davies, MA; Deng, W; Fox, PS; Gupta, S; Huang, S; Hwu, P; Hwu, WJ; Kim, KB; Lazar, AJ; Liu, W; Madden, TL; Ng, CS; Papadopoulos, NE; Prieto, VG; Wright, JJ; Xu, Q1
Lanocita, R; Procopio, G; Verzoni, E1
Dranitsaris, G; Fang, F; Huang, L; Lacouture, ME; Vincent, MD; Yu, J1
Akerley, WL; Flaherty, LE; Kirkwood, JM; Lao, CD; Margolin, KA; Moon, J; Othus, M; Sondak, VK; Sosman, JA1
Albiges, L; Caty, A; Dietrich, PY; Duclos, B; Escudier, B; Geoffrois, L; Gravis, G; Guillot, A; Joly, F; Kohser, F; Laguerre, B; Legouffe, E; Negrier, S; Oudard, S; Rolland, F; Theodore, CA1
Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S1
Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S1
Allavena, P; Mantovani, A1
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C1
Chen, Z; Cheng, AL; Fang, F; Guan, Z; Kang, YK; Kim, JS; Lentini, G; Pan, H; Qin, S; Tak, WY; Tsao, CJ; Voliotis, D; Xu, J; Yang, TS; Yu, S; Zou, J1
Bruix, J; Dominguez, S; Germanidis, G; Greten, TF; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Nadel, A; Raoul, JL; Ricci, S; Scherubl, H; Scheulen, ME; Sherman, M; Voliotis, D1
Galle, PR; Marquardt, JU; Teufel, A; Wörns, M1
Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J1
Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L1
Chang, YF; Chen, CL; Chen, CW; Chiang, IT; Hwang, JJ; Kuo, YC; Lin, WC; Su, SH1
Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA1
Aoyagi, Y; Fujimaki, S; Kubota, M; Matsuda, Y; Ohkoshi, S; Sanpei, A; Takamura, M; Wakai, T; Yamagiwa, S; Yano, M1
Bruns, CJ; Cyran, CC; Dietrich, O; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Pietsch, H; Reiser, MF; Schwarz, B; Sourbron, S; von Einem, J; Wintersperger, BJ1
Bull, VH; Rajalingam, K; Thiede, B1
Babić, Z; Balzarini, J; Crkvenčić, M; Kralj, M; Mikecin, AM; Petrova, M; Rajić, Z; Vanderleyden, J; Zorc, B1
Im, SA; Kang, BY; Kang, YK; Kwon, HC; Lee, SS; Park, SH; Park, SR; Ryoo, BY; Ryu, MH1
Anract, P; Babinet, A; Boudou-Rouquette, P; Dumaine, V; Goldwasser, F; Larousserie, F; Mir, O1
Augsten, M; Björklund, AC; Egevad, L; Grander, D; Kharaziha, P; Kroemer, G; Li, Q; Nilsson, S; Panaretakis, T; Rodriguez, P; Rundqvist, H; Ullén, A; Wiklund, P1
Colecchia, M; Iacovelli, R; Mariani, L; Procopio, G; Torelli, T; Verzoni, E1
Caravetta, A; Guarino, R; Mollo, F; Peluso, L; Rombolà, F; Spinoso, A1
Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M1
Gong, RY; Li, XF; Shi, LH; Wang, K; Wang, M; Yan, ZL; Yuan, B1
Capdevila, J; Corral, J; Grande, E; Grau, JJ; Halperin, I; Iglesias, L; Martínez-Trufero, J; Obiols, G; Segura, A; Tabernero, J; Vaz, MÁ1
Bay, JO; Blay, JY; Bompas, E; Bousquet, G; Chevreau, C; Clisant, S; Collard, O; Cupissol, D; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Lemaitre, L; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM1
Sleijfer, S1
Dudgeon, C; Peng, R; Sebastiani, A; Wang, P; Yu, J; Zhang, L1
Bies, RR; Jin, Y; Karrison, TG; Maitland, ML; Ratain, MJ; Sharma, MR; Stadler, WM1
Kondo, M; Maeda, S; Morimoto, M; Morioka, Y; Moriya, S; Nozaki, A; Numata, K; Tanaka, K1
Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B1
Han, SH; Kang, H; Park, H; Park, K1
Bui, B; Coindre, JM; Italiano, A; Kind, M; Maki, RG; Roubaud, G1
Meyer, P; Missana, A1
Corey, SJ; Park, BJ; Whichard, ZL1
Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R1
Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA1
Celeghini, C; Melloni, E; Norcio, A; Secchiero, P; Voltan, R; Zauli, G1
Buettner, R; Chang, S; Hedvat, M; Jove, R; Jove, V; Liu, L; Scuto, A; Tian, Y; Van Meter, T; Wen, W; Yang, F; Yen, Y; Yip, ML1
An, S; Choi, JI; Kim, HB; Kim, HY; Koh, YH; Nam, BH; Park, JW; Woo, SM1
Ayuso, C; Barrufet, M; Bruix, J; Burrel, M; de Lope, CR; Forner, A; Llovet, JM; Real, MI; Reig, M; Tremosini, S1
Faris, JE; Zhu, AX1
Chang, C; Hsu, CL; Huang, CK; Hung, YC; Jeng, LB; Lin, TY; Ma, WL; Wu, MH; Yeh, CC; Yeh, S1
Du, H; He, L; Lv, N; Ren, J; Wang, S1
Alsinet, C; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Minguez, B; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC1
Boulanger, G; Edeline, J; Jouan, F; Martin, B; Oger, E; Patard, JJ; Rioux-Leclercq, N; Vigneau, C; Zerrouki, S1
Ibrahim, N; Walsh, WR; Yang, JL; Yu, Y1
Hatanaka, Y; Minami, T; Nozawa, M; Shimizu, N; Tsuji, H; Uemura, H; Yamamoto, Y1
Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L1
Agarwal, S; Elmquist, WF1
Chang, KH; Chen, YJ; Cheng, SB; Hwang, WL; Teng, CL1
Bellail, AC; Ding, L; Hao, C; Liu, Y; Lu, G; Olson, JJ; Sun, SY; Wang, G; Wei, F; Yuan, C1
Gupta, GN; Singer, EA; Srinivasan, R1
Ancukiewicz, M; Boucher, Y; Demetri, GD; Duda, DG; Eder, JP; Jain, RK; Lahdenranta, J; Morgan, JA; Quek, R; Raut, CP1
Bruix, J; Forner, A; Llovet, JM1
Atrash, B; Avery, S; Bavetsias, V; Blagg, J; de Haven Brandon, A; Eccles, SA; Faisal, A; Gonzalez de Castro, D; Linardopoulos, S; Mair, D; Mirabella, F; Moore, AS; Pearson, AD; Raynaud, FI; Sun, C; Swansbury, J; Valenti, M; Workman, P1
Deblois, F; Devic, S; Heravi, M; Holmes, J; Liang, L; Muanza, T; Radzioch, D; Tomic, N1
Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R1
Choi, JS; Chung, SH; Joo, CK; Seo, JW1
Aste, MG; Buti, S; Conte, PF; Cosmai, L; Del Giovane, C; Di Lorenzo, G; Grosso, F; Iacovelli, R; Invernizzi, R; Lucia Manenti, A; Masini, C; Moscetti, L; Onofri, A; Ortega, C; Pagano, M; Porta, C; Procopio, G; Sabbatini, R1
Cheung, AM; Choi, WW; Chow, HC; Eaves, C; Fung, TK; Han, HH; Ho, C; Kwong, YL; Leung, AY; Lok, S; Ma, AC; Man, CH1
Ishii, M; Kamo, R; Kobayashi, H; Kumei, A; Tamiya, H; Yanagihara, S1
Chiang, IT; Hsu, FT; Hwang, JJ; Liu, YC1
George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB1
Liu, BX; Ying, JE; Zhu, LM1
Bruix, J; Lathia, CD; Llovet, JM; Meinhardt, G; Peña, CE; Shan, M1
George, J; Nguyen, V; van der Poorten, D1
Czeche, S; Feldt, S; Franzmann, A; Ludwig, WD; Quinzler, R; Schulz, M; Schüssel, K1
Culig, Z; Erb, HH; Hobisch, A; Oh, SJ; Santer, FR1
Dummer, R; Karpova, MB; Levesque, MP; Mangana, J1
Abrams, SL; Andreeff, M; Bergamo, P; Chiaretti, S; Ciuffreda, L; Cognetti, F; Del Bufalo, D; Foà, R; Konopleva, M; Marchetti, A; Mascolo, MG; McCubrey, JA; Milella, M; Petrucci, MT; Ricciardi, MR; Scerpa, MC; Steelman, LS; Tafuri, A; Tavolaro, S; Tsao, T1
Dufour, JF1
Hidaka, H; Kaneko, T; Koizumi, W; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M1
Chan, P; Cheung, TT; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T1
Döme, B; Török, S1
Abraldes, JG; Bosch, J; D'Amico, M; Fernández, M; García-Pagán, JC; García-Pras, E; Mejías, M1
Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tang, Y; Tye, G; Yacoub, A1
Ara, T; Buettner, R; DeClerck, YA; Jove, R; Jove, V; Nam, S; Seeger, R; Wang, Y; Wu, J; Xin, H; Xu, Y; Yang, F; Yu, H1
LeBlanc, M; Tangen, C1
Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B1
Bozzarelli, S; Carnaghi, C; Giordano, L; Pedicini, V; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Sclafani, F; Tronconi, MC1
Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O1
Camidge, DR; Dasari, A; Diab, S; Drabkin, HA; Flaig, TW; Gore, L; Jimeno, A; Lewis, KD; Messersmith, WA; Weekes, CD1
Cillo, U; Lombardi, G; Ramirez Morales, R; Vitale, A1
Artéaga, C; Brardjanian, S; Coton, T; Fabries, P; Guisset, M; Pauleau, G1
Boudou-Rouquette, P; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mallet, V; Mir, O; Pol, S; Ropert, S; Sogni, P1
Mudur, G1
Jung, CK; Kang, JH; Kim, JO; Oh, JE; Shin, JY; Yoon, SA; Zhang, XH1
Chan, SL; Ma, BB; Mok, T1
Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS1
Graziadei, I; Grünberger, B; Hucke, F; Kölblinger, C; Königsberg, R; Maieron, A; Müller, C; Peck-Radosavljevic, M; Pinter, M; Sieghart, W; Stauber, R; Vogel, W1
Hye Khan, MA; Imig, JD; Nagasawa, T1
Attkisson, E; Aust, MM; Ferreira-Gonzalez, A; Grant, S; Rahmani, M; Williams, DC1
Spechler, SJ; Wang, DH; Xie, B1
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, JL; Park, I; Park, K; Park, S; Song, C1
Li, ZD; Liao, Y; Liu, Y; Zuo, GQ1
Haritoglou, C; Hirneiss, C; Kampik, A; Kernt, M; Koenig, S; Neubauer, AS; Thiele, S; Ulbig, MW1
An, L; Bai, W; Chang, X; Chen, Y; Lou, M; Lu, Y; Lv, J; Qu, J; Wang, C; Yang, Y; Zeng, Z; Zhou, L1
Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M1
Espat, NJ; Falanga, V; Katz, SC; Kurniali, PC; O'Gara, K; Somasundar, P; Wang, LJ; Wang, X1
Chen, J; He, Z; Sun, W; Xu, W; Yao, J1
Cohen, RA; Feusner, JH; Lo, L; Marsh, AM1
Abell, AN; Chen, X; Darr, DB; Duncan, JS; Earp, HS; Frye, SV; Gomez, SM; Granger, DA; Graves, LM; He, X; Hoadley, KA; Jin, J; Johnson, GL; Johnson, NL; Jordan, NV; Kim, WY; Kuan, PF; Major, B; Midland, AA; Nakamura, K; Perou, CM; Sharpless, NE; Smalley, DM; Usary, J; Whittle, MC; Zawistowski, JS; Zhou, B1
Baldus, C; Basara, N; Brugger, W; Burchert, A; Dreger, P; Fey, M; Finck, A; Giagounidis, A; Götze, K; Heinicke, T; Kröger, M; Linn, YC; Metzelder, SK; Meyer, RG; Mori, M; Müller, L; Neubauer, A; Reiter, A; Salih, HR; Schäfer-Eckart, K; Scholl, S; Schroeder, T; Schultheis, B; Stuhlmann, R; Vöhringer, M1
Cortes, J; Daver, N1
Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M1
Braun, S; Brummer, T; Capper, D; Eisenhardt, AE; Fiala, GJ; Halbach, S; Heilmann, K; Herr, R; Röring, M; Saunders, DN; Schamel, WW; von Deimling, A1
Cui, PH; Doddareddy, MR; Edwards, RJ; Ghassabian, S; Hibbs, DE; Murray, M; Rawling, T; Tattam, BN; Zhou, F1
Barbare, JC; Chauffert, B; Diouf, M; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC; Trécherel, E1
Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T1
Heo, J; Woo, HY2
Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR1
Chan, SL; Johnson, P1
Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, Y; Wang, ZJ1
Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, KH; Kim, SG; Kim, YJ; Kim, YS; Lee, JE; Lee, SH1
Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, EH; Kim, SU; Lee, DY; Park, JY; Park, MS; Seong, J1
Byun, SS; Hong, SK; Jeong, CW; Jeong, SJ; Kwak, C; Lee, SE; Yoon, CY1
Byrne, M; Estfan, B; Kim, R1
Basu, B; Kaye, SB; Molife, LR; Moreno Garcia, V1
Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS1
Hayashi, N; Ikeda, I; Inoue, T; Kishida, T; Kobayashi, K; Kubota, Y; Makiyama, K; Minamimoto, R; Miura, T; Murakami, T; Nakaigawa, N; Noguchi, S; Ohgo, Y; Sano, F; Tateishi, U; Ueno, D; Yao, M1
Amato, R; DeFoe, M; Saxena, S; Willis, J; Zhai, J1
Bai, XZ; Han, XR; Sun, Y1
Aktürk, M; Baloş Törüner, F; Coşkun, U; Demirci, U; Konca Degertekin, C1
Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT1
Escobar-Jiménez, F; García-Martín, A; López-Ibarra Lozano, PJ; Triviño-Ibáñez, EM1
Dong, Z; Nör, JE; Zeitlin, BD1
Anichini, A; Barbati, C; Carlo-Stella, C; Corradini, P; Devizzi, L; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Guidetti, A; Lanocita, R; Locatelli, SL; Malorni, W; Marchianò, A; Matteucci, P; Mortarini, R; Pierdominici, M; Tarella, C1
Lucas, LM1
De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R1
Anderson, BE; Mackay, D; Svoboda, RM; Welsch, MJ1
Fujisawa, M; Gleave, ME; Kususda, Y; Miyake, H1
Hou, T; Li, Y; Ma, Y; Peng, H; Ren, Z; Wei, Y; Zhao, Q1
Hagiwara, S; Inoue, T; Kudo, M; Nagai, T; Nishida, N; Sakurai, T; Ueshima, K; Watanabe, T1
Powles, T1
Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G1
Freeman, C; Giles, F; Swords, R1
Arcaroli, J; Azad, N; Carducci, MA; Dasari, A; Diaz, LA; Donehower, RC; Hidalgo, M; Laheru, DA; McManus, M; Messersmith, WA; Quackenbush, K; Rudek, MA; Taylor, GE; Wright, JJ; Zhao, M1
Gradishar, WJ1
Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY1
Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K1
Duan, F; Gu, J; Jia, D; Liu, X; Ren, S; Ruan, Y; Sun, L; Sun, Z; Wang, L; Zhou, L1
Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W1
Kuczyk, MA; Schnoeller, TJ; Schrader, AJ; Schrader, M; Steffens, S1
Cheng, CW; Chong, TW; Huynh, H; Lau, WK; Ong, RW; Sim, HG; Sim, MY; Yuen, JS1
Aiello, RA; Alì, M; Caruso, M; La Rocca, R; Licciardello, P; Sanò, MV; Scandurra, G; Taibi, E; Todaro, FM1
Fabris, L; Ferrero, C; Fiorotto, R; Kim, AK; Locatelli, L; Morell, CM; Okolicsanyi, S; Spirli, C; Strazzabosco, M1
He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y1
Donsky, RS; Fletcher, JA; Griffith, DJ; Heinrich, MC; Liang, CW; Marino-Enriquez, A; McKinley, A; Patterson, J; Presnell, A; Taguchi, T1
Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Kanekawa, T; Matsui, D; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N1
Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M1
Cicala, MV; Fassina, A; Finco, I; Frigo, AC; Iacobone, M; Mantero, F; Mariniello, B; Pezzani, R; Rosato, A; Rubin, B; Zuccolotto, G1
Allegood, J; Bareford, MD; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Ogretmen, B; Park, MA; Poklepovic, A; Spiegel, S1
Spârchez, Z1
Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K1
Buchler, T; Cathomas, R; Chastonay, R; Haile, SR; Knuth, A; Liewen, H; Porta, C; Renner, C; Rothermundt, C; Samaras, P; Siciliano, RD; Stenner, F; Stoll, S1
Cagan, RL; Dar, AC; Das, TK; Shokat, KM1
Du, H; Li, H; Lin, A; Peng, C; Qiu, W; Seewoo, V; Shen, B; Wang, J; Yang, W1
Bouzin, C; Calderon, PB; Charette, N; Danhier, P; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Kengen, J; Magat, J; Mignion, L; Sonveaux, P; Starkel, P; Verrax, J1
Agarwala, SS; Chen, CC; Garay, CC; Gesme, DH; Guo, A; Hess, GP; Hill, JW; Liu, Z1
Bilim, VN; Kato, T; Kawazoe, H; Nagaoka, A; Naito, S; Tomita, Y; Ugolkov, AV; Yuuki, K1
Ayala, R; Canal, A; Castro, N; Grande, C; Martínez-López, J; Rueda, D1
Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M1
Biasco, G; Erente, G; Lolli, C; Mandrioli, A; Nannini, M; Pantaleo, MA; Saponara, M1
Filipiak, KJ; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Waśko-Grabowska, A; Zaborowska, M; Żołnierek, J1
Celeghini, C; di Iasio, MG; Lanza, F; Melloni, E; Ongari, M; Secchiero, P; Tiribelli, M; Voltan, R; Zauli, G1
Bass, MB; Deptala, A; Dirix, LY; Escudier, B; Fishman, M; Koralewski, P; Kracht, K; Puhlmann, M; Ramlau, R; Ravaud, A; Rini, B; Rogowski, W; Sun, YN; Szczylik, C; Tannir, NM; Tomczak, P1
Chen, G; Huang, N; Huang, XP; Lin, X; Peng, S; Roth, BL; Wang, S; Wang, SX; Wang, Y; Whaley, R; Zhang, G1
Dong, J; Evers, BM; Gao, T; Gulhati, P; Kim, JT; Lee, EY; Sasazuki, T; Shirasawa, S; Stevens, PD; Valentino, JD; Weiss, HL; Zaytseva, YY1
Bronowicki, JP; Chen, XP; Cihon, F; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK1
Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R1
Endo, Y; Kai, K; Kawai, T; Koujima, T; Matsumoto, Y; Miyamoto, M; Nobuhisa, T; Sato, S; Toda, K; Watanabe, N; Watanabe, T; Watanabe, Y1
Fujisawa, A; Matsumura, Y; Miyachi, Y; Ono, S; Tanioka, M; Tanizaki, H1
Cowey, CL; Gohil, H; Khandani, AH; Moore, DT; Rathmell, WK1
Bockisch, A; Ertle, J; Lauenstein, TC; Müller, S; Schlaak, JF; Schlosser, TW; Theysohn, JM1
Chen, CS; Chen, JM; Gong, GQ; Liu, LX; Liu, QX; Liu, R; Luo, JJ; Qian, S; Qu, XD; Wang, JH; Yan, ZP1
Huang, W; Jiang, F; Li, S; Li, Y; Yao, S; Yao, Z; Yu, S; Yuan, S; Zhan, W; Zhao, Y1
Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D1
Chiang, CP; Hung, CT; Wu, BY1
Gold, KA; Kim, E; Zhang, J1
Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D1
Bae, SH; Chung, YH; Kim, BI; Kim, JA; Koh, KC; Lee, D; Lee, HC; Lee, JH; Park, NH; Shim, JH; Shin, ES; Yoon, JH1
Billemont, B; Blanchet, B; Boudou-Rouquette, P; Cabanes, L; Coriat, R; Franck, N; Goldwasser, F; Mir, O; Ropert, S; Tod, M1
Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S1
Fujimoto, K; Gemma, A; Horiuchi-Yamamoto, Y; Inoue, Y; Johkoh, T; Kudoh, S; Sakai, F; Taniguchi, H1
Geisberg, C; Pentassuglia, L; Sawyer, DB1
Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Neri, E; Parisi, G; Romano, A; Sacco, R; Sodini, E; Tumino, E1
Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R1
Fuziwara, CS; Hirokawa, M; Matsuse, M; Mitsutake, N; Miyauchi, A; Nishihara, E; Ogi, T; Saenko, VA; Suzuki, K; Tanimura, S; Yamashita, S1
Angulo, P; Chen, C; Creasy, KT; Daily, MF; Evers, BM; Gedaly, R; Hundley, J; Shah, M; Spear, BT1
Avril, MF; Billemont, B; Blanchet, B; Coriat, R; Franck, N; Goldwasser, F; Lebbe, C; Mir, O; Pécuchet, N; Tod, M; Viguier, M1
Dahan, L; Delpero, JR; Esterni, B; François, E; Gasmi, M; Genre, D; Gilabert, M; Giovannini, M; Gonçalves, A; Lamy, R; Largillier, R; Moureau-Zabotto, L; Perrier, H; Raoul, JL; Re, D; Seitz, JF; Tchiknavorian, X; Turrini, O; Viens, P1
He, X; Hu, BS; Li, Y; Lu, LG; Luo, XN; Shao, PJ; Yu, XY1
Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H1
Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S; Satoh, T; Tabata, K; Tanabe, K1
Chen, J; Chen, L; Jiang, Y; Li, C; Li, Y; Ma, Y1
Cao, L; Li, B; Li, YM; Sui, CJ; Yin, ZF; Zhang, XF; Zhou, YM1
Yan, SJ; Zhang, FM; Zhang, H1
Gao, H; Hu, S; Jiang, H; Kong, J; Li, Z; Shi, B; Yang, Y; Yao, M; Zhang, P1
Kashima, T; Ohno, Y; Tachibana, M1
Hidaka, H; Kobayashi, S; Kondo, M; Matsunaga, K; Morimoto, M; Numata, K; Ohkawa, S; Okuse, C; Okuwaki, Y; Shibuya, A; Suzuki, M; Takada, J; Tanaka, K1
Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R1
Hatano, E; Iwaisako, K; Koyama, Y; Miyagawa-Hayashino, A; Nagata, H; Nakamura, K; Narita, M; Taura, K; Uemoto, S1
Halfdanarson, TR; Naraev, BG; Strosberg, JR1
Bria, E; Pilotto, S; Tortora, G1
Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G2
Beumer, JH; Bitran, JD; Christner, SM; Egorin, MJ; Lestingi, TM; Nabhan, C; Tolzien, K; Valdez, TV; Villines, D1
Alsinet, C; Barretina, J; Bruix, J; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Mazzaferro, V; Minguez, B; Newell, P; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC1
Singal, AG; Subramanian, M; Yopp, AC1
Giaccone, G; Killian, KJ; Lee, C; Lee, HS; Luo, J; Meltzer, PS; Petrini, I; Roncalli, M; Santoro, A; Steinberg, SM; Tsokos, M; Wang, Y; Zucali, PA1
Bhaumik, S; Biswas, T1
Feng, M; Liu, X; Wang, Q; Wang, Z; Yu, T; Yuan, Y; Zhuang, H1
Barbero, C; Campisi, P; Centofanti, P; Giorgi, M; Molino, F; Rinaldi, M; Salizzoni, S1
Kaklamani, V; Raffin, M; Reddy, S1
Banerjee, P; Basu, A; Choi, AM; Gasser, M; Mizumura, K; Otterbein, LE; Pal, S; Waaga-Gasser, AM; Wegiel, B1
Choi, J; Hwang, JJ; Jang, S; Jeong, IG; Kim, CS; Kim, DE; Kim, MJ; Lee, JH; Ro, S1
Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E1
Claasen, J; Frenzel, LP; Gehrke, I; Hallek, M; Krause, G; Kuckertz, M; Patz, M; Veldurthy, A; Wendtner, CM1
Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC1
Alberola, V; Bennouna, J; Biesma, B; Eisen, T; Gans, S; Gottfried, M; Heigener, D; Le Marie, E; Liao, M; Montegriffo, E; Ong, TJ; Paz-Ares, LG; Santoro, A; Strauss, UP; Sun, Y; Syrigos, K; Vansteenkiste, J; von Pawel, J; Zhang, L1
Baumann, C; Dahal, BK; Davie, N; Evans, S; Fairman, D; Ghofrani, HA; Grimminger, F; Kilty, I; Kojonazarov, B; Kosanovic, D; Luitel, H; Majewski, M; Phillips, P; Pullamsetti, SS; Schermuly, RT; Seeger, W; Sydykov, A; Tian, X; Wayman, C; Weissmann, N1
Amigo, G; Antón, A; Esquerdo, G; García-Otín, AL; Lanzuela, M; Martín-Duque, P; Pazo-Cid, RA; Pérez-Gracia, JL; Trufero, JM1
Fukuda, K; Kataoka, M; Ono, T; Sano, M; Satoh, T; Tamura, Y1
Brown, P; Leahy, D; Levis, M; Li, L; Nguyen, B; Small, D; Williams, AB1
Arai, Y; Kawashima, A; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M1
Kaneko, S; Yamashita, T1
Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H2
Chen, KF; Chen, PJ; Hsu, CY; Huang, JW; Kim, I; Liu, CY; Shiau, CW; Tai, WT1
Matsui, O1
Yamashita, T1
Hatano, E; Kokudo, N; Nakajima, J; Numata, K1
Furuse, J; Ikeda, K; Ikeda, M; Izumi, N; Kokudo, N; Kudo, M; Matsui, O; Tateishi, R; Yamashita, T1
Díaz-Rubio, E; Ladero, JM; Manzano, A; Puente, J; Sastre, J; Zugazagoitia, J1
Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E1
He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF1
Fukui, I; Kitsukawa, S; Saito, K; Takahashi, S; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J; Yuasa, T1
Aikata, H; Chayama, K; Hiramatsu, A; Honda, Y; Kawaoka, T; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Takahashi, S; Takaki, S; Tanaka, M; Waki, K1
Arao, T; Arii, S; Hagiwara, S; Haji, S; Hakamada, K; Hiasa, Y; Hidaka, H; Hirooka, M; Hisai, H; Iso, Y; Izumi, N; Kanazawa, A; Kimura, H; Kubota, K; Kudo, M; Kumada, T; Kuzuya, T; Matsumoto, K; Nagai, T; Nishio, K; Sakurai, T; Sato, S; Shimada, M; Toyoda, H; Toyoki, Y; Tsuchiya, K; Ueshima, K; Utsunomiya, T; Yasui, K1
Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C1
Açmaz, G; Akkar, OB; Atilgan, R; Boztosun, A; Kosar, MI; Ozer, H1
Alexandre, J; Batteux, F; Chaussade, S; Chéreau, C; Coriat, R; Goldwasser, F; Mir, O; Nicco, C; Ropert, S; Weill, B1
Fan, X; Haney, CR; Karczmar, GS; Markiewicz, E; Mustafi, D; Stadler, WM1
Inoue, T; Kawa, G; Kawabata, T; Kinoshita, H; Komai, Y; Matsuda, T; Uemura, Y1
Bitzer, M; Föller, M; Jilani, K; Lang, E; Lang, F; Lupescu, A; Pasham, V; Plate, A; Qadri, SM; Shaik, N; Zbidah, M; Zelenak, C1
Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Golmard, JL; Loriot, MA; Mir, O; Narjoz, C; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M1
Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW1
Chou, H; Fiel, MI; Friedman, SL; Hong, F1
Fínek, J1
Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY1
Friedman, SL1
Chung, HC; Jeong, I; Jeung, HC; Kim, GE; Kim, YB; Lee, K; Rha, SY1
Saito, K1
Anmarkrud, JA; Huitfeldt, HS; Line, PD; Liu, SZ; Scholz, H; Shi, JH; Wierød, L; Zhang, SJ1
Baker, SD; Chaudhry, AS; Finkelstein, D; Gibson, A; Inaba, H; Li, L; Roberts, JL; Rubnitz, JE; Schuetz, EG; Zimmerman, EI1
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S1
Chen, GG; Ho, RL; Lai, PB; Liu, LP1
Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL1
Secchiero, P; Tisato, V; Voltan, R; Zauli, G1
Dogan, E; Koca, D; Olmez, A; Yalcin, S1
Abou-Alfa, GK; Ang, C; O'Reilly, EM1
Ahn, SK; Eum, KH; Kang, H; Lee, M1
Gao, PT; Han, BH; Li, GL; Li, HJ; Ma, J; Mao, WF; Shao, MH; Yuan, CG1
Chen, D; Chen, W; Liang, LJ; Yang, D; Yin, XY; Zhao, P1
Björkholm, M; Celsing, F; De Raeve, H; Fristedt, C; Grandér, D; Gruber, A; Jernberg-Wiklund, H; Johnsson, P; Kharaziha, P; Kokaraki, G; Laane, E; Li, Q; Osterborg, A; Panaretakis, T; Panzar, M; Vanderkerken, K; Zhivotovsky, B1
Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L1
Maly, DJ; Ranjitkar, P1
Arie, S1
Chu, SH; Civin, C; Collector, M; Heiser, D; Huso, D; Kaplan, I; Li, L; Sharkis, SJ; Small, D1
Abraham, J; Carew, JS; Chua, YX; Druker, BJ; Giles, FJ; Glover, JM; Keller, C; Kilcoyne, A; Loriaux, MM; Michalek, JE; Nelon, LD; Ouyang, Y; Pal, R; Rubin, BP; Tyner, JW1
Balis, FM; Choyke, PL; Dombi, E; Fox, E; Jayaprakash, N; Kim, A; Korf, B; Martin, S; Muradyan, N; Reddy, A; Tepas, K; Turkbey, B; Widemann, BC; Wolters, P1
Brümmendorf, TH; Gambacorti-Passerini, C; Wege, H1
Axelrod, M; Capaldo, BJ; Gioeli, D; Jensen, K; Mackey, A; Roller, DG; Weber, MJ1
Adamson, PC; Balis, FM; Baruchel, S; Blaney, SM; Burke, M; Fox, E; Glade Bender, J; Ingle, AM; Kim, A; Stempak, D; Weigel, B; Widemann, BC1
Allensworth, JL; Devi, GR; Diehl, AM; Lyerly, HK; Morse, MA; Rangwala, F; Smith, GR; Thomas, Z; Williams, KP1
Boni, C; Bracarda, S; Caserta, C; Cinquini, M; Cortesi, E; De Angelis, V; Di Costanzo, F; Falcone, A; Gasparro, D; Labianca, R; Mucciarini, C; Paglino, C; Pazzola, A; Porta, C; Santoro, A1
Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y1
Ebert, MP; Schott, E; Trojan, J1
Hanumanthu, PL; Keechilat, P; Koyakutty, M; Malarvizhi, GL; Menon, D; Menon, K; Mony, U; Nair, S; Prabhu, R; Retnakumari, AP; Sidharthan, N; Thampi, MV1
Ma, YT; Palmer, DH1
Bottai, G; Santarpia, L1
Dekker, H; Galvani, E; Giovannetti, E; Honeywell, R; Labots, M; Lind, JS; Peters, GJ; Sciarrillo, R; Smit, EF; Verheul, HM1
Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G1
Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ1
Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Chu, PY; Ichikawa, K; Liu, CY; Shiau, CW; Tai, WT1
Bussolati, B; Cassoni, P; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A1
Carbone, DP; Hanna, NH; Lee, JW; Schiller, JH; Traynor, AM; Wakelee, HA1
Boedi, P; Ganggaiswari, A; Gani, RA; Hasan, I; Lesmana, LA; Luwia, MS; Waspodo, A1
Berger, MR; Galle, PR; Gockel, I; Graf, C; Hainz, M; Hamdi, S; Maderer, A; Moehler, M; Schimanski, CC; Schmidtmann, I; Theobald, M; Wehler, TC1
Del Rio, A; Grossi, V; Ingravallo, G; Liuzzi, M; Martelli, N; Murzilli, S; Napoli, A; Simone, C1
Tan, P; Wei, A1
Kondo, T1
Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T1
Bechstein, WO; Trojan, J; Welker, MW; Zeuzem, S1
Barbier, EL; Bouchet, A; Christen, T; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Serduc, R1
Puche-Sanz, I; Vázquez-Alonso, F1
O'Connor, TM; O'Reilly, SP; Power, DG; Teo, M1
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S1
Camera, L; Colao, A; Del Prete, M; Esposito, R; Faggiano, A; Fonti, R; Marotta, V; Palmieri, G; Ramundo, V; Salvatore, M; Vitale, M1
Breaker, K; Clemons, J; Flaig, TW; Gao, D; Garfield, D; Naam, M1
Fang, D; Gao, J; Liu, J; Rao, Z; Zhang, A; Zhang, B; Zhang, Y; Zhao, J; Zhao, Y1
Chen, J; Fang, H; He, Z; Sun, W; Xu, W; Yao, J1
Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N1
Atkinson, B; Chen, A; Sevin, A1
Andreeff, M; Borthakur, G; Jin, L; Kantarjian, H; Konopleva, M; Lu, H; Miida, T; Tabe, Y1
Arma, D; Balabaud, C; Bexiga, MG; Bioulac-Sage, P; Blanc, JF; Castain, C; Chevet, E; Higa, A; Le Bail, B; Marza, E; Rosenbaum, J; Simpson, JC; Taouji, S; Yi, P1
Banzi, M; Boni, C; Carnaghi, C; Ceriani, R; Cortesi, E; Covini, G; De Giorgio, M; Fagiuoli, S; Fanello, S; Ferrari, D; Giordano, L; Labianca, R; Latini, L; Locopo, N; Lutman, FR; Mucciarini, C; Naimo, S; Porta, C; Pressiani, T; Rimassa, L; Salvagni, S; Santoro, A; Tommasini, MA; Torzilli, G; Tronconi, MC1
Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS1
Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C1
Allemeersch, J; Carmeliet, P; Casteleyn, C; Colle, I; Coulon, S; Geerts, A; Heindryckx, F; Libbrecht, L; Stassen, JM; Terrie, E; Van Vlierberghe, H1
Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M1
Bandeali, S; Brammer, JE; Lulla, PD; Lynch, GR1
Fetterly, GJ; Jusko, WJ; Ma, WW; Pawaskar, DK; Straubinger, RM2
Dai, B; Qin, XJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP1
Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I1
Fan, J; Huang, XW; Qiu, SJ; Shi, RY; Wang, WM; Wang, Z; Xu, Y; Yang, XR; Zhang, X; Zhou, J1
Assouline, SE; Brandwein, J; Caplan, S; Couban, S; Eisenhauer, EA; Foo, A; Kamel-Reid, S; Leber, B; Macdonald, DA; Walsh, W1
Banzato, A; Bertorelle, R; Ciccarino, P; Della Puppa, A; Denaro, L; Farina, P; Fiduccia, P; Gardiman, MP; Lombardi, G; Polo, V; Zagonel, V; Zustovich, F1
Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W1
Chang, CC; Chen, YC; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Lin, YL1
Dingemans, AM; Grigorieva, J; Groen, HJ; Kuiper, JL; Lind, JS; Roder, H; Roder, J; Smit, EF1
He, L; Hu, Y; Li, Q; Liu, M; Xi, M; Zhao, L1
Bühler, A; Döhner, H; Jebaraj, BM; Kienle, D; Stilgenbauer, S; Winkler, D; Zenz, T1
Luyken, J; Neuhaus, T1
Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B1
Cabrera, R; Clark, V; Firpi, R; Horne, P; Limaye, AR; Mills, R; Morelli, G; Nelson, DR; Soldevila-Pico, C1
Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK1
Rosenthal, H; von Falck, C; Wacker, F1
Albiges, L; Escudier, B; Iacovelli, R; Lanoy, E1
Hildt, E; Himmelsbach, K1
Cabrera, R; Cao, M; Liu, C; Nelson, DR; Ogunwobi, OO; Puszyk, WM; Tian, C; Wang, T; Zhao, X1
Cronauer, MV; Höpfner, M; Nitzsche, B; Schrader, AJ; Schrader, M; Streicher, W; Zengerling, F1
Dekervel, J; Nevens, F; Van Cutsem, E; van Malenstein, H; van Pelt, J; Verslype, C; Windmolders, P1
Duffy, A; Greten, TF; Wilkerson, J1
Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ1
Karakiewicz, PI; Sun, M; Trinh, QD1
Cabibbo, G; Campisi, G; Compilato, D; Genco, C1
Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M1
Sattler, M; Weisberg, E1
Dekkers, OM; Smit, JW; Verloop, H1
Fukuda, K; Kataoka, M; Satoh, T; Yanagisawa, R; Yoshino, H1
Chao, Y; Chung, YH; Han, G; Kim, BI; Lee, TY; Shao, GL; Wang, J; Yang, J; Yoon, JH2
Boersma-van Ek, W; de Jong, S; de Vries, EG; Hollema, H; Kleibeuker, JH; Kruyt, FA; Pennarun, B1
Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P1
Hensley, JR; Kulik, L; Lacouture, ME; Mulcahy, M; Nardone, B; Rademaker, A; West, DP1
Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J1
Atkins, MB; Cheng, S; Choueiri, TK; Pastorek, J; Qu, AQ; Signoretti, S1
Gu, K; He, M; Jiang, GL; Lai, S; Ma, N; Ren, Z; Shao, C; Yu, W; Yu, Z; Yuan, D; Zhang, X; Zhao, J1
Baker, SD; Billups, CA; Davidoff, AM; Fofana, D; Furman, WL; Hu, S; Leung, W; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Reddick, WE; Santana, VM; Spunt, SL; Stewart, CF; Turner, D; Wu, J1
Fouzas, I; Klein, CG; Kykalos, S; Nowak, KW; Paul, A; Sotiropoulos, GC; Vernadakis, S1
Bertossi, M; De Sanctis, R; De Vincenzo, F; Di Tommaso, L; Fattuzzo, G; Giordano, L; Lorenzi, E; Mancini, L; Masci, G; Perrino, M; Rimassa, L; Roncalli, MG; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA; Zuradelli, M1
Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y1
Hernandez-Gea, V; Llovet, JM; Villanueva, A1
Adachi, M; Akaza, H; Hyodo, I; Murai, M; Naito, S; Tsukamoto, T1
Bex, A; de Bruijn, R; Horenblas, S; Kroon, BK; Powles, T; Prevoo, W1
Grill, V; Melloni, E; Rimondi, E; Secchiero, P; Zauli, G1
Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M1
Altun, A; Boztosun, A; Gulturk, S; Kiliçkap, S; Müderris, II; Ozer, H; Yanik, A1
Al-Riyami, AZ; Forrest, D; Hudoba, M; Young, S1
Dei Tos, AP; Del Vescovo, R; Frezza, AM; Santini, D; Schiavon, G; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB1
Lin, CI; Lorch, JH; Ruan, DT; Whang, EE1
Carr, BI; Cavallini, A; Correale, M; D'Alessandro, R; Di Carlo, A; Iacovazzi, PA; Lippolis, C; Messa, C; Refolo, MG1
Huang, GL; Liu, GJ; Lü, MD; Wang, W; Xie, XH; Xie, XY; Xu, M; Xu, ZF; Zheng, SG; Zheng, YL1
Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY1
Arkadopoulos, N; Dimitriadis, G; Psyrri, A; Smyrniotis, V; Vassilakopoulou, M1
Galle, PR; Gamstätter, T; Koch, S; Marquardt, JU; Nguyen-Tat, M; Niederle, IM; Schuchmann, M; Schulze-Bergkamen, H; Weinmann, A; Wörns, MA1
Hoekstra, R; Honeywell, RJ; Peters, GJ; van Erp, NP; Verheul, HM; Westgeest, HM1
Ceder, S; Kharaziha, P; Panaretakis, T; Sanchez, C1
Hegde, U; Kaloudis, E; Patel, V1
Chang, AY; Wang, M1
Guo, H; Lv, Y; Nan, KJ; Ruan, ZP; Tian, T; Wang, WJ; Xu, R1
Bearz, A; Berretta, M; Cacopardo, B; Dal Maso, L; De Re, V; Di Benedetto, F; Facchini, G; Fiorica, F; Garlassi, E; Lleshi, A; Nasti, G; Spina, M; Tirelli, U1
Chen, CL; Cheng, YF; Hsu, HC; Kuo, YH; Lu, SN; Wang, CC; Wang, JH1
Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L1
Ararat, M; Atkinson, MA; Brusko, T; Cabrera, R; Chang, LJ; Liu, C; Nelson, DR; Wasserfall, C; Xu, Y1
Burgers, SA; Dingemans, AM; Groen, HJ; Heideman, DA; Kunst, PW; Mellema, WW; Smit, EF; Thunnissen, E; van Wijk, A1
Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS1
Chen, J; Sun, W; Xu, WF; Yao, JW1
Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ1
Basso, U; Bertuzzi, A; Boglione, A; Comandone, A; De Sanctis, R; Giordano, L; Lutman, FR; Marcon, I; Santoro, A; Soto Parra, H; Stroppa, E1
Collier, J; Eisen, T; Fairfax, BP; Kaplan, R; Macaulay, VM; Meade, AM; Pratap, S; Protheroe, A; Ritchie, AW; Roberts, IS1
Cohen, MS; Cohen, SM; Mukerji, R; Samadi, AK; Timmermann, BN1
Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Navarro, A; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S1
Hu, GY; Yang, L; Yu, SY1
Fujishima, N; Habuchi, T; Hasunuma, N; Hatakeyama, S; Horikawa, Y; Inoue, T; Narita, S; Notoya, T; Numakura, K; Ohyama, C; Satoh, S; Tsuchiya, N1
Shlomai, A1
Bräuninger, A; Gattenlöhner, S; Holz, MS; Janning, A; Renné, C; Spieker, T1
Dai, X; Ganten, MK; Ganten, TM; Höh, K; Schlemmer, HP; Schmidt, B; Xu, K1
Bardet, V; Boudou Rouquette, P; Bouscary, D; Chapuis, N; Chesnais, V; Coriat, R; Fontenay, M; Kaltenbach, S; Kosmider, O; Mayeux, P; Radford-Weiss, I; Tamburini, J; Willems, L1
Acierno, R; Alberti, S; del Boccio, P; Giannelli, G; Maffia, M; Pieragostino, D; Sacchetta, P; Salzet, M; Simeone, P; Tinelli, A; Toto, C; Vergara, D1
Atkins, MB; Flaherty, KT; Flaherty, L; Kefford, R; Kirkwood, JM; Lee, SJ; Leming, P; Schuchter, LM; Zhao, F1
Arai, Y; Nakayama, M; Nishimura, K1
Ambring, A; Björholt, I; Lesén, E; Odén, A; Stierner, U1
Flaherty, KT; Heitjan, DF; Kang, HC; Keefe, SM; O'Dwyer, PJ; Rosen, MA; Siegelman, ES; Tan, KS1
Cappelleri, JC; Chen, C; Foley, G; Healey, PJ; Kroes, M; Larkin, J; Mitchell, S; Paine, A; Tumur, I1
Goertz, RS; Knieling, F; Strobel, D; Waldner, MJ1
Hayasaka, K; Kanno, M; Kawakami, T; Mitsui, T; Onoda, T; Sato, H; Takahashi, N1
Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Ellerkamp, V; Fuchs, J; Hildenbrand, S; Thomale, J; Warmann, SW1
Chang, CY; Cheng, AL; Hsu, C; Lin, CY; Lin, KL; Liu, SH; Ou, DL; Shen, YC1
Arizumi, T; Kudo, M; Ueshima, K1
Bernatik, T; Goertz, RS; Knieling, F; Neurath, MF; Strobel, D; Waldner, MJ; Wildner, D; Zopf, S1
Chen, CS; Chen, WM; Cheng, CL; Chiu, KY; Ho, HC; Li, JR; Ou, YC; Su, CK; Wang, SS; Yang, CK; Yang, CR1
Brunello, F; Brunocilla, PR; Cantamessa, A; Carucci, P; Castiglione, A; Ciccone, G; Gaia, S; Rizzetto, M; Rolle, E1
Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM1
Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M1
Bogot, N; Grenader, T; Rosenbaum, E; Shavit, L; Zilber, S1
Borker, R; Fonseca, E; Hess, G1
Hara, J; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Seike, K; Takagi, Y1
Frampas, E; Koscielny, S; Lassau, N; Vilgrain, V; Vullierme, MP; Zappa, M1
Pal, SK; Vogelzang, NJ1
Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A1
Beijnen, JH; Harmsen, S; Maas-Bakker, RF; Meijerman, I; Schellens, JH1
He, ZY; Hua, XD1
Hammock, BD; Hee Hwang, S; Li, C; Shiu, EY; Wecksler, AT; Weiss, RH; Wettersten, HI1
Bruno, R; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Enea, M; Gasbarrini, A; Grieco, A; Iavarone, M; Petta, S; Villa, E; Zavaglia, C1
Bar-Yehuda, S; Benjaminov, O; Ciuraru, NB; Cohen, S; Farbstein, M; Fishman, P; Fishman, S; Harpaz, Z; Kerns, WD; Medalia, G; Patoka, R; Silverman, MH; Singer, B; Stemmer, SM1
Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T1
Brandt, R; Dredge, K; Hammond, E1
An, CM; Han, ZK; Li, ZJ; Ma, J; Tang, PZ; Wang, Z1
Furuichi, Y; Imai, Y; Kamiyama, N; Moriyasu, F; Rognin, N; Saito, K; Sugimoto, K1
Ahn, SY; Kweon, YO; Lee, HS; Park, SY; Tak, WY1
Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R1
Choi, YJ; Heo, K; Lee, JH; Shim, JW; Yang, K1
Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S1
Ding, ZB; Fan, J; Huang, XY; Ke, AW; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Xiao, YS; Yan, J; Zhang, C; Zhang, X; Zhou, J1
Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z1
Bellmunt, J; Bracarda, S; Brueckner, A; Dutcher, J; Escudier, B; Hutson, TE; Knox, J; Molnar, I; Procopio, G1
Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y1
Chen, B; Chen, W; Huang, YH; Li, JP; Yang, JY1
Barbieri, F; Carra, E; Daga, A; Favoni, RE; Florio, T; Marubbi, D; Pattarozzi, A1
Fang, F; Feng, G; Huang, H; Li, G; Pu, C; Ye, X1
Chi, ZH; Cui, CL; Guo, J; Lian, B; Mao, LL; Sheng, XN; Si, L; Yang, SY1
Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X1
Amarapurkar, D; Chao, Y; Chen, PJ; Cheng, AL; Geschwind, JF; Goh, KL; Han, KH; Kudo, M; Lee, HC; Lee, RC; Lesmana, LA; Lim, HY; Paik, SW; Park, JW; Poon, RT; Tan, CK; Tanwandee, T; Teng, G1
Beuselinck, B; Blesius, A; Chevreau, C; Escudier, B; Oudard, S; Ravaud, A; Rolland, F1
Chen, YJ; Huang, YC; Ko, WC; Lee, JJ; Lin, JC; Liu, CL; Liu, TP; Wu, CH1
Angevin, E; Castellano, D; Chang, J; Escudier, B; Gschwend, JE; Harzstark, A; Kay, A; Lin, CC; Lopez-Martin, JA; Sen, P; Shi, M; Soria, JC1
Hong, S; Hong, SS; Jung, KH; Lee, H; Park, BH; Seo, JH; Son, MK; Yan, HH; Yun, SM1
Baker, SD; Gibson, AA; Hu, S; Li, L; Orwick, SJ; Roberts, JL; Sparreboom, A; Zimmerman, EI1
Bihan, H; Cohen, R; Coindre, JM; Des Guetz, G; Le Jeune, S; Mourad, JJ1
Fukamachi, S; Hosokai, H; Matsuzaki, Y; Mizuguchi, Y; Saya, H; Shimizu, A1
Ashikari, A; Kobayashi, H; Kohno, Y; Namitome, R; Nishiyama, T; Saito, S; Yagi, Y1
Bartsch, DK; Buchholz, M; Fendrich, V; Holler, JP; Maschuw, K; Rehm, J; Slater, EP; Waldmann, J1
Chen, YJ; Hsu, ML; Huang, WP; Huang, YC; Ko, WC; Lee, JJ; Lin, JC; Liu, CL; Liu, TP; Wu, CH1
Andrés, R; Arranz, JA; Cruz, J; del Muro, XG; Domenech, M; Gallardo, E; Maroto, JP; Meana, JA; Mellado, B; Perez-Gracia, JL1
Anichini, A; Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mortarini, R1
Choi, HN; Hong, SE; Jin, HO; Kim, EK; Kim, HA; Kim, JH; Lee, JK; Noh, WC; Park, IC1
Ashida, S; Fukuhara, H; Inoue, K; Kamada, M; Karashima, T; Kuroda, N; Shuin, T; Taguchi, T; Tamura, K1
Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D1
Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P1
Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Lin, CS; Liu, CY; Shiau, CW; Tai, WT1
Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M2
Bolondi, L; Burroughs, A; Dufour, JF; Galle, PR; Mazzaferro, V; Piscaglia, F; Raoul, JL; Sangro, B1
Komine, M; Maekawa, T; Maki, N; Murata, S; Ohtsuki, M; Takatsuka, Y1
Rose, S1
Afonso, FJ; Anido, U; Antón-Aparicio, L; Fernández-Calvo, O; Lázaro, M; León, L; Ramos, M; Vázquez-Estévez, S1
Biasco, G; Brandi, G; Calzà, L; Caraceni, P; Cirignotta, F; de Rosa, F; Girolamo, SD; Ricci, CS; Tufoni, M1
Agris, PF; Fanning, KD; Francis, SP; Harris, KA; Katz, J; Lacy, M; Nicholas, BD; Pagana, J; Shin, JB1
Dai, Z; Fan, J; Gu, F; Huang, X; Jiang, J; Tan, C; Wang, Z; Xu, M; Yan, J; Zhou, J1
Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD1
Ambe, CM; Anderson, AJ; Avital, I; Burka, D; Chen, JQ; Goldsmith, PK; Hari, DM; Herrmann, MA; Koizumi, T; Langan, RC; Miller, TC; Mullinax, JE; Ray, S; Rudloff, U; Stojadinovic, A; Thorgeirsson, SS; Wiegand, GW; Xin, HW1
Chen, EX; Colomer, R; Duncan, G; Grewal, M; Krzyzanowska, M; Moore, MJ; Petronis, J; Quintela-Fandino, M; Siu, LL; Stathis, A; Wang, L; Webster, S; Young, A1
Conroy, MD; Liu, AX; Liu, C; Schmidt, ES; Sviripa, V; Truong, J; Watt, DS; Zhang, W1
Chen, L; Gu, J; He, H; Liu, H; Liu, J; Liu, W; Liu, Y; Pan, D; Wang, S; Wu, Q; Xu, J; Xu, L; Zhang, H; Zhu, Y1
Ackermann, K; Friess, H; Galle, PR; Hartmann, D; Heikenwalder, M; Otto, G; Protzer, U; Puschnik, A; Reisinger, F; Ringelhan, M; Schiemann, M; Schuchmann, M; Sprinzl, MF; Weinmann, A1
He, K; Yu, J; Zhang, L; Zheng, X1
Addeo, R; Cennamo, G; Del Prete, S; Iodice, P; Montella, L; Palmieri, R; Russo, P; Sperlongano, P; Sperlongano, R; Vincenzi, B1
Kim, DY; Kim, YH1
Jiang, W; Zeng, ZC1
Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X1
Grønbæk, H; Køstner, AH; Ladekarl, M; Lassen, U; Olesen, RK; Sorensen, M1
Aglietta, M; Alberghini, M; Basiricò, M; Bruno, S; Capozzi, F; D'Ambrosio, L; Dell'Aglio, C; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Marchiò, S; Picci, P; Pignochino, Y; Sangiolo, D; Soster, M; Torchiaro, E1
Che, X; Chen, F; Chen, X; Fan, B; Song, X; Wang, J; Wang, X; Yang, D; Zhang, Z1
Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ1
Bies, RR; Jin, Y; Kang, SP; Karrison, TG; Maitland, ML; Ratain, MJ; Sharma, MR; Stadler, WM; Wu, K1
Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W1
Abadie-Lacourtoisie, S; Azzouzi, AR; Bigot, P; Chautard, D; Delva, R; Hoarau, N; Latteux, G; Lebdai, S1
Annunziata, CM; Azad, N; Calvo, K; Chen, CC; Choyke, P; Davidson, B; Edelman, DC; Henning, R; Kohn, EC; Meltzer, P; Minasian, L; Steinberg, SM; Venkatesan, A; Wood, BJ; Yu, M1
Fetterly, GJ; Hylander, BH; Jusko, WJ; Ma, WW; Pawaskar, DK; Repasky, EA; Straubinger, RM2
Vogel, W1
Chen, XG; Feng, ZQ; Huo, LC; Jin, XF; Li, Y; Qin, AF; Song, HR; Wang, K; Zhang, LJ1
Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR; Sasanuma, H1
Chang, TC; Chao, CC; Huang, SL; Sun, NK1
Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M1
Kim, BK; Kim, DY; Kim, EH; Kim, SU1
Ding, ZB; Fan, J; Gu, CY; Hui, B; Liu, WR; Peng, YF; Qiu, SJ; Shi, YH; Yang, H; Zhou, J1
Chao, Y; Feng, G; Han, G; Liu, Z; Lu, L; Shao, G; Teng, G; Wang, J; Wang, M; Yang, J; Yang, R1
Hui, KM; Ooi, LL; Xia, H1
Chen, KF; Cheng, AL; Hsieh, CY; Huang, CY; Lin, CS; Shiau, CW; Tai, WT1
Chan, JA; Jackson, N; Kulke, MH; Malinowski, P; Mayer, RJ; Regan, E1
de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A1
Berasain, C1
Brouwer, KL; Gnoth, MJ; Han, T; Lang, D; Lee, JK; Nebot, N; Proctor, WR; Radtke, M; Swift, B; Thakker, DR1
Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J1
Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A1
Awasthi, N; Hinz, S; Schwarz, MA; Schwarz, RE; Zhang, C1
Bhoori, S; Bongini, M; Flores Reyes, M; Germini, A; Grossi, G; Mariani, L; Mazzaferro, V; Sposito, C1
Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC1
Eibl, K; Haritoglou, C; Kampik, A; Kernt, M; König, S; Langer, J; Liegl, RG; Siedlecki, J; Thiele, S1
Bai, W; Fan, DM; Guan, S; Han, GH; Li, HL; Li, HP; Liu, JS; Wang, WJ; Wu, JB; Xu, RC; Yin, ZX; Zhang, ZL; Zhao, Y1
Gaba, RC; Guzman, G; Kumar, N; Li, Y; Martinez, EM; Parvinian, A; van Breemen, RB; Yap, FY1
Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E1
Bruno, R; Claret, L; Mercier, F1
Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM1
Eriksson, J; Hendrikse, NH; Poot, AJ; Rongen, M; Schuit, RC; Stigter-van Walsum, M; van der Wildt, B; van Dongen, GA; Windhorst, AD1
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y1
Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J1
Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L1
Grybäck, P; Kanter, L; Lewensohn, R; Nilsson, S; Sandström, P; Shah, CH; Sherif, A; Ullén, A; Viktorsson, K1
Harada, M; Honma, Y; Shimizu, S; Takehara, T1
Ewig, JM; Iyer, P; Mayer, JL1
Villanueva, A1
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, DH; Lee, JL; Park, I; Park, K; Park, SJ; Song, C1
D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P2
Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D1
Salem, R; Weintraub, JL1
Piscaglia, F; Salvatore, V; Venerandi, L1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A1
Kearns, PR; Knapper, S; Moore, AS; Pearson, AD; Zwaan, CM1
Banerjee, SK; Hashmi, M; Huang, CH; Leblanc, M; Mehta, S; Moon, J; Rinehart, E; Urba, SG; Williamson, S; Wolf, GT1
Banzo, I; Carril, JM; Martínez-Rodríguez, I1
Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M1
Barbare, JC; Chatelain, D; Chauffert, B; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Henaut, L; Louandre, C; Maziere, JC; Regimbeau, JM; Sabbagh, C1
Grözinger, G; Horger, M; Plentz, R1
Majno, P; Mentha, G; Toso, C1
Robert, C; Sibaud, V1
Bozzarelli, S; Carnaghi, C; Destro, A; Di Tommaso, L; Giordano, L; Ligorio, C; Personeni, N; Pressiani, T; Rimassa, L; Roncalli, M; Santoro, A; Tronconi, MC1
Pavlick, AC1
Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z1
Suh, SJ; Yim, HJ1
O'Neil, B; Sampat, KR1
Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bresci, G; Faggioni, L; Ginanni, B; Romano, A; Sacco, R1
Bhattacharyya, H; Cella, D; Chen, C; Escudier, B; Kim, S; Motzer, R; Rini, B; Rosbrook, B; Tarazi, J1
Boni, C; Bozzarelli, S; Carnaghi, C; Chiara Banzi, M; Chiara Tronconi, M; Cortesi, E; Fagiuoli, S; Fanello, S; Foa, P; Giordano, L; Personeni, N; Pressiani, T; Rimassa, L; Romano Lutman, F; Rota Caremoli, E; Salvagni, S; Santoro, A1
Akiba, J; Kusano, H; Nakayama, M; Ogasawara, S; Ueda, K; Yano, H1
Bay, JO; Blay, JY; Bompas, E; Chaigneau, L; Chevreau, C; Cioffi, A; Clisant, S; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Penel, N; Ray-Coquard, I; Robin, YM1
Chong, DQ; Choo, SP; Tan, IB; Toh, HC1
Colombo, N; Herzog, TJ; Kim, BG; Lhommé, C; Markowska, J; Oza, A; Petrenciuc, O; Ray-Coquard, I; Scambia, G; Sehouli, J; Shan, M1
Bex, A1
Chen, C; Escudier, B; Gore, ME; Hariharan, S; Hutson, TE; Kim, S; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Rini, BI; Rosbrook, B; Tarazi, J; Tomczak, P1
Cho, JY; Choi, MS; Gwak, GY; Kim, YG; Koh, KC; Lee, JH; Lim, HK; Lim, HY; Min, YW; Paik, SW; Paik, YH; Yoo, BC1
Haraldsdottir, S; Ing, SW; Kendra, K; Li, Q; Olencki, TE; Villalona-Calero, MA1
Calvani, N; Chiuri, V; Cinieri, S; Fedele, P; Gnoni, A; Lorusso, V; Maiello, E; Morelli, F; Orlando, L; Scavelli, C1
Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA1
Anthony Greco, F; Hainsworth, JD; Penley, WC; Shipley, DL; Thompson, DS; Waterhouse, DM; Webb, CD1
Gong, F; Ma, J; Shen, J; Zhang, F; Zhang, L; Zhang, P1
Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E1
Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ1
Ammi, M; Azzouzi, AR; Baumert, H; Beauval, JB; Bensalah, K; Berger, J; Bernhard, JC; Bigot, P; Escudier, B; Fardoun, T; Grenier, N; Hétet, JF; Lagabrielle, S; Lebdai, S; Long, JA; Paparel, P; Patard, JJ; Rioux-Leclercq, N; Rouprêt, M; Soulié, M; Xylinas, E1
Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H1
Waxman, DJ; Zhang, K1
Funakoshi, T; Galsky, MD; Latif, A1
Duan, W; George, J; Hu, Z; Lam, V; McLeod, D; Qiao, L; Tian, A; Wang, XM; Wilson, GS1
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T1
Aparo, S; Bakalarski, P; Berz, D; Charpentier, KP; Dubel, G; Eng, Y; Espat, J; Faricy-Anderson, K; Kaubisch, A; Luppe, D; Mantripragada, K; Martel, D; Miner, T; Perez, K; Plette, A; Rosati, K; Safran, H; Victor, J; Wingate, P1
Chung, CW; Jeong, YI; Kang, DH; Kim, CH; Kim, DH; Kwak, TW; Lee, HM1
Chandran, P; Gupta, N; Keechilat, P; Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP1
Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T1
Dent, P; Fisher, PB; Grant, S; Hamed, HA; Yamaguchi, Y1
Ferrero, S; Leone Roberti Maggiore, U; Valenzano Menada, M; Venturini, PL1
El Tal, AK; Ganger, LK; Mehregan, DA; Remichofsky, CJ1
Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J1
Dekervel, J; van Pelt, J; Verslype, C1
Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H1
Dai, XF; Ding, J; Ma, CM; Ren, JH; Wu, G; Zhang, RG1
Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM1
Gong, R; Liu, LR; Nie, LH; Song, TR; Wang, JZ; Wazir, R; Wei, Q; Zhao, RN1
Aloia, TA; Boktour, M; Burroughs, SG; Frenette, CT; Gaber, AO; Galati, J; Ghobrial, RM; Kaseb, A; Monsour, H1
Abecassis, M; Atassi, R; Baker, T; Ganger, D; Hickey, R; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, M; Nayar, R; Salem, R; Vouche, M; Yaghmai, V1
Bioulac-Sage, P; Blanc, JF; Carteret, T; Laumonier, H; Poullenot, F; Saric, J1
Shen, HJ; Wang, YH; Xu, J1
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T1
Bargellini, I; De Maria, N; De Simone, P; Dufour, JF; Goulis, I; Marinho, RT1
De Vita, F; Di Marco, V; Koskinas, J; Semela, D; Toniutto, P; Verslype, C1
Barbier, L; Belghiti, J; Faivre, S; Fuks, D; Le Treut, YP; Muscari, F; Pessaux, P1
Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY1
Al Ghazal, A; Arndt, A; Cronauer, MV; Kraft, K; Müller, J; Schrader, AJ; Schrader, M; Skowronek, P; Steinestel, J; Steinestel, K1
Fiel, I; He, X; Savić, R; Schuchman, EH1
Fu, SH; Hammock, BD; Hwang, SH; Morisseau, C; Nguyen, LV; Wecksler, AT; Zhang, G1
Augsten, M; Eriksson, LC; Hultcrantz, R; Mollbrink, A; Stål, P1
Harada, M; Honma, Y2
Bourget, K; Cui, PH; Gillani, TB; Murray, M; Rawling, T; Wang, XS; Zhou, F1
Chen, YL; Ding, X; Fang, W; Gao, F; Gao, Z; Ji, G; Liu, Y; Wang, J; Zhang, J1
Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD1
Carithers, R; Halldorson, J; Jia, N; Lin, EH; Liou, I; Perkins, J; Rao, S; Reyes, J; Stohr, E; Yeh, M1
Chen, JW; Guo, YJ; Huang, WS; Meng, XC; Pang, PF; Shan, H; Zhou, B; Zhu, KS1
Stein, SM1
Lu, J; Qiu, Y; Shen, N; Wang, Z; Wei, Y; Yang, G; Yang, N; Yi, B1
Bedikian, AY; Falchook, G; Fu, S; Ganesan, P; Hong, DS; Janku, F; Kies, M; Kurzrock, R; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Wolff, RA1
Fischer, T; Heidel, FH; Jentsch-Ullrich, K; Krogel, C; Luehr, H; Schalk, E; Schnoeder, TM; Wolleschak, D1
Aziz, K; Cades, JA; Chettiar, ST; Cosgrove, D; Gajula, RP; Gandhi, N; Geschwind, JF; Hales, RK; Herman, JM; Kumar, R; Maitra, A; Menon, S; Pawlik, TM; Taparra, K; Torbenson, MS; Tran, PT; Velarde, E; Wild, AT; Williams, RD; Wong, J; Zeng, J1
Bai, J; Chen, YL; Ding, X; Gai, L; Li, HP; Xu, L; Xu, Q; Ye, XL; Zhang, L; Zhang, X; Zhang, YX1
Angulo, P; Chen, C; Cohen, DA; Daily, MF; Evers, BM; Galuppo, R; Gedaly, R; Hundley, J; Musgrave, Y; Shah, M; Spear, BT1
Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R1
Rombolà, F; Spinoso, A1
Helft, PR1
Choi, KY; Joh, JW; Kang, KJ; Kim, DS; Kim, G; Kim, JP; Kwon, JH; Lee, N; Moon, YH; Park, JY; Shin, JH; Wang, HJ; Yu, YS1
Ayuso, C; Bruix, J; Darnell, A; Forner, A; Llarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F2
Baker, SD; Cai, X; Chen, Z; Christensen, R; Inaba, H; Li, L; Navid, F; Regel, J1
Atil, B; Berger, W; Groza, D; Heffeter, P; Jungwirth, U; Keppler, BK; Koellensperger, G; Körner, W; Kryeziu, K; Mohr, T1
Al-Marrawi, MY; Brennan, MC; Dykes, TM; El-Deiry, WS; Saroya, BS; Yang, Z1
Arai, Y; Ikeda, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Satake, M; Shimizu, S; Takahashi, H; Ueno, H1
Chan, C; Felsher, DW; Gamrekelashvili, J; Greten, TF; Hewitt, S; Kapanadze, T; Kapoor, V; Korangy, F; Ma, C; Manns, MP; Zender, L; Zhao, F1
Prado, CM1
Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM1
Albiges-Sauvin, L; Antoun, S; Baracos, VE; di Palma, M; Escudier, B; Fizazi, K; Iacovelli, R; Lanoy, E; Loriot, Y; Merad-Taoufik, M1
Fukunishi, S; Higuchi, K; Nishikawa, T; Nouda, S; Sanomura, M; Sasaki, Y; Takahashi, Y; Umegaki, E1
Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM1
Cao, D; Chen, C; Chen, SZ; Ding, J; Feng, GS; Han, T; Huang, L; Sun, W; Tang, L; Wang, HY; Wang, X; Wen, W; Wu, MC; Xiang, DM1
Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG1
Itoh, K; Komai, Y; Matsubara, N; Mukai, H; Naito, Y; Sakai, Y1
Gong, K; Li, J; Li, W; Liu, T; Mei, L; Wan, J; Yu, C1
Aikata, H; Awai, K; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Kan, H; Kawaoka, T; Kobayashi, T; Masaki, K; Miyaki, D; Naeshiro, N; Nakahara, T; Takahashi, S; Urabe, A1
Ainora, ME; Annicchiarico, BE; Caracciolo, G; Di Stasio, E; Garcovich, M; Gasbarrini, A; Landolfi, R; Lupascu, A; Pompili, M; Ponziani, F; Rapaccini, GL; Riccardi, L; Roccarina, D; Siciliano, M; Zocco, MA1
Cho, HJ; Choi, HS; Choi, JH; El-Gamal, MI; Kim, G; Lee, SH; Oh, CH; Sim, T; Yoo, KH1
Dokduang, H; Juntana, S; Khuntikeo, N; Loilome, W; Namwat, N; Riggins, GJ; Techasen, A; Yongvanit, P1
Burkhardt, C; Johnson, C; Miller, KD; Mina, LA; Yu, M; Zon, R1
Biolato, M; Grieco, A; Lombardo, A1
Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S1
Chen, MH; Chen, ML; Cheng, AL; Lu, WC; Yan, BS; Yang, PC; Yu, SL1
Chang, YC; Cheng, AL; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL1
Dufour, JF; Erös de Bethlenfalva-Hora, C; Geier, A; Kettenbach, J; Mertens, JC; Piguet, AC; Schmitt, J; Terracciano, L; Weimann, R1
Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M1
Ikehata, Y; Kitamura, H; Masumori, N; Takahashi, S; Tsukamoto, T1
Gascoyne, RD; Go, RS; Greenwald, DR; Horning, S; Kahl, BS; King, D; Kolesar, J; Li, H; Luger, SM; Patel, T1
Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH1
Bianco, R; Damiano, V; Formisano, L; Martignoni, G; Massari, F; Nappi, L; Rosa, R; Scarpa, A; Tortora, G1
Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E1
Beil, W; Holstein, A; Kovacs, P1
Chen, D; Li, SQ; Liang, LJ; Peng, BG; Xiao, WK; Yin, XY; Zhao, P1
Bartsch, DK; Doll, D; Greene, BH; Hoffmann, S; Khoruzhyk, M; Ramaswamy, A; Roth, S; Wunderlich, A1
Hashida, T; Inokuma, T; Kanamori, K; Kitada, N; Konishi, A; Suginoshita, Y; Tanaka, S1
Banerjee, P; Begum, S; Castellanos, MR; Debata, PR; Genzer, O; Kleiner, MJ; Mata, A1
Abernethy, AP; Chen, C; George, DJ; Harrison, MR; Kirkendall, DT; Korytowsky, B; Stepanski, EJ; Walker, MS1
Enomoto, M; Fujii, H; Hagihara, A; Iwai, S; Kawada, N; Kawamura, E; Morikawa, H; Tamori, A; Teranishi, Y1
Donnellan, F; Gill, S; Haque, M; Hashim, AM; Shingina, A; Suen, M; Weiss, AA; Yoshida, EM1
An, JZ; Dou, KF; Gong, ZB; He, Y; Li, JJ; Li, QJ; Li, XL; Wang, DS; Wang, S; Yang, F; You, N; Zhou, L1
Natori, T; Yamaguchi, M1
Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM1
Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M1
Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S1
Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M1
Bian, X; Bie, P; Cui, Y; Liu, C; Liu, L; Qian, C; Shan, J; Shen, J; Wu, L; Xia, F; Xu, Y; Yang, Z; Zhang, Q; Zhang, X1
Hargreaves, S; Hull, D; Hussain, SA; Johnson, PJ; Ma, YT; Palmer, DH; Ross, PJ; Smith, AJ1
Finn, RS; Gish, RG; Marrero, JA1
Fan, WZ; Huang, YH; Li, JP; Wang, Y; Yang, JY; Zhang, YQ1
Adjei, AA; Bible, KC; Croghan, G; Erlichman, C; Jett, J; Kaufmann, SH; Kumar, SK; Markovic, SN; Marks, R; Molina, J; Moynihan, T; Qin, R; Quevedo, F; Richardson, R; Tan, A1
Chen, XG; Huang, HH; Jin, B; Li, Y; Lu, CS; Ma, C; Tang, K; Yin, DL1
Allegra, M; Bahadoran, P; Ballotti, R; Bastian, BC; Bollag, G; Botton, T; Burton, EA; Garrido, MC; LeBoit, PE; McCalmont, TH; Nelson, T; Rocchi, S; Sparatta, A; Vemula, SS; Yeh, I1
Aljubran, A; Maraiki, F1
Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W1
Aulitzky, W; Berdel, WE; Blau, I; Brandts, C; Brunnberg, U; Duyster, J; Ehninger, G; Fischer, T; Giagounidis, A; Heinecke, A; Krämer, A; Kreuzer, KA; Krug, U; Kunzmann, V; Müller-Tidow, C; Neubauer, A; Noppeney, R; Ottmann, O; Reichle, A; Sauerland, MC; Schaich, M; Serve, H; Steffen, B; Stuhlmann, R; Thiede, C; Wagner, R; Wandt, H1
Amoroso, D; Andreuccetti, M; Falcone, A; Fontana, A; Galli, C; Galli, L; Landi, L; Lombardi, G; Porta, C; Zagonel, V; Zustovich, F1
Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE1
Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH1
Moroni, M; Zanlorenzi, L1
Chen, KF; Chen, PJ; Chu, PY; Huang, HP; Huang, JW; Liu, CY; Shiau, CW; Tai, WT1
Greer, PA; Leduc, C; Nagaria, TS; Sangrar, W; Squire, JA; Williams, JL1
Di Fiore, A; Di Fiore, F; Drieux, F; François, A; Kermiche-Rahali, S; Scotté, M1
Cha, J; Han, KH; Kim, JW; Lee, IJ; Seong, J1
Baracos, VE; Maia, YL; Ormsbee, M; Prado, CM; Sawyer, MB1
Barney, BM; Bauer, HJ; Laack, NN; Macdonald, OK; Markovic, SN; Miller, RC; Olivier, KR; Sarkaria, JN1
Chen, CL; Dooley, S; Feldman, D; French, SW; Jeong, JH; Kashiwabara, C; Liu, JC; Machida, K; Mishra, L; Petrovic, L; Sher, L; Tsukamoto, H1
Brandt, U; Bruix, J; Chen, LT; Finn, RS; Gomez-Martin, C; Kang, YK; Kim, TY; Klümpen, HJ; Kunz, T; Paquet, T; Poon, RT; Rodriguez-Lope, C; Sellami, D; Yau, T1
Cucchetti, A; Dietrich, CF; Piscaglia, F; Salvatore, V1
Feng, M; Li, G; Lu, L; Qian, X; Rao, J; Wang, X; Zhang, F1
D'Andrea, K; Flaherty, KT; Jilaveanu, LB; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Wilson, M; Zhao, F; Zito, CR1
Chang, KC; Chen, KF; Chu, PY; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, LM1
Escudero-Ortiz, V; Pérez-Ruixo, JJ; Valenzuela, B2
Lang, H; Ricke, J; Schlaak, J1
Deng, YR; Diehl, AM; Gershwin, ME; He, XS; Lian, ZX; Liu, CH; Liu, P; Lu, FT; Ma, HD; Tsuneyama, K; Wang, YH; Yang, W1
Dikomey, E; Gal, A; Gleißner, L; Grénman, R; Grob, TJ; Knecht, R; Kriegs, M; Laban, S; Petersen, C; Steinmeister, L1
Kobayashi, M; Komatsu, K; Kubo, T; Kurokawa, S; Morita, T; Nakano, K; Natsui, S; Nukui, A1
Cormode, DP; Farokhzad, OC; Fayad, ZA; Gianella, A; Kim, Y; Labarre, MP; Langer, R; Mieszawska, AJ; Mulder, WJ; Ozcan, C; Petrov, A; Priem, B; van Rooy, I1
Assenat, E; Causse, A; Del Rio, M; Evrard, A; Gongora, C; Jarlier, M; Leconet, W; Martineau, P; Mazard, T; Robert, B; Simony, J; Torro, A; Vezzio-Vie, N; Ychou, M1
Alfieri, RR; Bonelli, MA; Caffarra, C; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; La Monica, S; Petronini, PG1
Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S1
Baker, SD; Buaboonnam, J; Enemark, EJ; Inaba, H; Mullighan, CG; Neale, GA; Olsen, SR; Orwick, S; Rubnitz, JE; Shurtleff, S; Wang, YD; Zatechka, DS; Zimmerman, EI1
Hiyama, Y; Kato, S; Matsuda, Y; Shibamori, K; Tabata, H; Takei, F; Yanase, M1
Ichiyanagi, N; Kamata, S; Yoshinaga, A1
Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C1
Feng, FE; Jiang, ZH; Lin, XQ; Lu, J1
Armand, JP; de Baere, T; Dessen, P; Lassau, N; Lazar, V; Le Berre, MA; Loriot, Y; Massard, C; Meurice, G; Peña, C; Robert, C; Robert, T; Soria, JC1
Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L1
Kelley, RK1
Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I1
Ding, LM; Guo, J; Kang, XS; Li, LJ; Qiu, YQ; Shen-Tu, JZ; Tan, FL; Zhou, J1
He, X; Zhang, T1
Angarano, G; Bronte, E; Bronte, F; Bronte, G; Cicero, G; Cusenza, S; Di Marco, V; Fiorentino, E; Firenze, A; Fontana, T; Rolfo, C; Russo, A1
Albiges, L; Escudier, B; Ferté, C; Fizazi, K; Iacovelli, R; Koscielny, S; Loriot, Y; Rocher, L; Soria, JC1
Kubota, Y; Makiyama, K; Nakaigawa, N; Nakamura, M; Sakata, R; Sano, F; Tatenuma, T; Yao, M1
Hosoya, N; Iwaba, A; Kanno, H; Kato, T; Kawazoe, H; Mashima, E; Nagaoka, A; Naito, S; Nishida, H; Sakurai, T; Tomita, Y; Yamakawa, M1
Büning, H; Decker, G; Gonzalez-Carmona, MA; Lukacs-Kornek, V; Meumann, N; Raskopf, E; Sauerbruch, T; Schmidt-Wolf, IG; Sievers, E; Strassburg, CP; Vogt, A1
Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC1
Bompas, E; Chaigneau, L; Chevreau, C; Fournier, C; Isambert, N; Penel, N; Valentin, T1
Paglino, C; Porta, C; Vercelli, A1
Cai, J; Mallick, R; Wogen, J1
Aronson, P; Uhlenhake, EE; Watson, AC1
Alonso, V; Capdevila, J; Castellano, D; Durán, I; García-Carbonero, R; Llanos, M; Manzano Mozo, JL; Salazar, R; Sastre, J; Sevilla, I1
Garnick, MB1
Alekseev, BY; Alyasova, A; Berkenblit, A; Bondarenko, I; Cella, D; Eisen, T; Esteves, B; Harza, M; Hutson, TE; Ivanescu, C; Kogan, M; Krivoshik, A; Lesovoy, V; Lipatov, O; Lyulko, O; Motzer, RJ; Nosov, D; Sternberg, CN; Strahs, A; Szczylik, C; Tomczak, P1
Ardisson, V; Audrain, O; Boucher, E; Clement, B; Edeline, J; Garin, E; Lenoir, L; Lepareur, N; Pracht, M; Raoul, JL1
Broom, RJ; Dranitsaris, G; Schmitz, S1
Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y1
Benedetto, C; Bussolati, B; Moggio, A; Pittatore, G; Revelli, A1
Aplenc, R; Caparas, M; Cullen, P; Johnston, DL; Nagarajan, R; Schulte, F; Sung, L1
Tan-Shalaby, J1
Columbano, A; Giordano, S1
Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL1
Hagihara, H; Honda, M; Ikeda, F; Iwadou, S; Kaneko, S; Kariyama, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Obi, S; Onishi, H; Sato, S; Sato, T; Shiraha, H; Takabatake, H; Takaguchi, K; Takaki, A; Takeuchi, Y; Takuma, Y; Yamamoto, K1
Baker, SD; Buaboonnam, J; Hu, S; Inaba, H; Janke, LJ; Orwick, S; Ramachandran, A; Roberts, MS; Stewart, CF; Turner, DC; Zimmerman, EI1
Abdel-Rahman, O; Elsayed, ZA1
He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB2
Albers, P; de Geeter, P; Fenner, M; Feyerabend, S; Hakenberg, O; Heidenreich, A; Heinzer, H; Kamradt, J; Klotz, T; Krege, S; Kühn, M; Retz, M; Rexer, H; Roigas, J; Schrader, M; vom Dorp, F; Wülfing, C; Zastrow, S1
Agrogiannis, G; Chatziioannou, AN; Fokas, D; Kavatzas, N; Kostomitsopoulos, NG; Loxas, D; Malagari, K; Siskos, AP; Tamvakopoulos, C; Tsigkou, O1
Audard, V; Bahleda, R; Baumelou, A; Bouachi, K; Bourry, E; Izzedine, H; Khayat, D; Lang, P; Mangier, M; Massard, C; Ollero, M; Ory, V; Pawlak, A; Péchoux, C; Sahali, D; Sendeyo, K; Soria, JC; Zhang, SY1
Derbel Miled, O; Dionne, C; Droz, JP; Flechon, A; Negrier, S; Neidhart, EM; Segura-Ferlay, C; Terret, C1
Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P1
Bartz-Schmidt, KU; Bayyoud, T; Hofmann, J; Spitzer, M; Yoeruek, E1
Dermeche, S; Gravis, G; Guerin, M; Salem, N; Walz, J1
Lee, YJ; Shin, SY1
Barnadas, A; Barriuso, J; Casado, E; Gallego, R; Garcia Foncillas, J; Garcia-Albeniz, X; Iranzo, V; Juez, I; Martin-Richard, M; Maurel, J; Pericay, C; Queralt, B; Saigi, E; Visa, L1
Cheng, AL; Chung, HC; Kang, YK; Kudo, M; Lanzalone, S; Lechuga, MJ; Lin, DY; Omata, M; Park, JW; Pitman Lowenthal, S; Poggi, G; Qin, S; Raymond, E; Song, X; Xu, J; Yang, L1
Aucejo, F; Menon, KV; Murali, AR; Romero-Marrero, C1
Abdulghani, J; Allen, JE; Dicker, DT; El-Deiry, WS; Goldenberg, D; Humphreys, R; Liu, YY; Smith, CD1
Bolon, B; Grever, MR; Kinghorn, AD; Kogure, T; Lucas, DM; Patel, T; Yan, I1
Ishizuka, O; Nishizawa, O; Suzuki, H; Suzuki, T; Ueno, M1
Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W1
Baba, T; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yoshioka, Y1
Barletta, E; Cannella, L; Daniele, B; Germano, D; Tinessa, V1
Goldwasser, F; Hescot, S; Vignaux, O1
Baglioni, M; Baron Toaldo, M; Bolondi, L; Chieco, P; Cipone, M; D'Adamo, S; Giovannini, C; Gramantieri, L; Ventrucci, C1
Fu, B; Gong, P; Gu, Y; Liao, W; Qin, M; Ren, J; Xu, C1
Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Kuzuya, T; Matsuda, S; Muraoka, M; Nakanishi, H; Nakata, T; Nishimura, T; Suzuki, S; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Yasui, Y1
Huang, T; Song, XS; Zhang, ZW1
Chen, L; Guo, Z; He, S; Wang, G; Wei, Y; Wu, Y; Zhang, Y; Zhou, J1
Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M1
Baron Toaldo, M; Bolondi, L; Cipone, M; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L1
Afzal, A; Beckett, BR; Doung, YC; Hayden, JB; Holtorf, ML; Huang, W; Hung, AY; Jones, RL; Mansoor, A; Meyer, JM; Mori, M; Perlewitz, KS; Pommier, RF; Rodler, ET; Ryan, CW; Tudorica, A; Vetto, JT; Woodward, WJ1
Ding, JF; Zhong, DF1
Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T1
Amos, S; Hussaini, IM; Kirzner, J; Sherman, JH; Siu, A1
Azzarà, A; Benedetti, E; Buda, G; Caracciolo, F; Carulli, G; Fontanelli, G; Galimberti, S; Orciuolo, E; Petrini, M; Rocco, M1
Fan, L; Han, TT; Li, JY; Xu, W1
Boyer, M; Davis, ID; Guo, Y; Liew, MS; Quaggiotto, M; Tafreshi, A; Thientosapol, E1
Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM1
Ahn, SH; Chang, S; Chon, CY; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY; Park, Y1
Alden, C; Blumenschein, GR; Davis, SE; Diao, L; Erasmus, J; Fossella, FV; Girard, L; Gupta, S; Herbst, RS; Heymach, JV; Hicks, ME; Hong, WK; Kies, MS; Kim, ES; Lee, JJ; Lippman, SM; Liu, S; Mao, L; Minna, JD; Peyton, M; Saintigny, P; Stewart, DJ; Tang, X; Tran, HT; Tsao, AS; Wang, J; Wistuba, I1
Bitran, JD; Cygan, P; Galvez, AG; Lestingi, TM; Meyer, A; Nabhan, C; Tolzien, K1
Adelmann, CH; Baccarini, M; Busaidy, NL; Ching, G; Chitsazzadeh, V; Ciurea, AM; Curry, JL; Duvic, M; Dwyer, DW; Ehrenreiter, K; Ma, H; Ojeda, SS; Ruggieri, R; Tannir, NM; Tsai, KY; Vin, H1
Bae, JS; Chung, MJ; Jang, KY; Kim, DG; Kim, KM; Moon, WS; Noh, SJ1
Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H1
Chang, CY; Huang, YS; Su, BH; Tseng, YJ; Tu, YS1
Aitini, E; Barni, S; Berardi, R; Bidoli, P; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Conte, P; Di Costanzo, F; Faloppi, L; Ferrari, D; Labianca, R; Mosconi, S; Siena, S; Sobrero, A; Tonini, G; Villa, F; Zagonel, V1
Chen, L; Qin, J; Wang, GL; Wei, YZ; Xu, YY; Zhang, YX; Zhou, JM; Zhu, YY1
Aupérin, A; Ayyoub, M; Caignard, A; Caillat-Zucman, S; Chaba, K; Chaput, N; Dessen, P; Eggermont, A; Flament, C; Jacquelot, N; Jacques, Y; Mateus, C; Messaoudene, M; Mortier, E; Poirier-Colame, V; Porta, C; Robert, C; Romero, AI; Rusakiewicz, S; Valmori, D; Vielh, P; Zitvogel, L1
Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H1
Alpini, G; Fallon, MB; Hu, B; Venter, J; Wu, W; Yang, W; Zhang, J1
Liu, YL; Wang, JL; Wang, ZH; Xi, Y; Zhang, Q1
Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K1
Bai, F; Belli, LS; Mancuso, A; Puoti, M; Zavaglia, C1
Al-Shukri, S; Bair, AH; Chen, C; Hutson, TE; Kim, S; Lesovoy, V; Lipatov, ON; Rosbrook, B; Stus, VP; Vogelzang, NJ1
Larkin, J; Yousaf, N1
Airaksinen, AJ; Hirvonen, JT; Kaasalainen, MH; Liu, D; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarparanta, MP; Wang, CF1
Gao, B; Lu, M; Qiao, X; Wang, X; Xue, D; Zhang, Y1
Chen, W; Deng, J; Li, X; Wu, XY; Zhang, L; Zhang, YN; Zhong, CJ; Zhong, N1
Chen, K; Li, B; Shen, J; Wang, G; Wang, H; Xu, Z; Yang, M; Zeng, B; Zhu, W1
Chang, YL; Cheng, AL; Hsu, CH; Huang, CY; Shao, YY1
Bal-Mahieu, C; Baldeyrou, B; Bay, JO; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Fournier, C; Italiano, A; Lansiaux, A; Le Cesne, A; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM1
Igarashi, Y; Ishii, K; Kanayama, M; Kanekawa, T; Kobayashi, K; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N1
Bamias, A; Bearz, A; Bellmunt, J; Imarisio, I; Melichar, B; Paglino, C; Porta, C; Procopio, G; Sabbatini, R; Schmidinger, M; Tinelli, C1
Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F1
Novara, G; Zustovich, F1
Cabibbo, G; Cammà, C; Craxì, A; Maida, M1
Agostini, V; Andreone, P; Biasco, G; Bolondi, L; Brandi, G; Cucchetti, A; de Rosa, F; di Girolamo, S; Golfieri, R; Gramenzi, A; Pinna, AD; Sama, C; Serra, C; Trevisani, F1
Stirner, B; Thangaraj, H1
Hu, BS; Li, Y; Liang, HY; Lu, LG; Shao, PJ1
Li, W; Lu, Y; Qin, Y; Qu, X; Wang, R1
Chen, Y; Duda, DG; Duyverman, AM; Hiddingh, L; Huang, P; Huang, Y; Jain, RK; Koppel, C; Lauwers, GY; Reiberger, T; Roberge, S; Samuel, R; Zhu, AX1
Cheng, NS; Chow, AK; Lam, CS; Ng, L; Pang, RW; Poon, RT; Wan, TM; Wong, SK; Yau, TC1
Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J1
Blanchet, B; Boudou-Rouquette, P; Freyer, G; Goldwasser, F; Hénin, E; Thomas-Schoemann, A; Tod, M; Vidal, M1
Hatano, E; Ishii, T; Seo, S; Taura, K; Uemoto, S; Yasuchika, K1
Fukatsu, A; Gotoh, M; Hattori, R; Kuroda, M; Kuwahara, K; Morikawa, T; Sassa, N; Shimoyama, Y; Shiroki, R; Tsuzuki, T; Yoshino, Y1
Chen, KF; Chen, PJ; Chen, YL; Chu, PY; Hsu, CY; Hsu, YC; Huang, JW; Li, YS; Shiau, CW; Tai, WT1
Brockmöller, J; Tzvetkov, MV1
Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK1
Agnello, F; Brancatelli, G; Cabibbo, G; Furlan, A; Genco, C; Giannitrapani, L; Lagalla, R; Marin, D; Midiri, M; Salvaggio, G1
Bjarnason, GA; Escudier, B; Esteban, E; Hariharan, S; Hutson, TE; Lim, HY; Lu, DR; Motzer, RJ; Niethammer, A; Pittman, KB; Senico, P1
Cho, T; Emura, M; Igarashi, S; Kobayashi, Y; Nakamura, T; Nomizo, T; Nomura, N; Seto, R1
Luo, QY; Qiu, ZL; Shen, CT2
Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A1
Hu, B; Mohty, M; Savani, BN; Vikas, P1
Dent, P1
Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY1
He, XD; Liu, H; Qin, SK; Tao, L; Tong, XH; Wang, ZS; Wu, Q; Yang, Y; Zheng, RS1
A, M; H J, H; L, M; M, K; N, M; P J, G; S, B1
Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R1
Groothuis, GM; Olinga, P; Oosterhuis, D; Westra, IM1
Chen, MS; Gao, HJ; Xu, L; Zhang, YJ1
Bhatt, VR; Ganti, AK1
Akaza, H; Fukuyama, T1
George, DJ; Liu, NS; Liu, Z; Qi, CZ; Signorovitch, JE; Wang, X; Wong, MK; Yang, H1
Carriere, C; Eisendle, K; Kluge, R; Mazzoleni, G; Pichler, M1
Abeni, E; Arici, B; Barlati, S; Conde, I; De Petro, G; Grossi, I; Portolani, N; Salvi, A; Specchia, C1
Deng, LF; Jia, QA; Li, JH; Ren, ZG; Shen, HJ; Sun, XJ; Wang, YH1
Ahmad, S; Khattak, J; Murad, S; Naqi, N1
Garcia-Roig, M; Lokeshwar, V; Ortiz, N1
Bonington, S; Denton, K; Homer, J; Lee, LW; Mak, SK; Silva, P; Slevin, NJ; Swindell, R; Sykes, AJ; Thomson, DJ; Yap, BK1
Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Park, HC; Sohn, W; Yoo, BC; Yu, JI1
Eto, M; Kimura, G; Minami, H; Naito, S; Nonomura, N; Shinohara, N; Tokunaga, S1
Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM1
Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M1
Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T1
Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H1
Appleman, LJ; Bass, MB; Friberg, G; Friedland, D; Gordon, MS; Hong, DS; Kurzrock, R; Mendelson, DS; Rasmussen, E; Samlowski, WE; Tannir, N; Vogelzang, NJ; Wu, BM; Zhong, ZD1
Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I1
Chow, W; Chung, C; Frankel, P; Hurria, A; Luu, T; Mortimer, J; Somlo, G1
bin-Noordin, MI; Davoudi, ET; Javar, HA; Kadivar, A; Sabeti, B1
Chow, S; Gutierrez, JO; Karovic, S; Karrison, TG; Kistner-Griffin, E; Maitland, ML; Thomeas, V; Wroblewski, K1
Mei, J; Wang, Z; Zhu, X1
Chen, K; Janssen, HL; Man, K; Metselaar, HJ; Pan, Q; Peppelenbosch, MP1
He, J; Li, YS; Wei, LX; Wei, X; Xu, F; Yu, FF; Zhang, TY; Zhang, XJ1
Burger, S; Gallè, B; Mair, G; Miller, I; Steinborn, R; Walter, I; Wolfesberger, B1
Barbare, JC; Chauffert, B; Galmiche, A1
Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Hinkel, R; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; Sourbron, S; von Einem, JC; Wintersperger, BJ1
Noguchi, S; Takizawa, H; Yamauchi, Y1
El-Gamal, MI; Oh, CH1
Chen, CH; Chen, LC; Chen, YJ; Chien, PH; Chien, YF; Hsieh, YL; Hsu, SC; Huang, WC; Hung, CM; Lin, YM; Tu, CY1
Kanazawa, A; Kawasaki, Y; Kioka, K; Kodai, S; Komatsu, H; Nakai, T; Nakajima, T; Ohira, G; Shimizu, S; Tsukamoto, T; Yamazoe, S1
Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H1
Boerman, OC; Boers-Sonderen, MJ; de Weijert, MC; Desar, IM; Langenhuijsen, JF; Leenders, WP; Mulders, PF; Muselaers, CH; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van Herpen, CM1
Petrou, PK; Talias, MA1
Baker, SD; de Bruijn, P; Hu, S; Mathijssen, RH; Sparreboom, A1
Bellesoeur, A; Billemont, B; Blanchet, B; Carton, E; Clerc, J; Goldwasser, F; Groussin, L; Mir, O1
Choi, Y; Hur, DY; Kim, D; Kim, YS; Lee, HK; Park, GB2
Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M1
Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L1
Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK1
Aparicio, J; Ayuso, JR; Conill, C; Feliu, J; Fuster, D; García-Mora, C; Martín, M; Maurel, J; Petriz, ML; Sánchez-Santos, ME1
Dong, S; Gao, J; Gu, F; Ke, S; Kong, F; Kong, J; Pan, B; Shen, Q; Sun, H; Sun, W; Zhang, Q; Zheng, L1
Dowlati, A; Fu, P; Halmos, B; Ma, P; Mekhail, T; Nickolich, M; Pennell, N; Sharma, N1
Ali, SM; Araujo, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Subbiah, V; Wang, K; Wang, WL; Westin, SN1
Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB1
Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M1
Hagihara, A; Ikeda, M; Imanaka, K; Inaba, Y; Katayama, K; Kato, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sato, Y; Shimizu, S; Suzuki, E; Tamai, C; Ueno, H1
Chen, GY; Cheng, Y; Huang, C; Li, AW; Su, J; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhou, CC; Zhou, Q1
Ackerl, M; Dieckmann, K; Flechl, B; Hainfellner, J; Hassler, MR; Marosi, C; Preusser, M; Sax, C; Widhalm, G; Wöhrer, A1
Chang, H; Kim, KM; Kim, YJ; Lee, DW; Lee, HJ; Lee, JS1
Liu, X; Shi, G; Wang, L; Wang, Q; Wu, R1
Abdel-Rahman, O; Fouad, M3
Balakan, O; Berk, V; Bilici, A; Buyukberber, S; Cinkir, HY; Demirci, U; Erdogan, B; Gumus, M; Kaplan, MA; Oflazoglu, U; Oksuzoglu, B; Ozdemir, N; Ozkan, M; Ozturk, T; Tastekin, D; Tonyali, O; Turkmen, E; Unal, OU; Uyeturk, U; Yasar, N1
Cheng, Y; Li, A; Luo, R; Zhu, Y1
Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Kwon, OS; Shin, SK; Yoon, HH1
Abd-Alhaseeb, MM; Abou-El-Ela, SH; Moustafa, YM; Zaitone, SA1
Bangen, JM; Gassler, N; Liedtke, C; Sonntag, R; Trautwein, C1
Dong, X; He, C; Jiang, H; Jiang, X; Ma, L; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Zhai, B; Zhao, D1
Andreeff, M; Arana Yi, C; Borthakur, G; Brandt, M; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Levis, M; Luthra, R; O'Brien, S; Pierce, S; Pratz, K; Ravandi, F; Thomas, D1
Li, Y; Meng, Q; Shen, J; Sun, H; Yin, Q; Yu, H; Zhang, Z1
Bao, J; Dai, Z; Lan, Y; Tu, W; Wei, T; Zhao, B1
Barroso-Sousa, R; Evangelista, J; Fragoso, MC; Hoff, AO; Kulcsar, MA; Lerario, AM; Lin, CS; Lourenço, DM; Papadia, C1
Arizumi, T; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Osaki, Y; Sakurai, T; Takeda, H; Takita, M; Ueshima, K; Yada, N1
Feng, L; Liu, T; Liu, Y; Wang, L; Yao, Y; Yu, D; Zhang, L; Zhang, N1
Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M1
Eberst, E; Guillot, B; Kluger, N; Pageaux, GP; Rigau, V1
Bearzi, I; Benedetti, A; Bianconi, M; Bitetto, D; Bolondi, L; Cascinu, S; Colombo, M; D'Errico, A; De Minicis, S; Facchetti, F; Faloppi, L; Fava, G; Gemini, S; Giampieri, R; Granito, A; Iavarone, M; Loretelli, C; Mandolesi, A; Marinelli, S; Piscaglia, F; Scartozzi, M; Svegliati Baroni, G; Toniutto, P; Vavassori, S; Venerandi, L1
Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E1
Aktaş, E; Aras, Y; Aydoseli, A; Bilir, A; Civelek, E; Ergüven, M; Gürtekin, M; Imer, M; Sabancι, PA; Yazιhan, N1
Stadler, WM1
Chiba, T; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O1
Chen, CH; Chen, CS; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC1
De Lichtenberg, TH; Hermann, GG; Holm, ML; Højer Larsen, MJ; Mansourvar, Z; Rørth, M; Scheike, T1
Baar, K; Carraway, KL; Gilda, JE; Gomes, AV; Hammock, BD; Hwang, SH; Leon, LJ; Patton, A; Wecksler, AT; Weiss, RH; Wettersten, HI1
Alba, G; Carlson, T; Chen, A; Coberly, S; Dai, K; Eksterowicz, J; Hollenback, D; Huard, J; Kamb, A; Keegan, K; Li, C; Li, Z; Liang, L; Liu, L; Lo, MC; Ma, J; McGee, LR; Medina, J; Ngo, R; Orf, J; Quéva, C; Ragains, M; Wang, X; Weidner, M; Wickramasinghe, D; Zhao, S1
Bruix, J; Gores, GJ; Mazzaferro, V1
Bögemann, M; Herrmann, E; Hertle, L; Hoffmeister, I; Krabbe, LM; Moritz, R; Papavassilis, P; Thielen, B1
Li, Z; Wang, K; Zhang, H1
Benedetti, A; Bianconi, M; Bitetto, D; Cascinu, S; D'Anzeo, M; De Minicis, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Scartozzi, M; Svegliati Baroni, G; Toniutto, P1
Borys, D; Boutin, RD; Canter, RJ; Christensen, SD; Lee, LY; Li, CS; Monjazeb, AM; Olusanya, A; Tamurian, RM1
Schmidinger, M1
Bjarnason, GA; Cai, C; Davis, ID; De Giorgi, U; Escudier, B; Esteban, E; Grünwald, V; Kollmannsberger, C; Lee, JL; Marker, M; Melichar, B; Motzer, RJ; Porta, C; Rha, SY; Shi, MM; Squires, M; Sternberg, CN; Szczylik, C; Urbanowitz, G; Vogelzang, NJ; Zolnierek, J1
Bergmann, L; Burkholder, I; Gauler, T; Grünwald, V; Kahl, C; Kube, U; Maute, L; Weikert, S1
Anichini, A; Carbone, A; Carlo-Stella, C; Cleris, L; Locatelli, SL; Malorni, W; Pierdominici, M; Saba, E; Stirparo, GG; Tartari, S1
Cabanillas, ME; Dadu, R; Dong, W; Feng, L; Lai, SY; Regone, RM; Thomas, L1
Liu, LL; Pan, YH; Yun, JP; Zhang, CZ; Zhang, MF1
Abdel-Rahman, O; Abdelwahab, M; Abdelwahab, S; Elbassiony, M; Ellithy, M; Shaker, M1
Atkinson, BJ; Flaherty, AL; Jonasch, E; Matrana, MR; Shetty, AV; Tannir, NM1
Karagoz, E; Tanoglu, A1
Amann, J; Araujo, L; Carbone, DP; Greulich, H; Horn, L; Imielinski, M; Kaplan, B; Meyerson, M; Schiller, J; Villalona-Calero, MA1
Inoue, K; Kamada, M; Karashima, T; Kawada, C; Komatsu, T; Kuroda, N; Niimura, M; Shuin, T; Udaka, K1
Chen, Y; Li, J; Li, W; Liu, X; Wan, J; Yu, C1
Berlin, J; Cardin, DB; Chan, E; DeVore, R; Goff, L; Grigorieva, J; Holloway, M; Li, CI; McClanahan, P; Meyer, K; Schlabach, L; Shyr, Y; Winkler, C1
Antonuzzo, L; Arena, U; Boni, L; Colagrande, S; Di Costanzo, F; Fani, B; Forte, P; Gallori, D; Gianni, E; Inghilesi, AL; Laffi, G; Marra, F; Pradella, S; Tomcikova, D1
Brose, MS; Frenette, CT; Keefe, SM; Stein, SM1
Grande, C; Walko, CM1
Chen, LF; Liang, SN; Liu, J; Shao, HB; Su, HY; Xu, K1
Chu, JH; Li, WB; Qin, YZ; Qu, XJ; Song, ZY; Wang, RQ; Zhao, CR1
Jiang, X; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O1
de Man, RA; Schrier, GH; van der Geest, LG; van Erpecum, KJ; van Meer, S; Verheij, J; Verhoef, C1
Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS1
Bhinder, A; Carson, WE; Clinton, SK; Geyer, S; Kendra, K; Lam, E; Lesinski, GB; Mace, TA; Monk, P; Mortazavi, A; Olencki, T; Tahiri, S1
Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O1
Bao, X; Chen, J; He, X; Li, Y; Niu, B; Yu, H; Zhang, Z; Zhu, J1
Bondì, ML; Cavallaro, G; Craparo, EF; Giammona, G; Sardo, C; Serio, R; Zizzo, MG1
Chow, HC; Gill, H; Kwong, YL; Lam, SS; Leung, AY; Man, CH; Sun, MK1
Liang, JY; Lü, MD; Pan, FS; Xie, XY; Xu, M; Zheng, SG; Zheng, YL1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R1
Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Han, HS; Khin, MW; Lai, HK; Lim, TG; Lo, RH; Poon, DY; Singh, H; Soo, KC; Tan, SB; Tay, KH1
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ1
Andreeff, M; Borthakur, G; Chen, Y; Cortes, JE; Gao, C; Jacamo, RO; Konopleva, M; Ramachandran, A; Ravandi, F; Zhang, W1
Chen, J; Guo, H; Li, S; Li, Y; Liang, X; Meng, H; Shi, B; Zhang, D; Zhu, Y1
Busaidy, NL; Cabanillas, ME; Cote, GJ; Dadu, R; Devine, C; Habra, MA; Hernandez, M; Hu, MI; Jimenez, C; Sellin, RV; Sherman, SI; Waguespack, SG; Ying, AK1
Carbotti, M; Coppola, R; De Florio, L; Galati, G; Graziano, A; Panasiti, V; Rinati, MV; Zanframundo, S1
Deng, DF; Ding, LM; Kang, XS; Qiu, YQ; Tan, FL; Yu, W; Zhou, J1
Chen, C; Geng, ZM; Huanchen, S; Jha, RK; Li, B; Li, WZ; Wang, L; Zheng, JB1
Bakris, GL; Cohen, EE; Fleming, GF; House, LK; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; Ratain, MJ; Rudek, MA; Thomeas, V; Wen, Y; Wright, JJ; Wu, K1
Lazarevich, NL; Makarova, AS1
Banna, G; Bracarda, S; Burattini, L; Calvani, N; Ciuffreda, L; Contu, A; De Giorgi, U; Derosa, L; Felici, A; Ferrari, V; Ferraù, F; Galligioni, E; Gasparro, D; Gernone, A; Iacovelli, R; Lo Re, G; Morelli, F; Pia Brizzi, M; Porta, C; Procopio, G; Rizzo, M; Sabbatini, R; Sava, T; Taibi, E; Zustovich, F1
Holderfield, M; Nagel, TE; Stuart, DD1
Chen, CL; Chen, WY; Honda, K; Kawasaki, K; Masuda, M; Miyanaga, A; Nakamura, Y; Ono, M; Sakuma, T; Yamada, T1
Honda, M; Isobe, T; Komatsu, R; Kuramoto, S; Shindoh, H; Tabo, M1
Bae, SH; Song, MJ1
Cai, G; Chen, H; Han, G; Liu, L; Qi, X; Wang, M; Zhao, Y1
Belghiti, J; Bouattour, M; Bruno, O; Castera, L; Dreyer, C; Faivre, S; Larroque, B; Raymond, E; Ronot, M; Vilgrain, V; Wassermann, J1
Ferrari, S; Paioli, A; Palmerini, E1
Bertens, D; Desar, IM; Kessels, RP; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Punt, CJ; van Herpen, CM; van Spronsen, DJ; Vissers, KC1
Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC1
Bauernhofer, T; Brämswig, K; Brodowicz, T; Girschikofsky, M; Hilbe, W; Hochreiner, G; Kühr, T; Leitgeb, C; Martel, A; Mlineritsch, B; Petzer, A; Ploner, F; Ressler, S; Romeder, F; Seebacher, V; Stöger, H; Wöll, E1
Croft, SL; Sanderson, L; Yardley, V1
Aguado, L; Idoate, MA; Iñarrairaegui, M; Lera, JM; Pretel, M1
Barberis, M; Brunelli, V; Catania, C; Dal Zotto, L; Danesi, R; de Braud, F; De Pas, T; Delmonte, A; Diena, T; Fumagalli, C; Noberasco, C; Rampinelli, C; Santarpia, M; Spitaleri, G; Toffalorio, F; Vecchio, F; Zangarini, M; Zucchetti, M1
Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F1
Duan, H; Gao, M; Guo, J; Liu, J; Meng, L; Peng, Y; Wang, X; Zhang, H; Zhao, Z; Zhu, M1
Abecassis, M; Al-Saden, P; Baker, T; Cotliar, J; Ganger, D; Habib, A; Karp, J; Koppe, S; Kulik, L; Lacouture, M; Lewandowski, RJ; Mulcahy, MF; Salem, R; Vouche, M1
Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y1
de Vos, R; Koldenhof, JJ; Teunissen, SC; Tillier, CN; Verheul, HM; Walraven, M; Witteveen, PO1
Andreozzi, M; Angel, P; Ben-Neriah, Y; Breuhahn, K; Finkelstein, R; Ganten, T; Grunewald, M; Hess, J; Horwitz, E; Kanarek, N; Koschny, R; Mogler, C; Nemeth, J; Pappo, O; Pikarsky, E; Porat, RM; Quagliata, L; Reuter, H; Schirmacher, P; Schweitzer, N; Shibolet, O; Shoham, A; Stein, I; Terracciano, L; Tornillo, L; Vogel, A; Zreik, F1
Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K1
Delabesse, E; Guenounou, S; Récher, C1
Haybaeck, J; Petru, E; Smolle, E; Taucher, V1
Chen, C; Daily, MF; Galuppo, R; Gedaly, R; Maynard, E; Shah, M; Spear, BT1
Alexandre, J; Blanchet, B; Boissier, E; Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Giroux, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Vidal, M1
Belli, LS; Mancuso, A; Mazzarelli, C; Perricone, G; Zavaglia, C1
Daniele, B; Germano, D1
Fan, JG; Li, GM; Pan, Q; Sun, C; Wang, J; Wang, YG1
Geng, CX; Ji, YX; Lan, KT; Liu, SC; Nie, KK; Sun, L; Zhang, L; Zhang, ZC; Zhang, ZF; Zhuang, XJ; Zou, X1
Chen, W; Chen, Y; Deng, DY; Ren, M; Shang, C; Wang, J; Xiang, Q; Zhang, H; Zhang, L1
Dong, X; Hu, F; Jiang, H; Jiang, X; Liu, B; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Xu, J; Zhai, B; Zhao, D1
Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D1
Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K1
D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F1
Choi, HS; Kim, SW; Lee, B; Nam, SW; Park, KC1
Barbe, M; Berretta, RM; Dunn, J; Duran, JM; Force, T; Gao, E; Gross, P; Houser, SR; Husain, S; Kubo, H; Lal, H; Makarewich, CA; Sharp, TE; Starosta, T; Trappanese, D; Vagnozzi, RJ; Yu, D1
de Waal, R; de Weijert, M; Desar, I; Hulsbergen-van de Kaa, C; Kats-Ugurlu, G; Leenders, W; Maass, C; Mulders, P; Muselaers, S; Oosterwijk, E; Oosterwijk-Wakka, J; van Herpen, C; van Krieken, H1
Akisik, FM; Anderson, S; Bu, G; Cardenes, HR; Chiorean, EG; Clark, R; Deluca, J; DeWitt, J; Helft, P; Johnson, CS; Johnston, EL; Loehrer, PJ; Perkins, SM; Sandrasegaran, K; Schneider, BP; Shahda, S; Spittler, AJ1
Herrick, WG; Moriarty, T; Nguyen, TV; Peyton, SR; Sleiman, M1
Chen, J; Kim, DH; Larson, AC; Lewandowski, RJ; Li, W; Omary, RA; Shea, LD; Sheu, AY; Zhang, Z1
Pitoia, F1
Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK1
Chang, FY; Chao, TT; Chen, KF; Chen, PT; Chen, YL; Shiau, CW; Su, WP; Tai, WT; Wang, CY; Weng, CY; Yu, CJ; Yuan, A1
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO1
Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Estrov, Z; Garcia-Manero, G; Kantarjian, HM; Konopleva, M; Luthra, R; Ravandi, F1
Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA1
Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K1
Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F1
Bernardi, M; Bolondi, L; Cappelli, A; Cucchetti, A; Erroi, V; Fiumana, S; Golfieri, R; Gramenzi, A; Granito, A; Marinelli, S; Mosconi, C; Pettinato, C; Trevisani, F1
Dudek, A; Konety, SH; Masri, SC; Misselt, AJ1
Raza, A; Sood, GK1
Miyahara, K; Nouso, K; Yamamoto, K1
Ara, M; Pastushenko, E1
Haraldsdottir, S; Shah, MH1
Bastholt, L; Brose, MS; Chung, J; de la Fouchardiere, C; Elisei, R; Jarzab, B; Kappeler, C; Molnár, I; Nutting, CM; Pacini, F; Paschke, R; Peña, C; Schlumberger, MJ; Sherman, SI; Shong, YK; Siena, S; Smit, JW1
Bai, XL; Chen, YW; Fu, QH; Hu, QD; Liang, TB; Su, RG; Su, W; Zhang, Q1
Aigner, B; Artl, M; Niederkorn, A; Richtig, E; Schwantzer, G; Wackernagel, W1
Biondani, P; DE Braud, F; Grassi, P; Porcu, L; Procopio, G; Testa, I; Torri, V; Verzoni, E1
Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC1
Chen, XQ; Li, ZY; Lin, TY; Wang, YL1
Chen, LJ; Chen, YZ; Cheng, C; Fu, XY; Li, LL; Tang, Y; Wei, YQ; Xiang, R; Yang, J; Yang, LL; Yang, SY; Zhong, L; Zhou, S; Zou, C1
Mu, H; Song, TQ; Wang, M; Wei, K; Zhang, W1
Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ1
Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN1
Chen, W; Guo, E; Liu, Z; Lu, L; Peng, X; Wang, Y; Yan, T; Yang, X; Ye, L; Zhou, F1
Bhatt, VR; Ganti, AK; Schwarz, JK; Wang, J1
Bargellini, I; Bartolozzi, C; Masi, G; Mismas, V; Sacco, R; Scionti, A; Vivaldi, C1
Allen, JC; Bloom, MC; Cohen, KJ; Dhall, G; Eberhart, CG; Fisher, MJ; Goldberg, JD; Harter, DH; Hochman, T; Jones, DT; Karajannis, MA; Korshunov, A; Legault, G; Merkelson, A; Milla, SS; Pfister, SM; Resnick, AC; Sievert, AJ; Wisoff, JH; Zagzag, D1
Bodoky, G; Fassan, M; Gyöngyösi, B; Járay, B; Kiss, A; Schaff, Z; Székely, E; Végh, É1
Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE1
Burra, P; Castelli, G; Cillo, U; Farinati, F; Giacomin, A; Senzolo, M; Vitale, A1
Imagawa, DK; Reataza, M1
Srimuninnimit, V; Sriuranpong, V; Suwanvecho, S1
Graham, RM; Thompson, JW; Webster, KA1
Fu, SR; He, X; Hu, BS; Huang, JW; Li, JP; Li, Y; Lu, LG; Zhan, MX; Zhang, YQ1
Altun, A; Altun, GG; Babacan, N; Bahceci, A; Kacan, SB; Kacan, T; Sarac, B; Seker, MM1
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z1
Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J1
Aoyagi, Y; Fujimaki, S; Hirose, Y; Kobayashi, T; Kubota, M; Matsuda, Y; Osawa, M; Sakata, J; Takamura, M; Wakai, T; Yamagiwa, S1
Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L1
Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B1
Llovet, JM1
Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P1
Black, EP; Karabakhtsian, RG; Massarweh, S; Moss, J; Napier, D; Romond, E; Slone, S; Wang, C; Weiss, H1
Cui, LJ; Li, AJ; Ma, SL; Wu, B; Wu, MC; Yin, L; Yuan, H1
Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR1
Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y1
Elledge, R; Elledge, RO; Raskauskiene, D1
Bella, A; Guerra, JR; Lolo, D; Suelves, AM1
Dixon, SJ; Gleason, CE; Hayano, M; Lee, ED; Patel, DN; Skouta, R; Slusher, BS; Stockwell, BR; Tatonetti, NP; Thomas, AG; Welsch, M1
Shouval, D1
Ito, K; Sugino, K; Takami, H1
Chen, D; Chen, M; Kuang, M; Lencioni, R; Peng, B; Peng, H; Peng, S; Shen, S; Wang, Y1
Antonucci, M; Cabibbo, G; Gadaleta-Caldarola, G; Galati, G; Lombardi, G; Mazza, G; Sacco, R; Tremosini, S1
Jiang, L; Liu, H; Liu, X; Shi, G; Wang, X1
Falchi, L; Lu, G; Luthra, R; Lyle, LM; Mehrotra, M; Newberry, KJ; Patel, KP; Popat, U; Verstovsek, S1
Ai, DL; Fu, JL; Li, J; Liu, CZ; Peng, XM; Wang, HM; Wang, JY; Yang, B; Yu, Q; Zhang, LZ; Zhao, Y; Zhou, L1
Bambury, RM; Morris, PG1
DeWille, J; Hicks, M; Hu, Q; Macrae, E1
Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P1
Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M1
Akasaka, K; Hisamichi, K; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H; Tsuchiya, M; Yanagi, T1
Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Giannuzzi, G; Lippolis, C; Messa, C; Refolo, MG1
Bogdanova, A; Daryadel, A; Frossard, N; Gassmann, M; Lehalle, C; Mueller, X; Seifert, B; Tavakoli, R; Zünd, G1
Barbarotta, L; Cooper, D; Foss, F; Gibson, JF; Irizarry, D; Lansigan, F; Seropian, S1
Feng, GS; Luo, X1
Fujisawa, M; Furukawa, J; Kusuda, Y; Miyake, H1
Luo, J; Shao, G; Zheng, J1
Chapiro, J; Duran, R; Geschwind, JF1
Fujiya, T; Hasegawa, Y; Kakugawa, Y; Kinouchi, M; Miura, K; Philchenkov, A; Satoh, M; Yamamoto, K1
Abou-Alfa, GK; Harding, JJ1
Emadi, A; Karp, JE; Pratz, KW; Sammons, SL; Smith, BD1
Bruera, G; Cannita, K; Carducci, S; Coletti, G; Ficorella, C; Giordano, AV; Iapadre, N; Manetta, R; Ricevuto, E; Saltarelli, P; Vicentini, R1
Baron Toaldo, M; Bolondi, L; Croci, L; Diana, A; Marinelli, S; Milazzo, M; Palamà, C; Pecorelli, A; Piscaglia, F; Salvatore, V; Venerandi, L1
Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP1
Bao, LF; Cao, XQ; Dai, YC; Gan, MF; Li, ZY; Liang, XD; Lu, HS; Ma, SL; Wang, DD; Zhang, LM; Zhang, SR; Zheng, BJ1
Arnold, B; Augustin, HG; Bergeest, JP; Géraud, C; Goerdt, S; Hu, J; Komljenovic, D; Mogler, C; Neumann, A; Rohr, K; Runge, A; Schirmacher, P; Wieland, M1
Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S1
Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA1
Atkinson, B; Eatock, M; Graham, U1
Bulla, K; Kolligs, F; Malfertheiner, P; Peck-Radosavljevic, M; Reimer, P; Ricke, J; Sangro, B; Schott, E; Schütte, K; Verslype, C; Walecki, J1
Brown, WS; Khalili, JS; Lizee, G; McIntyre, BW; Rodriguez-Cruz, TG1
Bie, P; Chen, X; Hu, P; Zhang, L1
Alsaied, OA; Banerjee, S; Chugh, R; Jensen, EH; Krosch, TC; Saluja, A; Sangwan, V; Vickers, SM1
Czarnecka, AM; Oborska, S; Rzepecki, P; Szczylik, C1
Chen, YF; Liao, MB; Peng, HS; Wang, HY; Xie, Y; Xu, L; Zhang, MY; Zhang, YJ; Zheng, XF1
Ady, JW; Belin, LJ; Chen, CT; Chen, NG; Fong, Y; Heffner, J; Johnsen, C; Klein, E; Love, D; Mojica, K; Pugalenthi, A; Szalay, AA; Yu, YA1
Döring, C; Filmann, N; Hansmann, ML; Hartmann, S; Herrmann, E; Mertens, A; Peveling-Oberhag, J; Piiper, A; Trojan, J; Welker, MW; Zeuzem, S1
Blanchard, F; Di Fiore, F; Nouhaud, FX; Pfister, C; Rebibo, JD; Sabourin, JC1
Elsner, A; Fitzner, B; Heuschkel, M; Jaster, R; Krause, BJ; Lange, F1
Cheung, FY; Chiang, CL; Chong, M; Jolivet, J; Kwok, C; Kwong, P; Lai, M; Lee, C; Lee, FA; Leung, KC; Siu, SW; Tung, S; Zee, BC1
Bogaerts, E; Colle, I; Descamps, B; Devisscher, L; Geerts, A; Janssens, S; Lambrecht, BN; Laukens, D; Libbrecht, L; Paridaens, A; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vanhove, C; Verhelst, X1
Alsina, AE; Arrobas, J; Franco, E; Kemmer, N; Makris, A; Nenos, V; Sucre, E1
Esumi, S; Kawasaki, Y; Kitamura, Y; Matsunaga, H; Miura, T; Nakamura, H; Sendo, T; Takeda, T; Yagi, K1
Gandhi, S; Grewal, H; Sengodan, P1
Altekruse, SF; Dickie, LA; Duffy, AG; Greten, TF; Kish, JK; McGlynn, KA; McNeel, TS; Rahma, OE; Ulahannan, SV1
Blay, JY; Dumont, AG; Dumont, SN; Reynoso, D; Trent, JC; Yang, D1
Andoh, A; Bamba, S; Fujiyama, Y; Inatomi, O; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M1
Liu, C; Liu, L; Long, J; Ni, QX; Sun, HC; Tang, ZY; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, W; Zhu, XD1
Bito, T; Hirai, M; Hirano, T; Kume, M; Makimoto, H; Mizumoto, A; Mukai, A; Nakagawa, T; Nishigori, C; Nishimura, K; Uda, A; Yamamoto, K; Yamashita, K1
Courville, E; Liegel, J; Sachs, Z; Ustun, C1
Anouar, Y; Baudin, E; Denorme, M; Dubessy, C; Gonzalez, BJ; Roux, C; Yon, L1
Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A1
Kim, SW; Lee, B; Nam, SW; Park, KC; Yang, KJ1
Bernardo, L; Borger, DR; Chen, YB; Durazzo, T; Fathi, AT; Kroshinsky, D; Lin, WM; McAfee, SL; Piris, A; Sadrzadeh, H1
Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ1
Bhargava, P; Bhosale, P; Choi, JI; Imagawa, DK; Lall, C; Seery, TE; Tirkes, T1
He, C; Liu, J; Mao, K; Sun, J; Tan, C; Wang, J; Wu, G; Xiao, Z; Xu, K; Zeng, Y; Zhang, J1
Anel, A; Azaceta, G; Galán-Malo, P; Jarauta, V; López-Royuela, N; Marzo, I; Naval, J; Palomera, L; Pardo, J; Ramírez-Labrada, A1
Augello, C; Barberis, M; Bosari, S; Carnaghi, C; Di Tommaso, L; Fagiuoli, S; Faversani, A; Labianca, R; Maggioni, M; Pressiani, T; Rimassa, L; Roncalli, M; Rota Caremoli, E; Santoro, A; Spagnuolo, G; Vaira, V1
Cho, NP; Cho, SD; Hong, IS; Jung, JY; Nam, JS; Shin, JA; Yu, HJ1
Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E1
Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH1
Alvarez-Barrientos, A; Bertran, E; Cepeda, EB; Fabra, À; Fabregat, I; Fernández-Rodríguez, CM; Fernández-Salguero, P; Fernando, J; Giannelli, G; Malfettone, A; Raimondi, G; Sancho, P; Vilarrasa-Blasi, R1
Cao, Y; Chen, W; Ding, Y; Jiang, C; Shi, H; Wang, Z; Wu, J; Zhang, G1
Anak, O; Assenat, E; Blanc, JF; Cattan, S; Chen, CL; Chen, LT; Daniele, B; Dorval, E; Furuse, J; Jappe, A; Kang, YK; Kudo, M; Lim, HY; Peck-Radosavljevic, M; Perraud, K; Poon, RT; Santoro, A; Sellami, DB; Vogel, A; Zhu, AX1
Gottesman, MM; Lavi, O; Skinner, J1
Chi, H; Meng, Z; Wang, H; Wang, P; Xu, L; Zhu, X1
Basso, U; Maruzzo, M; Montesco, MC; Rastrelli, M; Roma, A; Zanardi, E1
Bernards, R; Groenendijk, FH; Hauptmann, M; Horlings, HM; Jonkers, J; Mellema, WW; Schut, E; Smit, EF; van den Heuvel, MM; van der Burg, E; Willems, SM1
Guo, DH; Pei, F; Si, HY; Tang, ZH; Wang, DX; Wang, WL; Xiao, BK; Xie, TT; Zhang, XY; Zhu, M1
Baron Toaldo, M; Bolondi, L; Cipone, M; Croci, L; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L1
Chandran, CB; Flombaum, CD; Glezerman, IG; Salvatore, SP; Seshan, SV; Usui, J1
Bruix, J; Forner, A; Gilabert, M; Raoul, JL1
Bai, M; Han, GH; Yang, M; Yuan, JQ1
Guo, QQ; Wang, QD; Yang, GR; Zhao, YL1
Coplin, MA; Donahue, RN; Farsaci, B; Grenga, I; Hodge, JW; Lepone, LM; Molinolo, AA1
Ji, B; Liu, K; Liu, S; Liu, Y; Wang, Y; Zhang, W2
Harms, GS; Jaiswal, BS; Mooz, J; Oberoi-Khanuja, TK; Rajalingam, K; Seshagiri, S; Tikkanen, R; Wang, W1
Bavishi, K; Bazargan, A; Black, J; Cummins, KD; D'Rozario, J; Filshie, R; Hertzberg, M; Jane, SM; Lane, S; Nikovic, S; Ninkovic, S; Ritchie, D; Scott, A; Sutrave, G; Wei, A; Yannakou, CK1
Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC1
Akarsu, S; Çarsanbali, S; Fetil, E; İlknur, T; Lebe, B1
Batalla, A; Blay, P; Curto, JR; Menéndez, L1
Bandyopadhyay, S; Burlingame, AL; Gordan, JD; Hann, B; Levin, RS; McCormick, F; Oses-Prieto, JA; Salt, M; Shokat, KM; Sos, ML; Webber, JT1
En, LM; Hao, L; Ju, H; Juan, LW; Kai, HY1
Ghimire, KB; Shah, BK1
Gao, C; Peng, FH; Peng, LK1
Chen, XG; Feng, ZQ; Li, Y; Wang, K; Yang, HZ; Zhang, LJ1
Anand, BS; Fitzmorris, P; Shoreibah, M; Singal, AK1
Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL1
Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H1
Lykkesfeldt, AE; Pedersen, AM; Thrane, S; Yde, CW1
Tan-Shalaby, JL1
Daoudaki, M; Fouzas, I1
Fu, SR; He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhan, MX; Zhao, W; Zhao, Y; Zheng, YB1
Bianco, V; Francini, E1
Chen, S; Dong, L; Fang, Y; Hu, T; Huang, X; Ji, L; Liu, T; Shen, X; Tang, W; Wang, Y; Weng, S; Wu, J; Xue, R; Zhang, S1
Braeuning, A; Kirschnick, M; Muche, S; Schwarz, M1
Bisagni, G; Boni, C; Gnoni, R; Pagano, M; Panebianco, M; Rossi, G; Sierra, NM1
Hsiao, HH; Liu, TP; Lo, HL; Wei, LS; Yang, PM1
Bulai Livideanu, C; Christol, C; Hautier-Mazeereuw, J; Lamant, L; Paul, C; Pauwels, C; Peron, JM; Severino-Freire, M; Sibaud, V; Tournier, E1
Craveiro, RB; Dilloo, D; Ehrhardt, M; Holst, MI; Pietsch, T1
Dauch, D; Eilers, M; Geffers, R; Hohmeyer, A; Kang, TW; Laufer, S; Leibold, J; Longerich, T; Lowe, SW; Malek, NP; McJunkin, K; Pesic, M; Powers, S; Rudalska, R; Schirmacher, P; Sipos, B; von Thun, A; Weiss, KH; Wuestefeld, T; Zender, L; Zuber, J1
Cheong, J; Jung, HU; Kim, HY; Park, BS; Yoo, KS; Yoo, SH; Yoo, YH; Yun, I1
Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H1
Chen, S; Lin, H; Tao, C1
Jeong, KY; Lee, EJ; Seong, J; Yang, SH1
Burki, TK1
Bonekamp, S; Corona-Villalobos, CP; Cosgrove, D; Geschwind, JF; Halappa, VG; Kamel, IR; Pawlik, TM; Reyes, D1
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M1
Endo, M; Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y1
Antin, JH; Ballen, K; Chen, YB; Connolly, C; Curtis, M; Cutler, C; Del Rio, C; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Joyce, A; Lane, AA; Levis, M; Li, S; McAfee, S; Rajkhowa, T; Rudek, M; Soiffer, R; Spitzer, TR; Valles, B; Verselis, S1
Anichini, A; Carlo-Stella, C; Corradini, P; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Giordano, L; Guidetti, A; Locatelli, SL; Malorni, W; Marchianò, A; Mortarini, R; Russo, D; Sorasio, R; Viviani, S1
Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M1
Jung, WG; Kim, EH; Kim, MS1
Gores, GJ1
Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF1
Hamilton, G; Rath, B1
Koyanagi, T; Masumoto, A; Morita, Y; Motomura, K; Senju, T; Suzuki, H; Tajiri, H; Yada, M1
Rupasinghe, HP; Sudan, S1
Erlacher, M; Hertrampf, A; Herz, C; Kleinhans, C; Lamy, E; Mersch-Sundermann, V; Platz, S; Rohn, S; Schüler, J; Stetter, N; Wagner, M; Zimmermann, S1
Bruix, J; Di Donato, R; Gazzola, A; Reig, M2
Aichler, M; Borgmann, DM; Feuchtinger, A; Hauck, SM; Huber, K; Keller, U; Li, Z; Schwaiger, M; Walch, A; Zitzelsberger, H1
Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC1
Choi, GH; Han, S; Kang, YK; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH1
Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N1
Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, HJ; Kim, JK; Kim, SU; Kweon, YO; Lee, HW; Lee, JI; Lee, KS; Lee, S; Park, JY; Park, SY; Tak, WY1
Barroso-Sousa, R; Bento, Ada S; Blanco, BP; da Fonseca, LG; Hoff, PM; Pfiffer, TE; Sabbaga, J; Valente, GL1
Giusti, M; Minuto, F; Monti, E; Morbelli, S; Mortara, L; Pera, G; Sambuceti, G1
Fan, W; Huang, Y; Ke, S; Li, J; Ran, H; Wang, W; Wang, Y; Yang, J; Zhang, F; Zhang, Y1
Adjei, AA; Chai, F; Dy, GK; Goff, L; Lamar, M; Ma, WW; Martell, R; Means-Powell, JA; Puzanov, I; Saif, MW; Santoro, A; Savage, RE; Schwartz, B; Simonelli, M; Sosman, J; Zucali, P1
Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH1
Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J1
Chen, X; Feng, Z; Li, C; Li, Y; Niu, F; Tang, K; Yang, H; Zhang, L; Zhou, W1
Bortlicek, Z; Buchler, T; Kubackova, K; Linke, Z; Melichar, B; Pavlik, T; Pokorna, P; Prausova, J; Vyzula, R1
Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M1
Buonomano, P; Camera, L; Circelli, L; Colao, A; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Modica, R; Ramundo, V; Rubino, M; Sciammarella, C1
Gadot, N; Lassau, N; Leguerney, I; Pénault-Llorca, F; Robin, N; Scoazec, JY; Victorin, S1
Chen, J; Shi, JH; Wang, J; Zhu, YY1
Alexandre de Azevedo, R; Barbuto, JA; Bydlowski, SP; Ferreira, AK; Jorge, SD; Levy, D; Pizzo, CR; Rodrigues, CP; Salomon, MA; Teixeira, SF1
Albines, GS; Fernández-Molina, J; Fuentes-Martínez, N; Mesa, A; Pérez, R; Rodríguez, M; Varela, M1
Chen, KF; Chiang, HC; Chu, PY; Hsu, CY; Huang, JW; Ko, CH; Li, YS; Lin, MW; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH1
Kim, JI; Kim, SY; Lee, MH; Lee, SJ1
Ahmed, M; Coleman, CN; Curran, WJ; Dicker, AP; Finkelstein, SE; Houghton, P; Kirsch, DG; Machtay, M; Monjazeb, AM; Teicher, BA; Vikram, B; Wang, D; Wong, P; Xu-Welliver, M1
D'Argenio, DZ; Hsu, CP; Huard, J; Kuchimanchi, M; Lu, JF; Ma, J; Sun, YN; Weidner, M; Xu, G; Xu, Y; Zhang, Y1
Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M1
Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL1
Chang, YF; Chuang, HY; Hwang, JJ; Liu, RS1
Liu, BL; Liu, X; Qi, MY; Xu, B; Zhou, NC1
Bie, P; Huan, HB; Lau, WY; Ma, KS; Xia, F1
Binder, H; Elsäßer, A; Schmidtmann, I; Weinmann, A1
Abiraj, K; Boerman, OC; Franssen, GM; Gerrits, D; Lok, J; Oyen, WJ; Terry, SY1
Bolondi, L; Boni, C; Bruzzi, P; Cammà, C; Colombo, M; Craxi, A; Danesi, R; Daniele, B; Di Costanzo, GG; Fagiuoli, S; Santoro, A; Spandonaro, F; Trevisani, F1
Falchook, GS; Fu, S; Hong, DS; Huang, M; Janku, F; Jiang, Y; Kurzrock, R; Lin, Q; Naing, A; Parkhurst, K; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R1
Chen, G; Li, H; Wang, Z; Xu, X; You, W; Zhang, J; Zhou, D1
Baert, M; Chauffert, B; Diouf, M; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Saidak, Z1
Kawabata, M; Kuroyanagi, J; Miyabe, M; Nishimura, Y; Shimada, Y; Tanaka, T; Umemoto, N; Zhang, B1
Li, H; Liang, Q; Liu, B; Ma, Y; Mei, X; Wang, Y1
Adjei, AA; Brady, W; DePaolo, D; Ding, Y; Dy, GK; Fetterly, G; Ma, WW; Ngamphaiboon, N; Reungwetwattana, T; Zhao, Y1
Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L1
Bracarda, S; D Buono, S; Hamzaj, A; Marrocolo, F; Paglino, C; Porta, C; Sisani, M; Sternberg, CN1
Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N3
Chen, WT; Jeng, WJ; Lin, CC; Lin, CY; Lin, SM; Sheen, IS1
Chen, KF; Hung, MH; Shiau, CW; Tai, WT1
Dai, B; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Wang, HK; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP1
Albers, P; Greife, A; Hader, C; Knievel, J; Lübke, T; Niegisch, G; Schmitz, I; Schulz, WA1
Corssmit, EP; Kapiteijn, E; Links, TP; Oosting, SF; Schneider, TC; van der Horst-Schrivers, AN1
Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J1
Dou, K; Du, X; Feng, X; Guo, C; Jia, W; Liu, T; Ma, K; Qin, X; Wang, Z; Xu, J; Xu, R; Yang, S; Zhao, H1
Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Mazzaroppi, S; Pellicelli, AM; Petrioli, R; Pira, T; Roviello, G1
Arvat, E; Castiglione, A; Ciccone, G; Felicetti, F; Gallo, M; Michelon, F; Nervo, A; Piovesan, A; Viansone, AA; Zichi, C1
He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D1
Dill, MT; Djonov, V; Heim, MH; Hlushchuk, R; Makowska, Z; Quagliata, L; Rothweiler, S; Semela, D; Terracciano, L1
Fujii, Y; Hatano, T; Horie, S; Kawata, N; Kimura, G; Kondo, T; Kume, H; Morita, M; Murakami, M; Nakajima, K; Nakazawa, H; Ohno, Y; Okegawa, T; Oya, M; Saito, K; Takahashi, S; Wakumoto, Y; Yamaguchi, R1
Adenis, A; Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Cassier, P; Chaigneau, L; Chevreau, C; Collard, O; Cropet, C; Cupissol, D; Duffaud, F; Eberst, L; Gentet, JC; Le Cesne, A; Marec-Berard, P; Pautier, P; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Thyss, A1
Becherer, A; Dierneder, J; Gallowitsch, H; Hoffmann, M; Lind, P; Lindner, C; Lipp, R; Niederle, B; Pall, G; Pirich, C; Raderer, M; Romeder, F; Virgolini, I1
Mullangi, R; Sharma, K; Srinivas, NR; Suresh, PS1
Akker, Nv; Benzina, A; Gagliardi, M; Koole, LH; Molin, DG; Wang, Y1
Galanis, A; Levis, M1
Hiraoka, A; Ikeda, M; Izumi, N; Kadoya, M; Kudo, M; Matsui, O; Minami, T; Miyayama, S; Ogasawara, S; Okusaka, T; Tsuchiya, K; Ueshima, K; Yamakado, K; Yamashita, T1
Seong, J; Yoon, HI1
Kudo, M; Shimada, M; Tanaka, K1
Bazzica, M; Di Gion, P; Fucile, C; Lantieri, F; Marenco, S; Marini, V; Martelli, A; Mattioli, F; Picciotto, A; Pieri, G; Robbiano, L; Savarino, V; Stura, P; Zuccoli, ML1
Argilés, JM; Busquets, S; López-Soriano, FJ; Penna, F; Toledo, M1
Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Kim, D; Makarević, J; Reiter, M; Tsaur, I1
Ahn, H; Böckenhoff, A; Escudier, B; Guo, J; Jäger, D; Korbenfeld, E; Leonhartsberger, N; Ma, JH; Mardiak, J; Stauch, K; Ye, DW; Yu, J; Zemanova, M1
Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z1
Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S1
Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Nagel, C; Warmann, SW1
Cai, H; Kong, WT; Tang, Y; Wang, WP; Yuan, HX; Zhang, XL1
Seino, S; Tsuchiya, A; Watanabe, M1
Bresci, G; Caparello, C; Felder, M; Fornaro, L; Granito, A; Masi, G; Mismas, V; Musettini, G; Sacco, R; Vivaldi, C1
Chao, CC; Lin, YT; Lu, HP1
Dai, C; Jia, C; Peng, S; Xu, F; Xu, Y; Zhao, Y1
Jiao, Y; Lu, X; Tang, W; Wu, J; Xin, BT; Zhang, Y; Zheng, Y; Zhou, X1
Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V1
Ackermann, K; Esposito, I; Galle, PR; Heikenwälder, M; Lang, H; Protzer, U; Puschnik, A; Schad, A; Schlitter, AM; Sprinzl, MF; Weinmann, A1
Cowen, EW; Massey, PR; Okman, JS; Wilkerson, J1
Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V1
Gong, W; Liu, DJ; Liu, J; Sun, P; Xu, YT; Yu, GS; Zheng, SZ1
Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S1
Chiba, T; Kanogawa, N; Kobayashi, K; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O1
Narang-Master, J; Rizzolo, D1
Luo, CL; Wu, XH; Zhao, CX1
Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC1
Gillani, TB; Murray, M; Rawling, T1
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ1
Bernardini, M; Brossa, A; Bussolati, B; Fiorio Pla, A; Genova, T; Gkika, D; Grolez, G; Leroy, X; Prevarskaya, N; Villers, A1
Fukuda, H; Hidaka, H; Ishii, T; Kobayashi, S; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Nakazawa, T; Nozaki, A; Numata, K; Ohkawa, S; Okuse, C; Sakamaki, K; Shibuya, A; Suzuki, M; Tanaka, K1
Gao, ZH; Li, Y; Qu, XJ1
Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A1
Artaza Varasa, T; de la Cruz Pérez, G; Gómez Rodríguez, R; González de Frutos, C; Muñoz López, D; Romero Gutiérrez, M; Ruano Díaz, L; Sánchez Ruano, JJ1
Fischer, K; Göke, B; Kolligs, FT; op den Winkel, M; Paprottka, PM; Rauch, B; Schmidt, L; Straub, G1
Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H1
Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P1
Ball, DW; Byrd, D; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, J; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Sherman, SI; Sturgeon, C; Tuttle, RM; Waguespack, SG; Wang, TN; Wirth, LJ1
Chen, J; Chen, S; Wu, B; Xi, W; Yu, H1
Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC1
Bardeesy, N; Chen, Y; Duda, DG; Fan, C; Hato, T; Huang, P; Huang, Y; Jain, RK; Kitahara, S; Ng, MR; Ochiai, H; Ramjiawan, RR; Reddy, TP; Reiberger, T; Unan, EC; Zhu, AX1
Fang, Q; Liu, S; Sun, J; Xu, H; Zhan, C; Zhang, S; Zhang, Y; Zhao, L1
Bode, B; Cathomas, R; Fuchs, B; Rothermundt, C; Schwitter, M; von Moos, R1
Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV1
Bruix, J; Carrilho, FJ; Evans, TR; Jensen, M; Kang, YK; Leberre, MA; Llovet, JM; Meinhardt, G; Qin, S; Rosmorduc, O; Ross, PJ; Santoro, A; Thuluvath, PJ; Zhu, AX1
Antar, A; Bazarbachi, A; Kharfan-Dabaja, MA; Mahfouz, R1
Duan, F; Fan, QS; Fu, JX; Liu, FY; Wang, MQ; Zhang, L1
Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J; Zuo, Y1
Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC1
Liu, C; Meng, FD; Pang, Q; Qu, K; Wang, ZX; Wei, JC; Wu, QF; Zhang, LQ1
Berger, W; Dornetshuber-Fleiss, R; Heffeter, P; Heilos, D; Lemmens-Gruber, R; Mohr, T; Novicky, A; Richter, L; Süssmuth, RD; Zlesak, M1
Boige, V; Ducreux, M; Ferté, C; Hollebecque, A; Malka, D1
Ardizzoni, A; Campanini, N; Dal Bello, B; Fanello, S; Maria, SE; Missale, G; Negri, FV; Poggi, G; Porta, C; Rossi, S; Salvagni, S; Tinelli, C1
Karakurt Eryılmaz, M; Kıvrak Salim, D; Musri, FY; Mutlu, H; Şenol Coşkun, H; Tural, D; Ünal, B1
Albares, MP; Berbegal, L; Blanes, MM; de León, FJ1
Chan, SY; Cheng, AL; Hsu, CH; Lu, LC; Shao, YY; Shau, WY1
Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH1
Huang, YS; Xue, Z; Zhang, H1
Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A1
Bedi, A; Bishop, J; Chung, CH; Gilbert, J; Haigentz, M; Leon, ME; Murphy, B; Neil Hayes, D; Nieva, J; Ravi, R; Saba, N; Schell, MJ; Sidransky, D; Tanvetyanon, T; Zhao, X1
Handkiewicz-Junak, D; Jarzab, B; Krajewska, J1
Choi, HJ; Han, J; Han, KH; Kim, GM; Lim, S1
Chung, YH; Jung, J; Kang, YK; Kim, GA; Kim, JH; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Yoon, SM1
Hu, W; Liu, XH; Lv, SQ; Wang, XH; Yuan, Q; Zhu, HC1
Colevas, AD; Gruber, JJ1
Barceló-Batllori, S; Bell, O; Corra, M; de Leiva, A; González, C; Lerma, E; Mato, E; Moral, A; Orera, I; Pérez, JI; Selva, L1
Chan, JK; Chung, AY; Endaya, BB; Gnecchi, M; Ho, IA; Hui, KM; Huynh, H; Iyer, NG; Lam, PY; Leong, HS; Lim, KH; Newman, JP; Sia, KC; Toh, XY; Yulyana, Y1
Cao, H; Chen, L; Chen, Y; Gu, W; He, X; Huang, Y; Li, Y; Wang, Y; Xu, M; Yin, Q; Yu, H; Zhang, Z1
Jin, G; Liu, Y; Sun, K; Tian, Y; Wang, Y; Yang, X; Zhang, Q; Zhou, C1
Colquhoun, S; Hata, K; Hoon, DS; Hoshino, H; Huang, SK; Iida, Y; Ohta, K; Ono, S; Wang, J1
Hagström, MV; Hirvonen, JT; Kaasalainen, MH; Mäkilä, EM; Salonen, JJ; Santos, HA; Wang, CF1
Chen, M; Gao, H; Huang, J; Li, S; Wang, H; Xu, L; Zhang, Y; Zhou, Z1
Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G2
Belli, L; Cabibbo, G; Cammà, C; Enea, M; Galvano, A; Mancuso, A; Mazzola, A; Perricone, G; Zavaglia, C1
Coy, DH; Sun, G; Sun, L; Yu, Y1
Hsia, CY; Hsu, CY; Huang, YH; Huo, TI; Lee, RC; Lee, YH; Lin, HC; Liu, PH; Su, CW1
Barbara, M; Basso, M; Biolato, M; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Della Corte, C; Grieco, A; Iavarone, M; Maida, M; Vavassori, S1
Chen, CY; Chen, SC; Feng, CW; Feng, YM; Lee, MY; Lu, CL1
Deng, J; Ji, Z; Li, H; Li, Y; Yu, H; Zhang, Y1
Feng, X; Hu, Y; Liu, A; Liu, D; Peng, J1
Cohen, MS; White, PT1
Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A1
Li, CS; Liu, QY; Qi, HL; Zhuang, BJ1
Brendel, C; Burchert, A; Fouladi, F; Henkenius, K; Hub, F; Jehn, LB; Metzelder, SK; Neubauer, A; Stiewe, T1
Azijli, K; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Honeywell, RJ; Peters, GJ; Poel, D; Rovithi, M; Verheul, HM1
Aguilar, G; Chan, YC; Chen, CL; Kabiling, CS; Pillai, VG; Wang, CC1
Bai, Y; Guo, X; Kang, H; Lu, L; Lu, M; Qu, Z; Ren, Z; Shi, L; Song, T; Wang, H; Wang, X; Yang, W; Yang, Y; Ye, SL; Zhou, W; Zhu, K1
Liu, J; Zhang, B; Zhang, X; Zhou, T1
Bi, F; Hao, P; Li, J; Li, Q; Wen, F; Xia, F; Yan, W; Yang, Y; Zhang, P1
Boucher, E; Boudjema, K; Breton, M; Clement, B; Edeline, J; Garin, E; Icard, N; Laffont, S; Lenoir, L; Mesbah, H; Raoul, JL; Rohou, T; Rolland, Y; Sulpice, L1
Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L1
Rupasinghe, HV; Sudan, S1
Kirstein, MM; Klöpper, A; Lehmann, U; Manns, MP; Ringe, KI; Schmidt, S; Schweitzer, N; Vogel, A; Wedemeyer, H1
Ishijima, N; Kanki, K; Shimizu, H; Shiota, G1
Chen, G; Derwahl, M; Nicula, D; Renko, K1
Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M1
Fu, Q; Liu, J; Liu, Y; Ouyang, H; Qiao, K; Shen, Z; Tao, S; Wang, W; Wu, J; Wu, Y; Xie, Y; Yang, X; Ye, X; Zhang, J; Zhang, JB1
Ali, LA; Elmashad, N; Elmashad, W; Farouk, M; Ibrahim, WS; Mayah, WW; Taha, A1
Dai, JQ; Gao, F; Li, G; Li, GC; Liu, X; Mu, J; Ren, JJ; Song, YP; Wang, H; Wang, L; Wang, QX; Xie, J; Zhang, XB; Zhang, YJ; Zhou, NC1
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z1
Cen, J; He, X; Hu, C; Hui, L; Li, C; Li, Y; Mu, W; Qiu, Z; Qu, Z; Ren, H; Shi, X; Zhang, H1
Airaksinen, AJ; Hirvonen, JT; Hyvönen, ML; Laakkonen, PM; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarparanta, MP; Wang, CF1
Bellentani, S; Biasco, G; Brandi, G; De Lorenzo, S; Di Girolamo, S; Saccoccio, G1
Booth, L; Chuckalovcak, J; Cruickshanks, N; Dent, P; Hamed, HA; Poklepovic, A; Roberts, JL; Tavallai, M1
Kumar, S1
Li, K; Liu, Y; Ma, N; Qiao, L; Wang, F; Wang, J; Xu, S; Yue, H1
Gu, D; Pan, X; Qian, L; Shan, Y; Xue, B; Yang, D; Zheng, B; Zhou, J; Zhu, H1
An, L; Chen, Y; Feng, F; Gao, X; Lu, Y; Qu, J; Sun, H; Wang, C; Wang, F; Yang, Y; Zeng, Z; Zhang, C1
Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP1
Jin, Y; Lin, L; Lin, Y; Tan, Y; Wang, D; Zhang, Y; Zheng, C1
Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y1
Hosoda, Y; Kakita, N; Kim, Y; Nagai, K; Nishino, M; Okano, M; Tsujinaka, T; Yamada, Y; Yamasaki, M; Yasui, M1
Dong, R; Kang, M; Yang, Q; Zhang, S; Zhao, J1
Lee, HW; Park, JG; Park, SY1
Blair, HA; Plosker, GL1
Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC1
Colao, A; Faggiano, A; Marotta, V1
Addario, L; Caporaso, N; Cordone, G; de Stefano, G; Di Costanzo, GG; Farella, N; Imparato, M; Lampasi, F; Lanza, AG; Tortora, R1
Chen, L; Dong, Q; Liu, M; Ruan, M1
Lauer, R; Rao, A1
Bornemann, L; Dicken, V; Moltz, JH; Peitgen, HO; Scheuring, U; Zaim, S1
Barba, M; Bernardini, C; Castellini, L; Gasbarrini, A; Maulucci, G; Pani, G; Piscaglia, AC; Pontoglio, A; Puglisi, MA; Samengo, D; Scatena, R; Spelbrink, JN; Tesori, V1
Araki, H; Gotoh, M; Hattori, R; Kimura, T; Sassa, N; Tanaka, K; Tsuzuki, T; Yamada, S; Yoshino, Y1
Arias, A; Catania, VA; Ceballos, MP; Ciriaci, N; Ghanem, CI; Luquita, MG; Mottino, AD; Rigalli, JP; Ruiz, ML; Villanueva, SS1
Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J1
Kawai, K; Minemura, M; Nakajima, T; Sugiyama, T; Tajiri, K1
de Bont, ES; den Dunnen, WF; Hoving, EW; Kampen, KR; Lourens, HJ; Meeuwsen-de Boer, TG; Scherpen, FJ; Sie, M; Zomerman, WW1
Abdel-Maksoud, MS; El-Gamal, MI; Gamal El-Din, MM; Oh, CH; Yoo, KH1
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Giroux, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Tlemsani, C1
Chen, YL; Cheng, YS; Chuai, ML; Ding, XY; Lee, KK; Li, Y; Wang, G; Wang, XY; Yang, XS1
Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A1
English, PA; Escudier, B; Huang, X; Kim, S; Loomis, AK; Motzer, RJ; Rini, BI; Rosbrook, B; Tarazi, J; Williams, JA1
Bussom, S; Cheng, YC; Guan, F; Hu, R; Huang, X; Jiang, Z; Lam, W; Liu, SH; Wang, J; Yen, Y; Zhao, H1
Choi, WW; Chow, HC; Gill, H; Ip, AH; Kwong, YL; Leung, AY; Man, CH1
Brochot, E; Castelain, S; Descamps, V; Duverlie, G; Fournier, C; François, C; Galmiche, A; Helle, F; Hoffmann, TW; Izquierdo, L; Louandre, C; Martin, E1
Hoshida, Y; Kishikawa, T; Koike, K; Kojima, K; Kondo, Y; Noyama, T; Ohishi, M; Ohno, M; Ota, S; Otsuka, M; Sato, M; Shibata, C; Soga, T; Sun, X; Takata, A; Takehana, K; Tan, PS; Yoshikawa, T1
Fishman, MN; Foreman, PK; Fulp, WJ; Tomshine, J1
Delire, B; Stärkel, P1
Azuma, K; Esaki, M; Kitazono, T; Matsumoto, T; Nakamura, S; Ooho, A; Yanai, S1
Alloisio, M; Fatuzzo, G; Lorenzi, E; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA1
Kim, YH; Lee, EW; Quirk, M; Saab, S1
Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY1
Choi, HS; Hahm, JS; Jun, DW; Kim, JO; Lee, HL; Lee, KN; Lee, OY; Tae, HJ; Yoon, BC1
Qin, S; Zhang, S1
Eto, M; Harada, M; Horlad, H; Kawano, Y; Komohara, Y; Maeda, Y; Motoshima, T; Takeuchi, A; Takeya, M; Tanoue, K1
de Man, RA; Ijzermans, JN; Klümpen, HJ; Schrier, JG; van der Geest, LG; van Erpecum, KJ; van Meer, S1
Chow, LP; Feng, WC; Ho, WC; Hsu, CH; Shao, YY; Tsai, MH; Yeh, CC1
Ai, H; Han, L; Liu, S; Mi, R; Song, Y; Wang, P; Wei, X; Yin, Q; Zhang, Y; Zhao, H1
Booth, L; Cruz-Luna, T; Cycon, KA; Dent, P; Doern, CD; Fidanza, A; Nourbakhsh, A; Plamondon, P; Roberts, JL; Siembida, P; Smith, E; Tavallai, M1
Chao, Y; Chen, YT; Huang, YH; Huo, TI; Lee, FY; Lee, IC; Li, CP; Lin, HC; Su, CW1
Bil, J; Bobrowicz, M; Bojarczuk, K; Dwojak, M; Giannopoulos, K; Golab, J; Lech-Maranda, E; Malenda, A; Pyrzynska, B; Siernicka, M; Tomczak, W; Winiarska, M1
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O3
Cao, L; Choyke, P; Do, K; Doroshow, JH; Eugeni, M; Figg, WD; Holkova, B; Jacobs, P; Kang, Z; Kummar, S; Larkins, E; Lindenberg, ML; Peer, CJ; Raffeld, M; Steinberg, SM; Turkbey, B; Wright, JJ1
Benevento, F; Bolondi, L; Granito, A; Marinelli, S; Piscaglia, F; Renzulli, M; Terzi, E; Venerandi, L1
Fujisawa, M; Miyake, H; Tei, H1
Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C1
Ha, TY; Hong, HN; Hwang, S; Kim, N; Moon, KM; Ryoo, BY; Song, GW; Tak, E; Won, YJ1
Choi, YI; Ha, TY; Hong, HN; Hwang, S; Kim, N; Ryoo, BY; Song, GW; Tak, E; Won, YJ; Yoon, SY1
Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N1
Chen, C; Cheng, Z; Cong, WM; Ding, J; Feng, GS; Han, T; Li, HY; Liu, N; Shen, WF; Sun, HL; Sun, W; Wang, HY; Wang, RY; Wang, X; Wen, W; Wu, MC; Xiang, DM1
Abbattista, MR; Gu, Y; Guise, CP; Jamieson, SM; Nickel, JE; Patterson, AV; Pullen, SM; Wilson, WR1
Anseth, KS; Jones, CE; Leight, JL; Lin, AJ; Tokuda, EY1
Gavrancic, T; Park, YH1
Bruckner, T; Ganten, MK; Ganten, TM; Koschny, R; Schuessler, M1
Britten, M; Broecker-Preuss, M; Fuhrer, D; Mann, K; Müller, S; Schmid, KW; Worm, K1
Abei, M; Danjoh, I; Hyodo, I; Nakamura, Y; Shirota, R; Yamada, T; Yamashita, T1
Chae, HB; Kang, HY; Kang, YW; Kim, AN; Kim, HS; Kim, SB; Kim, SH; Ko, SY; Lee, BS; Lee, ES; Lee, HY; Lee, JD; Lee, SH; Lee, TH; Noh, R; Song, IH1
Dong, M; Kong, FM; Li, YJ; Zhou, JP1
Abe, Y; Aiura, K; Ei, S; Hibi, T; Itano, O; Kishida, N; Kitagawa, Y; Kitago, M; Masugi, Y; Sakamaoto, M; Shinoda, M; Tanabe, M; Tanimoto, A; Ueno, A; Yagi, H1
de Stefano, G; Farella, N; Iodice, V1
Dou, H; Feng, K; Jiang, X; Li, Z; Wang, T; Zhang, Y; Zhou, F1
Cho, M; Choi, CW; Heo, J; Hong, YM; Kang, DH; Kim, HW; Lim, W; Park, SB; Woo, HY; Yoon, KT2
Ang, MK; Chau, NM; Chowbay, B; Haaland, B; Hui, KM; Koh, TS; Li, WY; Lim, WT; Ng, QS; Tan, DS; Tan, EH; Tan, IB; Thng, CH; Toh, CK1
Ho, TH; Hoang, A; Huang, Y; Johnson, MM; Jonasch, E; Liu, XD; Tamboli, P; Wang, F; Warneke, CL1
Chen, Y; Ding, J; Ding, R; Dou, K; Gao, Y; Guo, X; Liu, D; Lv, X; Ruan, B; Zhou, T1
Cheng, BY; Ching, RH; Lau, EY; Lee, TK; Lo, J; Ma, MK; Ng, IO1
Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG2
Chen, E; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S1
Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D1
Barone, M; Carr, BI; Di Leo, A; Facciorusso, A; Licinio, R1
Ai, H; Mi, R; Wang, P; Wei, X; Xu, H; Yin, Q1
Du, Z; He, X; Li, Q; Tang, R; Wen, F; Yang, Y; Zhang, J; Zhang, P; Zhou, J1
Kalyan, A; Kulik, L; Nimeiri, H1
Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Yoo, BC1
Hanai, T; Ideta, T; Imai, K; Kochi, T; Miyazaki, T; Shimizu, M; Shiraki, M; Suetsugu, A; Takai, K1
Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U1
Baker, SD; Durmus, S; Gibson, AA; Hu, S; Li, L; Mani, S; Panetta, JC; Schinkel, AH; Sparreboom, A; Vasilyeva, A; Wagenaar, E1
Aglietta, M; Basiricò, M; Canta, M; Capozzi, F; Cemmi, F; Dell'Aglio, C; Gammaitoni, L; Grignani, G; Inghilleri, S; Luisetti, M; Marchiò, S; Morbini, P; Pignochino, Y; Piloni, D; Pozzi, E; Sangiolo, D; Soster, M; Stella, GM; Zorzetto, M1
De Velasco, MA; Hatanaka, Y; Kura, Y; Minami, T; Nishio, K; Nozawa, M; Oki, T; Ozeki, T; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshikawa, K; Yoshimura, K1
Sioulas, AD; Triantafyllou, K1
Büchler, MW; Ganten, T; Gotthardtp, D; Hoffmann, K; Jäger, D; Karapanagiotou-Schenkel, I; Kollmar, O; Nadalin, S; Radeleff, B; Schemmer, P; Settmacher, U; von Kalle, C1
Petrou, P2
Barrois, C; Berger, F; Cassier, P; El-Madani, M; Freyer, G; Guitton, J; Hénin, E; Lachuer, J; Lefort, T; Rodriguez-Lafrasse, C; Slimane, K; Tod, M; Valette, PJ; You, B1
Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Yildiz, C1
Bhatt, VR; Giri, S; Hamdeh, S; Schwarz, JK1
Bhak, J; Hong, SH; Hwang, JA; Kim, BC; Kim, BH; Kim, JS; Lee, JA; Lee, SH; Lee, YS; Nam, S; Park, JW; Shin, A1
Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L1
Karedan, T; Perez, CA; Wang, E1
Bornhäuser, M; Brendel, C; Burchert, A; Charles, J; Ellenrieder, V; Gattenlöhner, S; Hessmann, E; Inselmann, S; Metzelder, SK; Michel, C; Neubauer, A; Rehberger, M; Sohlbach, K; Solovey, M; Stiewe, T; Ten Haaf, A; von Bonin, M; Wang, Y1
Labgaa, I; Villanueva, A1
Chan, SY; Cheng, AL; Hsu, CH; Huang, CY; Lin, TH; Shao, YY1
Ku, CY; Lin, HY; Lin, JY; Lu, SC; Wang, YR1
Chapiro, J; Duran, R; Geschwind, JF; Schernthaner, RE1
Chen, J; Shi, JH; Wang, J; Wang, Q; Zhu, YY1
Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J1
Aldridge, J; Atkins, MB; Conley, C; Flaherty, KT; Giobbie-Hurder, A; Hodi, FS; Ibrahim, N; Lawrence, DP; McDermott, DF; Mier, JW; Sullivan, RJ1
Amoroso, D; Angelico, M; Attili, A; Barni, S; Benedetti, A; Buonadonna, A; Burlone, ME; Calvani, N; Cascinu, S; Cengarle, R; Cillo, U; Crocè, LS; Cuttone, F; D'Angelo, S; Di Costanzo, F; Erminero, C; Fava, G; Gasbarrini, A; Germano, D; Giannitrapani, L; Giovanis, P; Lencioni, R; Lorusso, V; Magini, G; Marenco, S; Marignani, M; Massa, E; Montesarchio, V; Noto, A; Palmieri, V; Picardi, A; Poggi, G; Proserpio, I; Saitta, C; Sansonno, D; Tumulo, S; Villa, E; Zolfino, T1
Altomonte, J; Braren, R; Dworniczak, J; Ebert, O; Esposito, I; Feuchtinger, A; Groß, C; Heid, I; Heß, J; Rummeny, E; Sayyed, S; Schlitter, AM; Schwaiger, M; Settles, M; Steiger, K; Steingötter, A; Unger, K; Walch, A; Zitzelsberger, H1
Bensalah, K; Ouzaid, I1
Brzózka, K; Mikula, M; Rzymski, T; Wiklik, K1
Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Ishiko, T; Nakamura, K; Nitta, H; Okabe, H; Sasaki, M1
Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC1
Chen, J; Harris, KR; Kim, DH; Larson, AC; Lewandowski, RJ; Li, W; Shea, LD; White, SB; Yap, JW1
Huang, A; Shi, Y1
Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P1
Bao, J; Che, S; Hao, C; Li, Z; Liu, J; Qian, Z; Shang, H; Wang, H; Zhang, H; Zhang, X; Zhao, H1
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW1
Calucci, L; Cappello, V; Ciofani, G; de Julian Fernandez, C; Forte, C; Gemmi, M; Grillone, A; Innocenti, C; Mattoli, V; Mondini, A; Moscato, S; Riva, ER; Ronca, F; Sacco, R1
Chen, DS; Chen, KF; Chen, PJ; Cheng, HR; Huang, HP; Jao, P; Jeng, YM; Kao, JH; Liu, CH; Liu, CJ; Shiau, CW; Su, TH; Tai, WT; Tseng, TC; Yang, HC1
Fujie, S; Fukubayashi, K; Izumi, K; Kawasaki, T; Kikuchi, K; Naoe, H; Sasaki, Y; Setoyama, H; Tanaka, M; Tateyama, M; Watanabe, T; Yoshimaru, Y1
Eriksson, LA; Gao, C; Grøtli, M1
Jia, B; Jin, Z; Liu, K; Liu, S; Liu, Y; Tan, L; Zhang, W1
Li, S; Liu, R; Liu, Y; Shen, H; Wang, P; Yin, L1
Izumi, N; Joko, K; Nishijima, N; Nishio, K; Orito, E; Osaki, Y; Sakai, K; Takeda, H; Uchida, Y1
Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A1
Ghosh, AK; Giroux, V; Jossé, R; Luo, J; Pommier, Y; Zhang, YW1
Chang, E; Foerster, S; Gondek, L; Huso, DL; Levis, M; Li, L; Lim, Y; Ma, H; Marchionni, L; Matsui, W; McGovern, K; Merchant, AA; Peacock, CD; Small, D; Smith, BD; Wang, Q; Watkins, DN1
Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM1
Brown, JM; Chang, DT; Deng, L; Giaccia, A; Koong, AC; Le, QT; Loo, BW; Pai, RK; Pollom, EL; Shultz, DB1
Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T1
Cosgrove, DP; Feng, AL; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK1
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT1
Austin, T; Beckman, RA; Cheng, AL; Greenberg, J; He, AR; Hung, CH; Izumi, N; Kang, YK; Kudo, M; Lim, HY; Ryoo, BY; Sheen, IS; Shiratori, S; Wang, Q1
Guo, XL; Li, WB; Lu, YY; Wang, JJ; Zhang, XK1
Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; George, DJ; Manola, JB; Margolin, KA; McDermott, DF; Pins, M1
Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM1
Guo, WH; Lu, J; Wang, XZ; Zhang, JX; Zheng, JF1
Fan, W; Fu, S; Huang, J; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y; Zhu, K1
Abada, PB; Baron, AD; Blanc, JF; Chang, SC; Chau, I; Chung, HC; Kubackova, K; Kudo, M; Okusaka, T; Park, JO; Pastorelli, D; Pfiffer, TE; Poon, R; Ryoo, BY; Sastre, J; Schwartz, JD; Trojan, J; Yang, L; Yen, CJ; Zhu, AX1
Cha, TL; Chang, SY; Chen, MR; Chen, YC; Chuang, MJ; Ho, JY; Hsiao, PW; Huang, SM; Lee, HJ; Lin, CC; Lin, HK; Lin, VC; Sun, GH; Tang, SH; Tsai, YT; Wu, ST; Yu, CP; Yu, DS1
Agulnik, M; Carneiro, BA; Carneiro, RM; Giles, FJ; Kopp, PA1
Bessarabova, M; Dorner, A; Gulbekyan, G; Hope, A; Kolpakova-Hart, E; Li, B; Merberg, D; Nikolsky, Y; Pustovalova, O; Schu, M; Shin, H; Trepicchio, WL1
Trojan, J; Waidmann, O1
Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Mazzi, V; Miccoli, M; Miccoli, P; Politti, U; Ulisse, S1
Chen, MS; Li, SP; Pawlik, TM; Spolverato, G; Xu, L; Zhang, YJ; Zhao, J; Zhou, DS1
Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y1
Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K1
Huang, YH; Siao, FY; Yen, HH1
Im, GH; Jeon, TY; Kim, CK; Kim, JH; Lee, JH; Park, BK1
Cheng, SP; Chuang, JH; Lin, LL; Shieh, DB; Wang, PW; Wang, SY; Wei, YH1
Azmi, AN; Chan, WK; Goh, KL1
Aedo, V; Cristina, V; Faivre, S; Raymond, E1
Antonelli, A; Baldini, E; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Politti, U; Spisni, R; Ulisse, S1
Igarashi, Y; Ikehara, T; Ishii, K; Kikuchi, Y; Kogame, M; Makino, H; Matsui, T; Nagai, H; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M1
Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L1
Bodoky, G; Bronowicki, JP; Croitoru, A; Daniele, B; Mathurin, P; Papandreou, C; Ratziu, V; Serejo, F; Stål, P; Turnes, J1
He, D; Liu, R; Lu, X; Sun, C; Tang, C; Wei, X; Wu, Z; Zheng, D; Zhou, M1
Abbate, I; Brandi, M; De Rose, F; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A1
Hashimoto, Y; Iizuka, J; Kennoki, T; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K1
Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P1
Heikenwalder, M; O'Connor, T; Weber, A1
Cai, X; Chen, J; Huang, D; Jin, R; Liang, X; Liang, Y; Lin, H; Liu, J; Yan, H; Ying, H; Yu, H; Zhao, J; Zhou, S1
Cheng, AL; Fan, HH; Feng, ZR; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL; Shyue, SK1
Cheng, X; Cheng, Y; Kuang, Y; Pan, X; Yang, X1
Chen, L; Liang, S; Liu, J; Shao, H; Su, H; Xu, K1
Bettinger, D; Brunner, TB; Neeff, HP; Schultheiß, M; Thimme, R1
Albiges, L; Escudier, B1
Hayward, S; Iakovou, G; Laycock, SD1
Chun, HG; Chun, HJ; Hong, SH; Hwang, SW; Jung, ES; Lee, JE; Lee, JM; Lee, MA; Lee, SH1
Hijikawa, T; Ishizaki, M; Kaibori, M; Kitade, H; Kon, M; Matsui, K; Yamada, M; Yanagida, H; Yokoigawa, N; Yoshioka, K1
Amela, EY; Bertucci, F; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Collard, O; Isambert, N; Italiano, A; Laurence, V; Le Cesne, A; Lebellec, L; Penel, N; Saada-Bouzid, E; Salas, S; Tresch-Bruneel, E1
Llovet, JM; Torrecilla, S1
Adachi, M; Akaza, H; Gemma, A; Hyodo, I; Iijima, M; Inuyama, L; Itoh, H; Okayama, Y; Oya, M; Sunaya, T1
Chen, DS; Chen, KF; Chen, PJ; Lin, WH; Shiau, CW; Teng, YC; Tsai, TF; Wang, SH; Yeh, SH1
Blaney, SM; Fox, E; Jayaprakash, N; Kim, A; Krailo, M; Weigel, B; Widemann, BC1
Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L1
Amore, E; Augello, G; Bondì, ML; Botto, C; Cervello, M; Craparo, EF; Emma, MR1
Angarano, G; Brunetti, O; Faloppi, L; Gnoni, A; Guarini, A; Licchetta, A; Lorusso, V; Lupo, L; Memeo, V; Palasciano, G; Palmieri, V; Pisconti, S; Russo, A; Santini, D; Scartozzi, M; Silvestris, N1
Chang, CC; Chen, Y; Chiang, WH; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC1
Berretta, M; Di Francia, R; Tirelli, U1
Cheng, K; Cheng, Z; Fan, Q; Huang, W; Lu, X; Yang, M; Zhang, L; Zhang, R1
Hamdeh, S; Khanal, N; Lanspa, S; Upadhyay, S1
Gerull, S; Halter, JP; Heim, D; Medinger, M; Passweg, JR; Tschan-Plessl, A1
Álamo-Martínez, JM; Barcena, JA; Barrera-Pulido, L; Bernal-Bellido, C; Blanco-Fernández, G; Gila-Bohórquez, A; Gómez-Bravo, MA; González, R; Marín-Gómez, LM; Muntané, J; Navarro-Villarán, E; Nogales-Muñoz, A; Pacheco, D; Padilla, CA; Padillo, FJ; Pereira, S; Rodríguez-Hernández, A; Sarrias-Giménez, A; Serrablo-Requejo, A; Serrano-Díaz-Canedo, J; Soriano-De Castro, LB; Suárez-Artacho, G; Torres-Nieto, MA1
Cen, X; Deng, P; Du, C; Fu, D; Gu, H; Hu, C; Kong, J; Li, Y; Long, H; Luo, L; Shao, X; Wang, H; Zhao, Q; Zhao, Y; Zhu, R1
Casado Sáenz, E; Falagan, S; García Sánchez, S; Gómez-Raposo, C; Hernández Jusdado, R; Moreno Rubio, J; Moreno, V; Sereno, M; Zambrana Tébar, F1
Byrd, JC; Caligiuri, MA; Campbell, AR; Carson, WE; Fairchild, ET; Grignol, VP; Guenterberg, KD; Jaime-Ramirez, AC; Karpa, VI; Kondadasula, SV; Lesinski, GB; Levine, KM; Mace, TA; Markowitz, J; Martin del Campo, SE; McClory, S; Monk, JP; Mortazavi, A; Mundy-Bosse, BL; Olencki, TE; Pan, X; Paul, BK; Shah, MH; Tridandapani, S; Trikha, P1
Arencibia, JM; Augusto, EA; Groner, B; Ibrahim, AA; Kakoschky, B; Köberle, V; Korf, HW; Korkusuz, H; Kronenberger, B; Piiper, A; Pleli, T; Schmithals, C; Vafaizadeh, V; Vogl, TJ; Waidmann, O; Zeuzem, S1
Hur, DY; Kim, D; Kim, JW; Kim, YS; Park, GB; Roh, KH; Sun, H; Yang, JW1
Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S1
Dong, X; Li, J; Li, T; Liu, F; Wang, F; Wang, X; Wang, Y; Wei, H; Xiu, P; Xu, Z; Zhong, J1
Di Cesare Mannelli, L; Farina, C; Ghelardini, C; Maresca, M; Scherz, MW1
Kim, JK; Seo, MS; Shim, JY1
Bao, WD; Chen, TW; Cheng, SQ; Deng, YZ; Feng, YY; Guan, DX; Koeffler, HP; Li, JJ; Long, LY; Qiu, L; Shi, J; Xie, D; Zhang, EB; Zhang, XL; Zhang, Y; Zhao, JS1
Assanelli, A; Bernardi, M; Carrabba, MG; Ciceri, F; Corti, C; De Freitas, T; Lupo Stanghellini, MT; Marktel, S; Messina, C; Peccatori, J; Piemontese, S; Tresoldi, C; Vago, L1
Abbate, I; Brandi, M; Daniele, A; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A; Sabbà, C1
Antonucci, M; Bargellini, I; Cabibbo, G; Marceglia, S; Mismas, V; Sacco, R1
Berger, M; Bouvier, N; Capanu, M; Herrera, JM; Ilson, DH; Janjigian, YY; Ku, GY; Socci, ND; Tang, LH; Vakiani, E; Viale, A1
Chen, Y; Chern, GG; Chiang, T; Gao, DY; Lin, TT; Liu, CH; Liu, JY1
Nishio, K; Togashi, Y1
Gemma, A; Miyanaga, A1
Kato, S1
Abastado, JP; Chew, V; Ho, V; Kaldis, P; Lee, J; Lim, TS; Steinberg, J; Szmyd, R; Tham, M; Yaligar, J1
Arora, R; Astorga-Wells, J; Bonnet, P; Brehmer, D; Di Michele, M; Gevaert, K; Jacoby, E; Linders, JT; Martens, L; Stes, E; van Heerde, E; Vandenbussche, J; Vandermarliere, E; Zubarev, R1
Ford, LA; Freyer, CW; Griffiths, EA; Muppidi, MR; Portwood, S; Thompson, JE; Wang, ES; Wetzler, M1
Aigner, A; Kiprianova, I; Kögel, D; Milosch, N; Mohrenz, IV; Remy, J; Seifert, V1
Kiyota, N1
Chen, W; Lv, Y; Xie, R; Yu, J; Zhang, J1
Afaq, F; Agarwal, J; Athar, M; Baxter, RD; Elmets, CA; Hunt, KM; Pal, HC1
Andreeff, M; Badar, T; Borthakur, G; Champlin, R; Cortes, JE; Daver, N; Garcia Manero, G; Kadia, TM; Kantarjian, HM; Konopleva, M; Luthra, R; Nogueras-Gonzalez, GM; Oran, B; Patel, K; Ravandi, F; Wierda, WG1
Fu, Y; Sima, H; Yang, G; Yang, N; Zhang, H; Zhu, N1
D'Andrea, K; Flaherty, KT; Khare, S; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Roszik, J; Schuchter, LM; Wilson, MA; Woodman, SE; Wubbenhorst, B; Zhao, F1
Chung, J; Hong, SH; Joo, KJ; Kim, CS; Kim, S; Kim, SH; Kim, TN; Kwak, C; Kwon, TG; Lee, SE; Nam, BH; Seo, IY; Seo, SI; Song, K2
Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H1
Dong, D; Dong, X; He, C; Jiang, H; Jiang, X; Li, B; Sun, X; Xu, S; Zhai, B1
Fang, D; Guo, G; Huang, L; Li, X; Song, Y; Yu, X; Zhang, C; Zhang, X; Zhou, L1
Ali, SM; Chmielecki, J; Chudnovsky, J; Elvin, JA; Gay, L; Gray, A; Johnson, A; Lipson, D; Miller, VA; Nakamura, BN; Roels, S; Ross, JS; Stephens, PJ; Vergilio, JA; Wang, K; Wong, MK; Yelensky, R1
Djokovic, D; Duarte, A; Gigante, J; Harris, AL; Pinho, M; Trindade, A1
Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS1
Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A1
Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M1
Bandukwala, H; Belsúe, V; Casares, N; Coffer, PJ; Durántez, M; Gorraiz, M; Hervás-Stubbs, S; Lasarte, JJ; Lourenço, AR; Lozano, T; Oyarzábal, J; Prieto, J; Riezu-Boj, JI; Ruiz, M; Sarobe, P; Villanueva, L1
Chen, L; Chen, T; Cui, Y; Fang, T; Ge, C; Jiang, G; Li, H; Li, J; Li, M; Liu, J; Tian, H; Xie, H; Yao, M; Zhang, L1
Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S1
Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS1
Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C1
Covell, LL; Ganti, AK1
Fujisawa, M; Harada, K; Imai, S; Miyake, H; Miyazaki, A1
Gish, RG1
Gholam, P1
Abouzied, Mel-D; Aklabi, S; Duaiji, N; Hammami, MM; Mutairi, G; Qattan, N; Sous, MW1
Bose, SK; Di Bisceglie, AM; Kwon, YC; Meyer, K; Ray, R; Ray, RB; Steele, R1
Chua, MS; Lu, WJ; So, SK; Wei, W1
Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J1
Choi, BI; Choi, WS; Han, JK; Kim, J; Kim, JH; Kim, YJ; Yoon, SH1
Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F1
Fang, T; Hu, F; Jin, X; Pan, S; Sun, X; Xu, L; Yan, H; Zhai, B; Zhao, D1
Fujisawa, M; Harada, K; Imai, S; Miyake, H1
Aitini, E; Andrikou, K; Barni, S; Berardi, R; Bianconi, M; Bittoni, A; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Faloppi, L; Fanello, S; Ferrari, D; Giampieri, R; Labianca, R; Mosconi, S; Scartozzi, M; Sobrero, A; Torri, V; Zaniboni, A1
Fukunaga, K; Iwasaki, K; Kohno, K; Kurokawa, T; Murata, S; Ohkohchi, N; Zheng, YW1
Cabibbo, G; Cammà, C; Maida, M; Petta, S1
Boers-Sonderen, MJ; De Geus-Oei, LF; Desar, IM; Fütterer, JJ; Mulder, SF; Mulders, PF; Oyen, WJ; Van Der Graaf, WT; Van Herpen, CM1
Aci-Sèche, S; Bonnet, P; Bosc, N; Meyer, C; Wroblowski, B1
Devapatla, B; Sharma, A; Woo, S1
Baltatzis, G; Björklund, AC; Chioureas, D; Egevad, L; Fonseca, P; Gogvadze, V; Grandér, D; Kharaziha, P; Lennartsson, L; Nilsson, S; Panaretakis, T; Rodriguez, P; Zhivotovsky, B1
Booth, L; Carter, J; Dent, P; McGuire, WP; Poklepovic, A; Roberts, JL; Webb, T1
Cheng, AL; Hsu, CH; Shao, YY1
Gao, ZL; Lin, CH; Liu, QZ; Men, CP; Wang, J; Wang, K; Wu, JT; Yu, SQ; Yuan, HJ1
Ameye, L; Barbuto, AM; Ceyssens, S; Delaunoit, T; Deleporte, A; Demolin, G; El Mansy, H; Filleul, B; Flamen, P; Garcia, C; Guiot, T; Hendlisz, A; Holbrechts, S; Houbiers, G; Lhommel, R; Maréchal, R; Moreau, M; Paesmans, M; Peeters, M; Piccart, M; Van den Eynde, M; Van Laethem, JL1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kuzuya, T; Nakano, I1
Cardones, AR; Chu, EY; Dahut, WL; Kong, HH; Pichard, DC1
Wirth, LJ1
Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C1
Almeida, S; Correia, A; Hirvonen, J; Mäkilä, E; Salonen, J; Santos, HA; Shahbazi, MA1
Burns, K; Knights, KM; Mackenzie, PI; Miners, JO; Nair, PC; Rowland, A1
Ito, D; Kawanishi, K; Kojima, K; Ohki, T; Sato, K; Seki, M; Tagawa, K; Toda, N; Yamada, T; Yamagami, M1
Fan, W; Fu, S; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y1
Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H1
Arai, Y; Eto, M; Fujioka, T; Hashine, K; Hinotsu, S; Hirao, Y; Kawano, Y; Kimura, G; Matsubara, A; Mita, K; Naito, S; Shinohara, N; Tatsugami, K; Tsukamoto, T1
Adhoute, X; Blanc, JF; Boucher, E; Boudjema, K; Campillo-Gimenez, B; Clément, B; Crouzet, L; Edeline, J; Garin, E; Guillygomarc'h, A; Lenoir, L; Pracht, M; Rohou, T; Rolland, Y1
Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Rebibo, JD1
Kanda, M; Kodera, Y; Sugimoto, H1
Ekser, B; Fridell, JA; Klingler, KR; Kubal, CA; Maluccio, MA; Mangus, RS; Nagai, S; Tector, AJ1
Gabrilove, J; Jing, Y; Wang, R; Waxman, S; Xia, L1
Heaton, N; Karani, J; Peddu, P; Quaglia, A; Satyadas, T; Sharma, R; Suddle, A1
Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, M; Lee, S; Park, SY; Yoon, JH1
Chubachi, S; Nakagawa, T1
Ajiki, T; Fukumoto, T; Fukushima, K; Gon, H; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Shinzeki, M; So, S; Takebe, A; Tanaka, M; Urade, T1
Aino, H; Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tajiri, N; Tanaka, M; Torimura, T1
Gu, WJ; Ma, CG; Qin, XJ; Shi, GH; Wang, HK; Ye, DW; Zhang, HL; Zhou, LP1
Chen, L; Sun, J; Yang, X1
Cao, G; Li, J; Li, X; Qin, C1
Hisamichi, K; Jin, Y; Kataoka, Y; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H1
Carr, BI; D'Alessandro, R; Messa, C; Refolo, MG1
Akiba, J; Bae, KH; Igawa, T; Kurisawa, M; Kusano, H; Nakayama, M; Ogasawara, S; Sanada, S; Suekane, S; Sumi, A; Todoroki, K; Ueda, K; Xu, K; Yano, H1
Anders, RA; Fan, J; Gao, YB; Hu, B; Maitra, A; Sun, C; Sun, D; Sun, HX; Sun, YF; Tang, WG; Xu, Y; Yang, XR; Zhu, QF1
Chandra, S; Dahl, NA; McMasters, RL; Michaels, ST; O'Brien, MM1
Chang, B; Chen, JC; Chiang, IT; Hsu, FT; Hwang, JJ; Kwang, WK; Liu, YC1
Kitano, M; Kudo, M; Nishida, N; Sakurai, T1
Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Inoue, T; Iwanishi, M; Kitai, S; Kitano, M; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N1
Liang, Y; Su, Z; Yao, Y; Zhang, N1
Azoulay, D; Carra, MC; de'Angelis, N; Landi, F1
Deguchi, T; Horie, K; Kato, T; Kawata, K; Kikuchi, M; Miyazaki, T; Mizutani, K; Nakano, M; Seike, K; Takagi, K; Takai, M; Tsuchiya, T; Ushikoshi, H; Yasuda, M; Yokoi, S1
Zhong, JH1
Hidaka, H; Kobayashi, S; Koizumi, W; Kondo, M; Matsunaga, K; Morimoto, M; Nakazawa, T; Numata, K; Ohkawa, S; Okuse, C; Takada, J; Tanaka, K1
Chen, T; Cheng, X; Jia, Y; Jiang, T; Li, J; Liu, T; Liu, Z; Wang, F; Zeng, J; Zhang, C; Zhang, L; Zhu, H1
Cai, J; Ye, X; Zhu, Y1
Chen, L; Luo, R; Tang, Q; Wang, M; Wu, C; Zheng, P; Zhu, W1
Brunetti, O; Casadei Gardini, A; Cascinu, S; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Masi, G; Nanni, O; Ricca Rosellini, S; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Tamburini, E; Tenti, E; Ulivi, P; Vivaldi, C1
Chen, Z; Liu, Y; Lou, G; Song, X; Wang, J; Wu, S; Yang, F1
Alkhatib, A; Allam, N; Gomaa, A; Rewisha, E; Waked, I1
Chao, CC; Lin, YT1
Afaq, F; Athar, M; Diamond, AC; Elmets, CA; Kappes, JC; Katiyar, SK; Pal, HC; Strickland, LR1
Crawford, K; Dusing, M; Frischer, JS; Knod, JL1
Andoh, A; Hira, D; Morita, SY; Noda, S; Saita, T; Shin, M; Shioya, M; Terada, T; Yamamoto, Y1
Ahn, JH; Cho, YM; Lee, DH; Lee, JL; Park, I1
Park, JG1
Amore, E; Azzolina, A; Balasus, D; Bondì, ML; Botto, C; Cervello, M; Mazzaglia, A; Scala, A; Sortino, G1
Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W1
Chen, L; Ge, N; Li, J; Liu, H; Qian, H; Shi, L; Sun, B; Wu, M; Yang, X; Yang, Y; Yin, Z; Zhang, X1
Brandon, VL; Chen, MY; Hsu, LC; Jandial, R; Jove, R; Li, G; Lin, J; Yang, F; Yin, Y; Zou, Z1
Barbare, JC; Bochereau, F; Chauffert, B; Degonville, J; Drullion, C; Fournier, E; François, C; Galmiche, A; Gicquel, A; Godin, C; Houessinon, A; Louandre, C; Nyga, R; Pluquet, O; Saidak, Z1
Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK1
Chaudary, N; Clarke, B; Fan, S; Fyles, A; Glicksman, R; Haider, M; Hill, RP; Kim, S; MacKay, H; Milosevic, MF; Oza, AM; Pintilie, M; Townsley, CA; Yeung, I1
Daver, N; Konopleva, M1
Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M1
Chen, TC; Chen, YC; Chien, CC; Lee, YC; Wu, MS; Yu, MC1
Chen, Y; Chiang, T; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC; Wan, D; Wang, L1
Chang, HC; Chen, CS; Chen, YW; Chiu, HC; Huang, YT; Shiau, CW; Su, JC; Teng, LJ1
Grünwald, V; Ivanyi, P1
Adjibade, P; Coudert, L; Fournier, MJ; Khandjian, EW; Mazroui, R; Quevillon Huberdeau, M; Savard, A; St-Sauveur, VG1
George, J; Hebbard, L; Qiao, L; Wilson, G; Wu, G; Zhou, G1
Correia, A; De Stefano, L; Lamberti, A; Rea, I; Santos, HA; Shahbazi, MA; Terracciano, M1
Cai, J; Wang, KL; Yang, YC; Yin, J; Zhang, J; Zhang, ZT1
Chen, X; Liu, C; Lu, Y; Miao, H; Tang, B; Wang, L; Xu, Q; Yang, Z1
Gao, JJ; Inagaki, Y; Shi, ZY; Tang, W; Xia, JF1
Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J1
Danhier, P; Gallez, B; Gregoire, V; Jordan, BF; Magat, J; Masquelier, J; Mignion, L; Muccioli, GG; Porporato, PE; Sonveaux, P1
Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M1
Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F1
Cai, Y; Li, H; Li, Y; Wang, K; Zhang, Y1
Cheng, AL; Cheng, YC; Feng, ZR; Hsu, C; Lin, LI; Ou, DL; Shao, YY1
Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W1
Abdel-Rahman, O2
Cartenì, G; Vitale, MG1
Chen, L; Dong, S; Gao, J; Ji, L; Kong, F; Kong, J; Pan, B; Sun, W; Zheng, L1
Chen, L; Guo, Y; Hao, H; Jiang, H; Jiang, X; Ma, J; Shi, J; Wang, Y; Zhang, D1
BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H1
Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT1
Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ1
Huang, J; Liu, L; Luo, Y; Ma, L; Qian, C; Shan, J; Shen, J; Xu, Y; Yang, Z; Yao, C1
Chen, P; Li, P; Lu, J; Lu, X; Wang, F; Wang, J; Wang, Q; Wang, Y; Wang, Z; Wu, G; Yuan, J; Zhang, L; Zheng, Y1
Alsinet, C; Cabellos, L; Cornella, H; Desbois-Mouthon, C; Domingo-Domenech, J; Hoshida, Y; Llovet, JM; Lozano, JJ; Martinez-Quetglas, I; Moeini, A; Peix, J; Sia, D; Solé, M; Torrecilla, S; Tovar, V; Vidal, S; Villanueva, A1
Abou-Alfa, GK; Ang, C; Gamblin, TC; Gatalica, Z; He, R; Millis, SZ; Miura, JT; Reddy, SK; Xiu, J; Yee, NS1
Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF1
Bai, XL; Chen, ZL; Fu, QH; Li, GG; Liang, TB; Lou, Y; Sun, X; Zhang, JY; Zhang, Q1
Ali, FR; Griffiths, CE; Yiu, ZZ1
Baker, SD; Chen, T; Du, G; Gibson, AA; Hu, S; Inaba, H; Maitland, ML; Mascara, GP; Ong, SS; Orwick, SJ; Sparreboom, A; Vasilyeva, A; Vogel, P; Zimmerman, EI1
Chang, MJ; Chao, TI; Chen, KF; Chen, MH; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH1
Hongo, F; Hosokawa, T; Itoh, Y; Kanbayashi, Y; Miki, T; Moriguchi, M; Yamaguchi, K; Yasui, K1
Hammock, BD; Hwang, SH; Li, H; Liao, J; Liu, JY; Wecksler, AT; Yang, GY; Yang, J; Yang, Y1
Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D1
Adhoute, X; Bayle, O; Beaurain, P; Blanc, JF; Bourlière, M; Bronowicki, JP; Castellani, P; Conroy, G; Edeline, J; Monnet, O; Muller, C; Pénaranda, G; Perrier, H; Pol, B; Raoul, JL1
Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T1
de Castro, G; de Castroneves, LA; de Freitas, RM; Fukushima, JT; Hoff, AO; Hoff, PM; Jorge, AA; Kulcsar, MA; Lima, JV; Negrão, MV; Papadia, C; Simão, EF; Tavares, MR1
Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A1
Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ1
Czarnecka, AM; Kornakiewicz, A; Solarek, W; Szczylik, C1
Chen, Y; Chen, Z; Li, Y; Liu, C; Lu, J; Qian, F; Wang, S; Wu, G1
Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C1
Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X1
Cao, L; Chen, L; Ge, N; Li, J; Qian, H; Sun, B; Yin, Z; Zhai, B; Zhang, X; Zhao, L1
Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z1
Caracciolo, J; Gill, J; Goldberg, J; Hale, GA; Isakoff, MS; Juan, TH; Lee, JK; Lush, RM; Manning, K; Mascarenhas, L; Neuger, AM; Reed, DR; Sandler, E; Smith, T; Sullivan, DM1
Aguilar-Suárez, LE; Barroso-Flores, J; Galindo-Murillo, R1
Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A1
Ayav, A; Bronowicki, JP; Claudon, M; Gavanier, M; Laurent, V; Orry, X; Sellal, C1
Mihaila, RG1
Daido, Y; Kitamura, Y; Nishimoto, K; Shinchi, Y; Takao, M; Tokonabe, S; Yoshii, H1
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lu, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yip, CS; Yuan, Y; Zhang, S; Zhou, J1
Bao, G; Du, B; Gong, P; Ma, Y; Zhai, X; Zhao, M1
Arén, O; de Marinis, F; Hirsh, V; Juhász, E; Mok, TS; Novello, S; Ong, TJ; Paz-Ares, L; Peña, C; Schmelter, T; Seto, T; Smit, EF; Sun, Y; Wakelee, HA; Wu, YL; Yang, JC; Zhang, L1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C1
Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK2
Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y1
Mokdad, AA; Singal, AG; Yopp, AC1
Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M1
Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X1
Gwon, DI; Han, K; Kim, JH; Ko, GY; Sung, KB1
Chun, G; Dua, S; Hiensch, R; Meinhof, K; Nandedkar, D1
Fiskus, W; Mitsiades, N1
Ni, Y; Tian, J; Wang, H; Wang, W; Yao, Z; Ye, L1
Fujimoto, S; Kimura, T; Miyamoto, H; Muguruma, N; Okamoto, K; Takayama, T; Takeishi, S; Tanaka, H; Tanaka, T; Taniguchi, T; Tomonari, T1
Meng, Z; Ning, Z; Wang, H; Xu, L; Zhang, C; Zhu, X1
Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B1
Ha, AS; Imran, TF; Joseph, J; Shah, R; Thomas, R1
Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T1
Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J1
Adametz, D; Boldanova, T; Colombi, M; Dazert, E; Hall, MN; Heim, MH; Jenoe, P; Moes, S; Quagliata, L; Roth, V; Terracciano, L1
Atabey, N; Erdal, E; Firtina Karagonlar, Z; Iscan, E; Koc, D1
Blüthgen, N; Brummer, T; Fritsche-Guenther, R; Kempa, S; Sers, C; Witzel, F1
Bazin, I; Bondarenko, I; Ciuleanu, T; Deptala, A; Ding, M; Egger, J; Fox, NL; Giantonio, B; Gribbin, M; Humphreys, R; Kalyani, RN; Lungulescu, D; Miron, L; Rodriguez-Torres, M; Sun, W; Wissel, P1
Cai, Y; Gao, D; Gao, L; Jia, B; Lai, J; Liu, H; Liu, Z; Wang, F; Zhang, C1
Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H1
Matoba, H; Seta, S1
Asaoka, T; Doki, Y; Eguchi, H; Kawamoto, K; Marubashi, S; Mori, M; Mukai, Y; Nagano, H; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H1
Deguchi, S; Inoue, T; Kanazawa, A; Murata, A; Nakajima, T; Nishiguchi, Y; Sakae, M; Shimizu, S; Tachimori, A; Tamamori, Y; Tsukamoto, T; Yamamoto, A; Yamamoto, S; Yamashita, Y1
Deguchi, S; Kanazawa, A; Kawasaki, Y; Kioka, K; Kurihara, S; Murata, A; Nakai, T; Sakae, M; Shimizu, S; Tashima, T; Tsukamoto, T1
Bruix, J; Chau, GY; Del Arbol, LR; Guglielmi, A; Han, G; Kim, DY; Leberre, MA; Lencioni, R; Llovet, JM; Luca, A; Meinhardt, G; Nicholson, K; Niu, W; Paik, SW; Reig, M; Tak, WY; Yang, J1
Cai, Z; Chiu, DK; Koh, HY; Lai, RK; Law, CT; Lin, SH; Ng, IO; Tse, AP; Wong, CC; Wong, CM; Xu, IM1
Barbero-Camps, E; Bárcena, C; Colell, A; de Gregorio, E; Fernandez-Checa, JC; García-Ruiz, C; Marí, M; Martinez-Nieto, GA; Morales, A; Moutinho, C; Stefanovic, M; Tutusaus, A; Villanueva, A1
Archibald, M; Greish, K; Nehoff, H; Pritchard, T; Rosengren, RJ; Taurin, S1
Guo, GH; Hu, MD; Jia, LH; Liu, HB; Zhang, KH1
Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H1
Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolé, F; Santoni, M; Verri, E1
Li, X; Song, Y; Xiao, Y; Xing, Y; Xing, Z; Zhang, P; Zhao, J1
Garg, P; Shaikh, N; Sharma, M1
Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K1
Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM1
de la Fouchardière, C2
Cai, H; Cao, Q; Chen, J; Chu, H; Cui, L; Dong, B; Huang, Y; Ji, J; Jiang, M; Ju, X; Li, P; Li, X; Liu, F; Qin, C; Shao, P; Sun, L; Sun, X; Wang, J; Wang, M; Wang, S; Wang, X; Wu, B; Ye, D; Yin, C; Zhang, H; Zhang, Z; Zhao, H; Zhou, H; Zhou, L; Zhu, J; Zou, Q1
Bai, W; Cai, H; Chen, H; Fan, D; Guo, W; Han, G; He, C; Jia, J; Liu, L; Niu, J; Xia, J; Yang, M; Yin, Z; Yuan, J; Zhang, L; Zhao, Y1
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C1
Diekstra, MH; Gelderblom, H; Guchelaar, HJ; Swen, JJ1
Chen, KF; Chen, LJ; Chen, YL; Chu, PY; Huang, JW; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH1
Jiang, D; Liu, Y; Wang, T; Xiao, Y; Yang, S; Yu, D; Zhang, B; Zhang, J; Zhang, N1
Brekken, RA; Cheng, X; Huang, X; Li, L; Thorpe, PE; Yopp, AC1
Jaffry, A; Jean, GW; Khan, SA; Mani, RM1
Callaghan, C; Dash, S; Lee, BR; Liu, J; Maddox, M; Mandava, SH; Peralta, D; Tarr, MA1
Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R1
Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF1
Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X1
Duda, DG; Hato, T; Zhu, AX1
Brade, AM; Brierley, J; Cho, C; Dawson, LA; Dinniwell, R; Kim, J; Knox, J; Ng, S; Ringash, J; Wong, RR1
Darstein, F; Galle, PR; Grimm, D; Hoppe-Lotichius, M; Koch, S; Lautem, A; Lieb, J; Schad, A; Schattenberg, JM; Vollmar, J; Weinmann, A; Weyer, V; Wörns, MA; Zimmermann, T1
Chen, KF; Chen, YL; Chu, PY; Hung, MH; Shiau, CW; Shih, CT; Tai, WT; Yu, HC1
Bodoky, G; Buehlmann, M; Demeter, G; Dufour, JF; Feilchenfeldt, J; Horber, D; Koeberle, D; Lakatos, G; Li, Q; Montemurro, M; Peck-Radosavljevic, M; Rauch, D; Ribi, K; Roth, AD; Saletti, P; Samaras, P; Tschanz, B; Wagner, AD1
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S1
Albers, T; Booth, L; Bottaro, D; Chen, CS; Dent, P; Ecroyd, H; Lebedyeva, IO; Proniuk, S; Roberts, JL; Shuch, B; Tavallai, M; Wang, D; Zukiwski, A1
Chen, C; Hu, H; Li, H1
Okano, S1
Goto, K; Iino, M; Kikuchi, N; Tanaka, T1
Bisulli, M; Casadei Gardini, A; Cascinu, S; Corbelli, J; Donati, G; Faloppi, L; Foschi, FG; Frassineti, GL; Gardini, A; Giampalma, E; La Barba, G; Marisi, G; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Veneroni, L1
Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X1
Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS1
Horai, T; Horiike, A; Ishikawa, Y; Kaburaki, K; Kawano, Y; Kudo, K; Motoi, N; Nishio, M; Ohyanagi, F; Takeuchi, K; Tambo, Y; Tanimoto, A; Uenami, T; Yanagitani, N1
Bersanelli, M; Buti, S; Castagneto, B; Di Meglio, G; Leonetti, A; Masini, C; Pellegrino, B1
Alonso López, S; Burgos, Rde L; Fernandez Cebrián, JM; Fernández Rodríguez, C; Gutiérrez Garcia, ML; LIedó Navarro, JL; Loinaz Segurola, C; Martel Villagrán, J; Martín Ríos, D; Ochando Cerdán, F1
Abdel-Rahman, OM; Elsayed, Z1
Brüssow, C; Guckenberger, M; Pestalozzi, B; Riesterer, O; Stieb, S; Weiler, S1
Bayhan, T; Cetin, M; Gumruk, F; Isgandarova, F; Kuskonmaz, B; Tavil, B; Unal, S1
Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A1
Han, KH; Han, SY; Heo, J; Kim, DY; Kim, HJ; Kim, YH; Kweon, YO; Lee, BS; Lee, HC; Lee, WS; Lim, HY; Ryoo, BY; Um, SH; Woo, HY; Yoon, JH; Yoon, SK1
Arenas, JI; Buades-Mateu, J; Bustamante, FJ; de la Rosa, PA; de la Torre, MA; Gil, C; Iñarrairaegui, M; Lorente, S; Lué, A; Sangro, B; Serrano, MT; Testillano, M1
Ahn, KS; Baek, SH; Kim, C; Shim, BS; Um, JY1
Brummer, T; Dengjel, J; Ellermann, J; Gretzmeier, C; Halbach, S; Hu, Z; Wöhrle, FU1
Gao, M; Hua, H; Jiang, Y; Kong, Q; Luo, T; Wang, J; Yin, Y1
Bin, L; Heqing, Y; Linfa, L; Xuemei, Y1
Cao, Y; Chen, EB; Dai, Z; Fan, J; Hu, ZQ; Huang, XW; Wang, Z; Zhou, J; Zhou, SL; Zhou, ZJ1
El-Sahrawy, HM; Fahmy, HH; Ismail, MM; Khalifa, NM; Nossier, ES1
Dinçaslan, H; Ensari, A; Kiremitçi, S; Özçakar, ZB; Taktak, A; Yalçınkaya, F; Yılmaz, S1
Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T1
Cai, X; Chang, C; Jin, RA; Li, G; Lin, H; Ma, WL; Shi, L; Sun, Y; Xu, J; Yeh, S1
Abrantes, AM; Botelho, MF; Brito, AF; Casalta-Lopes, JE; Gonçalves, AC; Laranjo, M; Mamede, AC; Ribeiro, M; Sarmento-Ribeiro, AB; Tralhão, JG1
Dickson, N; Drosick, D; Earwood, C; Hainsworth, JD; Inhorn, R; Murphy, P; Yardley, DA1
Ammendola, AS; Bitzer, M; Cillo, U; Dollinger, MM; Ganten, TM; Gerken, G; Giannini, EG; Hauns, B; Henning, SW; Hentsch, B; Herz, T; Holzapfel, J; Horger, M; Lauer, UM; Mais, A; Malek, NP; Montesarchio, V; Pegoraro, S; Santoro, A; Scheulen, ME; Siveke, JT; Trevisani, F; Wege, H; Wörns, MA; Zagonel, V1
Boakye, J; Chaiteerakij, R; Chen, G; Ding, X; Huang, S; Li, Y; Moser, CD; Ndzengue, A; Roberts, LR; Shaleh, H; Sinicrope, FA; Smith, CD; Thomas, MB; Zhou, Y; Zou, X1
Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B1
Boo, YP; Chen, KF; Chen, LJ; Chen, MH; Chen, YL; Chu, PY; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH1
Chan, HF; Chen, M; Hu, J; Liang, G; Skibba, M; Zhang, J1
Chen, D; Chen, W; Lai, J; Liang, L; Xiao, W; Yin, X; Zhang, K1
Delhaas, T; Gagliardi, M; Grandfils, C; Knetsch, ML; Koole, LH; Molin, DG; Sevrin, C; van den Akker, NM; Wang, Y1
Atkins, MB; Carducci, M; Cella, D; Choueiri, TK; Coomes, R; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, M; Kane, C; Kohli, M; Kuzel, TM; Manola, J; Matin, S; Pili, R; Pins, M; Puzanov, I; Sexton, WJ; Stadler, W; Uzzo, RG; Wagner, L; Wilding, G; Wong, YN; Wood, CG1
Dai, Y; Liu, X; Sun, K; Wang, H1
Brierley, JD; Brock, KK; Coolens, C; Dawson, LA; Dinniwell, R; Kassam, Z; Kim, J; Knox, JJ; Swaminath, A; Wong, R1
Beck, JF; Ernst, J; Ernst, T; Gruhn, B; Rinke, J; Schäfer, V; Wittig, S1
Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C1
Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J1
Cheng, KS; Chou, JW; Huang, CW1
Chen, MS; Cheng, SQ; Cong, WM; Guo, WX; Lau, WY; Mao, YL; Meng, Y; Shi, J; Sun, BC; Wang, K; Wu, MC; Yang, YF; Zhang, YJ1
Chen, KH; Chou, YH; Hsieh, CH; Lu, YF; Weng, MT1
Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B1
Li, H; Liu, D; Yan, D; Yao, X; Zeng, H1
Brose, MS; Chen, EY; Cohen, AB; Feldman, MD; Johnson, BA; Ma, C; Pappas-Paxinos, M; Stopenski, SJ; Tang, W; Troxel, AB; Yarchoan, M1
de Gramont, A; Faivre, S; Raymond, E1
Galsky, MD; Mehrazin, R; Sfakianos, J; Tsao, CK1
Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E1
Kini, S; Panda, D; Poojari, R; Srivastava, R1
Borg, Å; Cordero, E; Haraldsson, K; Hemann, MT; Kabir, NN; Kazi, JU; Levander, F; Lindblad, O; Macaulay, L; Pietras, K; Puissant, A; Ramos, A; Rönnstrand, L; Stegmaier, K; Sun, J; Vallon-Christersson, J1
Chen, D; Chen, R; He, W; Kang, R; Niu, X; Sun, X; Tang, D1
Becker, B; Busch, CJ; Dikomey, E; Gleißner, L; Grénman, R; Hoffer, K; Knecht, R; Kriegs, M; Laban, S; Möckelmann, N; Omniczynski, M; Petersen, C; Rieckmann, T; Rothkamm, K; Steinmeister, L1
Boone, DL; Booth, L; Chuckalovcak, J; Dent, P; Koromilas, AE; McGuire, WP; Poklepovic, A; Roberts, JL; Stringer, DK; Tavallai, M1
Stone, L1
Chen, GH; Fu, CC; Gu, B; Han, Y; Ma, X; Miao, M; Qiu, HY; Shen, HJ; Sun, AN; Tang, XW; Wu, DP1
Gao, F; Huang, C; Sun, R; Wang, H; Zhang, S; Zhang, Y1
Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z1
Antony, AN; Bisetto, S; Doria, C; Hoek, JB; Levine, M; Monti, DA; Newberg, A; Rouleau, L1
Bai, W; Duran, R; Fan, D; Gu, S; Guan, S; Guo, W; Han, G; Li, H; Liu, J; Lv, W; Ma, Y; Mu, W; Qin, X; Ren, W; Sahu, S; Wang, W; Wang, Y; Yin, Z; Zhang, Z; Zhao, Y1
Jimenez, CR; Knol, JC; Lind, JS; Pham, TV; Rovithi, M; Smit, EF; Verheul, HM; Voortman, J1
Jerkovich, F; Pitoia, F1
Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY1
Baker, SD; Edginton, AN; Panetta, JC; Vasilyeva, A; Zimmerman, EI1
Bai, T; Chen, J; Chen, JZ; Li, LQ; Lu, Z; Ma, L; Peng, YC; Qin, HG; Xiang, BD; Xie, ZB; Ye, HH; Ye, JZ1
Amadori, D; Casadei Gardini, A; Cascinu, S; Corbelli, J; Della Corte, C; Facchetti, F; Faloppi, L; Foschi, FG; Frassineti, GL; Iavarone, M; Lauletta, G; Marisi, G; Nanni, O; Neri, LM; Scarpi, E; Scartozzi, M; Tamberi, S; Tenti, E; Ulivi, P; Valgiusti, M1
Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM1
Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M2
Ameye, L; Delaunoit, T; Deleporte, A; Demolin, G; Flamen, P; Garcia, C; Gauthier, N; Guiot, T; Hendlisz, A; Holbrechts, S; Lhommel, R; Maréchal, R; Van den Eynde, M; Vierasu, I; Woff, E1
Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F1
Balsara, B; Chan, SL; Chao, Y; Cheng, AL; Han, G; Ikeda, M; Kang, YK; Kudo, M; Lim, HY; Numata, K; Pan, H; Poon, RT; Rodriguez, AM; Sukeepaisarnjaroen, W; Thongprasert, S; Wang, Y; Wu, CC; Yang, TS; Zhang, Y1
Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS1
Dicken, V; Felsch, M; Lehmacher, W; Scheuring, UJ; Zaim, S1
Abd El-Fattah, EE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, EG1
Fujiwara, T; Kagawa, S; Katsube, R; Kimura, F; Matsukawa, A; Ninomiya, T; Noma, K; Nouso, K; Ohara, T; Shirakawa, Y; Tazawa, H; Tomono, Y; Urano, S; Yamamoto, K1
Hu, P; Tang, F; Wang, Z; Xie, C1
Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP1
Chen, GG; Ho, RL; Hu, B; Lai, PB; Lee, CG; Leung, BC; Liu, Y; Lu, G; Ren, J; Su, X; Wang, Y; Yang, S1
Fan, Z; Gao, Y; Huang, F; Jiang, Q; Liu, Q; Sun, J; Xu, N; Xuan, L; Zhang, Y1
Cai, XB; Hou, Y; Li, J; Liu, B1
Chan, TH; Chen, L; Chow, RK; Fang, S; Guan, XY; Jiang, L; Li, Y; Liu, M; Ma, NF; Song, Y; Xi, S; Yang, X; Yuan, YF; Zeng, TT1
Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF1
Aplan, PD; Bruner, JK; Duffield, AS; Ghiaur, G; Greenblatt, SM; Jones, RJ; Jung, E; Li, L; Ma, HS; Nguyen, B; Shirley, CM; Small, D1
Kim, HR; Kim, JH; Kim, S; Kwack, K; Lee, MG; Lim, SM; Moon, YW; Park, HS1
Chen, W; Dan, Y; Li, M; Li, W; Liu, K; Mo, P; Qin, L; Tong, Z; Wang, W; Yu, C1
Furuse, J; Ikeda, M; Ito, Y; Izumi, N; Kadoya, M; Kokudo, N; Kudo, M; Numata, K; Okusaka, T; Takayama, T; Yamashita, S1
Chen, SH; Chen, YY; Cheng, KS; Chou, JW; Chuang, PH; Feng, CL; Hsiao, WD; Kao, JT; Lai, HC; Peng, CY; Su, WP; Yu, CJ1
Fu, P; Li, Q; Wen, F; Wheeler, J; Yang, Y; Zhang, P1
Amadori, D; Bianchini, E; Casadei Gardini, A; Frassineti, GL; Gallani, ML; Masini, C; Maugeri, A; Menozzi, S; Minguzzi, M; Nanni, O; Palazzini, S; Restuccia, S; Scarpi, E; Tenti, E; Valgiusti, M1
Keck, B; Lieb, V; Lüdecke, G; Sikic, D1
Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Ogawa, H; Umeshita, K; Wada, H; Yamada, D; Yamashita, M1
Cai, X; Cang, Y; Chen, J; Huang, D; Ji, T; Jin, R; Li, G; Liang, X; Lin, H; Liu, J; Liu, X; Xie, A; Zhang, J; Zhao, J1
Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Liu, D; Liu, K; Wen, S; Zhan, G1
Amadoz, A; Carbonell-Caballero, J; Crespo, D; Çubuk, C; Dopazo, J; Hidago, MR; Medina, I; Salavert, F1
Bae, SH; Cho, YY; Chung, JW; Gwak, GY; Heo, J; Kim, do Y; Kim, HC; Kim, YH; Kim, YJ; Lee, M1
DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY1
Chen, H; Fisher, DE; Li, Y; Sun, J; Westover, KD; Xia, Y; Zhang, J1
Chen, Y; Ding, J; Fang, T; Guo, LN; Li, T; Liang, D; Lv, GS; Lv, HW; Tan, YX; Tang, L; Tang, SH; Wang, CZ; Wang, HY; Wu, FQ; Yang, W; Yu, LX1
Aycart, SN; Berger, Y; Edwards, MP; Heskel, M; Kim, E; Labow, DM; Sarpel, U; Spivack, JH; Sweeney, R1
Chen, J; Cho, S; Kim, DH; Larson, AC; Na, K; Park, SJ; Park, W1
Arachchi, N; Bell, S; Dev, A; Doyle, A; Fink, MA; Gill, R; Gow, PJ; Hong, T; Kemp, W; Knight, V; Kronborg, I; Lubel, J; Marsh, P; Mohsen, W; Nicoll, A; Roberts, S; Rodov, M; Ryan, M; Strasser, SI; Varma, P1
Guo, X; Han, G; Li, H; Qi, X; Zhao, Y1
Cui, SX; Gao, ZH; Qu, XJ; Shi, WN; Song, ZY; Wang, SQ; Yu, XF1
Gan, H; Gu, W; Shi, G; Wang, B; Wang, H; Ye, D; Zhang, H; Zhou, L; Zhu, Y1
Fan, XX; Huang, YC; Li, ZY; Liu, ZW; Pan, WT; Wang, YJ; Wu, ZM; Yang, P; Yao, K; Ye, YL; Zhou, FJ1
Chen, B; Cooper, JL; Dovey, OM; Friedrich, M; Grove, CS; Huang, Y; Lee, B; Mupo, A; Varela, I; Vassiliou, GS1
Gerber, JM; Grunwald, MR; Induru, R; McDonnell, MH1
Kim, do Y; Kim, GM; Kim, MD; Kim, SH; Lee, do Y; Park, SI; Shin, M; Shin, W; Won, JY1
Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Coriat, R; François, C; Galmiche, A; Ganne, N; Godin, C; Gutierrez, L; Houessinon, A; Louandre, C; Mongelard, G; Régimbeau, JM; Saidak, Z; Sauzay, C; Takahashi, S1
Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK2
He, J; Sun, J; Sun, T; Zeng, M; Zeng, Z; Zhang, S1
Chan, AL; Leung, HW; Liu, CF1
Campana, D; Chang, YH; Kamiya, T1
Deng, YR; Hou, X; Li, X; Lian, ZX; Liu, WB1
Abraham, LJ; Callus, BA; Diepeveen, LA; Dwyer, BJ; Elsegood, CL; Finch-Edmondson, ML; Kampmann, SS; Kong, GS; Olynyk, JK; Passman, AM; Stewart, SG; Tirnitz-Parker, JE; Woo, K; Yeoh, GC; Yeung, SY1
Adachi, M; Akaza, H; Ito, Y; Kabu, K; Oya, M; Tatsugami, K1
Ducerf, C; Golse, N; Mabrut, JY; Merle, P; Radenne, S; Rode, A1
Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W1
Blanc, JF; Campillo-Gimenez, B; Collins, P; Darby, S; Edeline, J; Evans, J; Hubner, RA; Iwuji, C; Johnson, P; King, J; Ma, YT; Meyer, T; Muazzam, I; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D1
Abbiati, RA; Manca, D1
Abe, H; Baba, H; Kamimura, H; Kamimura, K; Kawai, H; Kobayashi, Y; Ogawa, K; Shinagawa, Y; Suda, T; Terai, S; Yamagiwa, S; Yokoo, T1
Evans, TR; Gane, E; Jeffers, M; Kang, YK; Meinhardt, G; Peña, CE; Rosmorduc, O; Ross, P; Santoro, A; Vogel, A; Zhu, AX1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R1
Arai, K; Honda, M; Horii, R; Kaneko, S; Kawaguchi, K; Kitamura, K; Mizukoshi, E; Sakai, Y; Terashima, T; Yamashita, T1
Kong, P; Liao, J; Liu, Y; Shen, Z; Wang, X; Yi, H; Zeng, D; Zhang, X1
Delcambre, C; Dutriaux, C; Heutte, N; Joly, F; Lesimple, T; Mouriaux, F; Neidhart-Berard, EM; Parienti, JJ; Penel, N; Peyro Saint Paul, L; Pham, AD; Piperno-Neumann, S; Servois, V; Thyss, A1
Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ1
Fergusson, D; Henderson, VC; Kimmelman, J; MacKinnon, N; Mattina, J1
Fujisaki, H; Hara, J; Nakano, Y; Nitani, C; Okada, K; Yamasaki, K1
Andreoli, JM; Baker, T; Gabr, A; Hickey, R; Kallini, JR; Kircher, S; Kulik, L; Lewandowski, RJ; Salem, R1
Abdelmaksoud, AH; Attar, IE; Aziz, AO; Elbaz, TM; Nabeel, MM; Omran, D; Shousha, HI1
Chapiro, J; Duran, R; Gebauer, B; Geschwind, JF; Gorodetski, B; Lee, H; Lenis, D; Lin, M; Nonyane, BA; Pawlik, TM; Pekurovsky, V; Schernthaner, R; Schlachter, T; Stuart, EA; Tamrazi, A1
Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S1
Ahmad Panahi, H; Faramarzi, M; Farjadian, F; Heidarinasab, A1
Bai, Q; Guo, J; Liu, L; Long, Q; Qu, Y; Wang, J; Xi, W; Xia, Y; Xiong, Y; Xu, J1
Dolcet, X; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Matias-Guiu, X; Mirantes, C; Santacana, M1
Cappello, J; Ghandehari, H; Hellgeth, JW; Jensen, MM; Nourbakhsh, I; Poursaid, A; Sampath, S; Weisenberger, M1
Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH1
Amantea, MA; Chen, Y; Nickens, DJ; Pithavala, YK; Valota, O; Zierhut, ML1
Cui, X; Hua, L; Liu, J; Lu, C; Ni, R; Qu, L; Shen, Z; Wu, M1
Abdulghani, J; Cooper, T; Derr, J; Dicker, D; El-Deiry, WS; Finnberg, NK; Gallant, JN; Gokare, P; Goldenberg, D; Liao, J; Liu, J; Whitcomb, T1
Gong, X; Liu, Y; Wang, T; Yang, S; Zhang, B; Zhang, N1
Macaluso, FS; Maida, M; Valenza, F; Virdone, R1
Chikui, K; Igawa, T; Matsuo, M; Nakiri, M; Nishihara, K; Ogasawara, N; Suekane, S; Suyama, S; Ueda, K1
Furlan, A; Marsh, JW; Patchett, N1
Ashman, LK; Don, AS; Dun, MD; Enjeti, A; Flanagan, H; Guthridge, MA; Harrison, C; Kahl, R; Lee, EM; Lock, RB; Mashkani, B; Moore, A; Morris, J; Panicker, N; Powell, JA; Skelding, KA; Smith, AM; Thomas, D; Toop, H; Verrills, NM1
Augello, G; Bachvarov, D; Cancila, V; Candido, S; Cervello, M; Emma, MR; Gulino, A; Iovanna, JL; Libra, M; Loria, GR; McCubrey, JA; Montalto, G; Puleio, R1
Lv, L; Mei, ZC; Zeng, J1
Chen, YL; Ding, X; Gao, Z; Gu, T; Liu, W; Qu, M; Wang, W; Wu, X; Xu, L; Zhang, W1
Bie, P; Huan, HB; Lau, WY; Li, XW; Ma, KS; Wen, XD; Wu, LL; Xia, F1
Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC1
Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME1
Borentain, P; Gerolami, R; Gregoire, E; Louis, G1
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K1
Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J1
Chen, LZ; Dai, ZY; Li, CL; Li, WW; Pan, J; Wan, HG; Wang, XJ; Yao, LZ; Zhu, J1
Choi, HG; Choi, JY; Kim, JO; Poudel, BK; Thapa, RK; Yong, CS1
Cai, XF; Chen, J; Chen, K; Chen, X; Cheng, ST; Huang, AL; Huang, LX; Li, WY; Liu, B; Ren, JH; Tang, H; Tao, NN; Yang, QX; Zhang, WL; Zhou, HZ; Zhou, L1
Blaziene, A; Chomiciene, A; Linauskiene, K; Malinauskiene, L; Vitkauskaite, E1
Arora, JS; Ashe, S; Halliburton, G; He, J; John, VT; Khismatullin, DB; Murad, HY; Yu, H1
De Velasco, MA; Haji, S; Iida, H; Ishizaki, M; Kaibori, M; Kanazawa, A; Kitade, H; Kubo, S; Kwon, AH; Matsui, K; Matsushima, H; Nagano, H; Nishio, K; Sakai, K; Takeda, Y; Takemura, S; Tsukamoto, T; Wada, H1
Azumi, J; Sakabe, T; Shiota, G; Tsubota, T1
Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P1
Jarzab, B; Krajewska, J; Kukulska, A1
Tan, S; Tong, J; Yu, J; Zhang, L; Zou, F1
Itoh, Y; Moriguchi, M; Umemura, A1
Cho, NC; El-Damasy, AK; Keum, G; Nam, G; Pae, AN1
Cheng, AL; Feng, WC; Hsu, CH; Lin, HH; Lu, LC; Shao, YY1
Hong, TH; Kim, DG; Na, GH; You, YK1
Alyea, EP; Antin, JH; Ballen, KK; Brunner, AM; Chen, YB; Collier, K; Connolly, C; Cutler, CS; Deangelo, DJ; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Koreth, J; Li, S; McAfee, SL; Nikiforow, S; Soiffer, RJ; Spitzer, TR; Stone, RM; Wadleigh, M1
Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M1
Cao, M; Liu, C; Lu, Z; Nelson, D; Ren, Y; Wang, T; Zhao, X1
Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH1
Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL1
Durmus, S; Schinkel, AH; van Hoppe, S1
Li, LQ; Liao, YY; Peng, NF; Tong, TJ; Zhong, JH1
Jalkanen, S; Joensuu, H; Laukkanen, MO; Laurila, JP; Salmi, M1
Cao, J; Cao, X; Li, D; Peng, Y; Quan, M; Ren, K; Sheng, X; Song, Z; Xiao, Q; Zeng, W; Zheng, Y; Zou, H1
Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tanaka, M; Torimura, T1
Chen, X; Cui, T; Diao, X; Huang, S; Sun, J1
Addeo, R; Del Prete, S; Montella, L; Palmieri, G1
Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J1
Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JH; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK1
Abdel-Naim, AB; Badawy, NN; El-Ahwany, E; Khalifa, AE; Liu, AW; Tolba, MF; Youssef, MM; Zada, S1
Jia, HL; Qin, LX1
Chang, LL; Chen, Y; Chen, ZB; He, QJ; Hu, Y; Lin, WK; Lou, JS; Wan, ZQ; Wang, DD; Yang, B; Ye, S; Ying, MD; Zhou, TY; Zhou, YL; Zhu, H; Zhuang, LH1
Farinati, F; Murer, F; Peserico, G; Pozzan, C1
Cao, J; He, HG; Huang, JL; Liu, F; Lu, JH; Shen, YN; Shi, CF; Shi, Y; Wang, ZC; Wei, YP; Yang, GS; Yuan, JY; Zhu, N1
Gui, RR; Han, LJ; Hou, YJ; Song, YP; Zhang, YL; Zhao, HF; Zhou, J; Zu, YL1
Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK1
Baulies, A; Fernández, A; Fernández-Checa, JC; Garcia-Ruiz, C; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C; Ordóñez, R; Prieto-Domínguez, N1
Li, Q; Wen, F; Zhang, P1
Han, KH; Jung, I; Seong, J; Yoon, HI1
Chapiro, J; Geschwind, JF1
Gao, Y; Guo, G; Li, H; Liu, K; Ma, X; Meng, Q; Song, Z; Wang, D; Wang, L; Zhang, X; Zhang, Y; Zhao, C1
Chung, YH; Ha, Y; Kang, YK; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Park, SR; Ryoo, BY; Ryu, MH; Shim, JH1
Burgoyne, AM; Durden, DL; Garlich, JR; Ikeda, S; Joshi, S; Kono, Y; Morales, GA; Sicklick, JK; Singh, AR1
Al-Shukri, S; Andrews, GI; Bair, AH; Hutson, TE; Lipatov, ON; Rosbrook, B; Shparyk, Y; Stus, VP; Vogelzang, NJ1
Basu, S; Joshi, A1
Addario, L; Caporaso, N; Cordone, G; Di Costanzo, GG; Falco, L; Guarino, M; Morisco, F; Tortora, R1
Finkenstedt, A; Zoller, H1
Lange, N; Loscher, C; Mkounga, P; Nkengfack, AE; Sass, G; Tiegs, G; Tontsa, AT; Wegscheid, C1
Chen, HA; Kuo, TC; Ma, JT; Su, JL; Sung, SY; Tseng, CF; Yang, CY; Yang, ST; Yen, CJ1
Bins, S; El Bouazzaoui, S; Eskens, FA; Lenting, A; Mathijssen, RH; Oomen-de Hoop, E; van Doorn, L; van Schaik, RH1
Chiba, T; Inoue, M; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Wakamatsu, T; Yokosuka, O1
Fujita, T; Iwamura, M; Matsumoto, K; Nishi, M; Tabata, K; Yoshida, K1
Abdel-Rahman, O; Hubner, RA; Lamarca, A; McNamara, MG; Salu, I; Valle, JW1
Dikomey, E; Köcher, S; Kriegs, M; Müller-Goebel, J; Petersen, C; Riedel, M; Rothkamm, K; Struve, N1
Abhari, BA; Fulda, S; Hinrichs, TM; Lange, M; Liese, J1
Brizzi, MP; Di Maio, M; Pignataro, D; Scagliotti, GV; Tampellini, M1
Abada, PB; Fujii, H; Furuse, J; Hatano, E; Ikeda, M; Ishii, H; Kaneko, S; Kawazoe, S; Kudo, M; Kudo, T; Masumoto, A; Morita, S; Obi, S; Ohkawa, S; Okusaka, T; Osaki, Y; Shimada, M; Sugiyama, G; Tateishi, R; Tsuji, A; Ukai, K; Wada, Y; Yang, L; Yokosuka, O; Zhu, AX1
Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T1
Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C1
Castinetti, F; Eroukhmanoff, J; Penel, N; Salas, S1
Li, J; Shen, F; Wan, X; Wang, K; Wu, D; Xia, Y; Yan, Z; Yang, P; Zhai, X1
Baroni, GS; Bernardi, M; Biasini, E; Borzio, F; Cabibbo, G; Caturelli, E; Ciccarese, F; Di Marco, M; Farinati, F; Felder, M; Foschi, FG; Garuti, F; Gasbarrini, A; Giannini, EG; Gramenzi, A; Lenzi, B; Masotto, A; Morisco, F; Pecorelli, A; Piscaglia, F; Rapaccini, GL; Sacco, R; Trevisani, F; Virdone, R; Zoli, M1
Hosoi, H; Imamura, T; Ishida, H; Kanayama, T; Kawashima-Goto, S; Miyachi, M; Nakatani, T; Osone, S; Sugimoto, A; Takai, A; Tamura, S; Tsuma, Y1
Furuse, J; Hagihara, A; Ikeda, M; Inaba, Y; Ishii, H; Kaneko, S; Kojima, Y; Kudo, M; Morimoto, M; Nakamori, S; Ohmura, T; Okusaka, T; Sato, K; Sato, T; Shimizu, S; Sugimoto, R; Tahara, T; Yasui, K2
Chen, KF; Fan, LC; Hung, MH; Jiang, JK; Shiau, CW; Tai, WT; Teng, HW; Yang, SH1
Abel, T; Haralampiev, I; Herrmann, A; Huster, D; Luckner, M; Müller, P; Scheidt, HA1
Ahmad, L; Akhlaq Mughal, M; Hassan, M; Iqbal, Z; Khan, A; Khan, I; Nasir, F; Raza, A1
Bruix, J; Reig, M; Ribeiro de Souza, A1
Abdelmageed, MM; El-Demerdash, E; El-Naga, RN; Elmazar, MM1
Buchfelder, M; Eyüpoglu, IY; Rauh, M; Savaskan, NE; Sehm, T; Wiendieck, K1
Imramovský, A; Kryštof, V; Páchniková, G; Slaninová, I; Uldrijan, S1
Casadei Gardini, A; de Stefano, G; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Negri, FV; Santini, D; Scarpi, E; Scartozzi, M; Silvestris, N; Valgiusti, M1
Alsinet, C; Dauch, D; Esteller, M; Llovet, JM; Lujambio, A; Martinez-Quetglas, I; Moeini, A; Pinyol, R; Portela, A; Rodriguez-Carunchio, L; Solé, M; Thung, S; Torrecilla, S; Tovar, V; Villanueva, A; Zender, L1
Garg, M; Guha, C; Kaubisch, A; Ohri, N1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I2
Al-Khadimi, G; Allen, N; Chowdhury, R; Heaton, N; Korantzis, I; O'Grady, J; Papadatos-Pastos, D; Ross, PJ; Sarker, D; Suddle, A; Thillai, K; Ziogas, DC1
Cho, NP; Cho, SD; Chung, TH; Jang, B; Jeong, JH; Kim, LH; Shin, JA; Won, DH; Yang, IH1
Chen, L; Liu, H; Liu, J; Liu, Y; Wang, X; Wang, Z; Yang, J1
Azzariti, A; Caligiuri, A; Dituri, F; Giannelli, G; Lupo, L; Mancarella, S; Porcelli, L; Quatrale, AE1
Bertucci, F; Blay, JY; Bompas, E; Camoin, L; Clisant, S; Decoupigny, E; Goncalves, A; Laurence, V; Lebellec, L; Mir, O; Penel, N; Toiron, Y; Tresch-Bruneel, E1
Dai, B; Gu, WJ; Shi, GH; Wan, FN; Wang, HK; Ye, DW; Zhang, HL; Zhu, Y1
Bolzacchini, E; Chini, C; Pinotti, G1
Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M1
Aburas, S; Colagrande, S; Inghilesi, AL; Marra, F; Nardi, C; Taliani, GG1
Bai, W; Cai, H; Fan, D; Han, G; Liu, L; Niu, J; Wang, E; Wang, W; Xia, D; Xia, J; Yang, M; Yin, Z; Zhang, L; Zhang, Z; Zhao, Y1
Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP1
Cai, X; Chang, C; Chen, J; Li, G; Lin, H; Shi, L; Sun, Y; Xu, J1
Dong, X; Han, P; Jiang, H; Jiang, X; Qiao, H; Sun, X; Tan, G; Tang, S; Zhai, B1
Au, CH; Chan, TL; Cher, CY; Cheung, AM; Gill, H; He, BL; Ho, DN; Ho, ES; Ip, HW; Kwong, YL; Lam, SS; Leung, AY; Liang, R; Ma, ES; Man, CH; Ng, NK; So, CC; So, CW; Tamburini, J; Wong, WW1
Ding, Y; Jiang, C; Luo, D; Qu, Z; Wu, J1
Brzostek, T; Kawalec, P; Kózka, M; Malinowska-Lipień, I1
He, C; Li, Q; Liu, C; Liu, Q; Ma, W; Tao, L; Wang, X; Xue, D; Zhang, J; Zhang, W1
Camille, N; Dang, RP; Genden, EM; Le, VH; McFarland, D; Miles, BA; Misiukiewicz, KJ; Teng, MS1
Han, XY; Hu, J; Huang, H; Huang, Y; Sun, J; Ying, SW; Zheng, YL1
Chen, B; Chen, Y; Hu, B; Hua, L; Liu, J; Wu, M; Yan, D; Zhang, C; Zhang, X; Zhao, F; Zhou, H1
Delgado-Fernández, M; Galindo, MJ; García, MA; Garcia-Deltoro, M; Ibarra, S; Merchante, N; Merino, E; Mínguez, C; Montero-Alonso, M; Pineda, JA; Revollo, B; Rivero-Juárez, A; Rodríguez-Arrondo, F; Romero-Palacios, A; Téllez, F1
Abou-Alfa, GK; Dika, IE; Harding, JJ1
Bourlon, MT; Breaker, K; Clemons, JE; Flaig, TW; Gao, D; Lam, ET; Trigero, S1
Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C1
Alvares, C; Chakraborty, M; Conner, C; Gosrani, D; Mahdi, AJ; Rayment, R; Rees, A; Wilson, K1
Balkrishnan, R; Lok, AS; Marshall, VD; Nathan, H; Parikh, ND; Shahinian, V; Singal, AG1
Ando, M; Ando, Y; Gyawali, B; Honda, K; Shimokata, T1
Fleischmann, M; Hilgendorf, I; Hochhaus, A; Sayer, HG; Schmidt, V; Schnetzke, U; Scholl, S; Schrenk, KG1
Chen, X; He, L; Huang, Y; Liang, C; Liu, Z; Ma, Z; Shi, C; Zhang, Z1
Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T1
Amendola, F; Calvanese, A; Coppola, C; DI Sarno, A; Gatti, P; Giorgio, A; Giorgio, V; Matteucci, P; Merola, F; Merola, MG; Montesarchio, L; Santoro, B1
An, D; Dong, M; Feng, M; Guan, Z; Jiang, S; Kuerban, K; Li, J; Peng, Y; Wang, Q; Ye, L1
Andres, D; Becker, A; Fernandez-Montalvan, AE; Georgi, V; Mueller-Fahrnow, A; Stegmann, CM1
Bian, J; Cheng, Y; Duan, J; Gao, X; Wu, H; Yang, Y; You, L; Zhang, L; Zhang, X; Zhu, Q1
Ding, S; Gao, D; Gao, M; Liu, S; Lv, J; Niu, Z; Wang, X; Wang, Z1
Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E1
Cheow, PC; Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Goh, BK; Liew, WM; Lo, RH; Low, AS; Ng, DC; Soo, KC; Tan, SB; Tay, KH; Thng, CH; Wong, JS1
Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G1
Elsadek, B; Kratz, F; Mansour, A; Saleem, T; Warnecke, A1
Arachchi, NJ; Bhullar, A; Bhullar, M1
Arase, Y; Hirose, S; Kagawa, T; Mine, T; Okabe, H; Shiraishi, K; Shomura, M; Takahira, S; Tsuruya, K1
Igarashi, Y; Ikehara, T; Shimizu, R; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M1
Anai, S; Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y1
Bao, Y; Chen, C; Li, J; Liu, B; Liu, J; Qu, L; Sun, S; Tan, H; Wang, J; Wang, L; Wei, D; Wu, D; Wu, Z; Xu, Z; Yang, F1
Heo, J; Woo, HY; Yoo, SY1
Bian, CB; Bollard, J; Hoshida, Y; Llovet, JM; Lujambio, A; Miguela, V; Molina-Sánchez, P; Nakagawa, S; Nguyen, CB; Roberto, MP; Ruiz de Galarreta, M; Sia, D; Tovar, V; Venkatesh, A1
Bai, R; Huang, C; Peng, R; Wei, D; Zhang, H1
Li, W; Wang, M; Wu, C; Xu, S; Zheng, P; Zhu, W; Zhu, Y1
Han, C; Ungerleider, N; Wu, T; Yao, L; Zhang, J1
Horne, DA; Kowolik, CM; Lin, M; Overman, LE; Xie, J1
Chen, JC; Chen, YC; Chien, YC; Chuang, HY; Hsu, FT; Hwang, JJ1
Bennett, LL; Mondal, A1
Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH1
Cai, X; Chen, G; Chen, L; Fu, T; Jin, W; Ma, D; Yu, F; Yu, Z; Zhang, J; Zhang, Y1
Bi, XY; Cai, JQ; Han, Y; Huang, Z; Li, H; Li, MX; Li, ZY; Yao, XS; Zhang, YF; Zhao, DB; Zhao, H; Zhao, JJ; Zhou, JG1
Abdel-Rahman, O; Lamarca, A1
Wu, CH; Wu, X; Zhang, HW1
Kerbel, RS; Kuczynski, EA1
Bouattour, M; de Gramont, A; Faivre, S; Soubrane, O1
Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T1
Cao, D; Fu, GB; Guo, LN; Huang, S; Liu, J; Qin, CJ; Tang, L; Wang, HY; Wang, MD; Wu, H; Yan, HX; Zeng, M; Zhang, HL; Zhao, LH; Zhou, X1
Amikura, K; Kageyama, Y; Kokudo, T; Miyazaki, Y; Sakamoto, H; Takahashi, A; Takano, M1
Chen, PT; Chen, SC; Grevel, J; Hu, CT; Jeng, LB; Le Berre, MA; Lin, SM; Liu, X; Lu, SN; Meinhardt, G; Mitchell, DY; Peña, CA; Prins, K; Yang, SS1
Chen, S; Fu, S; Li, Y; Liang, C; Liu, Z; Lu, L; Zhu, Y1
Bergheim, D; Branchi, V; Dietrich, D; Dietrich, J; Fischer, HP; Goltz, D; Kalff, JC; Kristiansen, G; Matthaei, H; Semaan, A1
Forgez, P; Galmiche, A; Liu, J; Paradis, V; Segal-Bendirdjian, E; Stadler, N; Wendum, D; Wu, Z1
Bauernhofer, T; Gerger, A; Hutterer, GC; Karbiener, M; Kiesslich, T; Mayr, C; Pehserl, AM; Pichler, M; Resel, M; Ress, AL; Scheideler, M; Stadelmeyer, E; Stanzer, S; Stiegelbauer, V1
Chen, XW; Han, JH; Hong, D; Ma, TC; Niu, M; Sun, J; Xu, K1
Baumhauer, A; Bodoky, G; Breder, V; Bronowicki, JP; Bruix, J; Cheng, AL; Finn, RS; Gerolami, R; Granito, A; Han, G; Huang, YH; Kudo, M; LeBerre, MA; Llovet, JM; Masi, G; Meinhardt, G; Merle, P; Ollivier-Hourmand, I; Pracht, M; Qin, S; Rosmorduc, O; Ross, PJ; Song, T; Yokosuka, O1
Chuang, WL; Lin, ZY1
Ghoshal, K; Jacob, ST; Motiwala, T; Reyes, R; Wani, NA1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A1
Alberts, SR; Borad, M; Gatalica, Z; Hubbard, JM; Kumar, S; Loui, WS; Mahoney, MR; Roberts, LR; Smyrk, TC1
Anderson, DG; Conte, D; Fischer, A; Hough, S; Kennedy, Z; Li, Y; Moore, J; Mou, H; Park, A; Pomyen, Y; Song, CQ; Thorgeirsson, S; Wang, XW; Weng, Z; Xue, W; Yin, H; Zender, L1
Fan, N; Feng, T; Hou, Z; Huang, Q; Li, Y; Ling, S; Liu, L; Liu, Y; Shi, L; Song, L; Tian, Y; Wang, M; Xu, F; Yang, X; Zhao, F1
Blesing, C; Braconi, C; Collins, P; Darby, S; Hubner, RA; Iwuji, C; Johnson, P; King, J; Kirkwood, A; Meyer, T; Muazzam, I; Nash, S; Nobes, J; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D1
Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M1
Arihara, Y; Hayasaka, N; Kamihara, Y; Kato, J; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Nakamura, H; Okagawa, Y; Osuga, T; Takada, K; Usami, M1
He, D; Liu, F; Meng, Z; Shao, G; Wang, J; Wang, Z; Yang, J; Yip, CS1
Bearz, A; Demkow, T; Gore, ME; Jones, RJ; Kuczyk, M; Porta, C; Ravaud, A; Shapiro, J; Strauss, UP1
Caraglia, M; Castiello, F; Ferri, C; Giordano, A; Mosca, N; Panella, M; Potenza, N; Russo, A; Stiuso, P; Vanacore, D; Zappavigna, S1
Agard, DA; Duan, D; Elnatan, D; Logie, J; McLaughlin, CK; Shoichet, BK; Shoichet, MS; Torosyan, H1
Dai, XJ; Fan, JH; Liu, C; Liu, Q; Shen, YJ; Sun, WD; Sun, Y; Wang, J; Yang, H; Zhang, YQ; Zhao, JX1
Carter, JJ; Fretwell, LV; Woolard, J1
Katare, DP; Mishra, S1
Charamis, H; Esfahani, K; Ferrario, C; Langleben, A; Miller, WH; Nanni, O; Panasci, LC; Scarpi, E; Strepponi, I1
Bargellini, I; Fornaro, L; Lorenzoni, G; Masi, G; Vivaldi, C1
Hu, Y; Lin, A; Ma, C; Niu, Y; Shi, L; Su, Y; Zhang, C; Zhou, L; Zhu, X1
Brauner, J; Dudeck, O; Jürgens, J; Kalinski, T; Nass, N; Powerski, M; Ricke, J; Schulz, N; Seidensticker, M; Streit, S; Wybranski, C1
Arslan, A; Duensing, S; Grüllich, C; Hadaschik, B; Hallscheidt, P; Hatiboglu, G; Hohenfellner, M; Huesing, J; Pahernik, S; Radtke, JP; Roth, W; Teber, D; Tolstov, Y1
Chishima, T; Dry, SM; Eilber, FC; Elliott, I; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Nelson, SD; Russell, T; Singh, A; Tanaka, K; Yanagawa, J; Zhang, Y; Zhao, M1
Chen, PC; Guo, L; Huang, Y; Kwok, HF; Li, B; Li, L; Lin, Y; Meng, C; Neves, H; Xiao, Y; Yan, W1
Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C1
Berhane, S; Jackson, R; Johnson, P; Khan, H; Psarelli, EE1
Torjesen, I1
Byun, KS; Je, JH; Kang, SH; Kim, JH; Ko, E; Lee, HJ; Seo, YS; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL1
Bergadà, L; Boyd, J; Chen, BJ; Dolcet, X; Encinas, M; Eritja, N; Gatius, S; Llobet-Navàs, D; Martí, MD; Matias-Guiu, X; Ponce, J; Reventós, J; Ribera, J; Rodríguez-Barrueco, R; Santacana, M; Vidal, A; Villanueva, A; Yeramian, A1
Fritz, C; Guckenberger, M; Hoyer, M; Kroeze, SG; Lo, SS; Ricardi, U; Sahgal, A; Stahel, R; Stupp, R1
Chi, ZH; Guo, J; He, ZS; Li, XS; Sheng, XN; Wang, HK; Ye, DW; Zhang, HL1
Jang, H; Kim, EH; Roh, JL; Shin, D1
Calvisi, D; Eferl, R1
Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B1
Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT1
Cheng, AL; Hocke, J; Loembé, AB; Meyer, T; Palmer, DH; Yen, CJ1
Gao, L; Hu, CA; Huang, S; Tang, Y; Teng, Y; Wang, X1
Brachet, PE; Chevreau, C; Dos Santos, M; Joly, F1
Badary, OA; Barrois, C; Cassier, P; Colomban, O; El-Demerdash, E; El-Madani, M; El-Shenawy, SM; Freyer, G; Gagnieu, MC; Guitton, J; Hommel-Fontaine, J; Ibrahim, BM; Lefort, T; Maillet, D; Peron, J; Rodriguez-Lafrasse, C; Tod, M; Valette, PJ; You, B1
Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A1
Brown, P; Levis, M; Li, L; Ma, H; Nguyen, B; Small, D; Williams, AB; Young, DJ1
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A1
Angenstein, F; Baldauf, L; Daniel, EA; Kirches, E; Mawrin, C; Pachow, D; Scholz, J; Stork, O; Tuchen, M; Wilisch-Neumann, A1
Chen, KF; Chu, PY; Huang, CT; Huang, TT; Lau, KY; Lee, CH; Liu, CY; Shiau, CW; Su, JC; Tsai, WC; Tseng, LM; Wang, WL; Yang, HP1
Bedke, J; Burchardt, M; Kroeger, N; Stenzl, A1
Booth, L; Dent, P; Poklepovic, A; Roberts, JL1
Gallacher, D; Gallacher, J; Jones, A; Narov, K; Sampson, JR; Samsel, PA; Shen, MH; Yang, J1
Baglioni, M; Baldassarre, M; Baron Toaldo, M; Bolondi, L; Callegari, E; Casadei Gardini, A; Cescon, M; Fornari, F; Galassi, M; Giovannini, C; Gramantieri, L; La Bella, T; Marinelli, S; Marisi, G; Negrini, M; Patrizi, C; Pollutri, D; Ravaioli, M; Salvatore, V1
Li, Y; Liu, L; Lu, L; Tong, X; Wang, F; Wang, X; Wu, G; Xie, J; Xue, Q; Zheng, A; Zhou, H; Zhu, X1
Huang, L; Luo, C; Wen, T; Xiao, H; Xiong, M1
Gu, J; Huang, W; Mao, X; Wang, Y; Wang, Z; Xiao, M; Zhu, L1
Arizumi, T; Bettinger, D; Burlone, ME; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sharma, R; Thimme, R; Ward, C; Yen, C1
Abou-Alfa, GK; Agajanov, T; Beylergil, V; Boisserie, F; Carrasquilo, JA; Chen, YC; Cheng, AL; Di Laurenzio, L; Frenette, C; Gansukh, B; Hsu, CH; Larson, SM; Lee, R; Lin, ZZ; Lyashchenko, SK; Ma, J; Maki, Y; Morikawa, H; O'Donoghue, J; O'Neil, B; Ohishi, N; Ohtomo, T; Pandit-Taskar, N; Ruan, S; Schwartz, L; Shao, YY; Smith-Jones, PM; Tanaka, T; Wan, P; Yen, CJ1
He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y1
Cai, X; Chen, J; Liang, X; Liang, Y; Lin, S; Ma, R; Zhu, L1
Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Xi, W; Xiong, Y; Xu, J; Yao, J1
Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J1
Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Murakami, M; Noura, S; Shimizu, J; Shuto, T; Yasuyama, A; Yoshikawa, M1
Akahori, T; Hokuto, D; Kanehiro, H; Kawaguchi, C; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiwada, S; Nomi, T; Obara, S; Sho, M; Yamada, T; Yamato, I; Yasuda, S; Yoshikawa, T1
Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC1
Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML1
Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R1
Daniel, PT; Essmann, F; Gillissen, B; Preissner, R; Richter, A; Schulze-Osthoff, K1
Bian, S; Cai, H; Cui, Y; Fan, Y; Liang, J; Sui, J; Sun, Y; Xu, Z; Zhang, X; Zhou, L1
Chen, B; Chen, W; Dao, H; Huang, Y; Li, N; Liu, N; Yang, J1
Carlisle, B; Fergusson, D; Hachem, Y; Kimmelman, J; Mattina, J1
Almeida, PV; Correia, A; Herranz-Blanco, B; Hirvonen, J; Mäkilä, E; Salonen, J; Santos, HA; Shahbazi, MA; Shrestha, N1
Galmiche, A; Giacobbi, AS; Louandre, C; Mammeri, Y; Saidak, Z; Sauzay, C1
Ding, W; Wang, B; Xu, L1
Han, P; Jiang, H; Jiang, X; Li, H; Liu, B; Qiao, H; Sun, X; Tan, G; Zhai, B; Zhao, D1
Duan, XC; Guo, Y; Huang, D; Ren, W; Yao, X; Yin, YF; Zhang, Q; Zhang, S; Zhang, X; Zhong, T1
Aubert, RE; Clore, G; Epstein, RS; Herrera, V; Kourlas, H; La-Beck, NM; McLeod, HL; Walko, CM1
Dutta, R; Mahato, RI1
Cheng, S; Wang, K; Wang, M; Wu, M; Yang, G; Ye, X; Zhang, X1
Gao, C; Herr, I; Hoffmann, K; Lin, S; Petrulionis, M; Schemmer, P1
Al-Abdulla, R; Bantel, H; Bettinger, D; Geier, A; Jahn, D; Macias, RI; Marin, JJ; Weiss, J1
Acosta, LF; Butterfield, DA; Gedaly, R; Marti, F; Mitov, M; Poyil, P; Turcios, L; Vilchez, V1
Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawasaki, J; Maehara, Y; Motomura, T; Nagatsu, A; Soejima, Y; Uchiyama, H; Yoshizumi, T1
Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L2
Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H1
Atkin, C; Earwaker, P; Ma, YT; Pallan, A; Punia, P; Shetty, S1
Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Li, J; Li, Y; Lu, WH; Sun, Y; Wen, S; Xu, RH; Yang, J; Zhan, G1
Blaise, D; Charbonnier, A; D'Incan, E; Mohty, B; Rey, J; Sid, S; Vey, N1
Brade, AM; Brierley, J; Cho, C; Craig, T; Dawson, LA; Dinniwell, R; Goody, RB; Kassam, Z; Kim, J; Knox, JJ; Ringash, J; Wang, L; Wong, RKS1
Gobe, GC; He, Y; Hooper, J; Jeffery, PL; Lourie, R; McGuckin, MA; Morais, C; Ng, CP; Oancea, I; Seim, I; Shah, ET; Sheng, Y; Wong, KY1
Arizumi, T; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Toniutto, P1
Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W1
Liang, J; Liu, CQ; Meng, YM; Xu, J; Xu, L; Yan, J; Yu, XJ; Zheng, L; Zhuang, SM1
Bauer, J; Grimm, D; Magnusson, NE; Randrup Hansen, C; Wehland, M1
Bito, T; Hirai, M; Hirano, T; Ishida, T; Nakagawa, T; Nishigori, C; Shichiri, H; Tokura, M; Uda, A; Yamamoto, K; Yano, I1
Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M1
Aihara, A; Akiyama, Y; Arii, S; Ban, D; Kudo, A; Matsumura, S; Mitsunori, Y; Mogushi, K; Nakao, K; Ochiai, T; Ohata, Y; Shimada, S; Tanabe, M; Tanaka, S1
Arizumi, T; Bettinger, D; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Park, JW; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Thimme, R; Yen, C1
Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K1
Dragomir, A; Edqvist, PH; Enblad, G; Niinivirta, M; Pontén, F; Ullenhag, GJ1
Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM1
Ali, EN; El-Mokhtar, MA; Elsabahy, M; Elzeny, H; Fathi, HA; Hamad, MA; Li, R; Wooley, KL; Zhang, F; Zhang, S1
Chen, L; Ni, CF; Teng, GJ; Zhong, BY; Zhu, HD1
Brose, MS; DeSanctis, Y; Fellous, M; Lin, CC; Pitoia, F; Schlumberger, M; Smit, J; Sugitani, I; Tori, M1
Cheong, H; Hong, SM; Kim, N; Lee, CK; Lee, SS; Lee, Y; Son, WC1
Cao, J; Chen, Y; Li, W; Liu, K; Shang, C; Tan, W; Zhang, L; Zhong, J; Zhu, S1
Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C1
Bardeesy, N; Benes, CH; Chang, CC; Chang, CF; Chen, Y; Dima, S; Duda, DG; Duyverman, AM; Flaherty, KT; Gao, DY; Hsu, FF; Huang, P; Jain, RK; Jeng, KS; Kitahara, S; Lin, TT; Liu, CH; Liu, YC; Popescu, I; Ramjiawan, RR; Sung, YC; Zhu, AX1
Atkins, MB; Choueiri, TK; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Manola, J; Uzzo, RG1
Davidson, BR; Gurusamy, KS; Majumdar, A; Roccarina, D; Thorburn, D; Tsochatzis, E1
Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B1
Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M1
Bonhomme-Faivre, L; Cailliez, V; Farinotti, R; Mhiri, A; Noé, G; Paule, B; Saffroy, R; Tandia, M1
Ciani, O; Rognoni, C; Sommariva, S; Tarricone, R1
Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lu, SN; Rau, KM; Wang, JH; Wu, IP1
Alivon, M; Boutouyrie, P; De Lepper, AG; Delhaas, T; Giroux, J; Goldwasser, F; Reesink, KD; Spronck, B1
Keating, GM1
Fukuda, K; Inami, T; Kataoka, M; Kimura, G; Satoh, T; Yoshino, H1
Babajanyan, S; Bruenderman, E; Cohn, A; Foreman, P; Geschwind, JF; Gholam, P; Goldenberg, A; Mantry, P; Martin, RC; McGuire, B; Miksad, R; Piperdi, B; Sanyal, A; Zigmont, E1
Baglioni, M; Baron Toaldo, M; Bolondi, L; Cescon, M; Giovannini, C; Gramantieri, L1
Haga, Y; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Takahashi, K; Wu, S; Yokosuka, O1
Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY1
Amadori, D; Andreis, D; Bravaccini, S; Bronte, G; Cecconetto, L; Donati, C; Farolfi, A; Fedeli, A; Maltoni, R; Rocca, A; Schirone, A; Serra, P1
Cheng, HJ; Chu, YY; Li, G; Li, WB; Sun, CJ; Tian, ZH; Zhao, JC1
Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D1
Mu, S; Olerile, LD; Wang, T; Yu, X; Zhang, J; Zhang, N1
Lee, WJ; Tam, HP1
Chen, L; Wang, HY; Zheng, B; Zhu, YJ1
Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J1
Hu, XG; Huang, DS; Li, T; Xu, QR; Yang, HM; Yang, L; Ye, S; Zhao, XY1
Cao, XH; Lu, AQ; Lv, B; Qiu, F; Wang, XY1
Altman, RB; Giacomini, C; Giacomini, MM; Gong, L; Klein, TE; Maitland, ML1
Chang, Y; Cho, EJ; Cho, H; Cho, YY; Jo, A; Kim, JB; Kim, YJ; Lee, JH; Lee, M; Lee, S; Nam, JY; Yoon, JH; Yu, SJ1
Baker, SD; Bins, S; de Bruijn, P; Du, G; Eskens, F; Gibson, AA; Hamberg, P; Hu, S; Li, L; Mathijssen, R; Phelps, MA; Sparreboom, A; van Doorn, L; Vasilyeva, A1
Cho, HJ; Cho, HR; Choi, JW; Chung, JW; Kim, DD; Kim, HC; Park, JH1
Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T1
Chao, Y; Chen, SC; Yang, MH1
Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L1
Ahmed, SO; Aljurf, M; Antar, A; Battipaglia, G; Bazarbachi, A; Belhocine, R; Brissot, E; Dulery, R; Eder, S; El Cheikh, J; Giannotti, F; Isnard, F; Jestin, M; Lapusan, S; Legrand, O; Massoud, R; Mohty, M; Rasheed, W; Rubio, MT; Ruggeri, A; Shaheen, M; Vekhoff, A1
Guignabert, C; Humbert, M; Montani, D; Weatherald, J1
Karasawa, Y; Kawamura, S; Kojima, K; Kondo, M; Maeshima, S; Ohki, T; Seki, M; Shioda, Y; Tagawa, K; Toda, N1
Chang, HH; Chen, JS; Chia-Hsun Hsieh, J; Chou, WC; Hou, MM; Huang, CY; Lee, CL; Lin, YC; Teng, W; Tseng, YT; Yang, TS1
Chen, CP; Liao, XH; Liu, H; Lu, KP; Lu, W; Wang, J; Wang, L; Xu, H; Yang, D; Zhang, AL; Zheng, M; Zhou, XZ1
Chen, L; Huang, J; Liu, J; Mai, H; Mei, GH; Qu, H; Qu, N; Xu, X; Zhang, Y1
Best, J; Dechêne, A; Gerken, G; Lohmann, G; Schotten, C1
DeVere White, RW; Duan, Z; Ho, PY; Jian, C; Lam, KS; Lara, PN; Qiu, JX; Tu, MJ; Wun, T; Yu, AM; Yu, AX; Zhang, Q1
Friedman, T; Kishore, S; Madoff, DC1
Chen, J; Cheng, Y; Li, A; Liu, D; Liu, Y; Luo, R; Wang, B; Xu, W; Zheng, H; Zhu, Y1
Huachuan, Z; Jianhua, H; Li, R; Rongjian, S; Wubin, H; Yanjiao, G; Yue, W; Zhidong, L1
Braiteh, F; Burris, H; Cohn, AL; Foster, P; Kelley, RK; Lee, Y; Spira, A; Su, WC; Van Cutsem, E; Verslype, C; Vogelzang, N; Yang, TS1
Cho, EJ; Cho, H; Cho, KH; Cho, SH; Choi, WM; Hwang, CY; Jang, JJ; Kim, CY; Kim, K; Kim, YJ; Lee, JH; Lee, KB; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ1
Duan, P; Fan, L; Gao, Q; Qu, W; Ren, M; Shen, Y; Silwal, BM1
Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, HJ; Kim, HS; Park, CH; Rew, JS; Shin, SS; Yoon, JH1
Dybowski, N; Godl, K; Junghanss, C; Knuebel, G; Mueller, S; Murua Escobar, H; Roolf, C; Schaab, C; Sekora, A; Tebbe, A1
Mancuso, A; Maringhini, A1
Dhungel, B; Jayachandran, A; Mir, N; Shrestha, R; Steel, JC1
Chen, D; Eyupoglu, IY; Savaskan, N1
Chen, T; Cui, M; Cui, Y; Ge, C; Huo, Q; Li, H; Li, J; Sun, J; Tian, H; Xie, H; Yao, M; Zhao, F1
Caraglia, M; Cervi, C; Di Biase, S; Lo Re, O; Panebianco, C; Pazienza, V; Porto, S; Rappa, F; Vinciguerra, M1
Clare, KE; Dillon, JF; Miller, MH1
Sharma, R1
Chen, B; Cui, X; Hu, B; Hua, L; Liu, J; Shen, C; Shen, Y; Yan, D; Zhao, F1
Chen, HM; Chen, PJ; Cheng, AL; Hsu, CH; Lai, MS; Lu, LC; Shao, YY; Yeh, YC1
Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A1
Cao, V; Chen, L; Huang, W; Ting, J; Wilson, L1
Arneson, K; Attia, A; Chakravarthy, AB; Cmelak, AJ; Horn, L; Mondschein, J; Niermann, K; Puzanov, I; Stavas, M; Xia, F1
Allard, M; Blanchet, B; Costentin, C; Hulin, A; Joly, C; Khoudour, N; Rousseau, B; Tournigand, C1
Antonuzzo, L; Balestri, V; Brugia, M; Costanzo, FD; Giommoni, E; Laffi, A; Lunghi, A; Mazzoni, F; Mela, MM; Petreni, P1
Guo, Z; Li, T; Pu, J; Wei, X; Wu, Z; Zhu, D1
Lee, SJ; Lim, HY1
Badrinath, N; Heo, J; Woo, HY; Yoo, SY1
Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L1
Chang, Y; Cho, EJ; Chung, GE; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Nam, JY; Yoo, JJ; Yoon, JH; Yu, SJ1
Cai, W; Chen, Y; Huang, J; Huang, Y; Kong, W; Zhang, J; Zhou, L1
Lou, L; Quan, H; Wang, H1
Gülow, K; Kießling, MK; Klemke, CD; Krammer, PH; Nicolay, JP; Schlör, T; Süss, D1
Lim, SY; Menzies, AM; Rizos, H1
Ahn, KS; Baek, SH; Kim, C; Ko, JH; Lee, JH; Nam, D1
Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R1
Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ1
Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A1
Cho, EJ; Cho, Y; Cho, YY; Jun, J; Kim, H; Kim, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, S; Park, T; Yeo, I; Yoon, JH; Yu, SJ1
Aoki, Y; Arai, T; Atsukawa, M; Doi, H; Fukai, M; Itokawa, N; Kanto, T; Kimura, K; Mano, Y; Mizokami, M; Osawa, Y; Shoji, H; Sugiyama, M; Taketomi, A; Yoshio, S1
Abeni, E; Arici, B; De Petro, G; Marchina, E; Salvi, A; Traversa, M1
Agarwal, N; Gill, DM; Vaishampayan, U1
Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T1
Beukhof, CM; Bins, S; Chaker, L; de Herder, WW; de Rijke, YB; Mathijssen, RH; Peeters, RP; van Doorn, L; van Heerebeek, R; van Kemenade, FJ; Visser, TJ; Visser, WE1
Personeni, N; Pressiani, T; Rimassa, L; Santoro, A1
Go, ML; Huynh, H; Sim, MY; Yuen, JSP1
Franzesi, CT; Ippolito, D; Okolicsanyi, S; Querques, G; Sironi, S; Strazzabosco, M1
Choi, YK; Ham, HJ; Jang, SY; Jeon, HJ; Kim, BG; Kim, JG; Kim, JH; Kim, MJ; Lee, IK; Lee, JY; Park, KG; Park, SY1
Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I; Zając, A1
Abada, PB; Baron, AD; Blanc, JF; Borg, C; Bowman, L; Chau, I; Chung, HC; Cui, ZL; Girvan, AC; Kudo, M; Malfertheiner, P; Okusaka, T; Park, JO; Pastorelli, D; Peck-Radosavljevic, M; Poon, R; Ryoo, BY; Seitz, JF; Yang, L; Yen, CJ; Zhu, AX1
Abou-Alfa, GK; Bass, M; Blanc, JF; Bradley, M; Cebon, J; Ganten, T; Gupta, C; Hollywood, E; Liem, AK; Lipton, L; Litten, J; Ma, J; Miles, S; Saltz, LB; Trojan, J; Wu, B1
Murata, K; Nitta, N; Nitta-Seko, A; Ohta, S; Sonoda, A; Tomozawa, Y; Tsuchiya, K; Watanabe, S1
Ishihara, H; Kondo, T; Tanabe, K1
Eggert, T; Greten, TF1
Adam, R; Amaddeo, G; Bricault, I; Calderaro, J; Cherqui, D; Costentin, CE; Decaens, T; Duvoux, C; Ganne-Carrié, N; Laurent, A; Letoublon, C; Luciani, A; Mallat, A; Nault, JC; Paule, B; Roudot-Thoraval, F; Samuel, D; Vibert, E1
Li, L; Long, B; Yan, F; Yang, Y; Ye, T; Ye, X; Yi, H; Zhang, L1
Itoh, K; Matsueda, S; Morita, M; Muroya, D; Sasada, T; Shichijo, S; Shirahama, T; Yamada, A; Yamaguchi, R; Yutani, S1
Altamura, E; Azzariti, A; Cutrignelli, A; Denora, N; Di Fonte, R; Franco, M; Iacobazzi, RM; Laquintana, V; Lopalco, A; Lopedota, AA; Porcelli, L1
Atrih, A; Auciello, FR; Gowans, GJ; Hardie, DG; Hawley, SA; Lamont, DJ; Ross, FA1
Kim, D; Ko, HS; Park, GB1
Ji, B; Liu, J; Liu, K; Liu, Y; Meng, L1
Fujimoto, N; Kamba, T; Kitada, S; Komohara, Y; Ma, C; Motoshima, T; Nakayama, T; Pan, C; Takeya, M; Yamada, S; Yano, H1
Ito, KI; Ito, Y; Kabu, K; Onoda, N; Sugitani, I; Takahashi, S; Tsukada, K; Yamaguchi, I1
Cheng, YY; Ting, CT; Tsai, TH1
Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R1
Cheng, Z; Ke, X; Li, C; Li, H; Li, X; Liu, S; Qu, Y; Shen, Y; Wu, G; Xie, N; Xu, X; Yang, N; Yuan, X; Zhang, W; Zhou, J; Zu, X1
Cheng, LKW; Copland, JA; Ding, J; Ho, NPY; Lau, EYT; Lee, TKW; Leung, DHW; Lin, CH; Lo, J; Lo, RCL; Ma, MKF; Ma, S; Ng, IOL1
Collins, P; Cunningham, D; Evans, TRJ; Fox, R; Hacking, N; Hubner, RA; James, MW; Johnson, PJ; Ma, YT; Meyer, T; Palmer, DH; Primrose, JN; Ross, PJ; Stocken, DD; Stubbs, C; Sturgess, R; Wall, L; Watkinson, A1
Ahn, SH; Han, KH; Heo, JY; Jang, SK; Jang, SY; Jeon, MY; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Lee, HW; Lee, SH; Lee, YR; Park, JY; Park, SY; Tak, WY1
Gao, Q; Lin, H; Song, Y; Yang, Y; Zhao, L1
Benech, N; Saurin, JC; Walter, T1
Augustyns, K; Bräsen, JH; Feldmann, F; Fulda, S; Goossens, V; Hofmans, S; Jeong, M; Joossens, J; Lee, EW; Linkermann, A; Martens, S; Song, J; Takahashi, N; Tonnus, W; Van der Veken, P; Vandenabeele, P1
Baxi, SS; Cullen, G; Dunn, LA; Fagin, JA; Fury, MG; Ghossein, RA; Haque, S; Ho, AL; Pfister, DG; Sherman, EJ; Sima, CS1
Brade, A; Chung, C; Dawson, L; Longo, J; Milosevic, M; Murray, L; Oza, A; Wan, J; Wang, L1
Bunker, E; Chapnick, DA; Eckhardt, SG; Lee, S; Liu, X; Liu, Z; Peng, Y; Ramirez, A; Tan, AC; Zhang, C1
Galle, PR; Huber, Y; Koch, S; Labenz, C; Marquardt, JU; Prenosil, V; Schattenberg, JM; Weinmann, A; Wörns, MA1
Abdel-Wahab, R; Abdelsalam, ME; Al-Shamsi, HO; Aloia, TA; Amin, HM; Avritscher, R; Chun, YS; Conrad, C; Dahbour, I; Das, P; Hassan, MM; Kaseb, AO; Koay, EJ; Krishnan, S; Lacin, S; Mahvash, A; Murthy, R; Odisio, BC; Rashid, A; Shalaby, AS; Vauthey, JN; Yao, JC1
Dai, X; Ding, J; Fu, X; Geng, M; Huang, M; Huang, X; Liu, H; Shen, A; Sun, D; Wei, R; Yan, J; Zheng, X1
Bruix, J; Cheng, AL; De Sanctis, Y; Llovet, J; Meinhardt, G; Nakajima, K1
Bansal, P; Fekrazad, HM; Lee, FC; Patt, Y; Rojas-Hernandez, C1
Barbera, MA; Biasco, G; Brandi, G; Frega, G; Garajova, I; Lorenzo, S; Palloni, A; Pantaleo, MA; Tovoli, F1
Buder, R; Galle, PR; Ganten, TM; Gerken, G; Göhler, T; Koschny, R; Malfertheiner, P; Schott, E; Stauber, RE; Walther, M1
Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD1
Bouarioua, N; Bourmaud, A; Clavel, L; Merle, P; Phelip, JM; Roblin, X; Verot, C; Williet, N1
Chen, C; Chen, SZ; Cheng, Z; Cong, WM; Ding, J; Lee, TKW; Li, XF; Lu, XY; Ning, BF; Qu, L; Shen, WF; Sun, W; Wang, HY; Wen, W; Xia, MY; Xiang, DM; Yang, W; Zhou, TF1
Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M1
Karasic, TB; O'Dwyer, PJ; Rosen, MA1
Huang, X; Li, G; Li, W; Mu, X; Qian, X; Qin, J; Sun, B; Tan, S; Tan, Z; Wang, X; Xu, X; Zhang, W; Zhu, Z1
Fujii, Y; Ishioka, J; Kawamura, N; Kihara, K; Matsuoka, Y; Okuno, T; Saito, K; Uehara, S; Yamamoto, S; Yasuda, Y; Yokoyama, M; Yonese, J; Yuasa, T1
Decker, T; Göhler, T; Indorf, M; Nusch, A; Overkamp, F; Rösel, S; Sahlmann, J; Trarbach, T1
Cao, JY; Han, X; Li, HS; Yin, HS; Yu, XQ1
Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL1
Han, JK; Kim, JH; Lee, JH; Lee, S1
Ba, Q; Duan, X; Li, H; Li, J; Li, X; Wang, F; Wang, H; Yao, W; Yuan, Y; Zhang, S; Zhang, W1
Kollmann, D; Selzner, M; Selzner, N1
Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G1
Bai, T; Sun, Y; Wang, S; Wang, W; Zhao, Y; Zhu, R1
Biondi, RM; Brieger, A; Hinrichsen, I; Huhn, M; Passmann, S; Plotz, G; Weßbecher, IM; Zeuzem, S1
Brunetti, O; Casadei Gardini, A; Cascinu, S; Di Costanzo, GG; Ercolani, G; Faloppi, L; Foschi, FG; Granata, R; Marisi, G; Palmieri, VO; Scartozzi, M; Silvestris, N; Tortora, R1
Comerford, CM; Langabeer, SE; Murphy, PT; Quinn, J1
Arizumi, T; Hagiwara, S; Kamata, K; Kudo, M; Minaga, K; Minami, Y; Nishida, N; Sakurai, T; Takenaka, M; Watanabe, T; Yada, N1
Choi, HJ; Han, Z; Joo, Y; Kang, D; Oh, GH; Song, JJ1
Bao, B; Delaney, J; Groves, K; Ho, G; Kossodo, S; Morin, J; Narayanan, N; Peterson, JD; Rajopadhye, M; Tseng, JC; Zhang, J1
Covell, DG1
Bavari, S; Brahms, A; Kehn-Hall, K; Kota, K; Mudhasani, R; Nasar, F; Pinkham, C; Zamani, R1
Bardelang, D; Huang, Q; Lee, SMY; Wang, C; Wang, R; Yang, X1
Bettinger, D; Boettler, T; Brunner, TB; Buettner, N; Gkika, E; Glaser, N; Maruschke, L; Neumann-Haefelin, C; Schultheiss, M; Spode, R; Thimme, R1
Akhoundova, D; Aparicio, J; Bruixola, G; Caballero, J; Diaz-Beveridge, R; Giménez, A; Lorente, D; Rodrigo, E; Segura, Á1
Hayashi, Y; Machihara, K; Murakami, I; Namba, T; Tanaka, H1
Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ1
Appella, D; Avram, MJ; Chen, Z; Green, R; Gupta, P; Huang, M; Huang, S; Kandela, I; Liu, Y; Lou, G; Mazar, A; Norton, JT; Shank, NI; Tang, S; Wang, C1
Hoshino, T; Ishihara, H; Kakizaki, S; Kudo, T; Naganuma, A; Sato, K; Suzuki, Y; Takagi, H; Uehara, D; Yamada, M1
Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M1
Argirò, R; Levi Sandri, GB; Lucatelli, P; Saba, L1
Ballarin, R; Berretta, M; Di Benedetto, F; Guerrini, GP; Magistri, P; Pecchi, A; Tarantino, G1
Baselga, J; Bergh, J; Bermejo, B; Chan, A; Costa, F; Gómez, HL; Gómez, P; Gradishar, WJ; Huang, L; Hudis, CA; Maeda, P; Mángel, L; Meinhardt, G; Melichar, B; Nagai, SE; Rapoport, BL; Roché, H; Schwartzberg, LS; Zamagni, C; Zhang, J1
García Carretero, R; Rebollo-Aparicio, N; Romero Brugera, M; Vazquez-Gomez, O1
Beveridge, DJ; Brown, RM; Candy, P; Chaturvedi, V; Epis, M; Ganda, C; George, J; Kabir, TD; Kalinowski, F; Kopp, C; Leedman, PJ; Richardson, KL; Stuart, LM; Wintle, L; Yeoh, GC1
Kira, Y; Mizukami, Y; Sugawara, K; Tsuruta, D1
Kutkowska, J; Rapak, A; Strzadala, L1
Li, W; Sun, X; Tan, G; Wang, P; Zhai, B; Zhu, M1
Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W1
Chiba, T; Hara, H; Ishii, J; Kamma, H; Sawa, A; Yamamoto, H1
Chen, K; Dai, W; Fan, X; Feng, J; Guo, C; Li, J; Li, S; Liu, T; Lu, J; Lu, X; Mo, W; Wang, W; Wu, L; Xia, Y; Xu, L; Xu, S; Yu, Q; Zhang, Q; Zhou, Y1
Bito, T; Hirai, M; Hirano, T; Ishida, T; Kaku, K; Kume, M; Makimoto, H; Nakagawa, T; Nishigori, C; Nishioka, T; Shichiri, H; Yamamoto, K; Yano, I1
Zhang, H1
D'Addeo, K; Kaplan, DE; Mamtani, R; Mehta, R; Reiss, KA; Taddei, TH; Wileyto, EP; Yu, S1
Bao, XB; Chen, SN; Ding, ZX; He, J; Li, Z; Liu, H; Liu, SB; Qiu, QC; Shen, HJ; Wang, C; Xue, SL; Yang, J; Yao, H1
Amzal, B; Fu, S; Karcher, H; Lister, J; Meng, J1
Gandhi, S; George, S; Jain, RK1
Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhong, H; Zhou, L1
Bai, T; Chen, J; Li, LQ; Li, ZH; Qi, LN; Wu, FX; Yang, TB; Ye, JZ; Zhu, SL; Zou, L1
Chang, CS; Chao, Y; Chen, CY; Lee, TY; Lin, CC; Lo, GH; Wang, TE1
Pacini, F1
Agate, L; Bottici, V; Cappagli, V; Danesi, R; Del Re, M; Elisei, R; Giani, C; Lorusso, L; Matrone, A; Molinaro, E; Pieruzzi, L; Puleo, L; Valerio, L; Viola, D1
Biasoni, D; Busico, A; Calareso, G; Catanzaro, M; Colecchia, M; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Pennati, M; Perrone, F; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Togliardi, E; Torelli, T; Zaffaroni, N1
Azzolina, A; Balasus, D; Cervello, M; Emma, MR; Giammona, G; Loria, GR; Pitarresi, G; Porsio, B; Puleio, R; Puleo, S; Volpe, AB1
Bruner, JK; Jones, RJ; Levis, MJ; Li, L; Ma, HS; Pratilas, CA; Pratz, KW; Qin, ACR; Rudek, MA; Small, D1
Abd El Razik, HA; Abu-Serie, MM; El-Miligy, MM1
Bitzer, M; Horger, M; Kaufmann, S; Lauer, U; Nikolaou, K; Schulze, M; Thaiss, WM1
Jia, S; Lei, H; Wang, C; Wang, M; Xiao, Z; Xu, S; Zheng, P; Zhi, J; Zhu, W1
Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C1
Cheng, H; Dong, J; Hu, F; Sun, W; Xu, J; Zhai, B1
Bersanelli, M; Buti, S; DiPaola, RS; Haas, NB; Manola, J; Puligandla, M; Taguchi, S1
Clavreul, A; Lautram, N; Menei, P; Montero-Menei, CN; Pourbaghi-Masouleh, M; Roger, E1
Chow, PK; Gandhi, M; Gebski, V1
Bain, JR; Beak, JY; Huang, W; Ilaiwy, A; Jensen, BC; Johnson, GL; Muehlbauer, MJ; Newgard, CB; Parry, TL; Patterson, C; Willis, MS1
Chen, HM; Cheng, AL; Hsu, CH; Lee, YH; Li, YS; Lin, H; Shao, YY1
Gao, L; Lv, F; Shay, C; Teng, Y; Wang, X1
Sun, S; Wang, H; Xie, B; Yang, W; Yu, M1
Aprile, G; Brunetti, O; Casadei Gardini, A; Cascinu, S; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Granato, AM; Marisi, G; Negrini, G; Palmieri, V; Passardi, A; Perrone, G; Santini, D; Scartozzi, M; Silvestris, N; Tamburini, E; Tovoli, F; Valgiusti, M; Vespasiani-Gentilucci, U1
Blanc, JF; Campillo-Gimenez, B; Edeline, J; Faluyi, O; Ghazi, S; King, J; Ma, YT; Mathurin, J; Meyer, T; Palmer, DH1
Arvat, E; Berardelli, R; Felicetti, F; Gallo, M; Marchisio, F; Nervo, A; Piovesan, A1
Antarianto, RD; Arozal, W; Louisa, M; Rahmaniah, R; Soetikno, V; Yuyuntia, Y1
Chen, KF; Li, B; Li, Q; Liu, F; Wei, YG; Zhao, RC; Zhou, J1
Chan, KKW; Earle, CC; Jembere, N; Qiao, Y; Sapisochin, G; Thein, HH; Yoshida, EM; Zaheen, A1
Cai, X; Chen, J; Jin, RA; Liang, X; Lin, H; Sun, Y; Tang, M; Xu, J; Zheng, L1
Cai, X; Chen, J; Dai, Y; Ji, T; Liang, X; Liang, Y; Lin, H; Xie, Y; Xu, J; Yu, Q; Zhang, B1
El-Serag, HB; Johnson, MS; Zhu, AX1
Kudo, M; Nishida, N; Ueshima, K1
Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kudo, M; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Toyoda, H; Tsuji, K1
Dolgikh, N; Fulda, S1
Angus, SP; Beak, JY; Chen, X; Hicks, ST; Huang, W; Jensen, BC; Johnson, GL; Parry, TL; Sciaky, N; Stuhlmiller, TJ; Willis, MS; Zawistowski, JS1
Chen, GG; Lai, PBS; Liu, L; Niu, L; Ren, J; Yang, S1
Arai, J; Goto, K; Ito, S; Kaise, Y; Kato, N; Lim, LA; Matsubara, Y; Morimoto, S; Muroyama, R; Nakagawa, R; Stephanou, A; Tanoue, Y; Yoshida, H1
Basara, N; Burchert, A; Ditschkowski, M; Dreger, P; Fey, MF; Finck, A; Finke, J; Giagounidis, A; Götze, K; Kobbe, G; Lübbert, M; Metzelder, SK; Meyer, RG; Neubauer, A; Pabst, T; Salih, HR; Scholl, S; Schroeder, T; Wollmer, E1
Andersen, JB; Beguinot, F; Condorelli, G; Heim, MH; Hindupur, SK; Matter, MS; Ng, CKY; Nigro, C; Pallante, P; Piscuoglio, S; Quagliata, L; Quintavalle, C; Roth, W; Tagscherer, KE1
He, HL; Yao, WX1
Bruix, J; Lii Cheng, A; Llovet, J1
Berhane, S; Jackson, R; Johnson, PJ; Psarelli, E1
Akiyama, M; Chen, KR; Hioki, T; Makita, S; Takama, H; Watanabe, D1
Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS1
Fu, C; Gu, H; Han, Z; Lin, J; Lu, F; Yang, S1
Cai, M; Cao, Z; Chen, X; Lin, L; Shuai, X; Sun, W; Wang, Y; Zhu, K1
Adam, R; Allaham, W; Assenat, E; Aubé, C; Barraud, H; Bouattour, M; Brenot-Rossi, I; Bronowicki, JP; Castera, L; Chatellier, G; Costentin, C; Couturier, O; Dinut, A; Gerolami, R; Guiu, B; Ilonca, AD; Itti, E; Laurent, V; Lebtahi, R; Lewin, M; Luciani, A; Mathias, E; Mundler, O; Oberti, F; Pageaux, GP; Perdrisot, R; Pereira, H; Raoul, JL; Ronot, M; Samuel, D; Sarran, A; Seitz, JF; Sibert, A; Silvain, C; Tasu, JP; Vidal, V; Vilgrain, V1
Chen, X; Shao, J; Shen, Z; Xu, A; Zhao, R; Zheng, G1
Arima, K; Baba, H; Beppu, T; Chikamoto, A; Hashimoto, D; Hayashi, H; Higashi, T; Imai, K; Ishiko, T; Kaida, T; Nakagawa, S; Nitta, H; Okabe, H; Sasaki, Y; Takeyama, H; Taki, K; Tanaka, M1
Cai, R; Liao, Y; Ma, H; Pang, P; Song, R; Sun, H; Wang, H; Wang, S; Yan, Y; Zhang, H; Zhou, C; Zhou, X1
Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Kosloff, RA; Quinn, R; Rubin, MS; Shih, KC; Shipley, DL; Spigel, DR1
Bae, WK; Kim, DY; Kwon, SY; Min, JJ1
Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I1
Bae, SH; Choi, JY; Hwang, S; Jang, JW; Park, HL; Song, MJ; Sung, PS; Yang, K; Yoo, IR; Yoon, SK1
Elmasry, MS; Hassan, WS; Shalaby, AA; Zidan, DW1
Abdel-Rahman, O; Eissa, M; El Gewaity, M; Farag, K; Ghonaim, A; Nada, Y; Rashad, N; Saadawi, I; Sheha, A1
Fukuda, H; Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K1
Abdel Gaber, SA; Abdel Kader, MH; Hüttenberger, D; Müller, P; Stepp, H; Wittig, R; Zimmermann, W1
Fei, Z; Lu, M; Zhang, G1
Barney, LE; Hall, CL; Jansen, LE; Meyer, AS; Nguyen, TV; Peyton, SR; Schwartz, AD1
Liu, H; Ming, L; Sun, T1
Bo, LS; Ke, WB; Li, T; Meng, YP; Zhang, Y1
Chakraborti, A; Chawla, YK; Dhiman, RK; Kalra, N; Kanthaje, S; Makol, A1
Fujii, H; Hamamichi, S; Hori, Y; Ito, K; Matsui, J; Ozawa, Y; Umeda, IO1
Dong, LY; Du, C; Gao, JJ; Ni, YH; Qiao, Z; Sun, JY; Wang, K; Wang, LY; Yu, HX; Zhang, JH; Zhang, SS; Zhao, CR1
Chang, PY; Huang, YK; Lee, SW; Lee, TY; Shiu, SI; Yeh, HZ; Yen, CL1
Auriola, S; Bunch, L; Gynther, M; Han, L; Hansen, JC; Hansen, KB; Ishchenko, Y; Kayser, S; Larsen, Y; Malm, T; Nielsen, B; Petsalo, A; Pickering, DS; Proietti Silvestri, I1
Ge, M; Jin, S; Li, L; Long, B; Yang, M; Ye, T; Ye, X; Yi, H; Zhang, L1
Liu, LX; Liu, QX; Luo, JJ; Ma, JQ; Wang, JH; Yan, ZP; Zhang, W; Zhang, ZH1
Edwards, RJ; Ghassabian, S; Gillani, TB; Murray, M; Rawling, T1
Bärtschi, D; Berger, MD; Bodoky, G; Hayoz, S; Izzo, P; Klingbiel, D; Koeberle, D; Meier, UR; Plasswilm, L; Rauch, D; Roth, A; Saletti, P; Samaras, P; Schacher, S; von Moos, R; Winterhalder, RC; Yan, P; Zaugg, K; Zwahlen, D1
Jain, A; Katare, OP; Khurana, RK; Sharma, T; Singh, B1
Fan, XG; Fu, Y; Hu, X; Huang, Y; Li, N; Quan, J; Sun, L; Xiao, Y; Zhou, P; Zhou, R1
Barbera, MA; Bernardi, M; Brandi, G; Casadei Gardini, A; De Lorenzo, S; Di Costanzo, GG; Foschi, FG; Garuti, F; Granito, A; Inghilesi, AL; Marra, F; Sacco, R; Tortora, R; Tovoli, F; Trevisani, F1
Kitazawa, M; Kobayashi, A; Matsumura, T; Miyagawa, SI; Motoyama, H; Notake, T; Shimizu, A; Takeoka, M; Yokoi, K; Yokoyama, T1
Arizumi, T; Kudo, M1
Ando, M; Deguchi, A; Kokudo, Y; Kubo, A; Kudo, M; Masaki, T; Matsunaka, T; Minami, Y; Morishita, A; Morita, M; Moriya, A; Nagano, T; Nishida, N; Noda, T; Ogawa, C; Omura, A; Sakurai, T; Senoh, T; Shibatoge, M; Takaguchi, K; Tamaki, H; Tani, J; Tsutsui, A; Ueshima, K; Yoneyama, H1
Arai, K; Asahina, Y; Hara, Y; Hayashi, T; Honda, M; Kaneko, S; Mizukoshi, E; Nio, K; Okada, H; Sakai, Y; Suda, T; Sunagozaka, H; Takatori, H; Terashima, T; Yamashita, T1
Bosserhoff, AK; Dietrich, P; Fritz, V; Hartmann, A; Hellerbrand, C; Koch, A1
García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM1
Arakawa, Y; Bando, Y; Ikemoto, T; Imura, S; Ishikawa, D; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Takasu, C; Teraoku, H; Yoshimoto, T1
Matsumura, T; Matsushima, H; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y; Yoshitomi, M1
Cheng, IG; Hespel, L; Kato, K; Kobayashi, M; Lee, E; Matsunaga, YT; Nakajima, H; Pauty, J; Soncin, F; Takahashi, H; Usuba, R; Yger, F1
He, J; Jia, B; Yan, J; Yang, J1
Dworacki, G; Jaskula, E; Lange, A; Lange, J; Mordak-Domagala, M; Nowak, D; Sedzimirska, M; Simiczyjew, A1
Ai, S; Fu, H; Pan, T; Tang, L; Wang, F; Zhang, J1
Abe, S; Fujisawa, K; Furutani-Seiki, M; Goto, R; Inoue, R; Kamimura, K; Koyama, N; Nagoya, T; Nishina, H; Nozawa, Y; Ogawa, K; Sakai, N; Sakaida, I; Sakamaki, A; Shinagawa-Kobayashi, Y; Sugitani, S; Terai, S; Yanagi, M; Yokoo, T1
Abegg, VF; Bouitbir, J; Grünig, D; Krähenbühl, S; Mingard, C; Paech, F1
Broggini, M; Caiola, E; Frapolli, R; Garassino, MC; Iezzi, A; Marabese, M; Tomanelli, M; Valerio, R1
Benoukraf, T; Chow, EK; Fong, ELS; Hooi, L; Huynh, TH; Lin, QXX; Liu, Z; Mohd Abdul Rashid, MB; Toh, TB; Yu, H1
D'Addeo, K; Kaplan, DE; Mehta, R; Taddei, TH; Valderrama, A1
Cao, S; Cao, Y; Chai, Y; Feng, F; Jiang, Q; Li, BA; Li, R; Li, X; Liang, E; Liu, G; Shen, L; Sun, H; Sun, L; Wang, T; Xin, S; Yang, R; Yang, Y; Yang, Z; Zhu, H1
Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Wang, Z; Xiong, Y; Xu, J; Yang, Y1
Cheng, Y; Wang, B; Xu, J; Xu, W; Zheng, H; Zhu, Y1
Antoniewicz, MR; Au, J; DeWaal, D; Guzman, G; Hay, N; Jeon, SM; Long, CP; Nogueira, V; Patra, KC; Terry, AR1
Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X1
Cai, MY; Chen, BH; Guo, YJ; Huang, JJ; Huang, WS; Meng, XC; Zhou, JW; Zhu, KS1
Hasegawa, K; Kokudo, N; Kokudo, T1
Finn, RS; Llovet, JM1
Campillo-Gimenez, B; Edeline, J; Garin, E; Rolland, Y1
Chatellier, G; Dinut, A; Pereira, H; Vilgrain, V1
An, G; Bae, S; D'Cunha, R; Shao, J1
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S1
Baron, A; Blanc, JF; Cheng, AL; Dutcus, C; Evans, TRJ; Finn, RS; Guo, M; Han, G; Han, KH; Ikeda, K; Jassem, J; Komov, D; Kraljevic, S; Kudo, M; Lopez, C; Park, JW; Piscaglia, F; Qin, S; Ren, M; Saito, K; Tamai, T; Vogel, A1
Dong, X; Li, L; Li, Z; Lu, H; Shi, X; Sun, P; Yu, X; Zhong, J; Zhou, W1
Aramaki, T; Asagi, A; Furuse, J; Hosokawa, A; Ikeda, M; Ishii, H; Kaneko, S; Kato, N; Okusaka, T; Sano, K; Sato, T; Sugimoto, R; Suzuki, E; Yamaguchi, K; Yasui, K1
D'Addeo, K; Gade, TP; Kaplan, DE; Mehta, R; Taddei, TH1
Golinelli, G; Pia, F; Rosa, MS; Toso, A; Valletti, PA1
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J1
Chen, ZH; Cheng, SQ; Guo, WX; Wang, K; Zhang, XP1
Dore, GJ; Gomaa, A; Waked, I; Waziry, R1
Jiang, W; Li, L; Lian, ZX; Liu, QZ; Long, J; Wang, YC; Yan, K; Yang, JB; Zhao, YY; Zhao, ZB1
Jian, W; Li, C; Sun, X; Xie, F; Zhang, K1
Meyer, T1
Ali, S; Khan, MA; Ovais, M; Raza, A; Sohail, MF; Venkatraman, SS1
Cho, EJ; Cho, YY; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Yoon, JH; Yu, SJ1
Carlisle, B; Federico, CA; Kimmelman, J1
Agazzi, R; Colledan, M; Conte, G; De Giorgio, M; Fagiuoli, S; Iegri, C; Lucà, MG; Nani, R; Nicora, C; Pinelli, D; Sala, F; Sarti, D; Schranz, M; Sironi, S; Virotta, G1
Costentin, C; Durot, C; Hoeffel, C; Luciani, A; Mulé, S; Rahmouni, A; Thiefin, G1
Chen, CW; Hsu, FT; Kuo, YC; Pan, PJ; Tsai, JJ1
Almeida-Carvalho, SR; D'Ippolito, G; Loureiro-Matos, CA; Miziara-Gonzalez, A; Pereira-Lanzoni, V; Salzedas-Netto, AA; Souza-Silva, I; Szejnfeld, D; Tannus, RK1
Chi, H; Meng, Z; Wang, H; Zhang, C2
Andreone, A; Badea, RI; Benevento, F; Brocchi, S; Ferrarini, A; Golfieri, R; Mastroroberto, M; Morselli-Labate, AM; Negrini, G; Piscaglia, F; Renzulli, M; Tovoli, F1
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nakahara, T; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S1
Han, HK; Kim, HY; Lee, SH; Song, JG; Zhao, M1
Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W1
Akhtar, S; Arif, JM; Jamal, QMS; Kamal, MA; Khan, MKA; Sayeed, U; Shakeel, E; Sharma, M; Sharma, N; Siddiqui, MH1
Asabe, S; Asano, T; Mashima, H; Matsuura, K; Tsuboi, R1
Cai, M; Chen, J; Guo, Y; Huang, J; Huang, W; Lai, L; Zhou, J; Zhu, K1
Cai, L; Luo, L; Meng, X; Tang, Z1
Bamodu, OA; Chang, HL; Chen, HA; Lee, KF; Lee, WH; Tsai, JT; Tzeng, YM1
Kang, MK; Lee, HJ; Park, JG1
Chuang, PH; Ho, JC; Hsieh, ML; Hsieh, VC1
Asha, VV; Isaac, R; Jiji, SG; Philip, S; Praseetha, PK; Tom, G1
Anderton, K; Anis, M; Baron, A; Bendell, J; Bentz, T; Brisendine, A; Duddalwar, V; Edwards, A; El-Khoueiry, A; Garrett-Mayer, E; Siegel, AB; Thomas, MB; Weiss, G1
Fan, ZP; Huang, F; Liu, QF; Sun, J; Wang, ZX; Xu, N; Xuan, L; Ye, JY; Zhang, Y; Zhou, X1
Borok, J; Friedlander, SF; Han, AM; Kusari, A; Valderrama, AJ1
Chen, D; Chen, X; Chen, Y; Cui, T; Kabir, N; Ma, J; Mao, J; Pan, P; Yang, H; Yang, Y1
Edeline, J; Finn, RS; Galle, PR; Kudo, M; Raoul, JL; Reig, M1
Bonani, FA; Camargo, RY; Castro, G; Coura-Filho, GB; Danilovic, DLS; Freitas, RMC; Hoff, AO; Kulcsar, MA; Marui, S; Roitberg, FSR; Vanderlei, FAB1
Bettinger, D; Fichtner-Feigl, S; Schultheiß, M; Thimme, R1
An, L; Chen, L; Dai, Z; Feng, Y; Gan, H; Gong, C; Haydon, RC; He, F; He, TC; Huang, B; Huang, S; Ji, X; Lei, J; Liu, B; Liu, F; Liu, W; Luu, HH; Shu, Y; Wang, X; Wu, K; Wu, X; Wu, Y; Yan, S; Yang, C; Yu, X; Yuan, C; Zeng, L; Zeng, Z; Zhang, B; Zhang, L; Zhang, R; Zhang, W; Zhao, C1
Choi, GH; Jang, SJ; Jung, Y; Kim, JS; Kim, KM; Lee, HC; Yu, ES1
Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S1
Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX1
Huang, K; Liu, CH; Liu, HL; Lü, J; Sun, X; Tao, YY; Zhao, ZM1
Abaza, MSI; Al-Attiyah, RJ; Bahman, AA; Khoushiash, SI1
Cai, S; Chen, L; Jiang, Z; Li, A; Liang, Y; Liu, X; Ma, D; Tang, X; Zhang, Y1
Duo, J; Ma, X; Zhao, Y; Zhu, H1
Abo, D; Inaba, Y; Kodama, Y; Matsuo, K; Nakatsuka, A; Nishiofuku, H; Okubo, H; Sato, Y; Takaki, H; Yamakado, K; Yasumoto, T1
Chen, Y; Dong, H; Liu, X; Ma, Z; Wang, L; Xia, D; Xiong, Y1
Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, SJ; Lee, JE; Lim, JH; Park, JH; Rumman, M; Yan, HH1
Abraham, IE; Dudek, AZ; Liu, LI; Schmidt, TM; Uy, AB1
Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL1
Chen, XY; Dai, XJ; Lü, BH; Wang, J; Zhang, YF; Zhong, DF1
Álvares-da-Silva, MR; de Freitas, LBR; Grivicich, I; Longo, L; Santos, D1
Gu, C; Huang, Y; Liu, S; Mai, W; Nie, Y; Wang, K; Yang, H; Yu, G; Zhao, D; Zhong, Y1
Hirai, S; Kakinoki, N; Kamoshida, T; Ochi, M; Ohkawara, A; Ohkawara, H; Yanaka, A1
Cheng, B; Du, J; Fan, Y; Li, J; Li, X; Lin, W; Ling, C; Liu, D1
Hikasa, Y; Leong, ZP1
Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T1
Hu, J; Li, L; Liu, L; Wang, E; Wang, M; Zhao, W; Zhao, Y1
Fuss, H; Jung, S; Lademann, J1
Chen, J; Chen, RX; Cui, JF; Gao, DM; Lin, XH; Liu, HH; Ma, M; Ren, ZG; Zhang, R1
Ikeda, M; Kaneko, S; Kobayashi, M; Tahara, M1
Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, DH; Kim, S; Koh, YI; Sim, DW; Yu, J1
Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A1
Beraza, N; Musso, O1
Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E1
Dehua, WU; Xiaohui, C; Xin, LI1
Baer, MR; Dezern, A; Duong, VH; Emadi, A; Gocke, C; Gojo, I; Greer, J; Jones, RJ; Karp, J; Levis, M; Pratz, KW; Rosner, G; Rudek, MA; Smith, BD; Wright, JJ; Zahurak, M1
Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O1
Ahmed, AR; Alaaeldin, E; Allam, S; Elsadek, BE; Elsayed, MM; Mostafa, ME; Sarhan, HA; Shaykoon, MS1
Abballe, L; Allegri, L; Bulotta, S; Celano, M; Damante, G; Maggisano, V; Pecce, V; Russo, D1
Li, JX; Liang, GL; Liu, X; Tang, ST; Xiang, BD1
Bruix, J; Reig, M; Sanduzzi-Zamparelli, M; Sapena, V1
Berhane, S; Johnson, PJ; Labeur, TA1
Chen, J; Duda, DG1
Aballay Soteras, G; Alvares-da-Silva, MR; Alves, R; Anders, M; Arenas, JI; Bruix, J; Chagas, AL; Coll, S; da Fonseca, LG; Delgado, M; Di Costanzo, GG; Díaz-González, Á; França, A; Gallego, A; García Juárez, I; Giannini, EG; Granito, A; Hernáez, T; Hernández-Guerra, M; Huertas, C; Iavarone, M; Ladekarl, M; Leal, C; Lledó, JL; Lozano, M; Lue, A; Marín, J; Matilla, AM; Mello, V; Menéndez, J; Mínguez, B; Nault, JC; Pascual, S; Pereira, G; Perelló, C; Piñero, F; Pinter, M; Reig, M; Rimassa, L; Rodríguez de Lope, C; Rojas, Á; Sacco, R; Sala, M; Sánchez-Torrijos, Y; Sanduzzi-Zamparelli, M; Sangro, B; Varela, M; Vergara, M; Wörns, MA1
Chao, Y; Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Huang, PH; Hung, YP; Lee, RC; Lin, ZZ; Shao, YY; Shen, YC1
Ananth, S; Arora, SP; Gelfond, J; Ketchum, N; Mahalingam, D; Michalek, J1
Cao, J; Chen, X; Du, J; He, Q; Luo, P; Ma, S; Xu, Z; Yan, H; Yang, B; Zeng, S; Zhang, X; Zhang, Y; Zhao, Z; Zhu, Y1
Hopkins, AM; Rowland, A; Ruanglertboon, W; Sorich, MJ1
Adachi, T; Aibiki, T; Hiraoka, A; Iwasaki, R; Izumoto, H; Michitaka, K; Miyata, H; Mori, K; Nagamatsu, K; Ninomiya, T; Okazaki, H; Okudaira, T; Suga, Y; Tsubouchi, E; Tsuruta, M; Yamago, H; Yoshino, T1
Fletcher, P; Kunene, V; Ma, YT; Razak, RA1
Ayuso, C; Belmonte, E; Bruix, J; Darnell, A; Díaz, A; Díaz-González, Á; Feu, F; Forner, A; Gomes da Fonseca, L; Iserte, G; Llarch, N; Reig, M; Rimola, J; Sanduzzi-Zamparelli, M; Sapena, V1
Abou-Alfa, GK; Boussayoud, C; Capanu, M; Chou, JF; Do, GK; El Dika, I; Ferrer, CS; Harding, JJ; Iyer, R; Kelley, RK; Khalil, DN; Kuhn, P; Muenkel, K; Rodriguez-Lee, M; Ruiz, C; Shia, J; Tan, B; Wilton, J; Yarmohammadi, H1
Cao, B; Chen, DT; Kim, DW; Kim, R; Machado, C; Mahipal, A; Masawi, F; Tan, E; Wang, E; Yu, J1
Aby, ES; Bane, A; Debes, JD; Sultan, A; Wondifraw, Z1
Cheng, Z; Guo, Y; He, L; Song, S; Song, Y; Zhang, L1
Deng, Y; Dong, L; Li, Y; Liu, J; Liu, TT; Shen, XZ; Sun, Y; Weng, SQ; Yu, XN; Zhang, GC; Zhu, CF; Zhu, JM1
Ayuso, C; Belmonte, E; Boix, L; Bruix, J; Brunet, M; Corominas, J; da Fonseca, LG; Darnell, A; Díaz-González, Á; Forner, A; Iserte, G; LLarch, N; Millán, O; Reig, M; Samper, E; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F1
Hendrikse, NH; Hoekstra, OS; Honeywell, RJ; Lammertsma, AA; Mammatas, LH; Meijerink, M; Menke-van der Houven van Oordt, CW; Peters, GJ; Schuit, RC; Schwarte, LA; Verheul, HMW; Yaqub, M1
Carvalhana, S; Cortez-Pinto, H; Freitas, LC; Gaio, R; Marinho, RT; Moura, M; Nogueira, PJ; Reis, D1
Bottomly, D; Damnernsawad, A; Eide, CA; Kurtz, SE; McWeeney, SK; Nechiporuk, T; Tyner, JW1
Abdelghani, MB; Audemar, F; Blanc, JF; Bourgeois, V; Bronowicki, JP; Costentin, C; Deplanque, G; Edeline, J; Faroux, R; Khemissa, F; Locher, C; Mabile-Archambeaud, I; Manfredi, S; Monterymard, C; Obled, S; Perarnau, JM; Seitz, JF; Senellart, H; Villing, AL1
Colmenero, I; Hernández-Martín, Á; Martos-Cabrera, L; Mateos-Mayo, A; Ramírez-Lluch, M; Torrelo, A1
Braghiroli, MI; da Fonseca, LG; Hoff, PM; Marta, GN; Moura, F; Sabbaga, J1
Álvarez-Navascués, C; Álvarez-Velasco, R; Cadahía, V; Carballo-Folgoso, L; Castaño-García, A; Cuevas, J; González-Diéguez, ML; Lorca, R; Martín, M; Morís, C; Rodríguez, M; Varela, M1
Kim, SH; Lee, HJ; Park, SC; Shin, NR; Son, Y1
Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L1
Abrams, TA; Ahmed, M; Alsop, DC; Bockorny, B; Bullock, AJ; Faintuch, S; Goldberg, SN; Miksad, RA1
Farias, EC; Hoff, AO1
Araki, M; Ikegami, T; Kamoshida, T; Ochi, M1
Abbas, MN; Kichenadasse, G; Tan, WS1
Hu, SH; Lien, RY; Lu, LC; Lu, SF; Tung, HH; Wu, SL1
Guan, XY; Li, GB; Ma, X; Song, C; Wang, HL; Yang, LL; Yu, YM1
Chang, ML; Chen, WT; Lee, WC; Lin, CC; Lin, CL; Lin, SM; Shen, CH; Wu, TJ; Yeh, CT1
Aldrighetti, L; Antonucci, A; Baiocchi, GL; Baroni, GS; Bernasconi, DP; Biasini, E; Campani, C; Celsa, C; Chiarelli, M; Cipriani, F; Crespi, M; Donadon, M; Famularo, S; Ferrero, A; Ferri, S; Foschi, FG; Gasbarrini, A; Giuliante, F; Grazi, GL; Griseri, G; Jovine, E; Maestri, M; Mega, A; Memeo, R; Morisco, F; Pelizzaro, F; Raimondo, G; Rapaccini, GL; Romano, F; Ruzzenente, A; Sacco, R; Torzilli, G; Trevisani, F; Valle, RD1
Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ1
Bai, M; Gong, S; Guo, T; Hao, X; Lei, C; Li, X; Si, M; Song, S; Tian, H; Yang, W1
Habiba, YH; Helmy, MW; Houssen, ME; Omran, GA1
Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S1
Maeda, S; Momoi, Y; Yokota, S; Yonezawa, T1
Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T1
Claxton, L; Eastwood, A; Hodgson, R; Sharif-Hurst, S; Wade, R; Walton, M1
Chapin, WJ; Hwang, WT; Kaplan, DE; Karasic, TB; McCarthy, AM1
Deng, WX; Huang, ST; Li, JX; Li, LQ; Liang, CF; Liang, SX; Lin, XF; Long, MY; Lu, HY; Pang, YD; Su, TS; Xiang, BD; Zhang, J; Zhou, HM1
Alunni-Fabbroni, M; Benckert, J; Chow, PKH; Gasbarrini, A; Kuhl, C; Malfertheiner, P; Öcal, E; Pech, M; Ricke, J; Sangro, B; Schinner, R; Shuen, TWH; Toh, HC; Wildgruber, M1
Fang, S; Li, X; Liu, G; Ma, Y; Yang, J; Yang, X; Zhao, B1
Kuppusamy, P; Nagalingam, A; Saxena, NK; Sharma, D; Siddharth, S; Wu, Q1
Aydin, S; Brunello, L; Busca, A; Cattel, F; Dellacasa, CM; Dogliotti, I; Giaccone, L; Passera, R; Poggiu, M; Scaldaferri, M; Zallio, F1
Guo, F; Jin, X; Meng, J; Ren, D; Sun, Y; Wu, H; Zhang, H1
Li, J; Tan, XP; Wang, SL; Xiong, BH; Zhang, YX; Zuo, Q1
Chai, MY; Chen, DX; Dou, SS; Fu, Z; Kou, BX; Liu, XN; Wei, FL1
Chen, CT; Cheng, AL; Hsu, CH; Shao, YY1
Chang, SY; Chen, YC; Hsu, CS; Peng, TR; Wu, CC; Wu, TW1
Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Pal, SK; Porta, C; Rini, B; Verzoni, E; Zengin, ZB1
Aboulwafa, MM; Helmy, OM; Taha, AM; Zedan, H1
Cheon, C; Kim, B; Kim, DB; Lee, DK; Ribeiro, RIMA1
Chen, PH; Dai, HQ; Feng, J; Hooi, SC; Liao, XW; Lu, G; Lu, GD; Lu, PZ; Peng, T; Shen, HM; Su, WJ; Wang, LM; Wu, Y; Ye, XP; Zhou, J; Zhu, GZ1
Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A1
Chen, MY; Gong, JX; Hsu, CH; Setiawan, SA; Tzeng, DTW; Tzeng, YM; Weng, PW; Wu, ATH; Yadav, VK; Yang, Z; Yeh, CT1
Chen, Y; He, K; Liu, X; Song, W; Wang, S; Yang, Y; Yang, Z1
Chen, LW; Chien, CH; Chien, RN; Hu, CC; Liang, KH; Lin, CL; Lin, YH; Yeh, CT1
Ai, H; Chen, L; Ji, X; Mi, RH; Song, YP; Wei, XD; Yin, QS1
Gudkov, SV; Khabatova, VV; Turovsky, EA; Varlamova, EG1
Augu-Denechere, D; Bonnin, N; Calattini, S; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Peron, J; Puszkiel, A; Schwiertz, V; Tartas, S; Tod, M; Varnier, R; You, B1
Augu-Denechere, D; Bonnin, N; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Péron, J; Puszkiel, A; Rousset, P; Tartas, S; Tod, M; Trillet-Lenoir, V; You, B1
Aisner, J; Cerchio, R; Chan, N; Chen, S; Ganesan, S; Goodin, S; Gounder, M; Li, J; Lin, H; Malhotra, J; Marinaro, C; Mehnert, JM; Portal, DE; Shih, W; Silk, AW; Spencer, KR; Stein, MN1
Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A1
Bi, QC; Deng, ZQ; He, YQ; Liu, Y; Lv, YF; Tang, Q; Xie, CS1
Liang, B; Lu, H; Xia, X; Zheng, C1

Reviews

686 review(s) available for niacinamide and sorafenib

ArticleYear
BAY 43-9006: early clinical data in patients with advanced solid malignancies.
    Current pharmaceutical design, 2002, Volume: 8, Issue:25

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2002
BAY 43-9006: preclinical data.
    Current pharmaceutical design, 2002, Volume: 8, Issue:25

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Disease Progression; Humans; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2002
Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5

    Topics: Adult; Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Child; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Structure; Neoplasm Proteins; Neoplasms; Niacinamide; Oligodeoxyribonucleotides, Antisense; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Thionucleotides; Xenograft Model Antitumor Assays

2002
Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:1

    Topics: Benzenesulfonates; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2003
BAY-43-9006 Bayer/Onyx.
    Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drugs, Investigational; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Technology, Pharmaceutical

2003
Raf pathway inhibitors in oncology.
    Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:12

    Topics: Animals; Benzenesulfonates; Enzyme Inhibitors; Humans; MAP Kinase Signaling System; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib

2003
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
    The Journal of endocrinology, 2004, Volume: 183, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Mutation; Niacinamide; Oncogenes; Phenylurea Compounds; Phosphotransferases; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Neoplasms

2004
Raf kinase inhibitors in oncology.
    Onkologie, 2005, Volume: 28, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib

2005
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
    Current oncology reports, 2005, Volume: 7, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2005
Raf kinase as a target for anticancer therapeutics.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Membrane Proteins; Models, Biological; Neovascularization, Pathologic; Niacinamide; Oligonucleotides, Antisense; Phenylurea Compounds; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor Receptor-2

2005
Angiogenesis and lung cancer: prognostic and therapeutic implications.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-10, Volume: 23, Issue:14

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib

2005
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
    Current opinion in pharmacology, 2005, Volume: 5, Issue:4

    Topics: Animals; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib

2005
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    The Lancet. Oncology, 2005, Volume: 6, Issue:7

    Topics: Antibodies, Blocking; Antineoplastic Agents; Benzamides; Benzenesulfonates; ErbB Receptors; Hair Diseases; Humans; Imatinib Mesylate; Nail Diseases; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Skin Diseases; Sorafenib

2005
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
    BJU international, 2005, Volume: 96, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2005
Promising systemic therapy for renal cell carcinoma.
    Current treatment options in oncology, 2005, Volume: 6, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide

2005
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
    Clinical lung cancer, 2005, Volume: 7 Suppl 1

    Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2005
Novel agents for the treatment of advanced kidney cancer.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide

2004
Raf: a strategic target for therapeutic development against cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-20, Volume: 23, Issue:27

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Down-Regulation; Drug Delivery Systems; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Biology; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; raf Kinases; Sensitivity and Specificity; Signal Transduction; Sorafenib

2005
Update on angiogenesis inhibitors.
    Current opinion in oncology, 2005, Volume: 17, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2005
Regulation of c-Raf-1: therapeutic implications.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Niacinamide; Oligodeoxyribonucleotides, Antisense; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Thionucleotides

2003
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Clinical genitourinary cancer, 2005, Volume: 4, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; ErbB Receptors; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyridines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein

2005
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Eruptions; Exanthema; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2006
Targeted therapy for metastatic renal cell carcinoma.
    British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2006
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
    Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:12

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sorafenib

2005
[Progress in therapeutic strategy for renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2006
Sorafenib.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2006
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Current oncology reports, 2006, Volume: 8, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein

2006
What's new in pancreatic cancer treatment pipeline?
    Best practice & research. Clinical gastroenterology, 2006, Volume: 20, Issue:2

    Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha

2006
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 2

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2006
Molecule of the month. Sorafenib.
    Drug news & perspectives, 2006, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib

2006
Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
    Clinical genitourinary cancer, 2006, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate; Treatment Outcome

2006
Targeting Raf-kinase: molecular rationales and translational issues.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib

2006
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5

    Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Delivery Systems; Endpoint Determination; Floxuridine; Fluorouracil; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib; Survival Analysis; Treatment Outcome

2006
Molecular targeting therapy for renal cell carcinoma.
    International journal of clinical oncology, 2006, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib

2006
Cancer targets in the Ras pathway.
    Cold Spring Harbor symposia on quantitative biology, 2005, Volume: 70

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Design; Female; Genes, ras; Humans; Male; Models, Biological; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Signal Transduction; Sorafenib

2005
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Seminars in oncology, 2006, Volume: 33, Issue:4

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Extracellular Signal-Regulated MAP Kinases; Melanoma; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Isoforms; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib

2006
Raf kinases: oncogenesis and drug discovery.
    International journal of cancer, 2006, Nov-15, Volume: 119, Issue:10

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Disease Models, Animal; Enzyme Inhibitors; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib

2006
New treatment approaches in metastatic renal cell carcinoma.
    Current opinion in urology, 2006, Volume: 16, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2006
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib

2006
Sorafenib.
    Current opinion in oncology, 2006, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2006
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
    Nature reviews. Drug discovery, 2006, Volume: 5, Issue:10

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Combinatorial Chemistry Techniques; Drug Design; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2006
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Der Urologe. Ausg. A, 2006, Volume: 45, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2006
Molecular biology of renal cell carcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Exons; Humans; Indoles; Kidney Neoplasms; Molecular Biology; Mutation; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease

2006
Protein kinases as drug targets in cancer.
    Current cancer drug targets, 2006, Volume: 6, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzenesulfonates; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Trastuzumab

2006
New weapons to snuff out kidney cancer.
    Nursing, 2006, Volume: 36, Issue:12 Pt.1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib

2006
Targeted therapy for metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-10, Volume: 24, Issue:35

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2006
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Case Management; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2006
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Forecasting; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2006
Targeting von Hippel-Lindau pathway in renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Dec-15, Volume: 12, Issue:24

    Topics: Benzenesulfonates; Biomedical Research; Carcinoma, Renal Cell; Enzyme Inhibitors; Everolimus; Humans; Indoles; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2006
Sorafenib for the treatment of advanced renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Dec-15, Volume: 12, Issue:24

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Evaluation; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration

2006
Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.
    Clinical genitourinary cancer, 2006, Volume: 5 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2006
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
    Clinical genitourinary cancer, 2006, Volume: 5 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2006
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Clinical lung cancer, 2006, Volume: 8 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors

2006
Sorafenib in renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jan-15, Volume: 13, Issue:2 Pt 2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Research Design; Sorafenib; Time Factors

2007
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Drug insight: VEGF as a therapeutic target for breast cancer.
    Nature clinical practice. Oncology, 2007, Volume: 4, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Humans; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A

2007
Sorafenib: in advanced renal cancer.
    Drugs, 2007, Volume: 67, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib

2007
[Clinical studies with sorafenib (Nexavar) in metastatic melanoma].
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2007, Volume: 5, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Treatment Outcome

2007
[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
    Der Urologe. Ausg. A, 2007, Volume: 46, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Approval; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
    BJU international, 2007, Volume: 99, Issue:5 Pt B

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Leiomyomatosis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; von Hippel-Lindau Disease

2007
Combination of target agents: challenges and opportunities.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:5 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2007
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
    Nature reviews. Cancer, 2007, Volume: 7, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab

2007
Angiogenesis in cancer: molecular mechanisms, clinical impact.
    Langenbeck's archives of surgery, 2007, Volume: 392, Issue:3

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    The oncologist, 2007, Volume: 12, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Humans; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib

2007
Design of clinical trials of radiation combined with antiangiogenic therapy.
    The oncologist, 2007, Volume: 12, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiation Dosage; raf Kinases; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Sorafenib: delivering a targeted drug to the right targets.
    Expert review of anticancer therapy, 2007, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib

2007
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
    British journal of cancer, 2007, Jun-18, Volume: 96, Issue:12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A; Wound Healing

2007
[Clinical results of Nexavar for the treatment of kidney cancer].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2007, Volume: 17, Issue:1 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2007
Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Drug Evaluation; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib

2007
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jul-01, Volume: 13, Issue:13

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2007
The effect of recent drug approvals on translational research and drug development.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomedical Research; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; United States; United States Food and Drug Administration

2007
The role of targeted therapy in metastatic renal cell carcinoma.
    TheScientificWorldJournal, 2007, Mar-02, Volume: 7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
B-Raf kinase inhibitors for cancer treatment.
    Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Enzyme Inhibitors; Humans; Imidazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib

2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Current treatment options in oncology, 2007, Volume: 8, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1

2007
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Pharmacotherapy, 2007, Volume: 27, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Growth Factor; Sorafenib; Sunitinib

2007
[Effect of angiogenesis inhibitors on renal cell carcinoma].
    Magyar onkologia, 2007, Volume: 51, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A

2007
[The hepatocellular carcinoma: alternative therapeutical strategies].
    Zentralblatt fur Chirurgie, 2007, Volume: 132, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Genetic Therapy; Humans; Immunotherapy; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Time Factors

2007
Treatment options in renal cell carcinoma: past, present and future.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytokines; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2007
[Oral drugs inhibiting the VEGF pathway].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
[Angiogenesis and renal cell carcinoma].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors

2007
[Cutaneous side effects of antiangiogenic agents].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Pyridines; Pyrroles; Skin Diseases; Sorafenib; Sunitinib

2007
Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
    Onkologie, 2007, Volume: 30, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
    Expert review of anticancer therapy, 2007, Volume: 7, Issue:9

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2007
[Promising new treatment options for metastatic androgen-independent prostate cancer].
    Actas urologicas espanolas, 2007, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides

2007
Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Doxorubicin; Ethanol; Humans; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2007
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    BioEssays : news and reviews in molecular, cellular and developmental biology, 2007, Volume: 29, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2007, Volume: 12 Suppl 1

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome

2007
Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Clinical journal of oncology nursing, 2007, Volume: 11, Issue:5

    Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Drug Delivery Systems; Drug Eruptions; Drug Interactions; Drug Monitoring; Fatigue; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Compliance; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Risk Factors; Social Support; Sorafenib; Survival Rate; Treatment Outcome

2007
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
    Bulletin du cancer, 2007, Volume: 94, Issue:10

    Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2007
[Angiogenesis targeting in renal carcinomas].
    Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib

2007
New developments in multitargeted therapy for patients with solid tumours.
    Cancer treatment reviews, 2008, Volume: 34, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2008
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Drug Interactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
[Renal cell carcinoma and antiangiogenic therapies].
    Presse medicale (Paris, France : 1983), 2008, Volume: 37, Issue:4 Pt 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
    European urology, 2008, Volume: 53, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib

2008
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
    The oncologist, 2007, Volume: 12, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib

2007
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
    Clinical and experimental medicine, 2007, Volume: 7, Issue:4

    Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jan-15, Volume: 65, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Sorafenib: in hepatocellular carcinoma.
    Drugs, 2008, Volume: 68, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Doxorubicin; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2008
Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.
    Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thalidomide

2008
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions; Foot; Hand; Humans; Incidence; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Risk Factors; Skin; Skin Diseases; Sorafenib

2008
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
    The Lancet. Oncology, 2008, Volume: 9, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Incidence; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib

2008
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles

2008
[Molecular targeted therapy for renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 2008, Volume: 54, Issue:1

    Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Interferon-beta; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Liposomes; Mitochondrial Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2008
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
    Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1

    Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib

2007
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Current medicinal chemistry, 2008, Volume: 15, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab

2008
Novel advancements in the management of hepatocellular carcinoma in 2008.
    Journal of hepatology, 2008, Volume: 48 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Ethanol; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry.
    Toxicologic pathology, 2008, Volume: 36, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Drug Monitoring; Flow Cytometry; Gene Targeting; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
[Cutaneous side effects of sorafenib and sunitinib].
    Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:2

    Topics: Acrodermatitis; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hair Diseases; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib

2008
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Annales de dermatologie et de venereologie, 2008, Volume: Spec No 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2008
Chemotherapeutic agents and the skin: An update.
    Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids

2008
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
    The oncologist, 2008, Volume: 13, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Benzenesulfonates; Bevacizumab; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib

2008
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    Nederlands tijdschrift voor geneeskunde, 2008, Feb-16, Volume: 152, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2008
Mcl-1: a gateway to TRAIL sensitization.
    Cancer research, 2008, Apr-01, Volume: 68, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand

2008
Renal cell carcinoma.
    Current opinion in oncology, 2008, Volume: 20, Issue:3

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mutation; Niacinamide; Nomograms; Phenylurea Compounds; Prognosis; Pyridines; Sirolimus; Sorafenib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease

2008
Treatment options for metastatic renal cell carcinoma: a review.
    The Canadian journal of urology, 2008, Volume: 15, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Graft vs Host Disease; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2008
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
    Reviews on recent clinical trials, 2007, Volume: 2, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome

2007
[Lung cancer].
    Medizinische Klinik (Munich, Germany : 1983), 2008, May-15, Volume: 103, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib

2008
Early clinical studies of novel therapies for thyroid cancers.
    Endocrinology and metabolism clinics of North America, 2008, Volume: 37, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms

2008
Targeted therapy in advanced non-small-cell lung cancer.
    Seminars in respiratory and critical care medicine, 2008, Volume: 29, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2008
Sorafenib in lung cancer: clinical developments and future directions.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Forecasting; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factors

2008
K-ras as a target for lung cancer therapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2

    Topics: Benzamides; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sensitivity and Specificity; Sorafenib; Survival Analysis; Treatment Outcome

2008
[Oncology 2008].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate

2008
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
[Value of targeted therapies for renal cell cancer].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2008
Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
    Oncology nursing forum, 2008, Volume: 35, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Diffusion of Innovation; Humans; Incidence; Indoles; Interferon-alpha; Interleukin-2; Molecular Biology; Neoplasm Staging; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Rare Diseases; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2008
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Onkologie, 2008, Volume: 31, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Science; Skin Neoplasms; Sorafenib; Treatment Outcome

2008
An update on the medical therapy of advanced metastatic renal cell carcinoma.
    Scandinavian journal of urology and nephrology, 2008, Volume: 42, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Severity of Illness Index; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2008
Sorafenib (BAY 43-9006): review of clinical development.
    Current clinical pharmacology, 2006, Volume: 1, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Design; Drug Therapy, Combination; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib

2006
Targeted therapy in renal cell carcinoma.
    Current opinion in urology, 2008, Volume: 18, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
New therapies in renal cell carcinoma.
    Current opinion in supportive and palliative care, 2007, Volume: 1, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
    The oncologist, 2008, Volume: 13, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
Contemporary management of hepatocellular carcinoma.
    Clinical medicine (London, England), 2008, Volume: 8, Issue:4

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Hepatectomy; Humans; Iodine Radioisotopes; Iodized Oil; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Yttrium Radioisotopes

2008
[Molecular basis of targeted therapy in metastatic renal cancer].
    Der Pathologe, 2008, Volume: 29 Suppl 2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    The oncologist, 2008, Volume: 13, Issue:9

    Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2008
[Molecular targeted therapy for renal cell carcinoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Gene Targeting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein

2008
Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Cancer treatment reviews, 2008, Volume: 34, Issue:8

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2008
Novel drugs for renal cell carcinoma.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2008
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Alimentary pharmacology & therapeutics, 2008, Dec-01, Volume: 28, Issue:11-12

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Survival Rate

2008
Molecular targeted therapies in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib

2008
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:15

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2008
Medical therapies to extend survival in hepatocellular carcinoma.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:8

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate

2008
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
    The oncologist, 2008, Volume: 13, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recombinant Proteins; Sirolimus; Sorafenib; Sunitinib

2008
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
    Magyar onkologia, 2008, Volume: 52, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones

2008
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:10

    Topics: Animals; Benzenesulfonates; Drug Screening Assays, Antitumor; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2008
Vascular complications of selected cancer therapies.
    Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases

2008
Systemic therapy of hepatocellular carcinoma: are we making progress?
    Advances in therapy, 2008, Volume: 25, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Estrogens; Humans; Injections, Intravenous; Interferons; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Tretinoin

2008
Systemic therapy for metastatic renal cell carcinoma.
    The Urologic clinics of North America, 2008, Volume: 35, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytotoxins; Disease-Free Survival; Drug Therapy, Combination; Everolimus; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Stem Cell Transplantation; Sunitinib; TOR Serine-Threonine Kinases; Transplantation, Homologous

2008
Molecular therapy for the treatment of hepatocellular carcinoma.
    British journal of cancer, 2009, Jan-13, Volume: 100, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib

2009
Evolution of systemic therapy of advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2008, Nov-14, Volume: 14, Issue:42

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Somatostatin; Sorafenib; Thalidomide; Treatment Outcome

2008
Potential role of sorafenib in the treatment of acute myeloid leukemia.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:12

    Topics: Benzenesulfonates; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib

2008
Management of advanced hepatocellular carcinoma in the era of targeted therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Drug Delivery Systems; Epidermal Growth Factor; Humans; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Signal Transduction; Sorafenib

2009
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    The oncologist, 2009, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration

2009
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Zeitschrift fur Gastroenterologie, 2009, Volume: 47, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
    BMC cancer, 2009, Jan-27, Volume: 9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib

2009
Multimodal approaches to the treatment of hepatocellular carcinoma.
    Nature clinical practice. Gastroenterology & hepatology, 2009, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Ethanol; Humans; Injections; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Pyridines; Radiotherapy, Adjuvant; Salvage Therapy; Sorafenib; Waiting Lists

2009
New drugs for the treatment of hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; ErbB Receptors; Humans; Mitogen-Activated Protein Kinase 1; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Growth Factor; Signal Transduction; Sorafenib

2009
Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Drugs, 2009, Volume: 69, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2009
Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
[Targeted therapies and their indications in solid neoplasias].
    La Revue de medecine interne, 2009, Volume: 30, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
    Minerva gastroenterologica e dietologica, 2009, Volume: 55, Issue:2

    Topics: Algorithms; alpha-Fetoproteins; Anti-Infective Agents, Local; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Drug Therapy, Combination; Embolization, Therapeutic; Ethanol; Evidence-Based Medicine; Global Health; Hepatectomy; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Survival Rate; Texas; Treatment Outcome

2009
Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
    The Netherlands journal of medicine, 2009, Volume: 67, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Pharmacotherapy, 2009, Volume: 29, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Thyroid Function Tests; Treatment Outcome

2009
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
    Expert opinion on therapeutic targets, 2009, Volume: 13, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Embryonic Development; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Proteins; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sorafenib

2009
Targeting angiogenesis in bladder cancer.
    Current oncology reports, 2009, Volume: 11, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A

2009
Targeted therapies in metastatic renal cancer in 2009.
    BJU international, 2009, Volume: 103, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors

2009
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
    Biochimica et biophysica acta, 2009, Volume: 1795, Issue:2

    Topics: Benzenesulfonates; Biopsy, Needle; Humans; Isoquinolines; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Neoplasms

2009
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Clinical lung cancer, 2009, Volume: 10 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2009
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Targeted oncology, 2009, Volume: 4, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
    Current cardiology reports, 2009, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab

2009
Pathogenesis of hepatocellular carcinoma and molecular therapies.
    Current opinion in gastroenterology, 2009, Volume: 25, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Signal Transduction; Sorafenib

2009
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
    Cancer, 2009, May-15, Volume: 115, Issue:10 Suppl

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2009
Selection of patients with hepatocellular carcinoma for sorafenib.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2009, Volume: 7, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2009
Prognostic markers and new, innovative treatments in renal cell carcinoma.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2009, Volume: 20, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
Renal toxicity of targeted therapies.
    Targeted oncology, 2009, Volume: 4, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
[The treatment of hepatocellular carcinoma. New developments].
    Nederlands tijdschrift voor geneeskunde, 2009, Apr-04, Volume: 153, Issue:14

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome

2009
Sorafenib tosylate in advanced kidney cancer: past, present and future.
    Anti-cancer drugs, 2009, Volume: 20, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
BRAF signaling and targeted therapies in melanoma.
    Hematology/oncology clinics of North America, 2009, Volume: 23, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drugs, Investigational; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Humans; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2009
Angiogenesis regulated by VEGF and its receptors and its clinical application.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Current opinion in supportive and palliative care, 2009, Volume: 3, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
    Nature reviews. Urology, 2009, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib

2009
The role of antiangiogenesis therapy: bevacizumab and beyond.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
[Sorafenib(Nexavar)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
[Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Proliferation; Humans; Liver Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib

2009
Current management of hepatocellular carcinoma.
    The Medical clinics of North America, 2009, Volume: 93, Issue:4

    Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease Progression; Hepatectomy; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2009
Adverse effects of anticancer agents that target the VEGF pathway.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Brain Diseases; Capillary Leak Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Forecasting; Gastrointestinal Diseases; Hemorrhage; Humans; Indoles; Kidney Diseases; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing

2009
[Interferon alpha and half-dose sorafenib is an effective treatment modality for interferon alpha-resistant metastatic renal cell carcinoma: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2009, Volume: 55, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Targeted therapies in the treatment of advanced/metastatic NSCLC.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:14

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2009
VEGF inhibitors and prostate cancer therapy.
    Current molecular pharmacology, 2009, Volume: 2, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Quinazolines; Signal Transduction; Sorafenib; Thalidomide; Vascular Endothelial Growth Factors

2009
Sorafenib and sunitinib.
    The oncologist, 2009, Volume: 14, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Interactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
    Cancer treatment reviews, 2009, Volume: 35, Issue:8

    Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2009
Clinical pharmacokinetics of tyrosine kinase inhibitors.
    Cancer treatment reviews, 2009, Volume: 35, Issue:8

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution

2009
An overview of small-molecule inhibitors of VEGFR signaling.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cadherins; Clinical Trials, Phase III as Topic; Extracellular Matrix Proteins; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; National Cancer Institute (U.S.); Neoplasms; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Structure-Activity Relationship; Sunitinib; Transcription Factors; United States

2009
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    The Lancet. Oncology, 2009, Volume: 10, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Hemorrhage; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Sunitinib

2009
Molecular targeting for treatment of advanced hepatocellular carcinoma.
    The Korean journal of hepatology, 2009, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib

2009
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
    Cancer science, 2010, Volume: 101, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A

2010
Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
    Journal of hepato-biliary-pancreatic sciences, 2010, Volume: 17, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; United States

2010
[Molecular targeted drugs in the developmental stage: 2) Various molecular targets and therapeutic agents under investigation].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Aug-10, Volume: 98, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Resistance; ErbB Receptors; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factors

2009
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Oncology, 2009, Volume: 77, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Paresthesia; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Syndrome

2009
Review article: the management of hepatocellular carcinoma.
    Alimentary pharmacology & therapeutics, 2010, Feb-15, Volume: 31, Issue:4

    Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Eruptions; Female; Health Care Costs; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult

2010
Tyrosine kinase inhibitors and the thyroid.
    Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:6

    Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms

2009
Metastatic renal cell carcinoma: current standards of care.
    Clinical journal of oncology nursing, 2009, Volume: 13 Suppl

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
    Clinical journal of oncology nursing, 2009, Volume: 13 Suppl

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Drug Eruptions; Drug Monitoring; Fatigue; Humans; Indoles; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2009
Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
    Cancer investigation, 2010, Volume: 28, Issue:5

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Heart Diseases; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stroke Volume

2010
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Anti-cancer drugs, 2010, Volume: 21, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Diarrhea; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Syndrome; Treatment Outcome

2010
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
Compounds in clinical Phase III and beyond.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 180

    Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2010
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
    Annual review of medicine, 2010, Volume: 61

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Diagnostic Techniques; Niacinamide; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Sorafenib

2010
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
    Current opinion in hematology, 2010, Volume: 17, Issue:2

    Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine

2010
Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-15, Volume: 16, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Sorafenib.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 184

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2010
Toxicity of sorafenib: clinical and molecular aspects.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:2

    Topics: Animals; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Exanthema; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib

2010
Progress in the management of advanced renal cell carcinoma (RCC).
    Aktuelle Urologie, 2010, Volume: 41 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2010
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-01, Volume: 16, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Humans; MAP Kinase Signaling System; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2

2010
Targeted molecular therapies in thyroid carcinoma.
    Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:9

    Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms

2009
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    The oncologist, 2010, Volume: 15, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Cardiovascular Diseases; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2010
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
    Onkologie, 2010, Volume: 33 Suppl 1

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drugs, Investigational; Everolimus; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2010
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Chemotherapy, Adjuvant; Humans; Indoles; Neoadjuvant Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing

2010
Current strategy for staging and treatment: the BCLC update and future prospects.
    Seminars in liver disease, 2010, Volume: 30, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Forecasting; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Spain; Survival Analysis; Treatment Outcome

2010
Update on systemic therapies of metastatic renal cell carcinoma.
    World journal of urology, 2010, Volume: 28, Issue:3

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biopsy, Needle; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Everolimus; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sirolimus; Sorafenib; Sunitinib; Survival Analysis

2010
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
    Gastroenterologie clinique et biologique, 2010, Volume: 34, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
Raf inhibitors as therapeutic agents against neurodegenerative diseases.
    CNS & neurological disorders drug targets, 2010, Volume: 9, Issue:1

    Topics: Animals; Benzenesulfonates; Brain; Disease Models, Animal; Drug Design; Encephalitis; Humans; Inflammation Mediators; Neurodegenerative Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib

2010
Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension.
    Advances in experimental medicine and biology, 2010, Volume: 661

    Topics: Animals; Benzenesulfonates; Calmodulin-Binding Proteins; Gene Expression; Gene Expression Profiling; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Microarray Analysis; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib

2010
[Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib

2010
BRAF as therapeutic target in melanoma.
    Biochemical pharmacology, 2010, Sep-01, Volume: 80, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib

2010
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Humans; Incidence; Indoles; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism

2010
Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Expert opinion on investigational drugs, 2010, Volume: 19, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Novel inhibitors in development for hepatocellular carcinoma.
    Expert opinion on investigational drugs, 2010, Volume: 19, Issue:5

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drugs, Investigational; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib

2010
Antiangiogenesis agents in colorectal cancer.
    Current opinion in oncology, 2010, Volume: 22, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2010
Molecular therapy of pancreatic cancer.
    Minerva endocrinologica, 2010, Volume: 35, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A

2010
Experience with sorafenib and adverse event management.
    Critical reviews in oncology/hematology, 2011, Volume: 78, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypertension; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib

2011
[Treatment of locally advanced renal tumors].
    Actas urologicas espanolas, 2010, Volume: 34, Issue:2

    Topics: Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2010
Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Annals of surgical oncology, 2010, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2010
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2010
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
    Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sorafenib; Sunitinib

2010
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
    Journal of gastrointestinal cancer, 2010, Volume: 41, Issue:4

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Treatment of metastatic renal cell carcinoma.
    Nature reviews. Urology, 2010, Volume: 7, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib

2010
Clinical overview of sorafenib in breast cancer.
    Future oncology (London, England), 2010, Volume: 6, Issue:5

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib

2010
The hand-foot-syndrome associated with medical tumor therapy - classification and management.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010, Volume: 8, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2010
[Antiangionic drugs in soft tissue sarcoma].
    Bulletin du cancer, 2010, Volume: 97, Issue:6

    Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2010
[Focus on GIST management].
    Bulletin du cancer, 2010, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2010
In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.
    Current cancer drug targets, 2010, Volume: 10, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Docetaxel; Drug Interactions; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Taxoids

2010
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
    Orvosi hetilap, 2010, Jun-06, Volume: 151, Issue:23

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Developed Countries; Developing Countries; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Iron; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Neoplasms; Metabolic Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Smoking; Sorafenib

2010
Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity.
    Onkologie, 2010, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Male; Niacinamide; Peritoneal Neoplasms; Peritoneum; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Young Adult

2010
Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Humans; Liver Neoplasms; Models, Economic; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Survival Analysis; Treatment Outcome; United Kingdom

2010
[Anti-angiogenic drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Hypoxia-Inducible Factor 1; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2010
[Current therapy for hepatocellular carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Embolization, Therapeutic; Hepatic Artery; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2010
The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42 Suppl 3

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis

2010
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
    The oncologist, 2010, Volume: 15, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cardiovascular Diseases; Female; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2010
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
    Expert review of anticancer therapy, 2010, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
    Journal of gastroenterology, 2010, Volume: 45, Issue:8

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2010
Sorafenib: where do we go from here?
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:1

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; TOR Serine-Threonine Kinases

2010
Sorafenib: a clinical and pharmacologic review.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:11

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Child; Clinical Trials as Topic; Drug Approval; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; United States; United States Food and Drug Administration

2010
Hepatocellular carcinoma--what's new?
    Journal of visceral surgery, 2010, Volume: 147, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Metabolic Syndrome; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sorafenib; Treatment Outcome

2010
Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Oncology, 2010, Volume: 78 Suppl 1

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Treatment Outcome

2010
Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
    Oncology, 2010, Volume: 78 Suppl 1

    Topics: Algorithms; Asia; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2010
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2010, Volume: 61, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Structure-Activity Relationship; Sunitinib

2010
Present state of target therapy for disseminated renal cell carcinoma.
    Immunotherapy, 2010, Volume: 2, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
Tumor-stromal cell interactions and opportunities for therapeutic intervention.
    Current opinion in pharmacology, 2010, Volume: 10, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cell Communication; Endothelial Cells; Fibroblasts; Humans; Mesenchymal Stem Cells; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Stromal Cells

2010
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:13

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2010
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
    Dermatology (Basel, Switzerland), 2010, Volume: 221, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib

2010
Angiogenesis as a therapeutic target in urothelial carcinoma.
    Anti-cancer drugs, 2010, Volume: 21, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Matrix Metalloproteinases; Neoadjuvant Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays

2010
[Nonsurgical management of hepatocellular carcinoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2010, Volume: 14, Issue:6-7

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Radiotherapy, Conformal; Sorafenib; Yttrium Radioisotopes

2010
[Treatment of primary hepatocellular carcinoma].
    Orvosi hetilap, 2010, Sep-05, Volume: 151, Issue:36

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Internationality; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib

2010
Novel therapies for hypereosinophilic syndromes.
    The Netherlands journal of medicine, 2010, Volume: 68, Issue:1

    Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bone Marrow Transplantation; CD52 Antigen; Glycoproteins; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Interleukin-5; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib

2010
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
    Cancer treatment reviews, 2011, Volume: 37, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2011
Sorafenib in hepatocellular carcinoma.
    British journal of hospital medicine (London, England : 2005), 2010, Volume: 71, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2010
Developing better treatments in hepatocellular carcinoma.
    Expert review of gastroenterology & hepatology, 2010, Volume: 4, Issue:5

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Research Design; Sorafenib; Treatment Outcome

2010
[Multimodality treatment for hepatocellular carcinoma].
    Der Internist, 2010, Volume: 51, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Cooperative Behavior; Ethanol; Hepatectomy; Humans; Injections, Intralesional; Interdisciplinary Communication; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sorafenib; Survival Rate

2010
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Orvosi hetilap, 2010, Oct-24, Volume: 151, Issue:43

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins

2010
[Hepatocellular carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2010
[Molecular targeted therapy for renal cell carcinoma and other urological cancers].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Urologic Neoplasms

2010
Sorafenib: rays of hope in thyroid cancer.
    Thyroid : official journal of the American Thyroid Association, 2010, Volume: 20, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interactions; Humans; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms

2010
Inherited hepatocellular carcinoma.
    Best practice & research. Clinical gastroenterology, 2010, Volume: 24, Issue:5

    Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Genetic Predisposition to Disease; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Population Surveillance; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome; United States

2010
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis

2010
[Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Syndrome

2010
Antiangiogenic therapy for breast cancer.
    Breast cancer research : BCR, 2010, Volume: 12, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
    BJU international, 2011, Volume: 107, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Designer Drugs; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient-Centered Care; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome

2011
Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
    The Israel Medical Association journal : IMAJ, 2010, Volume: 12, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
    The oncologist, 2010, Volume: 15 Suppl 4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Standard of Care; Treatment Outcome

2010
The therapy of kidney cancer with biomolecular drugs.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indazoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases

2010
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab

2011
Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
    Angiogenesis, 2011, Volume: 14, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Endoscopy; Female; Humans; Indoles; Intestinal Perforation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib

2011
In pursuit of new anti-angiogenic therapies for cancer treatment.
    Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment

2011
Targeting EGFR in bilio-pancreatic and liver carcinoma.
    Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib

2011
Therapeutic advances in women's cancers.
    Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cetuximab; ErbB Receptors; Female; Genital Neoplasms, Female; Humans; Indoles; Intestinal Perforation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
Novel molecular therapies in hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor, IGF Type 1; Receptors, Platelet-Derived Growth Factor; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors

2011
Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
    International journal of clinical practice, 2011, Volume: 65, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Epidermal Growth Factor; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2011
[Sorafenib and radiotherapy association for hepatocellular carcinoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2011, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2011
Assessment of the treatment response of HCC.
    Abdominal imaging, 2011, Volume: 36, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Contrast Media; Ethanol; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Yttrium Radioisotopes

2011
Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.
    Radiology, 2011, Volume: 258, Issue:3

    Topics: Adenoma, Liver Cell; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cytogenetic Analysis; Focal Nodular Hyperplasia; Genetic Association Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed

2011
Sorafenib-associated hand-foot syndrome in Japanese patients.
    The Journal of dermatology, 2011, Volume: 38, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Foot Dermatoses; Hand Dermatoses; Humans; Japan; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Syndrome

2011
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
    The oncologist, 2011, Volume: 16 Suppl 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2011
Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
    The oncologist, 2011, Volume: 16 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2011
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
    The oncologist, 2011, Volume: 16 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
Sorafenib for advanced hepatocellular carcinoma: a systematic review.
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2011, Volume: 33, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
    Endocrine journal, 2011, Volume: 58, Issue:3

    Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms

2011
Sorafenib-induced premalignant and malignant skin lesions.
    International journal of dermatology, 2011, Volume: 50, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Niacinamide; Phenylurea Compounds; Precancerous Conditions; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib

2011
Sorafenib in renal cell carcinoma.
    Critical reviews in oncology/hematology, 2011, Volume: 80, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib

2011
[Sorafenib in combination with chemotherapy in the induction therapy for FLT3-ITD positive acute monocytic leukemia: a case report and literature review].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Monocytic, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
[Novelties in the treatment for advanced renal-cell cancer].
    Orvosi hetilap, 2011, Apr-24, Volume: 152, Issue:17

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
    Clinical and experimental nephrology, 2011, Volume: 15, Issue:3

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2011
[Treatment of metastatic renal cell carcinoma].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2011, Volume: 21, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2011
[Hepatocellular carcinoma].
    Nihon Geka Gakkai zasshi, 2011, Volume: 112, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Meta-analysis of dermatological toxicities associated with sorafenib.
    Clinical and experimental dermatology, 2011, Volume: 36, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Skin Diseases; Sorafenib

2011
Classic biphasic pulmonary blastoma: a case report and review of the literature.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Fatal Outcome; Humans; Intestinal Perforation; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pulmonary Blastoma; Pyridines; Sorafenib

2011
Novel molecular targeted therapies for refractory thyroid cancer.
    Head & neck, 2012, Volume: 34, Issue:5

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Sorafenib for HCC: a pragmatic perspective.
    Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
    Anti-cancer agents in medicinal chemistry, 2011, Volume: 11, Issue:6

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Signal Transduction; Sorafenib

2011
Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Gland; Vascular Endothelial Growth Factors

2011
[Indications and current development of new targeted therapies in pediatric oncology].
    Bulletin du cancer, 2011, Volume: 98, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases

2011
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2011
t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature.
    Leukemia research, 2011, Volume: 35, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Diagnosis, Differential; Humans; Myeloproliferative Disorders; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcr; Pyridines; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Translocation, Genetic

2011
Targeting angiogenesis in esophagogastric adenocarcinoma.
    The oncologist, 2011, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2012, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Diarrhea; Drug Eruptions; Europe; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Molecular Targeted Therapy; Mucositis; Niacinamide; Nursing Assessment; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Societies, Nursing; Sorafenib

2012
Targeted-therapy and imaging response: a new paradigm for clinical evaluation?
    Reviews on recent clinical trials, 2011, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2011
[Sorafenib in the treatment of hepatocellular carcinoma].
    Vnitrni lekarstvi, 2011, Volume: 57, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Clinical therapeutics, 2011, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib

2011
Sorafenib for the management of advanced renal cell carcinoma.
    Expert review of anticancer therapy, 2011, Volume: 11, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
[Targeting the RAS signalling pathway in cancer].
    Bulletin du cancer, 2011, Volume: 98, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib

2011
[Progression of sorafenib in the treatment of acute myeloid leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Hematology/oncology clinics of North America, 2011, Volume: 25, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A

2011
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
    Hematology/oncology clinics of North America, 2011, Volume: 25, Issue:4

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2011
Targeted drug therapies and cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 185

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
    Digestive diseases (Basel, Switzerland), 2011, Volume: 29, Issue:3

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib

2011
Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Digestive diseases (Basel, Switzerland), 2011, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Role of BRAF in thyroid oncogenesis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24

    Topics: Benzenesulfonates; Cell Transformation, Neoplastic; Genetic Predisposition to Disease; Humans; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Treatment Outcome

2011
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
    Bulletin du cancer, 2011, Volume: 98, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib

2011
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
    Medical molecular morphology, 2011, Volume: 44, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2011
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway

2011
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Epidemiologic Methods; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Young Adult

2011
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
    Critical reviews in oncology/hematology, 2012, Volume: 82, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease Management; Exanthema; Humans; Keratoacanthoma; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Pyridines; Severity of Illness Index; Skin; Sorafenib

2012
[Systemic treatment of renal cell carcinoma - recent update].
    Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:15-16

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib

2011
[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].
    Actas urologicas espanolas, 2012, Volume: 36, Issue:2

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyridines; Radiation Tolerance; Sorafenib; Von Hippel-Lindau Tumor Suppressor Protein

2012
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Antibiotics, Antineoplastic; Benzenesulfonates; Carcinoma, Hepatocellular; Doxorubicin; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Clinical experience with antiangiogenic therapy in leukemia.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
[Dermatologic side effects induced by new angiogenesis inhibitors].
    Bulletin du cancer, 2011, Volume: 98, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib

2011
The two faces of FBW7 in cancer drug resistance.
    BioEssays : news and reviews in molecular, cellular and developmental biology, 2011, Volume: 33, Issue:11

    Topics: Amyloid Precursor Protein Secretases; Apoptosis; Benzenesulfonates; Biphenyl Compounds; Cell Cycle Proteins; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MAP Kinase Signaling System; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Niacinamide; Nitrophenols; Paclitaxel; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Sulfonamides; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Ubiquitination; Vincristine

2011
Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.
    The oncologist, 2011, Volume: 16, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Female; Hand-Foot Syndrome; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Diagnostic and prognostic molecular markers in hepatocellular carcinoma.
    Disease markers, 2011, Volume: 31, Issue:3

    Topics: alpha-Fetoproteins; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Survival Rate; Tumor Microenvironment

2011
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
    Expert review of anticancer therapy, 2011, Volume: 11, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Management; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Drug and therapeutics bulletin, 2011, Volume: 49, Issue:11

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2011
Anti-angiogenic therapy: concept to clinic.
    Microcirculation (New York, N.Y. : 1994), 2012, Volume: 19, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2012
[Myocardial metastasis from renal cell carcinoma treated with sorafenib].
    Hinyokika kiyo. Acta urologica Japonica, 2011, Volume: 57, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
    Critical reviews in oncology/hematology, 2012, Volume: 83, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Delivery Systems; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2011, Volume: 31, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
    Medical molecular morphology, 2011, Volume: 44, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Sorafenib

2011
Signaling pathways in hepatocellular carcinoma.
    Oncology, 2011, Volume: 81 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factors

2011
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
    Oncology, 2011, Volume: 81 Suppl 1

    Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib

2011
Radiotherapeutic strategies in the management of hepatocellular carcinoma.
    Oncology, 2011, Volume: 81 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2011
Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
    Current medicinal chemistry, 2012, Volume: 19, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Discovery; Humans; Inhibitory Concentration 50; Liver Neoplasms; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
    Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2

    Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing

2012
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
    Clinical and experimental immunology, 2012, Volume: 167, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment

2012
[Hepatocellular carcinoma: what's new?].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:5

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diagnostic Imaging; Gene Expression Profiling; Humans; Immunosuppressive Agents; Liver Function Tests; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sirolimus; Sorafenib; Survival Rate; Treatment Outcome

2012
Sorafenib for the treatment of renal cancer.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:3

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Evidence-Based Medicine; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Time Factors; Treatment Outcome

2012
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-10, Volume: 30, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib

2012
Targeted therapy for biliary tract cancers.
    Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Gallbladder Neoplasms; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Panitumumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2012
Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
    Oncology reports, 2012, Volume: 27, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Humans; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Targeted therapeutic strategies for the management of renal cell carcinoma.
    Current opinion in oncology, 2012, Volume: 24, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Tuberous Sclerosis; United States

2012
Hepatocellular carcinoma.
    Lancet (London, England), 2012, Mar-31, Volume: 379, Issue:9822

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Ultrasonography

2012
Using NF-κB as a molecular target for theranostics in radiation oncology research.
    Expert review of molecular diagnostics, 2012, Volume: 12, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Radiation Oncology; Radiation Tolerance; Signal Transduction; Sorafenib

2012
Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
    World journal of gastroenterology, 2012, Feb-28, Volume: 18, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib

2012
Sorafenib in melanoma.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:4

    Topics: Animals; Benzenesulfonates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib

2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
    Magyar onkologia, 2012, Volume: 56, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib

2012
Advanced HCC: emerging molecular therapies.
    Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:1

    Topics: Antibodies, Monoclonal; Benzenesulfonates; California; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Evidence-Based Medicine; Global Health; Hepatectomy; Humans; Incidence; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome

2012
Management of hepatocellular carcinoma: beyond sorafenib.
    Current oncology reports, 2012, Volume: 14, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2012
Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:5

    Topics: Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Chemoembolization, Therapeutic; Hand-Foot Syndrome; Hepatitis, Viral, Human; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib; Treatment Outcome

2012
Molecular targeted therapy in acute myeloid leukemia.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine

2012
Sorafenib in liver cancer.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Combining antiangiogenics to overcome resistance: rationale and clinical experience.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A

2012
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
    Der Urologe. Ausg. A, 2012, Volume: 51, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides

2012
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
    Leukemia, 2012, Volume: 26, Issue:10

    Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine

2012
Sorafenib in locally advanced or metastatic breast cancer.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles

2012
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vena Cava, Inferior

2012
Sorafenib in non-small cell lung cancer.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:9

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Cardiac side effects of anticancer treatments: new mechanistic insights.
    Current heart failure reports, 2012, Volume: 9, Issue:3

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab

2012
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Oncology, 2012, Volume: 83, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2012
[Treatment of advanced hepatocellular carcinoma].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib

2012
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2012
[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2012
Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.
    Clinical drug investigation, 2012, Aug-08, Volume: 32 Suppl 2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Humans; Japan; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors

2012
Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.
    Clinical drug investigation, 2012, Aug-08, Volume: 32 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®).
    Clinical drug investigation, 2012, Aug-08, Volume: 32 Suppl 2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Japan; Liver Neoplasms; Medication Adherence; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors

2012
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles

2012
Hypothyroidism during treatment with tyrosine kinase inhibitors.
    Endokrynologia Polska, 2012, Volume: 63, Issue:4

    Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms

2012
State of the art of the therapeutic perspective of sorafenib against hematological malignancies.
    Current medicinal chemistry, 2012, Volume: 19, Issue:28

    Topics: Apoptosis; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Receptors, Vascular Endothelial Growth Factor; Sorafenib; TNF-Related Apoptosis-Inducing Ligand

2012
Targeted agents and systemic therapy in hepatocellular carcinoma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 190

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A

2013
Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management.
    Zeitschrift fur Gastroenterologie, 2012, Volume: 50, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2012
Impact of restricting access to high-cost medications for hepatocellular carcinoma.
    Expert review of pharmacoeconomics & outcomes research, 2012, Volume: 12, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Drug Costs; Health Services Accessibility; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; United Kingdom

2012
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
    Current pharmaceutical design, 2013, Volume: 19, Issue:5

    Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib

2013
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Current topics in medicinal chemistry, 2012, Volume: 12, Issue:15

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2012
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Nihon Jinzo Gakkai shi, 2012, Volume: 54, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2012
Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
    Transplant international : official journal of the European Society for Organ Transplantation, 2013, Volume: 26, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome

2013
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
    Magyar onkologia, 2012, Volume: 56, Issue:3

    Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2012
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluation; Everolimus; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome

2013
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2012, Volume: 11, Issue:5

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2012
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
    Anti-cancer drugs, 2013, Volume: 24, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Blood Pressure; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult

2013
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Incidence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib

2013
Extrahepatic spread of hepatocellular carcinoma.
    Panminerva medica, 2012, Volume: 54, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib

2012
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
    Nature reviews. Gastroenterology & hepatology, 2013, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Evidence-Based Medicine; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Precision Medicine; Sorafenib

2013
Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.
    Urology, 2013, Volume: 81, Issue:1

    Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Burden

2013
Pathways and targets in hepatocellular carcinoma.
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:10

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib

2012
[Advances in the study of structural modifications of multi-target anticancer drug sorafenib].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2012, Volume: 47, Issue:9

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship

2012
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Treatment Outcome; Young Adult

2013
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:3

    Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    American journal of clinical oncology, 2014, Volume: 37, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2

2014
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
    Seminars in liver disease, 2012, Volume: 32, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2012
Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:6

    Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Salvage Therapy; Sorafenib; Survival Rate; Treatment Outcome

2013
Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
    Oncology, 2013, Volume: 84 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Drug Carriers; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Yttrium Radioisotopes

2013
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2013, Volume: 39, Issue:7

    Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib

2013
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
    Anti-cancer drugs, 2013, Volume: 24, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid

2013
Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.
    Journal of hepatology, 2013, Volume: 59, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Discovery; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Treatment Failure

2013
Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Journal of vascular and interventional radiology : JVIR, 2013, Volume: 24, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome

2013
Novel therapies for children with acute myeloid leukaemia.
    Leukemia, 2013, Volume: 27, Issue:7

    Topics: Adenine Nucleotides; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Child; Clofarabine; Gemtuzumab; Humans; Immunotoxins; Leukemia, Monocytic, Acute; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2013
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
    Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles

2013
[Current status of molecular targeted therapies in hepatocellular carcinoma].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2013, Mar-25, Volume: 61, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Wnt Proteins

2013
Antiangiogenic therapies for advanced hepatocellular carcinoma.
    The oncologist, 2013, Volume: 18, Issue:4

    Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Fibroblast Growth Factors; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A

2013
Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Humans; Hypertension; Hypokinesia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib; Survival

2013
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
    Journal of human hypertension, 2013, Volume: 27, Issue:10

    Topics: Antineoplastic Agents; Blood Pressure; Chi-Square Distribution; Drug Administration Schedule; Humans; Hypertension; Incidence; Molecular Targeted Therapy; Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Severity of Illness Index; Sorafenib; Time Factors

2013
Sorafenib for ovarian cancer.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:8

    Topics: Animals; Antineoplastic Agents; Female; Humans; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2013
Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?
    Current opinion in oncology, 2013, Volume: 25, Issue:4

    Topics: Biological Products; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
    International urology and nephrology, 2013, Volume: 45, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Fatal Outcome; Humans; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Rare Diseases; Risk Assessment; Sorafenib; Tomography, X-Ray Computed

2013
Intermediate hepatocellular carcinoma: current treatments and future perspectives.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24 Suppl 2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2013
Sorafenib: from literature to clinical practice.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24 Suppl 2

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Evidence-Based Medicine; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Time Factors; Translational Research, Biomedical; Treatment Outcome

2013
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.
    Journal of hematology & oncology, 2013, Jun-11, Volume: 6

    Topics: Aged; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib

2013
Body composition in chemotherapy: the promising role of CT scans.
    Current opinion in clinical nutrition and metabolic care, 2013, Volume: 16, Issue:5

    Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed

2013
Sorafenib and thyroid cancer.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013, Volume: 27, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays

2013
A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:14

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Treatment Outcome

2013
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:8

    Topics: Antineoplastic Agents; Body Composition; Body Mass Index; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Niacinamide; Nutritional Status; Nutritional Support; Phenylurea Compounds; Sorafenib

2013
[Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:36

    Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Therapy, Computer-Assisted

2013
Molecular markers to predict response to therapy.
    Seminars in oncology, 2013, Volume: 40, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein

2013
Targeted therapies in hepatocellular carcinoma.
    Current medicinal chemistry, 2014, Volume: 21, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; ErbB Receptors; Humans; Liver; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2014
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:11

    Topics: Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides

2013
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
    Seminars in respiratory and critical care medicine, 2013, Volume: 34, Issue:5

    Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A

2013
Endometrial adult/progenitor stem cells: pathogenetic theory and new antiangiogenic approach for endometriosis therapy.
    Reproductive sciences (Thousand Oaks, Calif.), 2014, Volume: 21, Issue:3

    Topics: Adult; Adult Stem Cells; Angiogenesis Inhibitors; Animals; Endometriosis; Endometrium; Female; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Met as a therapeutic target in HCC: facts and hopes.
    Journal of hepatology, 2014, Volume: 60, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Models, Biological; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib

2014
Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
    Cancer treatment reviews, 2014, Volume: 40, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2014
Hepatocellular carcinoma: options for diagnosing and managing a deadly disease.
    Cleveland Clinic journal of medicine, 2013, Volume: 80, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Population Surveillance; Risk Factors; Sorafenib

2013
Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.
    Drugs & aging, 2013, Volume: 30, Issue:11

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    International journal of cancer, 2014, Aug-15, Volume: 135, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting

2014
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2013, Volume: 48, Issue:7

    Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2013
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
    Cancer biology & therapy, 2014, Volume: 15, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment

2014
[Medical treatment of renal cell carcinoma].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:15

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Sirolimus; Societies, Medical; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2013
Advanced kidney cancer: treating the elderly.
    Expert review of anticancer therapy, 2013, Volume: 13, Issue:12

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2013
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
    Expert review of anticancer therapy, 2013, Volume: 13, Issue:12

    Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Endocrine-related cancer, 2014, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms

2014
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
    Expert review of hematology, 2014, Volume: 7, Issue:2

    Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous

2014
Axitinib for the treatment of advanced renal cell carcinoma.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:2

    Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Rate

2014
Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?
    Current urology reports, 2014, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2014
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
    Annales d'endocrinologie, 2013, Volume: 74 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome

2013
Sorafenib in renal cell carcinoma.
    Pakistan journal of pharmaceutical sciences, 2014, Volume: 27, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2014
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2014, Volume: 20, Issue:3

    Topics: Antineoplastic Agents; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Glucocorticoids; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; IMP Dehydrogenase; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2014
Risk of treatment-related mortality with sorafenib in patients with cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 14, Issue:11

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Survival Rate

2014
New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma.
    Cancer letters, 2014, May-01, Volume: 346, Issue:2

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Sorafenib

2014
Novel therapeutic strategies for fibrotic lung disease: a review with a focus on epithelial-mesenchymal transition.
    Recent patents on inflammation & allergy drug discovery, 2014, Volume: 8, Issue:1

    Topics: Airway Remodeling; Animals; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Inflammation Mediators; Lung; Lung Diseases; Myofibroblasts; Niacinamide; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Respiratory Mucosa; Sorafenib; Stromal Cells; Transforming Growth Factor beta

2014
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    International journal of cancer, 2015, Jan-01, Volume: 136, Issue:1

    Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib

2015
Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.
    Critical reviews in oncology/hematology, 2014, Volume: 91, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2014
[Therapeutic effect of sorafenib on portal hypertension: research progress and mechanisms].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2014, Volume: 34, Issue:1

    Topics: Animals; Humans; Hypertension, Portal; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Hepatocellular carcinoma: clinical frontiers and perspectives.
    Gut, 2014, Volume: 63, Issue:5

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Decision Support Techniques; Embolization, Therapeutic; Genome-Wide Association Study; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib

2014
Sorafenib in metastatic thyroid cancer: a systematic review.
    The oncologist, 2014, Volume: 19, Issue:3

    Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms

2014
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
    Journal of clinical hypertension (Greenwich, Conn.), 2014, Volume: 16, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy; Humans; Hypertension; Incidence; Kidney Neoplasms; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome

2014
Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma.
    Klinicheskaia laboratornaia diagnostika, 2013, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib

2013
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
    British journal of cancer, 2014, Aug-12, Volume: 111, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Activation; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Multimerization; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; Vemurafenib

2014
Newer treatments for advanced hepatocellular carcinoma.
    The Korean journal of internal medicine, 2014, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiopharmaceuticals; Signal Transduction; Sorafenib; Treatment Outcome

2014
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors

2014
Emerging therapeutic targets for synovial sarcoma.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:7

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases

2014
Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:6

    Topics: Alopecia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; Hand-Foot Syndrome; Humans; Incidence; Mucositis; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk; Sorafenib

2014
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progression; Epithelial-Mesenchymal Transition; Female; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome

2014
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:5

    Topics: Antineoplastic Agents; Case Management; Drug Interactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Assessment; Sorafenib

2014
Systemic therapy of hepatocellular carcinoma: current status and future perspectives.
    World journal of gastroenterology, 2014, Mar-28, Volume: 20, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Evidence-Based Medicine; Glypicans; Hormones; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Medical Oncology; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2014
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:7

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine

2014
Sorafenib: targeting multiple tyrosine kinases in cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2014, Volume: 201

    Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2014
Hepatocellular carcinoma review: current treatment, and evidence-based medicine.
    World journal of gastroenterology, 2014, Apr-21, Volume: 20, Issue:15

    Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Evidence-Based Medicine; Humans; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Treatment Outcome

2014
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.
    World journal of gastroenterology, 2014, Apr-21, Volume: 20, Issue:15

    Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Hepatic Artery; Humans; Liver Neoplasms; Medical Oncology; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
    Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:10

    Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2014
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome

2014
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    Angiogenesis, 2014, Volume: 17, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2014
Sorafenib use in the transplant setting.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2014, Volume: 20, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Treatment Outcome

2014
Advances in managing hepatocellular carcinoma.
    Frontiers of medicine, 2014, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
    Cancer cell, 2014, May-12, Volume: 25, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Amplification; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Macrophages; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Development of molecular targeted drugs for advanced thyroid cancer in Japan.
    Endocrine journal, 2014, Volume: 61, Issue:9

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms

2014
Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Sorafenib (Nexavar) for thyroid cancer.
    The Medical letter on drugs and therapeutics, 2014, May-26, Volume: 56, Issue:1443

    Topics: Animals; Antineoplastic Agents; Dermatitis, Exfoliative; Humans; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms

2014
Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?
    La Radiologia medica, 2014, Volume: 119, Issue:7

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Embolization, Therapeutic; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Microspheres; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiography, Interventional; Sorafenib; Survival Rate

2014
The preclinical development of regorafenib for the treatment of colorectal cancer.
    Expert opinion on drug discovery, 2014, Volume: 9, Issue:9

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2014
Treating advanced hepatocellular carcinoma: How to get out of first gear.
    Cancer, 2014, Oct-15, Volume: 120, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2014
Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Aged; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors

2014
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2014
Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:14

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2014
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Human pathology, 2014, Volume: 45, Issue:9

    Topics: Acute Kidney Injury; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Retrospective Studies; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A

2014
Treatment of intermediate-stage hepatocellular carcinoma.
    Nature reviews. Clinical oncology, 2014, Volume: 11, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes

2014
Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Molecular biology reports, 2014, Volume: 41, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Publication Bias; Sorafenib; Treatment Outcome

2014
Management of hepatocellular carcinoma.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:5

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Hepatitis B; Hepatitis C; Hepatitis, Viral, Human; Humans; Incidence; Liver Neoplasms; Mass Screening; Niacinamide; Palliative Care; Phenylurea Compounds; Population Surveillance; Quality of Life; Sorafenib; Viral Hepatitis Vaccines

2015
Hepatocellular carcinoma.
    Wiener medizinische Wochenschrift (1946), 2014, Volume: 164, Issue:21-22

    Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib

2014
The evolving field of kinase inhibitors in thyroid cancer.
    Critical reviews in oncology/hematology, 2015, Volume: 93, Issue:1

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms

2015
Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.
    Nature reviews. Gastroenterology & hepatology, 2014, Volume: 11, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2014
A short update on cancer chemoresistance.
    Wiener medizinische Wochenschrift (1946), 2014, Volume: 164, Issue:21-22

    Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Resistance, Neoplasm; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; MicroRNAs; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2014
Systemic treatment.
    Best practice & research. Clinical gastroenterology, 2014, Volume: 28, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Humans; Indazoles; Indoles; Ipilimumab; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment

2014
Refining sorafenib therapy: lessons from clinical practice.
    Future oncology (London, England), 2015, Volume: 11, Issue:3

    Topics: Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retreatment; Sorafenib; Treatment Outcome

2015
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A

2015
Comparing comparators: a look at control arms in kidney cancer studies over the years.
    British journal of cancer, 2015, Jan-06, Volume: 112, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Sorafenib

2015
Adjuvant therapy for hepatocellular carcinoma after curative treatment.
    Digestive diseases (Basel, Switzerland), 2014, Volume: 32, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome

2014
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
    World journal of gastroenterology, 2014, Nov-07, Volume: 20, Issue:41

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Down-Regulation; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Treatment Outcome

2014
Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
    Future oncology (London, England), 2014, Volume: 10, Issue:12

    Topics: Antineoplastic Agents; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib

2014
Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.
    Biomedical chromatography : BMC, 2015, Volume: 29, Issue:6

    Topics: Animals; Chromatography, Liquid; Humans; Indoles; Mass Spectrometry; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2

2015
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.
    Oncology, 2014, Volume: 87 Suppl 1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Health Care Surveys; Hepatic Artery; Humans; Japan; Liver Function Tests; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Predictive Value of Tests; Sorafenib; Treatment Failure

2014
Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
    Oncology, 2014, Volume: 87 Suppl 1

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Precursors; Prothrombin; Radiotherapy, Adjuvant; Republic of Korea; Sorafenib; Treatment Outcome

2014
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Patient Safety; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome

2014
Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:6

    Topics: Antineoplastic Agents; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2015
Managing localized unresectable hepatocellular carcinoma.
    JAAPA : official journal of the American Academy of Physician Assistants, 2015, Volume: 28, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Early Detection of Cancer; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib

2015
The adverse effects of sorafenib in patients with advanced cancers.
    Basic & clinical pharmacology & toxicology, 2015, Volume: 116, Issue:3

    Topics: Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
New therapeutic strategy for hepatocellular carcinoma by molecular targeting agents via inhibition of cellular stress defense mechanisms.
    Journal of UOEH, 2014, Dec-01, Volume: 36, Issue:4

    Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cytoprotection; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Keratins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; Proteasome Inhibitors; Sorafenib; Unfolded Protein Response

2014
Treatment of hepatocellular carcinoma: beyond international guidelines.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Guidelines as Topic; Humans; Internationality; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib

2015
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drugs, Investigational; Humans; Liver Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Failure

2015
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials.
    Oncology, 2015, Volume: 88, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome

2015
Sorafenib for the treatment of thyroid cancer: an updated review.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Disease-Free Survival; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms

2015
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
    The oncologist, 2015, Volume: 20, Issue:2

    Topics: Disease-Free Survival; Humans; Indoles; Iodine Radioisotopes; MAP Kinase Kinase Kinase 1; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Thyroid Neoplasms

2015
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate

2015
Is Notch Signaling a Specific Target in Hepatocellular Carcinoma?
    Anti-cancer agents in medicinal chemistry, 2015, Volume: 15, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Doxorubicin; Gene Knockdown Techniques; Genetic Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Receptors, Notch; Signal Transduction; Sorafenib; Valproic Acid

2015
Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
    European journal of medical research, 2015, Feb-04, Volume: 20

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
The discovery and development of sorafenib for the treatment of thyroid cancer.
    Expert opinion on drug discovery, 2015, Volume: 10, Issue:4

    Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Drug Approval; Drug Design; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms

2015
Peri-operative use of sorafenib in liver transplantation: a time-to-event meta-analysis.
    World journal of gastroenterology, 2015, Feb-07, Volume: 21, Issue:5

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Chi-Square Distribution; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2015
Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.
    Cancer biology & therapy, 2015, Volume: 16, Issue:2

    Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Imidazoles; Indazoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome

2015
[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome

2014
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
    Targeted oncology, 2015, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms

2015
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
    Expert opinion on drug metabolism & toxicology, 2015, Volume: 11, Issue:5

    Topics: Animals; Antineoplastic Agents; Biological Transport; Glucuronides; Glucuronosyltransferase; Humans; Liver; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Tissue Distribution

2015
A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Approval; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Safety; Sorafenib

2015
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
    European journal of clinical investigation, 2015, Volume: 45, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinogenesis; Carcinoma, Hepatocellular; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Monomeric GTP-Binding Proteins; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; ras GTPase-Activating Proteins; ras Proteins; Rats; Sorafenib; Tumor Suppressor Proteins

2015
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
    Future oncology (London, England), 2015, Volume: 11, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Sorafenib; Thymus Neoplasms; TOR Serine-Threonine Kinases; Young Adult

2015
Management of hepatocellular carcinoma with portal vein thrombosis.
    World journal of gastroenterology, 2015, Mar-28, Volume: 21, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contraindications; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Portal Vein; Practice Guidelines as Topic; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Treatment Outcome; Venous Thrombosis

2015
[Sorafenib in combination with chemotherapy as induction therapy for FLT3-ITD positive acute myeloid leukemia:nine cases report and literatures review].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:3

    Topics: Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.
    World journal of surgical oncology, 2015, Apr-09, Volume: 13

    Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib

2015
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:3

    Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib

2015
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
    Expert review of gastroenterology & hepatology, 2015, Volume: 9, Issue:7

    Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides

2015
Systemic therapy of hepatocellular carcinoma: current and promising.
    Clinics in liver disease, 2015, Volume: 19, Issue:2

    Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines

2015
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
    Anti-cancer drugs, 2015, Volume: 26, Issue:7

    Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Treatment Failure

2015
Liquid biopsy in liver cancer.
    Discovery medicine, 2015, Volume: 19, Issue:105

    Topics: Alleles; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; DNA, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2015
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.
    The British journal of radiology, 2015, Volume: 88, Issue:1052

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Diffusion of Innovation; Embolization, Therapeutic; Female; Forecasting; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Niacinamide; Patient Selection; Phenylurea Compounds; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes

2015
CDK8 kinase--An emerging target in targeted cancer therapy.
    Biochimica et biophysica acta, 2015, Volume: 1854, Issue:10 Pt B

    Topics: Cyclin-Dependent Kinase 8; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Transcription, Genetic

2015
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.
    International journal of radiation oncology, biology, physics, 2015, Jul-01, Volume: 92, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Gastrointestinal Tract; Humans; Intestine, Small; Neoplasms; Neovascularization, Pathologic; Niacinamide; Organs at Risk; Phenylurea Compounds; Radiosurgery; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A

2015
Targeted therapies in advanced differentiated thyroid cancer.
    Cancer treatment reviews, 2015, Volume: 41, Issue:8

    Topics: Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Quinolines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Neoplasms

2015
Novel drugs in clinical development for hepatocellular carcinoma.
    Expert opinion on investigational drugs, 2015, Volume: 24, Issue:8

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Aggressive thyroid cancer: targeted therapy with sorafenib.
    Minerva endocrinologica, 2017, Volume: 42, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Mas; Sorafenib; Thyroid Neoplasms

2017
[Advanced hepatocellular carcinoma: importance of clinical trials].
    Revue medicale suisse, 2015, May-20, Volume: 11, Issue:475

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib

2015
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:2

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Venous Thrombosis

2015
Sorafenib: 10 years after the first pivotal trial.
    Future oncology (London, England), 2015, Volume: 11, Issue:13

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms

2015
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
    Cancer letters, 2015, Oct-10, Volume: 367, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Microenvironment

2015
Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
    International journal of clinical pharmacy, 2015, Volume: 37, Issue:6

    Topics: Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib

2015
New molecular therapies for hepatocellular carcinoma.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39 Suppl 1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Fibroblast Growth Factors; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sorafenib; Transforming Growth Factor beta

2015
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
    Expert opinion on therapeutic targets, 2015, Volume: 19, Issue:12

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; DNA Methylation; Drug Design; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment

2015
[Kinase inhibitors and their resistance].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib

2015
[Anti-angiogenesis and molecular targeted therapies].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2015
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2015
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Korea; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Safety; Sorafenib; Treatment Outcome

2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
    Targeted oncology, 2015, Volume: 10, Issue:3

    Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A

2015
Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Sorafenib

2015
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
    World journal of gastroenterology, 2015, Sep-28, Volume: 21, Issue:36

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Treatment Outcome

2015
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
    World journal of gastroenterology, 2015, Oct-07, Volume: 21, Issue:37

    Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Interleukin-6; Liver Neoplasms; Membrane Glycoproteins; Microtubule-Associated Proteins; Neoplasm Recurrence, Local; Niacinamide; Nuclear Proteins; Oncogenes; Phenylurea Compounds; Prognosis; Receptors, Immunologic; Sirtuin 1; Sorafenib; Trans-Activators; Transcription Factors; Treatment Outcome; Triggering Receptor Expressed on Myeloid Cells-1

2015
Congenital extrahepatic portosystemic shunt complicated by the development of hepatocellular carcinoma.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2015, Volume: 14, Issue:5

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Vascular Malformations

2015
Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.
    Cancer letters, 2016, Jan-01, Volume: 370, Issue:1

    Topics: Bevacizumab; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
    Medical science monitor : international medical journal of experimental and clinical research, 2015, Oct-18, Volume: 21

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Observational Studies as Topic; Phenylurea Compounds; Polymorphism, Genetic; Prognosis; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult

2015
Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:18

    Topics: Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Microenvironment

2015
Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
    World journal of gastroenterology, 2015, Oct-21, Volume: 21, Issue:39

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reoperation; Risk Factors; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome

2015
Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
    Journal of cancer research and therapeutics, 2015, Volume: 11 Suppl 2

    Topics: Antineoplastic Agents; Female; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Publication Bias; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2015
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
    Aktuelle Urologie, 2015, Volume: 46, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis

2015
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
    World journal of gastroenterology, 2015, Nov-14, Volume: 21, Issue:42

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Treatment Outcome

2015
Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
    Future oncology (London, England), 2016, Volume: 12, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib

2016
Clinical management of metastatic kidney cancer: the role of new molecular drugs.
    Future oncology (London, England), 2016, Volume: 12, Issue:1

    Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2016
Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
    Current drug targets, 2016, Volume: 17, Issue:7

    Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Genetic Predisposition to Disease; Humans; Liver Neoplasms; Male; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome

2016
Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
    Clinical and experimental dermatology, 2016, Volume: 41, Issue:4

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Psoriasis; Sorafenib

2016
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome

2016
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2016, Volume: 28, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A

2016
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2015, Volume: 159, Issue:4

    Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage; Drug Interactions; fms-Like Tyrosine Kinase 3; Genes, abl; Guanidines; Heme Oxygenase-1; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Osmolar Concentration; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfones; Tumor Hypoxia; Up-Regulation

2015
Treatment of hepatocellular carcinoma: beyond international guidelines.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Societies, Medical; Sorafenib; Survival Rate; Treatment Outcome

2016
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.
    World journal of gastroenterology, 2016, Jan-07, Volume: 22, Issue:1

    Topics: ADAM17 Protein; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Sorafenib; Venous Thrombosis

2016
Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2016
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
    Critical reviews in oncology/hematology, 2016, Volume: 99

    Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib

2016
Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    Annales d'endocrinologie, 2015, Volume: 76, Issue:1 Suppl 1

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Treatment Failure

2015
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
    Bulletin du cancer, 2016, Volume: 103, Issue:3

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2016
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
    Expert review of molecular diagnostics, 2016, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Gene Expression; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2016
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
    JAMA oncology, 2016, Volume: 2, Issue:4

    Topics: Antineoplastic Agents; Carcinoma; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms

2016
Antiangiogenic therapy in oncology: current status and future directions.
    Lancet (London, England), 2016, Jul-30, Volume: 388, Issue:10043

    Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2016
Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
    Hepatology international, 2016, Volume: 10, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
    Immunotherapy, 2016, Volume: 8, Issue:3

    Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Differentiation; Dendritic Cells; Humans; Immunosuppression Therapy; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Microenvironment

2016
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Anti-cancer drugs, 2016, Volume: 27, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2016
[New molecular target therapy for thyroid neoplasms and malignant melanomas].
    Nihon Jibiinkoka Gakkai kaiho, 2015, Volume: 118, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib

2015
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sorafenib; Survival Analysis; Treatment Outcome

2016
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    The Cochrane database of systematic reviews, 2016, Feb-16, Volume: 2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Embolization, Therapeutic; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Yttrium Radioisotopes

2016
Radiation recall dermatitis induced by sorafenib : A case study and review of the literature.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2016, Volume: 192, Issue:5

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiodermatitis; Radiotherapy, Conformal; Sorafenib; Treatment Outcome

2016
The role and mechanism of autophagy in sorafenib targeted cancer therapy.
    Critical reviews in oncology/hematology, 2016, Volume: 100

    Topics: Animals; Autophagy; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2016
Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
    Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Sorafenib

2016
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
    Urologic oncology, 2016, Volume: 34, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Forecasting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2016
Sorafenib for the treatment of multiple myeloma.
    Expert opinion on investigational drugs, 2016, Volume: 25, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferation; Humans; Lenalidomide; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thalidomide

2016
Selective use of sorafenib in the treatment of thyroid cancer.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Antineoplastic Agents; Cell Proliferation; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms

2016
The use of genetic alterations in the development of liver cancer drugs.
    Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:12

    Topics: Animals; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Liver Neoplasms; Mutation; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate

2015
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
    Der Urologe. Ausg. A, 2016, Volume: 55, Issue:5

    Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib

2016
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2016
Cutaneous manifestations in leukemia patients.
    Seminars in oncology, 2016, Volume: 43, Issue:3

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomycoses; Etoposide; Humans; Leukemia; Mastocytosis; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Skin Diseases, Bacterial; Skin Neoplasms; Sorafenib

2016
Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018, Volume: 16, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Feasibility Studies; Female; France; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Preliminary Data; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2018
Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy.
    Cancer research, 2016, 08-15, Volume: 76, Issue:16

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Neoplasms; Niacinamide; Phenylurea Compounds; Research Design; Sorafenib

2016
Systemic therapy in metastatic renal cell carcinoma.
    World journal of urology, 2017, Volume: 35, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2017
Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Clinics and research in hepatology and gastroenterology, 2016, Volume: 40, Issue:6

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib

2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
    World journal of urology, 2017, Volume: 35, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms

2017
Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
    Clinical journal of gastroenterology, 2016, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Immunotherapy; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib

2016
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2016, Volume: 27

    Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids

2016
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
    World journal of gastroenterology, 2016, Jul-21, Volume: 22, Issue:27

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Discovery; ErbB Receptors; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factors

2016
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
    Expert review of anticancer therapy, 2016, Volume: 16, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Design; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Selection; Phenylurea Compounds; Randomized Controlled Trials as Topic; Research Design; Sorafenib

2016
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:14

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2016
Targeted Therapy for Hepatocellular Carcinoma.
    Seminars in radiation oncology, 2016, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Cancer treatment reviews, 2016, Volume: 50

    Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein

2016
Challenges of advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2016, Sep-14, Volume: 22, Issue:34

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver; Liver Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Thrombosis

2016
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
    Expert review of anticancer therapy, 2016, Volume: 16, Issue:12

    Topics: Antineoplastic Agents; Humans; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome

2016
Neoadjuvant Therapy in Differentiated Thyroid Cancer.
    International journal of surgical oncology, 2016, Volume: 2016

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Humans; Indazoles; Japan; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Slovenia; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome

2016
Hepatocellular carcinoma in patients with HIV.
    Current opinion in HIV and AIDS, 2017, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Coinfection; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Mass Screening; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 02-01, Volume: 28, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Risk; Sorafenib

2017
Binding kinetics in drug discovery - A current perspective.
    Frontiers in bioscience (Landmark edition), 2017, 01-01, Volume: 22, Issue:1

    Topics: Animals; Drug Discovery; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Ligands; Molecular Conformation; Niacinamide; Oligopeptides; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Structure-Activity Relationship

2017
New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib

2017
Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Humans; Liver Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2017
Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.
    Medicine, 2016, Volume: 95, Issue:49

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Ramucirumab; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome

2016
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    European urology, 2017, Volume: 71, Issue:3

    Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2017
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Feb-20, Volume: 35, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib

2017
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
    Cancer treatment reviews, 2017, Volume: 53

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; CTLA-4 Antigen; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Radiosurgery; Sorafenib

2017
Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.
    Cancer treatment reviews, 2017, Volume: 53

    Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Treatment Outcome

2017
Kinase Inhibitors in Multitargeted Cancer Therapy.
    Current medicinal chemistry, 2017, Volume: 24, Issue:16

    Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2017
Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Oncotarget, 2017, Mar-21, Volume: 8, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2017
Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 88

    Topics: Animals; Cellular Microenvironment; Humans; Liver; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2017
Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Acta medica Indonesiana, 2016, Volume: 48, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2016
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
    Oncology, 2017, Volume: 92 Suppl 1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Membrane Transport Proteins; Niacinamide; Nivolumab; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Sorafenib

2017
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.
    PLoS biology, 2017, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Confidence Intervals; Humans; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Survival Analysis

2017
Recent advances in hepatocellular carcinoma therapy.
    Pharmacology & therapeutics, 2017, Volume: 173

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2017
Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Oncotarget, 2017, Apr-25, Volume: 8, Issue:17

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:3

    Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult

2017
Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
    BMC gastroenterology, 2017, Feb-14, Volume: 17, Issue:1

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2017
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
    International journal of molecular sciences, 2017, Feb-21, Volume: 18, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Management; Drug Resistance, Neoplasm; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2017
Renal cell carcinoma.
    Nature reviews. Disease primers, 2017, Mar-09, Volume: 3

    Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2017
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
    The Cochrane database of systematic reviews, 2017, Mar-10, Volume: 3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Severity of Illness Index; Sorafenib

2017
Sorafenib: A Review in Hepatocellular Carcinoma.
    Targeted oncology, 2017, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Sorafenib for the treatment of breast cancer.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome

2017
New knowledge of the mechanisms of sorafenib resistance in liver cancer.
    Acta pharmacologica Sinica, 2017, Volume: 38, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2017
PharmGKB summary: sorafenib pathways.
    Pharmacogenetics and genomics, 2017, Volume: 27, Issue:6

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Gene Regulatory Networks; Humans; Neoplasms; Niacinamide; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenylurea Compounds; Sorafenib

2017
Tivantinib for the treatment of hepatocellular carcinoma.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Sorafenib

2017
Update on Embolization Therapies for Hepatocellular Carcinoma.
    Current oncology reports, 2017, Volume: 19, Issue:6

    Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes

2017
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
    Current drug targets, 2017, Volume: 18, Issue:10

    Topics: Angiogenesis Inhibitors; Bevacizumab; Clinical Trials as Topic; Female; Humans; Indazoles; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Analysis; Treatment Outcome

2017
Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
    Current cancer drug targets, 2017, Volume: 17, Issue:8

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
    Current medicinal chemistry, 2017, Volume: 24, Issue:28

    Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Jaw Diseases; Niacinamide; Osteonecrosis; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib

2017
Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
    Expert opinion on emerging drugs, 2017, Volume: 22, Issue:2

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Design; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Receptors, Growth Factor; Sorafenib; Survival Rate

2017
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.
    Mediators of inflammation, 2017, Volume: 2017

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Niacinamide; Oncolytic Virotherapy; Oncolytic Viruses; Phenylurea Compounds; Sorafenib

2017
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Cancer, 2017, 06-01, Volume: 123, Issue:S11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2017
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017, Volume: 37

    Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolines; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2017
Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Expert review of anticancer therapy, 2017, Volume: 17, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate

2017
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
    Digestion, 2017, Volume: 96, Issue:1

    Topics: Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proton Therapy; Radiosurgery; Radiotherapy; Sorafenib; Survival Rate; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes

2017
Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
    Future oncology (London, England), 2017, Volume: 13, Issue:21

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Treatment Failure; Treatment Outcome

2017
Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
    Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Humans; Models, Biological; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate

2017
Bridging to liver transplantation in HCC patients.
    Langenbeck's archives of surgery, 2017, Volume: 402, Issue:6

    Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Preoperative Care; Risk Assessment; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Waiting Lists

2017
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:15

    Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Patient Selection; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib

2017
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
    Expert review of gastroenterology & hepatology, 2018, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Risk Factors; Sorafenib; Treatment Outcome

2018
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    PloS one, 2017, Volume: 12, Issue:9

    Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Nivolumab; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Retreatment; Sorafenib; Treatment Outcome

2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Urologic oncology, 2017, Volume: 35, Issue:11

    Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib

2017
Which patient with thyroid cancer deserves systemic therapy and when?
    Best practice & research. Clinical endocrinology & metabolism, 2017, Volume: 31, Issue:3

    Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Failure

2017
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
    Best practice & research. Clinical endocrinology & metabolism, 2017, Volume: 31, Issue:3

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Failure

2017
Angiogenesis Inhibitors in NSCLC.
    International journal of molecular sciences, 2017, Sep-21, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids

2017
Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
    Expert review of anticancer therapy, 2017, Volume: 17, Issue:12

    Topics: Adult; Antineoplastic Agents; Disease Progression; Female; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed

2017
New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.
    Biochimica et biophysica acta. Reviews on cancer, 2017, Volume: 1868, Issue:2

    Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Humans; Liver Neoplasms; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib

2017
A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.
    Bioscience reports, 2017, Dec-22, Volume: 37, Issue:6

    Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2017
Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
    BMC cancer, 2017, Nov-06, Volume: 17, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome

2017
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 44, Issue:2

    Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
    Oncology, 2017, Volume: 93 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib

2017
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
    Cancer treatment reviews, 2018, Volume: 68

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib

2018
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    BMC gastroenterology, 2018, Sep-04, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors

2018
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
    Expert opinion on drug safety, 2018, Volume: 17, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate

2018
Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.
    Medicine, 2018, Volume: 97, Issue:42

    Topics: Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Heart Atria; Heart Neoplasms; Humans; Killer Cells, Natural; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Remission Induction; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tumor Burden

2018
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
    Future oncology (London, England), 2019, Volume: 15, Issue:22

    Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2019
The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis.
    World journal of surgical oncology, 2020, Sep-11, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome

2020
A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
    World journal of surgical oncology, 2021, Jun-10, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome

2021
Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
    Expert review of molecular diagnostics, 2022, Volume: 22, Issue:3

    Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2022
Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery.
    Nutrients, 2022, Oct-12, Volume: 14, Issue:20

    Topics: Antineoplastic Agents; Biological Products; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Discovery; Humans; Liver Neoplasms; Medicine, Traditional; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2022

Trials

573 trial(s) available for niacinamide and sorafenib

ArticleYear
ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.
    International journal of clinical pharmacology and therapeutics, 2002, Volume: 40, Issue:12

    Topics: Administration, Oral; Adolescent; Adult; Aged; Benzenesulfonates; Biomarkers; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2002
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.
    International journal of clinical pharmacology and therapeutics, 2002, Volume: 40, Issue:12

    Topics: Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans; Maximum Tolerated Dose; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2002
Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters?
    International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12

    Topics: Benzenesulfonates; Biomarkers; Blotting, Western; Circadian Rhythm; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; Pyridines; Signal Transduction; Sorafenib

2003
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
    International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Benzenesulfonates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2003
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
    International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Benzenesulfonates; Doxorubicin; Humans; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2003
Kinase inhibition with BAY 43-9006 in renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 2

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Enzyme Inhibitors; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed

2004
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
    International journal of clinical pharmacology and therapeutics, 2004, Volume: 42, Issue:11

    Topics: Adult; Area Under Curve; Benzenesulfonates; Diarrhea; Drug Administration Schedule; Exanthema; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2004
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
    International journal of clinical pharmacology and therapeutics, 2004, Volume: 42, Issue:11

    Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Area Under Curve; Benzenesulfonates; Cholangiocarcinoma; Doxorubicin; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2004
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Colonic Neoplasms; Diarrhea; Extracellular Signal-Regulated MAP Kinases; Fatigue; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Safety; Sorafenib

2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
    British journal of cancer, 2005, May-23, Volume: 92, Issue:10

    Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2005
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:10

    Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2005
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Time Factors

2005
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Colorectal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Sorafenib

2005
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-01, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib

2006
Mechanisms of hypertension associated with BAY 43-9006.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-20, Volume: 24, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2006
Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
    Cytometry. Part B, Clinical cytometry, 2006, Volume: 70, Issue:3

    Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; Benzenesulfonates; CD13 Antigens; CD3 Complex; Drug Monitoring; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Hemolysis; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MAP Kinase Signaling System; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Sorafenib; Stem Cell Factor; Stem Cells; Tetradecanoylphorbol Acetate

2006
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib

2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
    British journal of cancer, 2006, Sep-04, Volume: 95, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; DNA Primers; Female; Genes, ras; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Proto-Oncogene Proteins B-raf; Pyridines; Safety; Sorafenib

2006
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-10, Volume: 24, Issue:26

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyridines; RNA, Neoplasm; Sorafenib; Survival Analysis; Treatment Outcome

2006
Randomized discontinuation trial of sorafenib (BAY 43-9006).
    Cancer biology & therapy, 2006, Volume: 5, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind Method; Drug Administration Schedule; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Reproducibility of Results; Research Design; Sorafenib; Treatment Outcome

2006
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2007
Sorafenib in advanced clear-cell renal-cell carcinoma.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2007
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-15, Volume: 13, Issue:6

    Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Immune System; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Treatment Outcome

2007
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome

2006
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-01, Volume: 13, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib

2007
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
    American journal of clinical oncology, 2007, Volume: 30, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Survival Analysis

2007
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
    Clinical lung cancer, 2007, Volume: 8, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate

2007
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; North Carolina; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA Mutational Analysis; Female; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Analysis; Treatment Outcome

2007
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-15, Volume: 13, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2007
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Rate

2007
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Eruptions; Female; Humans; Kidney Neoplasms; Lipase; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2007
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
    Cancer science, 2008, Volume: 99, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
Sorafenib TARGET trial results in Spanish patients.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:10

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spain; Treatment Outcome

2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
    British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Fatigue; Humans; Male; Middle Aged; Nausea; Niacinamide; Pain; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Biomarkers, Tumor; Canada; Cell Proliferation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2008
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-01, Volume: 14, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2008
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
    Cancer biology & therapy, 2008, Volume: 7, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Analysis

2008
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Journal of the National Cancer Institute, 2008, Feb-06, Volume: 100, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Survival; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Immunoblotting; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyridines; Sorafenib; Transplantation, Heterologous

2008
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
    Cancer, 2008, Apr-15, Volume: 112, Issue:8

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; CA-125 Antigen; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pilot Projects; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Reproducibility of Results; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A

2008
Sorafenib for metastatic renal cancer: the Princess Margaret experience.
    American journal of clinical oncology, 2008, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis

2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome; United States

2008
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
    Cancer science, 2008, Volume: 99, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Sorafenib

2008
Phase II trial of sorafenib in advanced thyroid cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms

2008
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Archives of dermatology, 2008, Volume: 144, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Drug Eruptions; Female; Foot Dermatoses; France; Hand Dermatoses; Humans; Incidence; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Sorafenib

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Analysis

2008
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2008
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-01, Volume: 14, Issue:15

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biopsy; Carboplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome

2008
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-01, Volume: 26, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Double-Blind Method; Female; Gadolinium DTPA; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Proportional Hazards Models; Prospective Studies; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2008
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
    Journal of the National Cancer Institute, 2008, Oct-15, Volume: 100, Issue:20

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Retrospective Studies; Sorafenib

2008
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.
    Current medical research and opinion, 2008, Volume: 24, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Canada; Carcinoma, Hepatocellular; Disease-Free Survival; Europe; Humans; Liver Neoplasms; Markov Chains; Models, Theoretical; Niacinamide; Phenylurea Compounds; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate

2008
Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN
    BMC cancer, 2008, Nov-26, Volume: 8

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Double-Blind Method; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib

2008
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-01, Volume: 27, Issue:1

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Taxoids

2009
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2009, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2009
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
    Cancer, 2009, Jan-15, Volume: 115, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
    BJU international, 2009, Volume: 103, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Orchiectomy; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; raf Kinases; Soft Tissue Neoplasms; Sorafenib; Treatment Outcome

2009
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-10, Volume: 27, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib

2009
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome

2009
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Hepatic Insufficiency; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Renal Insufficiency; Sorafenib; Treatment Outcome; Young Adult

2009
Phase II trial of sorafenib in metastatic thyroid cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-01, Volume: 27, Issue:10

    Topics: Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms

2009
[Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)].
    Revue medicale de Liege, 2009, Volume: 64, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Sorafenib

2009
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-01, Volume: 27, Issue:19

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Sorafenib; Young Adult

2009
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-10, Volume: 27, Issue:20

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Disease-Free Survival; Double-Blind Method; Fatigue; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Nausea; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.
    Nuclear medicine communications, 2009, Volume: 30, Issue:7

    Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2009
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
    Cancer, 2009, Sep-15, Volume: 115, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Transitional Cell; Disease-Free Survival; Drug Evaluation; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retreatment; Sorafenib; Urinary Bladder Neoplasms

2009
[Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Survival Rate; Syndrome; Young Adult

2009
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2009
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
    Anti-cancer drugs, 2009, Volume: 20, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2009
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Diarrhea; Disease-Free Survival; Double-Blind Method; Female; Hematologic Diseases; Humans; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Progestins; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vinca Alkaloids

2010
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Investigational new drugs, 2010, Volume: 28, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Demography; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Radiography; Sorafenib; Treatment Outcome

2010
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
    European journal of endocrinology, 2009, Volume: 161, Issue:6

    Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms

2009
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate

2010
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
    Cancer, 2010, Jan-01, Volume: 116, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-15, Volume: 15, Issue:22

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome

2009
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
    British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Gallbladder Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sorafenib

2010
New pharmacological developments in the treatment of hepatocellular cancer.
    Drugs, 2009, Volume: 69, Issue:18

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Meta-Analysis as Topic; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Severity of Illness Index; Signal Transduction; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
    Clinical pharmacology and therapeutics, 2010, Volume: 87, Issue:3

    Topics: Adult; Aged; Benzenesulfonates; Diarrhea; Drug Discovery; Drug Dosage Calculations; Exanthema; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2010
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
    Investigational new drugs, 2011, Volume: 29, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Demography; Female; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Young Adult

2011
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Octreotide; Phenylurea Compounds; Pyridines; Sorafenib; Survival; Treatment Outcome

2010
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Fatigue; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Wasting Syndrome

2010
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Body Mass Index; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sarcopenia; Sorafenib

2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:2

    Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2010
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
    Gynecologic oncology, 2010, Volume: 117, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinosarcoma; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Uterine Neoplasms

2010
Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/I
    Radiation oncology (London, England), 2010, Feb-12, Volume: 5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Research Design; Sorafenib

2010
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-20, Volume: 28, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Pyridines; Sorafenib; Treatment Outcome; Young Adult

2010
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis

2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Urologic Neoplasms; Urothelium

2011
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Biomarkers, Pharmacological; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome

2010
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Early Termination of Clinical Trials; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib

2010
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-10, Volume: 28, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Placebos; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2010
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-10, Volume: 28, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Young Adult

2010
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-10, Volume: 28, Issue:14

    Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult

2010
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jun-01, Volume: 16, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; ras Proteins; Sorafenib; Vascular Endothelial Growth Factors

2010
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
    Journal of hepatology, 2010, Volume: 53, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tegafur; Uracil

2010
A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
    Oncology, 2010, Volume: 78, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2010
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Journal of neuro-oncology, 2011, Volume: 101, Issue:1

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Cytochrome P-450 CYP3A; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Temozolomide

2011
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-20, Volume: 28, Issue:18

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Docetaxel; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome

2010
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:8

    Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma; Female; Humans; Hypothyroidism; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine

2010
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
    Radiology, 2010, Volume: 256, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2010
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4

    Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Blood Pressure; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ventricular Function, Left

2011
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-15, Volume: 16, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzoquinones; Clinical Trials, Phase II as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lactams, Macrocyclic; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis

2010
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
    Radiology, 2010, Volume: 256, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2010
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
    Cancer, 2010, Aug-01, Volume: 116, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide

2010
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib

2010
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
    European radiology, 2010, Volume: 20, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2010
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
    International journal of clinical practice, 2010, Volume: 64, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Clinical Trials, Phase IV as Topic; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Pyridines; Research Design; Sorafenib; Treatment Outcome

2010
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-01, Volume: 16, Issue:19

    Topics: Aged; Antigens, Neoplasm; Benzenesulfonates; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins p21(ras); Pyridines; Sorafenib; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2010
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Young Adult

2010
Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
    European journal of medical research, 2010, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib

2010
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Peritoneal Neoplasms; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2010
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Chicago; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Universities

2012
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Cancer, 2010, Dec-01, Volume: 116, Issue:23

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2010
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1

    Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease Progression; Female; Humans; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Stomach Neoplasms; Time Factors; Treatment Outcome

2012
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    British journal of cancer, 2010, Oct-12, Volume: 103, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Infliximab; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2010
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    American journal of clinical oncology, 2011, Volume: 34, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2011
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Sorafenib; Survival Rate; Treatment Outcome

2010
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
    Haematologica, 2011, Volume: 96, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate; Young Adult

2011
Sorafenib: rays of hope in thyroid cancer.
    Thyroid : official journal of the American Thyroid Association, 2010, Volume: 20, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interactions; Humans; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms

2010
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
    Breast cancer research and treatment, 2011, Volume: 125, Issue:1

    Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Sorafenib; Stem Cells; Time Factors; Treatment Outcome; Triazoles; United States

2011
[Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Zhonghua yi xue za zhi, 2010, Aug-17, Volume: 90, Issue:31

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Young Adult

2010
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
    The oncologist, 2010, Volume: 15, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Catheters, Indwelling; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Humans; Liver Neoplasms; Mitomycin; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2010
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
    British journal of cancer, 2010, Nov-23, Volume: 103, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-2

2010
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    JAMA, 2010, Nov-17, Volume: 304, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Doxorubicin; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-01, Volume: 29, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Survival Rate; Thrombocytopenia; Young Adult

2010
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Failure; Treatment Outcome

2011
A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
    PloS one, 2010, Dec-29, Volume: 5, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cyclin D1; DNA Mutational Analysis; Female; Humans; Ki-67 Antigen; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sequence Analysis, DNA; Signal Transduction; Sorafenib

2010
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
    Journal of clinical pharmacology, 2011, Volume: 51, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome

2011
A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.
    Cancer, 2010, Dec-15, Volume: 116, Issue:24

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib

2010
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Benzenesulfonates; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prospective Studies; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate; Treatment Outcome; Young Adult

2011
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Genes, ras; Humans; Lung Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib

2011
Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Burden

2012
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:4

    Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Neuroendocrine; Cell Differentiation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Female; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Niacinamide; Oncogene Protein p21(ras); Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; raf Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms

2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Compassionate Use Trials; Disease-Free Survival; Europe; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
    Journal of hepatology, 2011, Volume: 55, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Feasibility Studies; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Sorafenib; Tegafur; Uracil; Young Adult

2011
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
    PloS one, 2011, Feb-14, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Regional Blood Flow; Sorafenib; Survival Analysis

2011
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:5

    Topics: Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Isoenzymes; Melanoma; Midazolam; Niacinamide; Omeprazole; Phenylurea Compounds; Pyridines; Sorafenib

2011
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Cancer, 2011, Sep-15, Volume: 117, Issue:18

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2011
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cyclooxygenase 2; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Nucleoside Deaminases; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Ribonucleoside Diphosphate Reductase; Sorafenib; Tumor Suppressor Proteins

2012
[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Sorafenib

2011
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Interactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2011
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
    British journal of cancer, 2011, Apr-12, Volume: 104, Issue:8

    Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cluster Analysis; Cytokines; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Humans; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2012
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
    Journal of cancer survivorship : research and practice, 2011, Volume: 5, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quality of Life; Research Design; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Treatment Outcome

2011
Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
    BJU international, 2011, Volume: 108, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Failure; Treatment Outcome; Young Adult

2012
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
    Endocrine-related cancer, 2011, Volume: 18, Issue:4

    Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Blotting, Western; Carcinoma, Medullary; Case-Control Studies; Cell Transformation, Neoplastic; Cells, Cultured; Female; Germ-Line Mutation; Humans; Kidney; Luciferases; Male; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutagenesis, Site-Directed; Niacinamide; NIH 3T3 Cells; Pedigree; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Thyroid Neoplasms; Transcription Factor 4; Transcription Factors; Young Adult

2011
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pilot Projects; Pyridines; Sorafenib; Treatment Outcome

2011
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
    European journal of endocrinology, 2011, Volume: 165, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Population; Pyridines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome; United Kingdom; Young Adult

2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome

2011
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Half-Life; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nitrogen Mustard Compounds; Phenylurea Compounds; Prodrugs; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome

2011
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:7

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Retrospective Studies; Sorafenib; Sulfonamides; Survival Rate; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Young Adult

2011
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:14

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Survival Analysis; Treatment Outcome

2011
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Treatment Outcome

2012
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Clinical therapeutics, 2011, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib

2011
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination

2011
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
    Gynecologic oncology, 2011, Volume: 123, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib

2011
Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    European journal of radiology, 2012, Volume: 81, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Gland; Tomography, X-Ray Computed; Treatment Outcome

2012
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.
    Clinical lung cancer, 2011, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2011
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Treatment Outcome

2012
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
    Cancer investigation, 2011, Volume: 29, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib

2011
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Disease-Free Survival; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2012
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
    British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib

2011
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
    Cancer, 2012, Feb-01, Volume: 118, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sarcoma; Sorafenib; Survival Rate; Vascular Neoplasms

2012
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-20, Volume: 29, Issue:24

    Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib

2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Nitriles; Orchiectomy; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Time Factors; Tosyl Compounds; Treatment Failure

2012
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid ca
    BMC cancer, 2011, Aug-11, Volume: 11

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome

2011
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
    The oncologist, 2011, Volume: 16, Issue:9

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis

2011
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Oct-20, Volume: 29, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib

2011
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
    Pediatric blood & cancer, 2012, Volume: 58, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Child; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Transplantation, Homologous

2012
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Diarrhea; Disease Progression; Drug Therapy, Combination; Everolimus; Female; Humans; Immunosuppressive Agents; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome

2012
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Epidemiologic Methods; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Young Adult

2011
[Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:9

    Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Sorafenib; Survival Rate; Treatment Outcome

2011
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
    Neuro-oncology, 2011, Volume: 13, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution; Treatment Outcome; Young Adult

2011
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
    Gynecologic oncology, 2011, Volume: 123, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan

2011
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiang
    Der Urologe. Ausg. A, 2011, Volume: 50, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Disease Progression; Female; Germany; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor A

2011
Sorafenib in hepatocellular carcinoma - a post marketing evaluation.
    Immunopharmacology and immunotoxicology, 2012, Volume: 34, Issue:3

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Product Surveillance, Postmarketing; Protein Kinase Inhibitors; Pyridines; Registries; Sorafenib; Survival Rate

2012
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.
    Oncology, 2011, Volume: 81, Issue:2

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Endothelial Cells; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stem Cells

2011
Saturable absorption of sorafenib in patients with solid tumors: a population model.
    Investigational new drugs, 2012, Volume: 30, Issue:5

    Topics: Absorption; Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult

2012
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
    Investigational new drugs, 2012, Volume: 30, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Tolerance; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sorafenib

2012
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
    British journal of cancer, 2011, Nov-22, Volume: 105, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Treatment Failure; Treatment Outcome; Vascular Endothelial Growth Factor A

2011
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Lancet (London, England), 2011, Dec-03, Volume: 378, Issue:9807

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Young Adult

2011
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Proteins; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Sorafenib

2012
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
    Anti-cancer drugs, 2012, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; CD3 Complex; CD4 Antigens; Female; Forkhead Transcription Factors; Humans; Indoles; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome

2012
Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
    Pediatric blood & cancer, 2012, Jul-15, Volume: 59, Issue:1

    Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate

2012
Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome

2012
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
    European journal of endocrinology, 2012, Volume: 166, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib

2012
Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
    International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2012
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-10, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult

2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    BJU international, 2012, Volume: 109, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sorafenib; Treatment Outcome

2012
Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
    European radiology, 2012, Volume: 22, Issue:6

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Radiography; Sorafenib; Treatment Outcome

2012
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Feb-15, Volume: 18, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult

2012
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:8

    Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Reproducibility of Results; Risk Factors; Sorafenib; Young Adult

2012
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Feb-15, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome

2012
Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Israel; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vitamin B Complex

2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:10

    Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; China; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Placebos; Prognosis; Pyridines; Republic of Korea; Sorafenib; Taiwan; Time Factors; Treatment Outcome

2012
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
    Journal of hepatology, 2012, Volume: 56, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; alpha-Fetoproteins; Antineoplastic Agents; Aspartate Aminotransferases; Benzenesulfonates; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2012
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Treatment Outcome

2012
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cohort Studies; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Taxoids; Treatment Outcome

2012
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
    The oncologist, 2012, Volume: 17, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Endpoint Determination; Female; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2

2012
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Journal of hepatology, 2012, Volume: 56, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib

2012
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
    The oncologist, 2012, Volume: 17, Issue:3

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Double-Blind Method; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib

2012
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Capillary Permeability; Extracellular Fluid; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pressure; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sarcoma; Sorafenib; Vascular Endothelial Growth Factors

2012
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
    Blood, 2012, May-31, Volume: 119, Issue:22

    Topics: Adult; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Benzenesulfonates; Bone Marrow; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Janus Kinase 3; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 15; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Structure, Tertiary; Pyridines; Retinal Dehydrogenase; Sorafenib; Time Factors; Transplantation, Heterologous

2012
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-15, Volume: 18, Issue:8

    Topics: Alkaline Phosphatase; alpha-Fetoproteins; Angiopoietin-2; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2012
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib

2012
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-01, Volume: 30, Issue:13

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Brazil; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib; Time Factors; Treatment Outcome

2012
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat

2013
Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma.
    Cell biochemistry and biophysics, 2012, Volume: 63, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Cryotherapy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Microvessels; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2012
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jun-15, Volume: 18, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib

2012
The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
    Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2012
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
    Annals of surgical oncology, 2012, Volume: 19, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Melphalan; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Array Analysis; Skin Neoplasms; Sorafenib; Tissue Distribution

2012
A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2012
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
    British journal of haematology, 2012, Volume: 158, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Young Adult

2012
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
    Der Urologe. Ausg. A, 2012, Volume: 51, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides

2012
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tissue Distribution

2013
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Urologic oncology, 2013, Volume: 31, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome

2013
Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
    Medical ultrasonography, 2012, Volume: 14, Issue:2

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Ultrasonography

2012
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
    International journal of radiation oncology, biology, physics, 2013, Feb-01, Volume: 85, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Temozolomide; Vascular Endothelial Growth Factor A

2013
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
    Haematologica, 2012, Volume: 97, Issue:11

    Topics: Antineoplastic Agents; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Piperazines; Sorafenib; Tumor Suppressor Protein p53

2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
    Cancer, 2012, Dec-15, Volume: 118, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Recombinant Fusion Proteins; Sorafenib; Survival Rate

2012
Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
    Nuclear medicine communications, 2012, Volume: 33, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biological Transport; Carcinoma, Renal Cell; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Safety; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Young Adult

2012
Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.
    Journal of vascular and interventional radiology : JVIR, 2012, Volume: 23, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatopulmonary Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Radiotherapy, Adjuvant; Sorafenib; Treatment Outcome

2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Journal of hepatology, 2012, Volume: 57, Issue:4

    Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Hand-Foot Syndrome; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Severity of Illness Index; Sorafenib; Time Factors; Tumor Burden

2012
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Niacinamide; Orchiectomy; Phenylurea Compounds; Pilot Projects; Prednisone; Prospective Studies; Prostatic Neoplasms; Pyridines; Sorafenib; Taxoids; Testosterone

2012
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
    British journal of cancer, 2012, Jul-24, Volume: 107, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib

2012
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Ribonucleotide Reductases; Sorafenib

2012
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
    British journal of cancer, 2012, Aug-07, Volume: 107, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Castration; Drug Administration Schedule; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Retreatment; Sorafenib; Treatment Failure

2012
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-01, Volume: 30, Issue:25

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome

2012
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:10

    Topics: Advanced Oxidation Protein Products; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Female; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Kinetics; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Middle Aged; Niacinamide; Nitrates; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib

2012
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    European journal of endocrinology, 2012, Volume: 167, Issue:5

    Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Carcinoma, Papillary, Follicular; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2012
Ontogeny and sorafenib metabolism.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Oct-15, Volume: 18, Issue:20

    Topics: Adolescent; Age Factors; Azoles; Child; Child, Preschool; Cytochrome P-450 CYP3A; Female; Humans; Infant; Infant, Newborn; Liver; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sex Factors; Sorafenib; Triazoles; Voriconazole; Young Adult

2012
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib

2013
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Maximum Tolerated Dose; Neurofibroma, Plexiform; Neurofibromatosis 1; Niacinamide; Phenylurea Compounds; Sorafenib

2013
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Nov-01, Volume: 18, Issue:21

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Leukemia; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult

2012
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
    European urology, 2013, Volume: 63, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Recombinant Proteins; Sorafenib; Treatment Outcome

2013
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Survival Rate

2012
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome

2013
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes

2012
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
    British journal of cancer, 2012, Nov-20, Volume: 107, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
    Neuro-oncology, 2012, Volume: 14, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Young Adult

2012
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    BJU international, 2012, Volume: 110, Issue:11

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden

2012
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
    Thyroid : official journal of the American Thyroid Association, 2013, Volume: 23, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms

2013
Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
    International journal of cancer, 2013, May-15, Volume: 132, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Asia; Asian People; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Research Design; Sorafenib; Treatment Outcome

2013
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Severity of Illness Index; Sorafenib; Sunitinib

2012
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jan-01, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome; Young Adult

2013
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib

2013
[Serum pancreatic enzyme elevation under treatment with sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:11

    Topics: Adult; Aged, 80 and over; Amylases; Benzenesulfonates; Humans; Lipase; Male; Middle Aged; Niacinamide; Pancreas; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sarcoma; Sorafenib; Treatment Outcome

2013
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography

2013
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-01, Volume: 19, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Platinum; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Treatment Outcome

2013
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib; Treatment Outcome; Uvea; Uveal Neoplasms

2012
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sarcoma; Sorafenib

2013
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
    Anti-cancer drugs, 2013, Volume: 24, Issue:3

    Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Exanthema; Female; Glucuronosyltransferase; HLA-A24 Antigen; Humans; Kidney Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2013
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    European journal of radiology, 2013, Volume: 82, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Imaging, Three-Dimensional; Iopamidol; Liver Neoplasms; Male; Middle Aged; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Pilot Projects; Radiography, Dual-Energy Scanned Projection; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2013
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib

2013
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
    AJR. American journal of roentgenology, 2013, Volume: 200, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Female; Gadolinium; Humans; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2013
Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
    Ultraschall in der Medizin (Stuttgart, Germany : 1980), 2013, Volume: 34, Issue:1

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Dose-Response Relationship, Drug; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Regional Blood Flow; Sorafenib; Treatment Outcome; Ultrasonography

2013
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:3

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Axitinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand-Foot Syndrome; Heparin; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Outcome

2013
Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Surveys and Questionnaires

2013
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
    Investigational new drugs, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome; Wisconsin

2013
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    European journal of radiology, 2013, Volume: 82, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prognosis; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2013
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
    Clinical lung cancer, 2013, Volume: 14, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed

2013
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
    The oncologist, 2013, Volume: 18, Issue:1

    Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Sorafenib; Wnt Signaling Pathway

2013
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Journal of digestive diseases, 2013, Volume: 14, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Prospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2013
[Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion].
    Zhonghua yi xue za zhi, 2012, Nov-13, Volume: 92, Issue:42

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pleural Effusion; Sorafenib; Treatment Outcome

2012
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
    Neuro-oncology, 2013, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution

2013
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolones; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome

2013
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Mar-01, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Renal Cell; Drug Evaluation, Preclinical; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Survival Rate; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-1

2013
Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome

2013
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.
    British journal of cancer, 2013, Apr-02, Volume: 108, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Male; Middle Aged; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; raf Kinases; Sorafenib; Survival Rate; Tissue Distribution

2013
Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.
    TheScientificWorldJournal, 2013, Volume: 2013

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome

2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome

2013
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
    Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Pharmacological; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Predictive Value of Tests; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor Receptor-2

2013
Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial.
    Future oncology (London, England), 2013, Volume: 9, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Everolimus; Feasibility Studies; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A

2013
Sorafenib in patients with refractory or recurrent multiple myeloma.
    Hematological oncology, 2013, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome

2013
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Sirolimus; Sorafenib; Treatment Outcome

2013
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Oxonic Acid; Patient Compliance; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tegafur; Treatment Outcome

2014
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-01, Volume: 19, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Pemetrexed; Phenylurea Compounds; Platinum; Pleural Neoplasms; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate

2013
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
    British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Self Report; Sorafenib; Treatment Outcome; Young Adult

2013
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.
    The oncologist, 2013, Volume: 18, Issue:4

    Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
    Cancer, 2013, Jul-15, Volume: 119, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangioendothelioma, Epithelioid; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rare Diseases; Sorafenib; Time Factors; Treatment Outcome

2013
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
    Gynecologic oncology, 2013, Volume: 130, Issue:1

    Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Sorafenib

2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:6

    Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Quality of Life; Sorafenib; Surveys and Questionnaires; Time Factors; Treatment Outcome

2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
    Blood, 2013, Jun-06, Volume: 121, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Survival Rate; Tandem Repeat Sequences; Young Adult

2013
Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
    Cancer investigation, 2013, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Treatment Outcome

2013
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult

2013
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
    American journal of clinical oncology, 2015, Volume: 38, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Failure; Treatment Outcome; Young Adult

2015
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid

2013
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:5

    Topics: Aged; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Technetium Tc 99m Aggregated Albumin; World Health Organization; Yttrium Radioisotopes

2013
Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
    Anticancer research, 2013, Volume: 33, Issue:6

    Topics: Adolescent; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Sorafenib; Thalidomide; Young Adult

2014
Alternative formulations of sorafenib for use in children.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Humans; Ifosfamide; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Sarcoma; Sorafenib; Young Adult

2014
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A

2013
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2013
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).
    Journal of hematology & oncology, 2013, Jul-05, Volume: 6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome

2013
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-01, Volume: 19, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2013
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:4

    Topics: Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2013
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
    Trials, 2013, Jul-22, Volume: 14

    Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Receptor, ErbB-2; Research Design; Sorafenib; Time Factors; Treatment Outcome

2013
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2013, Volume: 11, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Drug Eruptions; Female; Germany; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prevalence; Recombinant Proteins; Risk Factors; Skin Neoplasms; Sorafenib; Treatment Outcome

2013
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Treatment Outcome; Young Adult

2013
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-01, Volume: 31, Issue:25

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Anticancer research, 2013, Volume: 33, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Survival Analysis; Temozolomide; Time Factors

2013
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
    British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Journal of hepatology, 2013, Volume: 59, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Everolimus; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib

2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib

2013
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography

2014
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Triazines; Young Adult

2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate; Triazines; Young Adult

2013
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
    European urology, 2014, Volume: 65, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Sirolimus; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden

2014
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Solitary Fibrous Tumors; Sorafenib; Treatment Outcome

2013
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bevacizumab; Diarrhea; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Sorafenib; Spain; Treatment Outcome

2013
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-20, Volume: 31, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Status; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome

2013
Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Group Processes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Parents; Phenylurea Compounds; Pyrazines; Quality of Life; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Young Adult

2013
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
    BJU international, 2014, Volume: 113, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Treatment Outcome; Urologic Neoplasms

2014
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib; Treatment Outcome

2013
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Treatment Outcome

2013
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Nov-10, Volume: 31, Issue:32

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib; Young Adult

2013
Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment.
    International journal of clinical oncology, 2014, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Surveys and Questionnaires; Treatment Outcome

2014
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
    Cancer, 2014, Jan-15, Volume: 120, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
[Efficacies of sorafenib plus interferon in advanced renal cell carcinoma: a report of 57 cases].
    Zhonghua yi xue za zhi, 2013, Jun-25, Volume: 93, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24

    Topics: Adult; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Preoperative Period; Radiography; Sarcoma; Sorafenib; Young Adult

2013
Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
    Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2014
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
    The oncologist, 2013, Volume: 18, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Retrospective Studies; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2013
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24

    Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Sorafenib; Survival Analysis; Taxoids; Treatment Failure

2014
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.
    Cancer research, 2014, Jan-01, Volume: 74, Issue:1

    Topics: Adult; Aged; CD4 Antigens; Cell Growth Processes; Female; Humans; Interleukin-15; Interleukin-15 Receptor alpha Subunit; Male; Melanoma; Middle Aged; Niacinamide; NK Cell Lectin-Like Receptor Subfamily K; Phenylurea Compounds; Sorafenib; Th1 Cells; Young Adult

2014
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiologic; Disease-Free Survival; Europe; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; North America; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Research Design; Severity of Illness Index; Sorafenib; Treatment Outcome

2013
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.
    Targeted oncology, 2014, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
    The oncologist, 2013, Volume: 18, Issue:12

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
    International journal of clinical practice, 2014, Volume: 68, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult

2014
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, 03-10, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Failure; Young Adult

2014
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Gut and liver, 2013, Volume: 7, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Sorafenib; Tomography, Spiral Computed; Venous Thrombosis

2013
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
    Urologic oncology, 2014, Volume: 32, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cross-Sectional Studies; Everolimus; Fatigue; Female; Humans; Incidence; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Physicians; Pyrroles; Quality of Life; Self Report; Sirolimus; Sorafenib; Sunitinib; Surveys and Questionnaires

2014
Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
    Hematology/oncology and stem cell therapy, 2014, Volume: 7, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Demography; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.
    Head & neck, 2015, Volume: 37, Issue:2

    Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Disease Progression; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Salivary Gland Neoplasms; Sorafenib

2015
The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Doxorubicin; Ethiodized Oil; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Republic of Korea; Sorafenib

2014
A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:2

    Topics: Aged; Antineoplastic Agents; Bandages, Hydrocolloid; Carcinoma, Renal Cell; Ceramides; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Surface Properties; Treatment Outcome

2014
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:8

    Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Sorafenib; Ventriculoperitoneal Shunt

2014
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:3

    Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Treatment Outcome

2014
Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.
    Clinical breast cancer, 2014, Volume: 14, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate; Vinblastine; Vinorelbine

2014
Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Angiopoietin-2; Biomarkers; Exercise; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult

2014
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:2

    Topics: Aged; Antibodies, Monoclonal; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indium Radioisotopes; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Radionuclide Imaging; Sorafenib

2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
    British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib

2014
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed

2014
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Sorafenib; Treatment Outcome

2014
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
    Journal of hematology & oncology, 2014, Jan-14, Volume: 7

    Topics: Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Immunohistochemistry; Middle Aged; Molecular Targeted Therapy; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; S100 Proteins; Sarcoma; Sequence Analysis, DNA; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2014
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
    British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A

2014
Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
    Cancer science, 2014, Volume: 105, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease-Free Survival; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 83, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinogenesis; China; ErbB Receptors; Female; Genotype; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Sequence Deletion; Sorafenib; Survival Analysis; Treatment Failure

2014
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
    Leukemia, 2014, Volume: 28, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
    Annals of surgical oncology, 2014, Volume: 21, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Prognosis; Radiotherapy, Conformal; Sarcoma; Sorafenib

2014
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib; Vascular Endothelial Growth Factor A

2014
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
    Cancer medicine, 2014, Volume: 3, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Quinazolines; Sorafenib

2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
    Targeted oncology, 2015, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2015
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2014, Volume: 37, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Interleukin-2; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT5 Transcription Factor; T-Lymphocytes, Regulatory

2014
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Prospective Studies; Sorafenib; Tegafur

2014
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Time Factors; Yttrium Radioisotopes

2014
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib

2014
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
    Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:1

    Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Young Adult

2014
Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
    BMC cancer, 2014, Mar-24, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cognition; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Memory; Middle Aged; Neoplasm Metastasis; Neuropsychological Tests; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib

2014
Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
    International journal of radiation oncology, biology, physics, 2014, Apr-01, Volume: 88, Issue:5

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fibrosis; Hand-Foot Syndrome; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiation Dosage; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis

2014
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
    The oncologist, 2014, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Sirolimus; Sorafenib

2014
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
    Journal of hepatology, 2014, Volume: 61, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Graft Rejection; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Radiation Dosage; Sorafenib; Yttrium Radioisotopes

2014
Sorafenib in liver function impaired advanced hepatocellular carcinoma.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2014, Volume: 29, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cross-Over Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult

2014
Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
    Radiology, 2014, Volume: 272, Issue:1

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Female; Humans; Liver Function Tests; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Rate; Tomography, Spiral Computed; Treatment Outcome; Venous Thrombosis

2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-15, Volume: 20, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate

2014
Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.
    Neoplasia (New York, N.Y.), 2014, Volume: 16, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2014, Jun-01, Volume: 89, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Genotype; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Radiotherapy, Intensity-Modulated; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2014
[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of pat
    Der Urologe. Ausg. A, 2014, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult

2014
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib

2014
Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Safety; Sorafenib; Survival Rate

2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
    Lancet (London, England), 2014, Jul-26, Volume: 384, Issue:9940

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome; Young Adult

2014
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
    British journal of cancer, 2014, 05-27, Volume: 110, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Temozolomide; Treatment Outcome

2014
Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib; Treatment Outcome

2014
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
    Neuro-oncology, 2014, Volume: 16, Issue:10

    Topics: Adolescent; Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child, Preschool; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; MAP Kinase Signaling System; Mice; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2014
Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
    Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Disease Progression; Drug Monitoring; Early Termination of Clinical Trials; Feasibility Studies; Female; Hand-Foot Syndrome; Humans; Hypertension; Kinetics; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Sorafenib; Vascular Endothelial Growth Factors

2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    British journal of cancer, 2014, Jun-10, Volume: 110, Issue:12

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden

2014
Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.
    Future oncology (London, England), 2014, Volume: 10, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Receptors, Estrogen; Sorafenib; Tamoxifen; Treatment Outcome

2014
Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014, Volume: 16, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib

2014
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
    Cancer medicine, 2014, Volume: 3, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2014
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2

    Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Europe; Follow-Up Studies; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Yttrium

2015
Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
    American journal of clinical oncology, 2016, Volume: 39, Issue:6

    Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Oligonucleotides; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome

2016
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
    JAMA, 2014, Jul-02, Volume: 312, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Everolimus; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Survival Analysis; Young Adult

2014
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
    International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Female; Humans; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reactive Oxygen Species; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2015
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib

2015
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Ethiodized Oil; Fatigue; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Poor results for everolimus in patients with liver cancer.
    The Lancet. Oncology, 2014, Volume: 15, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Everolimus; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sirolimus; Sorafenib; Survival Analysis; Treatment Failure

2014
Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.
    European radiology, 2015, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maryland; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Time Factors; Tumor Burden

2015
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutagenesis, Insertional; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate

2014
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Nov-15, Volume: 20, Issue:22

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Sorafenib; Treatment Outcome; Young Adult

2014
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2

2014
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
    Investigational new drugs, 2015, Volume: 33, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP2C19; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Sorafenib; Treatment Outcome; Young Adult

2015
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Dec-01, Volume: 20, Issue:23

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Carcinoma, Hepatocellular; Diphenylamine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides; Treatment Outcome

2014
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
    Head & neck, 2016, Volume: 38, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult

2016
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Investigational new drugs, 2015, Volume: 33, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins; PTEN Phosphohydrolase; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A

2015
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
    Investigational new drugs, 2015, Volume: 33, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Female; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2015
A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.
    Future oncology (London, England), 2014, Volume: 10, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult

2014
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2015
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
    BMC cancer, 2014, Nov-24, Volume: 14

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Pyrroles; Registries; Sarcoma; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2014
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemokine CXCL12; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors

2014
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Trials, 2014, Dec-03, Volume: 15

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Protocols; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Embolization, Therapeutic; France; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Research Design; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes

2014
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-10, Volume: 33, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Risk Factors; Sorafenib; Treatment Outcome

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult

2015
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Intention to Treat Analysis; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Niacinamide; Osteosarcoma; Phenylurea Compounds; Sirolimus; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult

2015
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
    Der Urologe. Ausg. A, 2015, Volume: 54, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib

2015
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Feb-20, Volume: 33, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Quinazolines; Sorafenib

2015
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
    Cancer medicine, 2015, Volume: 4, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome

2015
[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Salvage Therapy; Severity of Illness Index; Sorafenib; Spain; Treatment Outcome

2015
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral oncology, 2015, Volume: 51, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib

2015
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-10, Volume: 33, Issue:8

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Emulsions; Female; Hand-Foot Syndrome; Humans; Incidence; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Skin; Sorafenib; Surveys and Questionnaires; Treatment Outcome; Urea; Young Adult

2015
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:2

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:4

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; gamma-Glutamyltransferase; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate

2015
Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma.
    The oncologist, 2015, Volume: 20, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
Comparison of volumetric and linear serial CT assessments of lung metastases in renal cell carcinoma patients in a clinical phase IIB study.
    Academic radiology, 2015, Volume: 22, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Tomography, X-Ray Computed; Tumor Burden

2015
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Axitinib; Blood Pressure; Carcinoma, Renal Cell; Disease-Free Survival; Female; Genetic Association Studies; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Linkage Disequilibrium; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2015
Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance i
    Molecular & cellular proteomics : MCP, 2015, Volume: 14, Issue:6

    Topics: Amino Acids; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Galectin 1; Gene Knockdown Techniques; Humans; Isotope Labeling; Liver Neoplasms; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Interaction Maps; Proteomics; Sorafenib; Treatment Outcome

2015
A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2015, Volume: 14, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib; Vascular Endothelial Growth Factor A; Young Adult

2015
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.
    BMC cancer, 2015, Apr-18, Volume: 15

    Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Treatment Outcome

2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib

2015
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
    BMC cancer, 2015, May-11, Volume: 15

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Germany; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2015
Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.
    Future oncology (London, England), 2015, Volume: 11, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Everolimus; Humans; Models, Theoretical; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2015
SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
    Oncotarget, 2015, Jun-30, Volume: 6, Issue:18

    Topics: Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genome, Human; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Sorafenib; Symporters; Treatment Outcome

2015
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Sep-15, Volume: 21, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left

2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
    The oncologist, 2015, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2015
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib

2015
Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Radiology, 2015, Volume: 277, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Tomography, X-Ray Computed

2015
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
    Journal of hepatology, 2015, Volume: 63, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome

2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN C
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jul-20, Volume: 33, Issue:21

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; raf Kinases; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A

2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Ramucirumab; Remission Induction; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome

2015
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug Combinations; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome

2015
Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
    Future oncology (London, England), 2015, Volume: 11, Issue:18

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult

2015
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chordoma; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sarcoma; Sorafenib; Survival Rate

2015
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:9

    Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Kidney Neoplasms; Male; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rhabdomyosarcoma; Salvage Therapy; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Wilms Tumor; Young Adult

2015
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Survival Analysis

2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-15, Volume: 22, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; Double-Blind Method; Genes, ras; Humans; Melanoma; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Sorafenib; Treatment Outcome

2016
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Paclitaxel; Pain Measurement; Phenylurea Compounds; Quality of Life; Sorafenib; Urinary Bladder Neoplasms

2015
Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:10

    Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tiopronin

2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Double-Blind Method; Europe; Female; Hepatectomy; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; New Zealand; Niacinamide; North America; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; South America; Time Factors; Treatment Outcome; Young Adult

2015
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Endocrine-related cancer, 2015, Volume: 22, Issue:6

    Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Dyspnea; Fatigue; Female; Humans; Hypertension; Hypocalcemia; Incidence; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Weight Loss

2015
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
    Oncotarget, 2015, Oct-27, Volume: 6, Issue:33

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Sorafenib

2015
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
    Anticancer research, 2015, Volume: 35, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Withholding Treatment

2015
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Glucose-6-Phosphate; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prospective Studies; Radiography; Sorafenib; Survival Rate

2015
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Survival Rate; Time Factors

2015
Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
    The oncologist, 2015, Volume: 20, Issue:12

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Thrombosis; Treatment Outcome

2015
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure

2015
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    BMC cancer, 2015, Oct-09, Volume: 15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2015, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Serum Albumin; Serum Albumin, Human; Sorafenib; Treatment Outcome

2015
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.
    International journal of radiation oncology, biology, physics, 2016, Jan-01, Volume: 94, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Brachytherapy; Carcinoma, Squamous Cell; Cell Hypoxia; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Time Factors; Tumor Burden; Uterine Cervical Neoplasms

2016
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome

2015
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
    Investigational new drugs, 2016, Volume: 34, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2016
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 05-15, Volume: 22, Issue:10

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Diphenylamine; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides

2016
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
    Cancer medicine, 2016, Volume: 5, Issue:2

    Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Child; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2016
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
    Oncotarget, 2016, Feb-09, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Canc
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sorafenib; Treatment Outcome

2015
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
    Investigational new drugs, 2016, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors

2016
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2016
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Journal of hepatology, 2016, Volume: 64, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Double-Blind Method; Doxorubicin; Drug Carriers; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors; Treatment Outcome

2016
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
    Scientific reports, 2016, Feb-02, Volume: 6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Sorafenib; Survival Rate

2016
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
    Scientific reports, 2016, Feb-02, Volume: 6

    Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate

2016
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts.
    Annals of surgical oncology, 2016, Volume: 23, Issue:Suppl 5

    Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Endothelium; Female; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenotype; Phenylurea Compounds; Phosphatidylserines; Rituximab; Sorafenib; Xenograft Model Antitumor Assays

2016
Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, Volume: 118, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Rectal Neoplasms; Sorafenib; Treatment Outcome

2016
Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    International journal of radiation oncology, biology, physics, 2016, Mar-01, Volume: 94, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose Fractionation, Radiation; Female; Humans; Intestines; Liver; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Radiosurgery; Radiotherapy Dosage; Sorafenib

2016
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib

2016
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lung cancer (Amsterdam, Netherlands), 2016, Volume: 93

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Risk Factors; Sorafenib; Treatment Outcome

2016
Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
    Clinical breast cancer, 2016, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epothilones; Female; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib; Treatment Outcome

2016
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
    Journal of hepatology, 2016, Volume: 65, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Hydroxamic Acids; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides

2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Lancet (London, England), 2016, May-14, Volume: 387, Issue:10032

    Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2016
Changes in Liver Volume Observed Following Sorafenib and Liver Radiation Therapy.
    International journal of radiation oncology, biology, physics, 2016, Mar-15, Volume: 94, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Breath Holding; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Sorafenib; Time Factors; Tomography, Spiral Computed; Tumor Burden; Young Adult

2016
Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
    Journal of surgical oncology, 2016, Volume: 113, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome

2016
Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.
    Proteomics. Clinical applications, 2016, Volume: 10, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins p21(ras); Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome

2016
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asia, Eastern; Benzimidazoles; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2016
Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.
    Acta radiologica (Stockholm, Sweden : 1987), 2017, Volume: 58, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Data Interpretation, Statistical; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden

2017
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
    Oncotarget, 2016, 07-05, Volume: 7, Issue:27

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib; Treatment Outcome; Triple Negative Breast Neoplasms

2016
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-01, Volume: 22, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Sorafenib

2016
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.
    British journal of cancer, 2016, Jun-28, Volume: 115, Issue:1

    Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Uveal Neoplasms

2016
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    The oncologist, 2016, Volume: 21, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide

2016
Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
    Journal of vascular and interventional radiology : JVIR, 2016, Volume: 27, Issue:9

    Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chicago; Down-Regulation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Platelet-Derived Growth Factor; Prospective Studies; Radiopharmaceuticals; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes

2016
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    World journal of gastroenterology, 2016, Jun-21, Volume: 22, Issue:23

    Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Risk Factors; Sorafenib; Spain; Survival Rate; Treatment Outcome; Young Adult

2016
Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Hepatitis C; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Sorafenib

2016
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:1

    Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome

2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
    Journal of gastroenterology, 2017, Volume: 52, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Ramucirumab; Sorafenib; Treatment Outcome

2017
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2016
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2016
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
    Science translational medicine, 2016, 10-05, Volume: 8, Issue:359

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Culture Techniques; Cell Line, Tumor; Cluster Analysis; Drug Evaluation, Preclinical; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Remission Induction; Sorafenib; Treatment Outcome; Young Adult

2016
Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
    AIDS (London, England), 2017, 01-02, Volume: 31, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Spain; Survival Analysis; Treatment Outcome

2017
Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
    Oncotarget, 2017, Mar-07, Volume: 8, Issue:10

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diarrhea; Drug Administration Schedule; Exanthema; Fatigue; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2017
Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
    Anticancer research, 2016, Volume: 36, Issue:11

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib

2016
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    BMC cancer, 2016, 11-07, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Clinical Protocols; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Research Design; Sorafenib

2016
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 69

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Hand-Foot Syndrome; Humans; Hypertension; Immunohistochemistry; Male; Middle Aged; Myoepithelioma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Salivary Gland Neoplasms; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult

2016
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
    European journal of haematology, 2017, Volume: 98, Issue:4

    Topics: Adult; Allografts; Azacitidine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Salvage Therapy; Sorafenib; Survival Rate

2017
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Hepatology international, 2017, Volume: 11, Issue:2

    Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Sorafenib; Taiwan

2017
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet (London, England), 2017, 01-07, Volume: 389, Issue:10064

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2017
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
    Targeted oncology, 2017, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Young Adult

2017
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
    Anti-cancer drugs, 2017, Volume: 28, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Niacinamide; Peptides, Cyclic; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult

2017
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
    BJU international, 2017, Volume: 119, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Research Design; Sorafenib; Treatment Outcome

2017
Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vinblastine; Vinorelbine

2016
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.
    Langenbeck's archives of surgery, 2017, Volume: 402, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Double-Blind Method; Female; Hepatectomy; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Sorafenib; Treatment Outcome

2017
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Risk Factors; Sorafenib; Time Factors; Tomography, X-Ray Computed

2017
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.
    Future oncology (London, England), 2017, Volume: 13, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2017
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult

2017
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Glypicans; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib

2017
Phase I trial of radiation therapy and sorafenib in unresectable liver metastases.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017, Volume: 123, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiosurgery; Sorafenib

2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate

2017
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Hepatocellular; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis

2017
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.
    Clinical and translational science, 2017, Volume: 10, Issue:4

    Topics: Aged; Animals; Biological Transport; Dogs; Female; Glucuronides; HEK293 Cells; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Madin Darby Canine Kidney Cells; Male; Mice, Knockout; Middle Aged; Multidrug Resistance-Associated Protein 2; Niacinamide; Organic Anion Transporters, Sodium-Independent; Phenylurea Compounds; Rifampin; Sorafenib

2017
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 03-01, Volume: 28, Issue:3

    Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2017
A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.
    Journal of neuro-oncology, 2017, Volume: 133, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiosurgery; Sorafenib

2017
Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Chinese journal of cancer, 2017, May-18, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypoalbuminemia; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2017
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Nov-15, Volume: 109S

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2017
Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    International journal of cancer, 2017, 09-01, Volume: 141, Issue:5

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Flow Cytometry; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Monocytes; Niacinamide; Phenylurea Compounds; Pilot Projects; Proportional Hazards Models; Prospective Studies; Receptor, TIE-2; Response Evaluation Criteria in Solid Tumors; ROC Curve; Sorafenib

2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 81

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Ramucirumab; Sorafenib

2017
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    The oncologist, 2017, Volume: 22, Issue:7

    Topics: Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recombinant Fusion Proteins; Sorafenib; Treatment Outcome

2017
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
    Cancer science, 2017, Volume: 108, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Precision Medicine; Sorafenib; T-Lymphocytes, Cytotoxic; Treatment Outcome; Vaccination; Vaccines, Subunit

2017
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2017, Volume: 27, Issue:9

    Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Neuroendocrine; Diarrhea; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Japan; Male; Neoplasm Grading; Niacinamide; Patient Dropouts; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Tumor Burden

2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:8

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Embolization, Therapeutic; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2017
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Cancer, 2017, Nov-01, Volume: 123, Issue:21

    Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Radiation Tolerance; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2017
Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017, Volume: 124, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2017
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
    Journal of hepatology, 2017, Volume: 67, Issue:5

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Leukocyte Count; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib

2017
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
    The oncologist, 2017, Volume: 22, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    International journal of clinical oncology, 2017, Volume: 22, Issue:6

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2017
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
    BMC cancer, 2017, Jul-25, Volume: 17, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib; Treatment Outcome

2017
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8

    Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Outcome

2017
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
    Clinical breast cancer, 2017, Volume: 17, Issue:8

    Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Receptor, ErbB-2; Sorafenib; Taxoids; Treatment Outcome

2017
Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
    Medicine, 2017, Volume: 96, Issue:37

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Regression Analysis; Sorafenib; Survival Analysis; Taiwan; Treatment Outcome

2017
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
    Urologic oncology, 2018, Volume: 36, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Urinary Bladder Neoplasms

2018
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 11-01, Volume: 28, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Health Status Indicators; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate

2017
Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Digestive diseases (Basel, Switzerland), 2017, Volume: 35, Issue:6

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Serum Albumin; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2017
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
    Digestive diseases (Basel, Switzerland), 2017, Volume: 35, Issue:6

    Topics: Adult; Aged; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Serum Albumin; Sorafenib

2017
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes

2017
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Lung cancer (Amsterdam, Netherlands), 2017, Volume: 113

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Fatigue; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    World journal of gastroenterology, 2017, Nov-21, Volume: 23, Issue:43

    Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Portal Vein; Propensity Score; Retrospective Studies; Sorafenib; Stents; Survival Rate; Treatment Outcome; Venous Thrombosis

2017
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 89

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Female; Humans; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Radiotherapy, Adjuvant; Rectal Neoplasms; Sorafenib

2018
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
    Oncology, 2017, Volume: 93 Suppl 1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Treatment Outcome

2017
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Lancet (London, England), 2018, 03-24, Volume: 391, Issue:10126

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib; Survival Rate; Treatment Outcome

2018
Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib

2018
A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.
    Japanese journal of clinical oncology, 2018, Apr-01, Volume: 48, Issue:4

    Topics: Aged; Asian People; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome

2018
A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Oncology, 2018, Volume: 94, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2018
Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
    Journal of vascular and interventional radiology : JVIR, 2018, Volume: 29, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2018
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy.
    The oncologist, 2020, Volume: 25, Issue:9

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2020
Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients.
    International journal of clinical oncology, 2020, Volume: 25, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Progression-Free Survival; Sorafenib; Young Adult

2020
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    The oncologist, 2020, Volume: 25, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Sorafenib; Treatment Outcome

2020
A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer.
    The oncologist, 2020, Volume: 25, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridones; Pyrimidinones; Sorafenib

2020
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
    Hepatology international, 2021, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pravastatin; Prospective Studies; Sorafenib; Treatment Outcome

2021
Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.
    Digestive diseases and sciences, 2022, Volume: 67, Issue:7

    Topics: Carcinoma, Hepatocellular; Catheter Ablation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiofrequency Ablation; Retrospective Studies; Sorafenib; Treatment Outcome

2022
Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
    Cancer reports (Hoboken, N.J.), 2022, Volume: 5, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Urea

2022
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.
    Hepatology international, 2022, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Genotype; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2022
A cost analysis of sorafenib for desmoid tumors.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:3

    Topics: Aged; Costs and Cost Analysis; Fibromatosis, Aggressive; Humans; Medicare; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; United States

2023
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
    The oncologist, 2022, 03-11, Volume: 27, Issue:3

    Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2022
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 09-01, Volume: 28, Issue:17

    Topics: Carcinoma, Hepatocellular; Extracellular Vesicles; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteomics; Sorafenib

2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
    Clinical genitourinary cancer, 2022, Volume: 20, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A

2022
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
    Cancer chemotherapy and pharmacology, 2023, Volume: 91, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Everolimus; Female; Humans; Niacinamide; Phenylurea Compounds; Sorafenib

2023
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
    Cancer chemotherapy and pharmacology, 2023, Volume: 91, Issue:5

    Topics: Biomarkers; Everolimus; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Progression-Free Survival; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2023
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
    Oncotarget, 2023, 04-10, Volume: 14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Maximum Tolerated Dose; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Riluzole; Sorafenib

2023

Other Studies

2816 other study(ies) available for niacinamide and sorafenib

ArticleYear
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
    International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cell Cycle; Colonic Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib; Tumor Cells, Cultured

2003
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
    BMC cancer, 2004, Jun-01, Volume: 4

    Topics: Adenoma; Animals; Apoptosis; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Division; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2004
B-RAF is a therapeutic target in melanoma.
    Oncogene, 2004, Aug-19, Volume: 23, Issue:37

    Topics: Benzenesulfonates; Cell Line, Tumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2004
Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, Sep-25, Volume: 809, Issue:1

    Topics: Animals; Benzenesulfonates; Calibration; Enzyme Inhibitors; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib

2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Cancer research, 2004, Oct-01, Volume: 64, Issue:19

    Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Xenograft Model Antitumor Assays

2004
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
    Anti-cancer drugs, 2005, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA Adducts; Drug Antagonism; Humans; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib

2005
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Cancer research, 2005, Mar-15, Volume: 65, Issue:6

    Topics: Animals; Apoptosis; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Mice; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Sorafenib; Vascular Endothelial Growth Factor A

2005
Cancer. Encouraging results for second-generation antiangiogenesis drugs.
    Science (New York, N.Y.), 2005, May-27, Volume: 308, Issue:5726

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A

2005
Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:4

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Clinical Trials as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2005
Multi-kinase inhibitors create buzz at ASCO.
    Nature biotechnology, 2005, Volume: 23, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Biotechnology; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Phosphotransferases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2005
Clinical trials referral resource.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Referral and Consultation; Sorafenib; United States

2005
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
    Oncogene, 2005, Oct-20, Volume: 24, Issue:46

    Topics: Adamantane; Apoptosis; Base Sequence; Benzenesulfonates; Caspases; Cell Line, Tumor; DNA Primers; Down-Regulation; Enzyme Activation; Humans; Hydroquinones; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib

2005
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
    Annals of internal medicine, 2005, Aug-16, Volume: 143, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2005
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
    The Journal of biological chemistry, 2005, Oct-21, Volume: 280, Issue:42

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspase 7; Caspase 9; Caspases; Cell Line, Tumor; Chromatography; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Genes, Reporter; Humans; Immunoblotting; Immunoprecipitation; Jurkat Cells; K562 Cells; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Promoter Regions, Genetic; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Subcellular Fractions; Time Factors; Transcription, Genetic; Transfection; U937 Cells; Ubiquitin

2005
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5

    Topics: Adult; Antifungal Agents; Benzenesulfonates; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2006
Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.
    Journal of neuro-oncology, 2005, Volume: 74, Issue:2

    Topics: Adult; Benzenesulfonates; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Nerve Sheath Neoplasms; Neurofibroma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spinal Cord Neoplasms

2005
Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication.
    FEBS letters, 2006, Jan-23, Volume: 580, Issue:2

    Topics: Animals; Benzenesulfonates; Hepacivirus; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Binding; Proto-Oncogene Proteins c-raf; Pyridines; Replicon; RNA-Dependent RNA Polymerase; RNA, Small Interfering; Sorafenib; Viral Nonstructural Proteins; Virus Replication

2006
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
    Cancer research, 2006, Feb-01, Volume: 66, Issue:3

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Benzenesulfonates; Caspases; Cell Line, Tumor; Cell Nucleus; Cytochromes c; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Mitochondria; Mitochondrial Proteins; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Sorafenib

2006
BAY 43-9006 inhibition of oncogenic RET mutants.
    Journal of the National Cancer Institute, 2006, Mar-01, Volume: 98, Issue:5

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Cycle; Drug Administration Schedule; Enzyme Inhibitors; Fibroblasts; Immunoblotting; Inhibitory Concentration 50; Mice; Mice, Nude; Mutation; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Phosphotransferases; Proto-Oncogene Proteins c-ret; Pyridines; Sorafenib; Thyroid Neoplasms; Transfection; Transplantation, Heterologous

2006
Drug approval triggers debate on future direction for cancer treatments.
    Nature reviews. Drug discovery, 2006, Volume: 5, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Approval; Drug Design; Enzyme Inhibitors; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphotransferases; Pyridines; Sorafenib; United States; United States Food and Drug Administration

2006
BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5

    Topics: Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Transplantation, Heterologous

2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
    Blood, 2006, Aug-15, Volume: 108, Issue:4

    Topics: Benzamides; Benzenesulfonates; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; K562 Cells; Kidney Neoplasms; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib

2006
Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants.
    Oncogene, 2006, Oct-26, Volume: 25, Issue:50

    Topics: Aminacrine; Benzenesulfonates; Butadienes; Cell Transformation, Neoplastic; Clone Cells; Frameshift Mutation; Genes, Dominant; Genes, Recessive; Hematopoiesis; Humans; Interleukin-3; MAP Kinase Kinase Kinases; Mutagenesis, Insertional; Neoplastic Stem Cells; Niacinamide; Nitriles; Nitrogen Mustard Compounds; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Retroviridae; Sorafenib; STAT5 Transcription Factor; Transfection

2006
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays

2007
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Methods in enzymology, 2006, Volume: 407

    Topics: Benzenesulfonates; Cell Line; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2006
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Community Health Services; Cytokines; Disease Progression; Drug Delivery Systems; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Failure

2006
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Feb-01, Volume: 846, Issue:1-2

    Topics: Area Under Curve; Benzenesulfonates; Calibration; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2007
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
    Clinical and experimental dermatology, 2006, Volume: 31, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Keratosis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Photosensitivity Disorders; Protein Kinase Inhibitors; Pyridines; Sorafenib

2006
Trials probe new agents for kidney cancer.
    JAMA, 2006, Jul-12, Volume: 296, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib

2006
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Clinical genitourinary cancer, 2006, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2006
Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Delivery Systems; Humans; Indoles; Interleukin-2; Karnofsky Performance Status; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Nurse's Role; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Assessment; Safety Management; Sorafenib; Sunitinib; Survival Analysis

2006
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3

    Topics: Acetophenones; Annexin A5; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzopyrans; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; Enzyme Inhibitors; Glioma; Humans; Immunohistochemistry; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Folding; Protein Kinase C; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2006
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phospholipids; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Sulfur Hexafluoride; Survival Analysis; Treatment Outcome; Ultrasonography, Doppler

2006
New therapeutic options for renal cell carcinoma.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2006
Pharmacy benefit spending on oral chemotherapy drugs.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States

2006
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; K562 Cells; MAP Kinase Signaling System; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib

2006
Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cholangiocarcinoma; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Hypertensive Encephalopathy; Magnetic Resonance Imaging; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib; Syndrome

2006
Problems with the randomized discontinuation design.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Data Interpretation, Statistical; Drug Administration Schedule; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Survival Analysis; Treatment Outcome

2006
Speeding up cancer-drug development.
    The Lancet. Oncology, 2006, Volume: 7, Issue:10

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Multiple Myeloma; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2006
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
    The American journal of pathology, 2006, Volume: 169, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Laminin; Melanoma; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteoglycans; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib

2006
A tale of two drugs.
    Nature reviews. Drug discovery, 2006, Volume: 5, Issue:10

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Benzenesulfonates; Clofarabine; Drug Approval; Drug Design; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2006
Current and future management of GIST.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2006
Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
    Archives of dermatology, 2006, Volume: 142, Issue:11

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Foot; Hand; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Syndrome; Vasculitis, Leukocytoclastic, Cutaneous

2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:5

    Topics: Actins; Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Capillaries; Cell Line, Tumor; Female; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Regional Blood Flow; Sorafenib; Vascular Endothelial Growth Factor A

2007
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Oncogene, 2007, Jun-07, Volume: 26, Issue:27

    Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Blotting, Western; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; RNA Interference; RNA, Small Interfering; Roscovitine; Sorafenib; Sulfonamides; Transmembrane Activator and CAML Interactor Protein; Zinc Fingers

2007
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Cancer research, 2006, Dec-15, Volume: 66, Issue:24

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Transplantation, Heterologous

2006
Keratoacanthomas associated with sorafenib therapy.
    Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:1

    Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanthoma; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neck; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib

2007
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
    Leukemia, 2007, Volume: 21, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Humans; Kidney; Leukemia, Myeloid; Mice; Mice, Nude; Mutant Proteins; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recombinant Fusion Proteins; Sorafenib; Tandem Repeat Sequences; Transfection; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2007
Renal-cell carcinoma--molecular pathways and therapies.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Gene Silencing; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein

2007
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
    Haematologica, 2007, Volume: 92, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, Platelet-Derived Growth Factor beta; Sorafenib

2007
Hand-foot and stump syndrome to sorafenib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jan-20, Volume: 25, Issue:3

    Topics: Amputation Stumps; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot; Hand; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Syndrome

2007
Sorafenib-induced erythema multiforme.
    Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:3

    Topics: Administration, Oral; Benzenesulfonates; Erythema Multiforme; Female; Humans; Lung Neoplasms; Melanoma, Amelanotic; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2007
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
    Biochemical pharmacology, 2007, May-01, Volume: 73, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, IGF Type 1; Sorafenib; Tumor Cells, Cultured; Tyrphostins

2007
New drugs 07, part I.
    Nursing, 2007, Volume: 37, Issue:2

    Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States

2007
American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:2

    Topics: Anemia, Sickle Cell; Antibiotics, Antineoplastic; Antigens, CD20; Benzamides; Benzenesulfonates; CD40 Antigens; Diphenylamine; Hematologic Neoplasms; Hematology; Humans; Ki-1 Antigen; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib

2007
[Therapy sequence for renal cell carcinoma--new aspects!].
    Aktuelle Urologie, 2007, Volume: 38, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Approval; Humans; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thalidomide

2007
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    The oncologist, 2007, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Two new drugs for renal cell carcinoma.
    The Medical letter on drugs and therapeutics, 2007, Feb-26, Volume: 49, Issue:1255

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Newly approved therapies for RCC and their effect on the standard of care.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Interferons; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2007
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
    Neuroendocrinology, 2007, Volume: 85, Issue:1

    Topics: Benzenesulfonates; Digestive System Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; raf Kinases; rap1 GTP-Binding Proteins; Signal Transduction; Sorafenib; Tetrazolium Salts; Thiazoles

2007
ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
    Cancer treatment reviews, 2007, Volume: 33, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
    Medical hypotheses, 2007, Volume: 69, Issue:4

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urinary Bladder Neoplasms

2007
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
    The British journal of dermatology, 2007, Volume: 156, Issue:6

    Topics: Androstadienes; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Humans; MAP Kinase Signaling System; Melanoma; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib; Wortmannin

2007
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
    Southern medical journal, 2007, Volume: 100, Issue:3

    Topics: Acrodermatitis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Spinal Neoplasms

2007
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Cancer research, 2007, Apr-01, Volume: 67, Issue:7

    Topics: Benzenesulfonates; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA Interference; RNA, Small Interfering; Sorafenib; Transfection; Up-Regulation

2007
Pulmonary blastoma with renal metastasis responds to sorafenib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4

    Topics: Administration, Oral; Adult; Benzenesulfonates; Biopsy, Needle; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Neoplasms; Lung Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonectomy; Pulmonary Blastoma; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome

2007
Sorafenib-induced pancreatitis.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2007
Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
    European urology, 2007, Volume: 52, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2007
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
    Onkologie, 2007, Volume: 30, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Drug Costs; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2007
Interstitial nephritis in a patient taking sorafenib.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Inflammation; Kidney; Kidney Neoplasms; Leukocytes; Male; Nephritis, Interstitial; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2007
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
    Praxis, 2007, May-02, Volume: 96, Issue:18

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed

2007
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Proliferation; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Interleukin-3; Mice; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-sis; Pyridines; Pyrimidines; Sorafenib

2007
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
    Molecular and cellular biology, 2007, Volume: 27, Issue:15

    Topics: Animals; Benzenesulfonates; Calcium Signaling; Caspase 2; Caspases, Initiator; Cell Death; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Enzyme Induction; Eukaryotic Initiation Factor-2; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Phosphorylation; Protein Biosynthesis; Protein Folding; Protein Kinase Inhibitors; Pyridines; Reactive Oxygen Species; Regulatory Factor X Transcription Factors; RNA Splicing; Sorafenib; Transcription Factors; X-Box Binding Protein 1

2007
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
    Clinical genitourinary cancer, 2007, Volume: 5, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2007
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
    European urology, 2007, Volume: 52, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Survival Rate

2007
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Benzenesulfonates; Cell Division; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Transplantation, Heterologous

2007
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Cancer, 2007, Aug-01, Volume: 110, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A

2007
Can sorafenib cause hypothyroidism?
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Islet Cell; Female; Humans; Hypothyroidism; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib

2007
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Molecular pharmacology, 2007, Volume: 72, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; STAT5 Transcription Factor

2007
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
    Cancer cell, 2007, Volume: 12, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Benzenesulfonates; Cell Line, Tumor; Female; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Ubiquitin-Protein Ligases

2007
Sorafenib [corrected] in kidney cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome

2007
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jul-15, Volume: 13, Issue:14

    Topics: Benzenesulfonates; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Tumor Cells, Cultured; Vorinostat

2007
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
    JAMA, 2007, Jul-18, Volume: 298, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials, Phase III as Topic; Drug Combinations; Head and Neck Neoplasms; Humans; Liver Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Tegafur

2007
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
    Journal of translational medicine, 2007, Jul-18, Volume: 5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Eye Neoplasms; Humans; In Vitro Techniques; Lenalidomide; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Thalidomide; Xenograft Model Antitumor Assays

2007
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
    Radiology, 2007, Volume: 244, Issue:2

    Topics: Analysis of Variance; Animals; Benzenesulfonates; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Statistics, Nonparametric

2007
[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Aktuelle Urologie, 2007, Volume: 38, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Controlled Clinical Trials as Topic; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Kidney; Kidney Neoplasms; Meta-Analysis as Topic; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors

2007
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.
    The Journal of biological chemistry, 2007, Oct-05, Volume: 282, Issue:40

    Topics: Benzenesulfonates; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Lysosomes; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Endocrine Neoplasia Type 2a; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyridines; Sorafenib

2007
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Technology Transfer; Treatment Outcome

2007
[Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
    Der Urologe. Ausg. A, 2007, Volume: 46, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; T-Lymphocytes, Regulatory; Tumor Escape

2007
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
    The Journal of biological chemistry, 2007, Oct-12, Volume: 282, Issue:41

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; Bcl-2-Like Protein 11; bcl-X Protein; Benzenesulfonates; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand

2007
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-15, Volume: 13, Issue:16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib; Thiazoles

2007
Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
    Current oncology reports, 2007, Volume: 9, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2007
ASCO 2007: plenary top 5.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Medical Oncology; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Societies, Medical; Sorafenib; United States

2007
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
    World journal of gastroenterology, 2007, Sep-07, Volume: 13, Issue:33

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib

2007
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
    European urology, 2008, Volume: 53, Issue:2

    Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2008
Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib.
    Onkologie, 2007, Volume: 30, Issue:8-9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2007
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Experimental hematology, 2007, Volume: 35, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib

2007
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Journal of the National Cancer Institute, 2007, Oct-03, Volume: 99, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome

2007
Acute pancreatitis associated with sorafenib.
    Southern medical journal, 2007, Volume: 100, Issue:9

    Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Enzyme Inhibitors; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib; Tomography, X-Ray Computed

2007
Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment.
    Acta ophthalmologica, 2008, Volume: 86, Issue:4

    Topics: Administration, Oral; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Choroidal Neovascularization; Humans; Macular Edema; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
    Cancer research, 2007, Oct-01, Volume: 67, Issue:19

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Cell Growth Processes; Colorectal Neoplasms; Combined Modality Therapy; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Radiation; Drug Administration Schedule; Endothelial Cells; Female; G2 Phase; HCT116 Cells; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Retinoblastoma Protein; Sorafenib; Xenograft Model Antitumor Assays

2007
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Cancer research, 2007, Oct-01, Volume: 67, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Death Domain Receptor Signaling Adaptor Proteins; Down-Regulation; Drug Synergism; Humans; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; U937 Cells

2007
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypothyroidism; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Risk Assessment; Sorafenib; Thyroid Function Tests

2008
Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
    The oncologist, 2007, Volume: 12, Issue:10

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib

2007
Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Colonic Diseases; Colonoscopy; Diagnosis, Differential; Follow-Up Studies; Humans; Intestinal Perforation; Kidney Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rupture, Spontaneous; Sorafenib; Tomography, X-Ray Computed

2009
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines.
    The Journal of biological chemistry, 2008, Jan-11, Volume: 283, Issue:2

    Topics: Apoptosis; Benzenesulfonates; Cell Adhesion; Cell Death; Cell Line, Tumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Melanoma; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2008
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:11

    Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib

2007
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    The Journal of urology, 2008, Volume: 179, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2008
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
    Cancer, 2008, Jan-15, Volume: 112, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    The British journal of dermatology, 2008, Volume: 158, Issue:3

    Topics: Aged; Aged, 80 and over; Benzenesulfonates; Blister; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2008
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;
    European urology, 2008, Volume: 53, Issue:5

    Topics: Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; France; Humans; Incidence; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Treatment Outcome

2008
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-01, Volume: 26, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2008
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
    Leukemia, 2008, Volume: 22, Issue:4

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzenesulfonates; Cell Line; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mitochondria; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib

2008
[News in digestive oncology].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Combined Modality Therapy; Digestive System Neoplasms; Esophageal Neoplasms; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms

2008
Examining heterogeneity in phase II trial designs may improve success in phase III.
    Journal of the National Cancer Institute, 2008, Feb-06, Volume: 100, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Confounding Factors, Epidemiologic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Treatment Outcome

2008
Quantifying hypertension in patients with cancer treated with sorafenib.
    The Lancet. Oncology, 2008, Volume: 9, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2008
Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:2

    Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Therapy, Combination; Fluorescein Angiography; Humans; Macular Degeneration; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiography; Ranibizumab; Recurrence; Sorafenib

2008
FDA approves sorafenib for patients with inoperable liver cancer.
    Gastroenterology, 2008, Volume: 134, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration

2008
[New drugs; sunitinib and sorafenib].
    Nederlands tijdschrift voor geneeskunde, 2007, Dec-29, Volume: 151, Issue:52

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome

2007
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Journal of the National Cancer Institute, 2008, Feb-20, Volume: 100, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib

2008
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
    Physiological genomics, 2008, Apr-22, Volume: 33, Issue:2

    Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Complement C1q; Disease Models, Animal; Enzyme Activation; Gene Expression Profiling; Genomics; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Mitogen-Activated Protein Kinases; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred Dahl; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transforming Growth Factor beta3; Vascular Endothelial Growth Factor Receptor-2

2008
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
    Journal of pharmaceutical and biomedical analysis, 2008, Jan-22, Volume: 46, Issue:2

    Topics: Benzenesulfonates; Calibration; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sorafenib

2008
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.
    Blood, 2008, Jun-15, Volume: 111, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; CD8-Positive T-Lymphocytes; Cell Division; Cell Movement; Cells, Cultured; Cytokines; Dendritic Cells; Dextrans; Endocytosis; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indoles; Interleukin-4; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Toll-Like Receptor 4

2008
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:5

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transforming Growth Factor beta

2008
Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
    Dermatology online journal, 2007, Oct-13, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Facial Neoplasms; Humans; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib

2007
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
    The Journal of investigative dermatology, 2008, Volume: 128, Issue:8

    Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Flavonoids; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mitogen-Activated Protein Kinase Kinases; Morpholines; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sirolimus; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Wortmannin

2008
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
    Journal of the National Cancer Institute, 2008, Mar-19, Volume: 100, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Research Design; Sorafenib; Treatment Outcome

2008
Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.
    Melanoma research, 2008, Volume: 18, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Lower Extremity; Lymphatic Metastasis; Lymphedema; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2008
Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.
    Leukemia, 2008, Volume: 22, Issue:6

    Topics: Amino Acid Sequence; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blood Cells; Blotting, Western; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Hypersensitivity, Delayed; Immunization; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Lectins, C-Type; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Vascular Endothelial Growth Factor; Resting Phase, Cell Cycle; Sequence Homology, Amino Acid; Sorafenib; T-Lymphocytes

2008
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:1 Pt. 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Protocols; Contraindications; Disease-Free Survival; Humans; Liver Neoplasms; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sorafenib; Survival Rate

2008
[New drugs; sunitinib and sorafenib].
    Nederlands tijdschrift voor geneeskunde, 2008, Feb-23, Volume: 152, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Heart; Humans; Indoles; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
    Cancer biology & therapy, 2008, Volume: 7, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Nerve Sheath Neoplasms; Neurilemmoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiography, Thoracic; Sorafenib; Thoracic Wall; Treatment Outcome

2008
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
    BJU international, 2008, Volume: 102, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2008
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Differentiation; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; G1 Phase; Gene Silencing; Humans; Liposarcoma; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nerve Sheath Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib

2008
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate

2007
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:5

    Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Line, Tumor; Exons; Humans; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Thyroid Neoplasms

2008
Bowel perforation after radiotherapy in a patient receiving sorafenib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-10, Volume: 26, Issue:14

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Intestinal Perforation; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiation Injuries; Skin Neoplasms; Sorafenib

2008
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib

2008
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    The Journal of urology, 2008, Volume: 180, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
[Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Oxides; Phenylurea Compounds; Pyridines; Sorafenib

2008
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Sorafenib; STAT3 Transcription Factor

2008
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-01, Volume: 14, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Ceramides; Drug Synergism; Humans; Liposomes; Melanoma; Mitogen-Activated Protein Kinases; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib

2008
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea

2008
Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2008, Volume: 20, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis

2008
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
    Archives of dermatology, 2008, Volume: 144, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib

2008
Sorafenib-induced eruptive melanocytic lesions.
    Archives of dermatology, 2008, Volume: 144, Issue:6

    Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Diagnosis, Differential; Drug Eruptions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nevus, Pigmented; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin; Skin Neoplasms; Sorafenib

2008
Sorafenib-induced palmoplantar hyperkeratosis.
    Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Keratoderma, Palmoplantar; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.
    AJR. American journal of roentgenology, 2008, Volume: 191, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Mammary Neoplasms, Experimental; Niacinamide; Outcome Assessment, Health Care; Perfusion; Phenylurea Compounds; Prognosis; Pyridines; Rats; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2008
Reader seeks clarification on hand-foot skin reaction.
    Clinical journal of oncology nursing, 2008, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Information Services; Drug Labeling; Foot Dermatoses; Hand Dermatoses; Humans; Internet; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Semantics; Sorafenib

2008
Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
    Leukemia research, 2009, Volume: 33, Issue:2

    Topics: Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences

2009
18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
    The oncologist, 2008, Volume: 13, Issue:6

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2008
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
    Urologia internationalis, 2008, Volume: 80, Issue:4

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome; Vena Cava, Inferior

2008
Comment on Di Silverio et al.: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451-453.
    Urologia internationalis, 2008, Volume: 80, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Vena Cava, Inferior

2008
[Targeted therapy for metastatic bladder cancer].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms

2008
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Surveys; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Quality of Life; Salvage Therapy; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult

2009
[Regression of vena cava tumour thrombus in response to sorafenib].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Renal Veins; Sorafenib; Time Factors; Treatment Outcome; Venae Cavae; Venous Thrombosis

2008
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2008
A distinct cutaneous reaction to sorafenib and a multikinase inhibitor.
    International journal of dermatology, 2008, Volume: 47, Issue:7

    Topics: Administration, Oral; Benzenesulfonates; Biopsy, Needle; Drug Therapy, Combination; Follow-Up Studies; Head; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Neck; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Severity of Illness Index; Skin Diseases, Papulosquamous; Sorafenib; Treatment Outcome

2008
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
    Cancer science, 2008, Volume: 99, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Thyroid Neoplasms

2008
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
    Orvosi hetilap, 2008, Jul-13, Volume: 149, Issue:28

    Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib

2008
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
    Cancer, 2008, Sep-15, Volume: 113, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythrocyte Indices; Female; Hematologic Tests; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib

2008
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    The Journal of urology, 2008, Volume: 180, Issue:3

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease

2008
A Kaposi's sarcoma complete clinical response after sorafenib administration.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:9

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sarcoma, Kaposi; Skin Neoplasms; Sorafenib; Treatment Outcome

2008
Sorafenib in liver cancer--just the beginning.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Costs; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; raf Kinases; Sorafenib

2008
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
    Toxicological sciences : an official journal of the Society of Toxicology, 2008, Volume: 106, Issue:1

    Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles

2008
Challenges and pitfalls of combining targeted agents in phase I studies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2008
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-01, Volume: 14, Issue:15

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms

2008
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.
    Cancer research, 2008, Aug-01, Volume: 68, Issue:15

    Topics: Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Humans; MAP Kinase Signaling System; Mutagenesis, Site-Directed; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib

2008
Promising newer molecular-targeted therapies in head and neck cancer.
    Drugs, 2008, Volume: 68, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2008
[Targeted therapy - point blank or single shot].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2008
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
    Urology, 2008, Volume: 72, Issue:4

    Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Preoperative Care; Protein Kinase Inhibitors; Pyridines; Sorafenib

2008
About sorafenib in castration-resistant prostate cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Male; Niacinamide; Orchiectomy; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib

2008
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    European urology, 2008, Volume: 54, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome; Young Adult

2008
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Sirolimus; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2008
Watchdog set to reject four drugs for kidney cancer on the NHS.
    BMJ (Clinical research ed.), 2008, Aug-14, Volume: 337

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Approval; Drug Costs; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; State Medicine; Sunitinib; United Kingdom

2008
[New therapeutic regimes in metastasic renal-cell carcinoma].
    Der Internist, 2008, Volume: 49, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2008
[Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 4

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Effectively targeting BRAF in melanoma: a formidable challenge.
    Pigment cell & melanoma research, 2008, Volume: 21, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Treatment Outcome

2008
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-20, Volume: 26, Issue:24

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
    Journal of neuro-oncology, 2009, Volume: 91, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Cortex; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Searching for the Achilles' heel of melanoma cells: new treatment modalities.
    Pigment cell & melanoma research, 2008, Volume: 21, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Clinical Trials as Topic; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Melanoma; Niacinamide; Organoselenium Compounds; Phenylurea Compounds; Pyridines; Pyrimethamine; Skin Neoplasms; Sorafenib; Treatment Outcome; Urea; Vascular Endothelial Growth Factor Receptor-2

2008
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.
    Oncology, 2008, Volume: 74, Issue:3-4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Sample Size; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2008
Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
    Oncology, 2008, Volume: 74, Issue:3-4

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Renal Dialysis; Sorafenib

2008
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proctocolitis; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Journal of the National Cancer Institute, 2008, Sep-03, Volume: 100, Issue:17

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Sep-01, Volume: 14, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Death; Cell Line, Tumor; Drug Synergism; fas Receptor; Humans; Hydroxamic Acids; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat

2008
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:8

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib

2009
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
    Cancer biology & therapy, 2008, Volume: 7, Issue:10

    Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Caspase 8; Cell Survival; Ceramides; eIF-2 Kinase; Endoplasmic Reticulum; Eukaryotic Initiation Factor-2; fas Receptor; Humans; Hydroxamic Acids; Models, Biological; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vorinostat

2008
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
    Oncogene, 2009, Jan-08, Volume: 28, Issue:1

    Topics: Apoptosis; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glutamic Acid; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Valine

2009
Sorafenib-induced liver failure.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:8

    Topics: Adenocarcinoma, Follicular; Aged; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Liver Failure; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms

2008
[Renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2008
[Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
    Journal of translational medicine, 2008, Sep-29, Volume: 6

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles

2008
[Systemic therapy of metastasizing renal cell carcinoma].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Tomography, X-Ray Computed

2008
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
    Bulletin du cancer, 2008, Volume: 95, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2008
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32

    Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niacinamide; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2008
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32

    Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseases; Echocardiography; Electrocardiography; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2008
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2008, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Analysis of Variance; Barrett Esophagus; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyridines; Reference Values; Sorafenib

2008
Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.
    Cancer immunology, immunotherapy : CII, 2009, Volume: 58, Issue:6

    Topics: Apoptosis; Benzenesulfonates; CD28 Antigens; CD3 Complex; CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Flow Cytometry; Humans; Immunosuppressive Agents; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Antigen, T-Cell; Sirolimus; Sorafenib

2009
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:4

    Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome

2009
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.
    Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cisplatin; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thymus Neoplasms; Tomography, X-Ray Computed

2009
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.
    Journal of hematology & oncology, 2008, Oct-17, Volume: 1

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Male; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib

2008
[Eruptive nevi associated with sorafenib treatment].
    Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Middle Aged; Nevus; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Young Adult

2008
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:12

    Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Temozolomide; Treatment Outcome

2008
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    European urology, 2009, Volume: 55, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Withholding Treatment

2009
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    European urology, 2009, Volume: 55, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment

2009
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Circulation, 2008, Nov-11, Volume: 118, Issue:20

    Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Heart; Heart Ventricles; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyridines; Pyrimidines; raf Kinases; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Ventricular Remodeling

2008
Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
    Clinical drug investigation, 2008, Volume: 28, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2008
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-10, Volume: 26, Issue:35

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Survival; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Italy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Panitumumab; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Retrospective Studies; Sorafenib; Switzerland; Time Factors; Treatment Outcome

2008
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Cyclin D; Cyclins; Down-Regulation; Humans; Medulloblastoma; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transfection

2008
Severe cutaneous reaction to sorafenib: induction of tolerance.
    Acta dermato-venereologica, 2008, Volume: 88, Issue:6

    Topics: Aged; Benzenesulfonates; Dose-Response Relationship, Drug; Eczema; Female; Humans; Maximum Tolerated Dose; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2008
Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
    European urology, 2009, Volume: 55, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
[Vascular and renal effects of anti-angiogenic therapy].
    Nephrologie & therapeutique, 2008, Volume: 4, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Glomerular Filtration Rate; Glomerulonephritis; Humans; Indoles; Kidney; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib.
    The British journal of ophthalmology, 2009, Volume: 93, Issue:7

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blotting, Western; Choroidal Neovascularization; Dextrans; Dose-Response Relationship, Drug; Female; Fluoresceins; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-20, Volume: 26, Issue:36

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate

2008
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
    Cancer science, 2009, Volume: 100, Issue:1

    Topics: Animals; Benzamides; Benzenesulfonates; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2009
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
    Cancer research, 2008, Dec-01, Volume: 68, Issue:23

    Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Glypicans; Humans; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays

2008
Quo vadis with targeted drugs in the 21st century?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-01, Volume: 27, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; ErbB Receptors; Female; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib

2009
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
    Cancer, 2009, Jan-01, Volume: 115, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis

2009
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Hypertension; Incidence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quality of Life; Sorafenib

2008
Targeting metastatic melanoma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Dec-15, Volume: 65, Issue:24 Suppl 9

    Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Skin Neoplasms; Sorafenib; Thionucleotides

2008
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-10, Volume: 27, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate

2008
Sorafenib in advanced hepatocellular carcinoma.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2008
Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.
    Clinical drug investigation, 2009, Volume: 29, Issue:1

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Intensity-Modulated; Salvage Therapy; Sorafenib; Treatment Outcome

2009
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dermatitis, Exfoliative; Drug Eruptions; Female; Humans; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib; Treatment Outcome

2008
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
    Cancer control : journal of the Moffitt Cancer Center, 2009, Volume: 16, Issue:1

    Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes

2009
Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
    Journal of gastrointestinal cancer, 2007, Volume: 38, Issue:2-4

    Topics: Adult; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Female; Humans; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome

2007
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:1

    Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Sorafenib for liver cancer: the horizon broadens.
    The Lancet. Oncology, 2009, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Research Design; Sorafenib

2009
Cutaneous drug eruptions induced by sorafenib: a case series.
    Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Female; Humans; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2008
Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jan-15, Volume: 877, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Chromatography, Liquid; Female; Glucuronides; Liver; Male; Mice; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tandem Mass Spectrometry

2009
Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
    Biomedical research (Tokyo, Japan), 2008, Volume: 29, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Interferon-alpha; Kidney Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2008
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:4

    Topics: Animals; Benzenesulfonates; Collateral Circulation; Enteritis; Heme Oxygenase-1; Hepatitis; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Neovascularization, Physiologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Splanchnic Circulation

2009
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Body Weight; Disease Models, Animal; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Feb-20, Volume: 27, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib

2009
Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
    The oncologist, 2009, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; United States; United States Food and Drug Administration

2009
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    The oncologist, 2009, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    The oncologist, 2009, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Treating hepatocellular carcinoma without liver transplantation.
    Current gastroenterology reports, 2009, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
    Cancer letters, 2009, May-18, Volume: 277, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase C; Protein Kinase C beta; Pyridines; Pyrroles; Ribosomal Protein S6 Kinases; Signal Transduction; Sorafenib; Sunitinib

2009
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Aktuelle Urologie, 2009, Volume: 40, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Time Factors

2009
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Aktuelle Urologie, 2009, Volume: 40, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Cohort Studies; Data Interpretation, Statistical; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Surveys and Questionnaires; Time Factors; Urology

2009
Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2009, Volume: 7, Issue:5

    Topics: Aged; Angioedema; Antineoplastic Agents; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; Folliculitis; Foot Dermatoses; Hand Dermatoses; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Syndrome

2009
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:2

    Topics: Antibodies; Antigens, Neoplasm; Benzenesulfonates; Butadienes; CD28 Antigens; CD3 Complex; Epitopes; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Phytohemagglutinins; Protein Kinase Inhibitors; Pyridines; Receptors, Antigen, T-Cell; Signal Transduction; Sorafenib; T-Lymphocytes; Tetradecanoylphorbol Acetate

2009
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
    Journal of neurosurgery, 2009, Volume: 111, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib

2009
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
    International journal of clinical pharmacology and therapeutics, 2009, Volume: 47, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Blood Specimen Collection; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Kidney Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sorafenib; Time Factors

2009
Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
    Onkologie, 2009, Volume: 32, Issue:1-2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphatic Metastasis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2009
Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib.
    Onkologie, 2009, Volume: 32, Issue:1-2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Benzenesulfonates; Carcinoma, Hepatocellular; Dermatomyositis; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Prednisolone; Pyridines; Remission Induction; Sorafenib; Treatment Outcome

2009
Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
    The Journal of investigative dermatology, 2009, Volume: 129, Issue:3

    Topics: Aneuploidy; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Squamous Cell; Gene Expression Regulation, Neoplastic; Mice; Mice, Transgenic; Models, Biological; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A

2009
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Allergy, 2009, Volume: 64, Issue:6

    Topics: Amino Acid Sequence; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib

2009
Sorafenib is active on lung metastases from synovial sarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sarcoma, Synovial; Sorafenib; Time Factors; Treatment Outcome

2009
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
    Leukemia, 2009, Volume: 23, Issue:5

    Topics: Aged; Animals; Benzenesulfonates; Blast Crisis; Blotting, Western; Cells, Cultured; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Male; Mice; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Phosphorylation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sorafenib

2009
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Clinical genitourinary cancer, 2009, Volume: 7, Issue:1

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Niacinamide; Paresthesia; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
    Clinical genitourinary cancer, 2009, Volume: 7, Issue:1

    Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Inflammation; Keratoacanthoma; Keratosis, Actinic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib

2009
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Journal of cellular and molecular medicine, 2009, Volume: 13, Issue:8B

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Cell Line, Tumor; Liver Neoplasms, Experimental; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sirolimus; Sorafenib

2009
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bevacizumab; Dose-Response Relationship, Drug; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Vascular Endothelial Growth Factor A

2009
Major achievements in hepatocellular carcinoma.
    Lancet (London, England), 2009, Feb-21, Volume: 373, Issue:9664

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate; Ultrasonography

2009
[Diagnosis and treatment of hepatocellular carcinoma].
    Medicina clinica, 2009, Feb-28, Volume: 132, Issue:7

    Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Early Detection of Cancer; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib

2009
[Hand-foot syndrome and sorafenib].
    Bulletin du cancer, 2009, Volume: 96, Issue:2

    Topics: Benzenesulfonates; Dermatology; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Medical Oncology; Niacinamide; Pharmacy; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Sorafenib; Syndrome

2009
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63 Suppl 1

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Linear Models; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors

2009
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.
    Molecular cancer research : MCR, 2009, Volume: 7, Issue:3

    Topics: Angiopoietin-1; Animals; Apoptosis; Benzenesulfonates; Doxycycline; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; In Vitro Techniques; Melanoma, Experimental; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, TIE-2; Recombinant Proteins; Signal Transduction; Sorafenib; Transfection

2009
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    British journal of cancer, 2009, Apr-07, Volume: 100, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Cell Line, Tumor; Dendritic Cells; Humans; Indoles; Interleukin-12; Kidney Neoplasms; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Monocytes; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes; Vascular Endothelial Growth Factor A

2009
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice.
    Journal of pharmaceutical and biomedical analysis, 2009, May-01, Volume: 49, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality Control; Reference Standards; Reproducibility of Results; Sorafenib; Specimen Handling; Spectrophotometry, Ultraviolet

2009
Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Journal of cellular physiology, 2009, Volume: 220, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; RNA Interference; RNA, Messenger; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Time Factors

2009
Hyperkeratosis of nipple skin during sorafenib treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Breast Diseases; Carcinoma, Hepatocellular; Humans; Keratosis; Liver Neoplasms; Male; Niacinamide; Nipples; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
    Cancer letters, 2009, Jun-18, Volume: 278, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; I-kappa B Proteins; Liver Neoplasms; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; Transcription Factor RelA

2009
Efficient exploration of large combinatorial chemistry spaces by monomer-based similarity searching.
    Journal of chemical information and modeling, 2009, Volume: 49, Issue:4

    Topics: Algorithms; Benzenesulfonates; Chemistry, Organic; Combinatorial Chemistry Techniques; Computer Simulation; Databases, Factual; Metoprolol; Molecular Conformation; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Results; Software; Sorafenib

2009
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
    Cancer research, 2009, Apr-01, Volume: 69, Issue:7

    Topics: Animals; Benzenesulfonates; Cell Line; Drug Resistance; fms-Like Tyrosine Kinase 3; Indoles; Mice; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Receptors, Platelet-Derived Growth Factor; Sorafenib; Staurosporine; Tandem Repeat Sequences

2009
[Hepatocellular carcinoma management in the era of sorafenib].
    Gastroenterologie clinique et biologique, 2009, Volume: 33, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2009
Antiangiogenic therapy: not just for cancer anymore?
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension, Portal; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib

2009
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.
    British journal of pharmacology, 2009, Volume: 157, Issue:2

    Topics: Animals; Aorta; Benzenesulfonates; Blotting, Western; Hypertension, Portal; Liver; Liver Cirrhosis, Biliary; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; Signal Transduction; Sorafenib

2009
[Toxicity of radiation therapy and antiangiogenics combination: a case report].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2009, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Benzenesulfonates; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiodermatitis; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2009
[Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2009, Volume: 25, Issue:4

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Exocytosis; Flow Cytometry; Humans; Immunohistochemistry; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; Sorafenib

2009
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
    Journal of the National Cancer Institute, 2009, Apr-15, Volume: 101, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lentivirus Infections; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction; Smad2 Protein; Sorafenib; Stomach Neoplasms; Thrombospondin 1; Transforming Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2009
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
    Investigational new drugs, 2010, Volume: 28, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recurrence; Solitary Fibrous Tumors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ultrasonography

2010
The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2009, Volume: 19, Issue:4

    Topics: Adolescent; Benzenesulfonates; Carcinoma, Papillary; Child; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2009
Targeting ELF in therapy of liver cancer.
    Cancer biology & therapy, 2007, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carrier Proteins; Humans; Liver Neoplasms; Microfilament Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2007
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Cancer research, 2009, May-01, Volume: 69, Issue:9

    Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides

2009
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    BMC pharmacology, 2009, Apr-15, Volume: 9

    Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins

2009
The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
    Biochemistry, 2009, Jun-16, Volume: 48, Issue:23

    Topics: Animals; Benzenesulfonates; Cell Cycle Proteins; Crystallography, X-Ray; Humans; Ligands; Mice; Models, Molecular; Molecular Chaperones; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Ruthenium; Sorafenib

2009
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2009, Volume: 21, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
    Clinical and experimental nephrology, 2009, Volume: 13, Issue:4

    Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease Progression; Glomerulonephritis, IGA; Humans; Hypertension; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Sorafenib; Transplantation, Homologous

2009
Selecting promising treatments in randomized Phase II cancer trials with an active control.
    Journal of biopharmaceutical statistics, 2009, Volume: 19, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials, Phase II as Topic; Control Groups; Endpoint Determination; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome

2009
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
    Blood, 2009, Jun-25, Volume: 113, Issue:26

    Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome

2009
[Prospect of hepatocellular carcinoma in 2008].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diagnosis, Differential; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Polymerase Chain Reaction; Pyridines; Retrospective Studies; Sorafenib; Survival Rate

2009
A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment.
    Journal of hepatology, 2009, Volume: 50, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biological Evolution; Cholangiocarcinoma; Computational Biology; Databases, Genetic; Extracellular Space; Humans; MAP Kinase Signaling System; Mice; Multigene Family; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Sorafenib; Systems Biology

2009
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Thyroid : official journal of the American Thyroid Association, 2009, Volume: 19, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypothyroidism; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib

2009
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2009,Summer, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Evidence-Based Medicine; Government Regulation; Health Policy; Health Priorities; Health Services Accessibility; Health Services Needs and Demand; Humans; Insurance, Health, Reimbursement; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Research Support as Topic; Social Values; Sorafenib; Survival Analysis; Treatment Outcome

2009
Sequential sorafenib and sunitinib for renal cell carcinoma.
    The Journal of urology, 2009, Volume: 182, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2009
Targeting renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-10, Volume: 27, Issue:20

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
[Sorafenib reverses multidrug resistance of hepatoma cells in vitro].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:6

    Topics: Base Sequence; Benzenesulfonates; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thymoma; Thymus Neoplasms

2009
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
    Radiology, 2009, Volume: 251, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Image Processing, Computer-Assisted; Kidney Neoplasms; Linear Models; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spin Labels

2009
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
    Molecular pharmacology, 2009, Volume: 76, Issue:2

    Topics: Antigens, CD; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; HCT116 Cells; Humans; Hydroxamic Acids; JNK Mitogen-Activated Protein Kinases; Membrane Proteins; Niacinamide; Oxidoreductases; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat

2009
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Molecular pharmacology, 2009, Volume: 76, Issue:2

    Topics: Adenoviridae; Antineoplastic Agents; Autophagy; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Enzyme Inhibitors; fas Receptor; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; RNA, Small Interfering; Sorafenib; Transfection

2009
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    Cancer biology & therapy, 2009, Volume: 8, Issue:13

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Disease Models, Animal; Humans; Indoles; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Erythema multiforme induced by sorafenib.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:7

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Humans; Liver Function Tests; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sorafenib; Survival Rate

2009
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jul-15, Volume: 877, Issue:22

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2009
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
    Journal of the National Cancer Institute, 2009, Jun-16, Volume: 101, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Cytokines; Disease-Free Survival; Endothelial Cells; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A

2009
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
    Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 2009, Issue:1

    Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobins; Hemolysis; Humans; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Cutaneous and ocular toxicology, 2009, Volume: 28, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Erythema Multiforme; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2009
Localized dyskeratotic plaque with milia associated with sorafenib.
    Journal of drugs in dermatology : JDD, 2009, Volume: 8, Issue:6

    Topics: Acantholysis; Benzenesulfonates; Carcinoma, Hepatocellular; Diabetes Mellitus; Drug Eruptions; Hepatitis B; Humans; Keratosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Multiple Histology Phase II Trials.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jul-01, Volume: 15, Issue:13

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase II as Topic; Computer Simulation; Humans; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sarcoma; Sorafenib; Treatment Outcome

2009
Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
    Investigational new drugs, 2010, Volume: 28, Issue:5

    Topics: Annexin A5; Antineoplastic Agents; Benzenesulfonates; Cell Death; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Nelfinavir; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Phosphorylation; Propidium; Protein Stability; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib

2010
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    The British journal of dermatology, 2009, Volume: 161, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult

2009
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
    BMC cancer, 2009, Jun-28, Volume: 9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2009
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.
    International journal of cancer, 2009, Oct-01, Volume: 125, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Butadienes; Colonic Neoplasms; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; HCT116 Cells; HLA-A2 Antigen; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib

2009
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:28-29

    Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhea; Fatal Outcome; Humans; Ileostomy; Intestinal Perforation; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib; Ulcer

2009
Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Journal of the American Chemical Society, 2009, Sep-23, Volume: 131, Issue:37

    Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Sequence; Benzenesulfonates; Binding, Competitive; Catalytic Domain; Crystallography, X-Ray; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Stability; Fluorescent Dyes; Humans; Kinetics; Models, Molecular; Molecular Sequence Data; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Reproducibility of Results; Small Molecule Libraries; Sorafenib; Structure-Activity Relationship

2009
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:7

    Topics: Angiography; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome

2009
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Follow-Up Studies; Humans; Keratinocytes; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Time Factors

2009
Array of cutaneous adverse effects associated with sorafenib.
    Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:2

    Topics: Benzenesulfonates; Biopsy, Needle; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunohistochemistry; Incidence; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Risk Assessment; Skin Diseases; Sorafenib

2009
Surgical resection of renal cell carcinoma after targeted therapy.
    The Journal of urology, 2009, Volume: 182, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2009
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
    BMC cancer, 2009, Jul-21, Volume: 9

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; China; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2009
Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
    International journal of cancer, 2010, Mar-15, Volume: 126, Issue:6

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA, Antisense; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; GTPase-Activating Proteins; Humans; Indoles; Kidney Neoplasms; Kinetics; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Pyrroles; RNA, Small Interfering; Sorafenib; Sunitinib; Transfection; Tumor Burden

2010
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
    Cancer letters, 2010, Feb-01, Volume: 288, Issue:1

    Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib

2010
Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Cancer biology & therapy, 2009, Volume: 8, Issue:18

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; G1 Phase; Humans; In Situ Nick-End Labeling; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Retinoblastoma Protein; S Phase; Sarcoma, Synovial; Signal Transduction; Sorafenib

2009
Tumor endothelial cells join the resistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Cells, Cultured; Drug Resistance, Neoplasm; Endothelium, Vascular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Ranibizumab; Sorafenib

2009
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15

    Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Endoglin; Endothelium, Vascular; Fluorouracil; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Cell Surface; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor

2009
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Cancer research, 2009, Aug-15, Volume: 69, Issue:16

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin E; Drug Delivery Systems; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genes, ras; Genotype; Humans; Lung Neoplasms; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2009
[Expert consensus on standardization of the management of primary liver cancer].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:6

    Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Congresses as Topic; Hepatectomy; Hepatic Artery; Humans; Liver Transplantation; Lung Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Radiotherapy, Conformal; Sorafenib; Ultrasonography

2009
Diagnosis and management of leptomeningeal disease.
    Clinical journal of oncology nursing, 2009, Volume: 13, Issue:4

    Topics: Adult; Antineoplastic Agents, Alkylating; Benzenesulfonates; Dacarbazine; Female; Humans; Meningeal Carcinomatosis; Meningeal Neoplasms; Niacinamide; Phenylurea Compounds; Prevalence; Prognosis; Protein Kinase Inhibitors; Pyridines; Sorafenib; Temozolomide

2009
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
    Laboratory investigation; a journal of technical methods and pathology, 2009, Volume: 89, Issue:9

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Computational Biology; Humans; Image Interpretation, Computer-Assisted; Mice; Mice, SCID; Microvessels; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays

2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
    Blood, 2009, Oct-01, Volume: 114, Issue:14

    Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays

2009
Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2009, Volume: 35, Issue:11

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Humans; Keratoacanthoma; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib

2009
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
    Future oncology (London, England), 2009, Volume: 5, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; Melanoma; Mice; Microsomes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Sorafenib

2009
[Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib

2009
The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
    Research in veterinary science, 2010, Volume: 88, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bone Neoplasms; Caspase 3; Cell Count; Cell Line, Tumor; Dog Diseases; Dogs; Flow Cytometry; Ki-67 Antigen; Microscopy, Electron, Transmission; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib

2010
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
    Journal of hepatology, 2009, Volume: 51, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Drug Synergism; Female; Gene Dosage; Genes, ras; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinases; Pyridines; ras Proteins; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transplantation, Heterologous

2009
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors

2009
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:8

    Topics: Animals; Benzenesulfonates; Cell Line, Tumor; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Male; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Solubility; Sorafenib

2009
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase I as Topic; Cyclophosphamide; Doxorubicin; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Pyridines; Sorafenib

2009
Rectal fistulae resulting from treatment with sorafenib and bevacizumab.
    Gastrointestinal endoscopy, 2009, Volume: 70, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Rectal Fistula; Sorafenib

2009
Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function.
    Clinical genitourinary cancer, 2009, Volume: 7, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2009, Volume: 21, Issue:8

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Medical Audit; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; United Kingdom

2009
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
    BMC medicine, 2009, Aug-24, Volume: 7

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance; Extracellular Signal-Regulated MAP Kinases; Hepatocytes; Humans; Immunochemistry; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sorafenib

2009
Hepatocellular carcinoma: The beginning of a long journey.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Matrix Metalloproteinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
The histologic spectrum of epithelial neoplasms induced by sorafenib.
    Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Epithelium; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib

2009
Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
    BMC medicine, 2009, Aug-24, Volume: 7

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Extracellular Signal-Regulated MAP Kinases; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib

2009
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Fibrosis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Time Factors

2009
New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication.
    Gut, 2009, Volume: 58, Issue:12

    Topics: Antiviral Agents; Benzenesulfonates; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Hepacivirus; Hepatocytes; Humans; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Replicon; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Viral Nonstructural Proteins; Virus Replication

2009
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:1

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Schistosomiasis; Skin Neoplasms; Soft Tissue Neoplasms; Sorafenib; Thyroid Neoplasms

2010
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine

2009
Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
    American journal of hematology, 2009, Volume: 84, Issue:10

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib; Tandem Repeat Sequences; Treatment Outcome

2009
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
    Pediatric blood & cancer, 2010, Volume: 54, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Melanosis; Meningeal Neoplasms; Neurocutaneous Syndromes; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide; Treatment Outcome

2010
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:9

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Blotting, Western; Disease Models, Animal; Drug Synergism; Humans; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms

2009
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
    Neoplasia (New York, N.Y.), 2009, Volume: 11, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; G2 Phase; Humans; Immunoenzyme Techniques; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tissue Array Analysis; Xenograft Model Antitumor Assays

2009
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
    Journal of hepatology, 2009, Volume: 51, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Cell Proliferation; Cytokines; Down-Regulation; Hemodynamics; Hypertension, Portal; Ligation; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Splanchnic Circulation

2009
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
    The Journal of biological chemistry, 2009, Nov-13, Volume: 284, Issue:46

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Humans; In Situ Hybridization; Liver Neoplasms; Luciferases; Mice; Mice, Nude; MicroRNAs; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Transfection

2009
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult

2009
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Membrane Proteins; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins; Pyridines; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured

2009
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2010
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
    World journal of gastroenterology, 2009, Sep-21, Volume: 15, Issue:35

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Lysis Syndrome

2009
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2010
Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results.
    AJR. American journal of roentgenology, 2009, Volume: 193, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prognosis; Pyridines; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2009
Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism.
    Cancer biology & therapy, 2009, Volume: 8, Issue:20

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Calcium; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Activation; Glutathione; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Intracellular Space; Liver Neoplasms; Microscopy, Confocal; Mitochondria; Niacinamide; Oxidative Stress; Phenylurea Compounds; Pyridines; Reactive Oxygen Species; Sorafenib

2009
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cohort Studies; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A

2009
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19

    Topics: Adenosine Triphosphatases; Animals; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Carrier Proteins; Cells, Cultured; Drug Evaluation, Preclinical; Humans; Hydrolysis; Indoles; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Swine; Xenopus laevis

2009
[Palmoplantar cutaneous reaction to sorafenib].
    Actas dermo-sifiliograficas, 2009, Volume: 100, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases, Vesiculobullous; Sorafenib

2009
Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplifi
    Investigational new drugs, 2010, Volume: 28, Issue:6

    Topics: Angiogenesis Inducing Agents; Apoptosis; bcl-2-Associated X Protein; Benzenesulfonates; Caspase 3; Cell Cycle; Cell Proliferation; Cell Shape; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Flow Cytometry; Gene Amplification; Genistein; Humans; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neuroblastoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Signal Transduction; Sorafenib; Telomerase; Treatment Outcome; Tumor Suppressor Protein p53; Up-Regulation

2010
Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.
    Journal of pharmacological sciences, 2009, Volume: 111, Issue:2

    Topics: Benzenesulfonates; Cytosol; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Group IV Phospholipases A2; HeLa Cells; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; src-Family Kinases; Temperature; Tetradecanoylphorbol Acetate; Time Factors

2009
Rapid development of hypertension by sorafenib: toxicity or target?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19

    Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Pressure; Drug Delivery Systems; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Mice; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Everolimus: in advanced renal cell carcinoma.
    Drugs, 2009, Oct-22, Volume: 69, Issue:15

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2009
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2010, Volume: 16, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Factor VIII; Hemophilia A; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2010
Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
    Cancer, 2009, Oct-15, Volume: 115, Issue:20

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Protocols; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib

2009
The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    International journal of cancer, 2010, Apr-01, Volume: 126, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Colony-Forming Units Assay; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Furans; Humans; Immunoenzyme Techniques; Immunosuppression Therapy; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2010
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:6

    Topics: Animals; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Enzyme Activation; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tyrosine

2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A

2009
Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
    Annals of surgical oncology, 2010, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Caspases; Cell Cycle; Cell Proliferation; Cytochromes c; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Flow Cytometry; Heat-Shock Proteins; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured

2010
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
    British journal of cancer, 2009, Nov-17, Volume: 101, Issue:10

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Myelopoiesis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Substrate Specificity; Sulfonamides; Sunitinib

2009
Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
    International journal of clinical oncology, 2009, Volume: 14, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Immunosuppressive Agents; Incidental Findings; Interferon-alpha; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiotherapy, Adjuvant; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid

2009
Drug essentials. Small molecule multitargeted TKI therapy.
    Oncology (Williston Park, N.Y.), 2008, Volume: 22, Issue:11 Suppl N

    Topics: Benzenesulfonates; Drug Interactions; Humans; Indoles; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2008
Acute aortic dissection during sorafenib-containing therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Sorafenib-induced hepatic encephalopathy.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Hepatic Encephalopathy; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors

2009
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Transplantation; Markov Chains; Models, Theoretical; Monte Carlo Method; Niacinamide; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome; Waiting Lists

2010
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
    BMC cancer, 2009, Oct-31, Volume: 9

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms

2009
Sorafenib-induced bilateral osteonecrosis of femoral heads.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-10, Volume: 28, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Femur Head Necrosis; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2010
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Therapy for metastatic RCC--questions remain.
    Nature reviews. Urology, 2009, Volume: 6, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
    Cancer, 2010, Jan-01, Volume: 116, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2010
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
    Targeted oncology, 2009, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Skin Tests; Sorafenib

2009
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 67, Issue:2

    Topics: Antineoplastic Agents; Asian People; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma.
    Bioorganic & medicinal chemistry letters, 2010, Jan-01, Volume: 20, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship

2010
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Humans; Indoles; Male; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Journal of hepatology, 2010, Volume: 52, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2010
Successful treatment of a brain-metastasized renal cell carcinoma.
    German medical science : GMS e-journal, 2009, Oct-21, Volume: 7

    Topics: Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Parietal Lobe; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2009
Evidence-based urology in practice: when to believe a subgroup analysis?
    BJU international, 2010, Volume: 105, Issue:2

    Topics: Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Evidence-Based Medicine; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib

2010
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Journal of hepatology, 2010, Volume: 52, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2010
Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib.
    Cardiovascular toxicology, 2010, Volume: 10, Issue:1

    Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Apoptosis; Benzenesulfonates; Blotting, Western; Cardiotonic Agents; Caspase 3; Caspase 7; Cell Separation; Extracellular Signal-Regulated MAP Kinases; In Vitro Techniques; Iron Chelating Agents; L-Lactate Dehydrogenase; Microscopy, Fluorescence; Myocytes, Cardiac; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Razoxane; Sorafenib

2010
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Molecular cell, 2009, Nov-13, Volume: 36, Issue:3

    Topics: Animals; Benzenesulfonates; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Enzyme Activation; Humans; Immunoprecipitation; MAP Kinase Signaling System; Melanoma; Mice; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Sorafenib; Transfection

2009
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Dec-01, Volume: 66, Issue:23

    Topics: Aged; Anticoagulants; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Hemorrhage; Humans; International Normalized Ratio; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Warfarin

2009
Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:6

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine

2009
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
    Urology, 2010, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
NICE rules that drug used in advanced liver cancer is not cost effective for the NHS.
    BMJ (Clinical research ed.), 2009, Nov-23, Volume: 339

    Topics: Antineoplastic Agents; Benzenesulfonates; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; United Kingdom

2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
    Oncogene, 2010, Feb-25, Volume: 29, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Humans; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; STAT3 Transcription Factor; Vascular Endothelial Growth Factor A

2010
[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Aktuelle Urologie, 2010, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Benzenesulfonates; Carcinoma, Renal Cell; Cooperative Behavior; Data Collection; Drug Delivery Systems; Drug Utilization; Germany; Humans; Immunotherapy; Indoles; Interdisciplinary Communication; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Medical Oncology; Niacinamide; Patient Care Team; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Urology

2010
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:4

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Sorafenib

2010
Sorafenib-induced acute myocardial infarction due to coronary artery spasm.
    Journal of cardiology, 2009, Volume: 54, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Coronary Vasospasm; Humans; Kidney Neoplasms; Male; Myocardial Infarction; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Sorafenib

2009
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.
    Gastroenterology, 2010, Volume: 138, Issue:3

    Topics: Autocrine Communication; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Polarity; Hep G2 Cells; Hepacivirus; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Occludin; Permeability; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tight Junctions; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Virus Internalization

2010
Baying for a flexible drug price.
    Lancet (London, England), 2009, Nov-28, Volume: 374, Issue:9704

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Industry; Fees, Pharmaceutical; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Time Factors

2010
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
    Anti-cancer drugs, 2010, Volume: 21, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiodermatitis; Sorafenib; Sunitinib; Treatment Outcome

2010
Health policy: The UK 'postcode lottery' in renal cell carcinoma.
    Nature reviews. Urology, 2009, Volume: 6, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Health Care Rationing; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Regional Health Planning; Sorafenib; Sunitinib; Survival Rate; United Kingdom

2009
Platelet count less than SHARP: what does a case series reveal?
    Expert opinion on drug safety, 2010, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Platelet Count; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thrombocytopenia

2010
Sorafenib - a small molecule with big promise?
    Leukemia & lymphoma, 2010, Volume: 51, Issue:2

    Topics: Abdominal Pain; Acute Disease; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Fatigue; Humans; Leukemia, Myeloid; Metabolic Clearance Rate; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2010
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
    Molecular cancer, 2009, Dec-10, Volume: 8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Division; Cell Line, Tumor; Cytoskeletal Proteins; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2009
[Sorafenib-induced multiple eruptive keratoacanthomas].
    Annales de dermatologie et de venereologie, 2009, Volume: 136, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunosuppressive Agents; Keratoacanthoma; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Sunlight

2009
The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
    Journal of immunology (Baltimore, Md. : 1950), 2009, Dec-15, Volume: 183, Issue:12

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Indoles; K562 Cells; Killer Cells, Natural; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib

2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
    Blood, 2010, Feb-18, Volume: 115, Issue:7

    Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib

2010
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
    British journal of cancer, 2010, Jan-19, Volume: 102, Issue:2

    Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glycoproteins; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Peptides; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib

2010
Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Posterior Leukoencephalopathy Syndrome; Prognosis; Pyridines; Sorafenib

2010
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
    Journal of cellular and molecular medicine, 2011, Volume: 15, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mitosis; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rhodamines; Sorafenib; Stomach Neoplasms; Taxoids; Xenograft Model Antitumor Assays

2011
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2009, Volume: 9, Issue:12

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
[Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib

2009
[Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Fatigue; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
    The Journal of urology, 2010, Volume: 183, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:1

    Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2010
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2010
Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
    Pharmacotherapy, 2010, Volume: 30, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Chromatography, High Pressure Liquid; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Iontophoresis; Limit of Detection; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilocarpine; Pilot Projects; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Sorafenib; Sweat; Tandem Mass Spectrometry

2010
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
    The British journal of dermatology, 2010, Volume: 162, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib; Treatment Outcome

2010
Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:1

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Donors; Waiting Lists

2010
[Targeting KRAS pathway in NSCLC therapy].
    Bulletin du cancer, 2009, Volume: 96 Suppl

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib

2009
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
    Medicina clinica, 2010, May-08, Volume: 134, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Early Diagnosis; Embolization, Therapeutic; Female; Hemochromatosis; Hepatectomy; Hepatitis, Viral, Human; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mass Screening; Niacinamide; Obesity; Phenylurea Compounds; Prospective Studies; Pyridines; Registries; Retrospective Studies; Sorafenib; Spain; Treatment Outcome; Young Adult; Yttrium Radioisotopes

2010
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Cancer biology & therapy, 2009, Volume: 8, Issue:24

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lung Neoplasms; Mesothelioma; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand

2009
Hepatocellular carcinoma: sorafenib before liver transplantation?
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Experience with sorafenib and the elderly patient.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate

2010
Tyrosine kinase inhibitor-induced macrocytosis.
    Anticancer research, 2009, Volume: 29, Issue:12

    Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2009
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
    The oncologist, 2010, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Exanthema; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis

2010
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
    British journal of cancer, 2010, Feb-02, Volume: 102, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib

2010
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:1

    Topics: Animals; Antigens, Bacterial; Bacterial Toxins; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell Proliferation; Endocytosis; Humans; Matrix Metalloproteinases; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Time Factors; Xenograft Model Antitumor Assays

2010
Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Breast cancer research and treatment, 2010, Volume: 124, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; Aromatase; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Caspase 7; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cytochromes c; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Niacinamide; Nitriles; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Testosterone; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazoles

2010
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endometrial Neoplasms; fas Receptor; Female; Humans; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2010
Identification of bona fide esophageal adenocarcinoma cell lines.
    Journal of the National Cancer Institute, 2010, Feb-24, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Clinical Trials as Topic; DNA Fingerprinting; Esophageal Neoplasms; Humans; National Institutes of Health (U.S.); Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Repeat Sequences; United States

2010
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
    Journal of the National Cancer Institute, 2010, Feb-24, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma, Large Cell; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; DNA Fingerprinting; Esophageal Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Niacinamide; Oligonucleotides; Oligopeptides; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Stomach Neoplasms; Tandem Repeat Sequences; Telomerase; United States

2010
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:8

    Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib

2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Cancer, 2010, Mar-01, Volume: 116, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Compassionate Use Trials; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; North America; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2010
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Renal Insufficiency; Sorafenib; Sunitinib

2010
Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:4

    Topics: ADAM Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dipeptides; Down-Regulation; Histocompatibility Antigens Class I; Humans; Hydroxamic Acids; Killer Cells, Natural; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2010
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Biological Transport; Brain; Cell Line; Cell Line, Tumor; Dogs; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Mice; Mice, Transgenic; Models, Chemical; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-01, Volume: 16, Issue:3

    Topics: Apoptosis; Benzenesulfonates; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepacivirus; Hepatocytes; Humans; Liver Neoplasms; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Transfection; Viral Proteins

2010
A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma.
    The Netherlands journal of medicine, 2010, Volume: 68, Issue:1

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Hepatocellular; Choristoma; Diagnosis, Differential; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retroperitoneal Neoplasms; Retroperitoneal Space; Sorafenib; Testicular Neoplasms; Ultrasonography

2010
The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.
    Molecular cancer, 2010, Jan-27, Volume: 9

    Topics: Apoptosis; Benzenesulfonates; Bone Marrow Cells; Caspase 8; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cyclin B; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Nelfinavir; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Up-Regulation

2010
Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate

2010
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
    Scandinavian journal of gastroenterology, 2010, Volume: 45, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tomography, X-Ray Computed

2010
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.
    Leukemia research, 2010, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma, Large B-Cell, Diffuse; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Transfection

2010
Hepatocellular carcinoma: the search for innovative adjuvant therapies.
    Oncology (Williston Park, N.Y.), 2009, Volume: 23, Issue:14

    Topics: Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib

2009
[Renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.
    The oncologist, 2010, Volume: 15, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib

2010
Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
    Bioorganic & medicinal chemistry letters, 2010, Mar-01, Volume: 20, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Discovery; Humans; Imidazoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-raf; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship

2010
Choroidal metastasis of renal cell carcinoma: a case report.
    Japanese journal of ophthalmology, 2010, Volume: 54, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Choroid Neoplasms; Eye Enucleation; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Risk of bleeding not increased by sorafenib or sunitinib.
    The Lancet. Oncology, 2010, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib

2010
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Antiviral Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Carcinoma, Renal Cell; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, X; Everolimus; Female; Gene Fusion; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Research Report; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult

2010
Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
    Growth factors (Chur, Switzerland), 2010, Volume: 28, Issue:3

    Topics: Adult; Aged; Astrocytes; Benzenesulfonates; Cell Survival; Humans; Light; Middle Aged; Niacinamide; Optic Disk; Phenylurea Compounds; Placenta Growth Factor; Platelet-Derived Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyridines; Retina; Retinal Neovascularization; Sorafenib; Vascular Endothelial Growth Factor A

2010
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
    Dermatology online journal, 2010, Feb-15, Volume: 16, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Pyrroles; Retreatment; Sorafenib; Sunitinib; Treatment Outcome

2010
Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epothilones; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Xenograft Model Antitumor Assays

2010
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Carcinoma; Drug Evaluation, Preclinical; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2010
Optimal de novo design of MRM experiments for rapid assay development in targeted proteomics.
    Journal of proteome research, 2010, May-07, Volume: 9, Issue:5

    Topics: Algorithms; Animals; Artificial Intelligence; Benzenesulfonates; Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Linear Models; Markov Chains; Mass Spectrometry; Melanoma; Mice; Niacinamide; Peptide Fragments; Phenylurea Compounds; Proteome; Proteomics; Pyridines; Reproducibility of Results; Sorafenib

2010
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Sorafenib; Thyroid Neoplasms

2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    BJU international, 2010, Volume: 106, Issue:6

    Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Epidemiologic Methods; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2010
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Doxorubicin; Female; Humans; Injections, Subcutaneous; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tegafur; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays

2010
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:9

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Tomography, X-Ray Computed

2010
Painless acute pancreatitis associated with sorafenib treatment: a case report.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:2

    Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Male; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; Sorafenib

2011
Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Journal of cellular physiology, 2010, Volume: 224, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; BH3 Interacting Domain Death Agonist Protein; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fas Ligand Protein; Fas-Associated Death Domain Protein; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Pyridines; raf Kinases; Sorafenib; Vitamin K 1

2010
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
    American journal of clinical oncology, 2011, Volume: 34, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure

2011
Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
    Targeted oncology, 2010, Volume: 5, Issue:1

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Dosage Calculations; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib

2010
Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma, Hepatocellular; Disease Progression; Fatal Outcome; Hemobilia; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stents

2010
Highlights from the Eigth International Kidney Cancer Symposium.
    Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:12

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Humans; Kidney Neoplasms; Multigene Family; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2009
Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
    Biochemistry, 2010, May-04, Volume: 49, Issue:17

    Topics: Benzamides; Benzenesulfonates; Crystallography, X-Ray; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Structure; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship

2010
Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
    International journal of clinical oncology, 2010, Volume: 15, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Biotransformation; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sorafenib; Treatment Outcome

2010
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    BJU international, 2010, Volume: 106, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A

2010
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
    BJU international, 2011, Volume: 107, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2011
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
    Journal of hepatology, 2010, Volume: 52, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cyclin G1; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sorafenib; Staurosporine; Up-Regulation

2010
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
    Journal of hepatology, 2010, Volume: 52, Issue:5

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA Mutational Analysis; Everolimus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Point Mutation; Precision Medicine; Pyridines; Ribavirin; Sirolimus; Sorafenib

2010
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:3

    Topics: Algorithms; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Gadolinium DTPA; Humans; Infusion Pumps; Japan; Liver Neoplasms; Magnetic Resonance Imaging; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Protein Precursors; Prothrombin; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate

2010
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:4

    Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin E; DNA, Neoplasm; Glioblastoma; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Mutant Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Proteins; Phenylurea Compounds; Phosphorylation; Phosphotyrosine; Protein Binding; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Cells, Cultured; Vanadates

2010
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
    British journal of cancer, 2010, Apr-13, Volume: 102, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Skin Neoplasms; Sorafenib

2010
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.
    Current cancer drug targets, 2010, Volume: 10, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzenesulfonates; Breast Neoplasms; Calcium; Cell Division; Cell Line, Tumor; Cytosol; DNA Primers; Endoplasmic Reticulum; Flow Cytometry; Gefitinib; Humans; Lapatinib; Membrane Potentials; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib

2010
Prognostic factors in patients treated with VEGF-targeted therapies.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors

2010
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Off-Label Use; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome

2010
Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
    Journal of gastrointestinal cancer, 2010, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.
    International journal of urology : official journal of the Japanese Urological Association, 2010, Volume: 17, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Preoperative Care; Pyridines; Severity of Illness Index; Sorafenib; Tomography, X-Ray Computed

2010
In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:8

    Topics: Animals; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Brain; Caco-2 Cells; Digoxin; Humans; LLC-PK1 Cells; Male; Mice; Mice, Knockout; Niacinamide; Permeability; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Swine

2010
A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
    Leukemia research, 2010, Volume: 34, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Blast Crisis; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib

2010
[Renal cell carcinoma management and therapies in 2010].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Everolimus; Humans; Indoles; Interferons; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Metabolic Networks and Pathways; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
[Targeted therapies: sequential and combined treatments].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Cytokines; ErbB Receptors; Humans; Indoles; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Digestive System; Heart; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Injury; Mucous Membrane; Muscle Fatigue; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
[Advanced renal carcinomas with special situations. How to treat them?].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib; Survival Rate; Treatment Outcome

2010
Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.
    International journal of oncology, 2010, Volume: 36, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Nucleus; Cell Separation; Doxorubicin; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Flow Cytometry; Gene Knockdown Techniques; Humans; Hydrogen Peroxide; Kidney Neoplasms; NF-E2-Related Factor 2; Niacinamide; Oxidants; Oxidative Stress; Phenylurea Compounds; Phosphorylation; Pyridines; RNA, Small Interfering; Sorafenib

2010
Drug therapy: sorafenib.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:5

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Factors; Sorafenib

2010
Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
    Journal of cellular physiology, 2010, Volume: 224, Issue:2

    Topics: Actins; Benzenesulfonates; Carcinoma, Hepatocellular; Cofilin 1; Cytoskeleton; Enzyme Activation; Humans; Liver Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Phosphorylation; Phosphotyrosine; Proto-Oncogene Proteins c-met; Pyridines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Signal Transduction; Sorafenib

2010
Sorafenib-induced acute pancreatitis.
    JOP : Journal of the pancreas, 2010, May-05, Volume: 11, Issue:3

    Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; Sorafenib

2010
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
    Journal of hepatology, 2010, Volume: 53, Issue:1

    Topics: Animals; Apoptosis; Base Sequence; Benzenesulfonates; Caspase 3; Cell Cycle; Cell Proliferation; Cells, Cultured; Collagen Type I; DNA Primers; Down-Regulation; Hepatic Stellate Cells; Humans; In Vitro Techniques; Liver Cirrhosis; Male; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sorafenib

2010
Editorial comment.
    Urology, 2010, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome

2010
Editorial comment.
    Urology, 2010, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome

2010
Sorafenib plus valproic acid for infant spinal glioblastoma.
    Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Extracellular Signal-Regulated MAP Kinases; Female; Glioblastoma; Humans; Immunohistochemistry; Infant; MAP Kinase Kinase Kinases; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy; raf Kinases; Sorafenib; Spinal Cord Neoplasms; Valproic Acid

2010
Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Neuroscience letters, 2010, Jul-12, Volume: 478, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glioblastoma; Glioma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Random Allocation; Sorafenib; Treatment Outcome

2010
The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
    Asian journal of andrology, 2010, Volume: 12, Issue:4

    Topics: Apoptosis; Benzenesulfonates; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Survivin

2010
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
    Investigational new drugs, 2011, Volume: 29, Issue:6

    Topics: Adamantane; Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Caspase 3; Caspase 7; Catechols; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Female; Humans; Kidney Neoplasms; Mice; Mice, SCID; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Xenograft Model Antitumor Assays

2011
A case of variant angina in a patient under chronic treatment with sorafenib.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:8

    Topics: Angina Pectoris, Variant; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiac Catheterization; Chronic Disease; Coronary Angiography; Electrocardiography; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors

2010
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Aktuelle Urologie, 2010, Volume: 41, Issue:3

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Everolimus; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2010
Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.
    International journal of clinical and experimental pathology, 2010, Apr-23, Volume: 3, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Survival; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Humans; In Situ Nick-End Labeling; Neuroblastoma; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphorylation; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor

2010
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:8

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Female; Hematologic Diseases; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate

2010
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
    Nature medicine, 2010, Volume: 16, Issue:6

    Topics: Activating Transcription Factors; Animals; Apoptosis; Benzenesulfonates; Brain Neoplasms; Cyclic AMP Response Element-Binding Protein; Gene Expression Profiling; Glioma; Humans; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2010
Effect of sorafenib on experimental choroidal neovascularization in the rat.
    Clinical & experimental ophthalmology, 2010, Volume: 38, Issue:7

    Topics: Animals; Benzenesulfonates; Choroidal Neovascularization; Computer Systems; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Fluorescein Angiography; Gene Expression; Intercellular Adhesion Molecule-1; Lasers; Male; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyridines; Radiation Injuries; Rats; Rats, Inbred BN; Sorafenib; Vascular Endothelial Growth Factor A

2010
[Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Interleukin-2; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Pain; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib

2010
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.
    International journal of oncology, 2010, Volume: 37, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma; Drug Evaluation, Preclinical; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Male; Niacinamide; Phagosomes; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Pyridines; Sorafenib; Transfection; Tumor Cells, Cultured

2010
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:11

    Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Lysis Syndrome

2010
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
    Leukemia, 2010, Volume: 24, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myelomonocytic, Chronic; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms

2010
Non-pigmenting fixed drug eruption induced by sorafenib.
    Acta dermato-venereologica, 2010, Volume: 90, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib

2010
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
    Cancer research, 2010, Jun-15, Volume: 70, Issue:12

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Cells, Cultured; Colony-Forming Units Assay; Drug Synergism; Electrophoretic Mobility Shift Assay; Female; Fibroblasts; Humans; Immunoblotting; Immunoenzyme Techniques; Isoenzymes; Isothiocyanates; Luciferases; Mice; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; NF-kappa B; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Retinal Dehydrogenase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin; Sorafenib; Spheroids, Cellular; Sulfoxides; Thiocyanates; Xenograft Model Antitumor Assays

2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
    Leukemia, 2010, Volume: 24, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib

2010
Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Renal Dialysis; Sorafenib

2011
Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
    BJU international, 2010, Volume: 106, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Epidemiologic Methods; Female; Health Status; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Treatment Outcome

2010
ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells.
    Cancer biology & therapy, 2010, Aug-01, Volume: 10, Issue:3

    Topics: Antibiotics, Antineoplastic; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Doxorubicin; HeLa Cells; Humans; Keratinocytes; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; RNA, Small Interfering; Signal Transduction; Sorafenib

2010
[Effect of sorafenib combined with daunorubicin on K562 cell line].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:3

    Topics: Apoptosis; Benzenesulfonates; Daunorubicin; Drug Synergism; Humans; K562 Cells; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
    Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2010
Ultraviolet recall dermatitis reaction with sorafenib.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Benzenesulfonates; Fatal Outcome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiodermatitis; Sorafenib; Ultraviolet Rays

2011
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-01, Volume: 16, Issue:13

    Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Liposomes; Liver Neoplasms, Experimental; Lung Neoplasms; Macrophages; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays; Zoledronic Acid

2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2010
Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Radiotherapy; Sorafenib; Treatment Outcome; Yttrium

2010
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Consensus Development Conferences as Topic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Radiotherapy; Sorafenib; Treatment Outcome; Yttrium

2010
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib

2011
Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.
    International journal of oncology, 2010, Volume: 37, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Proliferation; Cell Survival; Down-Regulation; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Humans; Hydrogen Peroxide; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sorafenib; Tumor Cells, Cultured

2010
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
    Journal of medicinal chemistry, 2010, Aug-12, Volume: 53, Issue:15

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Biological Availability; Crystallography, X-Ray; Female; Humans; Hydrogen Bonding; Imidazoles; Mice; Mice, Inbred BALB C; Models, Molecular; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Binding; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Structure-Activity Relationship; Transplantation, Heterologous

2010
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Transplantation, 2010, Jul-15, Volume: 90, Issue:1

    Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
    Toxicologic pathology, 2010, Volume: 38, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Echocardiography; Heart; Immunohistochemistry; In Situ Nick-End Labeling; Indazoles; Indoles; Male; Microscopy, Electron, Transmission; Mitochondria; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Rats; Sorafenib; Sulfonamides; Sunitinib; Troponin I

2010
Management of hepatocellular carcinoma: from prevention to molecular targeted therapy.
    Oncology, 2010, Volume: 78 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis B virus; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Bioorganic & medicinal chemistry, 2010, Aug-01, Volume: 18, Issue:15

    Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Catalytic Domain; Computer Simulation; Crystallography, X-Ray; Drug Design; Hydrogen Bonding; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Naphthalenes; Niacinamide; Oligopeptides; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib

2010
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
    Leukemia research, 2010, Volume: 34, Issue:10

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib; Transplantation, Homologous

2010
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
    Journal of experimental & clinical cancer research : CR, 2010, Jul-14, Volume: 29

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; DNA, Neoplasm; Female; Foot Dermatoses; Genotype; Hand Dermatoses; Humans; Hypertension; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2

2010
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
    Cancer research, 2010, Aug-01, Volume: 70, Issue:15

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcium; Carboxylic Ester Hydrolases; Cell Line, Tumor; Ceramides; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Pyridines; Reactive Oxygen Species; Signal Transduction; Sorafenib; Vorinostat

2010
Sorafenib and thyrotoxicosis.
    Journal of endocrinological investigation, 2010, Volume: 33, Issue:6

    Topics: Benzenesulfonates; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Pyridines; Sorafenib; Thyrotoxicosis

2010
Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib

2011
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
    Clinical drug investigation, 2010, Volume: 30, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free Survival; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Translocation, Genetic; Treatment Outcome; Young Adult

2010
Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.
    Biochimica et biophysica acta, 2011, Volume: 1814, Issue:1

    Topics: Aryl Hydrocarbon Hydroxylases; Benzenesulfonates; Biocatalysis; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Econazole; Firefly Luciferin; Gas Chromatography-Mass Spectrometry; Humans; Isoenzymes; Liver; Mass Spectrometry; Miconazole; Niacinamide; Pharmaceutical Preparations; Phenylurea Compounds; Polymorphism, Genetic; Pyridines; Schizosaccharomyces; Sorafenib; Testosterone

2011
The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages.
    International immunopharmacology, 2010, Volume: 10, Issue:10

    Topics: Animals; Benzenesulfonates; Cell Line; Dinoprostone; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Interleukin-10; Interleukin-12; Macrophages; Mice; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Toll-Like Receptors

2010
18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2010, Volume: 54, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Humans; Lymphoma; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Pyridines; Radiopharmaceuticals; Sorafenib; Treatment Outcome

2010
Annular leukocytoclastic vasculitis associated with sorafenib administration.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Vasculitis, Leukocytoclastic, Cutaneous

2010
BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
    Molecular cancer research : MCR, 2010, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Biomarkers, Tumor; Biphenyl Compounds; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Liver; Liver Neoplasms; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Sulfonamides

2010
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.
    British journal of pharmacology, 2010, Volume: 160, Issue:7

    Topics: Annexin A5; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; ras Proteins; Sorafenib; Urinary Bladder Neoplasms

2010
Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
    International journal of urology : official journal of the Japanese Urological Association, 2010, Volume: 17, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2010
Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
    Annals of hematology, 2011, Volume: 90, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
    World journal of gastroenterology, 2010, Jul-28, Volume: 16, Issue:28

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
Sorafenib-associated psoriasiform skin changes.
    Cutis, 2010, Volume: 85, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hand; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Psoriasis; Pyridines; Sorafenib

2010
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
    Pediatric blood & cancer, 2010, Dec-01, Volume: 55, Issue:6

    Topics: Animals; Benzenesulfonates; Cell Line, Tumor; Child; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Xenograft Model Antitumor Assays

2010
Health-related quality of life and sorafenib.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib

2010
Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study.
    International journal of palliative nursing, 2010, Volume: 16, Issue:5

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Continuity of Patient Care; Diarrhea; Drug Eruptions; Drug Monitoring; Female; Humans; Hypertension; Liver Neoplasms; Niacinamide; Nurse's Role; Oncology Nursing; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Safety; Sorafenib

2010
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:8

    Topics: Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Fas Ligand Protein; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Phosphotyrosine; Protein Kinase Inhibitors; Pyridines; Reactive Oxygen Species; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sorafenib; src-Family Kinases; Vorinostat

2010
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.
    European radiology, 2011, Volume: 21, Issue:2

    Topics: Aged; Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2011
Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoradiotherapy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
    Journal of the Chinese Medical Association : JCMA, 2010, Volume: 73, Issue:5

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Sorafenib

2010
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome

2011
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
    Genome biology, 2010, Volume: 11, Issue:8

    Topics: Adenocarcinoma; Benzenesulfonates; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Selection, Genetic; Sorafenib; Sunitinib; Tongue Neoplasms

2010
Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
    Analytical and quantitative cytology and histology, 2010, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Drug Screening Assays, Antitumor; Endothelium, Vascular; Fluorescent Antibody Technique, Direct; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Pyridines; Sorafenib; Treatment Outcome

2010
From a cancer drug fund to value based pricing of drugs.
    BMJ (Clinical research ed.), 2010, Aug-12, Volume: 341

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; England; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; Wales

2010
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
    Investigational new drugs, 2011, Volume: 29, Issue:6

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Calcium Channel Blockers; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Felodipine; Humans; Hypertension; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Sorafenib and radiation: a promising combination in colorectal cancer.
    International journal of radiation oncology, biology, physics, 2010, Sep-01, Volume: 78, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Colorectal Neoplasms; Combined Modality Therapy; HT29 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiation Tolerance; Radiotherapy Dosage; Random Allocation; Sorafenib; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay

2010
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:8

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-01, Volume: 28, Issue:28

    Topics: Administration, Oral; Benzenesulfonates; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Clinical Trials, Phase II as Topic; Disease-Free Survival; Humans; Lymph Node Excision; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2010
Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
    Chemotherapy, 2010, Volume: 56, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib

2010
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
    Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:1

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2011
Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia.
    Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 2010, Volume: 72, Issue:1-2

    Topics: Benzenesulfonates; Humans; Hypereosinophilic Syndrome; mRNA Cleavage and Polyadenylation Factors; Niacinamide; Nuclear Pore Complex Proteins; Oncogene Proteins; Oncogene Proteins, Fusion; Phenylurea Compounds; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib

2010
Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
    International journal of urology : official journal of the Japanese Urological Association, 2010, Volume: 17, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
[Sorafenib].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:37

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Humans; Hypophosphatemia; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2010
Risk of arterial thrombosis not increased by sorafenib or sunitinib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

    Topics: Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Evidence-Based Medicine; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism

2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
    Oncology, 2010, Volume: 78, Issue:5-6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Ethnicity; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Safety; Sorafenib; Survival Analysis

2010
[Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:38

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Combined Modality Therapy; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Pyridines; Remission Induction; Retreatment; Sorafenib

2010
The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Liver Neoplasms; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; RNA, Small Interfering; Sorafenib; Sulfonamides

2010
The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication.
    Cellular and molecular life sciences : CMLS, 2011, Volume: 68, Issue:6

    Topics: Benzenesulfonates; Cytomegalovirus; DNA Primers; Genes, Immediate-Early; Humans; Immunoblotting; Luciferases; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Pyridines; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Virus Replication

2011
[Nexavar clinical registry].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Registries; Sorafenib

2010
Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
    Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1

    Topics: Aged; Antiretroviral Therapy, Highly Active; Benzenesulfonates; Carcinoma, Hepatocellular; Coinfection; Drug Synergism; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Immunomagnetic Separation; Immunotherapy, Adoptive; Indoles; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Linear Models; Nasopharyngeal Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib

2011
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2010
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
    American journal of physiology. Renal physiology, 2010, Volume: 299, Issue:5

    Topics: Benzenesulfonates; Blotting, Western; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Enzyme Activation; Epidermal Growth Factor; Epithelial Cells; Humans; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Polycystic Kidney, Autosomal Dominant; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib

2010
Targeting B-Raf as a treatment strategy for polycystic kidney disease.
    American journal of physiology. Renal physiology, 2010, Volume: 299, Issue:5

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Benzenesulfonates; Cell Proliferation; Cells, Cultured; Humans; Niacinamide; Phenylurea Compounds; Polycystic Kidney Diseases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Tolvaptan

2010
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Oncology reports, 2010, Volume: 24, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide

2010
Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.
    Journal of surgical oncology, 2010, Dec-01, Volume: 102, Issue:7

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Cyclin D1; Extracellular Signal-Regulated MAP Kinases; Humans; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Signal Transduction; Sorafenib

2010
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
[Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:8

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Female; Humans; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2010
Primitive neuroectodermal tumor of the kidney with inferior vena cava tumor thrombus during pregnancy response to sorafenib.
    Chinese medical journal, 2010, Aug-05, Volume: 123, Issue:15

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Kidney Neoplasms; Neuroectodermal Tumors, Primitive; Niacinamide; Phenylurea Compounds; Pregnancy; Pyridines; Radiography; Sorafenib; Thrombosis; Vena Cava, Inferior

2010
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
    British journal of cancer, 2010, Sep-07, Volume: 103, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry

2010
Sorafenib-induced destructive thyroiditis.
    Thyroid : official journal of the American Thyroid Association, 2010, Volume: 20, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, Chronic; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Propranolol; Protein Kinase Inhibitors; Pyridines; Sorafenib; Technetium; Thyroiditis

2010
Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2011, Volume: 119, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms

2011
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
    Radiology, 2010, Volume: 257, Issue:2

    Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Disease Models, Animal; Glioma; Heterocyclic Compounds; Macromolecular Substances; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Sorafenib

2010
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
    International journal of cancer, 2011, Jul-15, Volume: 129, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; T-Lymphocytes, Regulatory; Treatment Outcome

2011
Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.
    International journal of clinical oncology, 2011, Volume: 16, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Combinations; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Leukocytosis; Male; Medical Futility; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur

2011
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Cancer, 2011, Feb-01, Volume: 117, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyrotropin; Treatment Outcome

2011
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:10

    Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Drug Interactions; Drug Monitoring; Gastrointestinal Diseases; Humans; Liver Cirrhosis; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiography; raf Kinases; Sorafenib; Spain

2010
Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Drug Eruptions; Female; Folliculitis; Humans; Keratosis; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Skin; Sorafenib

2010
Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Female; Humans; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Xenograft Model Antitumor Assays

2011
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:11

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brachytherapy; Carcinoma, Hepatocellular; Cause of Death; Combined Modality Therapy; Follow-Up Studies; Humans; Iodine Radioisotopes; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Patient Care Planning; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Time Factors

2010
Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010, Nov-01, Volume: 878, Issue:29

    Topics: Benzenesulfonates; Chromatography, High Pressure Liquid; Humans; Niacinamide; Oxides; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Mass Spectrometry

2010
Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
    Anti-cancer drugs, 2011, Volume: 22, Issue:1

    Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Survival; DNA, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; src-Family Kinases; STAT3 Transcription Factor

2011
Transient perforating folliculitis induced by sorafenib.
    The Journal of dermatology, 2010, Volume: 37, Issue:9

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Folliculitis; Humans; Kidney Neoplasms; Male; Neutrophil Infiltration; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission, Spontaneous; Sorafenib

2010
Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
    International journal of dermatology, 2010, Volume: 49, Issue:10

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Diseases, Papulosquamous; Sorafenib; Stomatitis

2010
Atypical linear toxicodermia by sorafenib.
    International journal of dermatology, 2010, Volume: 49, Issue:10

    Topics: Adult; Benzenesulfonates; Biopsy; Edema; Female; Hepatolenticular Degeneration; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Diseases, Papulosquamous; Sorafenib

2010
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    European urology, 2010, Volume: 58, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Feasibility Studies; Female; Humans; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome

2010
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Nov-01, Volume: 16, Issue:21

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2010
Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
    Laboratory investigation; a journal of technical methods and pathology, 2011, Volume: 91, Issue:2

    Topics: Actins; Animals; Apoptosis; Benzenesulfonates; Caspase 3; Colorimetry; DNA Fragmentation; Hepatic Stellate Cells; Histological Techniques; Hypertension, Portal; Immunohistochemistry; Liver; Liver Cirrhosis, Biliary; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib; Vascular Resistance

2011
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Contrast Media; Drug Administration Schedule; Extracellular Fluid; Female; Fiber Optic Technology; Melanoma, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Phospholipids; Pressure; Pyridines; Regional Blood Flow; Sorafenib; Sulfur Hexafluoride; Time Factors; Transducers, Pressure; Ultrasonography, Doppler

2012
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
    Academic radiology, 2011, Volume: 18, Issue:1

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Follow-Up Studies; Gadolinium DTPA; Humans; Image Enhancement; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Tumor Burden

2011
Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:1

    Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Humans; Mice; Mice, Transgenic; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Subcellular Fractions; Thyroid Gland; Thyroid Neoplasms

2011
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1

    Topics: Antineoplastic Agents; Ascitic Fluid; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib

2011
Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
    Journal of clinical gastroenterology, 2011, Volume: 45, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome

2011
Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.
    Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib; Treatment Outcome; Venous Thrombosis

2011
Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
    Acta haematologica, 2010, Volume: 124, Issue:3

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult

2010
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
    The Journal of investigative dermatology, 2011, Volume: 131, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Benzenesulfonates; Cell Line, Tumor; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factor CHOP

2011
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation.
    Blood, 2010, Oct-14, Volume: 116, Issue:15

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Homologous

2010
[Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Tomography, X-Ray Computed; Uracil

2010
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
    Cancer biology & therapy, 2010, Dec-15, Volume: 10, Issue:12

    Topics: Adenoviridae; Animals; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Culture Media, Conditioned; fas Receptor; Gene Knockdown Techniques; Gene Transfer Techniques; Genetic Therapy; Humans; Interleukins; Kidney Neoplasms; Mice; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2010
The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
    BMC cancer, 2010, Oct-15, Volume: 10

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Humans; Jurkat Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Sorafenib; T-Lymphocytes

2010
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 336, Issue:1

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Blood-Brain Barrier; Brain; Cell Line; Dogs; Glioma; Humans; Male; Mice; Mice, Knockout; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
    Expert opinion on biological therapy, 2010, Volume: 10, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis

2010
111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Immunohistochemistry; Indium Radioisotopes; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Radionuclide Imaging; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A

2010
Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF.
    The British journal of ophthalmology, 2010, Volume: 94, Issue:11

    Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Light; Macular Degeneration; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Retinal Pigment Epithelium; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A

2010
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Exons; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sequence Deletion; Sorafenib; Thymus Neoplasms

2011
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
    Oncogene, 2011, Feb-24, Volume: 30, Issue:8

    Topics: Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Myeloproliferative Disorders; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Structure-Activity Relationship

2011
Oncogenic RAF: a brief history of time.
    Pigment cell & melanoma research, 2010, Volume: 23, Issue:6

    Topics: Benzenesulfonates; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Time Factors; Vemurafenib

2010
Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
    Urologia internationalis, 2010, Volume: 85, Issue:3

    Topics: Adult; Antigens, CD34; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Penile Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2010
Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
    The Journal of urology, 2010, Volume: 184, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
    Cancer science, 2010, Volume: 101, Issue:12

    Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Gene Expression Profiling; Humans; Mice; Mice, Nude; Niacinamide; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays

2010
Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.
    Cancer research, 2010, Nov-15, Volume: 70, Issue:22

    Topics: Animals; Anthracenes; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Binding Sites; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sp1 Transcription Factor; Transcription Factor AP-1; Transplantation, Heterologous

2010
Analysis of phosphoproteomics data.
    Methods in molecular biology (Clifton, N.J.), 2011, Volume: 696

    Topics: Amino Acid Sequence; Benzenesulfonates; Databases, Protein; Humans; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Proteomics; Pyridines; Signal Transduction; Sorafenib

2011
Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2010
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Administration Schedule; Feasibility Studies; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2010
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Failure; Treatment Outcome

2010
The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Capillary Permeability; Chromatography, High Pressure Liquid; Half-Life; Infusions, Intravenous; Macaca mulatta; Male; Metabolic Clearance Rate; Models, Animal; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tandem Mass Spectrometry

2012
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
    The Journal of urology, 2011, Volume: 185, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factors

2011
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Time Factors; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays

2010
Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
    Blood, 2011, Jan-20, Volume: 117, Issue:3

    Topics: Apoptosis; Benzenesulfonates; Calcium; Cell Survival; Chemokine CXCL12; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Immunoblotting; Intracellular Space; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, CXCR4; Signal Transduction; Sorafenib; Time Factors; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase

2011
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
    World journal of gastroenterology, 2010, Nov-21, Volume: 16, Issue:43

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome

2010
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
    Leukemia research, 2011, Volume: 35, Issue:3

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult

2011
Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib.
    Cancer biology & therapy, 2011, Feb-01, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chalcone; Drug Discovery; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2011
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
    Acta pharmacologica Sinica, 2010, Volume: 31, Issue:12

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib

2010
mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
    Journal of hepatology, 2011, Volume: 54, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Everolimus; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2011
Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
    Anticancer research, 2010, Volume: 30, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; Tumor Cells, Cultured

2010
Kidney cancer: Does hypothyroidism predict clinical outcome?
    Nature reviews. Urology, 2011, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib

2011
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:8

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Disease Progression; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Survival Rate

2010
Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2010, Volume: 8, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility Studies; Female; Humans; Liver Neoplasms; Liver Transplantation; Los Angeles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2010
Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.
    Leukemia research, 2011, Volume: 35, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Blast Crisis; Bone Marrow Diseases; fms-Like Tyrosine Kinase 3; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Repeat Sequences

2011
Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2011, Volume: 34, Issue:1

    Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; CD4-Positive T-Lymphocytes; Disease-Free Survival; Flow Cytometry; Forkhead Transcription Factors; Gene Expression; Humans; Immune Tolerance; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Leukocytes, Mononuclear; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; RNA, Messenger; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Treatment Outcome

2011
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Breast cancer research and treatment, 2011, Volume: 130, Issue:1

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Sorafenib; Survivin; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays

2011
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    World journal of urology, 2011, Volume: 29, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine

2011
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.
    Pharmacological research, 2011, Volume: 63, Issue:4

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Glycolysis; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Oxamic Acid; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thymidine

2011
Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
    Transplantation proceedings, 2010, Volume: 42, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
    Archives of dermatology, 2010, Volume: 146, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Drug Administration Routes; Follow-Up Studies; Humans; Leg; Male; Melanoma; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib

2010
Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cause of Death; Chemoembolization, Therapeutic; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult

2011
Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
    Nephrology (Carlton, Vic.), 2011, Volume: 16, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Kidney Neoplasms; Kidney Transplantation; Lung Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib

2011
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Anticancer research, 2010, Volume: 30, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2010
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
    Anticancer research, 2010, Volume: 30, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
RAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development.
    PloS one, 2010, Dec-28, Volume: 5, Issue:12

    Topics: Animals; Benzenesulfonates; Cell Differentiation; Cell Proliferation; Chick Embryo; Ear, Inner; Epithelial Cells; Gene Expression Regulation, Enzymologic; Insulin-Like Growth Factor I; Models, Biological; Neurons; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Stem Cells

2010
How I manage my patients with hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Ablation Techniques; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Management; Evidence-Based Medicine; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate

2011
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 337, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib

2011
Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer.
    Acta crystallographica. Section C, Crystal structure communications, 2011, Volume: 67, Issue:Pt 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Hydrogen Bonding; Molecular Conformation; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tosyl Compounds

2011
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Female; Humans; Immunologic Factors; Interleukin-10; Kidney Neoplasms; Leukocytes, Mononuclear; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; T-Lymphocytes; Transforming Growth Factor beta1

2011
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
    Cancer cell, 2011, Jan-18, Volume: 19, Issue:1

    Topics: Animals; Benzenesulfonates; Benzimidazoles; beta Catenin; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Centrosome; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA Damage; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Polycomb Repressive Complex 2; Proto-Oncogene Proteins c-raf; Pyridines; Rad51 Recombinase; Signal Transduction; Sorafenib; Spheroids, Cellular; Transcription Factors; Transplantation, Heterologous; Xenograft Model Antitumor Assays

2011
Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Myositis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Transfection

2011
[Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:11

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Dose-Response Relationship, Drug; Down-Regulation; Humans; Lymphangiogenesis; Lymphatic Vessels; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Random Allocation; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3

2010
[The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis

2010
Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
    Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:1-2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Complete response for advanced liver cancer during sorafenib therapy: case report.
    BMC gastroenterology, 2011, Jan-17, Volume: 11

    Topics: Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Treatment Outcome

2011
Invasive squamous cell carcinoma and sorafenib in a black patient.
    Archives of dermatology, 2011, Volume: 147, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib

2011
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
    World journal of gastroenterology, 2011, Jan-14, Volume: 17, Issue:2

    Topics: Aged; Antineoplastic Agents; Aspirin; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Spleen; Splenic Infarction; Tomography, X-Ray Computed; Treatment Outcome

2011
Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Cytotoxins; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2012
[Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2011, Volume: 108, Issue:5

    Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Cytoprotection; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retinal Pigment Epithelium; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Young Adult

2011
Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.
    Urology, 2011, Volume: 77, Issue:4

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Young Adult

2011
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
    Cancer biology & therapy, 2011, Mar-01, Volume: 11, Issue:5

    Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Flow Cytometry; Hep G2 Cells; Humans; Liver Neoplasms; Lysophospholipids; Mice; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Sphingosine; Xenograft Model Antitumor Assays

2011
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Apr-20, Volume: 29, Issue:12

    Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Time Factors; Treatment Outcome

2011
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
    Blood, 2011, Mar-24, Volume: 117, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome

2011
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
    BJU international, 2011, Volume: 108, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Markov Chains; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib; Sweden; United States

2011
Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Hydroxylation; Indoles; Liver; Microsomes, Liver; Midazolam; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2011
Biomarkers in renal cell carcinoma: what next?
    Current oncology reports, 2011, Volume: 13, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Humans; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome

2011
Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
    Anticancer research, 2011, Volume: 31, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sirolimus; Sorafenib; Treatment Outcome

2011
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Heterologous; Treatment Outcome

2011
Effect of sorafenib on murine liver regeneration.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:2

    Topics: Animals; Becaplermin; Benzenesulfonates; Cell Proliferation; Hepatectomy; Hepatocyte Growth Factor; Liver; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Models, Animal; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2011
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:2

    Topics: Aged; Antineoplastic Agents; Atrophy; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Gland; Thyroiditis; Ultrasonography

2011
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors

2012
Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
    Digestion, 2011, Volume: 83, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Young Adult

2011
Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.
    Experimental hematology, 2011, Volume: 39, Issue:4

    Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Cytarabine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Lymphoid Leukemia Protein; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Survival Analysis; Tandem Repeat Sequences; Tumor Suppressor Protein p53

2011
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.
    Leukemia, 2011, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering; Sorafenib; Stromal Cells; Tumor Cells, Cultured

2011
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
    European urology, 2011, Volume: 59, Issue:5

    Topics: Academic Medical Centers; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Boston; Carcinoma, Renal Cell; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Observer Variation; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Pyrroles; Reproducibility of Results; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A

2011
Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Molecular pharmaceutics, 2011, Apr-04, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Cells, Cultured; Dogs; Humans; Indoles; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Topoisomerase I Inhibitors; Topotecan

2011
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
    Urology, 2011, Volume: 77, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2011
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
    Pediatric blood & cancer, 2012, Volume: 58, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Proliferation; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Evaluation, Preclinical; Everolimus; Female; Hedgehog Proteins; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Integrases; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurofibroma, Plexiform; Neurofibromin 1; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sirolimus; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution; Tumor Burden

2012
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
    Laboratory investigation; a journal of technical methods and pathology, 2011, Volume: 91, Issue:4

    Topics: Animals; Benzenesulfonates; Bone Marrow Cells; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Disease Progression; Immunity, Cellular; Liver Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Spleen; T-Lymphocytes, Regulatory

2011
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Journal of gastroenterology, 2011, Volume: 46, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Xenograft Model Antitumor Assays

2011
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2011, Volume: 58, Issue:2

    Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine

2011
[Squamous cell carcinoma in a patient receiving sorafenib].
    Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cooperative Behavior; Follow-Up Studies; Humans; Interdisciplinary Communication; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A

2011
Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
    JAMA, 2011, Feb-23, Volume: 305, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Doxorubicin; Endpoint Determination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Reproducibility of Results; Sorafenib; Treatment Outcome

2011
An approach to meta-analysis of dose-finding studies.
    Statistics in medicine, 2011, Jul-30, Volume: 30, Issue:17

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Humans; Maximum Tolerated Dose; Meta-Analysis as Topic; Middle Aged; Models, Statistical; Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Tegafur

2011
Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Clinics and research in hepatology and gastroenterology, 2011, Volume: 35, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Fatal Outcome; Humans; Liver Neoplasms; Liver Transplantation; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.
    The Journal of biological chemistry, 2011, Apr-15, Volume: 286, Issue:15

    Topics: Amino Acid Substitution; Animals; Benzenesulfonates; Cation Transport Proteins; Cell Movement; Cell Size; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; HeLa Cells; Humans; Hydrogen-Ion Concentration; Indoles; Melanoma; Mutation, Missense; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyridines; Rabbits; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfonamides

2011
Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
    Cancer immunology, immunotherapy : CII, 2011, Volume: 60, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptor, Interferon alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib

2011
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    International journal of cancer, 2010, Dec-15, Volume: 127, Issue:12

    Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; In Vitro Techniques; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Rats; Sorafenib; Vitamin K

2010
[Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Functional analysis of microRNAs in human hepatocellular cancer stem cells.
    Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Pluripotent Stem Cells; Pyridines; Sorafenib; Twist-Related Protein 1

2012
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
    Bioorganic & medicinal chemistry, 2011, Mar-15, Volume: 19, Issue:6

    Topics: Amides; Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Computer Simulation; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; raf Kinases; Sorafenib; Structure-Activity Relationship

2011
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
    Urologic oncology, 2013, Volume: 31, Issue:3

    Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Urinary Bladder

2013
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Journal of hepatology, 2011, Volume: 55, Issue:5

    Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor

2011
NSCLC drug targets acquire new visibility.
    Journal of the National Cancer Institute, 2011, Mar-02, Volume: 103, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome

2011
Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:5

    Topics: Animals; Apoptosis; Benzenesulfonates; Cell Transdifferentiation; Cells, Cultured; Epithelial Cells; Hepatocytes; Mesoderm; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Transforming Growth Factor beta1

2011
A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:1

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed

2012
Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:5

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Erythropoietin; Feasibility Studies; Hematinics; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sample Size; Sorafenib; Treatment Outcome

2011
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.
    Nature, 2011, Mar-03, Volume: 471, Issue:7336

    Topics: Amino Acid Sequence; Animals; Apoptosis; Benzenesulfonates; Biphenyl Compounds; Cell Cycle Proteins; Cell Line, Tumor; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Glycogen Synthase Kinase 3; Humans; Mice; Molecular Sequence Data; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitrophenols; Phenylurea Compounds; Phosphorylation; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyridines; SKP Cullin F-Box Protein Ligases; Sorafenib; Sulfonamides; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitination

2011
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Humans; Keratoacanthoma; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib

2011
Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:7

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed

2011
Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
    Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:3

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Substrate Specificity; Sunitinib; Swine; Transfection

2011
Management of hepatocellular carcinoma: an update.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis C; Hepatitis, Autoimmune; Humans; Liver Neoplasms; Mass Screening; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography

2011
Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
    American journal of respiratory cell and molecular biology, 2011, Volume: 45, Issue:4

    Topics: Animals; Antihypertensive Agents; Benzamides; Benzenesulfonates; Blotting, Western; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Imatinib Mesylate; Male; Myosin Light Chains; Myosin-Light-Chain Phosphatase; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Artery; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Sorafenib; Vasodilation; Vasodilator Agents; Ventricular Function, Left; Ventricular Function, Right; Ventricular Pressure

2011
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
    Bulletin du cancer, 2011, Volume: 98, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Deoxycytidine; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Monitoring; Gemcitabine; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Rats; Rats, Inbred ACI; Sorafenib; Survival Analysis; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays

2011
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
    Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:4

    Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outcome; Humans; Imatinib Mesylate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiography; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2011
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome

2011
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
    British journal of clinical pharmacology, 2011, Volume: 72, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Glucuronosyltransferase; Humans; Liver Neoplasms; Male; Middle Aged; Models, Theoretical; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Statistics as Topic; UDP-Glucuronosyltransferase 1A9

2011
Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Urologic oncology, 2013, Volume: 31, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate

2013
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
    British journal of cancer, 2011, Mar-15, Volume: 104, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Down-Regulation; Humans; Kidney Neoplasms; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Which treatment modality should we choose for advanced hepatocellular carcinoma?
    The Korean journal of hepatology, 2010, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate

2010
[11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice.
    Bioorganic & medicinal chemistry letters, 2011, Apr-15, Volume: 21, Issue:8

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Brain; Carbon Radioisotopes; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Sorafenib

2011
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2011, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Liver Neoplasms; Melanoma; Mice; Mice, SCID; Niacinamide; Oncolytic Virotherapy; Phenylurea Compounds; Pyridines; Sorafenib; Vaccinia virus; Xenograft Model Antitumor Assays

2011
Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents.
    Archiv der Pharmazie, 2011, Volume: 344, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; HT29 Cells; Humans; Inhibitory Concentration 50; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Rhodanine; Sorafenib; Structure-Activity Relationship

2011
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
    BMC cancer, 2011, Mar-24, Volume: 11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Fatigue; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Oncology Service, Hospital; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2011
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-15, Volume: 17, Issue:12

    Topics: Adolescent; Adult; Benzenesulfonates; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Watchful Waiting; Young Adult

2011
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
    Leukemia, 2011, Volume: 25, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Binding, Competitive; Clinical Trials, Phase II as Topic; Cytarabine; Drug Synergism; Eukaryotic Initiation Factor-4E; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Ribavirin; RNA Caps; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay

2011
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:5

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis

2011
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    World journal of urology, 2011, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2011
All that glitters: sorafenib.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Lysis Syndrome

2011
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Cancer Care Facilities; Carcinoma, Renal Cell; Community Health Services; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; United States

2012
Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
    International journal of urology : official journal of the Japanese Urological Association, 2011, Volume: 18, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blood Sedimentation; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Kinetics; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Sorafenib

2011
A painful cranial bulge.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Niacinamide; Occipital Bone; Pain; Parietal Bone; Phenylurea Compounds; Pyridines; Skull Neoplasms; Sorafenib; Temporal Bone; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome

2011
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
    Cancer, 2011, Nov-01, Volume: 117, Issue:21

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2011
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carrier Proteins; Cell Proliferation; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Intracellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphoproteins; Pyridines; Random Allocation; Rats; Sirolimus; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A

2011
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Journal of the National Cancer Institute, 2011, Jun-08, Volume: 103, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Confounding Factors, Epidemiologic; Cytarabine; Disease Models, Animal; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Humans; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tandem Mass Spectrometry; Time Factors; Transplantation, Heterologous; Treatment Outcome

2011
Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
    The British journal of dermatology, 2011, Volume: 165, Issue:2

    Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Eruptions; Female; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    World journal of urology, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome

2013
BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.
    British journal of haematology, 2011, Volume: 155, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Hodgkin Disease; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib

2011
Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:11

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2011
[Sorafenib induces apoptosis of U937 cells via inhibiting WNT signal pathway].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:2

    Topics: Apoptosis; Benzenesulfonates; beta Catenin; Cell Proliferation; Cyclin D1; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; U937 Cells; Wnt Signaling Pathway

2011
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.
    Cell death & disease, 2011, Apr-28, Volume: 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Delayed-Action Preparations; Drug Resistance, Neoplasm; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Nitric Oxide; Octreotide; Oxidative Stress; Phenylurea Compounds; Phosphorylation; Pyridines; Reactive Oxygen Species; Sorafenib; Superoxide Dismutase; Treatment Outcome

2011
Laryngeal metastasis as first presentation of hepatocellular carcinoma.
    Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:4

    Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Combined Modality Therapy; Diagnosis, Differential; Diagnostic Imaging; Embolization, Therapeutic; Humans; Laryngeal Neoplasms; Laryngectomy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Thyroidectomy

2011
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2011
microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.
    FEBS letters, 2011, Jun-23, Volume: 585, Issue:12

    Topics: ADAM Proteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Proteins; MicroRNAs; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:7

    Topics: Amides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Structure-Activity Relationship; Sulfonamides; Urea

2011
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
    International journal of oncology, 2011, Volume: 39, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2011
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Female; Fluorouracil; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; Tegafur; Thymidylate Synthase

2011
The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.
    Biochemical pharmacology, 2011, Jul-15, Volume: 82, Issue:2

    Topics: Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Humans; Leupeptins; Liver Neoplasms; Neoplasm Proteins; NF-kappa B; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-rel; Pyridines; Sorafenib

2011
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2011
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:7

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Endonucleases; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Burden; X-ray Repair Cross Complementing Protein 1; Xenograft Model Antitumor Assays

2011
Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
    Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:5

    Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Fatal Outcome; Female; Humans; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib

2011
Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroxine

2011
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
    PloS one, 2011, Apr-29, Volume: 6, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
    Der Urologe. Ausg. A, 2011, Volume: 50, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disease Progression; Drug Delivery Systems; Everolimus; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2011
Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
    International journal of oncology, 2011, Volume: 39, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib; Wnt Proteins; Xenograft Model Antitumor Assays

2011
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:2

    Topics: Animals; Benzenesulfonates; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Mice; Niacinamide; Paracrine Communication; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib

2011
Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma.
    BMC gastroenterology, 2011, May-12, Volume: 11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; China; Disease Progression; Humans; Liver Neoplasms; Longitudinal Studies; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib

2011
Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib.
    Journal of the American Academy of Dermatology, 2011, Volume: 64, Issue:6

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Erythema; Hemorrhage; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Terminology as Topic

2011
Sorafenib-associated multivessel coronary artery vasospasm.
    Herz, 2011, Volume: 36, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Coronary Vasospasm; Electrocardiography; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Skin Neoplasms; Sorafenib; Structure-Activity Relationship

2011
Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals.
    European journal of radiology, 2012, Volume: 81, Issue:7

    Topics: Alanine Transaminase; Animals; Benzenesulfonates; Catheter Ablation; Cell Proliferation; Epidermal Growth Factor; Fluorescent Antibody Technique; Glutamate Dehydrogenase; Hepatocyte Growth Factor; Image Processing, Computer-Assisted; Liver; Male; Models, Animal; Necrosis; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A

2012
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
    American journal of physiology. Cell physiology, 2011, Volume: 301, Issue:3

    Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL5; Dichlororibofuranosylbenzimidazole; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Genes, Reporter; Half-Life; Humans; Immunotherapy, Active; Interleukin-8; Leupeptins; MAP Kinase Kinase Kinases; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyridines; Receptors, Interleukin-8B; RNA Stability; RNA, Messenger; RNA, Small Interfering; Sorafenib; Transfection; Tristetraprolin; Tumor Cells, Cultured; Vaccination

2011
Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:9

    Topics: Ablation Techniques; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Risk Factors; Sorafenib

2010
Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
    International journal of urology : official journal of the Japanese Urological Association, 2011, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Blood Sedimentation; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib

2011
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    BJU international, 2011, Volume: 108, Issue:8 Pt 2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2011
Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
    Biochemical pharmacology, 2011, Aug-01, Volume: 82, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survivin; TOR Serine-Threonine Kinases

2011
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
    Journal of cellular physiology, 2012, Volume: 227, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autocrine Communication; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Knockdown Techniques; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha

2012
Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.
    Current pharmaceutical biotechnology, 2012, Volume: 13, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Feedback, Physiological; Hypoxia; MAP Kinase Kinase 4; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Vascular Endothelial Growth Factor; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2012
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia

2011
[New therapeutic options for advanced thyroid cancer].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:22

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms

2011
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
    Molecular biology reports, 2012, Volume: 39, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Gene Expression Regulation, Enzymologic; Humans; Liver Neoplasms; Microscopy, Electron, Transmission; Morpholines; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Cancer research, 2011, Jul-15, Volume: 71, Issue:14

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Female; Glutamates; Guanine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution

2011
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-15, Volume: 17, Issue:16

    Topics: Alanine; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Knockout; Mice, Transgenic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Fibroblast Growth Factor; Sorafenib; Treatment Outcome; Triazines; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2

2011
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2011, May-07, Volume: 17, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Sorafenib

2011
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
    World journal of gastroenterology, 2011, May-21, Volume: 17, Issue:19

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2011
Severe sorafenib-induced hand-foot skin reaction.
    Dermatology online journal, 2011, May-15, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Disease Progression; Drug Eruptions; Fatal Outcome; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Diseases

2011
[In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2011, Volume: 27, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytokine-Induced Killer Cells; Cytotoxicity, Immunologic; Dendritic Cells; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
[KIT and KIT: from biology to clinical use].
    Bulletin du cancer, 2012, Feb-01, Volume: 99, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2012
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Chemotherapy, Adjuvant; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays

2011
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
    NMR in biomedicine, 2011, Volume: 24, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Volume; Carmustine; Cell Death; Cell Line, Tumor; Glioma; Humans; Magnetic Resonance Imaging; Male; Microvessels; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Staining and Labeling; Survival Analysis

2011
Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
    British journal of haematology, 2011, Volume: 152, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Lymphoma, Non-Hodgkin; Mitogen-Activated Protein Kinase 14; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay

2011
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
    Autophagy, 2011, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Small Interfering; Sorafenib; Time Factors; Treatment Outcome

2011
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.
    Pharmaceutical research, 2011, Volume: 28, Issue:12

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Female; Humans; Male; Neoplasms; Niacinamide; Orosomucoid; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Serum Albumin; Sorafenib; Young Adult

2011
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
    Toxicological sciences : an official journal of the Society of Toxicology, 2011, Volume: 122, Issue:2

    Topics: Animals; Benzenesulfonates; Bucladesine; Carcinoma, Renal Cell; Cell Line; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Hydroquinones; Kidney Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Niacinamide; Pentoxifylline; Phenylurea Compounds; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Rats; RNA, Small Interfering; Signal Transduction; Sorafenib; Theophylline; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins

2011
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Young Adult

2011
Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo.
    Journal of microencapsulation, 2011, Volume: 28, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cattle; Cell Line, Tumor; Drug Carriers; Female; Hemolysis; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Serum Albumin, Bovine; Sorafenib

2011
[News on melanoma from the 2010 Dermatology Days in Paris].
    Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:5 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome

2011
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
    Blood, 2011, Aug-25, Volume: 118, Issue:8

    Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzenesulfonates; DNA, Neoplasm; Drug Resistance, Neoplasm; Eosinophilia; ETS Translocation Variant 6 Protein; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Indoles; Male; Middle Aged; Molecular Sequence Data; Niacinamide; Oncogene Fusion; Oncogene Proteins, Fusion; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ets; Pyridines; Pyrroles; Repressor Proteins; Sorafenib; Sunitinib

2011
Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Bioorganic & medicinal chemistry, 2011, Jul-15, Volume: 19, Issue:14

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Mice; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Sorafenib; Stereoisomerism; Structure-Activity Relationship; Sulfonamides

2011
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Cancer, 2012, Jan-01, Volume: 118, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2012
Targeting STAT3 in hepatocellular carcinoma: sorafenib again….
    Journal of hepatology, 2011, Volume: 55, Issue:5

    Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; STAT3 Transcription Factor

2011
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2012
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Aktuelle Urologie, 2011, Volume: 42, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
    Pediatric blood & cancer, 2012, Volume: 58, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Female; Humans; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Thyroid Neoplasms

2012
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Female; Fluorouracil; Humans; Mice; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); Pyridines; Quinacrine; ras Proteins; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2011
Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.
    Hematological oncology, 2012, Volume: 30, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Benzenesulfonates; Central Nervous System Diseases; Cladribine; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib

2012
c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
    Cancer biology & therapy, 2011, Sep-15, Volume: 12, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclic AMP-Dependent Protein Kinases; Diethylnitrosamine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-raf; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; Vitamin K 1

2011
Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Electrophoresis, Gel, Two-Dimensional; Gene Expression; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteome; Sorafenib; Tandem Mass Spectrometry

2012
Pancreatic endocrine tumors: a report on a patient treated with sorafenib.
    Journal of Korean medical science, 2011, Volume: 26, Issue:7

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Humans; Liver Neoplasms; Male; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Tomography, X-Ray Computed

2011
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
    Cancer investigation, 2011, Volume: 29, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Indoles; Intestinal Perforation; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Vascular Endothelial Growth Factor A; Wound Healing

2011
Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult

2011
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
    British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays

2011
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
    The Journal of investigative dermatology, 2011, Volume: 131, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2011
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
    BMC cancer, 2011, Jul-14, Volume: 11

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2011
Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Portasystemic Shunt, Transjugular Intrahepatic; Prosthesis Failure; Pyridines; Sorafenib

2011
Sorafenib-induced eruption resembling pityriasis rubra pilaris.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Diagnosis, Differential; Drug Eruptions; Humans; Immunohistochemistry; Male; Niacinamide; Phenylurea Compounds; Pityriasis Rubra Pilaris; Pyridines; Risk Assessment; Severity of Illness Index; Sorafenib

2011
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Sorafenib; Transplantation, Homologous; Young Adult

2011
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
    Human molecular genetics, 2011, Oct-15, Volume: 20, Issue:20

    Topics: Animals; Animals, Genetically Modified; Benzenesulfonates; Caenorhabditis elegans; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Drosophila; Enzyme Activation; Humans; Indoles; Motor Activity; Mutation; Niacinamide; Oxidopamine; Parkinson Disease; Phenols; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Sorafenib; Synucleins

2011
Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer.
    PharmacoEconomics, 2011, Volume: 29, Issue:10

    Topics: Antineoplastic Agents; Azacitidine; Benzenesulfonates; Biomedical Research; Cost-Benefit Analysis; Humans; Kaplan-Meier Estimate; Models, Economic; Models, Statistical; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Technology Assessment, Biomedical; United Kingdom

2011
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
    Transplant international : official journal of the European Society for Organ Transplantation, 2011, Volume: 24, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Waiting Lists

2011
Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    The FEBS journal, 2011, Volume: 278, Issue:18

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Autophagy; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Doxorubicin; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitochondria, Liver; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib

2011
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
    Molecular cancer, 2011, Jul-26, Volume: 10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Humans; Imidazoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays

2011
[Adverse effects of new oncologic therapies].
    Praxis, 2011, Jul-27, Volume: 100, Issue:15

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab

2011
Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
    Journal of surgical oncology, 2012, Volume: 105, Issue:1

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome

2012
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    European urology, 2011, Volume: 60, Issue:6

    Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Germany; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; Treatment Failure

2011
Setting up a kinase discovery and development project.
    Current topics in microbiology and immunology, 2012, Volume: 355

    Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Discovery; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Enzyme Assays; Humans; Indoles; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Solubility; Sorafenib; Structure-Activity Relationship; Sulfonamides

2012
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Autophagy, 2011, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Remission Induction; Sorafenib; Survival Rate

2011
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
    Leukemia, 2012, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib

2012
Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Norisoprenoids; Phenylurea Compounds; Phosphorylation; Pyridines; rac1 GTP-Binding Protein; rho GTP-Binding Proteins; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2

2012
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-15, Volume: 17, Issue:16

    Topics: Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; International Cooperation; Kidney Neoplasms; Logistic Models; Male; Models, Biological; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Survival Analysis; Time Factors

2011
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.
    Digestive diseases (Basel, Switzerland), 2011, Volume: 29, Issue:3

    Topics: Aged; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Pyridines; Radiography; Sorafenib; Survival Analysis

2011
The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms; Urokinase-Type Plasminogen Activator

2011
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Current cancer drug targets, 2011, Volume: 11, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Random Allocation; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays

2011
[Long-standing differentiated thyroid carcinoma].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillary; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Diagnostic Errors; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Niacinamide; Palliative Care; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Tuberculosis, Miliary

2012
Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.
    International journal of pharmaceutics, 2011, Oct-31, Volume: 419, Issue:1-2

    Topics: Adhesiveness; Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biological Availability; Hydrogen-Ion Concentration; Male; Nanoparticles; Nanostructures; Niacinamide; Phenylurea Compounds; Polymethacrylic Acids; Porosity; Pyridines; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Solubility; Sorafenib; Suspensions

2011
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-15, Volume: 17, Issue:22

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glutamic Acid; Indoles; Melanoma; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2011
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
    Journal of clinical immunology, 2011, Volume: 31, Issue:6

    Topics: Animals; Anisoles; Astrocytes; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Proliferation; Cells, Cultured; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Imatinib Mesylate; Macrophages; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Sorafenib; T-Lymphocytes; Tumor Necrosis Factor-alpha

2011
Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2012
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    International journal of cancer, 2012, Aug-01, Volume: 131, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lysosomes; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Microtubule-Associated Proteins; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Proteins; Pyridines; RNA Interference; RNA, Small Interfering; Sequestosome-1 Protein; Sorafenib; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays

2012
Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
    Urologic oncology, 2012, Volume: 30, Issue:5

    Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Liver; Lung; Lymph Nodes; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Tomography, X-Ray Computed

2012
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-01, Volume: 18, Issue:5

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Hedgehog Proteins; Humans; Immunophenotyping; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nanocapsules; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Patched Receptors; Patched-1 Receptor; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Cell Surface; Recurrence; Signal Transduction; Sorafenib; Transcription Factors; Zinc Finger Protein GLI1

2012
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
    Cancer biology & therapy, 2011, Nov-01, Volume: 12, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Doxorubicin; Drug Synergism; Hep G2 Cells; Humans; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
    Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cell Line; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Erlotinib Hydrochloride; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Verteporfin; Wet Macular Degeneration

2012
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Journal of biochemistry, 2012, Volume: 151, Issue:1

    Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection

2012
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:8

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Statistics as Topic; Survival Rate; Tomography, X-Ray Computed

2011
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    BJU international, 2012, Volume: 109, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib; Survival Analysis

2011
Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
    Transplantation proceedings, 2011, Volume: 43, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib

2011
Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2011, Volume: 129, Issue:9

    Topics: Aged; Autoantibodies; Benzenesulfonates; Carcinoma, Bronchogenic; Cell Proliferation; Eye Proteins; Fatal Outcome; Fluorescein Angiography; Functional Laterality; Humans; Lung Neoplasms; Male; Melanocytes; Niacinamide; Ophthalmoscopy; Paraneoplastic Syndromes; Phenylurea Compounds; Plasmapheresis; Pyridines; Retina; Sorafenib; Tomography, Optical Coherence; Uveal Diseases; Visual Acuity; Visual Fields

2011
Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells.
    European journal of pharmacology, 2011, Nov-16, Volume: 670, Issue:1

    Topics: Adenosine Triphosphate; Aerobiosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Cell Survival; Energy Metabolism; Glycosylation; Humans; Liver Neoplasms; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Pyridines; Sorafenib

2011
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia.
    Bone marrow transplantation, 2012, Volume: 47, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Polycythemia; Pyridines; Sorafenib; Transplantation, Homologous; Unrelated Donors

2012
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
    Molecular cancer, 2011, Sep-19, Volume: 10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Melanoma; Mice; Mice, Nude; Mitochondria; Necrosis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Transport; Proto-Oncogene Proteins c-mdm2; Pyridines; RNA Interference; Sorafenib; Spiro Compounds; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2011
Interstitial granulomatous drug reaction to sorafenib.
    Archives of dermatology, 2011, Volume: 147, Issue:9

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Granuloma; Hand Dermatoses; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
    Investigative radiology, 2012, Volume: 47, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Cell Line, Tumor; Contrast Media; Iohexol; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Rats; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Statistics as Topic; Tomography, X-Ray Computed; Treatment Outcome

2012
[Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
    Gastroenterologia y hepatologia, 2011, Volume: 34, Issue:8

    Topics: Aged; Alcoholism; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Early Detection of Cancer; Ethanol; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sclerotherapy; Sorafenib; Spain

2011
Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1-carboxamide derivatives against melanoma cell line.
    Archiv der Pharmazie, 2011, Volume: 344, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyridines; Sorafenib; Structure-Activity Relationship

2011
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Urologic oncology, 2013, Volume: 31, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A

2013
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:10

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Case-Control Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome

2011
Hepatocellular carcinoma presenting with multiple bone and soft tissue metastases and atypical cytomorphological features--a rare case report.
    Diagnostic cytopathology, 2013, Volume: 41, Issue:7

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Radiography, Abdominal; Rare Diseases; Soft Tissue Neoplasms; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2013
Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prognosis; Pyridines; Retrospective Studies; Sorafenib; Survival Rate

2011
Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.
    Anticancer research, 2011, Volume: 31, Issue:10

    Topics: Anthracenes; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Melanoma; Morpholines; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib

2011
Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.
    Journal of gastrointestinal cancer, 2012, Volume: 43 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2012
Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
    Molecular medicine (Cambridge, Mass.), 2012, Feb-10, Volume: 18

    Topics: Apoptosis; Benzenesulfonates; Cell Survival; Cells, Cultured; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Pyridines; raf Kinases; Sorafenib; Tumor Cells, Cultured

2012
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
    Onkologie, 2011, Volume: 34, Issue:10

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Humans; Image Processing, Computer-Assisted; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neoplasm Invasiveness; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2011
The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics.
    Leukemia research, 2012, Volume: 36, Issue:1

    Topics: Abnormal Karyotype; Antineoplastic Agents; Benzenesulfonates; Cytogenetic Analysis; Drug Resistance, Neoplasm; Erythroid Cells; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Erythroblastic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences; Time Factors; Treatment Outcome

2012
[Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:10

    Topics: Anticoagulants; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Warfarin

2011
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
    Circulation research, 2011, Dec-09, Volume: 109, Issue:12

    Topics: Animals; Animals, Genetically Modified; Apoptosis; Benzenesulfonates; Cardiotoxins; Cell Survival; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Indoles; Male; Models, Animal; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Sunitinib; Zebrafish

2011
Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
    Molecular carcinogenesis, 2013, Volume: 52, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Benzenesulfonates; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cell Movement; Humans; Imidazoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyridines; Sorafenib; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor Receptor-2

2013
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cytokines; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Up-Regulation

2011
Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors.
    Bioorganic & medicinal chemistry letters, 2011, Dec-01, Volume: 21, Issue:23

    Topics: Benzenesulfonates; Drug Design; Enzyme Activation; Enzyme Inhibitors; Imidazoles; Isoindoles; Models, Molecular; Molecular Structure; Niacinamide; Phenylurea Compounds; Phthalazines; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Structure-Activity Relationship

2011
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    World journal of gastroenterology, 2011, Sep-14, Volume: 17, Issue:34

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Janus Kinase 2; Liver Neoplasms; Male; Mitogen-Activated Protein Kinase Kinases; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Rats; Signal Transduction; Sorafenib; STAT3 Transcription Factor

2011
Reversible cardiomyopathy associated with sunitinib and sorafenib.
    The New England journal of medicine, 2011, Oct-27, Volume: 365, Issue:17

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cardiomyopathies; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:1

    Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Pressure; Protein Kinase Inhibitors; Pyridines; Real-Time Polymerase Chain Reaction; Sorafenib; Syndrome; Treatment Outcome

2012
New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship; Thiazoles

2011
Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
    Histopathology, 2011, Volume: 59, Issue:3

    Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Depression; Female; Humans; Hypertension; Kidney Neoplasms; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2011
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2012
Role of sorafenib in renal cell carcinoma: focus on elderly patients.
    Expert review of anticancer therapy, 2011, Volume: 11, Issue:11

    Topics: Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
    British journal of haematology, 2012, Volume: 157, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib

2012
Chloracne-like drug eruption associated with sorafenib.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chloracne; Drug Eruptions; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
    Pediatric blood & cancer, 2012, Volume: 59, Issue:4

    Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Child; Female; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Remission Induction; Sorafenib

2012
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Data Collection; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Remission Induction; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult

2012
Tilting the AXIS towards therapeutic limits in renal cancer.
    Lancet (London, England), 2011, Dec-03, Volume: 378, Issue:9807

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2011
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2012
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult

2012
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Indoles; Male; Mass Spectrometry; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2012
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
    Experimental dermatology, 2011, Volume: 20, Issue:12

    Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome

2011
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
    British journal of cancer, 2011, Dec-06, Volume: 105, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate

2011
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
    International journal of clinical oncology, 2013, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2013
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-01, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cells, Cultured; Female; Humans; Keratinocytes; Male; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyridines; raf Kinases; ras Proteins; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Skin; Skin Neoplasms; Sorafenib; Tumor Suppressor Protein p53; Ultraviolet Rays

2012
Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Journal of chemical information and modeling, 2011, Dec-27, Volume: 51, Issue:12

    Topics: Allosteric Regulation; Benzamides; Benzenesulfonates; Catalytic Domain; Humans; Imatinib Mesylate; Indenes; Mitogen-Activated Protein Kinase 14; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Thermodynamics

2011
Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    The Journal of surgical research, 2012, Volume: 176, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Benzoquinones; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53

2012
A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis.
    Therapeutic drug monitoring, 2011, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Calibration; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Drug Stability; Fatal Outcome; Humans; Kidney Failure, Chronic; Limit of Detection; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Reproducibility of Results; Solid Phase Extraction; Sorafenib; Spectrometry, Mass, Electrospray Ionization

2011
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
    Endocrine-related cancer, 2012, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Survival; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Sirolimus; Sorafenib; Thyroid Neoplasms; TOR Serine-Threonine Kinases

2012
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
    Anticancer research, 2011, Volume: 31, Issue:11

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib; Treatment Outcome

2011
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Oncology, 2011, Volume: 81, Issue:3-4

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Pyridines; Sorafenib

2011
[Synthesis and biological evaluation of sorafenib thiourea derivatives].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2011, Volume: 46, Issue:9

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Molecular Structure; Niacinamide; Phenylurea Compounds; Sorafenib; Thiourea

2011
Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2011, Volume: 13, Issue:12

    Topics: Angiogenesis Inhibitors; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib

2011
Erythema multiforme-like drug reaction to sorafenib.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:12

    Topics: Adult; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; Erythema Multiforme; Female; Hand Dermatoses; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).
    The oncologist, 2011, Volume: 16, Issue:12

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2011
[Renal tolerance of targeted therapies].
    Bulletin du cancer, 2012, Mar-01, Volume: 99, Issue:3

    Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib

2012
SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
    Annals of surgical oncology, 2012, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Half-Life; Humans; Immunoenzyme Techniques; Immunoprecipitation; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proteolysis; Pyridines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirtuin 1; Sorafenib; Survival Rate; Young Adult

2012
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
    Pediatric blood & cancer, 2012, Volume: 59, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Neuroblastoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.
    Journal of Korean medical science, 2011, Volume: 26, Issue:12

    Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib

2011
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Inhibitory Concentration 50; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2011
Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:4

    Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique, Indirect; Forkhead Transcription Factors; Hepatoblastoma; In Situ Nick-End Labeling; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tetrazolium Salts; Thiazoles; Transplantation, Heterologous; Transplants

2012
Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
    Urologia internationalis, 2012, Volume: 88, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis

2012
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

    Topics: Animals; Apoptosis; Benzenesulfonates; Benzimidazoles; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Quinolones; RNA Interference; Sorafenib; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays

2012
Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.
    Leukemia, 2012, Volume: 26, Issue:6

    Topics: Benzenesulfonates; Blotting, Western; Cell Movement; Cell Survival; Chemokines; Chemotaxis; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Real-Time Polymerase Chain Reaction; Receptors, Antigen, B-Cell; RNA, Messenger; Sorafenib; src-Family Kinases; Syk Kinase; Tumor Cells, Cultured; Tumor Microenvironment

2012
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
    Journal of gastroenterology, 2012, Volume: 47, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Failure; Treatment Outcome

2012
Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

    Topics: Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gossypol; Humans; Male; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Time Factors; Xenograft Model Antitumor Assays

2012
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
    Journal of translational medicine, 2011, Dec-21, Volume: 9

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Mice; Mice, Nude; Microvessels; Niacinamide; Perfusion; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
    American journal of hematology, 2012, Volume: 87, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Interleukin-6; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2012
[Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed

2011
[Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed

2011
[The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Tomography, X-Ray Computed

2011
Multidisciplinary management of nonresectable hepatocellular carcinoma.
    Oncology, 2011, Volume: 81 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatitis B; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
    Oncology, 2011, Volume: 81 Suppl 1

    Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Republic of Korea; Sorafenib

2011
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
    Oncology, 2011, Volume: 81 Suppl 1

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Treatment Outcome

2011
Sorafenib: muscle wasting.
    Prescrire international, 2011, Volume: 20, Issue:122

    Topics: Benzamides; Benzenesulfonates; Humans; Imatinib Mesylate; Indoles; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Rhabdomyolysis; Sorafenib; Sunitinib

2011
Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden

2012
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-10, Volume: 30, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Remission Induction; Retrospective Studies; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome

2012
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult

2012
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    The Journal of surgical research, 2012, Volume: 176, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Drug Synergism; Feedback, Physiological; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Triazines

2012
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
    Cancer cell, 2012, Jan-17, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured

2012
Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; NF-kappa B; Niacinamide; Phenylurea Compounds; Pyridines; Radiation-Sensitizing Agents; Sorafenib; Xenograft Model Antitumor Assays

2012
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Tacrolimus

2012
Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling.
    Cancer letters, 2012, Jun-01, Volume: 319, Issue:1

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzenesulfonates; Caffeine; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Suppressor Proteins

2012
Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
    AJR. American journal of roentgenology, 2012, Volume: 198, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Humans; Image Interpretation, Computer-Assisted; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Random Allocation; Rats; Sorafenib

2012
Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells.
    Journal of proteome research, 2012, Mar-02, Volume: 11, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Shape; Cytochromes c; Down-Regulation; Enzyme Activation; Humans; Membrane Potential, Mitochondrial; Mitochondria; NADH Dehydrogenase; Neuroblastoma; Niacinamide; Phenylurea Compounds; Protein Interaction Maps; Proteolysis; Proteome; Pyridines; Reactive Oxygen Species; Signal Transduction; Sorafenib; Superoxide Dismutase

2012
New sorafenib derivatives: synthesis, antiproliferative activity against tumour cell lines and antimetabolic evaluation.
    Molecules (Basel, Switzerland), 2012, Jan-23, Volume: 17, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Objective response to sorafenib in advanced clear-cell sarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Humans; Knee; Male; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Pyridines; Sarcoma, Clear Cell; Sorafenib; Transcription Factors

2012
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
    Cell death & disease, 2012, Jan-26, Volume: 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Primary Cell Culture; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins pp60(c-src); Pyridines; Signal Transduction; Sorafenib

2012
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
    Clinical and experimental nephrology, 2012, Volume: 16, Issue:3

    Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib

2012
Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
    Acta medica (Hradec Kralove), 2011, Volume: 54, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Rupture, Spontaneous; Sorafenib

2011
Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
    Biochemical and biophysical research communications, 2012, Feb-17, Volume: 418, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Genes, Reporter; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Luciferases; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Pyridines; RNA, Messenger; Sorafenib; Transcription, Genetic

2012
Sorafenib in metastatic thyroid cancer.
    Endocrine-related cancer, 2012, Volume: 19, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms

2012
Phase II studies in soft tissue sarcoma: time for reappraisal.
    The oncologist, 2012, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Female; Hemangiosarcoma; Humans; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
    Oncogene, 2012, Nov-15, Volume: 31, Issue:46

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Genes, ras; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HCT116 Cells; Hep G2 Cells; HT29 Cells; Humans; Mice; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Transcription, Genetic; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2012
Resampling phase III data to assess phase II trial designs and endpoints.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-15, Volume: 18, Issue:8

    Topics: Benzenesulfonates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Treatment Outcome

2012
Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
    Anticancer research, 2012, Volume: 32, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Inflammation; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Severity of Illness Index; Sorafenib

2012
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
    Anticancer research, 2012, Volume: 32, Issue:2

    Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2012
A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    International journal of cardiology, 2012, Sep-20, Volume: 160, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiomyopathies; Coronary Angiography; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2012
Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib

2012
[Endocrinology].
    Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Benzenesulfonates; Carcinoma; Carcinoma, Medullary; Clinical Trials as Topic; Endocrine Gland Neoplasms; Endocrinology; Humans; Niacinamide; Phenylurea Compounds; Pituitary ACTH Hypersecretion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptors, Somatostatin; Somatostatin; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2012
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
    Cancer letters, 2012, Jul-01, Volume: 320, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epothilones; Female; Humans; Morpholines; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Pyrimidines; Signal Transduction; Sirolimus; Sorafenib; Tamoxifen; Thiazoles

2012
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-01, Volume: 18, Issue:7

    Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bilirubin; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Pilot Projects; Polymorphism, Genetic; Prostatic Neoplasms; Pyridines; Sorafenib; UDP-Glucuronosyltransferase 1A9

2012
MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
    British journal of haematology, 2012, Volume: 157, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Dasatinib; Down-Regulation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrimidines; Sorafenib; Thiazoles

2012
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
    Cancer biology & therapy, 2012, Volume: 13, Issue:6

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cerebellar Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytochromes c; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Medulloblastoma; NF-kappa B; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Sorafenib; Tumor Cells, Cultured

2012
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
    Journal of hepatology, 2012, Volume: 56, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib

2012
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:1

    Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Knockout; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Random Allocation; Receptors, Androgen; Sorafenib; Tumor Cells, Cultured

2012
Revealing multi-binding sites for taspine to VEGFR-2 by cell membrane chromatography zonal elution.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Mar-01, Volume: 887-888

    Topics: Alkaloids; Benzenesulfonates; Binding Sites; Cell Membrane; Chromatography; HEK293 Cells; Humans; Kinetics; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Results; Sorafenib; Vascular Endothelial Growth Factor Receptor-2

2012
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
    Journal of hepatology, 2012, Volume: 56, Issue:6

    Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Niacinamide; Panobinostat; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; RNA, Messenger; Sorafenib; Survivin; Xenograft Model Antitumor Assays

2012
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2012
Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
    BJU international, 2012, Volume: 110, Issue:6 Pt B

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Retrospective Studies; Sorafenib

2012
Sorafenib rechalenge in metastatic renal cell carcinoma.
    BJU international, 2012, Volume: 110, Issue:6 Pt B

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
    Molecular pharmaceutics, 2012, Mar-05, Volume: 9, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Blood-Brain Barrier; Blotting, Western; Breast Neoplasms; Female; Mice; Mice, Mutant Strains; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
    World journal of surgical oncology, 2012, Feb-17, Volume: 10

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Case-Control Studies; Chemotherapy, Adjuvant; China; Female; Health Status Indicators; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Statistics as Topic; Time Factors

2012
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
    Cancer letters, 2012, Sep-01, Volume: 322, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Humans; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Pyrroles; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2012
Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.
    Oncology, 2012, Volume: 82, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Leukemia, 2012, Volume: 26, Issue:7

    Topics: Animals; Apoptosis; Aurora Kinases; Benzenesulfonates; Benzothiazoles; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Quinazolines; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured

2012
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
    Anti-cancer drugs, 2012, Volume: 23, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Female; Flow Cytometry; G2 Phase; Gamma Rays; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays

2012
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins

2012
Inhibition of corneal neovascularization in rats by systemic administration of sorafenib.
    Cornea, 2012, Volume: 31, Issue:8

    Topics: Administration, Oral; Animals; Benzenesulfonates; Blotting, Western; Corneal Neovascularization; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor Receptor-2

2012
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
    BJU international, 2012, Volume: 110, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Contraindications; Female; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Renal Dialysis; Retrospective Studies; Sorafenib; Sunitinib

2012
Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
    Clinical and experimental dermatology, 2012, Volume: 37, Issue:7

    Topics: Antineoplastic Agents; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Scalp; Skin Neoplasms; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factors

2012
Intracranial metastasis from pediatric GI stromal tumor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome

2012
A maxillary mass in a HBV-cirrhotic patient.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Hepatitis B, Chronic; Humans; Immunohistochemistry; Liver Cirrhosis; Liver Neoplasms; Male; Maxillary Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed

2012
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Databases as Topic; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Hormones

2012
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
    Endocrine-related cancer, 2012, Volume: 19, Issue:3

    Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Down-Regulation; Humans; Male; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Sorafenib

2012
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
    Journal of molecular medicine (Berlin, Germany), 2012, Volume: 90, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; MAP Kinase Kinase 1; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Transcriptome; Tumor Cells, Cultured

2012
TACE with or without systemic therapy?
    Journal of hepatology, 2012, Volume: 56, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study.
    Journal of gastroenterology, 2012, Volume: 47, Issue:9

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Hemodynamics; Humans; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Prospective Studies; Pyridines; Sorafenib; Treatment Outcome; Ultrasonography, Doppler, Duplex

2012
Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
    American journal of physiology. Gastrointestinal and liver physiology, 2012, May-15, Volume: 302, Issue:10

    Topics: Animals; Antihypertensive Agents; Benzenesulfonates; Drug Therapy, Combination; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Phenylurea Compounds; Propranolol; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib

2012
Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
    Cancer biology & therapy, 2012, Volume: 13, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Survival; Central Nervous System Neoplasms; Drug Synergism; fas Receptor; Histone Deacetylase Inhibitors; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
    Cancer biology & therapy, 2012, Volume: 13, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Janus Kinase 2; Lysophospholipids; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neuroblastoma; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Signal Transduction; Sorafenib; Sphingosine; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2012
Choosing phase II endpoints and designs: evaluating the possibilities.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-15, Volume: 18, Issue:8

    Topics: Benzenesulfonates; Clinical Trials, Phase III as Topic; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib

2012
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2012, Volume: 57, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Monitoring; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2012
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Journal of hepatology, 2012, Volume: 57, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Division; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-3; Sorafenib; Xenograft Model Antitumor Assays

2012
Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
    Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:2

    Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib

2012
Indian health groups welcome country's first compulsory licence.
    BMJ (Clinical research ed.), 2012, Mar-16, Volume: 344

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Costs; Drug Industry; Drugs, Generic; Humans; India; Licensure; Niacinamide; Patents as Topic; Phenylurea Compounds; Pyridines; Sorafenib

2012
Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Cancer letters, 2012, Sep-28, Volume: 322, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2012
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:5

    Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Ultrasonography

2012
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Radiology, 2012, Volume: 263, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Contrast Media; Disease Progression; Doxorubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2012
Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.
    Clinical and experimental pharmacology & physiology, 2012, Volume: 39, Issue:5

    Topics: Acute Kidney Injury; Animals; Benzenesulfonates; Captopril; Growth Inhibitors; Hypertension; Male; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A

2012
Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Blood, 2012, Jun-21, Volume: 119, Issue:25

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzenesulfonates; Cells, Cultured; Drug Synergism; Female; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; Sorafenib; U937 Cells; Up-Regulation; Xenograft Model Antitumor Assays

2012
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrroles; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome

2012
[Sorafenib and octreotide combination therapy can inhibit proliferation of and induce apoptosis in human hepatoma cells].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:2

    Topics: Apoptosis; Benzenesulfonates; Cell Proliferation; Hep G2 Cells; Humans; Niacinamide; Octreotide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
    Retina (Philadelphia, Pa.), 2012, Volume: 32, Issue:8

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Humans; Immunohistochemistry; Indazoles; Light; Middle Aged; Neuropilin-1; Neuropilin-2; Neuropilins; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Retinal Pigment Epithelium; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2012
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
    PLoS genetics, 2012, Volume: 8, Issue:3

    Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2012
The effects of sorafenib on liver regeneration in a model of partial hepatectomy.
    The Journal of surgical research, 2012, Volume: 178, Issue:1

    Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Hepatectomy; Hepatocytes; Liver Cirrhosis; Liver Neoplasms; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Models, Animal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents.
    Bioorganic & medicinal chemistry, 2012, May-01, Volume: 20, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Structure-Activity Relationship; Thiourea

2012
Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
    Pediatric blood & cancer, 2012, Volume: 59, Issue:5

    Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Child, Preschool; Hepatoblastoma; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib

2012
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
    Cell, 2012, Apr-13, Volume: 149, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Breast Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Kinase 1; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proteome; Proto-Oncogene Proteins c-myc; Pyridines; Receptor Protein-Tyrosine Kinases; Sorafenib

2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
    Leukemia, 2012, Volume: 26, Issue:11

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib

2012
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.
    The EMBO journal, 2012, May-30, Volume: 31, Issue:11

    Topics: Benzenesulfonates; Caco-2 Cells; HCT116 Cells; HT29 Cells; Humans; Indoles; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides

2012
Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
    Biochemical pharmacology, 2012, Jul-15, Volume: 84, Issue:2

    Topics: Benzenesulfonates; Catalytic Domain; Cytochrome P-450 CYP3A; Humans; Inactivation, Metabolic; Microsomes, Liver; Models, Molecular; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Protein Conformation; Pyridines; Sorafenib

2012
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.
    International journal of cancer, 2012, Dec-15, Volume: 131, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; RNA Interference; Sorafenib

2012
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
    Cancer, 2012, Nov-01, Volume: 118, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Young Adult

2012
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
    World journal of surgical oncology, 2012, Apr-21, Volume: 10

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Glioma; Humans; Immunoenzyme Techniques; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; raf Kinases; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Vitamin K 1; Vitamins

2012
Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
    Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
    Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Bronchial Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2012
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Child; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Republic of Korea; ROC Curve; Sorafenib; Treatment Outcome; Young Adult

2012
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
    Urologic oncology, 2013, Volume: 31, Issue:8

    Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin-Like Growth Factor I; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-met; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sunitinib; Taxoids; Zinc Sulfate

2013
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
    American journal of clinical oncology, 2013, Volume: 36, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Treatment Outcome

2013
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
    BMC cancer, 2012, May-02, Volume: 12

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2012
The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells.
    Cellular signalling, 2012, Volume: 24, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Proteins; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; ras Proteins; Signal Transduction; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured

2012
Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
    Endocrine, 2012, Volume: 42, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hyperthyroidism; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Radionuclide Imaging; Sorafenib; Thyroid Function Tests; Thyroid Gland; Thyroiditis, Autoimmune

2012
Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
    Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Time Factors

2012
Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2013, Volume: 60, Issue:3

    Topics: Carcinoma, Neuroendocrine; Humans; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Thyroid Neoplasms

2013
RAIN-Droplet: a novel 3D in vitro angiogenesis model.
    Laboratory investigation; a journal of technical methods and pathology, 2012, Volume: 92, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Imaging, Three-Dimensional; Microscopy, Confocal; Microscopy, Electron, Transmission; Microvessels; Models, Biological; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spheroids, Cellular

2012
Painful leg mass.
    The Journal of family practice, 2012, Volume: 61, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neoplasms; Leg; Liver Neoplasms; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Pain; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Tomography, X-Ray Computed

2012
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Pyridines; Radiography; Sorafenib

2012
Multiple cutaneous metastatic chordomas from the sacrum.
    Journal of the American Academy of Dermatology, 2012, Volume: 66, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Chordoma; Female; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sacrum; Skin Neoplasms; Sorafenib

2012
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
    British journal of cancer, 2012, Jun-05, Volume: 106, Issue:12

    Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Clusterin; Disease Models, Animal; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Oligonucleotides, Antisense; Phenylurea Compounds; Pyridines; Sorafenib; Thionucleotides; Up-Regulation; Xenograft Model Antitumor Assays

2012
New use for an old drug: inhibiting ABCG2 with sorafenib.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:8

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Mitoxantrone; Molecular Conformation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Binding; Pyridines; Signal Transduction; Sorafenib

2012
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.
    British journal of cancer, 2012, Jun-05, Volume: 106, Issue:12

    Topics: AC133 Antigen; Adult; Aged; Animals; Antigens, CD; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Glycoproteins; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Niacinamide; Peptides; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Transcriptional Activation; Treatment Outcome

2012
Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:2

    Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A

2012
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    The Journal of pathology, 2012, Volume: 227, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2012
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome

2012
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis

2012
Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
    Biochemical and biophysical research communications, 2012, Jun-15, Volume: 422, Issue:4

    Topics: Animals; Antineoplastic Protocols; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Survival; Cyclin A; Cyclin B; Extracellular Signal-Regulated MAP Kinases; Humans; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; STAT1 Transcription Factor; STAT3 Transcription Factor

2012
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
    Journal of hepatology, 2012, Volume: 57, Issue:3

    Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Rats; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A

2012
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    International journal of oncology, 2012, Volume: 41, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; Mice; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Processing, Post-Translational; Pyridines; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Tumor Burden; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2012
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
    Future oncology (London, England), 2012, Volume: 8, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib

2012
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6

    Topics: Animals; Antineoplastic Agents, Hormonal; Benzenesulfonates; Bile Ducts; Caspase 3; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Cysts; Drug Therapy, Combination; Epithelial Cells; Ki-67 Antigen; Liver Diseases; MAP Kinase Signaling System; Mice; Mice, Knockout; Niacinamide; Octreotide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib; TRPP Cation Channels

2012
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:8

    Topics: Benzamides; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib

2012
Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma.
    Clinical & developmental immunology, 2012, Volume: 2012

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Count; Female; Humans; Immunity; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells; Treatment Outcome

2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sarcopenia; Sorafenib; Survival Analysis

2012
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
    Endocrine-related cancer, 2012, Volume: 19, Issue:4

    Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Child; Child, Preschool; Everolimus; Female; Humans; Infant; Male; Mice; Mice, Knockout; Mice, SCID; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult

2012
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
    Cancer biology & therapy, 2012, Volume: 13, Issue:9

    Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Endosomes; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Glutamates; Guanine; Humans; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein Phosphatase 2; Pyridines; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sorafenib; src-Family Kinases

2012
Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
    Medical ultrasonography, 2012, Volume: 14, Issue:2

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography

2012
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
    Oncology, 2012, Volume: 82, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
    Nature, 2012, Jun-06, Volume: 486, Issue:7401

    Topics: Animals; Benzenesulfonates; Cell Transformation, Neoplastic; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Extracellular Signal-Regulated MAP Kinases; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Molecular Targeted Therapy; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Polypharmacy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays

2012
The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines.
    Chemotherapy, 2012, Volume: 58, Issue:2

    Topics: Antigens, Differentiation; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Survival; E2F1 Transcription Factor; Hep G2 Cells; Humans; Liver Neoplasms; NF-kappa B; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; S-Adenosylmethionine; Sorafenib; Tumor Suppressor Protein p53

2012
Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 105, Issue:1

    Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Benzamides; Blotting, Western; Diphenylamine; Electron Spin Resonance Spectroscopy; Fibrosarcoma; Glutathione; Liver Neoplasms, Experimental; Mice; Neoplasms, Experimental; Niacinamide; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Radiation Tolerance; Sorafenib

2012
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2012
GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
    Biochemical and biophysical research communications, 2012, Jul-06, Volume: 423, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Glycogen Synthase Kinase 3; Humans; Kidney Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays

2012
Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.
    British journal of haematology, 2012, Volume: 158, Issue:4

    Topics: Aged; Amino Acid Sequence; Animals; Antineoplastic Agents; Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Point Mutation; Pyridines; Sequence Alignment; Sorafenib

2012
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.
    BMC cancer, 2012, Jun-11, Volume: 12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Coronary Angiography; Coronary Stenosis; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
    Kidney & blood pressure research, 2012, Volume: 35, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Comorbidity; Disease-Free Survival; Female; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Sorafenib; Treatment Outcome

2012
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
    Journal of medicinal chemistry, 2012, Jun-28, Volume: 55, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Cyproheptadine; Drug Approval; Drug Discovery; Ketanserin; Molecular Dynamics Simulation; Niacinamide; Phenylurea Compounds; Protein Conformation; Pyridines; Receptors, Serotonin; Sequence Homology, Amino Acid; Serotonin Antagonists; Sorafenib; United States; United States Food and Drug Administration; User-Computer Interface

2012
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
    Carcinogenesis, 2012, Volume: 33, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Synergism; Humans; Male; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2012
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
    International journal of clinical practice, 2012, Volume: 66, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Decision Making; Female; Humans; Liver Neoplasms; Male; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Professional Practice; Pyridines; Randomized Controlled Trials as Topic; Residence Characteristics; Sorafenib; Specialization

2012
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Exanthema; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Registries; Retrospective Studies; Skin; Sorafenib; Sunitinib; Treatment Outcome

2012
[A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib

2012
Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
    Archives of dermatology, 2012, Volume: 148, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Scalp; Skin Neoplasms; Sorafenib; Treatment Outcome

2012
The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
    BMC cancer, 2012, Jun-21, Volume: 12

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2012
Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.
    Bioorganic & medicinal chemistry, 2012, Jul-15, Volume: 20, Issue:14

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Structure-Activity Relationship; Urea

2012
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed

2012
Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.
    The Journal of dermatology, 2012, Volume: 39, Issue:12

    Topics: Antineoplastic Agents; Hand-Foot Syndrome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Psoriasis; Sorafenib; Ultraviolet Therapy

2012
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
    Cancer, 2013, Jan-01, Volume: 119, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Sorafenib; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2013
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
    The oncologist, 2012, Volume: 17, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Chromatography, Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Toxicity Tests; Treatment Outcome; Young Adult

2012
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
    International journal of clinical oncology, 2013, Volume: 18, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cough; Dyspnea; Female; Fever; Humans; Japan; Liver Neoplasms; Lung; Male; Marketing; Middle Aged; Niacinamide; Phenylurea Compounds; Pulmonary Alveoli; Sorafenib

2013
Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.
    Journal of gastrointestinal cancer, 2012, Volume: 43 Suppl 1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tomography, X-Ray Computed

2012
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2012
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
    International journal of cancer, 2013, Feb-01, Volume: 132, Issue:3

    Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; COS Cells; DNA, Neoplasm; Humans; Mice; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2013
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Anticancer research, 2012, Volume: 32, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Female; Furans; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2012
[Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma].
    Zhonghua yi xue za zhi, 2012, Apr-03, Volume: 92, Issue:13

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Eruptions; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib

2012
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2013, Volume: 251, Issue:1

    Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured

2013
Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sample Size; Sorafenib; Treatment Outcome

2012
The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Clinical laboratory, 2012, Volume: 58, Issue:5-6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib

2012
MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:10

    Topics: Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Chemotherapy, Adjuvant; DNA-Binding Proteins; Gene Expression Regulation; Hepatitis B; Humans; Immunohistochemistry; Liver Neoplasms; Minichromosome Maintenance Complex Component 7; Multivariate Analysis; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib

2012
Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles.
    International journal of nanomedicine, 2012, Volume: 7

    Topics: Animals; Benzenesulfonates; Chromatography, High Pressure Liquid; Fatty Acids; Female; Freeze Drying; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Phosphatidylcholines; Powders; Pyridines; Rabbits; Sorafenib

2012
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2012
Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:11

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Diagnosis, Differential; Female; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Portal Vein; Sorafenib

2012
[Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:7

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib

2012
Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
    Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:8

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2012
Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9.
    Journal of hepatology, 2012, Volume: 57, Issue:5

    Topics: Animals; Disease Models, Animal; Down-Regulation; Hepatectomy; Hepatic Veno-Occlusive Disease; Liver; Male; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib

2012
Sorafenib for lung cancer: is the "Battle" still open?
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:10

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Molecular mechanisms of sorafenib action in liver cancer cells.
    Cell cycle (Georgetown, Tex.), 2012, Aug-01, Volume: 11, Issue:15

    Topics: Apoptosis; Benzenesulfonates; Biological Transport; Carcinoma, Hepatocellular; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; DNA Replication; Gene Expression Profiling; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Transcription, Genetic

2012
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18

    Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cluster Analysis; Female; Gene Expression Profiling; Genomics; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Transforming Growth Factor beta; Wnt Proteins; Wnt Signaling Pathway

2012
Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2012, Volume: 10, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography, Abdominal; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2012
Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report.
    Journal of gastrointestinal cancer, 2013, Volume: 44, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Waiting Lists

2013
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
    Cell death & disease, 2012, Jul-19, Volume: 3

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aniline Compounds; Animals; Apoptosis Regulatory Proteins; Autophagy; bcl-X Protein; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; DNA Copy Number Variations; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; RNA Interference; RNA, Small Interfering; Sorafenib; Sulfonamides; Thymus Neoplasms; TOR Serine-Threonine Kinases; Transplantation, Heterologous

2012
From outlier to trendsetter.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2012, Sep-04, Volume: 184, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Industry; Drugs, Generic; Economic Competition; Global Health; Humans; India; Intellectual Property; Niacinamide; Patents as Topic; Phenylurea Compounds; Pyridines; Sorafenib

2012
Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Journal of surgical oncology, 2013, Volume: 107, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Down-Regulation; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta

2013
Right sided heart mass reveals hepatocellular carcinoma.
    Heart, lung & circulation, 2012, Volume: 21, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Sorafenib; Thrombosis

2012
Targeting angiogenesis in metastatic breast cancer.
    The oncologist, 2012, Volume: 17, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2012
Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules.
    The Journal of biological chemistry, 2012, Sep-14, Volume: 287, Issue:38

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Proteins; Beclin-1; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protoporphyrins; Pyridines; Sirolimus; Sorafenib

2012
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
    Anticancer research, 2012, Volume: 32, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Von Hippel-Lindau Tumor Suppressor Protein; Vorinostat

2012
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:7

    Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Skin Diseases; Sorafenib; Treatment Outcome

2012
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
    Onkologie, 2012, Volume: 35, Issue:7-8

    Topics: Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Thiazoles; Treatment Outcome; Tumor Cells, Cultured

2012
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012, Volume: 18, Issue:11

    Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; Hemodynamics; Inflammation; Liver; Male; MAP Kinase Signaling System; Necrosis; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; rho-Associated Kinases; RNA, Messenger; Sorafenib; Transplantation, Homologous

2012
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
    International journal of cardiology, 2013, Sep-10, Volume: 167, Issue:6

    Topics: Animals; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Ventricular Function, Right; Ventricular Remodeling

2013
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2012, Volume: 14, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib

2012
Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension.
    American journal of respiratory and critical care medicine, 2012, Aug-01, Volume: 186, Issue:3

    Topics: Adult; Benzenesulfonates; Cardiac Catheterization; Exercise Test; Female; Humans; Hypertension, Pulmonary; Neurofibromatosis 1; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vascular Resistance

2012
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
    Leukemia, 2013, Volume: 27, Issue:1

    Topics: Animals; Benzenesulfonates; Blotting, Western; Cells, Cultured; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Immunoprecipitation; Leukemia, Erythroblastic, Acute; Mice; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tandem Repeat Sequences

2013
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C-Reactive Protein; Carcinoma, Renal Cell; Confidence Intervals; Female; Humans; Hyponatremia; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocytosis; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Severity of Illness Index; Sodium; Sorafenib; Sunitinib

2012
Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.
    European journal of medicinal chemistry, 2012, Volume: 55

    Topics: Animals; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Humans; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Protein Kinases; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2012
Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
    Clinical drug investigation, 2012, Aug-08, Volume: 32 Suppl 2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Treatment Outcome

2012
Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
    Clinical drug investigation, 2012, Aug-08, Volume: 32 Suppl 2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Sorafenib; Time Factors

2012
Closing remarks.
    Clinical drug investigation, 2012, Aug-08, Volume: 32 Suppl 2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Approval; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2013
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Transplant international : official journal of the European Society for Organ Transplantation, 2012, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2012
[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
    Zhonghua yi xue za zhi, 2012, May-15, Volume: 92, Issue:18

    Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Liver Transplantation; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult

2012
Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    International journal of clinical oncology, 2013, Volume: 18, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib

2013
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Oncology, 2012, Volume: 83, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Precursors; Prothrombin; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed

2012
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA, Neoplasm; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factor 4; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Incidence; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Heterologous; Treatment Outcome

2013
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
    Future oncology (London, England), 2012, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Humans; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2012
The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model.
    Reproductive sciences (Thousand Oaks, Calif.), 2013, Volume: 20, Issue:1

    Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Models, Animal; Endometriosis; Female; Microvessels; Niacinamide; Phenylurea Compounds; Random Allocation; Rats; Rats, Wistar; Sorafenib; Treatment Outcome; Tretinoin

2013
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
    Technology in cancer research & treatment, 2013, Volume: 12, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Transplantation, Heterologous

2013
Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma.
    World journal of surgical oncology, 2012, Aug-20, Volume: 10

    Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sigmoid Diseases; Sorafenib

2012
Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2012, Volume: 30, Issue:4

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Size; Ceramides; Erythrocytes; Hemolysis; Humans; Liver Neoplasms; Niacinamide; Oxidative Stress; Phenylurea Compounds; Phosphatidylserines; Protein Kinase Inhibitors; Sorafenib

2012
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Risk Factors; Skin; Sorafenib; UDP-Glucuronosyltransferase 1A9

2012
Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:1

    Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Regulation; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Niacinamide; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; RNA; Sorafenib; Thioacetamide

2013
[Hepatocellular carcinoma - long-term treatable disease].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2012, Volume: 25, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
    Gastroenterology, 2012, Volume: 143, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Hep G2 Cells; Humans; Janus Kinases; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Repressor Proteins; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Suppressor Proteins

2012
Focus.
    Journal of hepatology, 2012, Volume: 57, Issue:5

    Topics: Animals; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Hepatic Veno-Occlusive Disease; Hepatitis C; Hepatocytes; Humans; Male; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Monocrotaline; Niacinamide; Phenylurea Compounds; Sorafenib; Viral Nonstructural Proteins

2012
Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.
    Journal of radiation research, 2013, Volume: 54, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Survival; Chemoradiotherapy; Colorectal Neoplasms; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; HT29 Cells; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiation Tolerance; Sorafenib; Treatment Outcome

2013
Editorial comment from Dr Saito to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2012
RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
    Journal of surgical oncology, 2013, Volume: 107, Issue:4

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorescent Antibody Technique; Hepatectomy; Hepatocytes; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Liver Regeneration; Molecular Targeted Therapy; Neoplasm Micrometastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Rats; Sorafenib

2013
Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Oct-15, Volume: 18, Issue:20

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2012
Clinicopathological characteristics of hepatocellular carcinoma in Turkey.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; alpha-Fetoproteins; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Risk Factors; Sorafenib; Turkey; Young Adult

2012
Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
    Molecular and cellular biochemistry, 2013, Volume: 372, Issue:1-2

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Caspase 3; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases

2013
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
    Acta pharmacologica Sinica, 2012, Volume: 33, Issue:10

    Topics: Antineoplastic Agents; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Real-Time Polymerase Chain Reaction; RNA Interference; Sorafenib; Vascular Endothelial Growth Factor Receptor-2

2012
[Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2012, Volume: 50, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult

2012
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
    Cancer research, 2012, Oct-15, Volume: 72, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Disease Models, Animal; DNA Primers; Female; Flow Cytometry; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Affinity purification of protein kinases that adopt a specific inactive conformation.
    Methods in molecular biology (Clifton, N.J.), 2012, Volume: 928

    Topics: Benzamides; Benzenesulfonates; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Sorafenib

2012
Bayer challenges India's first compulsory licence for generic version of cancer drug.
    BMJ (Clinical research ed.), 2012, Sep-06, Volume: 345

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Costs; Drug Industry; Drugs, Generic; Humans; India; Legislation, Drug; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.
    Cell stem cell, 2012, Sep-07, Volume: 11, Issue:3

    Topics: Animals; Bone Marrow; Bone Marrow Neoplasms; Cell Compartmentation; Cell Cycle; Cell Proliferation; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Neoplastic; Gene Knock-In Techniques; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Homeostasis; Male; Mice; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Promoter Regions, Genetic; RNA, Messenger; Side-Population Cells; Signal Transduction; Small Molecule Libraries; Sorafenib; Tandem Repeat Sequences

2012
An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.
    Biochemical and biophysical research communications, 2012, Sep-28, Volume: 426, Issue:3

    Topics: Animals; Benzamides; Benzenesulfonates; Cell Proliferation; Drug Resistance, Neoplasm; Imatinib Mesylate; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; raf Kinases; Receptor, Platelet-Derived Growth Factor alpha; Rhabdomyosarcoma, Alveolar; Sorafenib; src-Family Kinases; Tumor Cells, Cultured

2012
A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factor 4; Gene Amplification; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Diclofenac; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Phospholipases A2, Cytosolic; Signal Transduction; Skin Neoplasms; Small Molecule Libraries; Sorafenib

2012
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
    BMC cancer, 2012, Sep-10, Volume: 12

    Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Cell Survival; Drug Synergism; Enzyme Activation; Fluorouracil; Gene Expression Regulation, Enzymologic; Growth Inhibitors; Hep G2 Cells; Hepatic Stellate Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Thymidylate Synthase; Time Factors

2012
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
    International journal of oncology, 2012, Volume: 41, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia; Kidney Neoplasms; Mice; Mice, Nude; Misonidazole; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Radiopharmaceuticals; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays

2012
Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Molecular pharmaceutics, 2012, Nov-05, Volume: 9, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Nanomedicine; Nanoparticles; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptors, Transferrin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serum Albumin; Sorafenib; STAT5 Transcription Factor; Transferrin; Tumor Cells, Cultured

2012
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
    Current pharmaceutical design, 2013, Volume: 19, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Mass Spectrometry

2013
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
    Transplantation proceedings, 2012, Volume: 44, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib

2012
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    British journal of pharmacology, 2013, Volume: 168, Issue:3

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Sorafenib; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays

2013
Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis.
    Fertility and sterility, 2012, Volume: 98, Issue:6

    Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Cell Movement; Cell Proliferation; Cells, Cultured; Endometriosis; Endometrium; Female; Humans; Mesenchymal Stem Cells; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Young Adult

2012
Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients.
    Acta medica Indonesiana, 2012, Volume: 44, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Financial Support; Humans; Indonesia; Kaplan-Meier Estimate; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Program Evaluation; Proportional Hazards Models; Prospective Studies; Sorafenib; Young Adult

2012
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
    International journal of colorectal disease, 2013, Volume: 28, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Ki-67 Antigen; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2013
Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response.
    Cancer biology & therapy, 2012, Volume: 13, Issue:14

    Topics: Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Transplantation, Heterologous

2012
Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:4

    Topics: Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
    Anticancer research, 2012, Volume: 32, Issue:9

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thrombosis

2012
Evaluation of the relationship between MR estimates of blood oxygen saturation and hypoxia: effect of an antiangiogenic treatment on a gliosarcoma model.
    Radiology, 2012, Volume: 265, Issue:3

    Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Benzenesulfonates; Brain Neoplasms; Dextrans; Gliosarcoma; Hypoxia, Brain; Image Processing, Computer-Assisted; Immunohistochemistry; Linear Models; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Niacinamide; Nitroimidazoles; Oxygen; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Rats, Inbred F344; Reproducibility of Results; Sorafenib

2012
Editorial comment from Dr Vázquez-Alonso and Dr Puche-Sanz to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2012
Sorafenib-induced tuberculosis reactivation.
    Onkologie, 2012, Volume: 35, Issue:9

    Topics: Aged; Antineoplastic Agents; Antitubercular Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Latent Tuberculosis; Male; Niacinamide; Phenylurea Compounds; Secondary Prevention; Sorafenib; Treatment Outcome

2012
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
    Clinical endocrinology, 2013, Volume: 78, Issue:5

    Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome

2013
Thyroid dysfunction in patients treated with sunitinib or sorafenib.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Gland; Thyroid Hormones

2012
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
    Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flow Cytometry; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome; Vitamin K 2

2012
Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
    Bioorganic & medicinal chemistry letters, 2012, Nov-01, Volume: 22, Issue:21

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship

2012
Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:10

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2012
Tyrosine kinase inhibitor induced pancreatitis.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2013, Volume: 19, Issue:3

    Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib

2013
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
    Cancer letters, 2013, Feb-01, Volume: 329, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Hypoxia; Cellular Microenvironment; Coculture Techniques; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-pim-1; Sorafenib; Stromal Cells; Sulfonamides

2013
Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:12

    Topics: Adenosine Triphosphatases; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Secretory Pathway; Sorafenib

2012
Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.
    Clinical science (London, England : 1979), 2013, Volume: 124, Issue:7

    Topics: Animals; Benzenesulfonates; Common Bile Duct; Disease Models, Animal; Hemodynamics; Hepatopulmonary Syndrome; Ligation; Liver; Liver Cirrhosis, Biliary; Liver Diseases; Lung; Male; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2013
The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.
    Journal of hepatology, 2013, Volume: 58, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; Disease Models, Animal; Drug Therapy, Combination; Liver Neoplasms; Mice; Mice, Knockout; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placenta Growth Factor; Pregnancy Proteins; Sorafenib; Treatment Outcome

2013
[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 2012, Volume: 58, Issue:8

    Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Glucose Intolerance; Heart Failure; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib

2012
Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.
    Journal of gastrointestinal cancer, 2013, Volume: 44, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Tomography, X-Ray Computed

2013
Interactions of everolimus and sorafenib in pancreatic cancer cells.
    The AAPS journal, 2013, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Everolimus; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib

2013
c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Sorafenib; Survival Rate; Treatment Outcome

2013
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
    Oncology, 2013, Volume: 84, Issue:1

    Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome; Vomiting

2013
The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.
    European journal of clinical investigation, 2012, Volume: 42, Issue:12

    Topics: Animals; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib

2012
Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner.
    BMC cancer, 2012, Oct-22, Volume: 12

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib

2012
BRAF mutations in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Exons; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Sorafenib; Sulfonamides; Treatment Outcome

2013
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.
    Targeted oncology, 2012, Volume: 7, Issue:4

    Topics: Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Recurrence; Sorafenib; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Tumor Burden

2012
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:10

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2012
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Viral Load

2013
Effects of antiangiogenic therapy.
    Journal of vascular and interventional radiology : JVIR, 2012, Volume: 23, Issue:11

    Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cystoscopy; Embolization, Therapeutic; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Stents; Time Factors; Treatment Outcome

2012
The kinase inhibitor Sorafenib impairs the antiviral effect of interferon α on hepatitis C virus replication.
    European journal of cell biology, 2013, Volume: 92, Issue:1

    Topics: Antiviral Agents; Cell Line, Tumor; Hepacivirus; Humans; Interferon-alpha; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Virus Replication

2013
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
    Laboratory investigation; a journal of technical methods and pathology, 2013, Volume: 93, Issue:1

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochromes c; Down-Regulation; Gene Knockdown Techniques; GTP Phosphohydrolases; Humans; Liver; Liver Neoplasms; Mice; Mice, SCID; Mitochondria; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; RNA, Small Interfering; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2013
Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.
    International journal of molecular sciences, 2012, Volume: 13, Issue:9

    Topics: Androgens; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Protein Binding; Protein Isoforms; Protein Kinase Inhibitors; Receptors, Androgen; Signal Transduction; Sorafenib

2012
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
    Cancer letters, 2013, Feb-01, Volume: 329, Issue:1

    Topics: Anilides; Antineoplastic Agents; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Keratin-19; Liver Neoplasms; Morpholines; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Vimentin

2013
Conditional survival of patients with metastatic renal-cell carcinoma.
    The Lancet. Oncology, 2012, Volume: 13, Issue:11

    Topics: Carcinoma, Renal Cell; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis

2012
Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
    International journal of oncology, 2013, Volume: 42, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Humans; Hypoxia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2013
A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
    Haematologica, 2012, Volume: 97, Issue:11

    Topics: Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Piperazines; Sorafenib; Tumor Suppressor Protein p53

2012
Sorafenib therapy decreases the clearance of thyrotropin.
    European journal of endocrinology, 2013, Volume: 168, Issue:2

    Topics: Aged; Aged, 80 and over; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Function Tests; Thyroid Neoplasms; Thyrotropin

2013
Sorafenib is effective in the treatment of pulmonary veno-occlusive disease.
    Cardiology, 2012, Volume: 123, Issue:3

    Topics: Aged; Benzamides; Drug Therapy, Combination; Female; Hemodynamics; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pulmonary Veno-Occlusive Disease; Pyrimidines; Sorafenib; Treatment Outcome

2012
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
    The Journal of pathology, 2013, Volume: 229, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Therapy, Combination; Gene Knockdown Techniques; Humans; Intestinal Mucosa; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay

2013
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
    British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Osteonecrosis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2013
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Urologic oncology, 2013, Volume: 31, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Treatment Outcome

2013
Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
    Cancer letters, 2013, Feb-01, Volume: 329, Issue:1

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; DNA Damage; DNA Repair; Female; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Radiation-Sensitizing Agents; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2013
Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
    Transplantation proceedings, 2012, Volume: 44, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome

2012
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
    Oncology, 2013, Volume: 84, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyridines; raf Kinases; Risk Factors; Safety; Sorafenib; Survival Rate

2013
Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.
    Pharmaceutical research, 2013, Volume: 30, Issue:3

    Topics: Adult; Cell Proliferation; Drug Combinations; Drug Interactions; Everolimus; Female; Humans; Immunosuppressive Agents; Lymphocytes; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib

2013
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.
    Investigational new drugs, 2013, Volume: 31, Issue:3

    Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Humans; Leukocytes, Mononuclear; Macrophage Colony-Stimulating Factor; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Osteoclasts; Phenylurea Compounds; Protein Kinase Inhibitors; RANK Ligand; Sorafenib

2013
Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    World journal of gastroenterology, 2012, Oct-28, Volume: 18, Issue:40

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Disease Progression; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2012
The effect of sorafenib in postoperative adhesion formation in a rat uterine horn model.
    Clinical and experimental obstetrics & gynecology, 2012, Volume: 39, Issue:3

    Topics: Animals; Benzenesulfonates; Disease Models, Animal; Female; Immunohistochemistry; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats; Rats, Wistar; Sorafenib; Tissue Adhesions; Uterine Diseases; Uterus; Vascular Endothelial Growth Factor A

2012
Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Treatment Outcome

2013
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Surgery, 2012, Volume: 152, Issue:6

    Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Immunosuppressive Agents; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms

2012
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
    Journal of cellular physiology, 2013, Volume: 228, Issue:6

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors

2013
Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
    Acta radiologica (Stockholm, Sweden : 1987), 2013, Mar-01, Volume: 54, Issue:2

    Topics: Animals; Antineoplastic Agents; Catheter Ablation; Combined Modality Therapy; Disease Progression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A

2013
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult

2013
Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Humans; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2013
Multitargeted therapies for multiple myeloma.
    Autophagy, 2013, Feb-01, Volume: 9, Issue:2

    Topics: Animals; Disease Models, Animal; Humans; Mice; Models, Biological; Molecular Targeted Therapy; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib

2013
Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
    International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Lung; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib

2013
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
    Anti-cancer drugs, 2013, Volume: 24, Issue:3

    Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines

2013
PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
    Oncology research, 2012, Volume: 20, Issue:2-3

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Case-Control Studies; Cell Proliferation; Drug Resistance; Flow Cytometry; Humans; Immunoenzyme Techniques; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; PTEN Phosphohydrolase; Pyridines; Sorafenib; Survival Rate; Tumor Cells, Cultured

2012
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
    Anti-cancer drugs, 2013, Volume: 24, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular; Disease Progression; Female; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2013
Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Taiwan; Treatment Outcome

2013
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
    Bulletin du cancer, 2012, Volume: 99, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Cancer Care Facilities; Carcinoma, Renal Cell; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2012
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
    Cancer immunology, immunotherapy : CII, 2013, Volume: 62, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; CD4-Positive T-Lymphocytes; Coculture Techniques; Cytokines; Dose-Response Relationship, Immunologic; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-2 Receptor alpha Subunit; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Regulatory

2013
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
    The Journal of urology, 2013, Volume: 190, Issue:1

    Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dietary Supplements; Disease Models, Animal; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Hymecromone; Immunoblotting; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Random Allocation; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Drugmakers struggle with Indian patents.
    Cancer discovery, 2012, Volume: 2, Issue:12

    Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Industry; Humans; Imatinib Mesylate; India; Indoles; Niacinamide; Patents as Topic; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib

2012
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
    BMC cancer, 2012, Dec-11, Volume: 12

    Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Fatal Outcome; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib

2012
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    American journal of surgery, 2012, Volume: 204, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Withanolides

2012
Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-01, Volume: 19, Issue:3

    Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclin D1; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins c-bcl-2; Receptors, Antigen, B-Cell; Signal Transduction; Sorafenib; Stromal Cells; Transplantation, Heterologous

2013
Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.
    Chinese journal of cancer, 2013, Volume: 32, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Radiotherapy, Conformal; Sorafenib

2013
Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed?
    World journal of gastroenterology, 2012, Dec-14, Volume: 18, Issue:46

    Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Hepatocellular; Cell Death; Clinical Trials as Topic; DNA-Binding Proteins; Humans; Liver Neoplasms; Niacinamide; Oncogenes; Phenotype; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinolones; Sorafenib; Transcription Factors

2012
Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbazoles; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Furans; Hodgkin Disease; Humans; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Reed-Sternberg Cells; Signal Transduction; Sorafenib

2013
Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:3

    Topics: Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Hematopoiesis; Humans; Leukemia, Myelomonocytic, Chronic; Middle Aged; Niacinamide; Nucleic Acid Hybridization; Phenylurea Compounds; Sorafenib

2013
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.
    Molecular bioSystems, 2013, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Profiling; Humans; Mesoderm; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Interaction Maps; Protein Kinases; Proteome; Proteomics; Quinazolines; Sorafenib

2013
[Side effects of sorafenib and countermeasures].
    Hinyokika kiyo. Acta urologica Japonica, 2012, Volume: 58, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib

2012
Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Sweden; Young Adult

2013
Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.
    BMJ case reports, 2012, Dec-17, Volume: 2012

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Contrast Media; Fatal Outcome; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Panobinostat; Phenylurea Compounds; Sorafenib; Ultrasonography

2012
[Successful treatment with sorafenib for primary refractory acute monoblastic leukemia with FLT3-ITD].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Inverted Repeat Sequences; Leukemia, Monocytic, Acute; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2012
Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
    British journal of cancer, 2013, Feb-05, Volume: 108, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Cytostatic Agents; DNA Adducts; Enzyme Activation; Female; Hepatoblastoma; Humans; Liver Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Xenograft Model Antitumor Assays

2013
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
    British journal of cancer, 2013, Jan-15, Volume: 108, Issue:1

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Liver Neoplasms; Mice; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Sorafenib; Xenograft Model Antitumor Assays

2013
How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage.
    Digestive diseases (Basel, Switzerland), 2012, Volume: 30, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes

2012
Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.
    Digestive diseases (Basel, Switzerland), 2012, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2012
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2013
Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission, Spontaneous; Sorafenib

2013
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States

2013
[A case of hepatocellular carcinoma treated by resection of metachronous rib metastasis after primary hepatectomy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Ribs; Sorafenib

2012
[A case of curative resection for advanced hepatocellular carcinoma with portal vein tumor thrombus after hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis

2012
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome

2013
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013, Mar-12, Volume: 48, Issue:4-5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Pregnane X Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Steroid; Sorafenib

2013
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Iodized Oil; Liver Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate

2012
A novel p21 attenuator which is structurally related to sorafenib.
    Cancer biology & therapy, 2013, Volume: 14, Issue:3

    Topics: Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Niacinamide; Phenylurea Compounds; raf Kinases; RNA, Messenger; Sorafenib; Tumor Suppressor Protein p53

2013
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life Years; Sorafenib

2013
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Piperidones; Sorafenib; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays

2013
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glucuronidase; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Saponins; Sorafenib

2012
[Effects of sorafenib and liposome doxorubicin on human poorly differentiated thyroid carcinoma xenografts in nude mice].
    Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery, 2012, Volume: 47, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Liposomes; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2012
Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:4

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Contrast Media; Disease-Free Survival; Female; Ferric Compounds; Humans; Iron; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Perfusion Imaging; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2013
Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:5

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib

2013
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2013
The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression.
    Oncology reports, 2013, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Chemoradiotherapy; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Matrix Metalloproteinase 2; MCF-7 Cells; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib; Spheroids, Cellular

2013
The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Fluorouracil; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; NF-E2-Related Factor 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib

2013
αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:6

    Topics: 14-3-3 Proteins; alpha-Crystallin B Chain; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins c-fos; Snail Family Transcription Factors; Sorafenib; Transcription Factors

2013
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Cancer treatment reviews, 2013, Volume: 39, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2013
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
    British journal of cancer, 2013, Feb-05, Volume: 108, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2013
Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    Chinese medical journal, 2013, Volume: 126, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
    Cell cycle (Georgetown, Tex.), 2013, Feb-01, Volume: 12, Issue:3

    Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Down-Regulation; Glioblastoma; Humans; Intermediate Filament Proteins; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Nerve Tissue Proteins; Nestin; Niacinamide; Oligodendrocyte Transcription Factor 2; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib; SOXB1 Transcription Factors; STAT3 Transcription Factor; Tumor Cells, Cultured

2013
Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma.
    Disease markers, 2013, Volume: 34, Issue:2

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Sorafenib; Treatment Outcome

2013
Sorafenib induces autophagy and suppresses activation of human macrophage.
    International immunopharmacology, 2013, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Autophagy; B7-1 Antigen; Cells, Cultured; Cytokines; Dendritic Cells; Down-Regulation; Humans; Immunity, Innate; Immunosuppression Therapy; Lipopolysaccharide Receptors; Macrophage Activation; Macrophages; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reactive Oxygen Species; Sorafenib

2013
Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Cancer letters, 2013, May-01, Volume: 331, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; In Situ Nick-End Labeling; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Sorafenib; Sulfonamides

2013
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Mar-15, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Agents; Glucuronic Acid; HEK293 Cells; Humans; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Phenylurea Compounds; Solute Carrier Organic Anion Transporter Family Member 1B3; Sorafenib

2013
Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-20, Volume: 31, Issue:9

    Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Solitary Fibrous Tumors; Sorafenib

2013
Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Melanophores; Niacinamide; Oryzias; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib

2013
[Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2012, Volume: 103, Issue:5

    Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2012
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
    TheScientificWorldJournal, 2012, Volume: 2012

    Topics: Adenoma, Islet Cell; Animals; Antigens, Polyomavirus Transforming; Apoptosis; Disease Progression; Female; Insulin; Islets of Langerhans; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Rats; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden

2012
Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts.
    Transplantation, 2013, Mar-27, Volume: 95, Issue:6

    Topics: Animals; Antigens; Autophagy; Cell Survival; Dactinomycin; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Mice; Microscopy, Fluorescence; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Skin Transplantation; Sorafenib; Transplantation, Homologous

2013
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Leukemia, 2013, Volume: 27, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitogen-Activated Protein Kinases; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2013
Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells.
    Biochemical and biophysical research communications, 2013, Mar-01, Volume: 432, Issue:1

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Down-Regulation; Female; Gene Knockdown Techniques; Glucose; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Survivin; TOR Serine-Threonine Kinases

2013
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
    International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:9

    Topics: Aneuploidy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib; Transcriptome; Tumor Cells, Cultured

2013
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
    British journal of haematology, 2013, Volume: 161, Issue:1

    Topics: Actins; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemokine CXCL12; Chemotaxis; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Polymerization; Pyrazines; Sorafenib; Syndecan-1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays

2013
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Cell death & disease, 2013, Feb-07, Volume: 4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Transplantation, Heterologous

2013
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Precursors; Prothrombin; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome

2013
Pustular eruption induced by sorafenib in a case of psoriasis vulgaris.
    The Journal of dermatology, 2013, Volume: 40, Issue:4

    Topics: Aged; Asian People; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Severity of Illness Index; Skin Diseases, Vesiculobullous; Sorafenib

2013
Taking cancer-drug toxicity to heart.
    Cancer discovery, 2013, Volume: 3, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab

2013
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:3

    Topics: Aged; Brain Diseases, Metabolic; Carcinoma, Hepatocellular; Cognition Disorders; Electroencephalography; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mood Disorders; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome

2013
A novel role of cytosolic protein synthesis inhibition in aminoglycoside ototoxicity.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Feb-13, Volume: 33, Issue:7

    Topics: Alanine; Alkynes; Aminoglycosides; Animals; Anti-Bacterial Agents; Apoptosis; Blotting, Western; Cell Count; Chick Embryo; Cytosol; Ear Diseases; Enzyme Activation; Evoked Potentials, Auditory, Brain Stem; Glycine; Hair Cells, Auditory; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred CBA; Niacinamide; Organ Culture Techniques; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; RNA, Ribosomal; Sorafenib

2013
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:5

    Topics: Animals; Apoptosis; Disease Models, Animal; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; Liver Transplantation; Male; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred ACI; Rats, Inbred Lew; Sorafenib; Tissue Array Analysis

2013
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Immunocompromised Host; Immunosuppressive Agents; K562 Cells; Killer Cells, Natural; Lectins, C-Type; Liver Neoplasms; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2013
Label-retaining liver cancer cells are relatively resistant to sorafenib.
    Gut, 2013, Volume: 62, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Humans; Liver Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Stem Cells

2013
Fluorinated N,N'-diarylureas as AMPK activators.
    Bioorganic & medicinal chemistry letters, 2013, Mar-15, Volume: 23, Issue:6

    Topics: AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Halogenation; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Urea

2013
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
    Cancer science, 2013, Volume: 104, Issue:6

    Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatin Immunoprecipitation; Enhancer of Zeste Homolog 2 Protein; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polycomb Repressive Complex 2; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transfection

2013
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Drug Evaluation, Preclinical; Humans; Killer Cells, Natural; Liver Neoplasms; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013
Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series.
    Oncology, 2013, Volume: 84, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Quality of Life; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2013
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?.
    Oncology, 2013, Volume: 84 Suppl 1

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Ethiodized Oil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Retrospective Studies; Sorafenib; Survival Rate

2013
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Blood, 2013, Apr-18, Volume: 121, Issue:16

    Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Quinolines; Sorafenib

2013
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Survival; Chick Embryo; Everolimus; Female; Flow Cytometry; Humans; Immunohistochemistry; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred NOD; Mice, SCID; Multiprotein Complexes; Neovascularization, Pathologic; Niacinamide; Osteosarcoma; Phenylurea Compounds; Reactive Oxygen Species; RNA Interference; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays

2013
Zinc sensitizes prostate cancer cells to sorafenib and regulates the expression of Livin.
    Acta biochimica et biophysica Sinica, 2013, Volume: 45, Issue:5

    Topics: Actins; Adaptor Proteins, Signal Transducing; Apoptosis; Cell Line, Tumor; Cell Survival; Cytoskeleton; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Male; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Sorafenib; Zinc Sulfate

2013
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Oxonic Acid; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tegafur; Thymidylate Synthase

2013
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
    Clinical pharmacology and therapeutics, 2013, Volume: 93, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; Models, Statistical; Niacinamide; Phenylurea Compounds; Sorafenib

2013
[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2013
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Drug Interactions; Everolimus; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Biological; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib; Tandem Mass Spectrometry; Tissue Distribution

2013
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Animals; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Mice; Mice, SCID; Models, Biological; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays

2013
Liver tumors and loco-regional therapy.
    Wiener medizinische Wochenschrift (1946), 2013, Volume: 163, Issue:5-6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Evidence-Based Medicine; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Sorafenib

2013
[Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2012, Volume: 47, Issue:12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship

2012
Sorafenib inhibits liver regeneration in rats.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2013, Volume: 15, Issue:12

    Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Bilirubin; Body Weight; Cell Proliferation; Hepatectomy; Ki-67 Antigen; Liver; Liver Regeneration; Niacinamide; Organ Size; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib; Time Factors

2013
Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.
    Journal of cellular biochemistry, 2013, Volume: 114, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Endometrial Neoplasms; ets-Domain Protein Elk-1; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proteolysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Transcription, Genetic

2013
Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Sorafenib; Yttrium Radioisotopes

2013
Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
    Oncology reports, 2013, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib; U937 Cells; Up-Regulation

2013
α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: alpha-Fetoproteins; Animals; Autophagy-Related Protein 5; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Order; Gene Silencing; Genetic Vectors; Homologous Recombination; Humans; Liver Neoplasms; Male; Mice; Microtubule-Associated Proteins; Niacinamide; Organ Specificity; Phenylurea Compounds; Promoter Regions, Genetic; RNA Interference; Sorafenib; Tumor Burden

2013
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Smad7 Protein; Sorafenib; Transforming Growth Factor beta; Up-Regulation

2013
Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
    International journal of radiation oncology, biology, physics, 2013, Jul-01, Volume: 86, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Chemoradiotherapy; Cyclin D1; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Sorafenib; STAT3 Transcription Factor; Survivin

2013
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2013
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
    Gut, 2013, Volume: 62, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:6

    Topics: Adult; Animals; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Female; Hepatocytes; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2013
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2013
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Journal of experimental & clinical cancer research : CR, 2013, Mar-06, Volume: 32

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cytokines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Random Allocation; RNA-Binding Proteins; Sorafenib; Survival Analysis; Xenograft Model Antitumor Assays

2013
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
    Journal of hepatology, 2013, Volume: 59, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult

2013
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
    International journal of cancer, 2013, Oct-01, Volume: 133, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Deferoxamine; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Iron Regulatory Protein 2; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Oxidative Stress; Phenylenediamines; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; RNA Interference; Siderophores; Sorafenib

2013
[Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
    Klinische Monatsblatter fur Augenheilkunde, 2013, Volume: 230, Issue:3

    Topics: Angiogenesis Inhibitors; Astrocytes; Axitinib; Cell Survival; Cornea; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Corneal; Humans; Imidazoles; Indazoles; Lens, Crystalline; Microscopy, Phase-Contrast; Niacinamide; Optic Disk; Organ Culture Techniques; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Pigment Epithelium; Sorafenib; Sulfonamides; Trabecular Meshwork; Wet Macular Degeneration

2013
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; ROC Curve; Sorafenib; Treatment Outcome; Young Adult

2013
Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model.
    Journal of vascular and interventional radiology : JVIR, 2013, Volume: 24, Issue:5

    Topics: Animals; Antineoplastic Agents; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Ethiodized Oil; Liver; Male; Niacinamide; Phenylurea Compounds; Pilot Projects; Rabbits; Sorafenib; Tissue Distribution; Treatment Outcome

2013
Model-based drug development in oncology: what's next?
    Clinical pharmacology and therapeutics, 2013, Volume: 93, Issue:4

    Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; Models, Statistical; Niacinamide; Phenylurea Compounds; Sorafenib

2013
[Molecular targeted agent for hepatocellular carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib

2012
[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
    Nuclear medicine and biology, 2013, Volume: 40, Issue:4

    Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Cell Transformation, Neoplastic; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Radioactive Tracers; Radiochemistry; Rats; Sorafenib

2013
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:3

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Cholangiocarcinoma; Female; Humans; In Vitro Techniques; Liver Neoplasms; Molecular Sequence Data; Niacinamide; Oocytes; Organic Cation Transporter 1; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sorafenib; Treatment Outcome; Xenopus laevis

2013
Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.
    Anti-cancer drugs, 2013, Volume: 24, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Urothelium

2013
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Journal of gastroenterology, 2014, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Synergism; Humans; Leupeptins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Oligopeptides; Phenylurea Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib

2014
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
    Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:1

    Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Respiration, Artificial; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2014
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Chemotherapy, 2012, Volume: 58, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Young Adult

2012
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
    Future oncology (London, England), 2013, Volume: 9, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Fibrosis; Hepatitis B; Hepatitis C; Humans; Hypertension; Italy; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Weight Loss

2013
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    British journal of haematology, 2013, Volume: 161, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured

2013
Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2013
Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.
    Oncology reports, 2013, Volume: 29, Issue:6

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuropilin-1; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Retrospective Studies; Sorafenib

2013
Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy.
    Endocrine, 2013, Volume: 44, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome

2013
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Anticancer research, 2013, Volume: 33, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Dinoprostone; Drug Synergism; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Sorafenib; Sulfonamides; Tumor Cells, Cultured

2013
Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.
    Anticancer research, 2013, Volume: 33, Issue:4

    Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tumor Cells, Cultured

2013
Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Monitoring; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2013
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence.
    Journal of hepatology, 2013, Volume: 59, Issue:1

    Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Female; Gene Dosage; Genes, myc; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Retrospective Studies; Sorafenib; Treatment Outcome

2013
Innovations in the treatment of melanoma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; DNA, Antisense; Genetic Therapy; Humans; Immunologic Factors; Melanoma; Niacinamide; Phenylurea Compounds; Proteasome Inhibitors; Sorafenib

2004
Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:9

    Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neovascularization, Pathologic; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prospective Studies; Regional Blood Flow; Sorafenib; Treatment Outcome

2013
Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
    International journal of oncology, 2013, Volume: 42, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib

2013
The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
    Contemporary clinical trials, 2013, Volume: 36, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Epigenesis, Genetic; ErbB Receptors; Fibroblast Growth Factors; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2013
New options for second-line therapy of advanced renal cancer.
    The Lancet. Oncology, 2013, Volume: 14, Issue:6

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2013
Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?
    World journal of gastroenterology, 2013, Volume: 19, Issue:14

    Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome

2013
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome

2013
Case of sorafenib-induced thyroid storm.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16

    Topics: Adrenal Gland Neoplasms; Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Biomarkers; Bone Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Heart Arrest; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Muscle Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Respiratory Aspiration; Sorafenib; Thyroid Crisis; Thyroid Hormones

2013
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib

2013
Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
    International journal of nanomedicine, 2013, Volume: 8

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; Drug Delivery Systems; Ferrocyanides; Folic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Micelles; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma; MAP Kinase Signaling System; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sorafenib; Xenograft Model Antitumor Assays

2013
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
    World journal of urology, 2014, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Comorbidity; Dose-Response Relationship, Drug; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior

2014
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays

2013
Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells.
    Stem cells and development, 2013, Oct-01, Volume: 22, Issue:19

    Topics: AC133 Antigen; alpha-Fetoproteins; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Gene Expression Profiling; Glycoproteins; Humans; Hyaluronan Receptors; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Peptides; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Thy-1 Antigens

2013
Is India ready to lead the battle for fair access to medicines?
    The Lancet. Oncology, 2013, Volume: 14, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Drug and Narcotic Control; Drug Costs; Drug Industry; Drugs, Generic; Government Regulation; Health Policy; Health Services Accessibility; Humans; Imatinib Mesylate; India; Niacinamide; Patents as Topic; Phenylurea Compounds; Piperazines; Pyrimidines; Sorafenib

2013
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013, Volume: 71, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid

2013
[Drug now immediately available in Germany].
    Aktuelle Urologie, 2006, Volume: 37, Issue:5 Suppl

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Approval; Germany; Humans; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib

2006
Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
    International journal of nanomedicine, 2013, Volume: 8

    Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Evaluation, Preclinical; Drug-Eluting Stents; Human Umbilical Vein Endothelial Cells; Humans; Male; Matrix Metalloproteinase 2; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Polyesters; Sorafenib; Xenograft Model Antitumor Assays

2013
Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine.
    Nanomedicine : nanotechnology, biology, and medicine, 2013, Volume: 9, Issue:8

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Everolimus; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinases; Models, Molecular; Nanomedicine; Niacinamide; Phenylurea Compounds; Polyglactin 910; Protein Kinase Inhibitors; Sialic Acid Binding Ig-like Lectin 3; Sirolimus; Sorafenib; STAT5 Transcription Factor; TOR Serine-Threonine Kinases

2013
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Hepatocellular; Drug Eruptions; Drug Interactions; Drug Monitoring; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prednisolone; Sorafenib; Stomatitis; Treatment Outcome

2013
Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Journal of cellular physiology, 2013, Volume: 228, Issue:10

    Topics: Animals; bcl-2-Associated X Protein; bcl-Associated Death Protein; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Drug Synergism; fas Receptor; Female; Hep G2 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2013
Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
    International journal of dermatology, 2013, Volume: 52, Issue:12

    Topics: Aged; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Humans; Kidney Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib

2013
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
    BMJ case reports, 2013, May-15, Volume: 2013

    Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Artery Obstruction; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2013
Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    International journal of radiation biology, 2013, Volume: 89, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; DNA Repair; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; Sorafenib

2013
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Databases, Factual; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome

2013
Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation.
    Transplant international : official journal of the European Society for Organ Transplantation, 2013, Volume: 26, Issue:7

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2013
Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
    Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiography; Sorafenib; Treatment Outcome

2014
[Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Synergism; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Burden

2013
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19

    Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2013
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Annals of surgical oncology, 2013, Volume: 20, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma, Hepatocellular; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Sorafenib; Survival Rate; Young Adult

2013
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
    Angiogenesis, 2013, Volume: 16, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid

2013
Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Aged; Carcinoma in Situ; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Epithelial-Mesenchymal Transition; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Papillomaviridae; Papillomavirus Infections; Phenylurea Compounds; Sorafenib; Transfection; Urokinase-Type Plasminogen Activator; Urothelium; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms

2013
Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Recombinant Proteins; Signal Transduction; Sorafenib; Sphingolipids; Sphingomyelin Phosphodiesterase; Subcutaneous Tissue; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays

2013
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
    Bioorganic & medicinal chemistry letters, 2013, Jul-01, Volume: 23, Issue:13

    Topics: Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epoxide Hydrolases; Human Umbilical Vein Endothelial Cells; Humans; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyridines; Solubility; Sorafenib; Structure-Activity Relationship

2013
Sorafenib prolongs liver regeneration after hepatic resection in rats.
    The Journal of surgical research, 2013, Volume: 184, Issue:2

    Topics: Animals; Cell Proliferation; Hepatectomy; Hepatocytes; Liver; Liver Regeneration; Male; Models, Animal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; Time Factors; Transaminases

2013
Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Experimental cell research, 2013, Aug-15, Volume: 319, Issue:14

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Keratins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Inhibitors; Sorafenib; Ubiquitination; Unfolded Protein Response

2013
Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
    Biochemical pharmacology, 2013, Aug-01, Volume: 86, Issue:3

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MAP Kinase Signaling System; MCF-7 Cells; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Acetylation; Alveolar Epithelial Cells; Cell Line; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Histone Acetyltransferases; Histone Deacetylases; Histones; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Transforming Growth Factor beta1

2013
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Acetyltransferases; Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays

2013
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].
    Zhonghua yi xue za zhi, 2013, Mar-05, Volume: 93, Issue:9

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Thrombosis

2013
Hepatocellular carcinoma: perspective of an oncologist.
    Journal of clinical gastroenterology, 2013, Volume: 47 Suppl

    Topics: Antineoplastic Agents; Attitude of Health Personnel; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling.
    Molecular and cellular biochemistry, 2013, Volume: 381, Issue:1-2

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Wnt Signaling Pathway; Xenograft Model Antitumor Assays

2013
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; DNA Breaks, Double-Stranded; Gamma Rays; Gene Expression; Hindlimb; Histones; Humans; Liver Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2013
Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation.
    Cell death & disease, 2013, Jun-13, Volume: 4

    Topics: Alveolar Epithelial Cells; Animals; Apoptosis; Bleomycin; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Extracellular Matrix; Female; Fibroblasts; HEK293 Cells; Humans; Idiopathic Pulmonary Fibrosis; Male; Mice; Mice, Inbred C57BL; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Sorafenib; Transforming Growth Factor beta1

2013
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    The Journal of surgical research, 2013, Volume: 185, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Liver Neoplasms; MAP Kinase Signaling System; Morpholines; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines

2013
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
    Onkologie, 2013, Volume: 36, Issue:6

    Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome

2013
Long-term treatment of hepatocellular carcinoma with sorafenib.
    Le infezioni in medicina, 2013, Volume: 21, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors

2013
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; DNA Primers; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Microarray Analysis; Niacinamide; Phenylurea Compounds; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Sulfonamides

2013
A wife asks for futile therapy for her husband, a "fighter": how to respond?
    Oncology (Williston Park, N.Y.), 2013, Volume: 27, Issue:4

    Topics: Carcinoma, Renal Cell; Ethics, Medical; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cluster Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Messenger; Sorafenib; Transcriptome

2013
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6

    Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiography; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome

2013
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:15

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Mice; Mice, SCID; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Ruthenium; Sorafenib; Xenograft Model Antitumor Assays

2013
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
    Cancer biology & therapy, 2013, Volume: 14, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Off-Label Use; Panitumumab; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib

2013
Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
    Journal of gastroenterology, 2014, Volume: 49, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2014
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
    Journal of hepatology, 2013, Volume: 59, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Diethylnitrosamine; Disease Models, Animal; Granulocyte-Macrophage Colony-Stimulating Factor; Heterografts; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-myc; Sorafenib

2013
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Time Factors; Young Adult

2013
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
    Cancer, 2013, Sep-15, Volume: 119, Issue:18

    Topics: Aged; Antineoplastic Agents; Body Composition; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2013
Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
    Endoscopy, 2013, Volume: 45 Suppl 2 UCTN

    Topics: Aged, 80 and over; Antineoplastic Agents; Capsule Endoscopy; Carcinoma, Hepatocellular; Female; Gastrointestinal Hemorrhage; Humans; Intestine, Small; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:9

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Cyclin G1; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; SOXB1 Transcription Factors; TOR Serine-Threonine Kinases

2013
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:9

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Dogs; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
    Urology, 2013, Volume: 82, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Asymptomatic Diseases; Blood Cell Count; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Function Tests; Kidney Neoplasms; Liver Function Tests; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Patient Preference; Phenylurea Compounds; Population Surveillance; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors

2013
Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
    British journal of cancer, 2013, Jul-23, Volume: 109, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Carcinoma, Hepatocellular; Drug Synergism; HCT116 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Reactive Oxygen Species; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluation; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure; Treatment Outcome

2013
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
    Journal of hepatology, 2013, Volume: 59, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Endpoint Determination; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Ultrasonography

2013
Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: design, synthesis, and antiproliferative activity against melanoma cell line.
    Chemical & pharmaceutical bulletin, 2013, Volume: 61, Issue:7

    Topics: Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Isoquinolines; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Structure-Activity Relationship

2013
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:6

    Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sorafenib; Sunitinib

2013
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Thrombosis; Treatment Outcome; Ultrasonography; Ventricular Dysfunction

2013
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    International journal of cancer, 2014, Jan-15, Volume: 134, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Flow Cytometry; Liver Neoplasms, Experimental; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Tumor Microenvironment

2014
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 2; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays

2013
Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
    Clinical science (London, England : 1979), 2014, Volume: 126, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; Hepatocyte Growth Factor; Interleukin-10; Liver Neoplasms, Experimental; Macrophages; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; T-Lymphocytes; Transforming Growth Factor beta; Vascular Endothelial Growth Factors

2014
[A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy].
    Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:6

    Topics: Adrenalectomy; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    British journal of cancer, 2013, Aug-06, Volume: 109, Issue:3

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Growth Processes; Everolimus; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Random Allocation; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays

2013
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 346, Issue:3

    Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Dasatinib; DNA, Complementary; Female; Gene Dosage; Half-Life; Indoles; Male; Maternal-Fetal Exchange; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA; Sex Characteristics; Sorafenib; Sunitinib; Thiazoles

2013
Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma.
    Current drug safety, 2013, Volume: 8, Issue:2

    Topics: Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Interactions; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib

2013
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2013, Volume: 39, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; PTEN Phosphohydrolase; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult

2013
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
    The Journal of surgical research, 2013, Volume: 185, Issue:2

    Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays

2013
Sorafenib makes headway on metastatic thyroid cancer.
    Cancer discovery, 2013, Volume: 3, Issue:7

    Topics: Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor A

2013
[Analysis of factors affecting the duration of treatment with sorafenib in patients with hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:4

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Sorafenib; Time Factors

2013
Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O: rapid inhibition of Rb phosphorylation as a preamble to cyclin D1 inhibition.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:10

    Topics: Antineoplastic Agents; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Curcumin; Cyclin D1; Cyclin-Dependent Kinase 4; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Retinoblastoma Protein; Signal Transduction; Sorafenib; Sunitinib

2013
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2013, Volume: 27, Issue:7

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; British Columbia; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Insurance Coverage; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2013
MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
    Technology in cancer research & treatment, 2014, Volume: 13, Issue:1

    Topics: Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib

2014
[Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Humans; Imidazoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Zoledronic Acid

2013
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Radiology, 2013, Volume: 269, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2013
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
    Molecular pharmacology, 2013, Volume: 84, Issue:4

    Topics: Animals; Cell Communication; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Gonanes; Hep G2 Cells; Humans; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Thymoma; Thymus Neoplasms; Xenograft Model Antitumor Assays

2013
Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.
    Cancer letters, 2013, Oct-01, Volume: 339, Issue:1

    Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Gene Expression; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2013
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.
    British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Health Care Rationing; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; United Kingdom; Young Adult

2013
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
    Clinical advances in hematology & oncology : H&O, 2013, Volume: 11 Suppl 5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Rate

2013
[The analysis of the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma].
    Zhonghua yi xue za zhi, 2013, Apr-02, Volume: 93, Issue:13

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2013
Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib.
    Yao xue xue bao = Acta pharmaceutica Sinica, 2013, Volume: 48, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Solubility; Sorafenib; Structure-Activity Relationship; Urea

2013
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
    Pigment cell & melanoma research, 2013, Volume: 26, Issue:6

    Topics: Adolescent; Adult; Child, Preschool; Enzyme Activation; Female; Gene Rearrangement; Humans; Indoles; Male; MAP Kinase Signaling System; Melanocytes; Melanoma; Middle Aged; Molecular Targeted Therapy; Nevus, Epithelioid and Spindle Cell; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib; Young Adult

2013
Carotid and brachiocephalic arteries stenosis with long term use of sorafenib.
    Hematology/oncology and stem cell therapy, 2014, Volume: 7, Issue:1

    Topics: Angiography; Aorta, Thoracic; Brachiocephalic Trunk; Carotid Arteries; Constriction, Pathologic; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thigh; Time Factors; Tomography, X-Ray Computed

2014
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
    BMC cancer, 2013, Jul-29, Volume: 13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib

2013
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
    The oncologist, 2013, Volume: 18, Issue:8

    Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2013
Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
    Future oncology (London, England), 2013, Volume: 9, Issue:8

    Topics: Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Models, Molecular; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Random Allocation; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2014
Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
    Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; Drug Synergism; ErbB Receptors; Female; Flavonoids; Humans; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; raf Kinases; ras Proteins; Receptor, ErbB-2; Sorafenib; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

2013
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.
    World journal of surgical oncology, 2013, Aug-02, Volume: 11, Issue:1

    Topics: Aged; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis

2013
Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma.
    Yonsei medical journal, 2013, Volume: 54, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiotherapy; Sorafenib

2013
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).
    International journal of radiation oncology, biology, physics, 2013, Sep-01, Volume: 87, Issue:1

    Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Bevacizumab; Duodenal Diseases; Humans; Indazoles; Indoles; Intestinal Diseases; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography; Radiosurgery; Radiotherapy Dosage; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Stomach Ulcer; Sulfonamides; Sunitinib; Ulcer

2013
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:7

    Topics: AC133 Antigen; Adaptor Proteins, Signal Transducing; Animals; Antigens, CD; Antineoplastic Agents; Base Sequence; Carcinoma, Hepatocellular; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Homeodomain Proteins; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Nanog Homeobox Protein; Neoplastic Stem Cells; Niacinamide; Oncogenes; Peptides; Phenylurea Compounds; Phosphoproteins; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Sirolimus; Smad Proteins; Sorafenib; Spheroids, Cellular; Toll-Like Receptor 4; Transcription Factors; Transcriptional Activation; Transforming Growth Factor beta; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins

2013
Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution.
    Journal of hepatology, 2013, Volume: 59, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography

2013
Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case.
    Hepato-gastroenterology, 2013, Volume: 60, Issue:126

    Topics: Antineoplastic Agents; Humans; Liver Failure; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Breast cancer research : BCR, 2013, Volume: 15, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Female; Gene Expression; Humans; Immunohistochemistry; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; Sorafenib; STAT3 Transcription Factor

2013
Development and validation of a high-performance liquid chromatography ultraviolet method for lapatinib quantification in human plasma.
    Therapeutic drug monitoring, 2013, Volume: 35, Issue:6

    Topics: Acetonitriles; Administration, Oral; Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Lapatinib; Limit of Detection; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib; Spectrophotometry, Ultraviolet

2013
STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
    Journal of autoimmunity, 2013, Volume: 46

    Topics: Actins; Active Transport, Cell Nucleus; Animals; Carbon Tetrachloride; Cell Nucleus; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Gene Expression; Hepatocytes; Immunoblotting; Immunohistochemistry; Interleukin-6; Kinetics; Kupffer Cells; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Mice, Knockout; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; STAT3 Transcription Factor; Tissue Inhibitor of Metalloproteinase-1

2013
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013, Volume: 109, Issue:2

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Repair; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Radiation-Sensitizing Agents; raf Kinases; Sorafenib; Squamous Cell Carcinoma of Head and Neck

2013
Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:10

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Hemoglobins; Humans; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Treatment Outcome

2013
Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy.
    Bioconjugate chemistry, 2013, Sep-18, Volume: 24, Issue:9

    Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Doxorubicin; Drug Delivery Systems; Female; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Optical Imaging; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sorafenib

2013
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:10

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Xenograft Model Antitumor Assays

2013
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Breast cancer research and treatment, 2013, Volume: 141, Issue:1

    Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Anilides; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Energy Metabolism; Female; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mitochondria; Multiprotein Complexes; Neoplasm Proteins; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2013
Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
    Urologia internationalis, 2013, Volume: 91, Issue:4

    Topics: Aged; Betamethasone; Carcinoma, Renal Cell; Fatal Outcome; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prednisolone; Sirolimus; Skin; Sorafenib; Stevens-Johnson Syndrome

2013
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Oct-15, Volume: 19, Issue:20

    Topics: Adolescent; Alleles; Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Models, Molecular; Molecular Conformation; Mutation; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2013
[Treatment of hemodialyzed patient by targeted therapy in metastatic renal cell carcinoma: a case report].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2013, Volume: 104, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sirolimus; Sorafenib

2013
[Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2013, Volume: 104, Issue:4

    Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib

2013
[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:8

    Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Triazines

2013
Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
    African journal of traditional, complementary, and alternative medicines : AJTCAM, 2012, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Biological Products; Liver Neoplasms; Medicine, Traditional; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Sorafenib

2012
Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
    Cell biochemistry and biophysics, 2014, Volume: 68, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Interphase; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Taxoids

2014
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
    Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:8

    Topics: Animals; Antineoplastic Agents; Birt-Hogg-Dube Syndrome; Carcinoma, Renal Cell; Everolimus; Humans; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Mice, Knockout; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2013
[Extracorporeal partial nephrectomy and auto-transplantation after presurgical targeted therapy with tyrosine kinase inhibitors for renal cell cancer].
    Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:8

    Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Transplantation, Autologous; Treatment Outcome

2013
Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:3

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Humans; Immunotherapy; Interleukin-12; Liver Neoplasms; Mice; Mice, Inbred C3H; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:4

    Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirculation; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Platelet-Derived Growth Factor; Positron-Emission Tomography; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Splanchnic Circulation; Triazines; Vascular Endothelial Growth Factor A

2014
Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.
    European urology, 2014, Volume: 65, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib

2014
Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma.
    Current medical research and opinion, 2013, Volume: 29, Issue:12

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual; Female; Humans; Insurance Claim Review; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sex Factors; Sorafenib

2013
Sorafenib induced eruptive melanocytic lesions.
    Dermatology online journal, 2013, May-15, Volume: 19, Issue:5

    Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Humans; Kidney Neoplasms; Lentigo; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2013
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-20, Volume: 31, Issue:30

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib

2013
In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.
    Anticancer research, 2013, Volume: 33, Issue:9

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Combined Modality Therapy; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Radioisotopes; Rhenium; Sorafenib

2013
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?
    BMJ case reports, 2013, Sep-16, Volume: 2013

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vitamin B Complex

2013
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Journal of clinical gastroenterology, 2014, Volume: 48, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome

2014
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
    British journal of cancer, 2013, Oct-15, Volume: 109, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2013
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Blood, 2013, Nov-21, Volume: 122, Issue:22

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Sorafenib; Tandem Repeat Sequences; Xenograft Model Antitumor Assays

2013
Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2013
Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study.
    Journal of vascular and interventional radiology : JVIR, 2013, Volume: 24, Issue:11

    Topics: Alanine Transaminase; Angiogenesis Inhibitors; Animals; Bilirubin; Chemoembolization, Therapeutic; Chromatography, High Pressure Liquid; Ethiodized Oil; Feasibility Studies; gamma-Glutamyltransferase; Hepatic Artery; Liver; Male; Models, Animal; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Tandem Mass Spectrometry

2013
Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
    Kidney international, 2014, Volume: 85, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Base Sequence; Binding Sites; Biomarkers; Carrier Proteins; Case-Control Studies; Cell Line; Female; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Humans; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Nephrosis, Lipoid; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proteinuria; Renal Insufficiency; Sorafenib; Thrombotic Microangiopathies; Transcription Factor RelA; Transcription, Genetic; Transfection; Vascular Endothelial Growth Factors; Young Adult

2014
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
    Journal of geriatric oncology, 2013, Volume: 4, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Male; Neutropenia; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2013
Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells.
    Current eye research, 2014, Volume: 39, Issue:2

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers; Cell Line; Cell Survival; Enzyme-Linked Immunosorbent Assay; Epithelium, Corneal; Humans; Immunohistochemistry; Indoles; Membrane Proteins; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tetrazolium Salts; Thiazoles

2014
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
    World journal of surgical oncology, 2013, Sep-27, Volume: 11

    Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lung Neoplasms; Mediastinal Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2013
Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
    International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib

2013
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Synergism; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Janus Kinase 2; Neoplasms; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand

2013
Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Analysis of Variance; Animals; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Initiation Factor-4A; Humans; Inhibitory Concentration 50; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Niacinamide; Peptide Chain Initiation, Translational; Phenylurea Compounds; Sirolimus; Sorafenib; Survival Analysis; Triterpenes; Xenograft Model Antitumor Assays

2013
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
    Langenbeck's archives of surgery, 2013, Volume: 398, Issue:8

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; Treatment Outcome

2013
Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.
    Cancer biology & therapy, 2014, Volume: 15, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib

2014
Pancreatic atrophy--a new late toxic effect of sorafenib.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Atrophy; Diarrhea; Humans; Niacinamide; Pancreas; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib

2013
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
    Oncotarget, 2013, Volume: 4, Issue:10

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Female; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Receptor, Notch3; Receptors, Notch; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2013
Synthesis and biological evaluation of novel 4-(2-fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines bearing semicarbazone moieties as potent antitumor agents.
    Archiv der Pharmazie, 2013, Volume: 346, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; HT29 Cells; Humans; Hydrazones; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Semicarbazones; Sorafenib; Structure-Activity Relationship

2013
Synergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721.
    Journal of molecular histology, 2014, Volume: 45, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Cortactin; Endocytosis; Female; Gene Knockdown Techniques; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2014
Early prediction of treatment response to sorafenib with elastosonography in a mice xenograft model of hepatocellular carcinoma: a proof-of-concept study.
    Ultraschall in der Medizin (Stuttgart, Germany : 1980), 2013, Volume: 34, Issue:6

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Elasticity Imaging Techniques; Female; Heterografts; Liver; Liver Neoplasms, Experimental; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Burden

2013
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
    Clinical pharmacokinetics, 2014, Volume: 53, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Exanthema; Female; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult

2014
Sorafenib tosylate as a radiosensitizer in malignant astrocytoma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2014, Volume: 21, Issue:1

    Topics: Astrocytoma; Blotting, Western; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Niacinamide; Phenylurea Compounds; Radiation-Sensitizing Agents; Sorafenib

2014
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:1

    Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Young Adult

2014
Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinases; raf Kinases; Skin Neoplasms; Sorafenib

2014
Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
    International journal of oncology, 2014, Volume: 44, Issue:1

    Topics: Aged; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Serum Response Factor; Sorafenib; Vimentin

2014
The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:9

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate

2013
Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors.
    Molecules (Basel, Switzerland), 2013, Oct-31, Volume: 18, Issue:11

    Topics: Cholinesterase Inhibitors; Drug Design; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Structure-Activity Relationship

2013
A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
    BMC cancer, 2013, Nov-06, Volume: 13

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Gene Expression; Humans; Interferon-gamma; Liver Neoplasms; Male; NF-kappa B; Niacinamide; Phenylurea Compounds; Rats; RNA, Double-Stranded; Sorafenib; Toll-Like Receptor 3; Transcriptional Activation; Tumor Burden

2013
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
    Journal of gastroenterology, 2014, Volume: 49, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib

2014
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.
    American journal of physiology. Gastrointestinal and liver physiology, 2014, Jan-01, Volume: 306, Issue:1

    Topics: Animals; Common Bile Duct; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hepatopulmonary Syndrome; Ligation; Lung; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2014
Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib.
    Investigative ophthalmology & visual science, 2013, Dec-05, Volume: 54, Issue:13

    Topics: Animals; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Fundus Oculi; Humans; Liposomes; Male; Niacinamide; Oligopeptides; Phenylurea Compounds; Photochemotherapy; Photosensitizing Agents; Rats; Rats, Inbred BN; Receptors, Immunologic; Sorafenib; Vascular Endothelial Growth Factor A

2013
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
    Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:10

    Topics: Allografts; Allosteric Regulation; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diphenylamine; Drug Synergism; Female; Heterografts; Humans; Liver Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Sulfonamides

2013
Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:11-12

    Topics: Adult; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Drug Interactions; HIV Infections; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2013
Axitinib in advanced renal-cell carcinoma.
    The Lancet. Oncology, 2013, Volume: 14, Issue:13

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake.
    Biomaterials, 2014, Volume: 35, Issue:4

    Topics: Alkynes; Antineoplastic Agents; Azides; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Cycloaddition Reaction; Drug Carriers; Humans; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Porosity; Silicon; Sorafenib

2014
Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways.
    Molecular medicine reports, 2014, Volume: 9, Issue:1

    Topics: Autophagy; Cell Line; Cluster Analysis; Databases, Factual; Humans; Niacinamide; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib

2014
Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
    Molecular medicine reports, 2014, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib

2014
Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
    European journal of medicinal chemistry, 2013, Volume: 70

    Topics: Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Indoles; K562 Cells; Melanoma; Molecular Structure; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Structure-Activity Relationship; Sulfonamides; Vemurafenib

2013
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.
    Oncology, 2013, Volume: 85, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Gene Deletion; Genotype; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Sorafenib; Treatment Outcome

2013
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2014
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases

2013
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Animals; Biglycan; Gene Expression Regulation, Neoplastic; Humans; Indoles; Leucine; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyrroles; RNA, Messenger; Sorafenib; Sunitinib; Urinary Bladder Neoplasms

2013
Learning from practice: compulsory licensing cases and access to medicines.
    Pharmaceutical patent analyst, 2013, Volume: 2, Issue:2

    Topics: Antineoplastic Agents; Brazil; Canada; Commerce; Developing Countries; Drug Industry; Drugs, Generic; Health Services Accessibility; India; Licensure; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
    Chinese medical journal, 2013, Volume: 126, Issue:22

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2013
SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis.
    Bioscience trends, 2013, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorimetry; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:4

    Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; CD11b Antigen; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Disease Models, Animal; Hepatocyte Growth Factor; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Mice, Knockout; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Receptors, Chemokine; Receptors, CXCR4; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sorafenib

2014
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Heterografts; Humans; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
    International journal of oncology, 2014, Volume: 44, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asia; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; United States

2014
Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Young Adult

2014
High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter.
    Surgery today, 2014, Volume: 44, Issue:10

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk; Sorafenib; Survival Rate

2014
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
    Histopathology, 2014, Volume: 64, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sunitinib

2014
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:1

    Topics: Apoptosis; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2014
Polymorphic OCT1: a valid biomarker, but for which drugs?
    Pharmacogenomics, 2013, Volume: 14, Issue:16

    Topics: Biomarkers, Pharmacological; Cations; Humans; Metformin; Morphine; Niacinamide; Organic Cation Transporter 1; Pharmacogenetics; Phenylurea Compounds; Sorafenib

2013
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    La Radiologia medica, 2014, Volume: 119, Issue:4

    Topics: Aged; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Iopamidol; Liver Neoplasms; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2014
[A case of tuberculosis that occurred during treatment of hepatocellular carcinoma with sorafenib].
    Kekkaku : [Tuberculosis], 2013, Volume: 88, Issue:9

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Tuberculosis, Pulmonary

2013
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
    International urology and nephrology, 2014, Volume: 46, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A

2014
Multi-kinase inhibition in ovarian cancer.
    Cancer biology & therapy, 2014, Volume: 15, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib

2014
Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
    Oncology reports, 2014, Volume: 31, Issue:2

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Communication; Cell Line, Tumor; Cell Proliferation; Connexins; Drug Synergism; Gap Junctions; Glycyrrhetinic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Oleic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tretinoin

2014
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
    Urologic oncology, 2014, Volume: 32, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2014
Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.
    Toxicology and applied pharmacology, 2014, Jan-15, Volume: 274, Issue:2

    Topics: Animals; Becaplermin; Benzamides; Benzylisoquinolines; Cinnamates; Collagen Type I; Connective Tissue Growth Factor; Depsides; Down-Regulation; Gene Expression; HSP47 Heat-Shock Proteins; Imatinib Mesylate; Liver; Liver Cirrhosis; Male; Models, Biological; Niacinamide; Organ Culture Techniques; Perindopril; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-sis; Pyridones; Pyrimidines; Rats; Rats, Wistar; Rosmarinic Acid; Sorafenib; Transforming Growth Factor beta1; Valproic Acid

2014
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
    Nature reviews. Gastroenterology & hepatology, 2014, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neovascularization, Pathologic; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.
    Chinese journal of cancer, 2014, Volume: 33, Issue:5

    Topics: Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatic Artery; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Thrombosis; Vena Cava, Inferior

2014
Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
    Future oncology (London, England), 2014, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Squamous Cell Carcinoma of Head and Neck

2014
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
    Current medical research and opinion, 2014, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sirolimus; Sorafenib; Treatment Outcome

2014
Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
    Clinical and experimental dermatology, 2014, Volume: 39, Issue:2

    Topics: Aged; Antineoplastic Agents; Drug Eruptions; Hidradenitis Suppurativa; Humans; Leg Dermatoses; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2014
Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
    Molecular cancer, 2013, Dec-13, Volume: 12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib; Urokinase-Type Plasminogen Activator

2013
[Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:11

    Topics: Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Antagonism; Fluorouracil; Humans; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; STAT3 Transcription Factor

2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2014
Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014, Volume: 16, Issue:9

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Clusterin; Disease Models, Animal; Drug Resistance, Neoplasm; Inhibitory Concentration 50; Kidney Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Transcriptome

2014
Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
    Therapeutic drug monitoring, 2014, Volume: 36, Issue:3

    Topics: Antineoplastic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Lapatinib; Metabolic Clearance Rate; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Reproducibility of Results; Sorafenib; Spectrophotometry, Ultraviolet

2014
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
    Neurotoxicity research, 2014, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combination; Glioblastoma; Glioma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Necrosis; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib

2014
VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
    Cell biochemistry and biophysics, 2014, Volume: 69, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Osteoblasts; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib

2014
Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
    Oncology reports, 2014, Volume: 31, Issue:3

    Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Oligonucleotide Array Sequence Analysis; Oncogene Proteins v-fos; Osteosarcoma; Phenylurea Compounds; Receptors, CXCR4; S100 Calcium-Binding Protein A4; S100 Proteins; Sorafenib; Transcriptome

2014
In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2013, Dec-16, Volume: 13, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Contrast Media; Image Enhancement; Immunohistochemistry; Magnetic Resonance Imaging; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Rats; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Burden

2013
Diarylureas and diarylamides with pyrrolo[2,3-d]pyrimidine scaffold as broad-spectrum anticancer agents.
    Chemical & pharmaceutical bulletin, 2014, Volume: 62, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib

2014
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
    PloS one, 2013, Volume: 8, Issue:12

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Sorafenib

2013
[Three cases of recurrent hepatocellular carcinoma treated with laparoscopic hepatectomy after oral administration of sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Hepatectomy; Humans; Laparoscopy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib

2013
[A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Time Factors; Treatment Outcome

2013
Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.
    Expert review of pharmacoeconomics & outcomes research, 2014, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cyprus; Decision Support Techniques; Humans; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Quality-Adjusted Life Years; Reimbursement Mechanisms; Sorafenib

2014
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.
    British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4

    Topics: Animals; Biological Transport; Docetaxel; Drug Interactions; HEK293 Cells; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Knockout; Niacinamide; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Taxoids

2014
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:3

    Topics: Aged; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroglobulin; Thyroid Neoplasms

2014
ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells.
    International journal of oncology, 2014, Volume: 44, Issue:3

    Topics: Apoptosis; B-Lymphocytes; bcl-2-Associated X Protein; Herpesvirus 4, Human; Humans; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Reactive Oxygen Species; Sorafenib

2014
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
    World journal of gastroenterology, 2014, Jan-07, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome

2014
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Molecular cancer, 2014, Jan-13, Volume: 13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Immunohistochemistry; Indazoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    European journal of endocrinology, 2014, Volume: 170, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome

2014
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult

2014
Sorafenib-induced tumor response in a patient with metastatic epithelioid angiomyolipoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-10, Volume: 32, Issue:11

    Topics: Adult; Angiomyolipoma; Antineoplastic Agents; Biopsy, Needle; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2014
Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study.
    The British journal of radiology, 2014, Volume: 87, Issue:1035

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Liver; Liver Neoplasms, Experimental; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Rats; Rats, Wistar; Sorafenib; Tomography, Emission-Computed; Treatment Outcome

2014
Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Turkey

2013
Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2014, Jan-25, Volume: 63, Issue:1

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Clostridium; Clostridium Infections; Humans; Liver Abscess; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2014
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2014
Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo.
    Cell death & disease, 2014, Jan-30, Volume: 5

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cells, Cultured; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Proteins

2014
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Cellular signalling, 2014, Volume: 26, Issue:5

    Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Quinazolines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Up-Regulation

2014
Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA.
    Molecular pharmaceutics, 2014, Oct-06, Volume: 11, Issue:10

    Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Repressor Proteins; RNA, Small Interfering; Sorafenib; Survivin

2014
Electrochemical monitoring of an important biomarker and target protein: VEGFR2 in cell lysates.
    Scientific reports, 2014, Feb-05, Volume: 4

    Topics: Animals; Biosensing Techniques; Cell Line; Chitosan; Electrochemical Techniques; Endothelial Cells; Graphite; Immunoassay; Macaca mulatta; Niacinamide; Oxidation-Reduction; Phenothiazines; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retina; Sorafenib; Vascular Endothelial Growth Factor Receptor-2

2014
Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome.
    Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:6

    Topics: ACTH Syndrome, Ectopic; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pituitary-Adrenal System; Sorafenib; Thyroid Neoplasms

2014
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
    Journal of gastroenterology, 2014, Volume: 49, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2014
Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
    Nanoscale, 2014, Mar-21, Volume: 6, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Contrast Media; Drug Carriers; Hep G2 Cells; Histidine; Humans; Hydrogen-Ion Concentration; Lactic Acid; Magnetic Resonance Imaging; Mice; Nanoparticles; Neoplasms; Niacinamide; Particle Size; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Polymers; Radiography; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Transplantation, Heterologous

2014
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
    Transplantation, 2014, Jul-15, Volume: 98, Issue:1

    Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Radiopharmaceuticals; Radiotherapy, Adjuvant; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes

2014
Perforating folliculitis-like reaction related to sorafenib.
    Cutis, 2014, Volume: 93, Issue:1

    Topics: Antineoplastic Agents; Drug Eruptions; Folliculitis; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
    International journal of cancer, 2014, Sep-01, Volume: 135, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Liver Neoplasms; Lymphangiogenesis; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3

2014
Treatment of collecting duct carcinoma: current status and future perspectives.
    Anticancer research, 2014, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides

2014
Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated.
    Neurological research, 2014, Volume: 36, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytokines; ErbB Receptors; Glioblastoma; Humans; Lithium Chloride; Midkine; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Maturing of renal cancer therapeutics.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-10, Volume: 32, Issue:8

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2014
Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?
    International journal of clinical oncology, 2014, Volume: 19, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Mar-01, Volume: 20, Issue:5

    Topics: Animals; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2014
Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
    Scandinavian journal of urology, 2014, Volume: 48, Issue:4

    Topics: Aged; Algorithms; Carcinoma, Renal Cell; Combined Modality Therapy; Denmark; Enzyme Inhibitors; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome

2014
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.
    Anti-cancer drugs, 2014, Volume: 25, Issue:4

    Topics: Adamantane; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Autophagy; Benzamides; Caspases; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mitochondrial Membranes; Niacinamide; Oxidative Stress; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sorafenib; Urea

2014
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:4

    Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Naphthyridines; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; U937 Cells; Xenograft Model Antitumor Assays

2014
[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].
    Der Urologe. Ausg. A, 2014, Volume: 53, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2014
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
    Oncology reports, 2014, Volume: 31, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2014
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
    BMC cancer, 2014, Feb-20, Volume: 14

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Management; Female; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Retrospective Studies; Sorafenib; Treatment Outcome

2014
Third-line dovitinib in metastatic renal cell carcinoma.
    The Lancet. Oncology, 2014, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib

2014
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:5

    Topics: Adult; Aged; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2014
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
    Leukemia, 2014, Volume: 28, Issue:9

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carbamates; Cell Line, Tumor; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Imidazoles; Indoles; Membrane Proteins; Mice; Mice, SCID; Necrosis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Reactive Oxygen Species; Sorafenib; Up-Regulation; Xenograft Model Antitumor Assays

2014
NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Monomeric GTP-Binding Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Sorafenib; Young Adult

2014
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
    Journal of the Egyptian National Cancer Institute, 2014, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Egypt; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome

2014
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Treatment Outcome

2014
Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lymphocytes; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2014
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA, Neoplasm; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation, Missense; Niacinamide; Oncogenes; Phenylurea Compounds; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Sorafenib

2014
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:7

    Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    British journal of pharmacology, 2014, Volume: 171, Issue:13

    Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2014
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    World journal of gastroenterology, 2014, Jan-21, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2014
Management of sorafenib-related adverse events: a clinician's perspective.
    Seminars in oncology, 2014, Volume: 41 Suppl 2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Physicians; Sorafenib

2014
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
    Seminars in oncology, 2014, Volume: 41 Suppl 2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Nurses; Patient Education as Topic; Pharmacists; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib

2014
[Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2014, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2014
1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Cytosol; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sorafenib; Structure-Activity Relationship

2014
Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis.
    Experimental cell research, 2014, May-01, Volume: 323, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cells, Cultured; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Hep G2 Cells; Hepatocytes; Humans; Niacinamide; Phenylurea Compounds; Receptors, Androgen; RNA, Messenger; Sorafenib

2014
[Diagnostics and treatment of hepatocellular carcinoma: trends in the Netherlands in the period 2003-2011].
    Nederlands tijdschrift voor geneeskunde, 2014, Volume: 158

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Female; Hospitalization; Humans; Liver Neoplasms; Male; Middle Aged; Netherlands; Niacinamide; Palliative Care; Phenylurea Compounds; Retrospective Studies; Sorafenib

2014
The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
    Biomaterials, 2014, Volume: 35, Issue:15

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Drug Carriers; Humans; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanodiamonds; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach; Stomach Neoplasms

2014
[Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 4. Molecularly targeted agent].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Jan-10, Volume: 103, Issue:1

    Topics: Antineoplastic Agents; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Galactosylated polymeric carriers for liver targeting of sorafenib.
    International journal of pharmaceutics, 2014, May-15, Volume: 466, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Biological Availability; Drug Carriers; Ethylenediamines; Female; Galactose; Kidney; Liver; Lung; Mice, Inbred C57BL; Micelles; Niacinamide; Peptides; Phenylurea Compounds; Polyesters; Sorafenib; Spleen

2014
A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
    Blood, 2014, Apr-17, Volume: 123, Issue:16

    Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cation Transport Proteins; Cells, Cultured; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Hydrogen-Ion Concentration; Intracellular Space; K562 Cells; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Tandem Repeat Sequences

2014
Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells.
    DNA and cell biology, 2014, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cobalt; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A

2014
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    European urology, 2014, Volume: 66, Issue:3

    Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid

2014
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-01, Volume: 20, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mutation; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tandem Repeat Sequences

2014
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary, Follicular; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Salvage Therapy; Sorafenib; Thyroid Neoplasms; Treatment Failure

2014
Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2015, Volume: 29, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dermatomycoses; Humans; Liver Neoplasms; Male; Niacinamide; Opportunistic Infections; Phenylurea Compounds; Rhodotorula; Sorafenib

2015
Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
    Scientific reports, 2014, Mar-17, Volume: 4

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Gene Expression; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2014
Sorafenib inhibition of hepatic stellate cell proliferation in tumor microenvironment of hepatocellular carcinoma: a study of the sorafenib mechanisms.
    Cell biochemistry and biophysics, 2014, Volume: 69, Issue:3

    Topics: Actins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatic Stellate Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment

2014
More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.
    Endocrine-related cancer, 2014, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms

2014
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
    Future oncology (London, England), 2014, Volume: 10, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome

2014
Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
    Molecular & cellular proteomics : MCP, 2014, Volume: 13, Issue:6

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteomics; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2014
Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
    The Journal of toxicological sciences, 2014, Volume: 39, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Hypertension; Male; Niacinamide; Phenylurea Compounds; Quinazolines; Rats; Rats, Wistar; Risk; Signal Transduction; Sorafenib; Telemetry; Vascular Endothelial Growth Factor A

2014
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    The oncologist, 2014, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed

2014
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
    Anti-cancer drugs, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Soft Tissue Neoplasms; Sorafenib; Young Adult

2014
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:7

    Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2014
Acute generalized exanthematous pustulosis induced by sorafenib.
    JAMA dermatology, 2014, Volume: 150, Issue:6

    Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2014
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins.
    Antiviral research, 2014, Volume: 106

    Topics: Animals; Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; Enterovirus A, Human; Humans; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Sorafenib; Viral Proteins; Virus Replication

2014
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:7

    Topics: Adenocarcinoma, Follicular; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pleural Effusion, Malignant; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome

2014
Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Decision Making; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Netherlands; Niacinamide; Phenylurea Compounds; Pyrroles; Quality of Life; Self Report; Sorafenib; Sunitinib; Treatment Outcome

2014
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
    Cancer discovery, 2014, Volume: 4, Issue:6

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Hepatocytes; Humans; Liver Neoplasms; Macrophages; Male; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A

2014
Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
    Radiology, 2014, Volume: 272, Issue:2

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2014
Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
    European journal of haematology, 2014, Volume: 93, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Nuclear Proteins; Nucleophosmin; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tretinoin; Young Adult

2014
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Synergism; Female; Humans; Immunophenotyping; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; Sulfonamides; Survivin; Wnt Signaling Pathway

2014
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Interactions; Everolimus; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2014
RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; DNA Methylation; Drug Resistance, Neoplasm; Hep G2 Cells; High-Throughput Screening Assays; Histones; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Sorafenib

2014
[Metastasized renal cell carcinoma - research subjects needed!].
    Aktuelle Urologie, 2014, Volume: 45, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Niacinamide; Patient Selection; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides

2014
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-01, Volume: 20, Issue:11

    Topics: Anilides; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2014
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
    Journal of hepatology, 2014, Volume: 61, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Skin; Sorafenib

2014
Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:6

    Topics: Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; RNA, Small Interfering; Sorafenib

2014
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
    Journal of surgical oncology, 2014, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis

2014
Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Library; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Transcription Factors

2014
Sorafenib cardiotoxicity increases mortality after myocardial infarction.
    Circulation research, 2014, May-23, Volume: 114, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cats; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Heart; In Vitro Techniques; Male; Metoprolol; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib

2014
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening.
    Biomaterials, 2014, Volume: 35, Issue:22

    Topics: Antineoplastic Agents; Biomechanical Phenomena; Breast; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Collagen; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2014
Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors.
    Journal of controlled release : official journal of the Controlled Release Society, 2014, Jun-28, Volume: 184

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Microspheres; Niacinamide; Phenylurea Compounds; Polyglactin 910; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib

2014
Response to sorafenib treatment in advanced metastatic thyroid cancer.
    Arquivos brasileiros de endocrinologia e metabologia, 2014, Volume: 58, Issue:1

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; Follow-Up Studies; Heart Failure; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome

2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
    The oncologist, 2014, Volume: 19, Issue:5

    Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2014
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4

    Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Survival; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Cancer, 2014, Jul-15, Volume: 120, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Carbazoles; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Medical Records; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2014
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
    International journal of clinical oncology, 2015, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2015
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cause of Death; Embolization, Therapeutic; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Yttrium Radioisotopes

2015
Radiation recall reaction causing cardiotoxicity.
    Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2014, Apr-22, Volume: 16

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Chemoradiotherapy; Coronary Angiography; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Myocarditis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiation Dosage; Radiation Injuries; Risk Factors; Sorafenib; Whole Body Imaging

2014
New era for treatment in differentiated thyroid cancer.
    Lancet (London, England), 2014, Jul-26, Volume: 384, Issue:9940

    Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms

2014
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
    Acta ophthalmologica, 2014, Volume: 92, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Uveal Neoplasms

2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.
    Anticancer research, 2014, Volume: 34, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2014
Silencing of PKCη induces cycle arrest of EBV(+) B lymphoma cells by upregulating expression of p38-MAPK/TAp73/GADD45α and increases susceptibility to chemotherapeutic agents.
    Cancer letters, 2014, Aug-01, Volume: 350, Issue:1-2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Resistance, Neoplasm; Herpesvirus 4, Human; Humans; Membrane Potential, Mitochondrial; NF-kappa B; Niacinamide; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase C; Pyrazines; RNA Interference; RNA, Small Interfering; Sorafenib; Tumor Protein p73; Tumor Suppressor Proteins; Up-Regulation

2014
Therapeutic effects of sorafenib on the A549/DDP human lung adenocarcinoma cell line in vitro.
    Molecular medicine reports, 2014, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors

2014
A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
    International journal of cancer, 2014, Dec-15, Volume: 135, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Liver; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Sorafenib; Zebrafish

2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2014
Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Liver; Liver Neoplasms; Male; Microsomes, Liver; Middle Aged; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sorafenib; UDP-Glucuronosyltransferase 1A9

2014
Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma.
    Future oncology (London, England), 2014, Volume: 10, Issue:5

    Topics: Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Humans; Niacinamide; Phenylurea Compounds; Preoperative Period; Safety; Sorafenib; Treatment Outcome

2014
Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Oncology, 2014, Volume: 86, Issue:4

    Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed

2014
Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.
    The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2014, Volume: 62, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Female; Gene Expression; Humans; Liver; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis

2014
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    International journal of oncology, 2014, Volume: 45, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib; Vorinostat; Xenograft Model Antitumor Assays

2014
Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis.
    Oncotarget, 2014, Mar-15, Volume: 5, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Butadienes; Cell Hypoxia; Enzyme Inhibitors; Gene Knockdown Techniques; Heterografts; Humans; Hydrogen-Ion Concentration; Macrolides; MAP Kinase Signaling System; MCF-7 Cells; Membrane Proteins; Mice; Neoplasm Metastasis; Niacinamide; Nitriles; Phenylurea Compounds; Proto-Oncogene Proteins; Sorafenib; Tumor Burden; Vacuolar Proton-Translocating ATPases

2014
Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Withholding Treatment

2014
Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A

2014
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Skin Diseases; Sorafenib

2014
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Treatment Failure; Treatment Outcome; Valproic Acid

2014
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles

2014
Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
    World journal of gastroenterology, 2014, May-07, Volume: 20, Issue:17

    Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Transfection; Tumor Suppressor Protein p53; Vorinostat

2014
Postoperative but not preoperative treatment with sorafenib inhibits liver regeneration in rats.
    The Journal of surgical research, 2014, Volume: 191, Issue:2

    Topics: Animals; Body Weight; Cell Proliferation; Hepatectomy; Hepatocytes; Liver Regeneration; Niacinamide; Organ Size; Phenylurea Compounds; Postoperative Period; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib

2014
Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Japan; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2015
Metastatic involvement of the maxillary antrum from an uncommon source.
    Dental update, 2014, Volume: 41, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Embolization, Therapeutic; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Maxillary Sinus Neoplasms; Nephrectomy; Niacinamide; Palatal Neoplasms; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2014
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.
    BMJ case reports, 2014, May-19, Volume: 2014

    Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, Hepatocellular; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Scrotum; Severity of Illness Index; Sorafenib; Syndrome; Treatment Outcome

2014
Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis.
    eLife, 2014, May-20, Volume: 3

    Topics: 20-Hydroxysteroid Dehydrogenases; Amino Acid Transport System y+; Apoptosis; Biomarkers; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cystine; Endoplasmic Reticulum Stress; Glutamic Acid; Humans; Iron; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Sequence Analysis, RNA; Sorafenib; Structure-Activity Relationship; Transcriptome; Up-Regulation

2014
The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation.
    Journal of hepatology, 2014, Volume: 61, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes

2014
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:4

    Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Heterografts; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Guanine Nucleotide Exchange Factors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; T-Lymphoma Invasion and Metastasis-inducing Protein 1; Xenograft Model Antitumor Assays

2014
ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.
    Leukemia, 2014, Volume: 28, Issue:10

    Topics: Adult; Cytogenetics; Eosinophilia; ETS Translocation Variant 6 Protein; Female; fms-Like Tyrosine Kinase 3; Humans; Mutation; Myeloproliferative Disorders; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ets; Repressor Proteins; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome

2014
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:8

    Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Severity of Illness Index; Sorafenib; Venous Thromboembolism

2014
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib

2014
JUNB promotes the survival of Flavopiridol treated human breast cancer cells.
    Biochemical and biophysical research communications, 2014, Jul-18, Volume: 450, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Sorafenib; Transcription Factors; Treatment Outcome

2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2014
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib

2014
A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
    The Tohoku journal of experimental medicine, 2014, Volume: 233, Issue:2

    Topics: Acetonitriles; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Drug Stability; Humans; Ions; Liver Neoplasms; Mass Spectrometry; Niacinamide; Oxides; Phenylurea Compounds; Reference Standards; Solubility; Solutions; Sorafenib; Ultraviolet Rays

2014
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    BMC cancer, 2014, May-21, Volume: 14

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blood Platelets; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors

2014
Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway.
    Journal of cardiothoracic surgery, 2014, May-09, Volume: 9

    Topics: Animals; Becaplermin; Blood Pressure; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Heart Ventricles; Hypertrophy, Left Ventricular; Male; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins c-sis; Rats; Rats, Inbred Lew; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Sorafenib; Transforming Growth Factor beta1

2014
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
    BMC gastroenterology, 2014, May-03, Volume: 14

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Propensity Score; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis

2014
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.
    British journal of haematology, 2014, Volume: 167, Issue:1

    Topics: Antineoplastic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2014
VEGFA genomic amplification tailors treatment of HCCs with sorafenib.
    Cancer discovery, 2014, Volume: 4, Issue:6

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A

2014
Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.
    International journal of clinical oncology, 2015, Volume: 20, Issue:2

    Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyponatremia; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Serum Albumin; Sodium; Sorafenib; Sunitinib; Survival Rate

2015
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.
    American journal of hematology, 2014, Volume: 89, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Retreatment; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Treatment Outcome

2014
Multidisciplinary management of hepatocellular carcinoma in clinical practice.
    BioMed research international, 2014, Volume: 2014

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib

2014
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.
    BMC cancer, 2014, Jun-04, Volume: 14

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2

2014
Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
    Nanomedicine : nanotechnology, biology, and medicine, 2014, Volume: 10, Issue:8

    Topics: Apoptosis; Carcinoma, Hepatocellular; Doxorubicin; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Nanomedicine; Niacinamide; Phenylurea Compounds; Sorafenib; Transferrin

2014
Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, cdc; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Sorafenib

2014
An inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice.
    Cancer research, 2014, Aug-01, Volume: 74, Issue:15

    Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Humans; Liver Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
    Journal of cellular physiology, 2015, Volume: 230, Issue:1

    Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response

2015
Use of sorafenib in a corticotropin-secreting pancreatic neuroendocrine carcinoma.
    Pancreas, 2014, Volume: 43, Issue:5

    Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells.
    The Journal of biological chemistry, 2014, Aug-15, Volume: 289, Issue:33

    Topics: Cell Adhesion; Cytoskeleton; Gene Knockdown Techniques; Humans; Integrin alpha4beta1; Jurkat Cells; Lymphocyte Function-Associated Antigen-1; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptors, Vitronectin; Shear Strength; Sorafenib; Stress, Physiological; T-Lymphocytes; Vascular Cell Adhesion Molecule-1

2014
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
    Surgery, 2014, Volume: 156, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Models, Biological; NF-kappa B p50 Subunit; Niacinamide; Organophosphates; Phenanthrenes; Phenylurea Compounds; Prodrugs; Signal Transduction; Sincalide; Sorafenib; Translational Research, Biomedical; Xenograft Model Antitumor Assays

2014
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
    Future oncology (London, England), 2015, Volume: 11, Issue:1

    Topics: Adult; Aged; Bone Marrow Cells; Carcinoma, Renal Cell; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2015
Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hyperbaric Oxygenation; Liver Neoplasms; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tumor Stem Cell Assay

2014
Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.
    Surgery, 2014, Volume: 156, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Genetic Engineering; Humans; Liver Neoplasms; Niacinamide; Oncolytic Virotherapy; Phenylurea Compounds; Sorafenib; Vaccinia virus; Viral Plaque Assay; Virus Replication

2014
Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.
    Clinical science (London, England : 1979), 2015, Volume: 128, Issue:1

    Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Feasibility Studies; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Retrognathia; Sorafenib; Treatment Outcome

2015
[Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2014, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2014
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
    World journal of gastroenterology, 2014, Jun-28, Volume: 20, Issue:24

    Topics: Actins; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Indoles; Male; Matrix Metalloproteinase 2; Niacinamide; Pancreas; Pancreatic Stellate Cells; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats, Inbred Lew; RNA, Messenger; Signal Transduction; Sorafenib; Sunitinib; Time Factors; Transforming Growth Factor beta1

2014
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:8

    Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response

2014
Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
    The American surgeon, 2014, Volume: 80, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2014
Differential combined effect of COX inhibitors on cell survival suppressed by sorafenib in the HepG2 cell line.
    Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:7

    Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Proliferation; Cell Survival; Cyclooxygenase Inhibitors; Drug Synergism; Flow Cytometry; Hep G2 Cells; Humans; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Invasive hepatocellular carcinoma with recurrent pulmonary embolism: use of AngioVac cannula thrombectomy device for mechanical aspiration.
    The Journal of invasive cardiology, 2014, Volume: 26, Issue:7

    Topics: Adult; Angiography; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Fatal Outcome; Heart Atria; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pulmonary Embolism; Sorafenib; Suction; Thrombectomy; Vena Cava, Inferior

2014
Earlier presentation and application of curative treatments in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Child; Child, Preschool; Comorbidity; Early Diagnosis; Female; Humans; Incidence; Infant; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; SEER Program; Sorafenib; United States; Young Adult

2014
Targeted polytherapy in small cell sarcoma and its association with doxorubicin.
    Molecular oncology, 2014, Volume: 8, Issue:8

    Topics: Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Doxorubicin; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Sarcoma, Small Cell; Sorafenib; Vorinostat

2014
[Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:7

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erythema Multiforme; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prednisolone; Sorafenib

2014
The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib.
    Oncotarget, 2014, Jun-15, Volume: 5, Issue:11

    Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transcription Factors; Young Adult

2014
Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3).
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Antineoplastic Agents; Cell Line, Transformed; Cell Proliferation; Cyclic S-Oxides; Gene Expression Regulation; Humans; Indoles; Inhibitor of Apoptosis Proteins; Keratinocytes; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Survivin; Tetrazolium Salts

2014
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
    Haematologica, 2014, Volume: 99, Issue:11

    Topics: Antineoplastic Agents; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Retreatment; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome

2014
Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
    Cancer letters, 2014, Oct-01, Volume: 352, Issue:2

    Topics: Administration, Oral; Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Heterografts; Indoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; PC12 Cells; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyrroles; Rats; Sorafenib; Sunitinib; Time Factors; Tumor Burden

2014
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
    Cell metabolism, 2014, Aug-05, Volume: 20, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous

2014
Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.
    International journal of oncology, 2014, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Genome, Human; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; Sorafenib

2014
Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-10, Volume: 34, Issue:8

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib

2016
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis

2015
Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Cancer letters, 2014, Oct-01, Volume: 352, Issue:2

    Topics: 3' Untranslated Regions; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Genes, Reporter; Hep G2 Cells; Hepatitis B virus; Humans; Liver Neoplasms; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Transfection

2014
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase Inhibitors; Caspases; Cell Proliferation; Flow Cytometry; Humans; Mitochondria; Multiple Myeloma; Necrosis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured

2015
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:3

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Control Studies; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.
    Head & neck, 2015, Volume: 37, Issue:9

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; Heterografts; Humans; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Salivary Gland Neoplasms; Sensitivity and Specificity; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2015
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    The Journal of urology, 2015, Volume: 193, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib

2015
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Neoplasia (New York, N.Y.), 2014, Volume: 16, Issue:7

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2014
A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
    International journal of cancer, 2015, Feb-15, Volume: 136, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Hyaluronan Receptors; Liver Neoplasms, Experimental; Mice, Nude; Niacinamide; Phenotype; Phenylurea Compounds; Sorafenib; Transforming Growth Factor beta; Xenograft Model Antitumor Assays

2015
Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways.
    BioMed research international, 2014, Volume: 2014

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Coculture Techniques; Culture Media; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Hepatic Stellate Cells; Humans; Janus Kinase 2; Ligands; Liver Neoplasms; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; STAT3 Transcription Factor

2014
Network features suggest new hepatocellular carcinoma treatment strategies.
    BMC systems biology, 2014, Jul-29, Volume: 8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Signal Transduction; Sorafenib; Systems Biology; Transcriptome

2014
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
    Oncology reports, 2014, Volume: 32, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms, Experimental; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Signal Transduction; Snail Family Transcription Factors; Sorafenib; Transcription Factors

2014
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
    Anti-cancer drugs, 2014, Volume: 25, Issue:10

    Topics: Adult; Antineoplastic Agents; Axilla; Combined Modality Therapy; Dioxoles; Epirubicin; Fatal Outcome; Humans; Ifosfamide; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sarcoma, Synovial; Sorafenib; Tetrahydroisoquinolines; Trabectedin

2014
Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
    Molecular imaging and biology, 2015, Volume: 17, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Humans; Liver Neoplasms; Mice; Microbubbles; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Random Allocation; Software; Sorafenib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2

2015
Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma.
    Journal of Zhejiang University. Science. B, 2014, Volume: 15, Issue:8

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Xenograft Model Antitumor Assays

2014
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
    Cancer immunology research, 2014, Volume: 2, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Female; Flow Cytometry; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Vaccines, Synthetic

2014
miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.
    International journal of oncology, 2014, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
    Science signaling, 2014, Aug-05, Volume: 7, Issue:337

    Topics: Analysis of Variance; Binding, Competitive; Blotting, Western; Cell Movement; Dimerization; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Gene Knockdown Techniques; HEK293 Cells; Humans; Indenes; MAP Kinase Kinase 1; MAP Kinase Signaling System; Models, Molecular; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrazoles; RNA, Small Interfering; Sorafenib; Time-Lapse Imaging; Tumor Cells, Cultured

2014
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia.
    Blood cancer journal, 2014, Aug-08, Volume: 4

    Topics: Adolescent; Adult; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib

2014
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine

2014
Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:8

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Delayed onset perforating folliculitis associated with sorafenib.
    The Australasian journal of dermatology, 2014, Volume: 55, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Folliculitis; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors

2014
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.
    Cell reports, 2014, Aug-21, Volume: 8, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autocrine Communication; Benzamides; Cell Line, Tumor; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Female; Humans; Interleukin-6; MAP Kinase Signaling System; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation, Missense; Niacinamide; Oncogenes; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Xenograft Model Antitumor Assays

2014
Sorafenib regulating ERK signals pathway in gastric cancer cell.
    Environmental toxicology and pharmacology, 2014, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Microcystis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Sorafenib; Stomach Neoplasms

2014
Survival trends among patients with advanced renal cell carcinoma in the United States.
    Urologia internationalis, 2015, Volume: 94, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; SEER Program; Sorafenib; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; United States; Young Adult

2015
MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.
    Neoplasma, 2014, Volume: 61, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; DNA Methylation; Heme Oxygenase-1; Humans; Imatinib Mesylate; Kidney Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Piperazines; Promoter Regions, Genetic; Pyrimidines; Sorafenib

2014
[Synthesis and in vitro cytotoxic activities of sorafenib derivatives].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2014, Volume: 49, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship

2014
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:12

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Immunologic Factors; Interferon-gamma; Lenalidomide; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocyte Subsets; Thalidomide

2014
Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α.
    International journal of oncology, 2014, Volume: 45, Issue:5

    Topics: Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; MCF-7 Cells; Niacinamide; Nuclear Receptor Coactivator 3; Phenylurea Compounds; Pyrimidines; Sorafenib; Tamoxifen

2014
Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
    Oncology reports, 2014, Volume: 32, Issue:5

    Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Knockout Techniques; Genetic Vectors; Hep G2 Cells; Humans; In Vitro Techniques; Liver Neoplasms; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Plasmids; RNA, Small Interfering; Sorafenib

2014
Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
    BMJ case reports, 2014, Sep-01, Volume: 2014

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sorafenib; Ticlopidine; Time Factors; Tomography, X-Ray Computed

2014
The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2

2014
Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2014
BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.
    International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6

    Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tumor Suppressor Protein p53; Ubiquitination

2015
Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
    Anticancer research, 2014, Volume: 34, Issue:9

    Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib

2014
Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
    Anticancer research, 2014, Volume: 34, Issue:9

    Topics: Aged; Antineoplastic Agents; DNA Mutational Analysis; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Sorafenib; Thymoma; Thymus Neoplasms; Treatment Outcome

2014
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
    Anti-cancer drugs, 2015, Volume: 26, Issue:2

    Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Survival; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Knockdown Techniques; Hep G2 Cells; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Indazoles; Niacinamide; Phenylurea Compounds; Polycomb Repressive Complex 2; Pyridones; S-Adenosylmethionine; Sorafenib

2015
Acquired perforating dermatosis associated with sorafenib therapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:2

    Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Skin; Skin Diseases; Sorafenib

2016
In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
    Oncotarget, 2014, Aug-30, Volume: 5, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Medulloblastoma; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2014
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
    Nature medicine, 2014, Volume: 20, Issue:10

    Topics: Activating Transcription Factor 2; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 14; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2014
Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
    Cancer letters, 2014, Dec-01, Volume: 355, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Viral; Hep G2 Cells; Hepatitis B virus; Humans; Interferon-alpha; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Stability; Sorafenib; Trans-Activators; Transfection; Viral Regulatory and Accessory Proteins

2014
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Cancer letters, 2014, Dec-01, Volume: 355, Issue:1

    Topics: 2-Methoxyestradiol; Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; RNA Interference; Signal Transduction; Sorafenib; Time Factors; Transfection; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2014
The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.
    Gene, 2014, Nov-15, Volume: 552, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; G1 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Resting Phase, Cell Cycle; Sorafenib; Stomach Neoplasms

2014
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.
    Journal of radiation research, 2015, Volume: 56, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemokine CCL3; Chemoradiotherapy; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib; Treatment Outcome

2015
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Oncology, 2014, Volume: 87, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Drug Resistance, Neoplasm; Female; Hepatic Artery; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome

2014
Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.
    International journal of oncology, 2014, Volume: 45, Issue:6

    Topics: Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Sorafenib; Treatment Outcome

2014
The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells.
    Oncology reports, 2014, Volume: 32, Issue:6

    Topics: Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA Damage; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib

2014
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Amino acids, 2014, Volume: 46, Issue:12

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Metformin; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Urokinase-Type Plasminogen Activator

2014
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2014, Sep-21, Volume: 20, Issue:35

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden

2014
Flavonoid-enriched apple fraction AF4 induces cell cycle arrest, DNA topoisomerase II inhibition, and apoptosis in human liver cancer HepG2 cells.
    Nutrition and cancer, 2014, Volume: 66, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; DNA Fragmentation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Flavonoids; Hep G2 Cells; Humans; Liver Neoplasms; Malus; Niacinamide; Phenylurea Compounds; Sorafenib; Topoisomerase II Inhibitors

2014
The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC.
    Journal of cellular and molecular medicine, 2014, Volume: 18, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Damage; Gene Expression; Hep G2 Cells; Humans; Immunoblotting; Isothiocyanates; Kidney; Liver; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Telomerase; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2014
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
    Analytical chemistry, 2014, Nov-04, Volume: 86, Issue:21

    Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Immunohistochemistry; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution

2014
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
    American journal of clinical oncology, 2016, Volume: 39, Issue:5

    Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden

2016
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
    American journal of clinical oncology, 2017, Volume: 40, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib; Survival Rate

2017
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:7

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Republic of Korea; Retrospective Studies; Sorafenib; Treatment Outcome

2014
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Young Adult

2014
Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.
    Journal of endocrinological investigation, 2014, Volume: 37, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Stroke Volume; Thyroid Neoplasms; Treatment Outcome

2014
Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study.
    Targeted oncology, 2015, Volume: 10, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2015
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
    BMC cancer, 2014, Oct-10, Volume: 14

    Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Neoadjuvant Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Dehydrogenase; Sarcoma; Sorafenib; Sulfonamides; Tissue Array Analysis; Xenograft Model Antitumor Assays

2014
The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Animals; beta Catenin; Blotting, Western; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Hydrazines; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay

2015
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.
    Targeted oncology, 2015, Volume: 10, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Czech Republic; Databases, Factual; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult

2015
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Clinical radiology, 2014, Volume: 69, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Dermatitis; Diarrhea; Fatigue; Female; Fever; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis

2014
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
    Endocrine, 2015, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Failure

2015
Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin.
    Ultrasound in medicine & biology, 2015, Volume: 41, Issue:1

    Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Contrast Media; Endoglin; Female; Integrin alphaV; Intracellular Signaling Peptides and Proteins; Melanoma; Mice; Mice, Nude; Molecular Imaging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2

2015
Binding interaction between sorafenib and calf thymus DNA: spectroscopic methodology, viscosity measurement and molecular docking.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2015, Feb-05, Volume: 136 Pt B

    Topics: Animals; Cattle; Circular Dichroism; DNA; Hydrogen Bonding; Kinetics; Molecular Conformation; Molecular Docking Simulation; Niacinamide; Osmolar Concentration; Phenylurea Compounds; Protein Binding; Sorafenib; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics; Viscosity

2015
Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:8

    Topics: Antineoplastic Agents; Benzoxazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?
    Digestive diseases and sciences, 2015, Volume: 60, Issue:2

    Topics: Antineoplastic Agents; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Viral; Severity of Illness Index; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Viral Load

2015
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Carcinogenesis, 2014, Volume: 35, Issue:12

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatin Immunoprecipitation; DNA-Binding Proteins; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Liver Neoplasms; Luciferases; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Real-Time Polymerase Chain Reaction; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Arabidopsis putative MAP kinase kinase kinases Raf10 and Raf11 are positive regulators of seed dormancy and ABA response.
    Plant & cell physiology, 2015, Volume: 56, Issue:1

    Topics: Abscisic Acid; Arabidopsis; Arabidopsis Proteins; Gene Expression Regulation, Plant; Germination; MAP Kinase Kinase Kinases; Models, Biological; Mutation; Niacinamide; Phenylurea Compounds; Plant Dormancy; Plant Growth Regulators; Plants, Genetically Modified; Protein Kinase Inhibitors; Recombinant Proteins; Seeds; Sorafenib; Transcription Factors

2015
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
    Journal of pharmacokinetics and pharmacodynamics, 2014, Volume: 41, Issue:6

    Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden

2014
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
    Molecular medicine reports, 2015, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Head and Neck Neoplasms; Humans; Hyperplasia; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Burden

2015
Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; Immunosuppressive Agents; Immunotherapy, Adoptive; Lymphoma; Mice; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment

2014
[Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib

2014
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.
    World journal of gastroenterology, 2014, Oct-21, Volume: 20, Issue:39

    Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2014
Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
    Statistics in medicine, 2014, Dec-30, Volume: 33, Issue:30

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Decision Support Techniques; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Registries; Regression Analysis; Sorafenib

2014
Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Female; Head and Neck Neoplasms; Humans; Indium; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Oligopeptides; Phenylurea Compounds; Radioisotopes; Sorafenib; Time Factors; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2014
Possible Role of Raf-1 Kinase in the Development of Cerebral Vasospasm and Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats.
    Molecular neurobiology, 2015, Volume: 52, Issue:3

    Topics: Animals; Basilar Artery; Blood-Brain Barrier; Brain Damage, Chronic; Brain Edema; Cyclooxygenase 2; Disease Models, Animal; Down-Regulation; Interleukin-1beta; Interleukin-6; Male; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase Kinases; Nerve Tissue Proteins; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Sorafenib; Subarachnoid Hemorrhage; Vascular Endothelial Growth Factor A; Vasospasm, Intracranial

2015
Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Humans; L-Lactate Dehydrogenase; Necrosis; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured

2014
Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.
    Toxicological sciences : an official journal of the Society of Toxicology, 2015, Volume: 143, Issue:2

    Topics: Adult; Animals; Antineoplastic Agents; Cardiotoxicity; Down-Regulation; Glycoproteins; Heart; Humans; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib; Ventricular Dysfunction; Zebrafish

2015
Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:3

    Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Models, Animal; Humans; Immunotherapy; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2015
Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Digestive diseases (Basel, Switzerland), 2014, Volume: 32, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitals, University; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Survival Rate; Treatment Outcome

2014
Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Digestive diseases (Basel, Switzerland), 2014, Volume: 32, Issue:6

    Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Circulation; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2014
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.
    International journal of molecular sciences, 2014, Nov-07, Volume: 15, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium

2014
To treat or not to treat: developments in the field of advanced differentiated thyroid cancer.
    The Netherlands journal of medicine, 2014, Volume: 72, Issue:8

    Topics: Adenocarcinoma, Follicular; Aged; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2014
NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; HCT116 Cells; Hep G2 Cells; HT29 Cells; Humans; Male; MAP Kinase Kinase Kinases; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2015
Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
    The American journal of gastroenterology, 2014, Volume: 109, Issue:12

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2014
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.
    Journal of the American Geriatrics Society, 2014, Volume: 62, Issue:11

    Topics: Activities of Daily Living; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Endocrine, 2015, Volume: 49, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Thyroid Neoplasms; Thyroidectomy; Treatment Failure; Treatment Outcome; Young Adult

2015
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:4

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Proteins; Niacinamide; Oxides; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib

2015
Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model.
    Laboratory investigation; a journal of technical methods and pathology, 2015, Volume: 95, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Immunohistochemistry; Liver; Liver Neoplasms; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Electron; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Tumor Burden

2015
[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
    Nuklearmedizin. Nuclear medicine, 2015, Volume: 54, Issue:3

    Topics: Antineoplastic Agents; Chemoradiotherapy; Evidence-Based Medicine; Germany; Humans; Iodine Radioisotopes; Medical Oncology; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome

2015
Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy.
    Journal of biomaterials science. Polymer edition, 2015, Volume: 26, Issue:2

    Topics: Absorbable Implants; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemoembolization, Therapeutic; Cisplatin; Drug Delivery Systems; Drug Interactions; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Microspheres; Niacinamide; Phenylurea Compounds; Polyesters; Polymers; Porosity; Radiography; Sorafenib

2015
Inhibition of c-Kit by tyrosine kinase inhibitors.
    Haematologica, 2015, Volume: 100, Issue:3

    Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles

2015
Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
    Oncology, 2014, Volume: 87 Suppl 1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatic Artery; Hepatitis C; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Factors; Sorafenib; Treatment Failure

2014
Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
    Oncology, 2014, Volume: 87 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Japan; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Survivors; Tomography, X-Ray Computed; Treatment Outcome

2014
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Sorafenib

2015
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Animals; Antineoplastic Agents; Cachexia; Carcinoma, Lewis Lung; Colon; Colonic Neoplasms; Lung; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT3 Transcription Factor; Wasting Syndrome

2014
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Journal of cellular and molecular medicine, 2015, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2015
Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Treatment Outcome; Young Adult

2015
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Female; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Necrosis; Niacinamide; Oxidative Stress; Phenylurea Compounds; Reactive Oxygen Species; Retinoblastoma Protein; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2015
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
    Experimental cell research, 2015, Feb-01, Volume: 331, Issue:1

    Topics: Adult; Animals; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Child; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2015
Early treatment response to sorafenib for rabbit VX2 orthotic liver tumors: evaluation by quantitative contrast-enhanced ultrasound.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:4

    Topics: Animals; Contrast Media; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Tumor Burden; Ultrasonography

2015
A rare primary liver tumor that responded to sorafenib.
    Gastroenterology, 2014, Volume: 147, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Eukaryotic Initiation Factor-3; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib

2014
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.
    The International journal of biological markers, 2015, Feb-24, Volume: 30, Issue:1

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; ROC Curve; Sorafenib; Treatment Outcome

2015
Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis.
    Biochemical pharmacology, 2015, Jan-01, Volume: 93, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Precursors; Sorafenib; Thymosin; Transcription Factors

2015
Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    European journal of medicinal chemistry, 2015, Jan-27, Volume: 90

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Structure-Activity Relationship

2015
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
    British journal of cancer, 2015, Jan-06, Volume: 112, Issue:1

    Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Triazoles

2015
Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
    Journal of hepatology, 2015, Volume: 62, Issue:4

    Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Macrophage Activation; Macrophage Colony-Stimulating Factor; Macrophages; Niacinamide; Phenylurea Compounds; raf Kinases; Receptors, Cell Surface; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib

2015
Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
    World journal of gastroenterology, 2014, Nov-21, Volume: 20, Issue:43

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; China; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Rupture, Spontaneous; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2014
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbidity; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Tumor Burden; Venous Thrombosis

2015
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
    Clinical journal of gastroenterology, 2015, Volume: 8, Issue:1

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Necrosis; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Regional Blood Flow; Sorafenib; Vascular Access Devices

2015
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:1

    Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cadherins; Cyclooxygenase 2; Drug Resistance, Neoplasm; Humans; Hypoxia; Kidney Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Snail Family Transcription Factors; Sorafenib; Transcription Factors; Tumor Cells, Cultured

2015
Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.
    Chemical research in toxicology, 2015, Jan-20, Volume: 28, Issue:1

    Topics: Antineoplastic Agents; Biotransformation; Cell Cycle; Cell Survival; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Hep G2 Cells; Humans; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    BMC cancer, 2014, Dec-12, Volume: 14

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2

2014
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
    Journal of digestive diseases, 2015, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Drug Evaluation; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure

2015
[Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:2

    Topics: Aged; Aged, 80 and over; Alcoholism; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Diabetes Complications; Ethanol; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Remission Induction; Sorafenib

2015
Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
    Digestion, 2014, Volume: 90, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Epirubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tumor Burden

2014
Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
    Oncology, 2015, Volume: 88, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate

2015
Thyroid carcinoma, version 2.2014.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Anilides; Carcinoma, Neuroendocrine; Guidelines as Topic; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms

2014
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
    Zhonghua yi xue za zhi, 2014, Sep-09, Volume: 94, Issue:33

    Topics: Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Venous Thrombosis

2014
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
    Journal of hepatology, 2015, Volume: 62, Issue:5

    Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B, Chronic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Radiography; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome

2015
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib; Tumor Microenvironment

2015
MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?
    Oncology, 2015, Volume: 88, Issue:4

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Denosumab; Drug Resistance, Neoplasm; Humans; Male; Niacinamide; Osteosarcoma; Phenylurea Compounds; Prognosis; RANK Ligand; Remission Induction; Salvage Therapy; Sorafenib

2015
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
    European urology, 2015, Volume: 68, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib

2015
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:5

    Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Homologous; Treatment Outcome

2015
Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:11

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Injections, Intra-Arterial; Iodized Oil; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Treatment Outcome

2014
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Discovery; Enzyme Activation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Quinazolines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2014
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Acta pharmacologica Sinica, 2015, Volume: 36, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; Forkhead Transcription Factors; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Protein p53; Up-Regulation

2015
The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.
    Biochemical pharmacology, 2015, Feb-01, Volume: 93, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Depsipeptides; Dose-Response Relationship, Drug; Drug Synergism; Female; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Sorafenib; T-2 Toxin; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2015
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:8

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Resistance, Neoplasm; eIF-2 Kinase; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2

2015
Sorafenib-induced severe urticaria in a patient with hepatocellular cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:2

    Topics: Aged; Antineoplastic Agents; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Urticaria

2016
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure.
    Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:5

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethanol; Fatal Outcome; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Needles; Neoplasm Seeding; Niacinamide; Phenylurea Compounds; Radiofrequency Therapy; Sclerosing Solutions; Skin Neoplasms; Sorafenib

2015
Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
    Journal of pharmaceutical sciences, 2015, Volume: 104, Issue:3

    Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Kidney Neoplasms; Kinetics; Lactic Acid; Liposomes; Nanoparticles; Nanotechnology; Niacinamide; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Sorafenib; Technology, Pharmaceutical

2015
Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Xenograft Model Antitumor Assays

2015
Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Forecasting; Hepatitis B virus; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Survival Rate; Viral Load; Virus Activation

2015
Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
    Journal of vascular and interventional radiology : JVIR, 2015, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Comorbidity; Female; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiography; Republic of Korea; Risk Assessment; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis

2015
Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma.
    European journal of pharmacology, 2015, Feb-15, Volume: 749

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Survival; Cyclophilins; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Kidney Neoplasms; Male; Membrane Potential, Mitochondrial; Middle Aged; Niacinamide; Peptidyl-Prolyl Isomerase F; Phenylurea Compounds; Sorafenib

2015
The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours.
    Molecular and cellular endocrinology, 2015, Mar-15, Volume: 404

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Proteomics; Sorafenib; Thyroid Neoplasms; Two-Dimensional Difference Gel Electrophoresis; Up-Regulation; Voltage-Dependent Anion Channel 2; Young Adult

2015
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Proliferation; Culture Media, Conditioned; Fetus; Gene Knockdown Techniques; Humans; Indoles; Liver Neoplasms; Mesenchymal Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib; Sunitinib

2015
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
    Molecular pharmaceutics, 2015, Mar-02, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopharmaceutics; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Mice; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; Xenograft Model Antitumor Assays

2015
[Five-year therapeutic experience of sorafenib for patients with advanced renal cell carcinoma].
    Zhonghua yi xue za zhi, 2014, Dec-16, Volume: 94, Issue:46

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib

2014
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
    Oncotarget, 2015, Feb-20, Volume: 6, Issue:5

    Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Apoptosis; Binding Sites; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Pyrrolidinones; Quinolines; Sorafenib; Time Factors; Transfection; Up-Regulation

2015
Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy.
    Acta biomaterialia, 2015, Volume: 16

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Delayed-Action Preparations; Drug Delivery Systems; Endocytosis; Humans; Methotrexate; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Porosity; Silicon; Sorafenib; Spectroscopy, Fourier Transform Infrared; Static Electricity

2015
Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:6

    Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nucleosides; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Reduction Behavior; Sorafenib; Survival Rate

2015
Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.
    Bioscience trends, 2014, Volume: 8, Issue:6

    Topics: Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Care; Retrospective Studies; Sorafenib; Survival Analysis

2014
Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
    Journal of surgical oncology, 2015, Mar-15, Volume: 111, Issue:4

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Proportional Hazards Models; Serum Albumin; Sorafenib; Taiwan

2015
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Risk Assessment; Sorafenib; Survival Analysis; Withholding Treatment

2015
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Cyproheptadine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2015
Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Preoperative Period; Risk; Sorafenib; Treatment Outcome

2015
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tandem Repeat Sequences

2015
Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Signal Transduction; Sorafenib; Tandem Repeat Sequences

2015
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
    Cellular oncology (Dordrecht), 2015, Volume: 38, Issue:2

    Topics: Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Tandem Mass Spectrometry

2015
Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.
    World journal of surgery, 2015, Volume: 39, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden

2015
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Viral Load

2015
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:3

    Topics: Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Europe; False Positive Reactions; Female; Glass; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiometry; Retrospective Studies; Sorafenib; Thrombosis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes

2015
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Actins; Animals; Apoptosis; Cadherins; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Immunohistochemistry; Kidney Diseases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Smad3 Protein; Sorafenib; Transforming Growth Factor beta; Ureteral Obstruction

2015
Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells.
    Experimental biology and medicine (Maywood, N.J.), 2015, Volume: 240, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Proliferation; Cisplatin; DNA Fragmentation; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Esters; Fatty Acids; Flavonoids; Glucosides; Hep G2 Cells; Humans; Liver Neoplasms; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib

2015
Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.
    Acta gastro-enterologica Belgica, 2014, Volume: 77, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Cancer science, 2015, Volume: 106, Issue:5

    Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retinoids; Sorafenib; Tetrahydronaphthalenes; Tretinoin

2015
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Oncology reports, 2015, Volume: 33, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Metformin; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Sorafenib; Spheroids, Cellular; Thyroid Neoplasms; Tumor Stem Cell Assay

2015
PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
    Oncogene, 2015, Oct-29, Volume: 34, Issue:44

    Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; HEK293 Cells; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Sorafenib; Transcription, Genetic; Tumor Suppressor Proteins; Up-Regulation; Wnt Proteins

2015
Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate

2015
[Mechanisms of sorafenib induced NB4 cell apoptosis].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Down-Regulation; Humans; Leukemia, Promyelocytic, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Helper-Inducer

2015
Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Age Factors; Aged; Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Safety; Sorafenib; Survival Analysis; Treatment Outcome

2015
miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.
    Cell research, 2015, Volume: 25, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cytochrome P-450 CYP1B1; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Inactivation, Metabolic; Kidney Neoplasms; Liver Neoplasms; Mice; MicroRNAs; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2015
Multifunctional porous silicon nanoparticles for cancer theranostics.
    Biomaterials, 2015, Volume: 48

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Humans; Male; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Silicon; Sorafenib; Theranostic Nanomedicine

2015
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
    Tumori, 2015, Apr-28, Volume: 101, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Jaundice; Liver Failure, Acute; Liver Neoplasms; Male; Muscle Weakness; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Tremor

2015
Nexavar/Stivarga and viagra interact to kill tumor cells.
    Journal of cellular physiology, 2015, Volume: 230, Issue:9

    Topics: Apoptosis; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Signal Transduction; Sildenafil Citrate; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2015
Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2015
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    International journal of clinical oncology, 2015, Volume: 20, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Prospective Studies; Sorafenib

2015
MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
    Biochemical and biophysical research communications, 2015, Apr-03, Volume: 459, Issue:2

    Topics: Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Renal Cell; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Male; Membrane Proteins; MicroRNAs; Microtubule-Associated Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Sorafenib; Up-Regulation

2015
MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Current cancer drug targets, 2015, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sorafenib

2015
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2015, Volume: 48, Issue:5

    Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collagens; Glutathione Transferase; HSP90 Heat-Shock Proteins; Interleukin-10; Interleukin-6; Liver Cirrhosis; Matrix Metalloproteinase 9; Mitochondria, Liver; Niacinamide; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenylurea Compounds; Polarography; Protein Kinase Inhibitors; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transcription Factors

2015
Combination of Matrine and Sorafenib Decreases the Aggressive Phenotypes of Hepatocellular Carcinoma Cells.
    Chemotherapy, 2014, Volume: 60, Issue:2

    Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Matrines; Niacinamide; Phenotype; Phenylurea Compounds; Quinolizines; Sorafenib

2014
[A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2014
Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
    Oncology reports, 2015, Volume: 33, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Osteosarcoma; Phenylurea Compounds; Phosphorylation; Reactive Oxygen Species; Resting Phase, Cell Cycle; Sorafenib; Xenograft Model Antitumor Assays

2015
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
    World journal of gastroenterology, 2015, Feb-28, Volume: 21, Issue:8

    Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Interventional

2015
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
    Anticancer research, 2015, Volume: 35, Issue:3

    Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Keratin-18; Liver Neoplasms; Male; Necrosis; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2015
Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
    Endocrine, 2015, Volume: 50, Issue:3

    Topics: Antineoplastic Agents; Female; Humans; Iodine Radioisotopes; Liver; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sorafenib; Thyroid Neoplasms

2015
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
    Future oncology (London, England), 2015, Volume: 11, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome

2015
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:5

    Topics: Anilides; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Iodide Peroxidase; Iron-Binding Proteins; Microfilament Proteins; Muscle Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Thyrotropin; Signal Transduction; Sorafenib; Symporters; Thyroid Neoplasms

2015
The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing.
    Scientific reports, 2015, Mar-17, Volume: 5

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Respiration; Cell Survival; Deoxyglucose; Energy Metabolism; Glycolysis; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Reactive Oxygen Species; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2015
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
    American journal of clinical pathology, 2015, Volume: 143, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib

2015
Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genistein; Humans; Liver Neoplasms; Membrane Transport Proteins; MicroRNAs; Niacinamide; Phenylurea Compounds; Phytoestrogens; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Tumor Cells, Cultured

2015
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
    Journal of pediatric surgery, 2015, Volume: 50, Issue:9

    Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pneumothorax; Sarcoma, Ewing; Sarcoma, Synovial; Sorafenib; Wilms Tumor; Young Adult

2015
Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Skin Diseases, Vesiculobullous; Sorafenib

2015
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Apoptosis; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Ependymoma; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Signal Transduction; Sorafenib

2015
Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives.
    Bioorganic & medicinal chemistry letters, 2015, Apr-15, Volume: 25, Issue:8

    Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Niacinamide; Oxadiazoles; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship; Urea

2015
Effects of Antitumor Drug Sorafenib on Chick Embryo Development.
    Anatomical record (Hoboken, N.J. : 2007), 2015, Volume: 298, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Movement; Chick Embryo; Embryonic Development; Epithelial-Mesenchymal Transition; Gastrulation; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib

2015
PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.
    Scientific reports, 2015, Mar-30, Volume: 5

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drugs, Chinese Herbal; Humans; Liver Neoplasms; Medicine, Chinese Traditional; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Plant Extracts; Scutellaria baicalensis; Sorafenib; Tumor Microenvironment

2015
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
    Haematologica, 2015, Volume: 100, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Mice; Monocytes; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays

2015
The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.
    Antiviral research, 2015, Volume: 118

    Topics: Antiviral Agents; Cells, Cultured; Hepacivirus; Hepatocytes; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Virus Internalization; Virus Replication

2015
Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.
    Oncotarget, 2015, Apr-10, Volume: 6, Issue:10

    Topics: Animals; Apoptosis; Arginine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; MicroRNAs; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.
    Clinical journal of gastroenterology, 2015, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Duodenitis; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiation Injuries; Radiotherapy; Receptor Protein-Tyrosine Kinases; Sorafenib

2015
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Silybin; Silymarin; Sorafenib

2015
Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:1

    Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Creatinine; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Tomography, X-Ray Computed; Tumor Lysis Syndrome

2015
Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
    Chinese clinical oncology, 2015, Volume: 4, Issue:1

    Topics: Asia; Asian People; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome

2015
Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells.
    Oncology reports, 2015, Volume: 33, Issue:6

    Topics: Animals; Antibodies, Anti-Idiotypic; CD8-Positive T-Lymphocytes; CTLA-4 Antigen; Humans; Kidney Neoplasms; Lymphocyte Activation; Mice; Myeloid Cells; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatectomy; Hospitals; Humans; Liver Neoplasms; Male; Middle Aged; Netherlands; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate

2015
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
    Journal of cellular physiology, 2015, Volume: 230, Issue:10

    Topics: Animals; Bacterial Infections; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Escherichia coli; Heat-Shock Proteins; Humans; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Polynucleotide 5'-Hydroxyl-Kinase; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Virus Diseases

2015
Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
    Medicine, 2015, Volume: 94, Issue:14

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taiwan; Treatment Failure

2015
Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.
    Blood cancer journal, 2015, Apr-10, Volume: 5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Complement System Proteins; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Rituximab; Sorafenib

2015
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
    Investigational new drugs, 2015, Volume: 33, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome

2015
Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:6

    Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure

2015
Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
    Human cell, 2015, Volume: 28, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression; Gene Silencing; Humans; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib; Tumor Cells, Cultured

2015
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Indoles; Molecular Targeted Therapy; Niacinamide; Papillomaviridae; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib; TOR Serine-Threonine Kinases

2015
Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib

2015
Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Synergism; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vitamin K

2015
Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome

2015
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11; raf Kinases; Sorafenib

2015
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
    Cancer biology & therapy, 2015, Volume: 16, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Nitrogen Mustard Compounds; Phenylurea Compounds; Prodrugs; Sorafenib; Xenograft Model Antitumor Assays

2015
Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Apr-28, Volume: 112, Issue:17

    Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Collagenases; Humans; Hydrogels; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Tissue Scaffolds; Vemurafenib

2015
A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:4

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib

2015
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
    Oncology, 2015, Volume: 89, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreas; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2015
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    BMC cancer, 2015, Mar-26, Volume: 15

    Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms

2015
Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
    BMC cancer, 2015, Apr-11, Volume: 15

    Topics: Animals; Carcinoma, Hepatocellular; CD13 Antigens; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    BMC cancer, 2015, Apr-08, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome

2015
Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
    International journal of pharmaceutics, 2015, Jul-15, Volume: 489, Issue:1-2

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Folic Acid; Humans; Iron; Liver Neoplasms; Magnetic Phenomena; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Sorafenib

2015
Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
    Journal of gastrointestinal cancer, 2015, Volume: 46, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib

2015
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
    Oncotarget, 2015, May-20, Volume: 6, Issue:14

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Real-Time Polymerase Chain Reaction; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2015
Sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a report of four cases.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 65, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed

2015
Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2015, Volume: 88, Issue:3

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vinblastine; Vinorelbine

2015
RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis.
    Oncology reports, 2015, Volume: 33, Issue:6

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Endoribonucleases; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Liver Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Receptors for Activated C Kinase; Receptors, Cell Surface; Regulatory Factor X Transcription Factors; Signal Transduction; Sorafenib; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1

2015
Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD47 Antigen; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, SCID; Molecular Targeted Therapy; NF-kappa B; Niacinamide; Phenylurea Compounds; Random Allocation; Signal Transduction; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays

2015
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib

2015
Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.
    Cancer research, 2015, Jun-15, Volume: 75, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays

2015
[CLAG regimen in combination with sorafenib in the treatment of refractory acute myeloid leukemia:a case report].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2015
Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Prospective Studies; Risk Factors; Sorafenib; Survival Analysis; Terminology as Topic

2015
Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
    International journal of molecular sciences, 2015, Apr-28, Volume: 16, Issue:5

    Topics: Aged; Aging; Carcinoma, Hepatocellular; Demography; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Linear Models; Liver Neoplasms; Male; Multivariate Analysis; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Risk Factors; Sorafenib; Withholding Treatment

2015
Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.
    Cancer research, 2015, Jul-01, Volume: 75, Issue:13

    Topics: Animals; Female; Glucuronidase; Glucuronides; Hepatocytes; Humans; Intestines; Mice; Mice, Inbred C57BL; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Rats; Sf9 Cells; Sorafenib

2015
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    BMC cancer, 2015, May-08, Volume: 15

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytoskeletal Proteins; Drug Synergism; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mesothelioma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays

2015
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
    Journal of translational medicine, 2015, May-08, Volume: 13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Disease Models, Animal; Everolimus; Genetic Engineering; Homozygote; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Knockout; Neoplasms, Experimental; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Sorafenib

2015
Sorafenib-induced hand-foot syndrome.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:6

    Topics: Aged; Antineoplastic Agents; Hand-Foot Syndrome; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Cost-effectiveness analysis of axitinib through a probabilistic decision model.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; Uncertainty

2015
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
    Reproductive sciences (Thousand Oaks, Calif.), 2015, Volume: 22, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Indazoles; Indoles; Niacinamide; Ovarian Reserve; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2015
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Sorafenib; Tandem Repeat Sequences; Treatment Outcome

2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
    Leukemia, 2015, Volume: 29, Issue:7

    Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cyclosporine; Drug Resistance, Neoplasm; Flow Cytometry; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; NFATC Transcription Factors; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Survival Rate; Tandem Repeat Sequences; Tumor Cells, Cultured

2015
High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Aug-15, Volume: 21, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome

2015
Corosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Actins; Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Down-Regulation; Drug Synergism; Focal Adhesion Kinase 1; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; src-Family Kinases; Triterpenes; Vascular Endothelial Growth Factor Receptor-2

2015
Binding interaction of sorafenib with bovine serum albumin: Spectroscopic methodologies and molecular docking.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2015, Volume: 149

    Topics: Animals; Binding Sites; Cattle; Circular Dichroism; Energy Transfer; Kinetics; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Conformation; Serum Albumin, Bovine; Sorafenib; Spectrophotometry, Ultraviolet; Thermodynamics

2015
Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
    Die Pharmazie, 2014, Volume: 69, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome

2014
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
    Recenti progressi in medicina, 2015, Volume: 106, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib

2015
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Oct-01, Volume: 21, Issue:19

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Disease Models, Animal; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Sorafenib

2015
Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
    European urology, 2015, Volume: 68, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Early Termination of Clinical Trials; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Treatment Outcome

2015
Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
    International surgery, 2015, Volume: 100, Issue:5

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Loss, Surgical; Carcinoma, Hepatocellular; Combined Modality Therapy; Diagnostic Imaging; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Operative Time; Phenylurea Compounds; Sorafenib; Thrombosis; Vena Cava, Inferior

2015
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
    Anti-cancer drugs, 2015, Volume: 26, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2015
Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model.
    Biomaterials, 2015, Volume: 61

    Topics: Animals; Antineoplastic Agents; Capsules; Cell Line, Tumor; Contrast Media; Diffusion; Drug Monitoring; Ferric Compounds; Liver Neoplasms; Magnetic Resonance Imaging; Niacinamide; Particle Size; Phenylurea Compounds; Polyglactin 910; Rabbits; Sorafenib

2015
Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:11

    Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Rats; Sorafenib

2015
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
    American journal of hypertension, 2016, Volume: 29, Issue:2

    Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness

2016
CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
    Molecular medicine reports, 2015, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; COP9 Signalosome Complex; Cyclin D1; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Integrin beta1; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; NF-kappa B; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib; Transforming Growth Factor beta1

2015
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; DNA Transposable Elements; Drug Synergism; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Sorafenib; Tumor Suppressor Protein p53

2015
Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
    Advanced healthcare materials, 2015, Aug-05, Volume: 4, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dextrans; Drug Carriers; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Jun-09, Volume: 112, Issue:23

    Topics: Animals; Cell Line; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; STAT3 Transcription Factor

2015
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
    Cancer medicine, 2015, Volume: 4, Issue:8

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2015
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
    Journal of molecular modeling, 2015, Volume: 21, Issue:7

    Topics: Aminopyridines; Binding Sites; Humans; Indoles; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Sorafenib; Structural Homology, Protein; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2

2015
miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
    Oncology reports, 2015, Volume: 34, Issue:2

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; PTEN Phosphohydrolase; Sorafenib

2015
Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Polymerase Chain Reaction; Signal Transduction; Sorafenib

2015
Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
    Oncotarget, 2015, Aug-28, Volume: 6, Issue:25

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Female; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neuregulin-1; Niacinamide; Paraffin Embedding; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Sequence Analysis, DNA; Sequence Analysis, RNA; Sorafenib; Transforming Growth Factor alpha; Treatment Outcome; Tumor Suppressor Protein p53

2015
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
    Oncotarget, 2015, Aug-28, Volume: 6, Issue:25

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1

2015
Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation.
    Marine drugs, 2015, Jun-05, Volume: 13, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Chromatin; Chromosomes; Embryo, Mammalian; Fibroblasts; Humans; Macrolides; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Porifera; Proto-Oncogene Proteins c-raf; Sorafenib

2015
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
    Science translational medicine, 2015, Jun-10, Volume: 7, Issue:291

    Topics: Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Myeloproliferative Disorders; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Sorafenib; STAT5 Transcription Factor; Stem Cells; Veratrum Alkaloids; Zinc Finger Protein Gli2

2015
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
    The Canadian journal of urology, 2015, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2015
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
    Journal of translational medicine, 2015, Jun-13, Volume: 13

    Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays

2015
1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sorafenib; Wnt Signaling Pathway

2015
[Systemic therapy of soft tissue sarcomas].
    Voprosy onkologii, 2015, Volume: 61, Issue:2

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2015
Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy.
    Medical science monitor : international medical journal of experimental and clinical research, 2015, Jun-20, Volume: 21

    Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Synergism; Everolimus; Fluorescein-5-isothiocyanate; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolic Networks and Pathways; Metabolomics; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Sorafenib; Tetrazolium Salts; Thiazoles

2015
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.
    Oncotarget, 2015, Sep-15, Volume: 6, Issue:27

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Retrospective Studies; Sorafenib; Treatment Outcome

2015
Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.
    Cancer research, 2015, Sep-01, Volume: 75, Issue:17

    Topics: Aged; Animals; Apoptosis; Cell Line, Tumor; Death-Associated Protein Kinases; Disease-Free Survival; Drug Synergism; Female; Gene Knockout Techniques; Humans; Indoles; Kidney Neoplasms; Male; Mice; Middle Aged; Mitochondria; Niacinamide; Phenols; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Reactive Oxygen Species; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2015
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Models, Statistical; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Survival Analysis

2015
Long-term therapy with sorafenib is associated with pancreatic atrophy.
    The Journal of surgical research, 2015, Volume: 199, Issue:2

    Topics: Aged; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; China; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreas; Pancreatic Diseases; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Journal of digestive diseases, 2015, Volume: 16, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2015
Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
    Gastroenterology, 2015, Volume: 149, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Jejunum; Liver Neoplasms; Male; Niacinamide; Peritoneal Cavity; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Pneumoperitoneum; Sorafenib; Tomography, X-Ray Computed

2015
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
    The British journal of radiology, 2015, Volume: 88, Issue:1053

    Topics: Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Feasibility Studies; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2015
2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxyglucose; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Drug Synergism; Gene Expression; Glycolysis; Humans; Lactic Acid; Mutation; Niacinamide; Oxygen Consumption; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Thyroid Gland

2015
Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
    Journal of digestive diseases, 2015, Volume: 16, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib

2015
Sorafenib in the treatment of thyroid cancer.
    Expert review of anticancer therapy, 2015, Volume: 15, Issue:8

    Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms

2015
Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:132

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2014
Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:132

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult

2014
MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
    Oncotarget, 2015, Jul-30, Volume: 6, Issue:21

    Topics: Adult; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dual Specificity Phosphatase 1; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Immunohistochemistry; Lipopolysaccharides; Liver Neoplasms; Macrophages; Male; MicroRNAs; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Transforming Growth Factor beta1

2015
Systemic Treatment: Expecting Further Success.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:4

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A

2015
Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
    International journal of clinical oncology, 2016, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Renal Dialysis; Retrospective Studies; Risk Assessment; Sorafenib; Survival Rate; Treatment Outcome

2016
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
    Reproductive sciences (Thousand Oaks, Calif.), 2015, Volume: 22, Issue:9

    Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Extracellular Signal-Regulated MAP Kinases; Female; Heterografts; Humans; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Stromal Cells; Time Factors; Vascular Endothelial Growth Factor Receptor-2

2015
Next Generation of Preclinical Liver Cancer Models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Oct-01, Volume: 21, Issue:19

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Genomic Hybridization; Disease Models, Animal; Genetic Heterogeneity; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Sorafenib

2015
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Middle Aged; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2015
The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:131

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2014
[Hepatocellular Carcinoma: therapeutic options 2015].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:14

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Combined Modality Therapy; Evidence-Based Medicine; Humans; Internationality; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Sorafenib-Sunitinib Sequence: The Jury Is Out.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2015
Adaptive GPU-accelerated force calculation for interactive rigid molecular docking using haptics.
    Journal of molecular graphics & modelling, 2015, Volume: 61

    Topics: Algorithms; Animals; Aprotinin; Benchmarking; Binding Sites; Cattle; Chaperonin 10; Chaperonin 60; Computer Graphics; Epidermal Growth Factor; ErbB Receptors; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Binding; Proto-Oncogene Proteins B-raf; Sorafenib; Trypsin; User-Computer Interface

2015
Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 66, Issue:1

    Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Cervical Cord; Chemoembolization, Therapeutic; Gamma Rays; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Unknown Primary; Niacinamide; Pelvic Bones; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2015
[Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome

2015
Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
    Journal of the National Cancer Institute, 2015, Volume: 107, Issue:10

    Topics: Age Factors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hepatitis B; Hepatitis B virus; Incidence; Liver Neoplasms; Male; Mice; Mice, Transgenic; Niacinamide; Orchiectomy; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Signal Transduction; Sorafenib; Trans-Activators; Viral Regulatory and Accessory Proteins

2015
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:10

    Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Humans; Intra-Abdominal Fat; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Triazines

2015
Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
    International journal of pharmaceutics, 2015, Sep-30, Volume: 493, Issue:1-2

    Topics: Antineoplastic Agents; Caprylates; Cell Survival; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Hemolysis; Hep G2 Cells; Humans; Lipids; Microscopy, Electron, Scanning; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Sorafenib; Triglycerides

2015
CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Biomaterials, 2015, Volume: 67

    Topics: Animals; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Endocytosis; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Lipids; Liver Neoplasms; Male; Mice; Nanoparticles; Neoplasm Metastasis; Niacinamide; Phenotype; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Receptors, CXCR4; Sorafenib; Survival Analysis; Tumor Microenvironment

2015
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:14

    Topics: Antineoplastic Agents; Catheter Ablation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Engineering Melanin Nanoparticles as an Efficient Drug-Delivery System for Imaging-Guided Chemotherapy.
    Advanced materials (Deerfield Beach, Fla.), 2015, Sep-09, Volume: 27, Issue:34

    Topics: Animals; Antineoplastic Agents; Drug Carriers; Engineering; Hep G2 Cells; Humans; Melanins; Mice; Nanoparticles; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Photoacoustic Techniques; Positron-Emission Tomography; Solubility; Sorafenib; Water

2015
Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature.
    Journal of gastrointestinal cancer, 2016, Volume: 47, Issue:4

    Topics: Antineoplastic Agents; Humans; Intestinal Perforation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
    Annals of hematology, 2015, Volume: 94, Issue:11

    Topics: Adult; Aged; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Remission Induction; Retrospective Studies; Risk Factors; Sorafenib; Tandem Repeat Sequences; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult

2015
Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells.
    Redox biology, 2015, Volume: 6

    Topics: Antineoplastic Agents; Caspase 3; Caspase 8; Caspase 9; Cell Death; Cysteine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Niacinamide; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type III; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor, Type I; S-Nitrosothiols; Signal Transduction; Sorafenib

2015
NMR-Based Metabolic Profiling Reveals Neurochemical Alterations in the Brain of Rats Treated with Sorafenib.
    Neurotoxicity research, 2015, Volume: 28, Issue:4

    Topics: Amino Acids; Animals; Antioxidants; Brain; Cell Membrane; Energy Metabolism; Magnetic Resonance Imaging; Male; Metabolomics; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib

2015
A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
    Anti-cancer drugs, 2015, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib

2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Sep-01, Volume: 195, Issue:5

    Topics: Animals; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; Humans; Immunoblotting; Interferon-alpha; Interleukin-2; Janus Kinase 1; K562 Cells; Leukocytes, Mononuclear; Lymphocytes; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; STAT1 Transcription Factor; STAT5 Transcription Factor; Thyroid Neoplasms

2015
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
    Cancer research, 2015, Aug-01, Volume: 75, Issue:15

    Topics: Administration, Intravenous; Amino Acid Motifs; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Delivery Systems; Evans Blue; Gadolinium DTPA; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice, Nude; Mice, Transgenic; Niacinamide; Oligopeptides; Phenylurea Compounds; Sorafenib; Tissue Distribution

2015
Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells.
    Investigative ophthalmology & visual science, 2015, Volume: 56, Issue:9

    Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Amyloid Precursor Protein Secretases; Cell Movement; Cells, Cultured; DNA; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Herpesvirus 4, Human; Humans; Immunoblotting; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Retinal Pigment Epithelium; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Tumor Necrosis Factor-alpha; Vitreoretinopathy, Proliferative

2015
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
    Clinical journal of gastroenterology, 2015, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis

2015
Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
    Oncology reports, 2015, Volume: 34, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Meloxicam; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Thiazines; Thiazoles; Xenograft Model Antitumor Assays

2015
A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam.
    Neurotoxicology, 2015, Volume: 50

    Topics: Analgesics; Analysis of Variance; Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Imidazoles; Male; Neuralgia; Niacinamide; Pain Measurement; Pain Threshold; Phenylurea Compounds; Pyrroles; Rats; Rats, Sprague-Dawley; Reaction Time; Sorafenib; Time Factors

2015
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma.
    Yonsei medical journal, 2015, Volume: 56, Issue:5

    Topics: Aged; Antineoplastic Agents; Ascorbic Acid; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:6

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Disease Progression; Epithelial Cell Adhesion Molecule; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins

2015
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    European journal of haematology, 2016, Volume: 96, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retreatment; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome

2016
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Future oncology (London, England), 2015, Volume: 11, Issue:16

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2015
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Future oncology (London, England), 2015, Volume: 11, Issue:17

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Progression; Genetic Therapy; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A

2015
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboxymethylcellulose Sodium; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Immune System; Immunosuppressive Agents; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly I-C; Polylysine; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Toll-Like Receptor 3

2015
Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
    Journal of proteome research, 2015, Oct-02, Volume: 14, Issue:10

    Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Cell Line, Tumor; Cell Survival; Deuterium Exchange Measurement; Humans; Indoles; Isotope Labeling; MAP Kinase Signaling System; Mass Spectrometry; Molecular Dynamics Simulation; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Protein Structure, Secondary; Protein Structure, Tertiary; Proteolysis; Proteomics; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Trypsin; Vemurafenib

2015
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15 Suppl

    Topics: Azacitidine; Cell Line, Tumor; Decitabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis

2015
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
    Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:7

    Topics: Activating Transcription Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Cytochromes c; Gene Knockdown Techniques; Glioma; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitrophenols; Peptide Hydrolases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; STAT3 Transcription Factor; Sulfonamides; Tyrphostins

2015
[Molecular targeting treatment for thyroid cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib; Thyroid Neoplasms

2015
Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways.
    Natural product research, 2016, Volume: 30, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Curcumin; Dose-Response Relationship, Drug; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Thyroid Neoplasms

2016
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Flavonols; Humans; Immunohistochemistry; Melanoma; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
    American journal of hematology, 2015, Volume: 90, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Sorafenib; Survival Analysis; Transplantation, Homologous; Treatment Outcome

2015
LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; Sorafenib; Transplantation, Heterologous; Tumor Burden

2015
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    Oncotarget, 2015, Oct-06, Volume: 6, Issue:30

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays

2015
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
    Medicine, 2015, Volume: 94, Issue:34

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Treatment Outcome

2015
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
    International journal of cancer, 2016, Feb-15, Volume: 138, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Female; Gene Expression Profiling; Humans; Infant; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sorafenib; Transcriptome; Treatment Outcome; Young Adult

2016
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas.
    BMC cancer, 2015, Aug-28, Volume: 15

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Calcium-Binding Proteins; Disease Progression; Down-Regulation; Gene Deletion; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Neovascularization, Pathologic; Niacinamide; Papilloma; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2015
Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
    ACS applied materials & interfaces, 2015, Sep-16, Volume: 7, Issue:36

    Topics: Animals; Apoptosis; Calorimetry, Differential Scanning; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; Drug Liberation; Erythrocytes; Hemolysis; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liquid Crystals; Liver Neoplasms; Male; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Nanoparticles; Niacinamide; Phenylurea Compounds; Polymers; Rats; Rats, Sprague-Dawley; Sorafenib; Spectroscopy, Fourier Transform Infrared

2015
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome

2015
[Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:8

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Oct-01, Volume: 195, Issue:7

    Topics: Animals; Antineoplastic Agents; CD40 Ligand; Cell Proliferation; CTLA-4 Antigen; Female; Forkhead Transcription Factors; Humans; Immunotherapy; Interferon-gamma; Interleukin-17; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Interleukin-6; Jurkat Cells; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; NFATC Transcription Factors; Niacinamide; Ovalbumin; Peptide Fragments; Phenylurea Compounds; Promoter Regions, Genetic; Receptors, Antigen, T-Cell; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta

2015
An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Oncotarget, 2015, Sep-22, Volume: 6, Issue:28

    Topics: AC133 Antigen; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents; Aporphines; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Peptides; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA-Binding Proteins; Sorafenib; Survival Analysis; Time Factors; Transfection

2015
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
    Journal of oncology practice, 2015, Volume: 11, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2015
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.
    Archives of endocrinology and metabolism, 2015, Volume: 59, Issue:4

    Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Thyroidectomy

2015
Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
    Targeted oncology, 2016, Volume: 11, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2016
Treatment of intermediate-stage hepatocellular carcinoma.
    Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
Hepatocellular carcinoma: current questions and future directions.
    Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:3

    Topics: Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Drug Discovery; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2015
The role of sorafenib in hepatocellular carcinoma.
    Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Hypophosphatemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Research; Sorafenib; Treatment Failure; Treatment Outcome

2015
Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr
    BMC cancer, 2015, Sep-09, Volume: 15

    Topics: Adult; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Medullary; Cushing Syndrome; Diabetes Insipidus; Fatal Outcome; Humans; Hydrocortisone; Intussusception; Jejunal Diseases; Male; Niacinamide; Paraneoplastic Polyneuropathy; Phenylurea Compounds; Primary Dysautonomias; Sorafenib; Thyroid Neoplasms

2015
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
    Journal of virology, 2015, Volume: 89, Issue:22

    Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cyclic S-Oxides; Dasatinib; Epithelial-Mesenchymal Transition; Female; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imatinib Mesylate; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; RNA, Messenger; Sorafenib; Spheroids, Cellular; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Cells, Cultured

2015
NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
    Oncotarget, 2015, Oct-06, Volume: 6, Issue:30

    Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Doxycycline; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Mice, Nude; Microscopy, Fluorescence; Niacinamide; Nuclear Receptor Subfamily 4, Group A, Member 1; Phenylurea Compounds; Protein Binding; Proteolysis; RNA Interference; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2015
Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma.
    Ultrasound in medicine & biology, 2015, Volume: 41, Issue:12

    Topics: Animals; Antineoplastic Agents; Contrast Media; Disease Models, Animal; Feasibility Studies; Image Enhancement; Imaging, Three-Dimensional; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Reproducibility of Results; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2015
Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Apoptosis; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib

2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2016
The Eltrombopag antitumor effect on hepatocellular carcinoma.
    International journal of oncology, 2015, Volume: 47, Issue:5

    Topics: Apoptosis; Benzoates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrazines; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Receptors, Thrombopoietin; Sorafenib

2015
A Proteometric Analysis of Human Kinome: Insight into Discriminant Conformation-dependent Residues.
    ACS chemical biology, 2015, Dec-18, Volume: 10, Issue:12

    Topics: Animals; Binding Sites; Crystallography, X-Ray; Humans; Imatinib Mesylate; Least-Squares Analysis; Models, Molecular; Niacinamide; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Sorafenib

2015
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2015
Sorafenib-induced defective autophagy promotes cell death by necroptosis.
    Oncotarget, 2015, Nov-10, Volume: 6, Issue:35

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western; Cells, Cultured; Drug Resistance, Neoplasm; Embryo, Mammalian; Fibroblasts; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunoprecipitation; Male; Mice; Mice, Knockout; Microtubule-Associated Proteins; Necrosis; Niacinamide; Phagosomes; Phenylurea Compounds; Prostatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; RNA-Binding Proteins; Sorafenib; Tissue Array Analysis

2015
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
    Cancer biology & therapy, 2015, Volume: 16, Issue:11

    Topics: Antineoplastic Agents; Carboplatin; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Inhibitory Concentration 50; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Phenylurea Compounds; Sildenafil Citrate; Sorafenib

2015
Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.
    BioMed research international, 2015, Volume: 2015

    Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Perioperative Care; Peritoneum; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2015
Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
    JAMA dermatology, 2016, Volume: 152, Issue:2

    Topics: Aged; Antineoplastic Agents; Drug Eruptions; Erythema Multiforme; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.
    Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:4 Suppl 4

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms

2015
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
    Cancer, 2016, Jan-01, Volume: 122, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Risk Factors; SEER Program; Sorafenib; Sunitinib; Survival Analysis; United States

2016
Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells.
    ACS applied materials & interfaces, 2015, Oct-21, Volume: 7, Issue:41

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclodextrins; Drug Delivery Systems; Drug Liberation; Female; Flow Cytometry; Humans; Kidney; Liver; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Porosity; Rats; Silicon; Sorafenib; Spectroscopy, Fourier Transform Infrared

2015
The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.
    Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:12

    Topics: Humans; Indazoles; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib; Sulfonamides

2015
Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
    Clinical drug investigation, 2015, Volume: 35, Issue:11

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Humans; Japan; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2015
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Sorafenib; Venous Thrombosis; Yttrium Radioisotopes

2016
[Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2016, Volume: 26, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2016
Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival.
    Clinical transplantation, 2015, Volume: 29, Issue:12

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combined Modality Therapy; Follow-Up Studies; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Lymphocytes; Multivariate Analysis; Neoplasm Recurrence, Local; Neutrophils; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Survival Rate

2015
Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-01, Volume: 22, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Sorafenib; Tretinoin; Xenograft Model Antitumor Assays

2016
Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.
    Molecular medicine reports, 2015, Volume: 12, Issue:6

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorouracil; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-jun; Sorafenib

2015
[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatolenticular Degeneration; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Psoriasis; Recurrence; Sorafenib

2015
[Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:9

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib

2015
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Cancer medicine, 2015, Volume: 4, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Patient Compliance; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2015
Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
    Oncotarget, 2015, Nov-03, Volume: 6, Issue:34

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult

2015
Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
    The Tohoku journal of experimental medicine, 2015, Volume: 237, Issue:3

    Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Female; Half-Life; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Proportional Hazards Models; ROC Curve; Sorafenib; Time Factors; Withholding Treatment

2015
Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
    Acta biomaterialia, 2016, Volume: 29

    Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Hyaluronic Acid; Hydrogels; Interferon-alpha; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Tyramine; Xenograft Model Antitumor Assays

2016
A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Biochemical and biophysical research communications, 2015, Dec-25, Volume: 468, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Curcumin; Diffusion; Drug Synergism; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Niacinamide; Phenylurea Compounds; Polymers; Sorafenib; Treatment Outcome

2015
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Sorafenib; Stem Cell Transplantation

2016
Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo.
    Scientific reports, 2015, Oct-21, Volume: 5

    Topics: Animals; Apoptosis; Bone Neoplasms; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Humans; Mice; Mouth Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2015
Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2015
pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
    International journal of nanomedicine, 2015, Volume: 10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cations; Cell Proliferation; Chitosan; Drug Delivery Systems; Female; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liposomes; Mice; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib

2015
[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
    Hinyokika kiyo. Acta urologica Japonica, 2015, Volume: 61, Issue:9

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Myocardial Infarction; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:11

    Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2015
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    BMC research notes, 2015, Oct-26, Volume: 8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis

2015
Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
    Leukemia research, 2015, Volume: 39, Issue:12

    Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Metformin; Microtubule-Associated Proteins; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sorafenib; Tandem Repeat Sequences; TOR Serine-Threonine Kinases

2015
Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit.
    Molecules (Basel, Switzerland), 2015, Oct-23, Volume: 20, Issue:10

    Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Structure, Secondary; Protein Structure, Tertiary; Sorafenib; Structure-Activity Relationship; Sulfonylurea Compounds; Vascular Endothelial Growth Factor Receptor-2

2015
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:18

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2015
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
    Journal of hematology & oncology, 2015, Oct-29, Volume: 8

    Topics: Adipose Tissue; Adult; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Survival; Exosomes; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mesenchymal Stem Cells; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Microscopy, Confocal; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Xenograft Model Antitumor Assays

2015
Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Egypt; Female; Guideline Adherence; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Prospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2015
Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
    Oncotarget, 2015, Nov-17, Volume: 6, Issue:36

    Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Precursors; Sorafenib; Thymosin; Transfection

2015
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
    Oncotarget, 2016, Jan-12, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Movement; Cells, Cultured; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Flavonoids; Flavonols; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Melanoma; Mice, Nude; Mutation; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2016
Murine colitis treated with multitargeted tyrosine kinase inhibitors.
    The Journal of surgical research, 2016, Volume: 200, Issue:2

    Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2016
Quantification of Sorafenib in Human Serum by Competitive Enzyme-Linked Immunosorbent Assay.
    Biological & pharmaceutical bulletin, 2015, Volume: 38, Issue:11

    Topics: Animals; Antibodies; Antigens; Antineoplastic Agents; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Horseradish Peroxidase; Humans; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Serum Albumin, Bovine; Sorafenib

2015
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-1

2016
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:3

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Remission Induction; Republic of Korea; Retrospective Studies; Sorafenib

2015
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells.
    Biomacromolecules, 2015, Dec-14, Volume: 16, Issue:12

    Topics: Adamantane; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Survival; Cyclodextrins; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Erythrocytes; Hemolysis; Hepatocytes; Humans; Kinetics; Nanostructures; Niacinamide; Phenylurea Compounds; Sorafenib; Surface-Active Agents

2015
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
    Cancer, 2016, Feb-01, Volume: 122, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2016
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Oncotarget, 2016, Jan-19, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Fluorescent Antibody Technique; Follow-Up Studies; Humans; Immunoenzyme Techniques; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Sorafenib; Survival Rate; Tumor Cells, Cultured

2016
Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
    Journal of neurosurgery, 2016, Volume: 124, Issue:5

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Convection; Heterografts; Humans; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; STAT3 Transcription Factor; Transcriptional Activation

2016
Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.
    Cancer letters, 2016, Jan-28, Volume: 370, Issue:2

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Homeostasis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteins; Regulatory Factor X Transcription Factors; Sorafenib; Transcription Factors; Unfolded Protein Response

2016
A case series of anal melanoma including the results of treatment with imatinib in selected patients.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2016, Volume: 18, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Dacarbazine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Retrospective Studies; Sorafenib; Survival Rate

2016
Sorafenib and novel multikinase inhibitors in AML.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation.
    Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 31

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Female; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Membrane Potential, Mitochondrial; Mitochondria; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species; Sorafenib

2016
Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
    Journal of controlled release : official journal of the Controlled Release Society, 2016, Jan-10, Volume: 221

    Topics: Animals; Carbon Tetrachloride; Drug Carriers; Human Umbilical Vein Endothelial Cells; Lactic Acid; Liver; Liver Cirrhosis; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Polyglactin 910; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Kinase Inhibitors; Sorafenib

2016
In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Caenorhabditis elegans; Cell Line; Cell Survival; Disease Models, Animal; Female; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred C57BL; Microbial Sensitivity Tests; Niacinamide; Phenylurea Compounds; Sorafenib; Staphylococcal Infections; Staphylococcus epidermidis; Survival Analysis; Treatment Outcome

2016
Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.
    Oncotarget, 2015, Dec-22, Volume: 6, Issue:41

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytoplasmic Granules; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-2; Fluorescent Antibody Technique; Humans; In Situ Hybridization, Fluorescence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Sorafenib; Stress, Physiological; Transfection

2015
Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma.
    Discovery medicine, 2015, Volume: 20, Issue:110

    Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Green Fluorescent Proteins; Humans; Liver Neoplasms; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Octamer Transcription Factor-3; Phenylurea Compounds; Sorafenib; Spheroids, Cellular

2015
Surface bioengineering of diatomite based nanovectors for efficient intracellular uptake and drug delivery.
    Nanoscale, 2015, Dec-21, Volume: 7, Issue:47

    Topics: Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Diatomaceous Earth; Drug Carriers; Drug Delivery Systems; Erythrocytes; Hemolysis; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Microscopy, Confocal; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Propylamines; Silanes; Solubility; Sorafenib; Spectroscopy, Fourier Transform Infrared; Water

2015
Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
    Carbohydrate polymers, 2016, Jan-20, Volume: 136

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Female; Heparin; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Poloxamer; Sorafenib; Stomach Neoplasms

2016
Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.
    BMC gastroenterology, 2015, Nov-16, Volume: 15

    Topics: Angiogenic Proteins; Animals; Anti-Inflammatory Agents; Cytokines; Dimethylnitrosamine; Drug Therapy, Combination; Gadolinium; Hepatic Stellate Cells; Hepatocytes; Hydroxyproline; Kupffer Cells; Liver; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib

2015
Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.
    International journal of cancer, 2016, Apr-15, Volume: 138, Issue:8

    Topics: Animals; Antineoplastic Agents; Choline Kinase; Diffusion Magnetic Resonance Imaging; Female; Heterografts; Humans; Isoquinolines; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protons; Sorafenib; Sulfonamides

2016
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
    Journal of vascular and interventional radiology : JVIR, 2015, Volume: 26, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Gemcitabine; Humans; Niacinamide; Organoplatinum Compounds; Paclitaxel; Phenylurea Compounds; Pyridines; Radiation Tolerance; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes

2015
Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aporphines; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-beta; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Female; G2 Phase Cell Cycle Checkpoints; Humans; Liver Neoplasms; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2016
Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
    Cellular oncology (Dordrecht), 2016, Volume: 39, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Risk Factors; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult

2016
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 05-15, Volume: 22, Issue:10

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin E; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2016
Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
    Acta biochimica et biophysica Sinica, 2015, Volume: 47, Issue:12

    Topics: Animals; Aspirin; Benzylamines; Carcinoma, Hepatocellular; Cell Proliferation; Chemokine CXCL12; Cyclams; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; Sorafenib; Tumor Microenvironment

2015
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    BMC cancer, 2015, Nov-30, Volume: 15

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2015
Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways.
    Anti-cancer drugs, 2016, Volume: 27, Issue:3

    Topics: Animals; Apoptosis; Autophagy; Cell Line; Hepatic Stellate Cells; Humans; JNK Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Rats; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2016
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
    La Tunisie medicale, 2015, Volume: 93, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiography; Remission Induction; Sorafenib; Treatment Outcome

2015
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Journal of medical economics, 2016, Volume: 19, Issue:5

    Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib

2016
MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Cancer letters, 2016, Feb-28, Volume: 371, Issue:2

    Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; ras Proteins; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Sorafenib; Time Factors; Transfection; Xenograft Model Antitumor Assays

2016
The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
    Medicine, 2015, Volume: 94, Issue:49

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult

2015
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Gut, 2017, Volume: 66, Issue:3

    Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factors; Gene Expression; Gene Expression Profiling; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Receptor, Fibroblast Growth Factor, Type 1; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Somatomedins; Sorafenib; Spheroids, Cellular; Survival Rate; Xenograft Model Antitumor Assays

2017
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
    Journal of surgical oncology, 2016, Volume: 113, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Tumor Suppressor Protein p53

2016
Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5

    Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Flavonoids; Flavonols; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Mitochondria; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sorafenib; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2016
LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Smad3 Protein; Sorafenib; Xenograft Model Antitumor Assays

2016
Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.
    Cancer research, 2016, Jan-01, Volume: 76, Issue:1

    Topics: Animals; Cell Death; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Keratinocytes; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Niacinamide; Nuclear Receptor Subfamily 2, Group C, Member 2; Organic Anion Transporters; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Skin; Skin Diseases; Sorafenib; Transfection

2016
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Cancer letters, 2016, Feb-28, Volume: 371, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Activators; Humans; Liver Neoplasms; Mice, Nude; Niacinamide; Phenyl Ethers; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2016
Predictive factors for sorafenib-induced hand-foot skin reaction using ordered logistic regression analysis.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Jan-01, Volume: 73, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Logistic Models; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Retrospective Studies; Sorafenib; Young Adult

2016
Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
    Cancer letters, 2016, Feb-28, Volume: 371, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzoates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epoxide Hydrolases; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Genetic Predisposition to Disease; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Niacinamide; Oxylipins; Pancreatic Neoplasms; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Urea

2016
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment

2016
Sorafenib: osteonecrosis of the jaw.
    Prescrire international, 2015, Volume: 24, Issue:165

    Topics: Antineoplastic Agents; Humans; Jaw; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:4

    Topics: Aged; Algorithms; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Chi-Square Distribution; Decision Support Techniques; Female; France; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; ROC Curve; Sorafenib; Treatment Outcome

2016
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
    Oncotarget, 2016, Jan-26, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Hepatectomy; Hepatitis; Immunoenzyme Techniques; Inflammation; Liver Neoplasms; Liver Regeneration; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib

2016
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    Thyroid : official journal of the American Thyroid Association, 2016, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Outcome

2016
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
    International journal of clinical oncology, 2016, Volume: 21, Issue:4

    Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Polyethylene Glycols; Protein Precursors; Prothrombin; Recombinant Proteins; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A

2016
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.
    Oncology reports, 2016, Volume: 35, Issue:3

    Topics: Axitinib; Carcinoma, Renal Cell; Cell Communication; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Neoplastic Stem Cells; Niacinamide; Oxygen; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Microenvironment

2016
Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
    Molecular pharmaceutics, 2016, Feb-01, Volume: 13, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Dogs; Male; Niacinamide; Phenylurea Compounds; Polymers; Solubility; Sorafenib; Spectroscopy, Fourier Transform Infrared; Tablets; Tissue Distribution

2016
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Sorafenib; Time Factors; Withholding Treatment; Young Adult

2016
[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma].
    Zhonghua yi xue za zhi, 2015, Aug-11, Volume: 95, Issue:30

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2015
MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
[Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2015, Volume: 44, Issue:5

    Topics: Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Histones; Humans; Irinotecan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Sorafenib; Tumor Suppressor Protein p53

2015
A mixed DFT-MD methodology for the in silico development of drug releasing macrocycles. Calix and thia-calix[N]arenes as carriers for Bosutinib and Sorafenib.
    Journal of computational chemistry, 2016, Apr-15, Volume: 37, Issue:10

    Topics: Aniline Compounds; Calixarenes; Computer Simulation; Drug Carriers; Drug Liberation; Molecular Dynamics Simulation; Molecular Structure; Niacinamide; Nitriles; Phenylurea Compounds; Quantum Theory; Quinolines; Sorafenib

2016
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus
    European journal of radiology, 2016, Volume: 85, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2016
A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    The Keio journal of medicine, 2015, Volume: 64, Issue:4

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pancreatitis; Phenylurea Compounds; Sorafenib

2015
Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2016, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Hydrazones; Molecular Structure; Niacinamide; Phenylurea Compounds; Piperazines; Semicarbazones; Sorafenib

2016
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Current medical research and opinion, 2016, Volume: 32, Issue:4

    Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States

2016
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    Radiology, 2016, Volume: 279, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome

2016
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Radiography; Sorafenib; Treatment Outcome

2016
JAMA PATIENT PAGE. Treatment of Liver Cancer.
    JAMA, 2016, Jan-05, Volume: 315, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate

2016
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
    European urology, 2016, Volume: 70, Issue:3

    Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment

2016
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
    Cancer science, 2016, Volume: 107, Issue:4

    Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Metformin; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thioredoxins; Transcription Factors; Xenograft Model Antitumor Assays

2016
Early Radiation Toxicity from Yttrium-90 Radioembolization for Advanced Hepatocellular Carcinoma.
    American journal of respiratory and critical care medicine, 2016, Apr-01, Volume: 193, Issue:7

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Dyspnea; Embolization, Therapeutic; Hepatitis B virus; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Injury; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Radiation Exposure; Sorafenib; Ytterbium

2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2015
B-Raf Inhibition in the Clinic: Present and Future.
    Annual review of medicine, 2016, Volume: 67

    Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib

2016
DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Stomach Neoplasms; Tumor Burden

2016
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
    Oncotarget, 2016, Feb-09, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2016
Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.
    International journal of oncology, 2016, Volume: 48, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Bufanolides; Cell Cycle; Cell Movement; Cell Proliferation; Cell Survival; Chick Embryo; Cytokines; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Random Allocation; Rats; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2016
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Models, Molecular; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoid X Receptor alpha; Sorafenib; Sunitinib

2016
Heart failure associated with small molecule tyrosine kinase inhibitors.
    International journal of cardiology, 2016, Mar-01, Volume: 206

    Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib

2016
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
    BMC cancer, 2016, Jan-19, Volume: 16

    Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib; Thyroid Neoplasms

2016
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
    Cancer immunology, immunotherapy : CII, 2016, Volume: 65, Issue:3

    Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib

2016
Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, Feb-02, Volume: 113, Issue:5

    Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Proteomics; Sorafenib

2016
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Cancer science, 2016, Volume: 107, Issue:4

    Topics: Antibodies, Neutralizing; Apoptosis; Autocrine Communication; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; Sulfonamides

2016
Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
    Oncotarget, 2016, Feb-16, Volume: 7, Issue:7

    Topics: Apoptosis; Benzimidazoles; Blotting, Western; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2016
Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model.
    Biomaterials, 2016, Volume: 84

    Topics: Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Immunotherapy; Macrophages; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phototherapy; RAW 264.7 Cells; Sorafenib

2016
[Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome

2015
[Survival after Sorafenib Treatment for Advanced Recurrent Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Thrombosis; Treatment Outcome; Vena Cava, Inferior

2015
[Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diaphragm; Hepatectomy; Humans; Liver Neoplasms; Lung; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib

2015
[A Case of Multiple HCC with Vp2 and Vv3 Invasion Controlled by Multidisciplinary Treatment Including Surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cisplatin; Combined Modality Therapy; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Sorafenib

2015
[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Embolization, Therapeutic; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Powders; Sorafenib; Venous Thrombosis

2015
Transketolase counteracts oxidative stress to drive cancer development.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, Feb-09, Volume: 113, Issue:6

    Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Gene Knockdown Techniques; Glucose; Glutathione; Glycolysis; Humans; Liver Neoplasms; Male; Metabolome; Mice, Nude; Molecular Sequence Data; Niacinamide; Oxidative Stress; Pentose Phosphate Pathway; Peroxides; Phenylurea Compounds; Reactive Oxygen Species; RNA, Messenger; Sorafenib; Transketolase; Up-Regulation

2016
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
    Oncotarget, 2016, Feb-16, Volume: 7, Issue:7

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Ceramides; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucosyltransferases; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
    International journal of nanomedicine, 2016, Volume: 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Fluorescent Antibody Technique, Indirect; Humans; Male; Maleates; Micelles; Niacinamide; Phenylurea Compounds; Polystyrenes; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sorafenib; Tumor Cells, Cultured

2016
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
    BMJ open, 2016, Jan-27, Volume: 6, Issue:1

    Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib

2016
Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
    International journal of oncology, 2016, Volume: 48, Issue:4

    Topics: Anoikis; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Membrane Glycoproteins; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Sorafenib

2016
An improved approach for predicting drug-target interaction: proteochemometrics to molecular docking.
    Molecular bioSystems, 2016, Volume: 12, Issue:3

    Topics: Aldehyde Reductase; Anthracyclines; Antineoplastic Agents; Colchicine; Databases, Protein; Demecolcine; Drug Interactions; Models, Biological; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Proteomics; Reproducibility of Results; Sorafenib; Support Vector Machine

2016
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, Jan-29, Volume: 16

    Topics: Aged; Algorithms; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; raf Kinases; Remission Induction; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2016
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
    International journal of dermatology, 2016, Volume: 55, Issue:4

    Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Sulfonamides; Vemurafenib

2016
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:5

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Male; Mice; Models, Molecular; Niacinamide; p120 GTPase Activating Protein; Paired Box Transcription Factors; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Sorafenib

2016
Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
    Colloids and surfaces. B, Biointerfaces, 2016, May-01, Volume: 141

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Delivery Systems; Drug Liberation; Female; Gadolinium; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Mice; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; Treatment Outcome; Tumor Burden

2016
Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
    Journal of pharmaceutical sciences, 2016, Volume: 105, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Coumarins; Drug Compounding; Gold; Humans; Kidney Neoplasms; Lasers; Nanotubes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Serum Albumin; Solubility; Sorafenib

2016
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.
    BMC cancer, 2016, Feb-12, Volume: 16

    Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cation Transport Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organic Cation Transporter 1; Phenylurea Compounds; RNA, Messenger; Sorafenib

2016
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
    Oncogene, 2016, 09-15, Volume: 35, Issue:37

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays

2016
Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.
    Oncotarget, 2016, Mar-15, Volume: 7, Issue:11

    Topics: Antineoplastic Agents; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Indazoles; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Sorafenib; Sulfonamides

2016
[Treatment of refractory pulmonary metastases from hepatocellular carcinoma by transcatheter arterial chemoembolization using arsenic trioxide in combination with sorafinib].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib

2015
Sec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells.
    Apoptosis : an international journal on programmed cell death, 2016, Volume: 21, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Nerve Sheath Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Transcription, Genetic; Vesicular Transport Proteins

2016
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
    Oncotarget, 2016, Mar-22, Volume: 7, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Electrolytes; Female; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate

2016
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2016
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2016, Volume: 93

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2016
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Management; Drug-Related Side Effects and Adverse Reactions; Early Detection of Cancer; Europe; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pacific Islands; Phenylurea Compounds; Registries; Sorafenib; Young Adult

2016
Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:140

    Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cohort Studies; Embolization, Therapeutic; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Niacinamide; Patient Care Team; Phenylurea Compounds; Prospective Studies; Secondary Care Centers; Sorafenib; Treatment Outcome; Tumor Burden

2015
Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
    Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:3

    Topics: Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Posterior Leukoencephalopathy Syndrome; Salvage Therapy; Sorafenib

2016
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib

2017
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
    Cancer research and treatment, 2016, Volume: 48, Issue:4

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Republic of Korea; Sorafenib; Treatment Outcome

2016
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:8

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Logistic Models; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Retrospective Studies; Sorafenib; Spain; Survival Analysis; Yttrium Radioisotopes

2016
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
    BMC nephrology, 2016, Feb-25, Volume: 17

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Receptor-Like Protein Tyrosine Phosphatases, Class 4; Resveratrol; S Phase Cell Cycle Checkpoints; Signal Transduction; Sorafenib; STAT3 Transcription Factor; STAT5 Transcription Factor; Stilbenes

2016
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Cell communication and signaling : CCS, 2016, Feb-24, Volume: 14

    Topics: Adaptor Proteins, Signal Transducing; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Interaction Maps; Protein Kinase Inhibitors; Sorafenib; src-Family Kinases

2016
AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
    Oncotarget, 2016, Mar-29, Volume: 7, Issue:13

    Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays

2016
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Gastroenterology, 2016, Volume: 150, Issue:7

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Macrophages; Mice; Neutrophil Infiltration; Neutrophils; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Regulatory

2016
Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities.
    Molecules (Basel, Switzerland), 2016, Feb-26, Volume: 21, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Structure-Activity Relationship

2016
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
    Pediatric nephrology (Berlin, Germany), 2016, Volume: 31, Issue:6

    Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrexate; Nephrotic Syndrome; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proteinuria; Remission, Spontaneous; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Withholding Treatment

2016
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    Journal of gastroenterology, 2016, Volume: 51, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Child; Diarrhea; Disease Progression; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Hypertension; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Patient Acuity; Phenylurea Compounds; Product Surveillance, Postmarketing; Prospective Studies; Sex Factors; Sorafenib; Survival Rate; Withholding Treatment; Young Adult

2016
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Disease Models, Animal; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy, Adoptive; Interleukin-12 Subunit p35; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays

2016
New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin.
    Nutrition and cancer, 2016, Volume: 68, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Quercetin; Sorafenib; Tumor Suppressor Protein p53

2016
Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea.
    Journal of Korean medical science, 2016, Volume: 31, Issue:3

    Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Cross-Sectional Studies; Databases, Factual; Female; Humans; Insurance Claim Review; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Republic of Korea; Sorafenib

2016
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Oncotarget, 2016, Apr-12, Volume: 7, Issue:15

    Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Cells, Cultured

2016
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    Journal of hematology & oncology, 2016, Mar-08, Volume: 9

    Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays

2016
SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.
    Oncotarget, 2016, Apr-19, Volume: 7, Issue:16

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Xenograft Model Antitumor Assays

2016
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
    Nanomedicine : nanotechnology, biology, and medicine, 2016, Volume: 12, Issue:5

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Humans; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Polymers; Sorafenib

2016
Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
    Scientific reports, 2016, Mar-11, Volume: 6

    Topics: Adult; Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; RNA, Messenger; Signal Transduction; Sorafenib

2016
In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy.
    International journal of pharmaceutics, 2016, Apr-30, Volume: 503, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Drug Liberation; Embolization, Therapeutic; Female; Fibroblasts; Human Umbilical Vein Endothelial Cells; Mice, Inbred BALB C; Microspheres; Neoplasms; Niacinamide; Phenylurea Compounds; Polyesters; Sorafenib; Tumor Burden

2016
Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.
    Cellular and molecular neurobiology, 2016, Volume: 36, Issue:7

    Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Glioblastoma; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib

2016
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML.
    Annals of hematology, 2016, Volume: 95, Issue:6

    Topics: Alopecia; Antineoplastic Agents; Child, Preschool; Female; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Tissue Donors

2016
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult

2016
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Oncotarget, 2016, Jul-05, Volume: 7, Issue:27

    Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hepatitis B; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Proto-Oncogene Proteins c-raf; Recurrence; Retrospective Studies; Sorafenib

2016
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
    Medicine, 2016, Volume: 95, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiotherapy; Retrospective Studies; Sorafenib; Venous Thrombosis

2016
Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report.
    Medicine, 2016, Volume: 95, Issue:11

    Topics: Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Candidiasis; Carcinoma, Hepatocellular; Dose Fractionation, Radiation; Esophagitis; Fluconazole; Heartburn; Hiccup; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proton Pump Inhibitors; Sorafenib; Stomach Ulcer

2016
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
    Cancer biotherapy & radiopharmaceuticals, 2016, Volume: 31, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Sorafenib; Thrombosis; Treatment Outcome; Yttrium Radioisotopes

2016
pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
    Hormones & cancer, 2016, Volume: 7, Issue:3

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Endothelial Cells; Female; Gene Expression; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2016
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Targeted oncology, 2016, Volume: 11, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib

2016
Intracellular interactions of electrostatically mediated layer-by-layer assembled polyelectrolytes based sorafenib nanoparticles in oral cancer cells.
    Colloids and surfaces. B, Biointerfaces, 2016, Jul-01, Volume: 143

    Topics: Antineoplastic Agents; Apoptosis; Calcium Carbonate; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dextran Sulfate; DNA Fragmentation; Drug Carriers; Drug Compounding; Drug Liberation; Epithelial Cells; Humans; Kinetics; Mouth Mucosa; Nanoparticles; Niacinamide; Peptides; Phenylurea Compounds; Polyelectrolytes; Protein Kinase Inhibitors; Sorafenib; Static Electricity

2016
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
    Oncogene, 2016, 09-29, Volume: 35, Issue:39

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Morpholines; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays

2016
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:2

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Metallothionein; Mice, Nude; NF-E2-Related Factor 2; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
    Oncotarget, 2016, Apr-26, Volume: 7, Issue:17

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Proliferation; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib; Tumor Cells, Cultured; X-Rays

2016
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
    Oncotarget, 2016, Apr-26, Volume: 7, Issue:17

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.
    Nature reviews. Urology, 2016, Volume: 13, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2016
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
    Zhonghua nei ke za zhi, 2016, Apr-01, Volume: 55, Issue:4

    Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Remission Induction; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2016
Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
    Cancer biology & therapy, 2016, 06-02, Volume: 17, Issue:6

    Topics: Antineoplastic Agents; Female; Humans; Middle Aged; Niacinamide; Perivascular Epithelioid Cell Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Uterine Neoplasms

2016
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
    Anti-cancer drugs, 2016, Volume: 27, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays

2016
Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity.
    Free radical biology & medicine, 2016, Volume: 95

    Topics: Apoptosis; Ascorbic Acid; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Hydrogen Peroxide; Liver Neoplasms; Mitochondria; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    International journal of cancer, 2016, Aug-15, Volume: 139, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult

2016
Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
    Prescrire international, 2016, Volume: 25, Issue:168

    Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms

2016
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis

2016
Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:5

    Topics: Animals; Antineoplastic Agents; Computer Simulation; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Glucuronosyltransferase; Liver; Mice; Mice, Knockout; Models, Biological; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; UDP-Glucuronosyltransferase 1A9

2016
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    World journal of gastroenterology, 2016, Apr-07, Volume: 22, Issue:13

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Niacinamide; Odds Ratio; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis

2016
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib

2016
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:8

    Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Blood Vessels; Carcinoma, Hepatocellular; Contrast Media; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Osteopontin; Phenylurea Compounds; Repressor Proteins; Sequence Analysis, RNA; Signal Transduction; Sorafenib; Ultrasonography; Up-Regulation; Vascular Endothelial Growth Factor A; Vimentin; Zinc Finger E-box Binding Homeobox 2; Zinc Finger E-box-Binding Homeobox 1

2016
[Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:2

    Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib; Time Factors; Ultrasonography

2016
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
    Tumori, 2016, Nov-11, Volume: 102, Issue:Suppl. 2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Jaw; Liver Neoplasms; Male; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed

2016
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine

2016
Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor.
    Clinical and experimental medicine, 2017, Volume: 17, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents; beta Catenin; Cell Proliferation; Cyclin D1; Disease Models, Animal; Glutathione; Histocytochemistry; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rats; Sorafenib; Treatment Outcome

2017
Iron depletion enhances the effect of sorafenib in hepatocarcinoma.
    Cancer biology & therapy, 2016, 06-02, Volume: 17, Issue:6

    Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Iron; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis

2016
HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells.
    Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Stability; Signal Transduction; Sorafenib

2016
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Biochimica et biophysica acta, 2016, Volume: 1860, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2016
Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: 2-Methoxyestradiol; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP1A2; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, Estrogen; Sorafenib; Tumor Suppressor Protein p53

2016
[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Volume: 37, Issue:4

    Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Sorafenib; Treatment Outcome

2016
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
    World journal of gastroenterology, 2016, Apr-21, Volume: 22, Issue:15

    Topics: Administration, Oral; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2016
CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:5

    Topics: Animals; Carcinoma, Hepatocellular; Cell Differentiation; Cell Lineage; Chromatin; DNA Helicases; DNA-Binding Proteins; High-Throughput Nucleotide Sequencing; Liver Neoplasms; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Receptors, Estrogen; Sorafenib; Transcription Factors

2016
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
    Cell death & disease, 2016, Apr-21, Volume: 7

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Focal Adhesion Kinase 1; Galectin 1; Humans; Integrin alphaVbeta3; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Morpholines; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Sorafenib; Survival Rate

2016
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Blood, 2016, 06-09, Volume: 127, Issue:23

    Topics: Animals; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tandem Repeat Sequences; Tretinoin; Xenograft Model Antitumor Assays

2016
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Asian People; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Everolimus; Feasibility Studies; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Sorafenib; Young Adult

2016
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.
    Oncotarget, 2016, May-17, Volume: 7, Issue:20

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Nuclear Receptor Coactivator 3; Phenylurea Compounds; Signal Transduction; Sorafenib

2016
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
    Journal of gastroenterology, 2016, Volume: 51, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Product Surveillance, Postmarketing; Prospective Studies; Sorafenib; Treatment Outcome; Young Adult

2016
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.
    BMC gastroenterology, 2016, Apr-27, Volume: 16

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome

2016
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Hepatitis B; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Models, Economic; Niacinamide; Phenylurea Compounds; Quality of Life; Quality-Adjusted Life Years; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome

2016
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.
    Oncotarget, 2016, 06-28, Volume: 7, Issue:26

    Topics: Antineoplastic Agents; Capecitabine; Docetaxel; Drug Administration Schedule; Humans; Neoplasms; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pharmacovigilance; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taxoids; Treatment Outcome

2016
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucine; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib

2016
Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
    Oncotarget, 2016, Jul-05, Volume: 7, Issue:27

    Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Hep G2 Cells; Humans; K562 Cells; Liver Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Phosphorylation; Programmed Cell Death 1 Receptor; Signal Transduction; Sorafenib

2016
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
    Cancer letters, 2016, 07-28, Volume: 377, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; G2 Phase Cell Cycle Checkpoints; Genetic Predisposition to Disease; Glycolysis; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Pyruvates; Signal Transduction; Sorafenib; Tandem Repeat Sequences; Time Factors

2016
Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models.
    Nucleic acids research, 2016, 07-08, Volume: 44, Issue:W1

    Topics: Antineoplastic Agents; Breast Neoplasms; Computer Graphics; Computer Simulation; Drug Discovery; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Information Storage and Retrieval; Internet; Metabolic Networks and Pathways; Models, Statistical; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Signal Transduction; Software; Sorafenib

2016
Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis; Yttrium Radioisotopes

2016
[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2

    Topics: Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib; Treatment Outcome

2016
Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Cell Line, Tumor; Cell Proliferation; Genes, ras; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Receptors, Retinoic Acid; Sorafenib; Xanthones

2016
ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
    Journal of hepatology, 2016, Volume: 65, Issue:2

    Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, Adrenergic, beta-2; Signal Transduction; Sorafenib

2016
The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2016, Volume: 18, Issue:5

    Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2016
Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
    ACS applied materials & interfaces, 2016, 05-25, Volume: 8, Issue:20

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Delivery Systems; Hydrogen-Ion Concentration; Liver Neoplasms; Magnetic Resonance Imaging; Nanocomposites; Niacinamide; Phenylurea Compounds; Rats; Sorafenib

2016
Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
    Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:8

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome

2016
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Oncotarget, 2016, Jun-14, Volume: 7, Issue:24

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Antagonism; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphotransferases; Protein Precursors; Prothrombin; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2016
Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
    Future oncology (London, England), 2016, Volume: 12, Issue:15

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Sorafenib

2016
Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Eye Hemorrhage; Fundus Oculi; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice.
    Haematologica, 2016, Volume: 101, Issue:8

    Topics: Animals; Benzothiazoles; Drug Resistance; fms-Like Tyrosine Kinase 3; Gene Knock-In Techniques; Germ-Line Mutation; Humans; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured

2016
Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
    Journal of vascular and interventional radiology : JVIR, 2016, Volume: 27, Issue:7

    Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Feasibility Studies; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms, Experimental; Male; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Tissue Distribution; Vascular Endothelial Growth Factor A

2016
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
    Molecular cancer, 2016, 05-16, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Metallothionein; NF-E2-Related Factor 2; Niacinamide; Oxidation-Reduction; Oxidative Stress; Phenylurea Compounds; Prognosis; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Transcription, Genetic

2016
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
    The oncologist, 2016, Volume: 21, Issue:9

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2016
Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma.
    Oncotarget, 2016, Jul-26, Volume: 7, Issue:30

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Radiotherapy, Intensity-Modulated; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2016
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Radiation oncology (London, England), 2016, May-18, Volume: 11

    Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Markov Chains; Monte Carlo Method; Niacinamide; Phenylurea Compounds; Probability; Quality-Adjusted Life Years; Radiosurgery; Randomized Controlled Trials as Topic; Sorafenib; Taiwan

2016
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Cancer immunology research, 2016, Volume: 4, Issue:7

    Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cytotoxicity, Immunologic; Disease Models, Animal; Humans; Immunophenotyping; Immunotherapy; Immunotherapy, Adoptive; Killer Cells, Natural; Liver Neoplasms; Lymphocyte Activation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays

2016
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.
    Oncotarget, 2016, Jun-21, Volume: 7, Issue:25

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Macrophages; Male; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib

2016
Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.
    European journal of medicinal chemistry, 2016, Sep-14, Volume: 120

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lenalidomide; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Stem Cells; Thalidomide

2016
Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2016
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; France; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Analysis; United Kingdom; Young Adult

2016
Innovations and Improvements in Pharmacokinetic Models Based on Physiology.
    Current drug delivery, 2017, Volume: 14, Issue:2

    Topics: Animals; Humans; Liver; Mice; Models, Biological; Niacinamide; Phenylurea Compounds; Piperidines; Remifentanil; Sorafenib

2017
[Effective Prevention of Hand-Foot Syndrome by the Consumption of Dried Bonito Broth].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:4

    Topics: Aged; Antineoplastic Agents; Female; Fish Products; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    European urology, 2016, Volume: 70, Issue:6

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden

2016
Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma.
    BMC cancer, 2016, 05-31, Volume: 16

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Sorafenib; Treatment Outcome

2016
Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
    Oncotarget, 2016, Jun-28, Volume: 7, Issue:26

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Survival; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Humans; Integrin alphaVbeta3; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Osteopontin; Phenylurea Compounds; Prognosis; Risk; Signal Transduction; Sorafenib; Tumor Microenvironment

2016
Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
    Cancer medicine, 2016, Volume: 5, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Male; Neuroblastoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Retreatment; Sorafenib; Treatment Outcome

2016
Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases.
    Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate

2016
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
    European radiology, 2017, Volume: 27, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Survival Rate; Treatment Outcome; Venous Thrombosis

2017
Synthesis of thermosensitive magnetic nanocarrier for controlled sorafenib delivery.
    Materials science & engineering. C, Materials for biological applications, 2016, Oct-01, Volume: 67

    Topics: Acrylamides; Delayed-Action Preparations; Epoxy Compounds; Hot Temperature; Humans; Hydrogen-Ion Concentration; Magnetite Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
    The Journal of urology, 2016, Volume: 196, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Young Adult

2016
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 63

    Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neoplasms; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Sorafenib; Thyroid Neoplasms

2016
Silk-Elastinlike Protein Polymer Liquid Chemoembolic for Localized Release of Doxorubicin and Sorafenib.
    Molecular pharmaceutics, 2016, 08-01, Volume: 13, Issue:8

    Topics: Doxorubicin; Drug Liberation; Microscopy, Electron, Scanning; Niacinamide; Phenylurea Compounds; Polymers; Rheology; Silk; Sorafenib; Spectroscopy, Fourier Transform Infrared

2016
Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
    Journal of magnetic resonance imaging : JMRI, 2017, Volume: 45, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diffusion Magnetic Resonance Imaging; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Mice; Mice, Inbred BALB C; Motion; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2017
Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.
    CPT: pharmacometrics & systems pharmacology, 2016, Volume: 5, Issue:5

    Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Computer Simulation; Female; Humans; Liver Neoplasms; Male; Middle Aged; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
    Experimental and molecular pathology, 2016, Volume: 101, Issue:1

    Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Homeodomain Proteins; Humans; Immunohistochemistry; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Transcription Factors

2016
Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinacrine; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Transcription Factor RelA

2016
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
    International journal of nanomedicine, 2016, Volume: 11

    Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Drug Liberation; Female; Hemolysis; Humans; Inhibitory Concentration 50; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Suspensions; Tissue Distribution; Treatment Outcome; Veins

2016
Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
    Journal of gastrointestinal and liver diseases : JGLD, 2016, Volume: 25, Issue:2

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden

2016
Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.
    Journal of medical case reports, 2016, Jun-16, Volume: 10

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Time; Treatment Outcome

2016
Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2016
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
    Oncotarget, 2016, Jul-26, Volume: 7, Issue:30

    Topics: Animals; Cell Line, Tumor; Enzyme Activation; Fingolimod Hydrochloride; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Phosphatase 2; Sorafenib

2016
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
    Cell death & disease, 2016, 06-23, Volume: 7, Issue:6

    Topics: Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cell Survival; Computational Biology; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Transcription Factor RelB; Transcriptome; Young Adult

2016
Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.
    Journal of molecular medicine (Berlin, Germany), 2016, Volume: 94, Issue:10

    Topics: Adult; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Female; Fibroblasts; Humans; Keloid; Male; Middle Aged; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sincalide; Smad Proteins; Sorafenib; Transforming Growth Factor beta; Young Adult

2016
Last line therapy with sorafenib in colorectal cancer: A retrospective analysis.
    World journal of gastroenterology, 2016, Jun-21, Volume: 22, Issue:23

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Niacinamide; Off-Label Use; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Withholding Treatment

2016
Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome

2016
[Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus].
    Zhonghua yi xue za zhi, 2016, Jun-21, Volume: 96, Issue:23

    Topics: Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Endovascular Procedures; Humans; Iodine Radioisotopes; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Stents; Thrombosis; Treatment Outcome

2016
Receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy.
    International journal of nanomedicine, 2016, Volume: 11

    Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Death; Drug Carriers; Endocytosis; Folate Receptors, GPI-Anchored; Folic Acid; Graphite; Hemolysis; Humans; Hyperthermia, Induced; KB Cells; Male; Nanomedicine; Niacinamide; Phenylurea Compounds; Phototherapy; Rats; Sorafenib; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction

2016
Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
    Oncotarget, 2016, Aug-02, Volume: 7, Issue:31

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Glutathione S-Transferase pi; Glycogen Synthase Kinase 3; Humans; Liver Neoplasms; MAP Kinase Kinase 4; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; RNA, Messenger; Signal Transduction; Sirtuin 3; Sorafenib

2016
Severe adverse skin reaction and desensitization to sorafenib.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2016, Volume: 117, Issue:2

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Growth Processes; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immune Tolerance; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Urticaria; Young Adult

2016
Ablative Focused Ultrasound Synergistically Enhances Thermally Triggered Chemotherapy for Prostate Cancer in Vitro.
    Molecular pharmaceutics, 2016, 09-06, Volume: 13, Issue:9

    Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cryoelectron Microscopy; Drug Delivery Systems; High-Intensity Focused Ultrasound Ablation; Humans; Liposomes; Male; Microscopy, Confocal; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Sorafenib

2016
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
    Oncotarget, 2016, Aug-02, Volume: 7, Issue:31

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Female; Fibroblast Growth Factors; Gene Dosage; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Remission Induction; Retrospective Studies; Sequence Analysis, DNA; Sorafenib; Treatment Outcome

2016
miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
    Cancer science, 2016, Volume: 107, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; RNA Interference; Sorafenib; Tumor Suppressor Proteins

2016
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
    BMC cancer, 2016, 07-07, Volume: 16

    Topics: Aged; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Treatment Outcome

2016
Efficacy of lenvatinib in treating thyroid cancer.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:12

    Topics: Biomarkers; Calcitonin; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Half-Life; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroglobulin; Thyroid Neoplasms

2016
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
    Oncogene, 2017, 02-09, Volume: 36, Issue:6

    Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Female; Gene Knockout Techniques; HCT116 Cells; Heterografts; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transfection; Ubiquitin-Protein Ligases

2017
Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity.
    ChemMedChem, 2016, 08-05, Volume: 11, Issue:15

    Topics: Animals; Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Discoidin Domain Receptor 1; Drug Screening Assays, Antitumor; Humans; Male; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Receptor, trkA; Sorafenib; Vascular Endothelial Growth Factor Receptor-2

2016
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Cancer letters, 2016, 10-10, Volume: 381, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidinones; RNA Interference; RNAi Therapeutics; Sorafenib; Transfection; Wnt Signaling Pathway; Xenograft Model Antitumor Assays

2016
[Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2016
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
    World journal of gastroenterology, 2016, Jul-07, Volume: 22, Issue:25

    Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sirolimus; Sorafenib

2016
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
    British journal of haematology, 2016, Volume: 175, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult

2016
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3

    Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2016
Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells.
    Innate immunity, 2016, Volume: 22, Issue:7

    Topics: Animals; Bone Marrow Cells; Cell Differentiation; Cytokines; Dendritic Cells; Female; Humans; Immunomodulation; Liver Neoplasms; Liver Transplantation; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes

2016
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
    International urology and nephrology, 2016, Volume: 48, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult

2016
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
    Discovery medicine, 2016, Volume: 21, Issue:118

    Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magnetic Resonance Imaging; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Microwaves; Necrosis; Neoplasm, Residual; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Ultrasonography

2016
Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:11

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib

2016
Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
    International journal of cancer, 2016, 11-15, Volume: 139, Issue:10

    Topics: Animals; Cell Movement; Female; Indoles; Leukocytes; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Transendothelial and Transepithelial Migration

2016
Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.
    Oncology reports, 2016, Volume: 36, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Synergism; Flavonoids; Flow Cytometry; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
    Oncotarget, 2016, 09-27, Volume: 7, Issue:39

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Substitution; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Retreatment; Sorafenib; Time Factors; Treatment Outcome

2016
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.
    BMC cancer, 2016, 07-27, Volume: 16

    Topics: Carcinoma, Hepatocellular; Drug Eruptions; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Sorafenib; Treatment Outcome

2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors

2016
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
    Journal of hepatology, 2016, Volume: 65, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Registries; Sorafenib

2016
Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells.
    Scientific reports, 2016, 07-29, Volume: 6

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Genistein; Hepatocytes; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Sorafenib

2016
[Prediction and preventive strategies for recurrence after surgery for hepatocellular carcinoma].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, May-20, Volume: 24, Issue:5

    Topics: Biopsy; Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Immunotherapy; Interferons; Liver Neoplasms; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Osteopontin; Phenylurea Compounds; Sorafenib; Tumor Microenvironment

2016
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
    Scientific reports, 2016, 08-01, Volume: 6

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphoproteins; Prognosis; Protein Transport; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins

2016
Capecitabine in advanced hepatocellular carcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:10

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis

2016
Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
    Molecular carcinogenesis, 2017, Volume: 56, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Liver; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Prognosis; Repressor Proteins; Sorafenib; Wnt Proteins; Wnt Signaling Pathway

2017
[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Zhonghua nei ke za zhi, 2016, Aug-01, Volume: 55, Issue:8

    Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Secondary Prevention; Sorafenib; Survival Rate; Treatment Outcome

2016
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
    BMC cancer, 2016, 08-02, Volume: 16

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome

2016
Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
    Journal of pineal research, 2016, Volume: 61, Issue:3

    Topics: Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Melatonin; Mitophagy; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib

2016
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Cohort Studies; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Monte Carlo Method; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib

2016
The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Registries; Regression Analysis; Republic of Korea; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome; Young Adult

2016
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Decision-Making; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2016
Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
    Scientific reports, 2016, 08-04, Volume: 6

    Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Prospective Studies; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tissue Array Analysis; Vascular Endothelial Growth Factor Receptor-1

2016
Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
    Oncotarget, 2016, Nov-08, Volume: 7, Issue:45

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2016
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Genes, myc; Humans; Liver Neoplasms; Mice; Niacinamide; Nuclear Proteins; Oligopeptides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Transcription Initiation Site; Xenograft Model Antitumor Assays

2016
68Ga DOTATATE PET/CT in Differentiated Thyroid Carcinoma With Fibular Metastasis and Mixed Response to Sorafenib.
    Clinical nuclear medicine, 2016, Volume: 41, Issue:10

    Topics: Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2016
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.
    Targeted oncology, 2017, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Complications; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome

2017
Response to Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy by Borentain et al.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib

2016
The Limonoids TS3 and Rubescin E Induce Apoptosis in Human Hepatoma Cell Lines and Interfere with NF-κB Signaling.
    PloS one, 2016, Volume: 11, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Humans; Limonins; Liver Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib

2016
Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:5

    Topics: Angiopoietin-Like Protein 1; Angiopoietin-like Proteins; Angiopoietins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib

2016
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
    Pharmacogenomics, 2016, Volume: 17, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents; Female; Genotype; Glucuronosyltransferase; Humans; Liver Neoplasms; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib

2016
Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
    PloS one, 2016, Volume: 11, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2016
Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib.
    Anti-cancer drugs, 2016, Volume: 27, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate

2016
Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017, Volume: 19, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate

2017
Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Glioblastoma; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiation Tolerance; Signal Transduction; Sorafenib; X-Rays

2016
Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
    Biochemical pharmacology, 2016, Oct-15, Volume: 118

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase Inhibitors; Cell Death; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Drug Synergism; Enzyme Activation; Free Radical Scavengers; Humans; Liver Neoplasms; Niacinamide; Oleanolic Acid; Oxidative Stress; Phenylurea Compounds; Proteolysis; Reactive Oxygen Species; Sorafenib

2016
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    International journal of clinical oncology, 2017, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors

2017
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
    Progress in transplantation (Aliso Viejo, Calif.), 2016, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2016
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.
    BMC cancer, 2016, 08-24, Volume: 16

    Topics: Antineoplastic Agents; Chordoma; Graves Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2016
Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
    Oncotarget, 2016, Dec-13, Volume: 7, Issue:50

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; China; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2016
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Standard of Care; Survival Analysis; Treatment Outcome

2017
Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:4

    Topics: Child; Child, Preschool; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Tandem Repeat Sequences; Treatment Outcome

2017
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Oncotarget, 2016, Sep-27, Volume: 7, Issue:39

    Topics: Animals; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Movement; Colorectal Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial-Mesenchymal Transition; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Male; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; RNA Interference; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays

2016
The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition.
    Biochimica et biophysica acta, 2016, Volume: 1858, Issue:11

    Topics: Antineoplastic Agents; Ascorbic Acid; Cell Membrane; Cell Membrane Permeability; Cholesterol; Dithionite; Kinetics; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Phosphatidylcholines; Phosphatidylethanolamines; Pyridines; Sorafenib; Spin Labels; Staining and Labeling; Unilamellar Liposomes

2016
A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016, Oct-15, Volume: 1033-1034

    Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Dosage Forms; Niacinamide; Paclitaxel; Phenylurea Compounds; Piroxicam; Rabbits; Reproducibility of Results; Sorafenib; Ultraviolet Rays

2016
Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study.
    Scientific reports, 2016, 09-09, Volume: 6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; NADPH Oxidase 1; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
    Oncotarget, 2016, 11-15, Volume: 7, Issue:46

    Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Knockdown Techniques; Glioma; Humans; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Pyramidal Cells; Rats; Sorafenib; Temozolomide

2016
Substituted 2-hydroxy-N-(arylalkyl)benzamide sensitizes cancer cells to metabolic stress by disrupting actin cytoskeleton and inhibiting autophagic flux.
    Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 37

    Topics: Actin Cytoskeleton; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Niacinamide; Phenylalanine; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Stress, Physiological; Wound Healing

2016
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
    Oncotarget, 2016, 10-11, Volume: 7, Issue:41

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Inflammation; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib

2016
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Gastroenterology, 2016, Volume: 151, Issue:6

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Male; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Stem Cell Assay; Up-Regulation

2016
Sorafenib plus cisplatin for hepatocellular carcinoma.
    The Lancet. Oncology, 2016, Volume: 17, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome

2016
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.
    Oncology, 2016, Volume: 91, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Fever; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2016
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; London; Male; Middle Aged; Multivariate Analysis; Niacinamide; Odds Ratio; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

2017
Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.
    Archives of oral biology, 2017, Volume: 73

    Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Humans; Mouth Neoplasms; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Sorafenib; Staining and Labeling; Sulfonamides

2017
In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate.
    Journal of biomaterials science. Polymer edition, 2016, Volume: 27, Issue:17

    Topics: Acrylic Resins; alpha-Tocopherol; Animals; Cell Line, Tumor; Chemistry Techniques, Synthetic; Cystamine; Drug Carriers; Drug Liberation; Hemolysis; Humans; Hydrophobic and Hydrophilic Interactions; Male; Micelles; Nanostructures; Niacinamide; Oxidation-Reduction; Particle Size; Phenylurea Compounds; Rabbits; Rats; Sorafenib; Stereoisomerism

2016
Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Hepatic Stellate Cells; Humans; Integrin alpha3; Laminin; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured; Ubiquitination

2016
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
    Oncotarget, 2016, Nov-08, Volume: 7, Issue:45

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chordoma; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A

2016
Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
    Oncotarget, 2016, Oct-18, Volume: 7, Issue:42

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; Eosinophils; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Sorafenib; Young Adult

2016
Response of Malignant Thymoma to Sorafenib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016, Volume: 11, Issue:10

    Topics: Adult; Antineoplastic Agents; Female; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thymoma; Thymus Neoplasms; Treatment Outcome

2016
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    International journal of cancer, 2017, Jan-15, Volume: 140, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome

2017
The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
    EBioMedicine, 2016, Volume: 12

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2016
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
    Oncotarget, 2016, 11-08, Volume: 7, Issue:45

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Genetic Vectors; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; RNA, Long Noncoding; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2016
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Journal of experimental & clinical cancer research : CR, 2016, 09-30, Volume: 35, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Exosomes; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; Tumor Microenvironment

2016
Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2016, Volume: 39, Issue:5

    Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Cell Adhesion; Cell Movement; Chemokine CCL2; Chemokine CXCL11; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Humans; Kidney Tubules; Macrophages; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Niacinamide; Phenylurea Compounds; Receptors, CXCR3; RNA, Messenger; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Ureter; Ureteral Obstruction

2016
Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.
    Chinese medical journal, 2016, 10-20, Volume: 129, Issue:20

    Topics: Adult; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Thyroiditis

2016
Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma.
    Oncology reports, 2016, Volume: 36, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; RNA-Binding Proteins; Sorafenib; Young Adult

2016
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Cancer medicine, 2016, Volume: 5, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Erythrocyte Indices; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2016
Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2016, Nov-15, Volume: 23, Issue:12

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Ginkgo biloba; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Plant Extracts; Prospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2016
Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
    British journal of haematology, 2018, Volume: 180, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pregnancy; Pregnancy Complications, Neoplastic; Sorafenib; Treatment Outcome

2018
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Databases, Factual; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Medicare; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; SEER Program; Sorafenib; Survival Rate; United States

2017
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridazines; Retrospective Studies; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult

2017
Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
    Journal of magnetic resonance imaging : JMRI, 2017, Volume: 46, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Drug Monitoring; Early Detection of Cancer; Female; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2017
C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
    Applied microbiology and biotechnology, 2017, Volume: 101, Issue:4

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sorafenib; Sphingosine; TOR Serine-Threonine Kinases

2017
Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Cancer letters, 2017, 01-28, Volume: 385

    Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Receptors, Androgen; Signal Transduction; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2017
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Adenine; Animals; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Leucine; Lipid Metabolism; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2016
[Lenvatinib in radioiodine refractory thyroid carcinomas].
    Bulletin du cancer, 2016, Volume: 103, Issue:11

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Clinical Trials as Topic; Compassionate Use Trials; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms

2016
[Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].
    Bulletin du cancer, 2016, Volume: 103, Issue:11

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Diarrhea; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Practice Patterns, Nurses'; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib

2016
The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diethylnitrosamine; Doxorubicin; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms, Experimental; Male; Niacinamide; Phenylurea Compounds; Rats; Rats, Wistar; Serum Albumin; Sorafenib; Survival Rate

2017
Painful Rashes on the Palms and Soles.
    Annals of the Academy of Medicine, Singapore, 2016, Volume: 45, Issue:10

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.
    BMC cancer, 2016, 11-11, Volume: 16, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Social Behavior; Sorafenib; Treatment Outcome

2016
Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography.
    Journal of medical ultrasonics (2001), 2017, Volume: 44, Issue:1

    Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2017
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
    Oncology reports, 2017, Volume: 37, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle Proteins; Cell Line, Tumor; Disease-Free Survival; Everolimus; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Sunitinib; Treatment Outcome

2017
Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.
    Oncogene, 2017, 04-06, Volume: 36, Issue:14

    Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Interleukin-6; Kidney Neoplasms; Microarray Analysis; Niacinamide; Phenylurea Compounds; RNA, Long Noncoding; Signal Transduction; Sorafenib; STAT3 Transcription Factor

2017
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Gut, 2017, Volume: 66, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Drug Evaluation, Preclinical; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Retinoblastoma Binding Proteins; Sorafenib; Ubiquitin-Protein Ligases

2017
ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib.
    Xenobiotica; the fate of foreign compounds in biological systems, 2017, Volume: 47, Issue:11

    Topics: Antineoplastic Agents; HEK293 Cells; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sorafenib

2017
Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2017, Volume: 13, Issue:2

    Topics: Amides; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Picolinic Acids; Protein Conformation; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2017
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
    Molecular carcinogenesis, 2017, Volume: 56, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Quinolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Transforming Growth Factor beta

2017
NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.
    Oncotarget, 2016, Dec-27, Volume: 7, Issue:52

    Topics: Animals; Cell Line, Tumor; Cytarabine; DNA (Cytosine-5-)-Methyltransferase 1; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Polycomb Repressive Complex 1; Sorafenib

2016
Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Oncotarget, 2016, Dec-20, Volume: 7, Issue:51

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Survival; Chemoradiotherapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Promoter Regions, Genetic; Signal Transduction; Sorafenib; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays

2016
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 84

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Humans; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Resveratrol; Sorafenib; Stilbenes; Treatment Outcome

2016
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
    Yonsei medical journal, 2017, Volume: 58, Issue:1

    Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib

2017
Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
    Oncology reports, 2017, Volume: 37, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; GTPase-Activating Proteins; Humans; Liver Neoplasms; Male; Mice, Nude; Niacinamide; Phenylurea Compounds; RNA, Long Noncoding; Sorafenib; Xenograft Model Antitumor Assays

2017
Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
    Oncotarget, 2016, Dec-27, Volume: 7, Issue:52

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2016
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
    The Journal of surgical research, 2016, Volume: 206, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
    Chinese journal of cancer, 2016, Nov-25, Volume: 35, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
    Trials, 2016, 11-25, Volume: 17, Issue:1

    Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Time Factors; Treatment Outcome

2016
Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment.
    Cancer letters, 2017, 03-01, Volume: 388

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Glucose; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
    World journal of gastroenterology, 2016, Nov-14, Volume: 22, Issue:42

    Topics: Aged; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Phlebography; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis

2016
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
    Oncotarget, 2017, Jun-06, Volume: 8, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Young Adult

2017
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
    Virchows Archiv : an international journal of pathology, 2017, Volume: 470, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemokine CXCL12; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Hypoxia; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Sorafenib; Survival Analysis; Tissue Array Analysis; Young Adult

2017
Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.
    Cancer letters, 2017, 03-01, Volume: 388

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Neurotensin; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transfection

2017
Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
    International journal of molecular sciences, 2016, Dec-01, Volume: 17, Issue:12

    Topics: Animals; Caco-2 Cells; Cell Cycle Checkpoints; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib

2016
Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 86

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured

2017
Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.
    Gene expression, 2017, 02-10, Volume: 17, Issue:2

    Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Drug Synergism; G1 Phase; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Resting Phase, Cell Cycle; Sorafenib

2017
Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
    Gastroenterology, 2017, Volume: 152, Issue:5

    Topics: Animals; Benzimidazoles; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Cytoskeletal Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Neurofibromatosis 1; Genome-Wide Association Study; Hepatocytes; High-Throughput Nucleotide Sequencing; HMGA Proteins; HMGA2 Protein; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Nude; Mitogen-Activated Protein Kinases; Nerve Tissue Proteins; Niacinamide; Nitriles; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; ras Proteins; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2017
Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
    International journal of oncology, 2017, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Metformin; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017
Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2017, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Audit; Databases, Factual; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; United Kingdom; Young Adult

2017
Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Drug Synergism; Fucose; Fucosyltransferases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liposomes; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2016
Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Molecular biology reports, 2017, Volume: 44, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult

2017
MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.
    Journal of cellular physiology, 2017, Volume: 232, Issue:7

    Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Mas; Reproducibility of Results; Sorafenib; Up-Regulation

2017
Internal Structure and Preferential Protein Binding of Colloidal Aggregates.
    ACS chemical biology, 2017, 01-20, Volume: 12, Issue:1

    Topics: Bacterial Proteins; beta-Lactamases; Colloids; Coloring Agents; Congo Red; DNA; Dynamic Light Scattering; Estradiol; Fluoresceins; Fulvestrant; Niacinamide; Peptides; Phenylurea Compounds; Protein Binding; Protein Folding; Proteins; Ribosomal Proteins; Scattering, Small Angle; Sorafenib; Trypsin; Trypsin Inhibitors; X-Ray Diffraction

2017
Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
    Toxicology and applied pharmacology, 2017, Jan-15, Volume: 315

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Sorafenib; STAT3 Transcription Factor; Triterpenes

2017
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides

2017
Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 120, Issue:6

    Topics: Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chalcone; Chemoprevention; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Interaction Maps; Sorafenib; Vitamin K 1

2017
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 03-01, Volume: 28, Issue:3

    Topics: Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy.
    Bioconjugate chemistry, 2016, Dec-21, Volume: 27, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Liberation; HT29 Cells; Humans; Male; Matrix Metalloproteinase 2; Mice, Inbred BALB C; Nanoparticles; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Rats, Sprague-Dawley; Sorafenib; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays

2016
Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Anticancer research, 2017, Volume: 37, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Insulin; Interleukin-1beta; Liver Neoplasms; Niacinamide; Phenotype; Phenylurea Compounds; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Rabbits; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A

2017
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: Adolescent; Animals; Antineoplastic Agents; Biological Therapy; Bone Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; Molecular Targeted Therapy; Necrosis; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein Kinase Inhibitors; Salmonella typhimurium; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2017
Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
    Molecular medicine reports, 2017, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cardiotonic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Digitoxin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A

2017
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
    The American journal of case reports, 2017, Jan-03, Volume: 18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome

2017
Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund.
    BMJ (Clinical research ed.), 2017, 01-03, Volume: 356

    Topics: Advisory Committees; Antineoplastic Agents; Cost-Benefit Analysis; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; United Kingdom

2017
An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Journal of Korean medical science, 2017, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Down-Regulation; Female; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib; Survival Rate; Up-Regulation

2017
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.
    Autophagy, 2017, Mar-04, Volume: 13, Issue:3

    Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Disease Progression; Endometrial Neoplasms; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Humans; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2017
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
    BMC cancer, 2017, 01-05, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2017
Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
    Free radical biology & medicine, 2017, Volume: 104

    Topics: Amino Acid Transport System y+; Animals; Antioxidants; Apoptosis; Aspirin; Cell Line, Tumor; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glutathione; Head and Neck Neoplasms; Humans; Mice; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib; Xenograft Model Antitumor Assays

2017
CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?
    Gut, 2017, Volume: 66, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
    Tumori, 2017, May-12, Volume: 103, Issue:3

    Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
    Biochemical pharmacology, 2017, 04-01, Volume: 129

    Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides

2017
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Journal of experimental & clinical cancer research : CR, 2017, 01-09, Volume: 36, Issue:1

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fibroblast Growth Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Sorafenib; Up-Regulation

2017
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
    Oncotarget, 2017, Feb-14, Volume: 8, Issue:7

    Topics: Animals; Binding Sites; Blotting, Western; Carbazoles; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Gene Duplication; Humans; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tandem Repeat Sequences

2017
Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Animals; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cell Survival; Depsipeptides; Disease Models, Animal; Humans; Meningeal Neoplasms; Meningioma; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2017
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
    Molecular oncology, 2017, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Taxoids; Triple Negative Breast Neoplasms

2017
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
    European urology, 2017, Volume: 71, Issue:5

    Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk; Risk Assessment; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2017
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
    Oncotarget, 2017, Feb-21, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Sorafenib; Xenograft Model Antitumor Assays

2017
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
    Neoplasia (New York, N.Y.), 2017, Volume: 19, Issue:2

    Topics: Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Everolimus; GTPase-Activating Proteins; Kidney Neoplasms; Mice; Mice, Knockout; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis

2017
In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Jul-15, Volume: 23, Issue:14

    Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2017
MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
    Oncotarget, 2017, Feb-21, Volume: 8, Issue:8

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib

2017
Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.
    Cancer biology & therapy, 2017, Nov-02, Volume: 18, Issue:11

    Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib

2017
The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Databases, Factual; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Sorafenib

2017
Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 88

    Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Humans; Interferons; Interleukins; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice, Nude; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib

2017
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
    Oncotarget, 2017, Feb-28, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polypeptide N-acetylgalactosaminyltransferase; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2017
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
    European radiology, 2017, Volume: 27, Issue:9

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2017
[Treatment Experience with Sorafenib for Lung Metastases of Hepatocellular Carcinoma Complicated with Interstitial Pneumonia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2016
[A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2016
Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 04-01, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
    Gynecologic oncology, 2017, Volume: 145, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult

2017
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome

2017
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
    The Journal of biological chemistry, 2017, 04-21, Volume: 292, Issue:16

    Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Renal Cell; Caspase 8; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Flow Cytometry; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Conformation; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Sorafenib; TNF-Related Apoptosis-Inducing Ligand

2017
Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
    Nanoscale, 2017, Feb-23, Volume: 9, Issue:8

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; Glucans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    International journal of clinical pharmacology and therapeutics, 2017, Volume: 55, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Sorafenib

2017
Intracellular responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, 03-10, Volume: 249

    Topics: Antineoplastic Agents; Cell Line; Click Chemistry; Cross-Linking Reagents; Delayed-Action Preparations; DNA; Drug Liberation; Fluoresceins; Fluorescent Dyes; Humans; Maleic Anhydrides; Nanocomposites; Nanoparticles; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Polyethyleneimine; Polyvinyls; Porosity; Silicon; Sorafenib

2017
Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Cancer letters, 2017, 04-28, Volume: 392

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Dual Specificity Phosphatase 1; Dual Specificity Phosphatase 6; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; raf Kinases; Signal Transduction; Sorafenib; Time Factors

2017
Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
    Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Aortic Aneurysm, Abdominal; Aortic Dissection; Carcinoma, Hepatocellular; Endovascular Procedures; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Stents; Treatment Outcome

2017
Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Molecular oncology, 2017, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Male; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Signal Transduction; Sorafenib

2017
Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix.
    Drug delivery, 2017, Volume: 24, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Lactose; Male; Methylcellulose; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamines; Polyethylene Glycols; Polymers; Random Allocation; Rats; Rats, Sprague-Dawley; Sorafenib; Tumor Burden

2017
Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
    The oncologist, 2017, Volume: 22, Issue:2

    Topics: Cohort Studies; Female; Humans; Hypertension; Hypothyroidism; Indoles; Male; Middle Aged; Niacinamide; Pharmacoepidemiology; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2017
Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
    Journal of pineal research, 2017, Volume: 62, Issue:3

    Topics: Anthracenes; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; MAP Kinase Kinase 4; Melatonin; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib

2017
The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.
    Oncotarget, 2017, Feb-28, Volume: 8, Issue:9

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cell Membrane; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Octamer Transcription Factor-1; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib

2017
Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:6

    Topics: Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Energy Metabolism; Humans; Liver Neoplasms; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Sulfonamides

2017
Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma.
    Anticancer research, 2017, Volume: 37, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Liver Transplantation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome

2017
Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prealbumin; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Serum Albumin, Human; Sorafenib; Sunitinib; Treatment Outcome

2017
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
    Leukemia, 2017, Volume: 31, Issue:10

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Deoxyglucose; fms-Like Tyrosine Kinase 3; Glycolysis; Hematopoietic Stem Cells; Hexokinase; Humans; Hydrocarbons, Brominated; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Microsatellite Repeats; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Propionates; Proto-Oncogene Proteins c-akt; Sorafenib

2017
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
    Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Postoperative Care; Recurrence; Retreatment; Sorafenib; Treatment Outcome

2017
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
    International journal of cancer, 2017, 05-15, Volume: 140, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Mucins; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Tumor Cells, Cultured

2017
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
    Oncotarget, 2017, May-30, Volume: 8, Issue:22

    Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Inflammation; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk; Sorafenib; Survival Analysis

2017
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
    Head & neck, 2017, Volume: 39, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Radiation-Sensitizing Agents; Risk Assessment; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib

2017
Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-01, Volume: 23, Issue:15

    Topics: Adult; Aged; Animals; Biomarkers, Tumor; Blood Vessels; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Mice; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Receptors, CXCR4; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2017
Prostaglandin E
    Biochemical and biophysical research communications, 2017, 04-01, Volume: 485, Issue:2

    Topics: Alprostadil; Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Hand-Foot Syndrome; Humans; Keratinocytes; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Skin; Sorafenib; STAT3 Transcription Factor

2017
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Oncology, 2017, Volume: 92, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Time-to-Treatment; Treatment Outcome

2017
Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation; Histones; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2017
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis

2017
Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib.
    Oncology reports, 2017, Volume: 37, Issue:4

    Topics: Angiogenesis Inducing Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Homeodomain Proteins; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation

2017
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Cell Surface; Sorafenib; Sunitinib; Treatment Outcome

2017
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cytokine, 2017, Volume: 95

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Female; Hepatitis B; Humans; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Risk Factors; Sorafenib

2017
Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Injections, Intravenous; Mice; Molecular Structure; Nanoparticles; Niacinamide; Organophosphorus Compounds; Paclitaxel; Phenylurea Compounds; Polymers; RNA, Small Interfering; Sorafenib; Structure-Activity Relationship; Survival Rate

2017
Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
    Radiology, 2017, Volume: 284, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Contrast Media; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2017
Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
    Endocrine-related cancer, 2017, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Salvage Therapy; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Failure

2017
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.
    BioMed research international, 2017, Volume: 2017

    Topics: Bone Neoplasms; Carcinoma, Renal Cell; Demography; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib

2017
Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models.
    Acta radiologica (Stockholm, Sweden : 1987), 2017, Volume: 58, Issue:9

    Topics: Animals; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Heterografts; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Oncology research, 2017, Nov-02, Volume: 25, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Female; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases

2017
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
    Scientific reports, 2017, 03-09, Volume: 7

    Topics: Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line; Drug Delivery Systems; Humans; Liver Neoplasms; Mice; Nanoparticles; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib

2017
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Gastroenterology, 2017, Volume: 152, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Chaperonins; Computational Biology; Computer Simulation; Databases, Genetic; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Ethanolamine; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hep G2 Cells; HSP90 Heat-Shock Proteins; Humans; Liver Neoplasms; Male; Molecular Chaperones; Niacinamide; Niclosamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Time Factors; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays

2017
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib

2017
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Carcinoma, Hepatocellular; DNA; Drug Monitoring; Female; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2017
Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2017, Volume: 20, Issue:3

    Topics: Aged; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Hepatocellular; Cohort Studies; Cost-Benefit Analysis; Embolization, Therapeutic; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib; Survival

2017
Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:12

    Topics: Aged; Albuminuria; Antineoplastic Agents; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Failure

2017
Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2017, Volume: 40, Issue:8

    Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Blood Pressure; Carotid Arteries; Cohort Studies; Cross-Sectional Studies; Female; Humans; Indoles; Male; Manometry; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pulse Wave Analysis; Pyrroles; Sorafenib; Sunitinib; Vascular Stiffness

2017
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.
    Pulmonary pharmacology & therapeutics, 2017, Volume: 44

    Topics: Adolescent; Adult; Arterial Pressure; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Treatment Outcome

2017
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
    American journal of surgery, 2017, Volume: 213, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Registries; Sorafenib

2017
Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma.
    Scientific reports, 2017, 03-21, Volume: 7

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Diethylnitrosamine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Rats, Wistar; Scorpions; Signal Transduction; Sorafenib; Spider Venoms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor Receptor-2

2017
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Niacinamide; Osteopontin; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Mas; RNA Interference; RNA, Small Interfering; Sorafenib

2017
Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Failure; Treatment Outcome

2017
Rational drug design of indazole-based diarylurea derivatives as anticancer agents.
    Chemical biology & drug design, 2017, Volume: 90, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer-Aided Design; Drug Design; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Indazoles; Molecular Docking Simulation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib; Structure-Activity Relationship; Urea

2017
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:6

    Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing

2017
Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
    Nanomedicine (London, England), 2017, Volume: 12, Issue:8

    Topics: Animals; Carcinoma, Hepatocellular; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2017
Painful skin reaction.
    Emergency medicine journal : EMJ, 2017, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Emergency Service, Hospital; Hand-Foot Syndrome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib

2017
TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
    Oncology reports, 2017, Volume: 37, Issue:4

    Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Exome; Female; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins c-ret; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53

2017
Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
    Oncology reports, 2017, Volume: 37, Issue:4

    Topics: 3' Untranslated Regions; Adenine Nucleotide Translocator 2; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Male; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib; Up-Regulation

2017
3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Anoikis; Antineoplastic Agents; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyruvates; Reactive Oxygen Species; Sorafenib

2017
Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor.
    Scientific reports, 2017, 04-03, Volume: 7, Issue:1

    Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Chemoembolization, Therapeutic; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Liberation; Liver Neoplasms; Magnetic Resonance Imaging; Male; Materials Testing; Microspheres; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome; Triiodobenzoic Acids; Xenograft Model Antitumor Assays

2017
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Cancer letters, 2017, 07-10, Volume: 398

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Neoplasm; Histone Demethylases; Humans; Liver Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Pargyline; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Time Factors; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays

2017
Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
    The American journal of gastroenterology, 2017, Volume: 112, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
    Urologic oncology, 2017, Volume: 35, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult

2017
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Cancer, 2017, Aug-01, Volume: 123, Issue:15

    Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Homologous; Treatment Outcome; Young Adult

2017
Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".
    Pulmonary pharmacology & therapeutics, 2017, Volume: 45

    Topics: Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
    Advances in therapy, 2017, Volume: 34, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome

2017
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:2

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Taiwan; Time Factors; Treatment Outcome

2018
Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
    Oncotarget, 2017, May-02, Volume: 8, Issue:18

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; Mice; Niacinamide; NIMA-Interacting Peptidylprolyl Isomerase; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays

2017
In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
    Oncotarget, 2017, Jun-27, Volume: 8, Issue:26

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Pharmacogenomic Variants; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Sorafenib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult

2017
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
    Oncotarget, 2017, May-09, Volume: 8, Issue:19

    Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Disease Models, Animal; DNA; Doxorubicin; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Osteosarcoma; Phenylurea Compounds; RNA; Sorafenib; Xenograft Model Antitumor Assays

2017
Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
    Oncotarget, 2017, Apr-04, Volume: 8, Issue:14

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Rats; Rats, Wistar; Signal Transduction; Sorafenib

2017
Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
    Oncotarget, 2017, Mar-21, Volume: 8, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins pp60(c-src); Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017
Immune oncology in hepatocellular carcinoma-hype and hope.
    Lancet (London, England), 2017, Jun-24, Volume: 389, Issue:10088

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2017
Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cohort Studies; Disease Models, Animal; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Mice, Inbred BALB C; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Disulfide-Isomerases; Random Allocation; RNA, Messenger; Sorafenib; Statistics, Nonparametric; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017
Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
    Medicine, 2017, Volume: 96, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Tumor Burden

2017
Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
    Molecular & cellular proteomics : MCP, 2017, Volume: 16, Issue:7

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; fms-Like Tyrosine Kinase 3; Gene Regulatory Networks; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Sorafenib

2017
Management of hepatocellular carcinoma recurrence after liver transplant is far from perfect.
    American journal of surgery, 2018, Volume: 216, Issue:2

    Topics: Adult; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Registries; Sorafenib

2018
Ferroptosis and Cell Death Analysis by Flow Cytometry.
    Methods in molecular biology (Clifton, N.J.), 2017, Volume: 1601

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dactinomycin; Flow Cytometry; Humans; Indicators and Reagents; Iron; Necrosis; Niacinamide; Phenylurea Compounds; Piperazines; Propidium; Rats; Sorafenib

2017
Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.
    Cell death & disease, 2017, 05-04, Volume: 8, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dioxygenases; Disease Progression; Histone Demethylases; Histones; Humans; Ikaros Transcription Factor; Liver Neoplasms; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Signal Transduction; Sorafenib; Transplantation, Heterologous

2017
Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
    Journal of cellular physiology, 2018, Volume: 233, Issue:2

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Fasting; Gene Expression Regulation, Neoplastic; Glucose; Hep G2 Cells; Hepatic Stellate Cells; Humans; Lipopolysaccharides; Liver Cirrhosis, Experimental; Liver Neoplasms; Mice, Inbred C57BL; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Sorafenib; Time Factors

2018
Editorial: sorafenib toxicity, a biomarker of effect?
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2017
Editorial: sorafenib toxicity, a biomarker of effect? Authors' reply.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:11

    Topics: Biomarkers; Humans; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
    Pathology, research and practice, 2017, Volume: 213, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; GTP-Binding Proteins; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Survival Rate; Up-Regulation; Young Adult

2017
Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
    Anticancer research, 2017, Volume: 37, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult

2017
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 79

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2017
Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Thyroid : official journal of the American Thyroid Association, 2017, Volume: 27, Issue:8

    Topics: Aged; Antineoplastic Agents; Cell Differentiation; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Monte Carlo Method; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality of Life; Quinolines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Tumor Burden; United States

2017
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.
    Journal of pharmaceutical and biomedical analysis, 2017, Aug-05, Volume: 142

    Topics: Chromatography, Liquid; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tandem Mass Spectrometry

2017
[Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2017, Volume: 33, Issue:5

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Macrophages; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Immortal time bias or sorafenib effect in elderly patients with HCC?
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:2

    Topics: Aged; Antineoplastic Agents; Bias; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
    The Journal of pharmacology and experimental therapeutics, 2017, Volume: 362, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays

2017
Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
    Cancer research and treatment, 2018, Volume: 50, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2018
Midostaurin Gets FDA Nod for AML.
    Cancer discovery, 2017, Volume: 7, Issue:7

    Topics: Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Staurosporine; Treatment Outcome; United States; United States Food and Drug Administration

2017
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Biochemical and biophysical research communications, 2017, 07-15, Volume: 489, Issue:1

    Topics: Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imidazoles; Mutation; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured

2017
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
    Oncotarget, 2017, Jul-11, Volume: 8, Issue:28

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; MAP Kinase Signaling System; Membrane Proteins; Molecular Targeted Therapy; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat

2017
Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.
    Phytotherapy research : PTR, 2017, Volume: 31, Issue:7

    Topics: Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Humans; Niacinamide; Panax; Phenylurea Compounds; Phosphorylation; Plant Extracts; Proto-Oncogene Proteins c-jun; Sorafenib; Vascular Endothelial Growth Factor A

2017
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
    Stem cell research & therapy, 2017, 05-25, Volume: 8, Issue:1

    Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred NOD; Mice, SCID; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Sorafenib; Time Factors

2017
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Oncotarget, 2017, Jul-18, Volume: 8, Issue:29

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome

2017
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).
    Molecular & cellular proteomics : MCP, 2017, Volume: 16, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Female; Glycoproteins; Humans; Immunoglobulin J-Chains; Liver Neoplasms; Male; Mass Spectrometry; Middle Aged; Niacinamide; Phenylurea Compounds; Precision Medicine; Proteomics; Receptors, Scavenger; Retrospective Studies; Scavenger Receptors, Class B; Sorafenib; Survival Analysis; Treatment Outcome

2017
Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
    International journal of oncology, 2017, Volume: 51, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2017
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:5

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib

2017
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.
    The Journal of clinical endocrinology and metabolism, 2017, 08-01, Volume: 102, Issue:8

    Topics: Aged; Amino Acid Transport Systems, Neutral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chlorocebus aethiops; Cohort Studies; COS Cells; Female; Humans; In Vitro Techniques; Liver Neoplasms; Male; Middle Aged; Monocarboxylic Acid Transporters; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Symporters; Thyrotropin; Thyroxine; Triiodothyronine

2017
Value-Based pricing and the end of pharmaceutical pricing as we know it? A case study on sorafenib and axitinib.
    Pharmacological research, 2017, Volume: 124

    Topics: Axitinib; Humans; Imidazoles; Indazoles; Niacinamide; Pharmaceutical Preparations; Phenylurea Compounds; Sorafenib

2017
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
    PloS one, 2017, Volume: 12, Issue:6

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Deubiquitinating Enzyme CYLD; Dose-Response Relationship, Drug; Drug Combinations; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Inhibitor of Differentiation Protein 1; Kidney Neoplasms; Male; Mice; Mice, SCID; Naphthoquinones; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Signal Transduction; Sorafenib; Survivin; Tumor Suppressor Proteins; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays

2017
Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
    European journal of radiology, 2017, Volume: 90

    Topics: Blood Volume; Carcinoma, Hepatocellular; Feasibility Studies; Humans; Liver Neoplasms; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Sorafenib; Tomography, Spiral Computed

2017
PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Molecular cancer research : MCR, 2017, Volume: 15, Issue:9

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutamine; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; PPAR delta; Random Allocation; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2017
Temozolomide and sorafenib as programmed cell death inducers of human glioma cells.
    Pharmacological reports : PR, 2017, Volume: 69, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Phenylurea Compounds; RNA Interference; Sorafenib; Temozolomide

2017
Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model.
    Cardiovascular and interventional radiology, 2017, Volume: 40, Issue:11

    Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Drug Administration Schedule; Embolization, Therapeutic; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib

2017
Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2017, Volume: 21, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2017
Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; France; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib

2017
Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
    Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Humans; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib; Thyroid Neoplasms; TOR Serine-Threonine Kinases

2017
Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers.
    International journal of pharmaceutics, 2017, Aug-07, Volume: 528, Issue:1-2

    Topics: Asialoglycoprotein Receptor; Dendrimers; Disaccharides; Drug Carriers; Fluorescein-5-isothiocyanate; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib.
    Cell chemical biology, 2017, Jul-20, Volume: 24, Issue:7

    Topics: Allosteric Regulation; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Binding Sites; Catalytic Domain; Cell-Free System; Enzyme Activation; HEK293 Cells; HeLa Cells; Humans; Indans; Indoles; Mutagenesis, Site-Directed; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Serine-Threonine Kinases; Pyrimidines; Sorafenib; src-Family Kinases; Sulfonamides

2017
Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
    Molecular medicine reports, 2017, Volume: 16, Issue:2

    Topics: Basigin; Cell Line, Tumor; Cell Movement; Down-Regulation; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Female; Humans; Hyaluronan Receptors; Hyaluronan Synthases; Hyaluronic Acid; MAP Kinase Signaling System; Neoplasm Invasiveness; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib

2017
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Oncology reports, 2017, Volume: 38, Issue:2

    Topics: Apoptosis; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; Molecular Targeted Therapy; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; STAT3 Transcription Factor

2017
The significance of TIMD4 expression in clear cell renal cell carcinoma.
    Medical molecular morphology, 2017, Volume: 50, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Kidney Neoplasms; Male; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; RNA, Small Interfering; Sorafenib

2017
Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats.
    Molecules (Basel, Switzerland), 2017, Jun-22, Volume: 22, Issue:7

    Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Herb-Drug Interactions; Liver; Male; Medicine, Chinese Traditional; Niacinamide; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Sorafenib

2017
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:6

    Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2017
Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cancer letters, 2017, 09-10, Volume: 403

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Quassins; Sorafenib; Time Factors; Transcription, Genetic; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays

2017
Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
    Journal of hepatology, 2017, Volume: 67, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Hong Kong; Humans; Liver Neoplasms; Niacinamide; Pharmacogenomic Testing; Phenylurea Compounds; Sorafenib; Stearoyl-CoA Desaturase; Survival Analysis

2017
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.
    Gut and liver, 2017, Sep-15, Volume: 11, Issue:5

    Topics: Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Risk Factors; ROC Curve; Severity of Illness Index; Sorafenib; Survival Rate; Withholding Treatment

2017
Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.
    Immunotherapy, 2017, Volume: 9, Issue:8

    Topics: Carcinoma, Renal Cell; Cytokine-Induced Killer Cells; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Desmoid Tumors and Celecoxib with Sorafenib.
    The New England journal of medicine, 2017, 06-29, Volume: 376, Issue:26

    Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2017
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.
    Cell death & disease, 2017, 06-29, Volume: 8, Issue:6

    Topics: Animals; Apoptosis; Cell Death; Disease Models, Animal; Humans; Inflammation; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinases; Receptor-Interacting Protein Serine-Threonine Kinases; Reperfusion Injury; Sorafenib; Tumor Necrosis Factor-alpha

2017
Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response.
    The Journal of biological chemistry, 2017, 09-08, Volume: 292, Issue:36

    Topics: Cells, Cultured; Electron Transport; Electron Transport Complex II; Electron Transport Complex III; HEK293 Cells; Humans; Mitochondria; Mitochondrial Proton-Translocating ATPases; Niacinamide; Phenylurea Compounds; Protein Kinases; Sorafenib; Ubiquitin-Protein Ligases

2017
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Digestive diseases (Basel, Switzerland), 2018, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Liver Neoplasms; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult

2018
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.
    Oncology, 2017, Volume: 93, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; United States

2017
Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
    Cancer letters, 2017, 10-10, Volume: 406

    Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Regulatory-Associated Protein of mTOR; Sorafenib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2017
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Oct-01, Volume: 23, Issue:19

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib

2017
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
    Cancer science, 2017, Volume: 108, Issue:9

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Disease Progression; Enzyme Activation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperthermia, Induced; Liver Neoplasms, Experimental; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vitamin K 1; Xenograft Model Antitumor Assays

2017
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; France; Hand-Foot Syndrome; Humans; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2017
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:6

    Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Cell Self Renewal; Cell Transformation, Neoplastic; Chromosomal Instability; Chronic Disease; Female; Humans; Inflammation; Interleukin-6; Keratin-19; Liver; Liver Neoplasms; Macrophages; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Rats, Wistar; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha

2017
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A

2017
Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases.
    Medicine, 2017, Volume: 96, Issue:29

    Topics: Adult; Aged; Antineoplastic Agents; Blood Vessel Prosthesis; End Stage Liver Disease; Female; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Sorafenib; Treatment Outcome; Young Adult

2017
Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, Jul-20, Volume: 50, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Interleukin-27; Niacinamide; Phenylurea Compounds; Sorafenib; Urinary Bladder Neoplasms

2017
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
    Current medical research and opinion, 2017, Volume: 33, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib

2017
Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.
    European radiology, 2018, Volume: 28, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Sorafenib

2018
A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
    EBioMedicine, 2017, Volume: 22

    Topics: Abies; Animals; Binding Sites; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Hep G2 Cells; Humans; Immunosuppression Therapy; Liver Neoplasms; Macrophages; Mice; Niacinamide; Phenylurea Compounds; Plant Extracts; Receptors, CCR2; Sorafenib; THP-1 Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays

2017
Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Biomaterials, 2017, Volume: 143

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chitosan; Delayed-Action Preparations; Disaccharides; Drug Synergism; Humans; Hydrogen-Ion Concentration; Liver Neoplasms; Lung Neoplasms; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Porosity; Rats; Silicon Dioxide; Sorafenib; Triterpenes; Ursolic Acid

2017
Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells.
    Biochemical and biophysical research communications, 2017, 09-30, Volume: 491, Issue:4

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Haloperidol; Humans; Iron; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Receptors, sigma; Sigma-1 Receptor; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured

2017
Phosphorylation-dependent signaling controls degradation of DNA mismatch repair protein PMS2.
    Molecular carcinogenesis, 2017, Volume: 56, Issue:12

    Topics: Blotting, Western; Enzyme Inhibitors; HEK293 Cells; Humans; Marine Toxins; Mismatch Repair Endonuclease PMS2; Mutation; MutL Protein Homolog 1; MutL Proteins; Niacinamide; Oxazoles; Phenylurea Compounds; Phosphorylation; Proteolysis; Serine; Signal Transduction; Sorafenib; Threonine

2017
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.
    Targeted oncology, 2017, Volume: 12, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Retrospective Studies; Sorafenib

2017
Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis.
    Journal of clinical pathology, 2017, Volume: 70, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; DNA Mutational Analysis; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
    Cancer science, 2017, Volume: 108, Issue:10

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Liver; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins; Sorafenib; STAT3 Transcription Factor; Survival Analysis; Up-Regulation; Vascular Endothelial Growth Factor A

2017
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
    Chinese journal of cancer, 2017, Aug-08, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Treatment Outcome

2017
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Yonsei medical journal, 2017, Volume: 58, Issue:5

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; RNA, Small Interfering; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Xenograft Model Antitumor Assays

2017
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluorodeoxyglucose F18; Humans; Mice, Transgenic; Molecular Imaging; Neoplasm Transplantation; Niacinamide; Optical Imaging; Phenylurea Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Random Allocation; Receptors, Bombesin; Receptors, Transferrin; Sorafenib; Treatment Outcome; Tumor Burden

2017
A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Cluster Analysis; Data Mining; Databases, Factual; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Linear Models; Microarray Analysis; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome

2017
Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway.
    Journal of virology, 2017, 11-01, Volume: 91, Issue:21

    Topics: Adenosine Triphosphatases; Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Chlorocebus aethiops; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rift Valley Fever; Rift Valley fever virus; Secretory Pathway; Sorafenib; Tumor Cells, Cultured; Valosin Containing Protein; Vero Cells; Virion; Virus Release; Virus Replication

2017
Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor.
    Organic & biomolecular chemistry, 2017, Oct-04, Volume: 15, Issue:38

    Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cardiotoxicity; Cell Line, Tumor; Cell Survival; Embryo, Nonmammalian; Humans; Imidazoles; Macromolecular Substances; Magnetic Resonance Spectroscopy; Molecular Structure; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Sorafenib; Zebrafish

2017
Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
    BMC gastroenterology, 2017, Aug-10, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2017
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Diarrhea; Female; Humans; Inflammation; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Severity of Illness Index; Sorafenib; Treatment Outcome

2018
Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78.
    Biochemical and biophysical research communications, 2017, 10-07, Volume: 492, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Oxazines; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship

2017
6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:12

    Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Apoptosis; Aspartate Aminotransferases; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Naphthalimides; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2017
Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Acta medica Okayama, 2017, Volume: 71, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sex Factors; Sorafenib

2017
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
    International journal of immunopathology and pharmacology, 2017, Volume: 30, Issue:3

    Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Photochemotherapy; Photosensitizing Agents; Protein Kinase Inhibitors; Sorafenib

2017
Does Sorafenib Fit for All?
    Radiology, 2017, Volume: 284, Issue:3

    Topics: Humans; Niacinamide; Phenylurea Compounds; Sorafenib

2017
A typical presentation of a hepatocellular carcinoma in a middle-aged patient.
    BMJ case reports, 2017, Aug-21, Volume: 2017

    Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Bone Neoplasms; Carcinoma, Hepatocellular; Clavicle; Fatal Outcome; Fractures, Bone; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2017
A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:1

    Topics: Analysis of Variance; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Sorafenib

2018
Sorafenib stimulates human skin type mast cell degranulation and maturation.
    Journal of dermatological science, 2017, Volume: 88, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Apoptosis; Biopsy; Cell Count; Cell Degranulation; Cell Proliferation; Drug Eruptions; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Humans; Male; Mast Cells; Middle Aged; Niacinamide; Organ Culture Techniques; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Skin; Sorafenib; Stem Cell Factor; Vascular Endothelial Growth Factor A; Wortmannin; Young Adult

2017
Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.
    Cancer science, 2017, Volume: 108, Issue:11

    Topics: A549 Cells; Apoptosis; Betulinic Acid; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Flow Cytometry; Humans; Mutation; Niacinamide; Pentacyclic Triterpenes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sorafenib; Triterpenes

2017
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
    British journal of cancer, 2017, Sep-26, Volume: 117, Issue:7

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays

2017
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
    Endocrine journal, 2017, Nov-29, Volume: 64, Issue:11

    Topics: Adenylyl Cyclases; Cell Differentiation; Cell Proliferation; Colforsin; Cyclic AMP; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thyroid Neoplasms; Tumor Cells, Cultured

2017
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
    International journal of cancer, 2017, 12-15, Volume: 141, Issue:12

    Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphofructokinase-2; Sorafenib; Xenograft Model Antitumor Assays

2017
Effects of Ascorbyl-2-phosphate Magnesium on Human Keratinocyte Toxicity and Pathological Changes by Sorafenib.
    Biological & pharmaceutical bulletin, 2017, Volume: 40, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Cell Line; Hand-Foot Syndrome; Humans; Keratinocytes; Magnesium; Niacinamide; Phenylurea Compounds; Phosphorylation; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Skin; Sorafenib; STAT3 Transcription Factor

2017
Might Sorafenib combined with radiotherapy be better option for treating hepatocellular carcinoma with portal vein tumour thrombosis?
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis

2018
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Nov-01, Volume: 35, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2017
The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.
    Hematology (Amsterdam, Netherlands), 2018, Volume: 23, Issue:3

    Topics: Acute Disease; Adult; Asian People; China; Drug Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome; Young Adult

2018
Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    International urology and nephrology, 2017, Volume: 49, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Neutrophils; Niacinamide; Nutritional Status; Phenylurea Compounds; Preoperative Period; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Young Adult

2017
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    BMC cancer, 2017, Sep-12, Volume: 17, Issue:1

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome

2017
Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, Nov-28, Volume: 266

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Humans; Liver Neoplasms; Male; Mice, Nude; Nanoparticles; Niacinamide; Peptides; Phenylurea Compounds; Polymethacrylic Acids; Protein Kinase Inhibitors; Sorafenib

2017
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
    Cancer research, 2017, 10-15, Volume: 77, Issue:20

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays

2017
Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis.
    Future medicinal chemistry, 2017, Volume: 9, Issue:15

    Topics: Apoptosis; Binding Sites; Caspases; Cell Line, Tumor; Hep G2 Cells; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Piperazine; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Sorafenib; Staurosporine; Thiazolidines; Vascular Endothelial Growth Factor Receptor-2

2017
Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Acta radiologica (Stockholm, Sweden : 1987), 2018, Volume: 59, Issue:7

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Longitudinal Studies; Male; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Prognosis; Prospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2018
Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
    Bioorganic & medicinal chemistry, 2017, 10-15, Volume: 25, Issue:20

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Structure-Activity Relationship

2017
Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    PloS one, 2017, Volume: 12, Issue:9

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib

2017
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?
    Journal of experimental & clinical cancer research : CR, 2017, 09-29, Volume: 36, Issue:1

    Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2017
The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
    Future oncology (London, England), 2017, Volume: 13, Issue:25

    Topics: Brachytherapy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Humans; Liver Neoplasms; Microspheres; Multicenter Studies as Topic; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Yttrium Radioisotopes

2017
Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis.
    British journal of pharmacology, 2017, Volume: 174, Issue:24

    Topics: Animals; Heart; Liver; Metabolomics; Mice; Mice, Inbred Strains; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Plasma; Protein Kinase Inhibitors; Sorafenib; Tissue Distribution

2017
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.
    Japanese journal of clinical oncology, 2017, Oct-01, Volume: 47, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Humans; Interleukin-6; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Young Adult

2017
Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:1

    Topics: Acrylamides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factors; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Nitric Oxide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Sorafenib

2018
Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats.
    AAPS PharmSciTech, 2018, Volume: 19, Issue:2

    Topics: Administration, Oral; Animals; Biological Availability; Drug Carriers; Female; Lipids; Liver; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Sorafenib; Suspensions

2018
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Hypoglycemic Agents; Immunohistochemistry; Insulin; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metformin; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sirtuin 3; Sorafenib; Time Factors; Treatment Outcome

2017
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Decision Support Techniques; Disease-Free Survival; Female; France; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Serum Albumin, Human; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom

2017
Alpha mangostin Inhibits Hepatic Stellate Cells Activation Through TGF-β/Smad and Akt Signaling Pathways: An in vitro Study in LX2.
    Drug research, 2018, Volume: 68, Issue:3

    Topics: Actins; Animals; Biomarkers; Cell Proliferation; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Ki-67 Antigen; Male; Niacinamide; Phenylurea Compounds; Plasminogen Activator Inhibitor 1; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Smad3 Protein; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Xanthones

2018
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2017, Oct-15, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib

2017
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Cost-Benefit Analysis; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Sorafenib; Treatment Outcome

2017
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.
    Cell death & disease, 2017, 10-12, Volume: 8, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Indans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Sorafenib; STAT3 Transcription Factor; Sulfones

2017
Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
    Cancer medicine, 2017, Volume: 6, Issue:12

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone-Lysine N-Methyltransferase; Humans; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2017
The treatment path in hepatocellular carcinoma.
    Clinical advances in hematology & oncology : H&O, 2017, Volume: 15 Suppl 9, Issue:8

    Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate

2017
Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status.
    Anti-cancer drugs, 2017, Volume: 28, Issue:10

    Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Drug Synergism; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Rhabdomyosarcoma; Sorafenib; Sulfones

2017
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Recepto
    Journal of the American Heart Association, 2017, Oct-19, Volume: 6, Issue:10

    Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cells, Cultured; Dose-Response Relationship, Drug; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids; Female; Gene Expression Profiling; Heart; Heart Diseases; Indoles; Mice; Molecular Targeted Therapy; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Pyrroles; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Time Factors

2017
Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:5

    Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Carcinoma, Hepatocellular; Depression, Chemical; Gene Expression; Hep G2 Cells; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Messenger; Solubility; Sorafenib

2018
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult

2017
Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.
    Cell death & disease, 2017, 10-26, Volume: 8, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Sorafenib; Transfection; Young Adult

2017
Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".
    Journal of hepatology, 2018, Volume: 68, Issue:3

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2018
Predictors of sorafenib benefit in patients with hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 68, Issue:3

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2018
Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
    European journal of dermatology : EJD, 2017, 10-01, Volume: 27, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Leg Ulcer; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides

2017
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
    World journal of surgical oncology, 2017, Nov-02, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hematologic Neoplasms; Hepacivirus; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Patient Selection; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Serologic Tests; Sorafenib; Survival Rate; Young Adult

2017
Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.
    Contrast media & molecular imaging, 2017, Volume: 2017

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Ferric Compounds; Heterografts; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
    Biomaterials science, 2017, Nov-21, Volume: 5, Issue:12

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Combined Modality Therapy; Drug Delivery Systems; Drug Resistance, Neoplasm; Gene Transfer Techniques; Glypicans; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib

2017
Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Jan-01, Volume: 111

    Topics: Antineoplastic Agents; Apoptosis; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Humans; Liver Neoplasms; Nanoparticles; Niacinamide; Phenylurea Compounds; RNA Interference; RNA, Small Interfering; Silicon Dioxide; Sorafenib; Vascular Endothelial Growth Factor A

2018
Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.
    Surgery today, 2018, Volume: 48, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pneumonectomy; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2018
Potential Visualization of Sorafenib-Induced Acidosis Using 11C-Acetate PET/CT in Patients With Hepatocellular Carcinoma.
    Clinical nuclear medicine, 2018, Volume: 43, Issue:1

    Topics: Acetates; Acidosis; Aged, 80 and over; Carbon Radioisotopes; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib

2018
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
    British journal of cancer, 2017, Dec-05, Volume: 117, Issue:12

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib

2017
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:3

    Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sorafenib; Treatment Outcome

2018
Utility of Cremophor RH 40 as a micellar improvement for spectrofluorimetric estimation of sorafenib in pure form, commercial preparation, and human plasma.
    Luminescence : the journal of biological and chemical luminescence, 2018, Volume: 33, Issue:2

    Topics: Antineoplastic Agents; Fluorescence; Humans; Limit of Detection; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Sorafenib; Spectrometry, Fluorescence

2018
Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
    Expert review of gastroenterology & hepatology, 2018, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Disease Progression; Disease-Free Survival; Egypt; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult

2018
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
    Japanese journal of clinical oncology, 2017, Dec-01, Volume: 47, Issue:12

    Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib

2017
ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143.
    Journal of photochemistry and photobiology. B, Biology, 2018, Volume: 178

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Survival; Chlorophyllides; Diketopiperazines; Doxycycline; Gene Expression; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Humans; Light; Niacinamide; Phenylurea Compounds; Photosensitizing Agents; Porphyrins; Sorafenib

2018
Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 97

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Ginsenosides; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib

2018
A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance.
    Integrative biology : quantitative biosciences from nano to macro, 2017, Dec-11, Volume: 9, Issue:12

    Topics: Animals; Antineoplastic Agents; Benzamides; Biocompatible Materials; Cell Communication; Cell Line, Tumor; Diphenylamine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Humans; Hydrogels; Hydrogen; Linear Models; MAP Kinase Kinase Kinases; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Plastics; Sorafenib; Spheroids, Cellular; Systems Biology; Transcriptome; Tumor Microenvironment

2017
miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers.
    Pharmaceutical research, 2017, Volume: 34, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice, Nude; MicroRNAs; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tretinoin

2017
Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.
    Experimental biology and medicine (Maywood, N.J.), 2018, Volume: 243, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Severity of Illness Index; Sorafenib

2018
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
    Anticancer research, 2017, Volume: 37, Issue:12

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fibroblast Growth Factors; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2017
Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
    Acta pharmacologica Sinica, 2018, Volume: 39, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capsaicin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2018
Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome

2017
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
    Journal of medicinal chemistry, 2017, 12-14, Volume: 60, Issue:23

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Discovery; Drug Resistance, Multiple; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Receptors, N-Methyl-D-Aspartate; Sorafenib

2017
Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer.
    Oncology reports, 2018, Volume: 39, Issue:2

    Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Chloroquine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays

2018
Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Mar-01, Volume: 114

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Female; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Liver Cirrhosis; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult

2018
Development of a validated liquid chromatographic method for quantification of sorafenib tosylate in the presence of stress-induced degradation products and in biological matrix employing analytical quality by design approach.
    Biomedical chromatography : BMC, 2018, Volume: 32, Issue:5

    Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Hydrolysis; Limit of Detection; Linear Models; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sorafenib

2018
High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
    BMC cancer, 2017, Dec-15, Volume: 17, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cytosol; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Hep G2 Cells; HMGB1 Protein; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Transport; RNA, Small Interfering; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:2

    Topics: Administration, Metronomic; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate

2018
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Oncology reports, 2018, Volume: 39, Issue:2

    Topics: Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2018
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
    BMC cancer, 2017, Dec-19, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cytokines; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2017
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Gut, 2018, Volume: 67, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib

2018
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
    Endocrine, 2018, Volume: 59, Issue:2

    Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome

2018
The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Anticancer research, 2018, Volume: 38, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fibroblast Growth Factor 4; Hepatectomy; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate

2018
The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
    Internal medicine (Tokyo, Japan), 2018, May-15, Volume: 57, Issue:10

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiotherapy, Conformal; Retrospective Studies; Sorafenib; Survival Analysis

2018
A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
    EBioMedicine, 2018, Volume: 27

    Topics: Angiogenesis Inhibitors; Biological Assay; Blood Vessels; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microvessels; Models, Biological; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A

2018
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer.
    Nigerian journal of clinical practice, 2017, Volume: 20, Issue:11

    Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Blood Glucose; China; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Hyperglycemia; Incidence; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Registries; Sorafenib

2017
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.
    PloS one, 2018, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Bone Marrow Cells; CD8 Antigens; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Recurrence; Sorafenib; Transplantation, Homologous

2018
miR‑378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβ and c‑Raf.
    Molecular medicine reports, 2018, Volume: 17, Issue:3

    Topics: Adult; Antagomirs; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Matrix Metalloproteinase 2; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib

2018
Effect of histidine on sorafenib-induced vascular damage: Analysis using novel medaka fish model.
    Biochemical and biophysical research communications, 2018, 02-05, Volume: 496, Issue:2

    Topics: Animals; Antineoplastic Agents; Blood Flow Velocity; Blood Vessels; Carcinoma, Hepatocellular; Histidine; Humans; Liver Neoplasms; Niacinamide; Oryzias; Phenylurea Compounds; Sorafenib

2018
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
    Toxicology, 2018, 02-15, Volume: 395

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; Imidazoles; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Mitophagy; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridazines; Pyridines; Sorafenib

2018
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
    Scientific reports, 2018, 01-17, Volume: 8, Issue:1

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Humans; Lung Neoplasms; Mutation; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Pyrimidinones; Sorafenib

2018
Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer.
    Biomaterials, 2018, Volume: 159

    Topics: Carcinoma, Hepatocellular; Cell Survival; Elastic Modulus; Exome; Fluorescent Antibody Technique; Humans; Hydrogels; Liver Neoplasms; Niacinamide; Organoids; Phenylurea Compounds; Porosity; Sorafenib; Xenograft Model Antitumor Assays

2018
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.
    Medicine, 2018, Volume: 97, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Costs; Drug Prescriptions; Female; Gastroenterologists; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Retrospective Studies; Sorafenib; United States

2018
Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
    Biochimica et biophysica acta. General subjects, 2018, Volume: 1862, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice, SCID; Niacinamide; Phenylurea Compounds; Pregnane X Receptor; Protein Kinase Inhibitors; Receptors, Steroid; RNA Interference; Sorafenib; Xenograft Model Antitumor Assays

2018
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
    Urologic oncology, 2018, Volume: 36, Issue:5

    Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Interleukin-8A; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2018
Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:4

    Topics: Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Hepatic Stellate Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kupffer Cells; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Real-Time Polymerase Chain Reaction; Smad3 Protein; Sorafenib; Transforming Growth Factor beta1

2018
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
    Nature communications, 2018, 01-31, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells; Hexokinase; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Metabolic Flux Analysis; Metformin; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2018
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Radiology, 2018, Volume: 287, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Young Adult

2018
Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
    World journal of gastroenterology, 2018, Jan-28, Volume: 24, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Portal Vein; Prognosis; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Thrombosis; Young Adult

2018
Negative phase 3 study of
    The Lancet. Oncology, 2018, Volume: 19, Issue:2

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes

2018
Negative phase 3 study of
    The Lancet. Oncology, 2018, Volume: 19, Issue:2

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes

2018
Negative phase 3 study of
    The Lancet. Oncology, 2018, Volume: 19, Issue:2

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes

2018
Negative phase 3 study of
    The Lancet. Oncology, 2018, Volume: 19, Issue:2

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes

2018
Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, May-30, Volume: 117

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Dogs; Drug Interactions; Drug Resistance, Neoplasm; Flavonoids; LLC-PK1 Cells; Madin Darby Canine Kidney Cells; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Swine; Tissue Distribution

2018
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
    Oncology, 2018, Volume: 94, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Retrospective Studies; Sorafenib; Survival Rate

2018
Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
    International journal of molecular medicine, 2018, Volume: 41, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Clusterin; Gene Silencing; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib

2018
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:3

    Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1

2018
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
    Journal of vascular and interventional radiology : JVIR, 2018, Volume: 29, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2018
Skull Base Metastasis From Occult Renal Cell Carcinoma.
    The Journal of craniofacial surgery, 2018, Volume: 29, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Neoplasms, Unknown Primary; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Skull Base Neoplasms; Sorafenib; Sunitinib

2018
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
    BMC cancer, 2018, 03-02, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Safety; Sorafenib; Treatment Outcome

2018
Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:2

    Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2018
Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2018, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Comorbidity; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Survival Analysis

2018
Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
    Biomaterials science, 2018, Mar-26, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Homeodomain Proteins; Immunity, Cellular; Lymphocytes; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Sorafenib

2018
Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
    Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:1

    Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome

2018
Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
    The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis

2018
Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
    International journal of pharmaceutics, 2018, May-05, Volume: 542, Issue:1-2

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Butadienes; Cell Survival; Drug Carriers; Drug Liberation; Erythrocytes; Hemolysis; Hep G2 Cells; Humans; Inhibitory Concentration 50; Male; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Polyethylene; Protein Kinase Inhibitors; Sorafenib

2018
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
    BMC cancer, 2018, 03-20, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Sorafenib; Survival Rate

2018
Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval.
    BMJ (Clinical research ed.), 2018, 03-20, Volume: 360

    Topics: Antineoplastic Agents; Calcium Channel Blockers; Clinical Trials as Topic; Drug Approval; Drug Industry; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pregabalin; Pyrroles; Sorafenib; Sunitinib

2018
Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.
    Future oncology (London, England), 2018, Volume: 14, Issue:8

    Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Yttrium Radioisotopes

2018
Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Radiology, 2018, Volume: 288, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2018
Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
    Anticancer research, 2018, Volume: 38, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biflavonoids; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2018
Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems.
    PloS one, 2018, Volume: 13, Issue:4

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed

2018
Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    International journal of oncology, 2018, Volume: 52, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Drug Synergism; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2018
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    European radiology, 2018, Volume: 28, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Competence; Diagnostic Errors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2018
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:10

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microvessels; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2018
Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome.
    International journal of pharmaceutics, 2018, Jun-10, Volume: 544, Issue:1

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Survival; Chitosan; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Liposomes; Male; Niacinamide; Phenylurea Compounds; Polymethacrylic Acids; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Sorafenib

2018
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
    Urologic oncology, 2018, Volume: 36, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A

2018
Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2018, Volume: 14, Issue:6

    Topics: Angiogenesis Inhibitors; Asteraceae; Benzamides; Flavanones; HSP90 Heat-Shock Proteins; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Niacinamide; Phenylurea Compounds; Picolinic Acids; Protein Binding; Sorafenib; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2

2018
Rupture of a Small Hepatocellular Carcinoma in a Stable Disease State in a Patient Receiving Sorafenib Treatment.
    Chinese medical journal, 2018, Apr-20, Volume: 131, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rupture; Sorafenib; Treatment Outcome

2018
Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
    Radiology, 2018, Volume: 288, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2018
Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins.
    Molecular medicine reports, 2018, Volume: 17, Issue:6

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bufanolides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2018
Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
    Molecular medicine reports, 2018, Volume: 17, Issue:6

    Topics: Activating Transcription Factor 2; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Silencing; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase 10; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Small Interfering; Sorafenib; Tumor Necrosis Factor-alpha

2018
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
    Toxicology in vitro : an international journal published in association with BIBRA, 2018, Volume: 51

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Hepatocellular; Diterpenes; Endoplasmic Reticulum Chaperone BiP; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Phosphoproteins; Sorafenib; Transcription Factors; YAP-Signaling Proteins

2018
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
    Medicine, 2018, Volume: 97, Issue:17

    Topics: Adult; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; International Normalized Ratio; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome

2018
Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Value in health regional issues, 2018, Volume: 15

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib; Taiwan

2018
Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
    Life sciences, 2018, Aug-01, Volume: 206

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Biological Availability; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetite Nanoparticles; Male; Neoplasm Proteins; Niacinamide; Particle Size; Phenylurea Compounds; Polyvinyl Alcohol; Rats; Rats, Wistar; Sorafenib

2018
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
    Oncology, 2018, Volume: 95, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2018
[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
    Zhonghua nei ke za zhi, 2018, May-01, Volume: 57, Issue:5

    Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Transplantation, Homologous; Treatment Outcome

2018
Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
    Pediatric dermatology, 2018, Volume: 35, Issue:4

    Topics: Child; Diagnosis, Differential; Fluocinolone Acetonide; Glucocorticoids; Hand-Foot Syndrome; Humans; Male; Niacinamide; Orthotic Devices; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2018
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
    European journal of pharmacology, 2018, Aug-05, Volume: 832

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Silybin; Silymarin; Sorafenib; STAT3 Transcription Factor

2018
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
    Archives of endocrinology and metabolism, 2018, Volume: 62, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Treatment Outcome; Young Adult

2018
[Hepatocellular Carcinoma: New multimodal therapy concepts].
    Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib

2018
Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 47, Issue:3

    Topics: Carcinoma, Renal Cell; Cell Cycle; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Niclosamide; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib

2018
Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured

2018
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
    Toxicology letters, 2018, Oct-01, Volume: 295

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2018
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2018, May-23, Volume: 40, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome

2018
[Evaluation of cryptotanshinone inhibition of angiogenesis in human hepatic sinusoidal endothelial cells].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2016, Volume: 51, Issue:8

    Topics: Animals; Animals, Genetically Modified; Cell Proliferation; Cells, Cultured; Down-Regulation; Drugs, Chinese Herbal; Endothelial Cells; Humans; Neovascularization, Pathologic; Niacinamide; Nitric Oxide; Phenanthrenes; Phenylurea Compounds; Salvia miltiorrhiza; Sorafenib; von Willebrand Factor; Zebrafish

2016
Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action.
    International journal of molecular medicine, 2018, Volume: 42, Issue:3

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Drug Therapy, Combination; Fibroblasts; Humans; Inhibitory Concentration 50; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenols; Phenylurea Compounds; Sorafenib

2018
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Drug delivery, 2018, Volume: 25, Issue:1

    Topics: Animals; Antibodies; Antineoplastic Agents; Caproates; Carcinoma, Hepatocellular; Cell Line, Tumor; Glypicans; Hep G2 Cells; Humans; Lactones; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Polymers; Sorafenib; Xenograft Model Antitumor Assays

2018
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
    Medicine, 2018, Volume: 97, Issue:25

    Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed

2018
Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice.
    Parasitology research, 2018, Volume: 117, Issue:9

    Topics: Actins; Animals; Collagen Type I; Collagen Type III; Female; Liver; Liver Cirrhosis; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Praziquantel; Receptor, Platelet-Derived Growth Factor beta; Schistosoma japonicum; Schistosomiasis japonica; Sorafenib

2018
Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 47, Issue:5

    Topics: Cell Line, Tumor; Drug Synergism; Humans; Melatonin; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Melatonin; Signal Transduction; Sorafenib; STAT3 Transcription Factor

2018
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
    Anticancer research, 2018, Volume: 38, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Population Groups; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2018
Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
    Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Female; Humans; Immunotherapy, Adoptive; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2018
[Simultaneous determination of donafenib and its N-oxide metabolite in human plasma by liquid chromatography-tandem mass spectrometry].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2017, Volume: 52, Issue:3

    Topics: Antineoplastic Agents; Chromatography, Liquid; Humans; Niacinamide; Oxides; Phenylurea Compounds; Plasma; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2017
Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
    Digestive diseases (Basel, Switzerland), 2018, Volume: 36, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2018
Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.
    Oncology reports, 2018, Volume: 40, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured

2018
Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
    World journal of gastroenterology, 2018, Jul-28, Volume: 24, Issue:28

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; Foot; Hand; Humans; Incidence; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Pharmacists; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Skin; Sorafenib; Survival Analysis; Treatment Failure

2018
Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
    Oncology reports, 2018, Volume: 40, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2018
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
    Vascular pharmacology, 2018, Volume: 110

    Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Indoles; Male; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pulmonary Artery; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling

2018
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
    International heart journal, 2018, Sep-26, Volume: 59, Issue:5

    Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A

2018
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
    Anticancer research, 2018, Volume: 38, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib

2018
Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
    BMC cancer, 2018, Sep-18, Volume: 18, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen Type I; Disease Progression; Epithelial-Mesenchymal Transition; Extracellular Matrix; Humans; Hyperthermia, Induced; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2018
[Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2019
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.
    Gut, 2019, Volume: 68, Issue:10

    Topics: Carcinoma, Hepatocellular; Humans; Leukemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2019
[E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2019, Aug-30, Volume: 39, Issue:8

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Sorafenib

2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:2

    Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Transplantation, Homologous

2020
Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study.
    The oncologist, 2020, Volume: 25, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2020
Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
    International journal of nanomedicine, 2019, Volume: 14

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Weight; Carcinoma, Hepatocellular; Cell Proliferation; Drug Compounding; Drug Design; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liver; Liver Neoplasms; Male; Nanotubes, Carbon; Niacinamide; Rats, Wistar; Sorafenib; Spectroscopy, Fourier Transform Infrared; Static Electricity

2019
Quercetin improves the effects of sorafenib on growth and migration of thyroid cancer cells.
    Endocrine, 2020, Volume: 67, Issue:2

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib; Thyroid Neoplasms

2020
Letter: are sorafenib-related adverse events associated with prolonged survival?
    Alimentary pharmacology & therapeutics, 2020, Volume: 51, Issue:1

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2020
Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply.
    Alimentary pharmacology & therapeutics, 2020, Volume: 51, Issue:1

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2020
Response to: Prognostication of HCC patients under sorafenib is not always possible.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:5

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2020
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
    EBioMedicine, 2020, Volume: 52

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2020
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Europe; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sorafenib; Treatment Outcome

2020
The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.
    Journal of geriatric oncology, 2020, Volume: 11, Issue:7

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hispanic or Latino; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2020
s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide.
    Cell research, 2020, Volume: 30, Issue:9

    Topics: Aged; Aged, 80 and over; Animals; Disease Models, Animal; Endothelial Cells; Female; Foot; HaCaT Cells; Hand; Heparin-binding EGF-like Growth Factor; Humans; Keratinocytes; Keratosis; Male; Mice, Inbred ICR; Middle Aged; Mitogen-Activated Protein Kinase 9; Models, Biological; Niacinamide; Phosphorylation; Protein Stability; Sirtuin 1; Skin; Sorafenib

2020
Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.
    Clinical journal of gastroenterology, 2020, Volume: 13, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Psoriasis; Sorafenib; Treatment Outcome

2020
Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma.
    Journal of clinical gastroenterology, 2021, 02-01, Volume: 55, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Gastric Acid; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; United Kingdom

2021
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma.
    Journal of clinical gastroenterology, 2021, 03-01, Volume: 55, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Exocrine Pancreatic Insufficiency; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2021
Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia.
    European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiopia; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2020
Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma.
    Advanced healthcare materials, 2020, Volume: 9, Issue:21

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bismuth; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Liver Neoplasms; Mice; Niacinamide; Sorafenib

2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Sorafenib

2020
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021, 07-01, Volume: 62, Issue:7

    Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2021
Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2021
Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
    Haematologica, 2022, 01-01, Volume: 107, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors

2022
Penile and scrotal infundibular cysts in an adolescent treated with sorafenib.
    Pediatric dermatology, 2021, Volume: 38, Issue:2

    Topics: Adolescent; Carcinoma, Squamous Cell; Humans; Male; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib

2021
Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.
    Clinics (Sao Paulo, Brazil), 2021, Volume: 76

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib

2021
Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2021
Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
    International journal of molecular sciences, 2021, May-19, Volume: 22, Issue:10

    Topics: Apoptosis; Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Fibrinogen; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib

2021
Valuable insights from real-life experiences of advanced thyroid cancer treatment with sorafenib in Latin America.
    Archives of endocrinology and metabolism, 2021, 09-02, Volume: 65, Issue:4

    Topics: Antineoplastic Agents; Humans; Latin America; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms

2021
Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment.
    World journal of gastroenterology, 2021, Aug-28, Volume: 27, Issue:32

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Treatment Outcome

2021
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report.
    Journal of medical case reports, 2021, Sep-21, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib

2021
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
    Pharmacological research, 2022, Volume: 177

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirtuin 2; Sorafenib; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays

2022
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison.
    Annals of surgery, 2022, 04-01, Volume: 275, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2022
Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk.
    Life sciences, 2022, May-15, Volume: 297

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; NF-kappa B; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Sorafenib; Vascular Endothelial Growth Factor A

2022
Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
    The Journal of veterinary medical science, 2022, May-17, Volume: 84, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Dog Diseases; Dogs; Fibrosarcoma; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Rodent Diseases; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2022
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
    Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor A

2022
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2022, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; United Kingdom

2022
Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
    Cancer medicine, 2023, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Nivolumab; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2023
Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
    Radiation oncology (London, England), 2022, Jun-11, Volume: 17, Issue:1

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2022
The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma.
    Contrast media & molecular imaging, 2022, Volume: 2022

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Spleen; Vascular Endothelial Growth Factor A

2022
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
    International journal of molecular sciences, 2022, Jul-22, Volume: 23, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liver Neoplasms; Metformin; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2022
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
    International journal of hematology, 2022, Volume: 116, Issue:6

    Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Sorafenib; Transplantation, Homologous

2022
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.
    Cell reports, 2022, 08-16, Volume: 40, Issue:7

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Lipoylation; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proprotein Convertase 9; Proto-Oncogene Proteins c-akt; Sorafenib

2022
FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma.
    European journal of pharmacology, 2022, Sep-15, Volume: 931

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Ion Channels; Liver Neoplasms; Microfilament Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2022
[Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2022, Jul-20, Volume: 30, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A

2022
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study.
    Anticancer research, 2022, Volume: 42, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2022
Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.
    International immunopharmacology, 2022, Volume: 112

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Niacinamide; Nivolumab; Phenylurea Compounds; Sorafenib

2022
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.
    Scientific reports, 2022, 10-25, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Matrix Metalloproteinase 9; Niacinamide; Panitumumab; Phenylurea Compounds; Ramucirumab; Sorafenib

2022
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
    Experimental & molecular medicine, 2022, Volume: 54, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; Liver Neoplasms; Mitophagy; Niacinamide; Sorafenib

2022
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.
    International journal of molecular sciences, 2022, Dec-19, Volume: 23, Issue:24

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Sorafenib

2022
Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.
    Chemico-biological interactions, 2023, Jan-25, Volume: 370

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; MAP Kinase Signaling System; Mice; Niacinamide; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sorafenib

2023
Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    Current oncology (Toronto, Ont.), 2022, 12-29, Volume: 30, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2022
A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.
    International journal of molecular sciences, 2023, Jan-14, Volume: 24, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Genome-Wide Association Study; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib; Treatment Outcome

2023
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022, 11-14, Volume: 43, Issue:11

    Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides

2022
Ca
    International journal of molecular sciences, 2023, Jan-26, Volume: 24, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Cell Line, Tumor; Glioblastoma; Humans; Niacinamide; Phenylurea Compounds; Selenium; Sorafenib

2023
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 186

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fibromatosis, Aggressive; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult

2023
Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib.
    Biochemical pharmacology, 2023, Volume: 213

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Mice; Mice, Inbred Strains; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib

2023
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.
    BMC cancer, 2023, Oct-25, Volume: 23, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib

2023
chemdatabank.com